FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Joshi, SK Lee, L Lovett, DH Kang, H Kim, HT Delgado, C Liu, XH AF Joshi, Sunil K. Lee, Lawrence Lovett, David H. Kang, Heejae Kim, Hubert T. Delgado, Cynthia Liu, Xuhui TI Novel intracellular N-terminal truncated matrix metalloproteinase-2 isoform in skeletal muscle ischemia-reperfusion injury SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE matrix metalloproteinase-2; N-terminal truncated matrix metalloproteinase-2; skeletal muscle; hindlimb ischemia-reperfusion injury; hypoxia ID FOCAL CEREBRAL-ISCHEMIA; KAPPA-B INHIBITOR; TOLL-LIKE; PYRROLIDINE DITHIOCARBAMATE; ISCHEMIA/REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA; CARDIAC ISCHEMIA; MURINE HINDLIMB; UP-REGULATION; EXPRESSION AB Ischemia-reperfusion injury (IRI) occurs when blood returns to tissues following a period of ischemia. Reintroduction of blood flow results in the production of free radicals and reactive oxygen species that damage cells. Skeletal muscle IRI is commonly seen in orthopedic trauma patients. Experimental studies in other organ systems have elucidated the importance of extracellular and intracellular matrix metalloproteinase-2 (MMP-2) isoforms in regulating tissue damage in the setting of oxidant stress resulting from IRI. Although the extracellular full-length isoform of MMP-2 (FL-MMP-2) has been previously studied in the setting of skeletal muscle IRI, studies investigating the role of the N-terminal truncated isoform (NTT-MMP-2) in this setting are lacking. In this study, we first demonstrated significant increases in FL- and NTT-MMP-2 gene expression in C2C12 myoblast cells responding to re-oxygenation following hypoxia in vitro. We then evaluated the expression of FL- and NTT-MMP-2 in modulating skeletal muscle IRI using a previously validated murine model. NTT-MMP-2, but not FL-MMP-2 expression was significantly increased in skeletal muscle following IRI. Moreover, the expression of toll-like receptors (TLRs) -2 and -4, IL-6, OAS-1A, and CXCL1 was also significantly up-regulated following IRI. Treatment with the potent anti-oxidant pyrrolidine dithiocarbamate (PDTC) significantly suppressed NTT-MMP-2, but not FL-MMP-2 expression and improved muscle viability following IRI. This data suggests that NTT-MMP-2, but not FL-MMP-2, is the major isoform of MMP-2 involved in skeletal muscle IRI. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:502-509, 2016. C1 [Joshi, Sunil K.; Lee, Lawrence; Lovett, David H.; Kang, Heejae; Kim, Hubert T.; Delgado, Cynthia; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Joshi, Sunil K.; Lovett, David H.; Delgado, Cynthia] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kim, Hubert T.; Liu, Xuhui] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. RP Liu, XH (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.; Liu, XH (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. EM Liux@orthosurg.ucsf.edu FU Veterans Affairs Rehabilitation Research and Development Merit Review [RX000195] FX Grant sponsor: Veterans Affairs Rehabilitation Research and Development Merit Review; Grant number: RX000195. NR 49 TC 0 Z9 0 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2016 VL 34 IS 3 BP 502 EP 509 DI 10.1002/jor.22992 PG 8 WC Orthopedics SC Orthopedics GA DF5UT UT WOS:000371418700015 PM 26213293 ER PT J AU Burke, RE Whitfield, EA Hittle, D Min, SJ Levy, C Prochazka, AV Coleman, EA Schwartz, R Ginde, AA AF Burke, Robert E. Whitfield, Emily A. Hittle, David Min, Sung-joon Levy, Cari Prochazka, Allan V. Coleman, Eric A. Schwartz, Robert Ginde, Adit A. TI Hospital Readmission From Post-Acute Care Facilities: Risk Factors, Timing, and Outcomes SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Post-acute care; readmission; care transition ID SKILLED NURSING FACILITIES; PROSPECTIVE-PAYMENT SYSTEM; QUALITY-OF-CARE; POSTACUTE CARE; HOME RESIDENTS; OLDER-ADULTS; GEOGRAPHIC-VARIATION; FUNCTIONAL OUTCOMES; THERAPY INTENSITY; POSTHOSPITAL CARE AB Objectives: Hospital discharges to post-acute care (PAC) facilities have increased rapidly. This increase may lead to more hospital readmissions from PAC facilities, which are common and poorly understood. We sought to determine the risk factors and timing for hospital readmission from PAC facilities and evaluate the impact of readmission on patient outcomes. Design: Retrospective analysis of Medicare Current Beneficiary Survey (MCBS) from 2003-2009. Setting: The MCBS is a nationally representative survey of beneficiaries matched with claims data. Participants: Community-dwelling beneficiaries who were hospitalized and discharged to a PAC facility for rehabilitation. Intervention/Exposure: Potential readmission risk factors included patient demographics, health utilization, active medical conditions at time of PAC admission, and PAC characteristics. Measurements: Hospital readmission during the PAC stay, return to community residence, and all-cause mortality. Results: Of 3246 acute hospitalizations followed by PAC facility stays, 739 (22.8%) included at least 1 hospital readmission. The strongest risk factors for readmission included impaired functional status (HR 4.78, 95% CI 3.21-7.10), markers of increased acuity such as need for intravenous medications in PAC (1.63, 1.39-1.92), and for-profit PAC ownership (1.43, 1.21-1.69). Readmitted patients had a higher mortality rate at both 30 days (18.9% vs 8.6%, P <. 001) and 100 days (39.9% vs 14.5%, P <. 001) even after adjusting for age, comorbidities, and prior health care utilization (30 days: OR 2.01, 95% CI 1.60-2.54; 100 days: OR 3.79, 95% CI 3.13-4.59). Conclusions: Hospital readmission from PAC facilities is common and associated with a high mortality rate. Readmission risk factors may signify inadequate transitional care processes or a mismatch between patient needs and PAC resources. Published by Elsevier Inc. on behalf of AMDA - The Society for Post-Acute and Long-Term Care Medicine. C1 [Burke, Robert E.; Whitfield, Emily A.; Levy, Cari; Prochazka, Allan V.] Denver VA Med Ctr, Denver Seattle Ctr Innovat, Denver, CO USA. [Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO USA. [Hittle, David; Min, Sung-joon; Levy, Cari; Coleman, Eric A.] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA. [Schwartz, Robert] Univ Colorado, Sch Med, Dept Med, Div Geriatr Med, Aurora, CO USA. [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, Hosp Med Sect, 1055 Clermont St, Denver, CO 80220 USA. EM Robert.Burke5@va.gov RI bebarta, vikhyat/K-3476-2015; Siry, Bonnie/D-7189-2017 FU NIA NIH HHS [R03 AG050885] NR 58 TC 7 Z9 7 U1 7 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD MAR 1 PY 2016 VL 17 IS 3 BP 249 EP 255 DI 10.1016/j.jamda.2015.11.005 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA DE9IK UT WOS:000370950000012 PM 26715357 ER PT J AU Zhao, K Craig, JR Cohen, NA Adappa, ND Khalili, S Palmer, JN AF Zhao, Kai Craig, John R. Cohen, Noam A. Adappa, Nithin D. Khalili, Sammy Palmer, James N. TI Sinus irrigations before and after surgeryVisualization through computational fluid dynamics simulations SO LARYNGOSCOPE LA English DT Article DE Nasal irrigation; computational fluid dynamics; modeling; sinus surgery; sinusitis; frontal; maxillary; sphenoid; head position ID NASAL AIR-FLOW; CHRONIC RHINOSINUSITIS; ODORANT TRANSPORT; PARANASAL SINUSES; HUMAN NOSE; OLFACTION; DELIVERY; SURGERY; PENETRATION; MODEL AB Objectives/HypothesisTopical sinus irrigations play a critical role in the management of sinonasal disease, and the improvement in irrigant penetration into the sinuses postoperatively greatly contributes to the success of endoscopic sinus surgery. Prior investigations on postoperative sinus irrigations have been mostly limited to cadaver studies, which are labor intensive and do not capture the full dynamics of the flows. A pilot study was conducted to investigate the impact of surgery on sinus irrigation through computational fluid dynamics (CFD) simulations. Study DesignRetrospective computational study. MethodsPre- and postoperative computed tomography (CT) scans were obtained on a patient who underwent standard endoscopic surgeries for all sinuses, including a Draf III frontal sinusotomy. CT-based pre- and postoperative CFD models then simulated irrigations of 120 mL saline per nostril at 12 mL/s (typical of Sinugator) and 60 mL/s (SinusRinse Bottle), in two head positions: face parallel and at a 45 degrees angle to the ground. ResultsOverall, surgery most significantly improved frontal sinus irrigation, but surprisingly resulted in less maxillary and ethmoid sinuses penetration. This may due to the partial removal of the septum during the Draf III, causing most fluid to exit prematurely across the resected septum. Higher flow rate slightly improved ethmoid sinus irrigation, but resulted in less preoperative contralateral maxillary sinus penetration. ConclusionsCFD modeling of sinonasal irrigations is a novel technique for evaluating irrigant penetration of individual sinus cavities. It may prove useful in determining the optimal degree of surgery or the ideal irrigation strategy to allow for maximal and targeted sinus irrigant penetration. C1 [Zhao, Kai] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 915 Olentangy River Rd, Columbus, OH 43212 USA. [Craig, John R.; Cohen, Noam A.; Adappa, Nithin D.; Khalili, Sammy; Palmer, James N.] Univ Penn, Dept Otorhinolaryngol, 5 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Zhao, K (reprint author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, 915 Olentangy River Rd, Columbus, OH 43212 USA.; Palmer, JN (reprint author), Univ Penn, Dept Otorhinolaryngol, 5 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA. EM zhao.1949@osu.edu; james.palmer@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932 FU NIH NIDCD [R01 DC013626] FX This work was supported by NIH NIDCD R01 DC013626 to K.Z. NR 24 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD MAR PY 2016 VL 126 IS 3 BP E90 EP E96 DI 10.1002/lary.25666 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA DF3KM UT WOS:000371242800001 PM 26467934 ER PT J AU Konadhode, RR Pelluru, D Shiromani, PJ AF Konadhode, Roda Rani Pelluru, Dheeraj Shiromani, Priyattam J. TI Unihemispheric Sleep: An Enigma for Current Models of Sleep-Wake Regulation SO SLEEP LA English DT Editorial Material ID SLOW-WAVE SLEEP; GABA RELEASE; MAMMALIAN SLEEP; LOCUS-COERULEUS; WAKING CYCLE; MCH NEURONS; REM-SLEEP; FUR SEALS; DISCHARGE; STATE C1 [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Konadhode, Roda Rani; Pelluru, Dheeraj; Shiromani, Priyattam J.] Med Univ S Carolina, Dept Behav Sci, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Shiromani, PJ (reprint author), Med Univ S Carolina, Dept Psychiat, Ralph H Johnson VA Med Ctr, 114 Doughty St, Charleston, SC 29425 USA. EM shiroman@musc.edu FU BLRD VA [I01 BX000798]; NINDS NIH HHS [NS084477, R01 NS052287, NS079940, NS052287] NR 50 TC 0 Z9 0 U1 12 U2 17 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 491 EP 494 AR PII sp-00020-16 DI 10.5665/sleep.5508 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800001 PM 26856898 ER PT J AU Fields, BG Behari, PP McCloskey, S True, G Richardson, D Thomasson, A Korom-Djakovic, D Davies, K Kuna, ST AF Fields, Barry G. Behari, Pratima Pathak McCloskey, Susan True, Gala Richardson, Diane Thomasson, Arwin Korom-Djakovic, Danijela Davies, Keith Kuna, Samuel T. TI Remote Ambulatory Management of Veterans with Obstructive Sleep Apnea SO SLEEP LA English DT Article DE obstructive sleep apnea; telemedicine; home sleep testing; auto-titrating positive airway pressure ID POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; DIAGNOSIS; POLYSOMNOGRAPHY; TELEMEDICINE; TELEHEALTH; ADHERENCE; CARE; AUTOTITRATION; VALIDATION AB Study Objectives: Despite significant medical sequelae of obstructive sleep apnea (OSA), the condition remains undiagnosed and untreated in many affected individuals. We explored the feasibility of a comprehensive, telemedicine-based OSA management pathway in a community-based Veteran cohort. Methods: This prospective, parallel-group randomized pilot study assessed feasibility of a telemedicine-based pathway for OSA evaluation and management in comparison to a more traditional, in-person care model. The study included 60 Veterans at the Philadelphia Veterans Affairs Medical Center and two affiliated community-based outpatient clinics. Telemedicine pathway feasibility, acceptability, and outcomes were assessed through a variety of quantitative (Functional Outcomes of Sleep Questionnaire, dropout rates, positive airway pressure [PAP] adherence rates, participant satisfaction ratings) and qualitative (verbal feedback) metrics. Results: There was no significant difference in functional outcome changes, patient satisfaction, dropout rates, or objectively measured PAP adherence between groups after 3 months of treatment. Telemedicine participants showed greater improvement in mental health scores, and their feedback was overwhelmingly positive. Conclusions: Our pilot study suggests that telemedicine-based management of OSA patients is feasible in terms of patient functional outcomes and overall satisfaction with care. Future studies should include larger populations to further elucidate these findings while assessing provider-and patient-related cost effectiveness. C1 [Fields, Barry G.] Emory Univ, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA. [Fields, Barry G.] Atlanta Vet Affairs Med Ctr, Decatur, GA 30030 USA. [Behari, Pratima Pathak; McCloskey, Susan; True, Gala; Richardson, Diane; Thomasson, Arwin; Korom-Djakovic, Danijela; Davies, Keith; Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Behari, Pratima Pathak; Kuna, Samuel T.] Univ Penn, Perelman Sch Med, Div Sleep Med, Philadelphia, PA 19104 USA. [Behari, Pratima Pathak; Kuna, Samuel T.] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Thomasson, Arwin] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Fields, BG (reprint author), Atlanta Vet Affairs Med Ctr, Sleep Med Ctr, 250 N Arcadia Ave, Decatur, GA 30030 USA. EM barry.fields@va.gov FU VISN 4 Competitive Pilot Project Fund FX This was not an industry supported study. Financial support was provided by VISN 4 Competitive Pilot Project Fund. The authors have indicated no financial conflicts of interest. NR 40 TC 5 Z9 5 U1 1 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 501 EP 509 AR PII sp-00254-15 DI 10.5665/sleep.5514 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800004 PM 26446115 ER PT J AU Stone, KL Blackwell, TL Ancoli-Israel, S Barrett-Connor, E Bauer, DC Cauley, JA Ensrud, KE Hoffman, AR Mehra, R Stefanick, ML Varosy, PD Yaffe, K Redline, S AF Stone, Katie L. Blackwell, Terri L. Ancoli-Israel, Sonia Barrett-Connor, Elizabeth Bauer, Douglas C. Cauley, Jane A. Ensrud, Kristine E. Hoffman, Andrew R. Mehra, Reena Stefanick, Marcia L. Varosy, Paul D. Yaffe, Kristine Redline, Susan CA Osteoporotic Fractures Men MrOS St TI Sleep Disordered Breathing and Risk of Stroke in Older Community-Dwelling Men SO SLEEP LA English DT Article DE stroke; sleep disordered breathing; nocturnal hypoxemia ID OSTEOPOROTIC FRACTURES; INSULIN-RESISTANCE; ISCHEMIC-STROKE; APNEA; SCALE; DETERMINANTS; ASSOCIATION; UPDATE; HEALTH; MROS AB Study Objectives: Men with sleep disordered breathing (SDB) may be at increased stroke risk, due to nocturnal hypoxemia, sleep loss or fragmentation, or other mechanisms. We examined the association of SDB with risk of incident stroke in a large cohort of older men. Methods: Participants were 2,872 community-dwelling men (mean age 76 years) enrolled in the MrOS Sleep Study, which gathered data from 2003 to 2005 at six clinical sites in the Unites States. SDB predictors (obstructive apnea-hypopnea index, apnea-hypopnea index, central apnea index, and nocturnal hypoxemia) were measured using overnight polysomnography. Incident stroke over an average follow-up of 7.3 years was centrally adjudicated by physician review of medical records. Results: One hundred fifty-six men (5.4%) had a stroke during follow-up. After adjustment for age, clinic site, race, body mass index, and smoking status, older men with severe nocturnal hypoxemia (>= 10% of the night with SpO(2) levels below 90%) had a 1.8-fold increased risk of incident stroke compared to those without nocturnal hypoxemia (relative hazard = 1.83; 95% confidence interval 1.12-2.98; P trend = 0.02). Results were similar after further adjustment for other potential covariates and after excluding men with a history of stroke. Other indices of SDB were not associated with incident stroke. Conclusions: Older men with severe nocturnal hypoxemia are at significantly increased risk of incident stroke. Measures of overnight oxygen saturation may better identify older men at risk for stroke than measures of apnea frequency. C1 [Stone, Katie L.; Blackwell, Terri L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Stone, Katie L.; Blackwell, Terri L.] San Francisco Coordinating Ctr, San Francisco, CA 94158 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA. [Bauer, Douglas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Ensrud, Kristine E.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA. [Ensrud, Kristine E.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Hoffman, Andrew R.; Stefanick, Marcia L.] Stanford Univ, Stanford Prevent Res Ctr, Dept Med, Palo Alto, CA 94304 USA. [Mehra, Reena] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Sleep Ctr,Neurol Inst, Cleveland, OH 44106 USA. [Varosy, Paul D.] Univ Colorado, Denver, CO 80202 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Redline, Susan] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Redline, Susan] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. RP Stone, KL (reprint author), San Francisco Coordinating Ctr, Res Inst, Calif Pacific Med Ctr, Mission Hall Global Hlth & Clin Sci Bldg, San Francisco, CA 94158 USA. EM kstone@sfcc-cpmc.net RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408; Mehra, Reena/0000-0002-6222-2675 FU National Institutes of Health; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; National Heart, Lung, and Blood Institute (NHLBI) [R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, R01 HL070839, R01 HL089467]; K 24 grant [AG031155]; ResMed, Inc; Philips Respironics; ResMed Foundation FX This was not an industry supported study. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. The National Heart, Lung, and Blood Institute (NHLBI) provides funding for the MrOS Sleep ancillary study "Outcomes of Sleep Disorders in Older Men" under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839. Dr Yaffe received funding from K 24 grant AG031155. The measurement of inflammation markers was funded by the NHLBI, grant number R01 HL089467. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the decision to submit the manuscript for publication. Dr. Stone has consulted for Merck. Dr. Ancoli-Israel is a consultant for Merck and Purdue University. Dr. Redline's institution has received grant funding from ResMed, Inc, Philips Respironics, and ResMed Foundation and equipment from them for use in NIH studies. The other authors have indicated no financial conflicts of interest. Analysis was performed at California Pacific Medical Center, Research Institute. NR 29 TC 1 Z9 1 U1 0 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 531 EP 540 AR PII sp-00349-15 DI 10.5665/sleep.5520 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800007 PM 26943468 ER PT J AU Lyamin, OI Lapierre, JL Kosenko, PO Kodama, T Bhagwandin, A Korneva, SM Peever, JH Mukhametov, LM Siegel, JM AF Lyamin, Oleg I. Lapierre, Jennifer L. Kosenko, Peter O. Kodama, Tohru Bhagwandin, Adhil Korneva, Svetlana M. Peever, John H. Mukhametov, Lev M. Siegel, Jerome M. TI Monoamine Release during Unihemispheric Sleep and Unihemispheric Waking in the Fur Seal SO SLEEP LA English DT Article DE unihemispheric sleep; norepinephrine; histamine; serotonin; acetylcholine; fur seal; marine mammals ID SLOW-WAVE SLEEP; BASAL FOREBRAIN NEURONS; SEROTONERGIC NEURONS; WAKE CYCLE; ACETYLCHOLINE-RELEASE; NUCLEUS BASALIS; WAKEFULNESS; HYPOCRETIN; HISTAMINE; CATAPLEXY AB Study Objectives: Our understanding of the role of neurotransmitters in the control of the electroencephalogram (EEG) has been entirely based on studies of animals with bilateral sleep. The study of animals with unihemispheric sleep presents the opportunity of separating the neurochemical substrates of waking and sleep EEG from the systemic, bilateral correlates of sleep and waking states. Methods: The release of histamine (HI), norepinephrine (NE), and serotonin (5HT) in cortical and subcortical areas (hypothalamus, thalamus and caudate nucleus) was measured in unrestrained northern fur seals (Callorhinus ursinus) using in vivo microdialysis, in combination with, polygraphic recording of EEG, electrooculogram, and neck electromyogram. Results: The pattern of cortical and subcortical HI, NE, and 5HT release in fur seals is similar during bilaterally symmetrical states: highest in active waking, reduced in quiet waking and bilateral slow wave sleep, and lowest in rapid eye movement (REM) sleep. Cortical and subcortical HI, NE, and 5HT release in seals is highly elevated during certain waking stimuli and behaviors, such as being sprayed with water and feeding. However, in contrast to acetylcholine (ACh), which we have previously studied, the release of HI, NE, and 5HT during unihemispheric sleep is not lateralized in the fur seal. Conclusions: Among the studied neurotransmitters most strongly implicated in waking control, only ACh release is asymmetric in unihemispheric sleep and waking, being greatly increased on the activated side of the brain. C1 [Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Lyamin, Oleg I.; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Lyamin, Oleg I.; Mukhametov, Lev M.] RAS, Severtsov Inst Ecol & Evolut, Moscow 117901, Russia. [Lyamin, Oleg I.; Kosenko, Peter O.; Korneva, Svetlana M.; Mukhametov, Lev M.] Utrish Dolphinarium Ltd, Moscow, Russia. [Lapierre, Jennifer L.; Peever, John H.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada. [Kosenko, Peter O.] Southern Fed Univ, Rostov Na Donu, Russia. [Kodama, Tohru] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Tokyo 113, Japan. [Bhagwandin, Adhil] Univ Witwatersrand, Fac Hlth Sci, Sch Anat Sci, Johannesburg, South Africa. RP Siegel, JM (reprint author), Univ Calif Los Angeles, VA GLAHS Sepulveda, Neurobiol Res 151A3, 16111 Plummer St North Hills, Los Angeles, CA 91343 USA. EM jsiegel@ucla.edu FU National Science Foundation [0919929]; National Institute of Health [MH064109, DA034748]; Russian Fund for Basic Research [13-04-01704, 14-04-32075]; Medical Research Service of the Dept. of Veterans Affairs; Utrish Dolphinarium Ltd.; National Science and Engineering Council of Canada; Canadian Institutes of Health Research FX This was not an industry supported study. This study was supported by grants from National Science Foundation (0919929), National Institute of Health MH064109, DA034748, Russian Fund for Basic Research (13-04-01704, 14-04-32075), Medical Research Service of the Dept. of Veterans Affairs, Utrish Dolphinarium Ltd., National Science and Engineering Council of Canada, and Canadian Institutes of Health Research. The authors have indicated no financial conflicts of interest. This study was performed at the University of California Los Angeles, Los Angeles, USA and Severtsov Institute of Ecology and Evolution, Moscow, Russia. NR 39 TC 2 Z9 2 U1 7 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2016 VL 39 IS 3 BP 625 EP 636 AR PII sp-00454-15 DI 10.5665/sleep.5540 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF1RB UT WOS:000371115800017 PM 26715233 ER PT J AU Chiao, E Stier, EA AF Chiao, Elizabeth Stier, Elizabeth A. TI Prevalence of anal human papillomavirus infection and anal human papillomavirus-related disorders in women: a systematic review REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Chiao, Elizabeth] Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. [Stier, Elizabeth A.] Boston Med Ctr, Dept Obstet & Gynecol, Boston, MA USA. RP Chiao, E (reprint author), Baylor Coll Med, Dept Med, Ctr Innovat Qual Effectiveness & Safety, Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. EM echiao@bcm.edu NR 3 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD MAR PY 2016 VL 214 IS 3 BP 411 EP 412 DI 10.1016/j.ajog.2015.10.917 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DF0JC UT WOS:000371024100049 PM 26522860 ER PT J AU Luo, SX Huang, EJ AF Luo, Sarah X. Huang, Eric J. TI Dopaminergic Neurons and Brain Reward Pathways From Neurogenesis to Circuit Assembly SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Review ID ENTERIC NERVOUS-SYSTEM; TGF-BETA SUPERFAMILY; EMBRYONIC STEM-CELLS; GROWTH-FACTOR-BETA; SURVIVAL IN-VIVO; SONIC-HEDGEHOG; VENTRAL MIDBRAIN; BASAL GANGLIA; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA AB Midbrain dopaminergic (DA) neurons in the substantia nigra pars compacta and ventral tegmental area regulate extrapyramidal movement and important cognitive functions, including motivation, reward associations, and habit learning. Dysfunctions in DA neuron circuitry have been implicated in several neuropsychiatric disorders, including addiction and schizophrenia, whereas selective degeneration of DA neurons in substantia nigra pars compacta is a key neuropathological feature in Parkinson disease. Efforts to understand these disorders have focused on dissecting the underlying causes, as well as developing therapeutic strategies to replenish dopamine deficiency. In particular, the promise of cell replacement therapies for clinical intervention has led to extensive research in the identification of mechanisms involved in DA neuron development. It is hoped that a comprehensive understanding of these mechanisms will Lead to therapeutic strategies that improve the efficiency of DA neuron production, engraftment, and function. This review provides a comprehensive discussion on how Wnta-catenin and sonic hedgehog Smoothened signaling mechanisms control the specification and expansion of DA progenitors and the differentiation of DA neurons. We also discuss how mechanisms involving transforming growth factor-beta and transcriptional cofactor homeodomain interacting protein kinase 2 regulate the survival and maturation of DA neurons in early postnatal life. These results not only reveal fundamental mechanisms regulating DA neuron development, but also provide important insights to their potential contributions to neuropsychiatric and neurodegenerative diseases. C1 [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Neurosci Grad Program, San Francisco, CA 94143 USA. [Luo, Sarah X.; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA. [Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, San Francisco, CA USA. RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA. EM eric.huang2@ucsf.edu OI Huang, Eric/0000-0002-5381-3801 FU NIH [OD010927, OD011915]; Department of Veterans Affairs [BX001108, BX001625]; Singapore Agency for Science, Technology, and Research (A*STAR) Scholar Program; University of California San Francisco Graduate Education in Medical Sciences (GEMS) Scholar Award FX Supported by NIH grants OD010927 and OD011915; the Department of Veterans Affairs grants BX001108 and BX001625 (E.J.H.); the Singapore Agency for Science, Technology, and Research (A*STAR) Scholar Program (S.X.L.); and the University of California San Francisco Graduate Education in Medical Sciences (GEMS) Scholar Award (S.X.L.). NR 100 TC 9 Z9 9 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2016 VL 186 IS 3 BP 478 EP 488 DI 10.1016/j.ajpath.2015.09.023 PG 11 WC Pathology SC Pathology GA DE9WY UT WOS:000370991800003 PM 26724386 ER PT J AU Cholerton, B Larson, EB Quinn, JF Zabetian, CP Mata, IF Keene, CD Flanagan, M Crane, PK Grabowski, TJ Montine, KS Montine, TJ AF Cholerton, Brenna Larson, Eric B. Quinn, Joseph F. Zabetian, Cyrus P. Mata, Ignacio F. Keene, C. Dirk Flanagan, Margaret Crane, Paul K. Grabowski, Thomas J. Montine, Kathleen S. Montine, Thomas J. TI Precision Medicine Clarity for the Complexity of Dementia SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Review ID ALZHEIMERS ASSOCIATION GUIDELINES; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID TAU; PARKINSONS-DISEASE; NATIONAL INSTITUTE; NEUROPATHOLOGIC ASSESSMENT; COHORT; BRAIN; BETA; RECOMMENDATIONS AB Three key elements to precision medicine are stratification by risk, detection of pathophysiological processes as early as possible (even before clinical presentation), and alignment of mechanism of action of intervention(s) with an individual's molecular driver(s) of disease. Used for decades in the management of some rare diseases and now gaining broad currency in cancer care, a precision medicine approach is beginning to be adapted to cognitive impairment and dementia. This review focuses on the application of precision medicine to address the clinical and biological complexity of two common neurodegenerative causes of dementia: Alzheimer disease and Parkinson disease. C1 [Cholerton, Brenna] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Zabetian, Cyrus P.; Mata, Ignacio F.; Grabowski, Thomas J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Keene, C. Dirk; Flanagan, Margaret; Montine, Kathleen S.; Montine, Thomas J.] Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA. [Crane, Paul K.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Grabowski, Thomas J.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. [Zabetian, Cyrus P.; Mata, Ignacio F.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. RP Montine, TJ (reprint author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA. EM tmontine@uw.edu RI Keene, Christopher/N-1806-2015 FU NIH [P50 AG005136, P50 NS062684, R01 AG042437, R01 NS065070, U01 AG006781]; Office of Research and Development Medical Research Service, Department of Veterans Affairs; Nancy and Buster Alvord Endowment FX Supported by NIH grants P50 AG005136 (T.J.M., C.D.K., T.J.G.), P50 NS062684 (T.J.M., C.P.Z., J.F.Q., T.J.G.), R01 AG042437 (P.K.C.), R01 NS065070 (C.P.Z.), and U01 AG006781 (E.B.L.); the Office of Research and Development Medical Research Service, Department of Veterans Affairs (C.P.Z., J.F.Q.); and the Nancy and Buster Alvord Endowment (T.J.M.). NR 56 TC 7 Z9 7 U1 4 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD MAR PY 2016 VL 186 IS 3 BP 500 EP 506 DI 10.1016/j.ajpath.2015.12.001 PG 7 WC Pathology SC Pathology GA DE9WY UT WOS:000370991800005 PM 26724389 ER PT J AU Benfield, J Maknojia, A Epstein, F AF Benfield, Jon Maknojia, Asif Epstein, Franklin TI Progressive Paraplegia from Spinal Cord Stimulator Lead Fibrotic Encapsulation A Case Report SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Epidural Electrode; Dorsal Myelopathy; Epidural Scar Tissue; Paraplegia; Spinal Cord Stimulator ID REGIONAL PAIN SYNDROME; MYELOPATHY SECONDARY; SCAR TISSUE; FOLLOW-UP; ELECTRODE; COMPLICATIONS; EXPERIENCE; HARDWARE; SURGERY AB Ten years after placement of a spinal cord stimulator (SCS) and resolution of pain, this patient presented with progressive paraplegia, worsening thoracic radicular pain at the same dermatome level of the electrodes, and bowel and bladder incontinence. Computed tomographic myelogram confirmed thoracic spinal cord central canal stenosis at the level of electrodes. After removal of the fibrotic tissue and electrodes, the patient had resolution of his thoracic radicular pain and a return of his pre-SCS pain and minimal neurologic and functional return. To the authors' knowledge, no studies have been identified with thoracic SCS lead fibrosis in the United States causing permanent paraplegia. Only one other case has been reported in Madrid, Spain. Patients with SCS presenting with loss of pain relief, new-onset radicular or neuropathic pain in same dermatome(s) as SCS electrodes, worsening neuromuscular examination, or new bladder or bowel incontinence need to be evaluated for complications regarding SCS implantation causing spinal stenosis and subsequent cord compression to avoid permanent neurologic deficits. C1 [Benfield, Jon] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA. [Maknojia, Asif] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurosurg, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA. [Epstein, Franklin] Audie L Murphy Vet Affairs Hosp, Dept Surg, San Antonio, TX USA. RP Benfield, J (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, 7703 Floyd Curl Dr MC 7843, San Antonio, TX 78229 USA. NR 21 TC 1 Z9 1 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2016 VL 95 IS 3 BP E30 EP E33 DI 10.1097/PHM.0000000000000411 PG 4 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DE9LJ UT WOS:000370958700001 PM 26495817 ER PT J AU Krenek, M Lyons, R Simpson, TL AF Krenek, Marketa Lyons, Robert Simpson, Tracy L. TI Degree of correspondence between daily monitoring and retrospective recall of alcohol use among men and women with comorbid AUD and PTSD SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID TIMELINE FOLLOW-BACK; ECOLOGICAL MOMENTARY ASSESSMENT; POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; VOICE RESPONSE IVR; DRINKING PATTERNS; CONSUMPTION; RELIABILITY; TECHNOLOGY; INSTRUMENT AB Background and ObjectivesThe majority of studies that have identified good correspondence between daily monitoring and retrospective recall of alcohol use have included participants who are relatively stable, are moderate drinkers, report abstinence, and are not diagnosed with comorbid disorders. The current study examined degree of correspondence between alcohol use that was reported daily via interactive voice response (IVR) telephone monitoring and retrospectively using an abbreviated Form-90 (Form-35) covering the same 35-day time period. MethodsParticipants were 54 men and women with comorbid alcohol dependence and posttraumatic stress disorder (PTSD) who reported drinking during the time period. ResultsResults indicated that participants reported more drinking days via IVR. Correspondence was strong between the reporting methods for aggregate-level alcohol use variables, including presence/absence of drinking days and heavy drinking days and standard drinks, and associations increased for weeks closer to the assessment date for drinking days and heavy drinking days. Day-to-day agreement was moderate for drinking days and heavy drinking days, though there was large between-person variability in correspondence between reporting methods. Post-hoc analyzes suggested that men and participants who drink more tend to have lower correspondence between assessment methods. Discussion and ConclusionsOverall, findings partially replicated previous research and extend our knowledge of alcohol assessment in a comorbid sample. Scientific SignificanceFindings highlight the importance of considering the influence that moderating variables have on reporting of alcohol use. (Am J Addict 2016;25:145-151) C1 [Krenek, Marketa; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. [Lyons, Robert] Seattle Inst Biomed & Clin Res, Seattle, WA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Krenek, M (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM marketa.krenek@va.gov FU National Institute on Alcohol Abuse and Alcoholism [1 R21 AA 17130-01]; Department of Defense CDMRP [11152009, W81XWH-BAA-11-1]; NIH/NIAAA [R01 AA 020252-01] FX This work was supported, in part by a grant from the National Institute on Alcohol Abuse and Alcoholism (1 R21 AA 17130-01) awarded to Tracy L. Simpson, PhD and Department of Defense CDMRP grant (11152009, W81XWH-BAA-11-1).; This work also supported in part by a grant from NIH/NIAAA (R01 AA 020252-01). NR 31 TC 1 Z9 1 U1 5 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD MAR PY 2016 VL 25 IS 2 BP 145 EP 151 DI 10.1111/ajad.12342 PG 7 WC Substance Abuse SC Substance Abuse GA DF3IV UT WOS:000371238400011 PM 26824635 ER PT J AU Bamman, MM Wick, TM Carmona-Moran, CA Bridges, SL AF Bamman, Marcas M. Wick, Timothy M. Carmona-Moran, Carlos A. Bridges, S. Louis, Jr. TI Exercise Medicine for Osteoarthritis: Research Strategies to Maximize Effectiveness SO ARTHRITIS CARE & RESEARCH LA English DT Review ID TRANSDERMAL DRUG-DELIVERY; TOTAL HIP-ARTHROPLASTY; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; CLUSTER-ANALYSIS; OLDER-ADULTS; INFLAMMATION; HEALTH; TRIAL; METAANALYSIS C1 [Bamman, Marcas M.] Univ Alabama Birmingham, Ctr Exercise Med & Comprehens Arthrit, Musculoskeletal Bone & Autoimmun Ctr, Birmingham, AL 35294 USA. [Bamman, Marcas M.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Wick, Timothy M.; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Ctr Exercise Med, BioMatrix Engn & Regenerat Med Ctr, Birmingham, AL 35294 USA. [Wick, Timothy M.; Bridges, S. Louis, Jr.] Univ Alabama Birmingham, Comprehens Arthrit Musculoskeletal Bone & Autoimm, Birmingham, AL 35294 USA. [Carmona-Moran, Carlos A.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. RP Bamman, MM (reprint author), Univ Alabama Birmingham, 966 McCallum Bldg,1720 Second Ave South, Birmingham, AL 35294 USA. EM mbamman@uab.edu FU NIH [RO1-HD-084124] FX Drs. Bamman and Bridges' work was supported by the NIH (grant RO1-HD-084124). NR 42 TC 0 Z9 0 U1 3 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2016 VL 68 IS 3 BP 288 EP 291 DI 10.1002/acr.22680 PG 4 WC Rheumatology SC Rheumatology GA DF0VG UT WOS:000371056700002 PM 26239196 ER PT J AU Barrera, TL Szafranski, DD Ratcliff, CG Garnaat, SL Norton, PJ AF Barrera, Terri L. Szafranski, Derek D. Ratcliff, Chelsea G. Garnaat, Sarah L. Norton, Peter J. TI An Experimental Comparison of Techniques: Cognitive Defusion, Cognitive Restructuring, and in-vivo Exposure for Social Anxiety SO BEHAVIOURAL AND COGNITIVE PSYCHOTHERAPY LA English DT Article DE Cognitive defusion; cognitive restructuring; exposure; social anxiety disorder ID THOUGHTS; THERAPY AB Background: One of the primary differences between Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) for anxiety is the approach to managing negative thoughts. CBT focuses on challenging the accuracy of dysfunctional thoughts through cognitive restructuring exercises, whereas ACT attempts to foster acceptance of such thoughts through cognitive defusion exercises. Previous research suggests that both techniques reduce the distress associated with negative thoughts, though questions remain regarding the benefit of these techniques above and beyond exposure to feared stimuli. Aims: In the present study, we conducted a brief experimental intervention to examine the utility of cognitive defusion + in-vivo exposure, cognitive restructuring + in-vivo exposure, and in-vivo exposure alone in reducing the impact of negative thoughts in patients with social anxiety disorder. Method: All participants completed a brief public speaking exposure and those in the cognitive conditions received training in the assigned cognitive technique. Participants returned a week later to complete a second exposure task and self-report measures. Results: All three conditions resulted in similar decreases in discomfort related to negative thoughts. ANOVA models failed to find an interaction between change in accuracy or importance and assignment to condition in predicting decreased distress of negative thoughts. Conclusions: These preliminary results suggest that changes in perceived importance and accuracy of negative thoughts may not be the mechanisms by which cognitive defusion and cognitive restructuring affect distress in the short-term. C1 [Barrera, Terri L.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Barrera, Terri L.] South Cent Mental Illness Res Educ & Clin Ctr, Houston, TX USA. [Szafranski, Derek D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Ratcliff, Chelsea G.] Univ Houston, Houston, TX 77004 USA. [Garnaat, Sarah L.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Norton, Peter J.] Monash Univ, Clayton, Vic 3800, Australia. RP Barrera, TL (reprint author), VA HSR&D Houston Ctr Excellence MEDVAMC 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM terrib@bcm.edu FU University of Houston; Department of Veterans Affairs South Central Mental Illness Research Education and Clinical Center (MIRECC); Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This research was supported by an internal grant from the University of Houston. The research was supported in part by the Department of Veterans Affairs South Central Mental Illness Research Education and Clinical Center (MIRECC), and the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). The views expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or the US Government. Conflict of Interest Statement: The authors declare they have no conflicts of interest to report. NR 6 TC 0 Z9 0 U1 8 U2 19 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1352-4658 EI 1469-1833 J9 BEHAV COGN PSYCHOTH JI Behav. Cognit. Psychther. PD MAR PY 2016 VL 44 IS 2 BP 249 EP 254 DI 10.1017/S1352465814000630 PG 6 WC Psychology, Clinical SC Psychology GA DE8AA UT WOS:000370857000011 PM 25683574 ER PT J AU Singh, JA Shah, N Edwards, NL AF Singh, Jasvinder A. Shah, Nipam Edwards, N. Lawrence TI A cross-sectional internet-based patient survey of the management strategies for gout SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE Gout; Cherry extract; Cherry juice; Complementary medicine; Allopurinol; Febuxostat; Internet study; Survey; Natural supplements; Diet modification ID QUALITY-OF-LIFE; PURINE-RICH FOODS; MEDICAL CONDITIONS; RISK-FACTORS; CARE; HEALTH; ADHERENCE; MEN; HYPERURICEMIA; BARRIERS AB Background: Almost half of the patients with gout are not prescribed urate-lowering therapy (ULT) by their health care provider and > 50 % use complementary and alternative therapies. Diet modification is popular among gout patients due to known associations of certain foods with gout flares. The interplay of the use of dietary supplements, diet modification, and ULT adherence in gout patients is not known. Despite the recent interest in diet and supplements, there are limited data on their use. Our objective was to assess ULT use and adherence and patient preference for non-pharmacological interventions by patients with gout, using a cross-sectional survey. Methods: People who self-reported physician-diagnosed gout during their visit to a gout website (http://gouteducation.org) were invited to participate in a brief anonymous cross-sectional Internet survey between 08/11/2014 to 04/14/2015 about the management of their gout. The survey queried ULT prescription, ULT adherence, the use of non-pharmacological interventions (cherry extract, diet modification) and the likelihood of making a lifelong diet modification for gout management. Results: A total of 499 respondents with a mean age 56.3 years were included; 74 % were males and 74 % were White. Of these, 57 % (285/499) participants were prescribed a ULT for gout, of whom 88 % (251/285) were currently taking ULT. Of those using ULT, 78 % (97/251) reported ULT adherence > 80 %. Gender, race, and age were not significantly associated with the likelihood of receiving a ULT prescription or ULT adherence > 80 %. Fifty-six percent of patients with gout preferred ULT as a lifelong treatment for gout, 24 % preferred cherry extract and 16 % preferred diet modification (4 % preferred none). Men had significantly lower odds of preferring ULT as the lifelong treatment choice for gout vs. other choices (p = 0.03). We found that 38.3 % participants were highly motivated to make a lifelong dietary modification to improve their gout (score of 9-10 on a 0-10 likelihood scale). Older age was significantly associated with high level of willingness to modify diet (p = 0.02). Conclusion: We found that only 57 % of gout patients reported being prescribed ULT. 40 % of gout patients preferred non-pharmacological interventions such as cherry extract and diet modification for gout management. The latter finding requires further investigation. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.; Shah, Nipam] Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Shah, Nipam] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Edwards, N. Lawrence] Univ Florida, Dept Med, Gainesville, FL USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Med, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. EM Jasvinder.md@gmail.com FU Division of Rheumatology at the University of Alabama at Birmingham FX This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Center, Alabama, USA. NR 37 TC 0 Z9 0 U1 5 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD MAR 1 PY 2016 VL 16 AR 90 DI 10.1186/s12906-016-1067-3 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DF1RO UT WOS:000371117100002 PM 26931313 ER PT J AU Mor, V Joyce, NR Cote, DL Gidwani, RA Ersek, M Levy, CR Faricy-Anderson, KE Miller, SC Wagner, TH Kinosian, BP Lorenz, KA Shreve, ST AF Mor, Vincent Joyce, Nina R. Cote, Danielle L. Gidwani, Risha A. Ersek, Mary Levy, Cari R. Faricy-Anderson, Katherine E. Miller, Susan C. Wagner, Todd H. Kinosian, Bruce P. Lorenz, Karl A. Shreve, Scott T. TI The rise of concurrent care for veterans with advanced cancer at the end of life SO CANCER LA English DT Article DE end-of-life care; hospices; neoplasms; palliative care; veterans ID HOSPICE ELIGIBILITY CRITERIA; PALLIATIVE CARE; MEDICARE; QUALITY; COSTS; ASSOCIATION; OUTCOMES; BENEFIT AB BACKGROUNDUnlike Medicare, the Veterans Health Administration (VA) health care system does not require veterans with cancer to make the terrible choice between receipt of hospice services or disease-modifying chemotherapy/radiation therapy. For this report, the authors characterized the VA's provision of concurrent care, defined as days in the last 6 months of life during which veterans simultaneously received hospice services and chemotherapy or radiation therapy. METHODSThis retrospective cohort study included veteran decedents with cancer during 2006 through 2012 who were identified from claims with cancer diagnoses. Hospice and cancer treatment were identified using VA and Medicare administrative data. Descriptive statistics were used to characterize the changes in concurrent care, hospice, palliative care, and chemotherapy or radiation treatment. RESULTSThe proportion of veterans receiving chemotherapy or radiation therapy remained stable at approximately 45%, whereas the proportion of veterans who received hospice increased from 55% to 68%. The receipt of concurrent care also increased during this time from 16.2% to 24.5%. The median time between hospice initiation and death remained stable at around 21 days. Among veterans who received chemotherapy or radiation therapy in their last 6 months of life, the median time between treatment termination and death ranged from 35 to 40 days. There was considerable variation between VA medical centers in the use of concurrent care (interquartile range, 16%-34% in 2012). CONCLUSIONSConcurrent receipt of hospice and chemotherapy or radiation therapy increased among veterans dying from cancer without reductions in the receipt of cancer therapy. This approach reflects the expansion of hospice services in the VA with VA policy allowing the concurrent receipt of hospice and antineoplastic therapies. (c) 2015 American Cancer Society. C1 [Mor, Vincent; Joyce, Nina R.; Cote, Danielle L.; Faricy-Anderson, Katherine E.; Miller, Susan C.] Providence Vet Hlth Adm VA Med Ctr, Ctr Innovat, Providence, RI USA. [Mor, Vincent; Miller, Susan C.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA. [Joyce, Nina R.] Harvard Univ, Sch Med, Dept Hlth Policy, Boston, MA USA. [Gidwani, Risha A.; Wagner, Todd H.] VA Palo Alto Healthcare Syst, VA Hlth Econ Resource Ctr, Palo Alto, CA USA. [Gidwani, Risha A.; Wagner, Todd H.; Lorenz, Karl A.] VA Palo Alto Healthcare Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Gidwani, Risha A.; Wagner, Todd H.; Lorenz, Karl A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Ersek, Mary; Kinosian, Bruce P.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA. [Ersek, Mary] US Dept Vet Affairs, Natl Performance Reporting & Outcomes Measurement, Washington, DC USA. [Levy, Cari R.] Eastern Colorado VA Healthcare Syst, Denver, CO USA. [Faricy-Anderson, Katherine E.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Kinosian, Bruce P.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Shreve, Scott T.] US Dept Vet Affairs, Hosp & Palliat Care Program, Washington, DC USA. [Shreve, Scott T.] Penn State Coll Med, Hershey, PA USA. RP Mor, V (reprint author), 121 South Main St,Box G-121-6, Providence, RI 02912 USA. EM vincent_mor@brown.edu FU US Department of Veterans Affairs [IIR 12-121]; Merit Review Award from Health Services Research and Development Service FX This work was supported by a Merit Review Award (IIR 12-121) from the Health Services Research and Development Service, US Department of Veterans Affairs. NR 21 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD MAR 1 PY 2016 VL 122 IS 5 BP 782 EP 790 DI 10.1002/cncr.29827 PG 9 WC Oncology SC Oncology GA DF2IP UT WOS:000371166300019 PM 26670795 ER PT J AU Rogal, SS Yan, P Rimland, D Lo Re, V Al-Rowais, H Fried, L Butt, AA AF Rogal, Shari S. Yan, Peng Rimland, David Lo Re, Vincent, III Al-Rowais, Hind Fried, Linda Butt, Adeel A. CA Erchives Elect Retrieved Cohort TI Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE CKD; HCV; Progressive CKD ID VIRUS-INFECTION; RENAL-DISEASE; UNITED-STATES; ASSOCIATION; VETERANS; RISK; FIBROSIS; SURVIVAL; THERAPY; COHORT AB We aimed to assess the incidence and progression of chronic kidney disease (CKD) following hepatitis C virus (HCV) seroconversion. This retrospective cohort study included Veterans with a confirmed HCV seroconversion between 2001 and 2014 and Veterans with negative HCV testing over the same time period. The outcomes included development of advanced CKD (eGFR < 60 mL/min/1.73 m(2) on two separate occasions at least 90 days apart, plus a a parts per thousand yen10 mL/min/1.73 m(2) decline from baseline) and progressive CKD (decline in eGFR of a parts per thousand yen30 mL/min/1.73 m(2) from baseline). Multivariable Cox proportional hazards models were used to evaluate the association between HCV and incident advanced and progressive CKD. The final cohort consisted of 71,528 Veterans, including 2589 with recently seroconverted HCV. Over a mean follow-up of 6 years, 36 % of patients with and 31 % without HCV developed advanced CKD (p < 0.001), and 35 % of patients with vs. 26 % without HCV developed progressive CKD (p < 0.001). After controlling for traditional risk factors, recently seroconverted HCV+ patients were significantly less likely to develop advanced CKD (HR 0.86; 95 % CI 0.79, 0.92), and HCV status was not significantly associated with progressive CKD (HR 0.93; 95 % CI 0.86, 1.00). Factors associated with developing advanced and progressive CKD included older age, female sex, diabetes, hypertension, development of cirrhosis, and substance abuse. In this cohort of newly infected US Veterans, HCV infection was associated with decreased incidence of advanced and unchanged risk of progressive CKD, suggesting a larger role for traditional risk factors in the development of CKD after HCV seroconversion. C1 [Rogal, Shari S.; Yan, Peng; Fried, Linda; Butt, Adeel A.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA. [Rogal, Shari S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Rimland, David] Atlanta VA Med Ctr, Decatur, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Al-Rowais, Hind] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA USA. [Fried, Linda; Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar. RP Rogal, SS (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C, Pittsburgh, PA 15240 USA.; Rogal, SS (reprint author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. EM rogalss@upmc.edu FU Gilead Sciences; AbbVie FX Dr. Butt reports grants (to the institution) from Gilead Sciences and AbbVie. Dr. Rogal reports a grant (to the institution) from Gilead Sciences. The other authors report no conflict of interest related to the submitted work. NR 33 TC 1 Z9 1 U1 49 U2 49 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2016 VL 61 IS 3 BP 930 EP 936 DI 10.1007/s10620-015-3918-z PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE9KT UT WOS:000370957000035 PM 26526451 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. CA USPSTF TI Screening for Impaired Visual Acuity in Older Adults US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID INTRAOCULAR-LENS IMPLANTATION; RANDOMIZED CONTROLLED-TRIAL; EYE CATARACT-SURGERY; MACULAR DEGENERATION; UNITED-STATES; CONTRAST SENSITIVITY; HEALTH-STATUS; PEOPLE; FALLS; RISK AB DESCRIPTION Update of the US Preventive Services Task Force (USPSTF) recommendation on screening for impaired visual acuity in older adults. METHODS The USPSTF reviewed the evidence on screening for visual acuity impairment associated with uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in the primary care setting; the benefits and harms of screening; the accuracy of screening; and the benefits and harms of treatment of early vision impairment due to uncorrected refractive error, cataracts, and age-related macular degeneration. POPULATION This recommendation applies to asymptomatic adults 65 years or older who do not present to their primary care clinician with vision problems. RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults. (I statement) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI 53706 USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM chair@uspstf.net OI Phillips, William/0000-0003-2802-4349 FU Agency for Healthcare Research and Quality (AHRQ) FX The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF. NR 31 TC 2 Z9 2 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 1 PY 2016 VL 315 IS 9 BP 908 EP 914 DI 10.1001/jama.2016.0763 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DF1DB UT WOS:000371077500021 ER PT J AU Barnett, ML Mehrotra, A Frolkis, JP Spinks, M Steiger, C Hehir, B Greenberg, JO Singh, H AF Barnett, Michael L. Mehrotra, Ateev Frolkis, Joseph P. Spinks, Melissa Steiger, Casey Hehir, Brandon Greenberg, Jeffrey O. Singh, Hardeep TI Implementation Science Workshop: Implementation of an Electronic Referral System in a Large Academic Medical Center SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE health information technology; program evaluation; primary care; implementation science ID HEALTH-CARE; FOLLOW-UP; GENERAL-PRACTITIONERS; PATIENT-SAFETY; SPECIALTY CARE; UNITED-STATES; COMMUNICATION; MODEL; RECORDS; NEIGHBORHOOD C1 [Barnett, Michael L.; Frolkis, Joseph P.; Greenberg, Jeffrey O.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA. [Steiger, Casey; Hehir, Brandon; Greenberg, Jeffrey O.] Brigham & Womens Phys Org, Boston, MA USA. [Spinks, Melissa] Par8o Inc, Newton, MA USA. [Barnett, Michael L.; Mehrotra, Ateev] Harvard Univ, Sch Med, Dept Hlth Care Policy, 180A Longwood Ave, Boston, MA 02115 USA. [Singh, Hardeep] Houston Vet Affairs Ctr Innovat Qual Effectivenes, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA. RP Barnett, ML (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180A Longwood Ave, Boston, MA 02115 USA. EM mlb748@mail.harvard.edu FU AHRQ HHS [R01 HS022087, R01HS022087]; PHS HHS [T32-HP10251] NR 53 TC 0 Z9 0 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2016 VL 31 IS 3 BP 343 EP 352 DI 10.1007/s11606-015-3516-y PG 10 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DF2HE UT WOS:000371162400023 PM 26556594 ER PT J AU Newell, J Yesavage, JA Taylor, JL Kraemer, HC Munro, CA Friedman, L Rosenberg, PB Madore, M Chao, SZ Devanand, DP Drye, LT Mintzer, JE Pollock, BG Porsteinsson, AP Schneider, LS Shade, DM Weintraub, D Lyketsos, CG Noda, A AF Newell, Jeffery Yesavage, Jerome A. Taylor, Joy L. Kraemer, Helena C. Munro, Cynthia A. Friedman, Leah Rosenberg, Paul B. Madore, Michelle Chao, Steven Z. Devanand, D. P. Drye, Lea T. Mintzer, Jacobo E. Pollock, Bruce G. Porsteinsson, Anton P. Schneider, Lon S. Shade, David M. Weintraub, Daniel Lyketsos, Constantine G. Noda, Art CA CitAD Res Grp TI Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Agitation; Sedation; Citalopram ID DEMENTIA; AGGRESSION; CLINICIAN; TRIAL AB Background: We found a benefit of citalopram for agitation in the Citalopram for Agitation in Alzheimer's Disease study (CitAD), and wondered if this was mediated by a sedative effect. CitAD was a randomized, placebo-controlled, double-blind, parallel group trial conducted at 8 academic centers in the United States and Canada from August 2009 to January 2013. One hundred sixty-two participants with probable Alzheimer's disease (AD) and clinically significant agitation were analyzed in this study. Participants received a psychosocial intervention and were randomized to receive either citalopram or placebo (approximately half assigned to each group). Participants were rated on the Neurobehavioral Rating Scale Agitation subscale and measures of sedation (i.e., fatigue and somnolence). Methods: Using the MacArthur Foundation procedures for documenting a mediator effect, we performed a secondary analysis examining whether sedation mediates the effect of treatment on agitation outcome. Results: We found a statistically significant mediating effect of sedation on agitation outcomes, but the magnitude of the effect was small, only explaining 11% of the variance in agitation, with a significant, but modest effect size of 0.16 (95% CI: 0.08 to 0.22). Conclusions: The benefit of citalopram was partly due to sedation but largely due to other mechanisms of action. Published by Elsevier Ltd. C1 [Newell, Jeffery] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. [Yesavage, Jerome A.; Taylor, Joy L.; Madore, Michelle; Chao, Steven Z.] Dept Vet Affairs Hlth Care Syst, Palo Alto, CA 94304 USA. [Yesavage, Jerome A.; Taylor, Joy L.; Kraemer, Helena C.; Friedman, Leah; Madore, Michelle; Noda, Art] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Yesavage, Jerome A.; Chao, Steven Z.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. [Munro, Cynthia A.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Bayview Med Ctr, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Munro, Cynthia A.; Rosenberg, Paul B.; Lyketsos, Constantine G.] Johns Hopkins Sch Med, Baltimore, MD 21205 USA. [Devanand, D. P.] New York State Psychiat Inst & Hosp, Div Geriatr Psychiat, New York, NY 10032 USA. [Devanand, D. P.] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. [Drye, Lea T.; Shade, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Mintzer, Jacobo E.] Roper St Francis Healthcare, Clin Biotechnol Res Inst, Charleston, SC 29401 USA. [Mintzer, Jacobo E.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. [Pollock, Bruce G.] Univ Toronto, CAMH, Campbell Inst, Toronto, ON M5S 2S1, Canada. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Dept Vet Affairs, Philadelphia, PA 19104 USA. RP Yesavage, JA (reprint author), Palo Alto VA Hlth Care Syst, 3801 Miranda Ave 151Y, Palo Alto, CA 94304 USA. EM yesavage@stanford.edu FU NIA and NIMH [R01AG031348]; NIH [AG05142, P50]; Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC); Medical Research Service of Department of Veterans Affairs FX This work was supported by NIA and NIMH, R01AG031348 and in part by NIH P50, AG05142 (USC, LSS). and by the Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) and the Medical Research Service of the Department of Veterans Affairs. The funding sources had a role in in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. NR 15 TC 2 Z9 2 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD MAR PY 2016 VL 74 BP 17 EP 21 DI 10.1016/j.jpsychires.2015.12.005 PG 5 WC Psychiatry SC Psychiatry GA DE8RS UT WOS:000370905000004 PM 26736036 ER PT J AU Peralta, CA Bibbins-Domingo, K Vittinghoff, E Lin, F Fornage, M Kopp, JB Winkler, CA AF Peralta, Carmen A. Bibbins-Domingo, Kirsten Vittinghoff, Eric Lin, Feng Fornage, Myriam Kopp, Jeffrey B. Winkler, Cheryl A. TI APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; AFRICAN-AMERICANS; VARIANTS ASSOCIATE; RACIAL-DIFFERENCES; UNITED-STATES; RISK; MICROALBUMINURIA; INSUFFICIENCY; NEPHROPATHY; PROGRESSION AB Variants in the APOL1 gene are associated with kidney disease in blacks. We examined associations of APOL1 with incident albuminuria and kidney function decline among 3030 young adults with preserved GFR in the Coronary Artery Risk Development in Young Adults (CARDIA) study. eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio were measured at scheduled examinations. Participants were white (n=1700), high-risk black (two APOL1 risk alleles, n=176), and low-risk black (zero/one risk allele, n=1154). Mean age was 35 years, mean eGFRcys was 107 ml/min per 1.73 m(2), and 13.2% of blacks had two APOL1 alleles. The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6-22.1) for high-risk blacks, 7.8 (6.4-9.4) for low-risk blacks, and 3.9 (3.1-4.8) for whites. Compared with whites, the odds ratio (95% confidence interval) for incident albuminuria was 5.71 (3.64-8.94) for high-risk blacks and 2.32 (1.73-3.13) for low-risk blacks. Adjustment for risk factors attenuated the difference between low-risk blacks and whites (odds ratio 1.21, 95% confidence interval 0.86-1.71). After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites. Low-risk blacks also had a faster yearly eGFRcys decline compared with whites, but this difference was attenuated after adjustment for risk factors and socioeconomic position. In conclusion, blacks with two APOL1 risk alleles had the highest risk for albuminuria and eGFRcys decline in young adulthood, whereas disparities between low-risk blacks and whites were related to differences in traditional risk factors. C1 [Peralta, Carmen A.; Bibbins-Domingo, Kirsten] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Peralta, Carmen A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Vittinghoff, Eric; Lin, Feng] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Kopp, Jeffrey B.] NIDDK, Kidney Dis Branch, Bethesda, MD 20892 USA. [Winkler, Cheryl A.] Leidos Biomed Inc, Basic Res Lab, Ctr Canc Res, Natl Canc Inst,Frederick Natl Lab, Frederick, MD USA. RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [5R03-DK095877-03]; Robert Wood Johnson Harold Amos Program; NIDDK Intramural Research Program; National Cancer Institute, National Institutes of Health (NIH) [HHSN26120080001E]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; National Heart, Lung, and Blood Institute (NHLBI); University of Alabama at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern University [HHSN268201300027C]; University of Minnesota [HHSN268201300028C]; Kaiser Foundation Research Institute [HHSN268201300029C]; Johns Hopkins University School of Medicine [HHSN268200900041C]; Intramural Research Program of the National Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005]; [R01-DK078124]; [P60006902]; [K24-DK103992] FX C.P. is funded by grant 5R03-DK095877-03 from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Robert Wood Johnson Harold Amos Program.; K.B.D. was funded by R01-DK078124, P60006902 and K24-DK103992.; J.B.K. was supported by the NIDDK Intramural Research Program. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health (NIH), under contract HHSN26120080001E.; The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.; The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging (NIA) and an infra-agency agreement between NIA and NHLBI (AG0005). This manuscript has been reviewed by CARDIA for scientific content. NR 23 TC 8 Z9 8 U1 1 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2016 VL 27 IS 3 BP 887 EP 893 DI 10.1681/ASN.2015020124 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA DF1LN UT WOS:000371101400024 PM 26180129 ER PT J AU Sun, C Molineros, JE Looger, LL Zhou, XJ Kim, K Okada, Y Ma, JY Qi, YY Kim-Howard, X Motghare, P Bhattarai, K Adler, A Bang, SY Lee, HS Kim, TH Kang, YM Suh, CH Chung, WT Park, YB Choe, JY Shim, SC Kochi, Y Suzuki, A Kubo, M Sumida, T Yamamoto, K Lee, SS Kim, YJ Han, BG Dozmorov, M Kaufman, KM Wren, JD Harley, JB Shen, N Chua, KH Zhang, H Bae, SC Nath, SK AF Sun, Celi Molineros, Julio E. Looger, Loren L. Zhou, Xu-jie Kim, Kwangwoo Okada, Yukinori Ma, Jianyang Qi, Yuan-yuan Kim-Howard, Xana Motghare, Prasenjeet Bhattarai, Krishna Adler, Adam Bang, So-Young Lee, Hye-Soon Kim, Tae-Hwan Kang, Young Mo Suh, Chang-Hee Chung, Won Tae Park, Yong-Beom Choe, Jung-Yoon Shim, Seung Cheol Kochi, Yuta Suzuki, Akari Kubo, Michiaki Sumida, Takayuki Yamamoto, Kazuhiko Lee, Shin-Seok Kim, Young Jin Han, Bok-Ghee Dozmorov, Mikhail Kaufman, Kenneth M. Wren, Jonathan D. Harley, John B. Shen, Nan Chua, Kek Heng Zhang, Hong Bae, Sang-Cheol Nath, Swapan K. TI High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry SO NATURE GENETICS LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; MULTIPLE AUTOIMMUNE-DISEASES; GENOME-WIDE ASSOCIATION; CD226 GLY307SER ASSOCIATION; PRIMARY SJOGRENS-SYNDROME; WILLIAMS-BEUREN SYNDROME; CHINESE HAN POPULATION; TFII-I; SUSCEPTIBILITY LOCI; CLINICAL-FEATURES AB Systemic lupus erythematosus (SLE) has a strong but incompletely understood genetic architecture. We conducted an association study with replication in 4,478 SLE cases and 12,656 controls from six East Asian cohorts to identify new SLE susceptibility loci and better localize known loci. We identified ten new loci and confirmed 20 known loci with genome-wide significance. Among the new loci, the most significant locus was GTF2IRDI-GTF21 at 7q11.23 (rs73366469, P-meta = 3.75 x 10(-117), odds ratio (OR) = 2.38), followed by DEF6, IL128, TCF7, TERT, CD226, PCNXL3, RASGRP1, SYNGR1 and SIGLEC6. We identified the most likely functional variants at each locus by analyzing epigenetic marks and gene expression data. Ten candidate variants are known to alter gene expression in cis or in trans. Enrichment analysis highlights the importance of these loci in B cell and T cell biology. The new loci, together with previously known loci, increase the explained heritability of SLE to 24%. The new loci share functional and ontological characteristics with previously reported loci and are possible drug targets for SLE therapeutics. C1 [Sun, Celi; Molineros, Julio E.; Kim-Howard, Xana; Motghare, Prasenjeet; Bhattarai, Krishna; Adler, Adam; Wren, Jonathan D.; Nath, Swapan K.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Looger, Loren L.] Janelia Res Campus, Howard Hughes Med Inst, Ashburn, VA USA. [Zhou, Xu-jie; Qi, Yuan-yuan; Zhang, Hong] Peking Univ, Hosp 1, Inst Nephrol, Key Lab Renal Dis,Minist Hlth China,Div Renal, Beijing 100871, Peoples R China. [Zhou, Xu-jie; Qi, Yuan-yuan; Zhang, Hong] Peking Univ, Minist Educ, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing 100871, Peoples R China. [Kim, Kwangwoo; Bang, So-Young; Lee, Hye-Soon; Kim, Tae-Hwan; Bae, Sang-Cheol] Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. [Okada, Yukinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Human Genet & Dis Divers, Tokyo, Japan. [Okada, Yukinori] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan. [Ma, Jianyang; Shen, Nan] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Rheumatol, Shanghai 200030, Peoples R China. [Kang, Young Mo] Kyungpook Natl Univ Hosp, Sch Med, Daegu, South Korea. [Suh, Chang-Hee] Ajou Univ Hosp, Dept Rheumatol, Suwon, South Korea. [Chung, Won Tae] Dong A Univ Hosp, Dept Internal Med, Busan, South Korea. [Park, Yong-Beom] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea. [Choe, Jung-Yoon] Daegu Catholic Univ Hosp, Dept Internal Med, Daegu, South Korea. [Shim, Seung Cheol] Chungnam Natl Univ Hosp, Daejeon Rheumatoid & Degenerat Arthrit Ctr, Daejeon, South Korea. [Kochi, Yuta; Suzuki, Akari; Yamamoto, Kazuhiko] RIKEN, Ctr Integrat Med Sci, Lab Autoimmune Dis, Yokohama, Kanagawa, Japan. [Kubo, Michiaki] RIKEN Ctr Integrat Med Sci, Lab Genotyping Dev, Yokohama, Kanagawa, Japan. [Sumida, Takayuki] Univ Tsukuba, Fac Med, Dept Internal Med, Tsukuba, Ibaraki, Japan. [Yamamoto, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan. [Lee, Shin-Seok] Chonnam Natl Univ Hosp, Dept Rheumatol, Gwangju, South Korea. [Kim, Young Jin; Han, Bok-Ghee] Korea Natl Inst Hlth, Osong, South Korea. [Dozmorov, Mikhail] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA. [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA. [Kaufman, Kenneth M.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Shen, Nan] Cincinnati Childrens Hosp Med Ctr, CAGE, Cincinnati, OH 45229 USA. [Chua, Kek Heng] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia. RP Nath, SK (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.; Bae, SC (reprint author), Hanyang Univ, Dept Rheumatol, Hosp Rheumat Dis, Seoul 133791, South Korea. EM scbae@hanyang.ac.kr; naths@omrf.org OI Suh, Chang-Hee/0000-0001-6156-393X FU Korea Center for Disease Control and Prevention at the Korea National Institute of Health; Ministry of Health and Welfare, Republic of Korea; US National Institutes of Health [AR060366, MD007909, AI103399, AI024717, AI083194, AI107176, TR001425, HG008666, HG006828]; US Department of Defense [PR094002]; US Department of Veterans Affairs; National Basic Research Program of China (973 program) [2014CB541902]; Research Fund of Beijing Municipal Science and Technology for the Outstanding PhD Program [20121000110]; National Natural Science Foundation of China [81200524, 81230072]; High-Impact Research Ministry of Education, Malaysia [UM.C/625/1/HIR/MoE/E000044-20001]; Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea [HI13C2124] FX We are grateful to the affected and unaffected individuals who participated in this study. We thank the research assistants, coordinators and physicians who helped in the recruitment of subjects, including the individuals in the coordinating projects. A part of the Korean control data was provided from the Korean Biobank Project supported by the Korea Center for Disease Control and Prevention at the Korea National Institute of Health. Genomic DNA from similar to 100 Korean patients with SLE was obtained from the Korean National Biobank at Wonkwang University Hospital, which is supported by the Ministry of Health and Welfare, Republic of Korea.; This work was supported by grants from the US National Institutes of Health (AR060366, MD007909, AI103399, AI024717, AI083194, AI107176, TR001425, HG008666 and HG006828), the US Department of Defense (PR094002), the US Department of Veterans Affairs, the National Basic Research Program of China (973 program) (2014CB541902), the Research Fund of Beijing Municipal Science and Technology for the Outstanding PhD Program (20121000110), the National Natural Science Foundation of China (81200524, 81230072) and High-Impact Research Ministry of Education Grant UM.C/625/1/HIR/MoE/E000044-20001, Malaysia. This study was also supported by a grant from the Korea Healthcare Technology R&D Project (HI13C2124), Ministry for Health and Welfare, Republic of Korea. NR 57 TC 14 Z9 15 U1 4 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD MAR PY 2016 VL 48 IS 3 BP 323 EP 330 DI 10.1038/ng.3496 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA DE8QW UT WOS:000370902600018 PM 26808113 ER PT J AU Kosheleva, E Spadoni, AD Strigo, IA Buchsbaum, MS Simmons, AN AF Kosheleva, Elena Spadoni, Andrea D. Strigo, Irina A. Buchsbaum, Monte S. Simmons, Alan N. TI Faking Bad: The Neural Correlates of Feigning Memory Impairment SO NEUROPSYCHOLOGY LA English DT Article DE fMRI; test of memory malingering; anterior cingulate cortex; mild traumatic brain injury; feigning ID TRAUMATIC BRAIN-INJURY; EVENT-RELATED FMRI; ANTERIOR CINGULATE; TEST-PERFORMANCE; WORKING-MEMORY; DECEPTION; ACTIVATION; CORTEX; LIE AB Objective: The detection of malingering in cognitive performance is a challenge in clinical and legal environments. Neuroimaging may provide an objective method for delineation of malingering. Method: A heterogeneous with concern of gender and racial-ethnic identity of 22 healthy volunteers completed the Tombaugh Test of Memory Malingering during an fMRI scan. Subjects were either instructed to perform optimally (not feigning) or to perform "as if they had a mild traumatic brain injury with memory impairment" (feigning). Results: A voxel-based multiple regression analysis revealed that during correct responses there was greater activation in the superior and medial prefrontal cortex during the feigning versus the not-feigning responses. Conclusions: This finding suggests that falsified memory performance requires greater activation of cognitive control networks to determine a correct selection. C1 [Kosheleva, Elena; Spadoni, Andrea D.; Simmons, Alan N.] San Diego Vet Affairs Hlth Care Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Kosheleva, Elena; Spadoni, Andrea D.; Buchsbaum, Monte S.; Simmons, Alan N.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Strigo, Irina A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Strigo, Irina A.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Simmons, AN (reprint author), San Diego VA, 3350 La Jolla Village Dr, San Diego, CA 92161 USA. EM ansimmons@ucsd.edu RI strigo, irina/L-9882-2016 OI strigo, irina/0000-0002-8799-716X FU Department of Veterans Affairs [I01-CX-000715-01, I01-CX-000816-01, 1 IK2 CX000864-01]; VA Center of Excellence in Stress and Mental Health FX This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research. Salary was supported by Department of Veterans Affairs via Merit Grant I01-CX-000715-01 to Alan N. Simmons; Grant I01-CX-000816-01 to Irina A. Strigo; Career Development Grant 1 IK2 CX000864-01 to Andrea D. Spadoni; and the VA Center of Excellence in Stress and Mental Health to Alan N. Simmons, Elena Kosheleva, and Andrea D. Spadoni. NR 46 TC 0 Z9 0 U1 1 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0894-4105 EI 1931-1559 J9 NEUROPSYCHOLOGY JI Neuropsychology PD MAR PY 2016 VL 30 IS 3 BP 377 EP 384 DI 10.1037/neu0000251 PG 8 WC Psychology, Clinical; Neurosciences; Psychology SC Psychology; Neurosciences & Neurology GA DF0ZS UT WOS:000371068800012 PM 26765340 ER PT J AU Patel, AK Newcomb, CW Liesegang, TL Pujari, SS Suhler, EB Thorne, JE Foster, CS Jabs, DA Levy-Clarke, GA Nussenblatt, RB Rosenbaum, JT Sen, HN Artornsombudh, P Kothari, S Kempen, JH AF Patel, Apurva K. Newcomb, Craig W. Liesegang, Teresa L. Pujari, Siddharth S. Suhler, Eric B. Thorne, Jennifer E. Foster, C. Stephen Jabs, Douglas A. Levy-Clarke, Grace A. Nussenblatt, Robert B. Rosenbaum, James T. Sen, H. Nida Artornsombudh, Pichaporn Kothari, Srishti Kempen, John H. CA Systemic Immunosuppressive Therapy TI Risk of Retinal Neovascularization in Cases of Uveitis SO OPHTHALMOLOGY LA English DT Article ID INFLAMMATORY OCULAR NEOVASCULARIZATION; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; POSTERIOR UVEITIS; PARS PLANITIS; DISC NEOVASCULARIZATION; OPTIC DISC; RETINOPATHY; PATHOGENESIS; MECHANISMS AB Purpose: To evaluate the risk of and risk factors for retinal neovascularization (NV) in cases of uveitis. Design: Retrospective cohort study. Participants: Patients with uveitis at 4 US academic ocular inflammation subspecialty practices. Methods: Data were ascertained by standardized chart review. Prevalence data analysis used logistic regression. Incidence data analysis used survival analysis with time-updated covariates where appropriate. Main Outcome Measures: Prevalence and incidence of NV. Results: Among uveitic eyes of 8931 patients presenting for initial evaluation, 106 of 13 810 eyes had NV (prevalence = 0.77%, 95% confidence interval [CI], 0.60-0.90). Eighty-eight more eyes developed NV over 26 465 eye-years (incidence, 0.33%/eye-year; 95% CI, 0.27-0.41). Factors associated with incident NV include age <35 years compared with >35 years (adjusted hazard ratio [aHR], 2.4; 95% CI, 1.5-3.9), current cigarette smoking (aHR, 1.9; 95% CI, 1.1-3.4), and systemic lupus erythematosus (aHR, 3.5, 95% CI, 1.1-11). Recent diagnosis of uveitis was associated with an increased incidence of NV (compared with patients diagnosed >5 years ago, aHR, 2.4 [95% CI, 1.1-5.0] and aHR, 2.6 [95% CI, 1.2-6.0] for diagnosis within <1 year vs. 1-5 years, respectively). Compared with anterior uveitis, intermediate uveitis (aHR, 3.1; 95% CI, 1.5-6.6), posterior uveitis (aHR, 5.2; 95% CI, 2.5-11), and panuveitis (aHR, 4.3; 95% CI, 2.0-9.3) were associated with a similar degree of increased NV incidence. Active (aHR, 2.1, 95% CI, 1.2-3.7) and slightly active (aHR, 2.4, 95% CI, 1.3-4.4) inflammation were associated with an increased incidence of NV compared with inactive inflammation. Neovascularization incidence also was increased with retinal vascular occlusions (aHR, 10, 95% CI, 3.0-33), retinal vascular sheathing (aHR, 2.6, 95% CI, 1.4-4.9), and exudative retinal detachment (aHR, 4.1, 95% CI, 1.3-13). Diabetes mellitus was associated with a somewhat increased incidence of retinal NV (aHR, 2.3, 95% CI, 1.1-4.9), and systemic hypertension (aHR 1.5, 95% CI, 0.89-2.4) was associated with nonsignificantly increased NV incidence. Results were similar in sensitivity analyses excluding the small minority of patients with diabetes mellitus. Conclusions: Retinal NV is a rare complication of uveitis, which occurs more frequently in younger patients, smokers, and those with intermediate/posterior/panuveitis, systemic vasculopathy, retinal vascular disease, or active inflammation. Inflammation and retinal NV likely are linked; additional studies are needed to further elucidate this connection. (C) 2016 by the American Academy of Ophthalmology. C1 [Patel, Apurva K.; Artornsombudh, Pichaporn; Kothari, Srishti; Kempen, John H.] Univ Penn, Scheie Eye Inst, Ophthalmol, Philadelphia, PA 19104 USA. [Newcomb, Craig W.; Kempen, John H.] Univ Penn, Scheie Eye Inst, Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Kempen, John H.] Univ Penn, Scheie Eye Inst, Ocular Inflammat Serv, Philadelphia, PA 19104 USA. [Patel, Apurva K.] Retina Northwest PC, Portland, OR USA. [Liesegang, Teresa L.; Suhler, Eric B.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Ophthalmol, Portland, OR 97201 USA. [Rosenbaum, James T.] Oregon Hlth & Sci Univ, Casey Eye Inst, Internal Med, Portland, OR 97201 USA. [Pujari, Siddharth S.] Om Eye Care Hosp, Belgaum, Karnataka, India. [Pujari, Siddharth S.; Foster, C. Stephen; Artornsombudh, Pichaporn; Kothari, Srishti] Massachusetts Eye Res & Surg Inst, Cambridge, MA USA. [Suhler, Eric B.] Portland VA Med Ctr, Portland, OR USA. [Thorne, Jennifer E.] Johns Hopkins Univ, Sch Med, Ophthalmol, Baltimore, MD USA. [Thorne, Jennifer E.; Jabs, Douglas A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Epidemiol, Baltimore, MD USA. [Foster, C. Stephen] Harvard Univ, Sch Med, Ophthalmol, Boston, MA USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Ophthalmol, New York, NY 10029 USA. [Jabs, Douglas A.] Icahn Sch Med Mt Sinai, Med, New York, NY 10029 USA. [Nussenblatt, Robert B.; Sen, H. Nida] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Levy-Clarke, Grace A.; Rosenbaum, James T.] Devers Eye Inst, Portland, OR USA. [Levy-Clarke, Grace A.] Tampa Bay Uveitis Ctr, Safety Harbor, FL USA. [Artornsombudh, Pichaporn] Chulalongkorn Univ, Div Ophthalmol, Naval Med Dept, Royal Thai Navy,Dept Ophthalmol,Fac Med,Somdech P, Bangkok, Thailand. RP Kempen, JH (reprint author), Univ Penn, Dept Ophthalmol, Ctr Prevent Ophthalmol & Biostat, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA. EM john.kempen@uphs.upenn.edu FU National Eye Institute [EY014943]; Research to Prevent Blindness (RPB); Paul and Evanina Mackall Foundation; Lois Pope Life Foundation; RPB James S. Adams Special Scholar Award; R.P.B. Harrington Special Scholar Award; Research to Prevent Blindness Senior Scientific Investigator Award; intramural funds of the National Eye Institute; Department of Veterans' Affairs FX Supported primarily by National Eye Institute Grant EY014943 (J.H.K.). Additional support was provided by Research to Prevent Blindness (RPB), the Paul and Evanina Mackall Foundation, and the Lois Pope Life Foundation. J.H.K. was an RPB James S. Adams Special Scholar Award recipient, J.E.T. was an R.P.B. Harrington Special Scholar Award recipient, and D.A.J. and J.T.R. were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. G.A.L.-C. was previously supported by and RBN and HNS continues to be supported by intramural funds of the National Eye Institute. E.B.S. receives support from the Department of Veterans' Affairs. None of the sponsors had any role in the design and conduct of the report; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of this manuscript. NR 32 TC 1 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD MAR PY 2016 VL 123 IS 3 BP 646 EP 654 DI 10.1016/j.ophtha.2015.10.056 PG 9 WC Ophthalmology SC Ophthalmology GA DE4UQ UT WOS:000370626300042 PM 26686964 ER PT J AU Chen, Y Seepersaud, R Bensing, BA Sullam, PM Rapoport, TA AF Chen, Yu Seepersaud, Ravin Bensing, Barbara A. Sullam, Paul M. Rapoport, Tom A. TI Mechanism of a cytosolic O-glycosyltransferase essential for the synthesis of a bacterial adhesion protein SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE O-glycosylation; bacterial adhesin; crystal structure; Ser/Thr-rich repeats; enzymatic mechanism ID CELLULOSE-BINDING DOMAIN; RICH REPEAT PROTEINS; ACCESSORY SEC LOCUS; WALL TEICHOIC-ACID; STREPTOCOCCUS-GORDONII; STAPHYLOCOCCUS-AUREUS; SURFACE PROTEIN; LINKED GLYCOSYLATION; GLCNAC TRANSFERASE; ENZYMATIC ANALYSIS AB O-glycosylation of Ser and Thr residues is an important process in all organisms, which is only poorly understood. Such modification is required for the export and function of adhesin proteins that mediate the attachment of pathogenic Gram-positive bacteria to host cells. Here, we have analyzed the mechanism by which the cytosolic O-glycosyltransferase GtfA/B of Streptococcus gordonii modifies the Ser/Thr-rich repeats of adhesin. The enzyme is a tetramer containing two molecules each of GtfA and GtfB. The two subunits have the same fold, but only GtfA contains an active site, whereas GtfB provides the primary binding site for adhesin. During a first phase of glycosylation, the conformation of GtfB is restrained by GtfA to bind substrate with unmodified Ser/Thr residues. In a slow second phase, GtfB recognizes residues that are already modified with N-acetylglucosamine, likely by converting into a relaxed conformation in which one interface with GtfA is broken. These results explain how the glycosyltransferase modifies a progressively changing substrate molecule. C1 [Chen, Yu; Rapoport, Tom A.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA. [Chen, Yu; Rapoport, Tom A.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Seepersaud, Ravin; Bensing, Barbara A.; Sullam, Paul M.] Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Rapoport, TA (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.; Rapoport, TA (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.; Sullam, PM (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Sullam, PM (reprint author), Univ Calif San Francisco, San Francisco, CA 94121 USA. EM paul.sullam@ucsf.edu; tom_rapoport@hms.harvard.edu FU National Institute of General Medical Sciences from the National Institutes of Health (NIH) [P41 GM103403]; DOE Office of Science by Argonne National Laboratory [DE-AC02-06CH11357]; Howard Hughes Medical Institute (HHMI)-Helen Hay Whitney Foundation fellowship; NIH [GM052586]; Department of Veterans Affairs, NIH [R01-AI041513, R01-AI106987]; Northern California Institute for Research and Education FX We thank the staff at the Advanced Photon Source of the Northeastern Collaborative Access Team (NE-CAT) beamline for help with data collection; Phil Jeffrey (Princeton University), Surajit Banerjee (NE-CAT), and Simon Jenni (Harvard Medical School) for help with crystallographic data merging and anisotropy correction; and Stephen Harrison for advice on initial backbone tracing. NE-CAT is supported by National Institute of General Medical Sciences Grant P41 GM103403 from the National Institutes of Health (NIH). This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Y.C. was supported by a Howard Hughes Medical Institute (HHMI)-Helen Hay Whitney Foundation fellowship. The work in the T.A.R. laboratory was supported by NIH Grant GM052586. T.A.R. is an HHMI Investigator. P.M.S. is supported by the Department of Veterans Affairs, NIH Grants R01-AI041513 and R01-AI106987, and the Northern California Institute for Research and Education. NR 53 TC 2 Z9 2 U1 6 U2 17 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 1 PY 2016 VL 113 IS 9 BP E1190 EP E1199 DI 10.1073/pnas.1600494113 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2WG UT WOS:000371204500011 PM 26884191 ER PT J AU Toledo, JB Gopal, P Raible, K Irwin, DJ Brettschneider, J Sedor, S Waits, K Boluda, S Grossman, M Van Deerlin, VM Lee, EB Arnold, SE Duda, JE Hurtig, H Lee, VMY Adler, CH Beach, TG Trojanowski, JQ AF Toledo, Jon B. Gopal, Pallavi Raible, Kevin Irwin, David J. Brettschneider, Johannes Sedor, Samantha Waits, Kayla Boluda, Susana Grossman, Murray Van Deerlin, Vivianna M. Lee, Edward B. Arnold, Steven E. Duda, John E. Hurtig, Howard Lee, Virginia M. -Y. Adler, Charles H. Beach, Thomas G. Trojanowski, John Q. TI Pathological alpha-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology SO ACTA NEUROPATHOLOGICA LA English DT Article DE Alzheimer disease; Parkinson disease; Dementia with Lewy bodies; Neuropathology; Diagnosis; Classification ID SPORADIC PARKINSONS-DISEASE; NEUROPATHOLOGIC ASSESSMENT; ASSOCIATION GUIDELINES; COGNITIVE IMPAIRMENT; DIAGNOSTIC-CRITERIA; NATIONAL INSTITUTE; DONATION PROGRAM; DEMENTIA; BRAIN; BODIES AB We investigated the distribution patterns of Lewy body-related pathology (LRP) and the effect of coincident Alzheimer disease (AD) pathology using a data-driven clustering approach that identified groups with different LRP pathology distributions without any diagnostic or researcher's input in two cohorts including: Parkinson disease patients without (PD, n = 141) and with AD (PD-AD, n = 80), dementia with Lewy bodies subjects without AD (DLB, n = 13) and demented subjects with AD and LRP pathology (Dem-AD-LB, n = 308). The Dem-AD-LB group presented two LRP patterns, olfactory-amygdala and limbic LRP with negligible brainstem pathology, that were absent in the PD groups, which are not currently included in the DLB staging system and lacked extracranial LRP as opposed to the PD group. The Dem-AD-LB individuals showed relative preservation of substantia nigra cells and dopamine active transporter in putamen. PD cases with AD pathology showed increased LRP. The cluster with occipital LRP was associated with non-AD type dementia clinical diagnosis in the Dem-AD-LB group and a faster progression to dementia in the PD groups. We found that (1) LRP pathology in Dem-AD-LB shows a distribution that differs from PD, without significant brainstem or extracranial LRP in initial phases; (2) coincident AD pathology is associated with increased LRP in PD indicating an interaction; (3) LRP and coincident AD pathology independently predict progression to dementia in PD, and (4) evaluation of LRP needs to acknowledge different LRP spreading patterns and evaluate substantia nigra integrity in the neuropathological assessment and consider the implications of neuropathological heterogeneity for clinical and biomarker characterization. C1 [Toledo, Jon B.; Gopal, Pallavi; Raible, Kevin; Irwin, David J.; Brettschneider, Johannes; Sedor, Samantha; Waits, Kayla; Boluda, Susana; Van Deerlin, Vivianna M.; Lee, Edward B.; Lee, Virginia M. -Y.; Trojanowski, John Q.] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Irwin, David J.; Grossman, Murray; Arnold, Steven E.; Hurtig, Howard] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Brettschneider, Johannes] Univ Ulm, Dept Clin Neuroanat & Neurol, D-89069 Ulm, Germany. [Arnold, Steven E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Adler, Charles H.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA. [Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ USA. RP Toledo, JB (reprint author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. EM jtoledo@mail.med.upenn.edu OI Toledo, Jon/0000-0003-4366-9268 FU NIH grants [AG05136, AG006781]; Morris K Udall Center for Parkinson's disease Research Core grants [P50 NS053488, NS062684]; National Institute of Neurological Disorders and Stroke (National Brain and Tissue Resource for Parkinson's Disease and Related Disorders) [U24 NS072026]; National Institute on Aging (Arizona Alzheimer's Disease Core Center) [P30 AG19610]; Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; [NS088341] FX This study was supported by NIH grants: AG05136, AG006781 and Morris K Udall Center for Parkinson's disease Research Core grants P50 NS053488 and NS062684. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. DJI is supported by NS088341. Finally, we thank our patients and their families for making this research possible. NR 47 TC 7 Z9 7 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD MAR PY 2016 VL 131 IS 3 BP 393 EP 409 DI 10.1007/s00401-015-1526-9 PG 17 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DE7LG UT WOS:000370817600005 PM 26721587 ER PT J AU Acharjee, S Teo, KK Jacobs, AK Hartigan, PM Barn, K Gosselin, G Tanguay, JF Maron, DJ Kostuk, WJ Chaitman, BR Mancini, GBJ Spertus, JA Dada, MR Bates, ER Booth, DC Weintraub, WS O'Rourke, RA Boden, WE AF Acharjee, Subroto Teo, Koon K. Jacobs, Alice K. Hartigan, Pamela M. Barn, Kulpreet Gosselin, Gilbert Tanguay, Jean-Francois Maron, David J. Kostuk, William J. Chaitman, Bernard R. Mancini, G. B. John Spertus, John A. Dada, Marcin R. Bates, Eric R. Booth, David C. Weintraub, William S. O'Rourke, Robert A. Boden, William E. TI Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial SO AMERICAN HEART JOURNAL LA English DT Article ID ELEVATION MYOCARDIAL-INFARCTION; ARTERY-DISEASE; GENDER-DIFFERENCES; CONSERVATIVE TREATMENT; UNSTABLE ANGINA; SEX-DIFFERENCES; YENTL-SYNDROME; HEART-DISEASE; MANAGEMENT; MEN AB Objectives To determine whether sex-based differences exist in clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in patients with stable coronary artery disease. Background A prior pre-specified unadjusted analysis from COURAGE showed that women randomized to PCI had a lower rate of death or myocardial infarction during a median 4.6-year follow-up with a trend for interaction with respect to sex. Methods We analyzed outcomes in 338 women (15%) and 1949 men (85%) randomized to PCI plus OMT versus OMT alone after adjustment for relevant baseline characteristics. Results There was no difference in treatment effect by sex for the primary end point (death or myocardial infarction; HR, 0.89; 95% CI, 0.77-1.03 for women and HR, 1.02, 95% CI 0.96-1.10 for men; P for interaction = .07). Although the event rate was low, a trend for interaction by sex was nonetheless noted for hospitalization for heart failure, with only women, but not men, assigned to PCI experiencing significantly fewer events as compared to their counterparts receiving OMT alone (HR, 0.59; 95% CI, 0.40-0.84, P < .001 for women and HR, 0.86; 95% CI, 0.74-1.01, P = .47 for men; P for interaction = .02). Both sexes randomized to PCI experienced significantly reduced need for subsequent revascularization (HR, 0.72; 95% CI, 0.62-0.83, P < .001 for women; HR, 0.84; 95% CI, 0.79-0.89, P < .001 for men; P for interaction = .02) with evidence of a sex-based differential treatment effect. Conclusion In this adjusted analysis of the COURAGE trial, there were no significant differences in treatment effect on major outcomes between men and women. However, women assigned to PCI demonstrated a greater benefit as compared to men, with a reduction in heart failure hospitalization and need for future revascularization. These exploratory observations require further prospective study. C1 [Acharjee, Subroto] Einstein Med Ctr Philadelphia, Philadelphia, PA USA. [Teo, Koon K.] Master Univ, Hamilton Gen Hosp, Hamilton, ON, Canada. [Jacobs, Alice K.] Boston Med Ctr, Boston, MA USA. [Hartigan, Pamela M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Barn, Kulpreet] Geisinger Med Ctr, Danville, PA 17822 USA. [Gosselin, Gilbert; Tanguay, Jean-Francois] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada. [Maron, David J.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Kostuk, William J.] London Hlth Sci Ctr, London, ON, Canada. [Chaitman, Bernard R.] St Louis Univ, Sch Med, St Louis, MT USA. [Mancini, G. B. John] Vancouver Hosp, Vancouver, BC, Canada. [Mancini, G. B. John] Hlth Sci Ctr, Vancouver, BC, Canada. [Spertus, John A.] Mid Amer Heart Inst, Kansas City, MO USA. [Dada, Marcin R.] Hartford Hosp, Hartford, CT 06115 USA. [Bates, Eric R.] Univ Michigan, Ann Arbor, MI 48109 USA. [Booth, David C.] Univ Kentucky, Med Ctr, Lexington, KY USA. [Weintraub, William S.] Christiana Care Hlth Syst, Newark, DE USA. [Weintraub, William S.] Ctr Outcomes Res, Newark, DE USA. [O'Rourke, Robert A.] South Texas Vet Hlth Care Syst, Audie Murphy Campus, San Antonio, TX USA. [Boden, William E.] Albany Med Coll, Stratton VA Med Ctr, Albany, NY 12208 USA. RP Boden, WE (reprint author), Samuel S Stratton VA Med Ctr, 113 Holland Ave, Albany, NY 12208 USA. EM william.boden@va.gov FU Amgen Merck Canada; Sanofi; Astra Zeneca; Gilead FX Dr GB John Mancini: <$10,000 grant, honoraria, speakers bureau: Amgen Merck Canada, Sanofi, Astra Zeneca.; Dr John Spertus: owns the copyright to the Seattle Angina Questionnaire, consultant for United Healthcare, St. Jude Medical, Abbott Vascular and Genentech, research grant from Gilead. NR 32 TC 3 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD MAR PY 2016 VL 173 BP 108 EP 117 DI 10.1016/j.ahj.2015.07.020 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DE7HO UT WOS:000370806800014 PM 26920603 ER PT J AU Levey, AS Bilous, R Shlipak, MG AF Levey, Andrew S. Bilous, Rudy Shlipak, Michael G. TI CKD and Diabetes: What Can We Learn From Their Similarities and Differences? SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; PROGRESSION; PREVENTION; PREDICTION; COMMUNITY; HEALTH; MODEL; CARE C1 [Levey, Andrew S.] Tufts Med Ctr, Boston, MA USA. [Bilous, Rudy] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Levey, AS (reprint author), Tufts Med Ctr, William B Schwartz Div Nephrol, Box 391,800 Washington St, Boston, MA 02111 USA. EM alevey@tuftsmedicalcenter.org NR 21 TC 0 Z9 0 U1 2 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2016 VL 67 IS 3 BP 360 EP 363 DI 10.1053/j.ajkd.2015.12.003 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA DE5UM UT WOS:000370698100008 PM 26916373 ER PT J AU Bhasin, B Velez, JCQ AF Bhasin, Bhavna Velez, Juan Carlos Q. TI Evaluation of Polyuria: The Roles of Solute Loading and Water Diuresis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Polyuria; water diuresis; solute excretion; urinary osmoles; hypernatremia ID NEPHROGENIC DIABETES-INSIPIDUS; SALT WASTING SYNDROME; OSMOTIC DIURESIS; DIFFERENTIAL-DIAGNOSIS; HYPERNATREMIA; HYPONATREMIA; THERAPY; VASOPRESSIN; MECHANISMS; CLEARANCE AB Polyuria, defined as daily urine output in excess of 3.0 to 3.5 L/d, can occur due to solute or water diuresis. Solute-induced polyuria can be seen in hospitalized patients after a high solute load from exogenous protein administration or following relief of urinary obstruction. Similar clinical scenarios are rarely encountered in the outpatient setting. We describe a case of polyuria due to high solute ingestion and excessive water intake leading to a mixed picture of solute and water diuresis. Restriction of the daily solute load and water intake resulted in complete resolution of polyuria. Determination of the daily excreted urinary osmoles may yield important clues to the cause of polyuria and should be included in the routine workup of polyuria. (C) 2016 by the National Kidney Foundation, Inc. C1 [Bhasin, Bhavna; Velez, Juan Carlos Q.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Nephrol Sect, Charleston, SC USA. RP Bhasin, B (reprint author), 96 Jonathan Lucas St,Clinical Sci Bldg, Charleston, SC 29425 USA. EM bhasinb@musc.edu RI Velez, Juan Carlos/N-3782-2016 NR 30 TC 2 Z9 2 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2016 VL 67 IS 3 BP 507 EP 511 DI 10.1053/j.ajkd.2015.10.021 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA DE5UM UT WOS:000370698100025 PM 26687922 ER PT J AU Montgomery, AE Dichter, ME Thomasson, AM Roberts, CB AF Montgomery, Ann E. Dichter, Melissa E. Thomasson, Arwin M. Roberts, Christopher B. TI Services Receipt Following Veteran Outpatients' Positive Screen for Homelessness SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID MENTAL-ILLNESS; SEXUAL TRAUMA; RISK; VIOLENCE; GENDER; IRAQ AB Introduction: The Veterans Health Administration seeks to reduce homelessness among Veterans by identifying, and providing prevention and supportive services to, patients with housing concerns. The objectives of this study were to assess the proportion of Veterans Health Administration patients who received homeless or social work services within 6 months of a positive screen for homelessness or risk in the Veterans Health Administration and the demographic and clinical characteristics that predicted services utilization. Methods: Data were from a cohort of 27,403 Veteran outpatients who screened positive for homelessness or risk between November 1, 2012 and January 31, 2013. During 2013, AORs were calculated using a mixed-effects logistic regression to estimate the likelihood of patients' receipt of VHA homeless or social work services based on demographic and clinical characteristics. Results: The majority of patients received services within 6 months post-screening; predictors of services utilization varied by gender. Among women, diagnosis of drug abuse and psychosis predicted receipt of services, being unmarried increased the odds of using services among those screening positive for homelessness, and a diagnosis of post-traumatic stress disorder increased the odds of receiving services for at-risk women. Among men, being younger, unmarried, not service-connected/Medicaideligible, and having a medical or behavioral health condition predicted receipt of services. Conclusions: Receipt of housing support services among Veterans post-homelessness screening differs by patient demographic and clinical characteristics. Future research should investigate the role that primary and secondary prevention interventions play in Veterans' resolution of risk for homelessness and experience of homelessness. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Montgomery, Ann E.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Dichter, Melissa E.; Thomasson, Arwin M.; Roberts, Christopher B.] US Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Thomasson, Arwin M.] Hosp Univ Penn, Penn Transplant Inst, 3400 Spruce St, Philadelphia, PA 19104 USA. RP Montgomery, AE (reprint author), 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM ann.montgomery2@va.gov FU U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans; Center for Health Equity Research and Promotion FX The contents of this article do not necessarily represent the views of the U.S. Department of Veterans Affairs or the U.S. Government. This study was funded by the U.S. Department of Veterans Affairs, National Center on Homelessness Among Veterans, and Center for Health Equity Research and Promotion. NR 26 TC 0 Z9 0 U1 3 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 336 EP 343 DI 10.1016/j.amepre.2015.06.035 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300009 PM 26564329 ER PT J AU Campbell, JA Walker, RJ Egede, LE AF Campbell, Jennifer A. Walker, Rebekah J. Egede, Leonard E. TI Associations Between Adverse Childhood Experiences, High-Risk Behaviors, and Morbidity in Adulthood SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RETROSPECTIVE COHORT; MENTAL-HEALTH; STATES; DISEASE; DISPARITIES; MORTALITY; IMPACT; DEATH; URBAN; US AB Introduction: Adverse childhood experiences (ACEs) are associated with early mortality and morbidity. This study evaluated the association among ACEs, high-risk health behaviors, and comorbid conditions, as well as the independent effect of ACE components. Methods: Data were analyzed on 48,526 U.S. adults from five states in the 2011 Behavioral Risk Factor Surveillance System survey. Exposures included psychological, physical, and sexual forms of abuse as well as household dysfunction such as substance abuse, mental illness, violence, and incarceration. Main outcome measures included risky behaviors and morbidity measures, including binge drinking, heavy drinking, current smoking, high-risk HIV behavior, obesity, diabetes, myocardial infarction, coronary heart disease, stroke, depression, disability caused by poor health, and use of special equipment because of disability. Multiple logistic regression assessed the independent relationship between ACE score categories and risky behaviors/comorbidities in adulthood, and assessed the independent relationship between individual ACE components and risky behaviors/comorbid conditions in adulthood controlling for covariates. Results: A total of 55.4% of respondents reported at least one ACE and 13.7% reported four or more ACEs. An ACE score >= 4 was associated with increased odds for binge drinking, heavy drinking, smoking, risky HIV behavior, diabetes, myocardial infarction, coronary heart disease, stroke, depression, disability caused by health, and use of special equipment because of disability. In addition, the individual components had different effects on risky behavior and comorbidities. Conclusions: In addition to having a cumulative effect, individual ACE components have differential relationships with risky behaviors, morbidity, and disability in adulthood after controlling for important confounders. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Campbell, Jennifer A.; Walker, Rebekah J.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Med, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA COIN, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA. EM egedel@musc.edu FU National Institute of Diabetes and Digestive and Kidney Disease (Principal Investigator, Leonard Egede) [K24DK093699-02] FX This study was supported by grant K24DK093699-02 from The National Institute of Diabetes and Digestive and Kidney Disease (Principal Investigator, Leonard Egede). LEE obtained funding for the study. JAC, RJW, and LEE designed the study and acquired, analyzed, and interpreted data. JAC, RJW, and LEE developed analysis, contributed to interpretation, and critically revised the manuscript for important intellectual content. All authors approved the final manuscript. This article represents the views of the authors and not those of NIH, Veterans Health Administration, or Health Services Research & Development. NR 38 TC 6 Z9 6 U1 7 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD MAR PY 2016 VL 50 IS 3 BP 344 EP 352 DI 10.1016/j.amepre.2015.07.022 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DD9QI UT WOS:000370260300010 PM 26474668 ER PT J AU Thrift, AP El-Serag, HB AF Thrift, Aaron P. El-Serag, Hashem B. TI Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID UNITED-STATES; BARRETTS-ESOPHAGUS; CIGARETTE-SMOKING; AFRICAN-AMERICANS; RISK; WHITES; TRENDS C1 [Thrift, Aaron P.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [El-Serag, Hashem B.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. RP Thrift, AP (reprint author), Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. NR 16 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2016 VL 14 IS 3 BP 330 EP 332 DI 10.1016/j.cgh.2015.10.028 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1HC UT WOS:000370376700007 PM 26528803 ER PT J AU Kang, XY Zhao, LN Leung, F Luo, H Wang, LM Wu, J Guo, XY Wang, XP Zhang, LH Hui, N Tao, Q Jia, H Liu, ZG Chen, ZQ Liu, JJ Wu, KC Fan, DM Pan, YL Guo, XG AF Kang, Xiaoyu Zhao, Lina Leung, Felix Luo, Hui Wang, Limei Wu, Ji Guo, Xiaoyang Wang, Xiangping Zhang, Linhui Hui, Na Tao, Qin Jia, Hui Liu, Zhiguo Chen, Zhangqin Liu, Junjun Wu, Kaichun Fan, Daiming Pan, Yanglin Guo, Xuegang TI Delivery of Instructions via Mobile Social Media App Increases Quality of Bowel Preparation SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Colon Cancer Screening; Bowel Preparation; ADR ID ADENOMA DETECTION RATE; COLORECTAL-CANCER; COLONOSCOPY PREPARATION; PATIENT EDUCATION; VALIDATION; RISK; RECOMMENDATIONS; INDICATORS; SOCIETY; IMPACT AB BACKGROUND & AIMS: Bowel preparation is closely linked to the quality of colonoscopy. We investigated whether delivery of instructions via a social media app increases the quality of colonoscopy by improving adequacy of bowel preparation. METHODS: We performed a prospective study at 3 endoscopic centers in China of 770 colonoscopy outpatients (18-80 years old) with convenient access to Wechat (a widely used mobile social media app) from May through November 2014. Patients were randomly assigned to groups that received standard education along with delivery of interactive information via Wechat (n = 387) or standard education (controls, n = 383). The primary outcome was proportion of patients with adequate bowel preparation (Ottawa score <6). Secondary outcomes included rates of adenoma detection and cecal intubation, cecal intubation time, rates of incomplete compliance with instructions, and patient willingness to repeat bowel preparation. RESULTS: Demographic features were comparable between the groups. A higher proportion of patients in the group that received social media instruction had adequate bowel preparation than the control group (82.2% vs 69.5%, P < .001). Among patients with successful colonoscopies, the group that received social media instruction had lower mean total and segmental Ottawa scores (P < .05). A higher proportion of patients receiving social media instruction also had cecal intubation (97.2% vs 93.2% in controls, P = .014) and were found to have adenomas (18.6% vs 12.0% in controls, P = .012). CONCLUSIONS: Instruction via a mobile social media app, in conjunction with regular instruction, increases subjective measures of adequacy of bowel preparation. Use of the app significantly increased the proportion of patients with successful cecal intubation and in whom adenomas were detected, indicating increased quality of colonoscopy. ClinicalTrials.gov number: NCT02140827 C1 [Kang, Xiaoyu; Luo, Hui; Guo, Xiaoyang; Wang, Xiangping; Zhang, Linhui; Hui, Na; Tao, Qin; Jia, Hui; Liu, Zhiguo; Wu, Kaichun; Fan, Daiming; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. [Zhao, Lina] Fourth Mil Med Univ, Xijing Hosp, Dept Radiotherapy, Xian 710032, Shaanxi, Peoples R China. [Leung, Felix] VA Greater Los Angeles Healthcare Syst, Sepulveda ACC, North Hill, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wang, Limei; Chen, Zhangqin] Shaanxi Second Peoples Hosp, Dept Gastroenterol, Xian, Peoples R China. [Wu, Ji; Liu, Junjun] Chancheng Cent Hosp Foshan, Dept Gastroenterol, Foshan, Peoples R China. RP Pan, YL; Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. EM yanglinpan@hotmail.com; xuegangguo@gmail.com FU National Natural Science Foundation of China [81172288, 81370585] FX Supported in part by the National Natural Science Foundation of China (81172288 and 81370585). NR 23 TC 5 Z9 5 U1 5 U2 20 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2016 VL 14 IS 3 BP 429 EP + DI 10.1016/j.cgh.2015.09.038 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1HC UT WOS:000370376700021 PM 26492848 ER PT J AU Khan, A Kanwal, F AF Khan, Anam Kanwal, Fasiha TI Treatment of Alcohol Use Disorders: Benchmarking Houston, Texas, and Philadelphia, Pennsylvania Reply SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Letter C1 [Khan, Anam] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kanwal, Fasiha] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA. [Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Kanwal, Fasiha] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Kanwal, Fasiha] Texas Med Ctr Digest Dis Ctr, Houston, TX USA. [Kanwal, Fasiha] Dan L Duncan Canc Ctr, Houston, TX USA. RP Khan, A (reprint author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2016 VL 14 IS 3 BP 487 EP 488 DI 10.1016/j.cgh.2015.12.010 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1HC UT WOS:000370376700037 PM 26689902 ER PT J AU Park, JJ Wong, DK Wahed, AS Lee, WM Feld, JJ Terrault, N Khalili, M Sterling, RK Kowdley, KV Bzowej, N Lau, DT Kim, WR Smith, C Carithers, RL Torrey, KW Keith, JW Levine, DL Traum, D Ho, S Valiga, ME Johnson, GS Doo, E Lok, ASF Chang, KM AF Park, Jang-June Wong, David K. Wahed, Abdus S. Lee, William M. Feld, Jordan J. Terrault, Norah Khalili, Mandana Sterling, Richard K. Kowdley, Kris V. Bzowej, Natalie Lau, Daryl T. Kim, W. Ray Smith, Coleman Carithers, Robert L. Torrey, Keith W. Keith, James W. Levine, Danielle L. Traum, Daniel Ho, Suzanne Valiga, Mary E. Johnson, Geoffrey S. Doo, Edward Lok, Anna S. F. Chang, Kyong-Mi CA Hepatitis B Res Network TI Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B SO GASTROENTEROLOGY LA English DT Article DE HBRN; LPS; IFN; IL10 ID IMMUNE-RESPONSE; VIRAL-HEPATITIS; SUSTAINED RESPONSE; PROGRAMMED DEATH-1; HBV INFECTION; E-ANTIGEN; PATHOGENESIS; ETHNICITY; GENOTYPE; THERAPY AB BACKGROUND & AIMS: T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). METHODS: We enrolled 200 adults with CHB who participated in the National Institutes of Health-supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide. T-cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyteassociated antigen-4 was examined by flow cytometry. Immune measures were compared with clinical parameters, including physician-defined immune-active, immune-tolerant, or inactive CHB phenotypes, in a blinded fashion. RESULTS: Compared with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequency of circulating FOXP3(+)CD127(-) regulatory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4. T-cell measures did not clearly distinguish between clinical CHB phenotypes, although the HBV core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg- patients (percent responders: 3% vs 23%; P = .00008). Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyteassociated antigen-4 increased T-cell responses to HBV, the effect was weaker in HBeAg+ than HBeAg- patients. Furthermore, T-cell responses to influenza and lipopolysaccharide were weaker in CHB patients than controls. CONCLUSIONS: HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms, including circulating HBeAg, but without distinct T-cell-based immune signatures for clinical phenotypes. These findings suggest additional T-cell-independent or regulatory mechanisms of CHB pathogenesis that warrant further investigation. C1 [Park, Jang-June; Torrey, Keith W.; Keith, James W.; Levine, Danielle L.; Traum, Daniel; Ho, Suzanne; Valiga, Mary E.; Chang, Kyong-Mi] Philadelphia Corporal Michael J Crescenz VA Med C, Philadelphia, PA USA. [Park, Jang-June; Torrey, Keith W.; Keith, James W.; Levine, Danielle L.; Traum, Daniel; Ho, Suzanne; Valiga, Mary E.; Chang, Kyong-Mi] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Wong, David K.; Feld, Jordan J.] Univ Toronto, Toronto, ON, Canada. [Wahed, Abdus S.; Johnson, Geoffrey S.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Lee, William M.] Univ Texas Southwestern, Dallas, TX USA. [Terrault, Norah; Khalili, Mandana] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sterling, Richard K.] Virginia Commonwealth Univ, Richmond, VA USA. [Kowdley, Kris V.] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Bzowej, Natalie] Calif Pacific Med Ctr, San Francisco, CA USA. [Lau, Daryl T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Kim, W. Ray] Mayo Clin, Rochester, MN USA. [Smith, Coleman] Univ Minnesota, Minneapolis, MN USA. [Carithers, Robert L.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Doo, Edward] NIDDK, NIH, Bethesda, MD 20892 USA. [Lok, Anna S. F.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Chang, KM (reprint author), Philadelphia VA Med Ctr, 3900 Woodland Ave, Philadelphia, PA 19104 USA.; Chang, KM (reprint author), Univ Penn, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM kmchang@mail.med.upenn.edu OI Wahed, Abdus/0000-0001-6911-7221; Wong, David/0000-0002-3310-3538 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U01, DK 082843, DK082863, DK082864, DK082866, DK082867, DK082871, U01 DK082872, DK082874, DK082919, DK082923, DK082927, DK082943, U01 DK082944]; NIDDK [A-DK-3002-001]; intramural program, NIDDK, National Institutes of Health (NIH); Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases) [P30DK50306]; Immunology Center (NIH Public Health Service Research Grant) [M01-RR00040]; Immunology Center (VA Merit Review) [BX000649, UL1TR000058]; NCATS (National Center for Advancing Translational Sciences, NIH) [UL1TR000058]; CTSA [UL1TR000004, UL1RR024986]; Clinical and Translational Science Award [CTSA] [UL1TR001111]; Gilead Sciences, Inc.; Roche Molecular Systems through the NIDDK; NIH [UO-1DK082866, R01-AI-47519]; Philadelphia VA Medical Research; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases [P30DK50306]; Molecular Biology and Cell Culture Core Facilities; NIH Public Health Service Research Grant [M01-RR00040]; Office of Research and Development, Department of Veterans Affairs FX The HBRN was funded by a U01 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to the following investigators Lewis R. Roberts, MB, ChB, PhD (DK 082843), Anna Suk-Fong Lok, MD (DK082863), Steven H. Belle, PhD, MScHyg (DK082864), Kyong-Mi Chang, MD (DK082866), Michael W. Fried, MD (DK082867), Adrian M. Di Bisceglie, MD (DK082871), William M. Lee, MD (U01 DK082872), Harry L. A. Janssen, MD, PhD (DK082874), Daryl T.-Y. Lau, MD, MPH (DK082919), Richard K. Sterling, MD, MSc (DK082923), Steven-Huy B. Han, MD (DK082927), Robert C. Carithers, MD (DK082943), Norah A. Terrault, MD, MPH (U01 DK082944), an interagency agreement with NIDDK: Lilia M. Ganova-Raeva, PhD (A-DK-3002-001) and support from the intramural program, NIDDK, National Institutes of Health (NIH): Marc G. Ghany, MD. Additional funding to support this study was provided to Kyong-Mi Chang, MD, the Immunology Center (NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306, NIH Public Health Service Research Grant M01-RR00040, VA Merit Review BX000649), Richard K. Sterling, MD, MSc (UL1TR000058, NCATS (National Center for Advancing Translational Sciences, NIH), Norah A. Terrault, MD, MPH (CTSA grant number UL1TR000004), Michael W. Fried, MD (Clinical and Translational Science Award [CTSA] grant number UL1TR001111), and Anna Suk-Fong Lok (CTSA grant number UL1RR024986). Additional support was provided by Gilead Sciences, Inc. and Roche Molecular Systems via a cooperative research and development agreement through the NIDDK. This study was supported by NIH grants UO-1DK082866 and R01-AI-47519; the Philadelphia VA Medical Research; NIH/NIDDK Center of Molecular Studies in Digestive and Liver Diseases P30DK50306 and its Molecular Biology and Cell Culture Core Facilities; the NIH Public Health Service Research Grant M01-RR00040. This material is based on work supported in part by the Office of Research and Development, Department of Veterans Affairs and with the resources and the use of facilities at the Philadelphia Corporal Michael J. Crescenz VA Medical Center. The contents of this work do not represent the views of the Department of Veterans Affairs or the United States Government. NR 52 TC 9 Z9 12 U1 3 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2016 VL 150 IS 3 BP 684 EP + DI 10.1053/j.gastro.2015.11.050 PG 17 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE5CH UT WOS:000370648100029 PM 26684441 ER PT J AU Kahi, CJ Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Robertson, DJ Rex, DK AF Kahi, Charles J. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Robertson, Douglas J. Rex, Douglas K. TI Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer SO GASTROENTEROLOGY LA English DT Article DE Colonoscopy; Colorectal Neoplasms; Surveillance ID EARLY RECTAL-CANCER; TRANSANAL ENDOSCOPIC MICROSURGERY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; FOLLOW-UP STRATEGIES; COLLEGE-OF-RADIOLOGY; CURATIVE RESECTION; CT COLONOGRAPHY; LOCAL EXCISION; RADICAL SURGERY AB The US Multi-Society Task Force has developed updated recommendations to guide health care providers with the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This document is based on a critical review of the literature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and CT colonography in this setting. The document addresses the effect of surveillance, with focus on colonoscopy, on patient survival after CRC resection, the appropriate use and timing of colonoscopy for perioperative clearing and for postoperative prevention of metachronous CRC, specific considerations for the detection of local recurrence in the case of rectal cancer, as well as the place of CT colonography and fecal tests in post-CRC surveillance. C1 [Kahi, Charles J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Kahi, Charles J.; Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Boland, C. Richard] Baylor Univ, Med Ctr, Dallas, TX USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Vet Affairs Palo Alto, Palo Alto, CA USA. [Kaltenbach, Tonya] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Kahi, CJ (reprint author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, 1481 W 10th St,111G, Indianapolis, IN 46202 USA. EM ckahi2@iu.edu NR 124 TC 9 Z9 9 U1 2 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2016 VL 150 IS 3 BP 758 EP + DI 10.1053/j.gastro.2016.01.001 PG 22 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE5CH UT WOS:000370648100034 PM 26892199 ER PT J AU Kahi, CJ Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Robertson, DJ Rex, DK AF Kahi, Charles J. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Robertson, Douglas J. Rex, Douglas K. TI Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID EARLY RECTAL-CANCER; TRANSANAL ENDOSCOPIC MICROSURGERY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST BARIUM ENEMA; FOLLOW-UP STRATEGIES; COLLEGE-OF-RADIOLOGY; CURATIVE RESECTION; CT COLONOGRAPHY; LOCAL EXCISION; RADICAL SURGERY AB The US Multi-Society Task Force has developed updated recommendations to guide health care providers with the surveillance of patients after colorectal cancer (CRC) resection with curative intent. This document is based on a critical review of the literature regarding the role of colonoscopy, flexible sigmoidoscopy, endoscopic ultrasound, fecal testing and CT colonography in this setting. The document addresses the effect of surveillance, with focus on colonoscopy, on patient survival after CRC resection, the appropriate use and timing of colonoscopy for perioperative clearing and for postoperative prevention of metachronous CRC, specific considerations for the detection of local recurrence in the case of rectal cancer, as well as the place of CT colonography and fecal tests in post-CRC surveillance. C1 [Kahi, Charles J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Kahi, Charles J.; Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Boland, C. Richard] Baylor Univ, Med Ctr Dallas, Dallas, TX USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Dominitz, Jason A.] Univ Washington, Sch Med, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Vet Affairs Palo Alto, Palo Alto, CA USA. [Kaltenbach, Tonya] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Kahi, CJ (reprint author), Indiana Univ Sch Med, Richard L Roudebush VA Med Ctr, 1481 W 10th St,111G, Indianapolis, IN 46202 USA. EM ckahi2@iu.edu NR 123 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2016 VL 83 IS 3 BP 489 EP U273 DI 10.1016/j.gie.2016.01.020 PG 20 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1AU UT WOS:000370359000002 PM 26802191 ER PT J AU Cadoni, S Leung, FW AF Cadoni, Sergio Leung, Felix W. TI Discrepancy in the classification of water immersion from water exchange colonoscopy Response SO GASTROINTESTINAL ENDOSCOPY LA English DT Letter ID CONTROLLED-TRIAL; CECAL INTUBATION; AIR INSUFFLATION; INFUSION C1 [Cadoni, Sergio] St Barbara Hosp, Digest Endoscopy Unit, Iglesias, CI, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Iglesias, CI, Italy. NR 9 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2016 VL 83 IS 3 BP 677 EP 678 DI 10.1016/j.gie.2015.11.012 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1AU UT WOS:000370359000058 PM 26897057 ER PT J AU Stockdale, SE Tang, LQ Pudilo, E Lucas-Wright, A Chung, BW Horta, M Masongsong, Z Jones, F Belin, TR Sherbourne, C Wells, K AF Stockdale, Susan E. Tang, Lingqi Pudilo, Esmeralda Lucas-Wright, Anna Chung, Bowen Horta, Mariana Masongsong, Zoe Jones, Felica Belin, Thomas R. Sherbourne, Cathy Wells, Kenneth TI Sampling and Recruiting Community-Based Programs Using Community-Partnered Participation Research SO HEALTH PROMOTION PRACTICE LA English DT Article DE CBPR; depression; anxiety ID RANDOMIZED CONTROLLED-TRIAL; QUALITY IMPROVEMENT; PRIMARY-CARE; AFRICAN-AMERICANS; DEPRESSION; INTERVENTION; SERVICES; DISPARITIES; PREVALENCE; ENGAGEMENT AB The inclusion of community partners in participatory leadership roles around statistical design issues like sampling and randomization has raised concerns about scientific integrity. This article presents a case study of a community-partnered, participatory research (CPPR) cluster-randomized, comparative effectiveness trial to examine implications for study validity and community relevance. Using study administrative data, we describe a CPPR-based design and implementation process for agency/ program sampling, recruitment, and randomization for depression interventions. We calculated participation rates and used cross-tabulation to examine balance by intervention status on service sector, location, and program size and assessed differences in potential populations served. We achieved 51.5% agency and 89.6% program participation rates. Programs in different intervention arms were not significantly different on service sector, location, or program size. Participating programs were not significantly different from eligible, nonparticipating programs on community characteristics. We reject claims that including community members in research design decisions compromises scientific integrity. This case study suggests that a CPPR process can improve implementation of a community-grounded, rigorous randomized comparative effectiveness trial. C1 [Stockdale, Susan E.; Chung, Bowen; Belin, Thomas R.; Wells, Kenneth] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Stockdale, Susan E.; Tang, Lingqi] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tang, Lingqi; Pudilo, Esmeralda; Masongsong, Zoe; Wells, Kenneth] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Lucas-Wright, Anna; Jones, Felica] Healthy African Amer Families II, Los Angeles, CA USA. [Lucas-Wright, Anna] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Chung, Bowen; Sherbourne, Cathy; Wells, Kenneth] RAND Corp, Santa Monica, CA USA. [Chung, Bowen] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Horta, Mariana] Princeton Univ, Princeton, NJ 08544 USA. [Belin, Thomas R.; Wells, Kenneth] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Stockdale, SE (reprint author), VA Greater Los Angeles Healthcare Syst, 16111 Plummer Ave,Bldg 25,Room A103, Sepulveda, CA 91343 USA. EM susan.stockdale@va.gov NR 35 TC 1 Z9 1 U1 2 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD MAR PY 2016 VL 17 IS 2 BP 254 EP 264 DI 10.1177/1524839915605059 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE6WF UT WOS:000370774400012 PM 26384926 ER PT J AU Osborn, KE Shytle, RD Frontera, AT Soble, JR Schoenberg, MR AF Osborn, Katie E. Shytle, R. Douglas Frontera, Alfred T. Soble, Jason R. Schoenberg, Mike R. TI Addressing Potential Role of Magnesium Dyshomeostasis to Improve Treatment Efficacy for Epilepsy: A Reexamination of the Literature SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Review DE magnesium; seizure; epilepsy; epileptogenesis; metal ion; electrolyte imbalance; ketogenic diet ID ASPARTATE-INDUCED SEIZURES; SECONDARY HYPOCALCEMIA; KETOGENIC DIET; FAMILIAL HYPOMAGNESEMIA; ANTIEPILEPTIC DRUGS; REFRACTORY EPILEPSY; CHILDHOOD EPILEPSY; AMERICAN-ACADEMY; DOUBLE-BLIND; DEFICIENCY AB Magnesium (Mg2+) is an abundant mineral in the body serving many biochemical functions. Magnesium supplementation has been shown to raise seizure threshold in animal and human studies, but the etiological contribution of magnesium deficiency to the onset and maintenance of epilepsy, as well as the degree to which it impacts antiepileptic drug efficacy, remains poorly understood. This may be due, at least in part, to the inherent limitations of commonly used serum levels as a measure of functional magnesium status, as well as insufficient data regarding relative bioavailabilities of various magnesium salts and chelates for use with humans. To date, I randomized clinical trial has been conducted assessing Mg2+ supplementation in epilepsy, and findings yielded promising results. Yet a notable dearth in the literature remains, and more studies are needed. To better understand the potential role of magnesium deficiency as a causal factor in epilepsy, more convenient and accurate measurement methods should to be developed and employed in randomized, controlled trials of oral magnesium supplementation in epilepsy. Findings from such studies have the potential to facilitate far-reaching clinical and economic improvements in epilepsy treatment standards. C1 [Osborn, Katie E.; Schoenberg, Mike R.] Univ S Florida, Morsani Coll Med, Dept Psychiat & Behav Neurosci, Tampa, FL USA. [Osborn, Katie E.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Shytle, R. Douglas; Schoenberg, Mike R.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL USA. [Frontera, Alfred T.; Schoenberg, Mike R.] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL 33620 USA. [Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. RP Schoenberg, MR (reprint author), USF Morsani Coll Med, Dept Psychiat & Behav Neurosci, 3515 E Fletcher Ave, Tampa, FL 33613 USA.; Schoenberg, MR (reprint author), USF Morsani Coll Med, Dept Neurol, 3515 E Fletcher Ave, Tampa, FL 33613 USA.; Schoenberg, MR (reprint author), USF Morsani Coll Med, Dept Neurosurg, 3515 E Fletcher Ave, Tampa, FL 33613 USA. EM mschoenb@health.usf.edu NR 66 TC 0 Z9 0 U1 0 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0091-2700 EI 1552-4604 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD MAR PY 2016 VL 56 IS 3 BP 260 EP 265 DI 10.1002/jcph.626 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DD8GB UT WOS:000370162700002 PM 26313363 ER PT J AU Qin, LM Bouchard, R Pugazhenthi, S AF Qin, LiMei Bouchard, Ron Pugazhenthi, Subbiah TI Regulation of cyclic AMP response element-binding protein during neuroglial interactions SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's disease; CREB; human neuroprogenitor cells; microglia; neuroinflammation; signal transduction ID MEDIATED DOWN-REGULATION; NECROSIS-FACTOR-ALPHA; HIPPOCAMPAL NEUROGENESIS; DIFFERENTIAL REGULATION; MICROGLIAL ACTIVATION; ALZHEIMERS-DISEASE; TRANSGENIC MICE; BCL-2 PROMOTER; CELLS; TRANSCRIPTION AB Communications between neurons and glial cells play an important role in regulating homeostasis in the central nervous system. cAMP response element-binding protein (CREB), a transcription factor, is down-regulated by neurotoxins, which are known to be released by activated glial cells. To determine the role of CREB signaling in neuroglial interactions, we used three neuroglial coculture models consisting of human neuroprogenitor cell (NPC)-derived neurons and human microglia. Conditioned medium from the Abeta (A)-activated microglia decreased CREB phosphorylation and brain-derived neurotrophic factor promoter activity (47%), whereas the same medium induced (p<0.01) the promoter of CXCL10, a chemokine, in NPC-derived neuron-rich cultures. These effects were reversed when microglia were exposed to A in the presence of minocycline, an anti-inflammatory agent. The expression of CREB targets, including brain-derived neurotrophic factor, synapsin-1, and BIRC3 decreased by 50-65% (p<0.01) in neurons isolated by laser capture microdissection in close proximity of microglia in neuroglial mixed cultures. Neuronal survival actively modulated microglial behavior when neurons and microglia were cocultured side-by-side on semicircles of ACLAR membrane. Neuronal injury, caused by the over-expression of dominant negative form of CREB, exacerbated A-mediated microglial activation, whereas CREB over-expression resulted in decreased microglial activation. Decreases in the levels of neuronal markers were observed when NPCs were differentiated in the presence of proinflammatory cytokines IL-1, tumor necrosis factor , or IL-6. Instead, the NPCs differentiated into a glial phenotype, and these effects were more pronounced in the presence of tumor necrosis factor . Our findings suggest that CREB down-regulation is an important component of defective neuroglial communications in the brain during neuroinflammation. C1 [Qin, LiMei; Bouchard, Ron; Pugazhenthi, Subbiah] Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO USA. [Bouchard, Ron; Pugazhenthi, Subbiah] Univ Colorado Denver, Dept Med, Aurora, CO USA. RP Pugazhenthi, S (reprint author), Univ Colorado, Denver VA Med Ctr, Anschutz Med Campus,Mail Stop 8106, Aurora, CO 80045 USA.; Pugazhenthi, S (reprint author), Univ Colorado, Dept Med, Anschutz Med Campus,Mail Stop 8106, Aurora, CO 80045 USA. EM subbiah.pugazhenthi@ucdenver.edu FU Veterans Administration [NEUD-004-07F] FX This work was carried out with the use of resources and facilities at the Denver VA Medical Center. This study was supported by Merit Review grant NEUD-004-07F from the Veterans Administration (to S.P.). RT-PCR analysis was performed at the University of Colorado Cancer Center Core Facility. Digital deconvolution microscopy was carried out at the VA Microscopy Core Facility. Authors declare that there is no conflict of interest associated with this manuscript. NR 42 TC 3 Z9 3 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2016 VL 136 IS 5 BP 918 EP 930 DI 10.1111/jnc.13497 PG 13 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DE5BT UT WOS:000370646500004 PM 26677139 ER PT J AU Samantaray, S Das, A Matzelle, DC Yu, SP Wei, L Varma, A Ray, SK Banik, NL AF Samantaray, Supriti Das, Arabinda Matzelle, Denise C. Yu, Shan P. Wei, Ling Varma, Abhay Ray, Swapan K. Banik, Naren L. TI Administration of low dose estrogen attenuates gliosis and protects neurons in acute spinal cord injury in rats SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE acute spinal cord injury; calpain; estrogen; estrogen receptors; gliosis; neuroprotection ID APOPTOTIC CELL-DEATH; TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-VESSELS; RECEPTOR-ALPHA; UP-REGULATION; NEUROPROTECTIVE AGENT; FUNCTIONAL RECOVERY; SIGNAL-TRANSDUCTION; CALPAIN INHIBITORS; CORTICAL-NEURONS AB Spinal cord injury (SCI) is a debilitating condition with neurological deficits and loss of motor function that, depending on the severity, may lead to paralysis. The only treatment currently available is methylprednisolone, which is widely used and renders limited efficacy in SCI. Therefore, other therapeutic agents must be developed. The neuroprotective efficacy of estrogen in SCI was studied with a pre-clinical and pro-translational perspective. Acute SCI was induced in rats that were treated with low doses of estrogen (1, 5, 10, or 100g/kg) and compared with vehicle-treated injured rats or laminectomy control (sham) rats at 48h post-SCI. Changes in gliosis and other pro-inflammatory responses, expression and activity of proteolytic enzymes (e.g., calpain, caspase-3), apoptosis of neurons in SCI, and cell death were monitored via Western blotting and immunohistochemistry. Negligible pro-inflammatory responses or proteolytic events and very low levels of neuronal death were found in sham rats. In contrast, vehicle-treated SCI rats showed profound pro-inflammatory responses with reactive gliosis, elevated expression and activity of calpain and caspase-3, elevated Bax:Bcl-2 ratio, and high levels of neuronal death in lesion and caudal regions of the injured spinal cord. Estrogen treatment at each dose reduced pro-inflammatory and proteolytic activities and protected neurons in the caudal penumbra in acute SCI. Estrogen treatment at 10g was found to be as effective as 100g in ameliorating the above parameters in injured animals. Results from this investigation indicated that estrogen at a low dose could be a promising therapeutic agent for treating acute SCI. C1 [Samantaray, Supriti; Das, Arabinda; Matzelle, Denise C.; Varma, Abhay; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA. [Yu, Shan P.; Wei, Ling] Emory Univ, Sch Med, Dept Anesthesia, Atlanta, GA USA. [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA. [Banik, Naren L.] Ralph H Johnson Vet Adm, Med Ctr, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurol & Neurosurg, 96 Jonathan Lucas St,Suite 309 CSB,MSC 606, Charleston, SC 29425 USA. EM baniknl@musc.edu FU NIH [R01-NS31622, R01 NS45967]; Veterans Administration [1IOBX00126 and 1IOBX002349]; South Carolina State Spinal Cord Research Fund [SCIRF-2015-P-01, SCIRF-2015-P-04, SCIRF-2015-I-01]; Department of Neurosurgery, MUSC; MUSC-CTSA program FX This work was supported in part by funding from NIH (R01-NS31622 and R01 NS45967); Veterans Administration (1IOBX00126 and 1IOBX002349); South Carolina State Spinal Cord Research Fund (SCIRF-2015-P-01, SCIRF-2015-P-04, and SCIRF-2015-I-01); Department of Neurosurgery, MUSC; and MUSC-CTSA program. We also thank Dr. Kelly Guyton for her valuable contribution to this work. Authors declare no conflict of interests. NR 73 TC 1 Z9 1 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD MAR PY 2016 VL 136 IS 5 BP 1064 EP 1073 DI 10.1111/jnc.13464 PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DE5BT UT WOS:000370646500016 PM 26662641 ER PT J AU Panchal, N Zide, M AF Panchal, Neeraj Zide, Michael TI The Parkland 12-Minute Checklist Tracheotomy SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article AB Purpose: To validate the surgical time and propose a new checklist or algorithm to execute a tracheotomy within 12 minutes with optimal outcomes. Materials and Methods: The authors designed and implemented a checklist method for tracheotomy based on 6 consecutive patients with respiratory failure and prolonged intubation in a medical intensive care unit. The primary outcome variable was surgical time for a tracheotomy performed by a fifth-or sixth-year resident under the supervision of the senior author (M.Z.). Results: Six consecutive patients undergoing tracheotomy (mean, 48 yr; range, 24 to 55 yr; 4 men and 2 women) were included in the study. The average time recorded from the incision to correct insertion of the tracheotomy tube and confirmation of carbon dioxide return by the anesthesiologist was 10.66 minutes (range, 8 to 12 minutes). Conclusion: This checklist facilitates the execution of a time-efficient and safe tracheotomy in less than 12 minutes. (C) 2016 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 74: 556-561, 2016 C1 [Panchal, Neeraj] Univ Texas Southwestern, Parkland Mem Hosp, Dallas, TX USA. [Panchal, Neeraj] Univ Penn, Dept Oral & Maxillofacial Surg, Philadelphia, PA 19104 USA. [Panchal, Neeraj] Philadelphia Vet Affairs Med Ctr, Dept Oral & Maxillofacial Surg, Philadelphia, PA USA. [Zide, Michael] Univ Texas SW Med Ctr Dallas, Div Oral & Maxillofacial Surg, Parkland Mem Hosp, Dallas, TX 75390 USA. RP Panchal, N (reprint author), 3400 Spruce St,5 White Bldg, Philadelphia, PA 19104 USA. EM neeraj.panchal@uphs.upenn.edu NR 7 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD MAR PY 2016 VL 74 IS 3 BP 556 EP 561 DI 10.1016/j.joms.2015.10.022 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DE1FX UT WOS:000370373300023 PM 26657394 ER PT J AU Mukherjee, R AF Mukherjee, Rupak TI Forewarned is forearmed: Benefits of remote ischemic preconditioning SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Editorial Material ID ISOLATED RAT-HEART; REPERFUSION INJURY; SEVOFLURANE; ISOFLURANE; PROTECTION; MYOCARDIUM C1 [Mukherjee, Rupak] Med Univ S Carolina, Dept Surg, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Mukherjee, Rupak] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Mukherjee, R (reprint author), Div Cardiothorac Surg, MSC 777,114 Doughty St,Ste 338, Charleston, SC 29426 USA. EM mukherr@musc.edu FU NIA NIH HHS [AG036954]; RRD VA [I21 RX001707] NR 14 TC 1 Z9 1 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2016 VL 151 IS 3 BP 786 EP 787 DI 10.1016/j.jtcvs.2015.10.089 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA DD9KR UT WOS:000370244700051 PM 26628358 ER PT J AU Barshes, NR Pisimisis, G Kougias, P AF Barshes, Neal R. Pisimisis, George Kougias, Panos TI Compartment syndrome of the foot associated with a delayed presentation of acute limb ischemia SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID FASCIOTOMY; ANKLE AB Compartment syndrome of the leg is a well-recognized complication known to follow urgent revascularization done for acute limb ischemia, but compartment syndrome of the foot has not been reported after the ischemia-reperfusion sequence. Herein we report a case of foot fasciotomy done for compartment syndrome that occurred after urgent revascularization. We suggest that foot fasciotomies should be considered in particular circumstances of acute lower leg ischemia, such as infrapopliteal thromboembolic events, prolonged ischemia, and persistent or worsening foot symptoms that follow revascularization and calf fasciotomies. C1 [Barshes, Neal R.; Pisimisis, George; Kougias, Panos] Baylor Coll Med, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Div Vasc & Endovasc Surg, Michael E DeBakey Dept Surg, Michael E DeBakey Vet Affairs Med Ctr,Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 16 TC 1 Z9 1 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD MAR PY 2016 VL 63 IS 3 BP 819 EP 822 DI 10.1016/j.jvs.2015.01.043 PG 4 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA DE6YI UT WOS:000370780400037 PM 25752690 ER PT J AU Ford, JM AF Ford, Judith M. TI Studying auditory verbal hallucinations using the RDoC framework SO PSYCHOPHYSIOLOGY LA English DT Article DE RDoC; Agency; Auditory verbal hallucinations; EEG; ERP; N1 ID COROLLARY DISCHARGE; SPEECH PRODUCTION; SCHIZOPHRENIA; CORTEX; SYMPTOMS; INITIATION; RESPONSES; TALKING; SOUNDS; BRAIN AB In this paper, I explain why I adopted a Research Domain Criteria (RDoC) approach to study the neurobiology of auditory verbal hallucinations (AVH), or voices. I explain that the RDoC construct of agency fits well with AVH phenomenology. To the extent that voices sound nonself, voice hearers lack a sense of agency over the voices. Using a vocalization paradigm like those used with nonhuman primates to study mechanisms subserving the sense of agency, we find that the auditory N1 ERP is suppressed during vocalization, that EEG synchrony preceding speech onset is related to N1 suppression, and that both are reduced in patients with schizophrenia. Reduced cortical suppression is also seen across multiple psychotic disorders and in clinically high-risk youth, but it is not related to AVH. The motor activity preceding talking and connectivity between frontal and temporal lobes during talking have both proved sensitive to AVH, suggesting neural activity and connectivity associated with intentions to act may be a better way to study agency and predictions based on agency. C1 [Ford, Judith M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA.; Ford, JM (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA.; Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM Judith.Ford@ucsf.edu FU Department of Veterans Affairs [I01CX000497]; National Institute of Mental Health [MH-58262] FX This work was supported by grants to JMF from Department of Veterans Affairs (I01CX000497) and National Institute of Mental Health (MH-58262). I would like to thank all of my coauthors of the work discussed in this paper. Special thanks go to Daniel H. Mathalon for ongoing inspiration and intellectual guidance, Brian J. Roach for making it all happen and his inspired data analysis, John Sweeney and his team for collecting data with our paradigm at his BSNIP site at the University of Illinois in Chicago, James Reilly for the heritability analysis of the BSNIP data, Jun Wang for his MRI-guided source analysis of the BSNIP data, Chi-Ming Chen for his analysis of the intracranial data, Veronica Perez for her analysis of the data from the clinical high-risk sample, Theda Heinks for her work on the pitch perturbation paradigm, Kevin Sitek for his work on the naturalistic formant variation analysis, Vanessa Palzes for her work on the button press paradigms, and to all the patients and their families for participating in this research. NR 64 TC 8 Z9 8 U1 5 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0048-5772 EI 1469-8986 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PD MAR PY 2016 VL 53 IS 3 SI SI BP 298 EP 304 DI 10.1111/psyp.12457 PG 7 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA DE2VL UT WOS:000370485200003 PM 26877116 ER PT J AU Cochran, G Gordon, AJ Field, C Bacci, J Dhital, R Ylioja, T Stitzer, M Kelly, T Tarter, R AF Cochran, Gerald Gordon, Adam J. Field, Craig Bacci, Jennifer Dhital, Ranjita Ylioja, Thomas Stitzer, Maxine Kelly, Thomas Tarter, Ralph TI Developing a framework of care for opioid medication misuse in community pharmacy SO RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY LA English DT Article DE Opioid misuse; Adherence; Medication management; Qualitative research ID RANDOMIZED CONTROLLED-TRIAL; BRIEF ALCOHOL INTERVENTIONS; GENERAL-PRACTICE; NONMEDICAL USE; DRUG-USE; THERAPY MANAGEMENT; CLINICAL-TRIAL; SETTINGS; HEALTH; PAIN AB Background: Prescription opioid misuse is a major public health concern in the US. Few resources exist to support community pharmacists engaging patients who misuse or are at risk for misuse. Objectives: This report describes the results of the execution of the ADAPT-ITT model (a model for modifying evidence-based behavioral interventions to new populations and service settings) to guide the development of a behavioral health framework for opioid medication misuse in the community pharmacy setting. Methods: Pharmacy, addiction, intervention, and treatment experts were convened to attend a one-day meeting to review the empirical knowledgebase and discuss adapting the screening, brief intervention, and referral to treatment (SBIRT) protocol for addressing opioid medication misuse in community pharmacy. Qualitative data gathered from the meeting were analyzed by 2 independent coders in a 2-cycle process using objective coding schemes. Percentage of agreement and Cohen's Kappa were calculated to assess coder agreement. Results: First-cycle coding identified 4 distinct themes, with coder percentage of agreement ranging from 93.5 to 99.6% and with Kappa values between 0.81 and 0.93. Second-cycle coding identified 10 sub-themes, with coder percentage of agreement ranging from 83 to 99.8% and with Kappa values between 0.58 and 0.93. Identified themes and sub-themes encompassed patient identification, intervention, prevention, and referral to treatment. Conclusions: Focus of screening efforts in the emerging model should capitalize on pharmacists' knowledge of medication management. Screening likewise should be multidimensional in order to facilitate patient-centered interventions that activate additional disciplines able to interface with patients at risk or involved in medication misuse. (C) 2016 Elsevier Inc. All rights reserved. C1 [Cochran, Gerald; Ylioja, Thomas] Univ Pittsburgh, Sch Social Work, 4200 Fifth Ave, Pittsburgh, PA 15260 USA. [Cochran, Gerald; Kelly, Thomas] Univ Pittsburgh, Dept Psychiat, 3811 Ohara St, Pittsburgh, PA 15213 USA. [Gordon, Adam J.] Univ Pittsburgh, Dept Med, Sch Med, M240 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Univ Dr C 151-C, Pittsburgh, PA 15240 USA. [Field, Craig] Univ Texas El Paso, Dept Psychol, El Paso, TX 79968 USA. [Bacci, Jennifer] Univ Pittsburgh, Sch Pharm, 501 Terrace St, Pittsburgh, PA 15213 USA. [Dhital, Ranjita] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, James Clerk Maxwell Bldg,57 Waterloo Rd, London SE1 8WA, England. [Stitzer, Maxine] Johns Hopkins Med, Behav Pharmacol Res Unit, 5510 Nathan Shock Dr, Baltimore, MD 21224 USA. RP Cochran, G (reprint author), Univ Pittsburgh, Sch Social Work, 4200 Fifth Ave, Pittsburgh, PA 15260 USA. EM gcochran@pitt.edu FU Staunton Farm Foundation FX This project was supported by a grant from the Staunton Farm Foundation, which had no involvement in the conceptualization, execution, or submission of this work. NR 49 TC 3 Z9 3 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7411 EI 1934-8150 J9 RES SOC ADMIN PHARM JI Res. Soc. Adm. Pharm. PD MAR-APR PY 2016 VL 12 IS 2 BP 293 EP 301 DI 10.1016/j.sapharm.2015.05.001 PG 9 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA DE1NB UT WOS:000370392600007 PM 26048710 ER PT J AU Walker, M El-Serag, HB Sada, Y Mittal, S Ying, J Duan, Z Richardson, P Davila, JA Kanwal, F AF Walker, M. El-Serag, H. B. Sada, Y. Mittal, S. Ying, J. Duan, Z. Richardson, P. Davila, J. A. Kanwal, F. TI Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID FATTY LIVER-DISEASE; PRIMARY-CARE PROVIDERS; UNITED-STATES; HEPATITIS-C; CARCINOMA; FIBROSIS; SURVEILLANCE; PROGNOSIS; POPULATION; ARTICLE AB BackgroundMost clinical practice guidelines recommend screening for HCC in patients with cirrhosis. However, patients with compensated cirrhosis are often asymptomatic and may remain unrecognised for years. AimsTo determine the extent to which cirrhosis is unrecognised in a US Veteran population with HCC, and to evaluate the association between lack of cirrhosis recognition and stage of HCC at diagnosis. MethodsWe reviewed the electronic medical records of a random sample of HCC cases diagnosed in the national Veterans Affairs system between 2005 and 2011. We conducted multivariable analyses adjusting for patients' demographics, comorbidity, aetiology of underlying disease and healthcare utilisation including HCC surveillance. ResultsOf 1201 patients with HCC and cirrhosis, 24.6% had unrecognised cirrhosis prior to HCC diagnosis. Older patients [>65 years, odds ratio (OR) 2.32], African Americans (OR 1.93), patients with alcoholic or NAFLD liver disease (OR 1.69 and 4.77 respectively), HIV (OR 3.02), and fewer comorbidities (Deyo 0 vs. 3, OR 2.42) had significantly higher odds of having unrecognised cirrhosis than comparison groups. Furthermore, patients with unrecognised cirrhosis were 6.5 times more likely to have advanced stage HCC at diagnosis. The effect of cirrhosis recognition on HCC stage remained significant after adjusting for pre-specified covariates (OR 3.37). ConclusionsIn one quarter of patients, cirrhosis was unrecognised prior to HCC diagnosis, and this group was significantly more likely to have advanced stage HCC. These findings emphasise the importance of timely evaluation for cirrhosis in at-risk populations as a critical step to improving outcomes for patients with HCC. C1 [Walker, M.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [El-Serag, H. B.; Sada, Y.; Mittal, S.; Ying, J.; Duan, Z.; Richardson, P.; Davila, J. A.; Kanwal, F.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effect & Safety IQuESt, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. [El-Serag, H. B.; Mittal, S.; Kanwal, F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Gastroenterol Sect, Houston, TX 77030 USA. [El-Serag, H. B.; Mittal, S.; Kanwal, F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Hepatol, Houston, TX 77030 USA. [Sada, Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Hematol & Oncol, Houston, TX 77030 USA. [Richardson, P.; Davila, J. A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Davila, JA; Kanwal, F (reprint author), Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effect & Safety IQuESt, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM jdavila@bcm.edu; fasiha.kanwal@va.gov FU National Cancer Institute [R01 CA160738]; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This material is based upon work supported by the National Cancer Institute (R01 CA160738, PI: Davila), and in part by the Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413). NR 31 TC 3 Z9 3 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD MAR PY 2016 VL 43 IS 5 BP 621 EP 630 DI 10.1111/apt.13505 PG 10 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA DD5QU UT WOS:000369980000007 PM 26784271 ER PT J AU Bergman, J Ballon-Landa, E Lorenz, KA Saucedo, J Saigal, CS Bennett, CJ Litwin, MS AF Bergman, Jonathan Ballon-Landa, Eric Lorenz, Karl A. Saucedo, Josemanuel Saigal, Christopher S. Bennett, Carol J. Litwin, Mark S. TI Community-Partnered Collaboration to Build an Integrated Palliative Care Clinic: The View From Urology SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE adult; attitude of health personnel; delivery of health care; integrated; interviews as topic; palliative care; patient care team; patient preference; physician's role; physicians; psychology; quality improvement; quality of health care; terminal care; urology ID END-OF-LIFE; ADVANCED CANCER; SUPPORTIVE CARE; QUALITY; HEALTH; INTERVENTION; PROVIDERS; ATTITUDES; OUTCOMES; PROJECT AB Background: We partnered with patients, families, and palliative care clinicians to develop an integrated urology-palliative care clinic for patients with metastatic cancer. We assessed clinician satisfaction with a multidisciplinary palliative care clinic model. Methods: We conducted semi-structured interviews with 18 clinicians who practice in our integrated clinic. We analyzed transcripts using a multistage, cutting-and-sorting technique in an inductive approach based on grounded theory analysis. Finally, we administered a validated physician job satisfaction survey. Results: Clinicians found that referring a patient to palliative care in the urology clinic was feasible and appropriate. Patients were receptive to supportive care, and clinicians perceived that quality of care improved following the intervention. Conclusion: An integrated, patient-centered model for individuals with advanced urologic malignancies is feasible and well received by practitioners. C1 [Bergman, Jonathan; Saucedo, Josemanuel; Saigal, Christopher S.; Bennett, Carol J.; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, 924 Westwood Blvd,Suite 1000, Los Angeles, CA 90024 USA. [Bergman, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90024 USA. [Bergman, Jonathan; Lorenz, Karl A.; Saigal, Christopher S.; Bennett, Carol J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ballon-Landa, Eric] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA. [Ballon-Landa, Eric] UC Irvine Sch Med, Irvine, CA USA. [Lorenz, Karl A.; Saigal, Christopher S.] RAND Corp, Santa Monica, CA USA. [Litwin, Mark S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med, 924 Westwood Blvd,Suite 1000, Los Angeles, CA 90024 USA. EM jbergman@mednet.ucla.edu RI Kausar, Nadia/D-7414-2016 NR 34 TC 1 Z9 1 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAR PY 2016 VL 33 IS 2 BP 164 EP 170 DI 10.1177/1049909114555156 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DD8TW UT WOS:000370200800009 PM 25326489 ER PT J AU Reinke, LF Feemster, LC Backhus, LM Gylys-Colwell, I Au, DH AF Reinke, Lynn F. Feemster, Laura C. Backhus, Leah M. Gylys-Colwell, Ina Au, David H. TI Assessment and Management of Symptoms for Outpatients Newly Diagnosed With Lung Cancer SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE lung cancer; newly diagnosed; symptom assessment; management ID OBSTRUCTIVE PULMONARY-DISEASE; EARLY PALLIATIVE CARE; ADULTS RECEIVING TREATMENT; HOME NURSING-CARE; OF-LIFE CARE; PROGNOSTIC INFORMATION; DISTRESS; COMMUNICATION; INTERVENTION; PREFERENCES AB Rationale: Little is known about symptom assessment around the time of lung cancer diagnosis. The purpose of this pilot study was to assess symptoms within 2 months of diagnosis and the frequency with which clinicians addressed symptoms among a cohort of veterans (n = 20) newly diagnosed with lung cancer. We administered questionnaires and then reviewed medical records to identify symptom assessment and management provided by subspecialty clinics for 6 months following diagnosis. Results: Half (50%) of the patients were diagnosed with early-stage non-small-cell lung cancer (NSCLC), stage I or II. At baseline, 45% patients rated their overall symptoms as severe. There were no significant differences in symptoms among patients with early- or late-stage NSCLC or small-cell lung cancer. Of the 212 clinic visits over 6 months, 70.2% occurred in oncology. Clinicians most frequently addressed pain although assessment differed by clinic. Conclusions: Veterans with newly diagnosed lung cancer report significant symptom burden. Despite ample opportunities to address patients' symptoms, variations in assessment exist among subspecialty services. Coordinated approaches to symptom assessment are likely needed among patients newly diagnosed with lung cancer. C1 [Reinke, Lynn F.; Feemster, Laura C.; Backhus, Leah M.; Gylys-Colwell, Ina; Au, David H.] Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv R&D, Seattle, WA USA. [Reinke, Lynn F.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Feemster, Laura C.; Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA. [Backhus, Leah M.] Univ Washington, Sch Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA. RP Reinke, LF (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv R&D, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM reinkl@uw.edu RI Kausar, Nadia/D-7414-2016 FU Office of Nursing Services from United States (US) Department of Veterans Affairs [NRI-01-001] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported a pilot project award from the Office of Nursing Services, #NRI-01-001 from the United States (US) Department of Veterans Affairs. NR 31 TC 2 Z9 2 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAR PY 2016 VL 33 IS 2 BP 178 EP 183 DI 10.1177/1049909114557635 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DD8TW UT WOS:000370200800011 PM 25376224 ER PT J AU Sharma, A Albergotti, WG Duvvuri, U AF Sharma, Arun Albergotti, W. Greer Duvvuri, Umamaheswar TI Applications of Evolving Robotic Technology for Head and Neck Surgery SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE head and neck; head and neck cancer; robotic surgery; transoral robotic surgery; thyroid ID SQUAMOUS-CELL CARCINOMA; CANCER AB Objective: Assess the use and potential benefits of a new robotic system for transoral radical tonsillectomy, transoral supraglottic laryngectomy, and retroauricular thyroidectomy in a cadaver dissection. Methods: Three previously described robotic procedures (transoral radical tonsillectomy, transoral supraglottic laryngectomy, and retroauricular thyroidectomy) were performed in a cadaver using the da Vinci Xi Surgical System. Surgical exposure and access, operative time, and number of collisions were examined objectively. Results: The new robotic system was used to perform transoral radical tonsillectomy with dissection and preservation of glossopharyngeal nerve branches, transoral supraglottic laryngectomy, and retroauricular thyroidectomy. There was excellent exposure without any difficulties in access. Robotic operative times (excluding set-up and docking times) for the 3 procedures in the cadaver were 12.7, 14.3, and 21.2 minutes (excluding retroauricular incision and subplatysmal elevation), respectively. No robotic arm collisions were noted during these 3 procedures. The retroauricular thyroidectomy was performed using 4 robotic ports, each with 8 mm instruments. Conclusions: The use of updated and evolving robotic technology improves the ease of previously described robotic head and neck procedures and may allow surgeons to perform increasingly complex surgeries. C1 [Sharma, Arun] So Illinois Univ, Div Otolaryngol Head & Neck Surg, Springfield, IL USA. [Albergotti, W. Greer; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA 15213 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Dept Otolaryngol, Pittsburgh, PA USA. Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Head & Neck Robot Surg,Eye & Ear Inst, Pittsburgh, PA 15213 USA. RP Duvvuri, U (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Head & Neck Robot Surg,Eye & Ear Inst, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM duvvuriu@upmc.edu FU Department of Veterans Affairs, Biomedical and Laboratory Science Research and Development group FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part from funds from the Department of Veterans Affairs, Biomedical and Laboratory Science Research and Development group. This works does not reflect the views of the Department of Veterans Affairs or the US government. NR 15 TC 1 Z9 2 U1 1 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD MAR PY 2016 VL 125 IS 3 BP 207 EP 212 DI 10.1177/0003489415606448 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA DD6YN UT WOS:000370070800004 PM 26391091 ER PT J AU Pearce, EN Lee, SL Magner, RW Garber, JR Campion, FX Leung, AM AF Pearce, Elizabeth N. Lee, Stephanie L. Magner, Richard Weissjames Garber, Jeffrey R. Campion, F. X. Leung, Angela M. TI Unique obstacles to establishing thyroid cancer registries SO JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY LA English DT Letter C1 [Pearce, Elizabeth N.; Lee, Stephanie L.] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02215 USA. [Pearce, Elizabeth N.; Garber, Jeffrey R.] Harvard Vanguard Med Associates, Div Endocrine, Boston, MA USA. [Magner, Richard Weissjames] Sanofi Co, Med Affairs Genzyme Corp, Cambridge, MA USA. [Garber, Jeffrey R.] Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA USA. [Campion, F. X.] Harvard Med Sch, Dept Populat Med, Boston, MA USA. [Campion, F. X.] Harvard Vanguard Med Associates, Dept Internal Med, Boston, MA USA. [Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol, Los Angeles, CA USA. RP Leung, AM (reprint author), VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA 90073 USA. EM AMLeung@mednet.ucla.edu FU NIH [K23HD068552]; Genzyme Corporation FX Supported by NIH K23HD068552 (AML). Some funds to support pilot efforts were provided by Genzyme Corporation as an Investigator Sponsored Study. NR 5 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2214-6237 J9 J CLIN TRANSL ENDOCR JI J. Clin. Transl. ENdocrinol. PD MAR PY 2016 VL 3 BP 12 EP 13 DI 10.1016/j.jcte.2015.12.003 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ER8QX UT WOS:000399087900003 ER PT J AU Haynes, PL Kelly, M Warner, L Quan, SF Krakow, B Bootzin, RR AF Haynes, Patricia L. Kelly, Monica Warner, Lesley Quan, Stuart F. Krakow, Barry Bootzin, Richard R. TI Cognitive Behavioral Social Rhythm Group Therapy for Veterans with posttraumatic stress disorder, depression, and sleep disturbance: Results from an open trial SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Veterans; Post-traumatic stress disorder; Depression; Insomnia; Cognitive behavioral therapy ID ADMINISTERED PTSD SCALE; RANDOMIZED CONTROLLED-TRIAL; CIRCADIAN-RHYTHMS; MAJOR DEPRESSION; PSYCHOLOGICAL TREATMENTS; COMORBID INSOMNIA; IMAGERY REHEARSAL; MENTAL-DISORDERS; VIETNAM VETERANS; COMBAT VETERANS AB Introduction: Cognitive Behavioral Social Rhythm Therapy (CBSRT) is a group psychotherapy tailored for Veterans with Posttraumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and sleep disturbances. The aims of this study were to introduce and present initial outcomes of Cognitive Behavioral Social Rhythm Therapy (CBSRT), a 12-week skills group therapy designed to improve sleep and mood by reducing chaotic or isolated lifestyles in Veterans with PTSD. Methods: Twenty-four male Veterans with at least moderate PTSD and MDD participated in this open trial. Main outcomes were the daily sleep diary for sleep disturbances, the Clinician-Administered PTSD Scale (CAPS) for PTSD, and the Hamilton Depression Rating scale for MDD. Results: Veterans improved on all measures (a) with large within subject effects on PTSD symptoms, MDD symptoms, and sleep quality, and (b) with 46-58% of the sample receiving clinically significant benefits on MDD and PTSD symptoms respectively. The consistency of social rhythms was associated with the average reduction in global CAPS scores over time. Only 13% of participants dropped-out of the group therapy prematurely suggesting that this new group therapy is relatively well-tolerated by Veterans. Limitations: Future research that employs a control condition is necessary to establish efficacy of CBSRT. Conclusions: Data from this initial pilot study demonstrate that CBSRT may be an effective group treatment option for Veterans presenting with all three symptom complaints. These data also suggest that daily routine may be an important mechanism to consider in the treatment of PTSD symptoms comorbid with depression. (C) 2015 Elsevier B.V. All rights reserved. C1 [Haynes, Patricia L.] Univ Arizona, Dept Hlth Promot Sci, 1295 N Martin Ave,POB 245209, Tucson, AZ 85724 USA. [Haynes, Patricia L.; Kelly, Monica; Warner, Lesley; Bootzin, Richard R.] Univ Arizona, Dept Psychiat, 1501 N Campbell Ave, Tucson, AZ 85724 USA. [Haynes, Patricia L.; Kelly, Monica; Warner, Lesley] Southern Arizona VA Hlth Care Syst, 3601 S 6th Ave,116B, Tucson, AZ 85723 USA. [Haynes, Patricia L.; Kelly, Monica; Bootzin, Richard R.] Univ Arizona, Dept Psychol, 1503 E Univ Blvd, Tucson, AZ 85721 USA. [Quan, Stuart F.] Univ Arizona, Dept Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA. [Quan, Stuart F.] Harvard Univ, Div Sleep Med, Sch Med, 164 Longwood Ave, Boston, MA 02115 USA. [Krakow, Barry] Maimonides Sleep Arts & Sci, 6739 Acad Rd NE Suite 380, Albuquerque, NM 87109 USA. [Warner, Lesley] VA Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. RP Haynes, PL (reprint author), Univ Arizona, Dept Hlth Promot Sci, 1295 N Martin Ave,POB 245209, Tucson, AZ 85724 USA. EM thaynes@email.arizona.edu FU American Sleep Medicine Foundation Career Development Grant [37-CA-06]; Institute for Mental Health Research Pilot Award FX This project was supported by the American Sleep Medicine Foundation Career Development Grant (Grant #37-CA-06) and the Institute for Mental Health Research Pilot Award. The authors gratefully acknowledge the assistance of Marta Williamson, Valerie Scheller, Sacha Brown, and Suzanne Perkins. Dr. Haynes, Ms. Kelly, and Ms. Warner are no longer affiliated with the Southern Arizona VA Health Care System. NR 94 TC 3 Z9 3 U1 12 U2 33 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD MAR 1 PY 2016 VL 192 BP 234 EP 243 DI 10.1016/j.jad.2015.12.012 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DB8UG UT WOS:000368791600032 PM 26748739 ER PT J AU Garcia, HA McGeary, CA Finley, EP McGeary, DD Ketchum, NS Peterson, AL AF Garcia, Hector A. McGeary, Cindy A. Finley, Erin P. McGeary, Donald D. Ketchum, Norma S. Peterson, Alan L. TI The influence of trauma and patient characteristics on provider burnout in VA post-traumatic stress disorder specialty programmes SO PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE LA English DT Article DE burnout; Veterans Health Administration; post-traumatic stress disorder; malingering; personality disorders ID COGNITIVE PROCESSING THERAPY; MENTAL-HEALTH PROVIDERS; COMPASSION SATISFACTION; BEHAVIORAL THERAPY; JOB BURNOUT; VETERANS; RECOMMENDATIONS; DISSEMINATION; PROFESSIONALS; FATIGUE AB ObjectiveProlonged exposure (PE) and cognitive processing therapy (CPT) - post-traumatic stress disorder (PTSD) treatments now available at the Veterans Health Administration (VHA) - expose the provider to graphic traumatic material. Little is known about the impact of traumatic material on VHA providers. The purpose of this study was to examine the relationship between trauma content, patient characteristics, and burnout among VHA PTSD Clinical Team (PCT) providers. It was hypothesized that trauma content and patient characteristics would significantly predict burnout in this population. DesignThis cross-sectional study consisted of 137 participants. The sample was mostly female (67%), Caucasian (non-Hispanic; 81%), and married (70%) with a mean age of 44.3years (SD=11.3). MethodsParticipants completed an electronic survey that assessed demographics, patient characteristics (i.e., anger, personality disorder, malingering), trauma content characteristics (e.g., killing of women and children) as well as burnout as measured by the Maslach Burnout Inventory-General Survey (MBI-GS; Maslach etal., 1996, Burnout inventory manual. Palo Alto: Consulting Psychologist Press). ResultsOver half of the study population reported being bothered by trauma content; however, trauma content did not predict burnout. Treating patients with personality disorders and suspected malingering predicted burnout in PCT providers. High numbers (77%) reported perceiving that emotional exhaustion impacted the quality of care they provided. ConclusionThese findings suggest an important role of burnout assessment, prevention, and treatment strategies at the VHA. C1 [Garcia, Hector A.; Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Garcia, Hector A.; McGeary, Cindy A.; McGeary, Donald D.; Peterson, Alan L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ketchum, Norma S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Garcia, HA (reprint author), Frank Tejeda Outpatient Clin, 5788 Eckhert Rd, San Antonio, TX 78240 USA. EM Hector.Garcia2@va.gov OI Finley, Erin/0000-0003-4497-7721 FU Practice Based Research Network, The University of Texas Health Science Center at San Antonio FX The research was supported in part by the Practice Based Research Network, The University of Texas Health Science Center at San Antonio. NR 43 TC 3 Z9 3 U1 4 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1476-0835 EI 2044-8341 J9 PSYCHOL PSYCHOTHER-T JI Psychol. Psychother.-Theory Res. Pract. PD MAR PY 2016 VL 89 IS 1 BP 66 EP 81 DI 10.1111/papt.12057 PG 16 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA DB9KE UT WOS:000368834000005 PM 25643839 ER PT J AU Han, SJ Jang, HS Kim, JI Lipschutz, JH Park, KM AF Han, Sang Jun Jang, Hee-Seong Kim, Jee In Lipschutz, Joshua H. Park, Kwon Moo TI Unilateral nephrectomy elongates primary cilia in the remaining kidney via reactive oxygen species SO SCIENTIFIC REPORTS LA English DT Article ID INDUCED FUNCTIONAL INJURY; HEPATOCYTE GROWTH-FACTOR; MAPK KINASE ACTIVATION; ISCHEMIA/REPERFUSION INJURY; OXIDATIVE STRESS; EPITHELIAL-CELLS; ISCHEMIC-INJURY; CILIOGENESIS; CYSTOGENESIS; HYPERTROPHY AB The length of primary cilia is associated with normal cell and organ function. In the kidney, the change of functional cilia length/mass is associated with various diseases such as ischemia/reperfusion injury, polycystic kidney disease, and congenital solitary kidney. Here, we investigate whether renal mass reduction affects primary cilia length and function. To induce renal mass reduction, mice were subjected to unilateral nephrectomy (UNx). UNx increased kidney weight and superoxide formation in the remaining kidney. Primary cilia were elongated in proximal tubule cells, collecting duct cells and parietal cells of the remaining kidney. Mn(III) Tetrakis (1-methyl-4-pyridyl) porphyrin (MnTMPyP), an antioxidant, reduced superoxide formation in UNx-mice and prevented the elongation of primary cilia. UNx increased the expression of phosphorylated ERK, p21, and exocyst complex members Sec8 and Sec10, in the remaining kidney, and these increases were prevented by MnTMPyP. In MDCK, a kidney tubular epithelial cell line, cells, low concentrations of H2O2 treatment elongated primary cilia. This H2O2-induced elongation of primary cilia was also prevented by MnTMPyP treatment. Taken together, these data demonstrate that kidney compensation, induced by a reduction of renal mass, results in primary cilia elongation, and this elongation is associated with an increased production of reactive oxygen species (ROS). C1 [Han, Sang Jun; Jang, Hee-Seong; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat, Daegu 700422, South Korea. [Han, Sang Jun; Jang, Hee-Seong; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, BK Project 21, Daegu 700422, South Korea. [Kim, Jee In] Keimyung Univ, Sch Med, Dept Mol Med, Daegu 705717, South Korea. [Kim, Jee In] Keimyung Univ, Sch Med, MRC, Daegu 705717, South Korea. [Lipschutz, Joshua H.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Ralph H Johnson Vet Affairs Med Ctr, Dept Med, Charleston, SC USA. RP Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, Dept Anat, Daegu 700422, South Korea.; Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, BK Project 21, Daegu 700422, South Korea. EM kmpark@knu.ac.kr FU National Research Foundation of Korea (NRF) - Korea government (MEST) [NRF-2014R1A11049549]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C2011] FX This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2014R1A11049549) and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare (HI14C2011), Republic of Korea. NR 31 TC 1 Z9 1 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD FEB 29 PY 2016 VL 6 AR 22281 DI 10.1038/srep22281 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF1OO UT WOS:000371109300002 PM 26923764 ER PT J AU Knight, EM Ruiz, HH Kim, SH Harte, JC Hsieh, W Glabe, C Klein, WL Attie, AD Buettner, C Ehrlich, ME Gandy, S AF Knight, Elysse M. Ruiz, Henry H. Kim, Soong Ho Harte, Jessica C. Hsieh, Wilson Glabe, Charles Klein, William L. Attie, Alan D. Buettner, Christoph Ehrlich, Michelle E. Gandy, Sam TI Unexpected partial correction of metabolic and behavioral phenotypes of Alzheimer's APP/PSEN1 mice by gene targeting of diabetes/Alzheimer's-related Sorcs1 SO ACTA NEUROPATHOLOGICA COMMUNICATIONS LA English DT Article DE Alzheimer's disease; Amyloid beta; Metabolic; Insulin; Glucose; Transgenic model ID AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E RECEPTOR; QUANTITATIVE TRAIT LOCUS; TRANSGENIC MOUSE MODEL; INSULIN-RESISTANCE; A-BETA; DIABETES-MELLITUS; LR11/SORLA EXPRESSION; RETROMER COMPLEX; DISEASE AB Introduction: Insulin resistance and type 2 diabetes mellitus (T2D) are associated with increased risk for cognitive impairment, Alzheimer's disease (AD) and vascular dementia. SORCS1 encodes a protein-sorting molecule genetically linked to both T2D and AD. The association of SORCS1 with both AD and T2D is sexually dimorphic in humans, with both disease associations showing more robust effects in females. Based on published evidence that manipulation of the mouse genome combining multiple genes related to cerebral amyloidosis, to T2D, or both, might provide novel mouse models with exacerbated amyloid and/or diabetes phenotypes, we assessed memory, glucose homeostasis, and brain biochemistry and pathology in male and female wild-type, Sorcs1 -/-, APP/PSEN1, and Sorcs1 -/- X APP/PSEN1 mice. Results: Male mice with either the APP/PSEN1 or Sorcs1 -/- genotype displayed earlier onset and persistent impairment in both learning behavior and glucose homeostasis. Unlike prior examples in the literature, the behavioral and metabolic abnormalities in male mice were not significantly exacerbated when the two disease model mice (Sorcs1 -/- models T2D; APP/PSEN1 models AD) were crossed. However, female Sorcs1 -/- X APP/PSEN1 mice exhibited worse metabolic dysfunction than Sorcs1 -/- knockout mice and worse memory than wild-type mice. The deletion of Sorcs1 from APP/PSEN1 mutant mice led to no obvious changes in brain levels of total or oligomeric amyloid-beta (A beta) peptide. Conclusions: In general, unexpectedly, there was a trend for gene targeting of Sorcs1-/- to partially mitigate, not exacerbate, the metabolic and amyloid pathologies. These results indicate that crossing AD model mice and T2D model mice may not always cause exacerbation of both the amyloidosis phenotype and the metabolic phenotype and highlight the unexpected pitfalls of creating mixed models of disease. C1 [Knight, Elysse M.; Kim, Soong Ho; Harte, Jessica C.; Ehrlich, Michelle E.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Knight, Elysse M.; Kim, Soong Ho; Harte, Jessica C.; Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Knight, Elysse M.; Kim, Soong Ho; Harte, Jessica C.; Gandy, Sam] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Ruiz, Henry H.; Hsieh, Wilson; Buettner, Christoph] Icahn Sch Med Mt Sinai, Dept Med, Diabet Obes & Metab Inst, New York, NY 10029 USA. [Glabe, Charles] Univ Calif Irvine, Irvine, CA 92697 USA. [Klein, William L.] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA. [Attie, Alan D.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA. [Ehrlich, Michelle E.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Glabe, Charles] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia. [Glabe, Charles] King Abdulaziz Univ, King Fahd Med Res Ctr, Expt Biochem Unit, Jeddah 21413, Saudi Arabia. RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Gandy, S (reprint author), Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.; Gandy, S (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. EM samuel.gandy@mssm.edu RI Faculty of, Sciences, KAU/E-7305-2017 FU BLRD VA [I01 BX000348]; NIA NIH HHS [R34 AG049649, P50 AG005138, U01 AG046170]; NIAAA NIH HHS [AA023416, R01 AA023416]; NIDDK NIH HHS [DK074873, DK082724, DK083568, K08 DK074873, R03 DK082724]; NINDS NIH HHS [NS075685, R01 NS075685]; RRD VA [I01 RX000684] NR 70 TC 2 Z9 2 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-5960 J9 ACTA NEUROPATHOL COM JI Acta Neuropathol. Commun. PD FEB 25 PY 2016 VL 4 AR 16 DI 10.1186/s40478-016-0282-y PG 15 WC Neurosciences SC Neurosciences & Neurology GA DE7SE UT WOS:000370836200001 PM 26916443 ER PT J AU Pott, GB Tsurudome, M Bamfo, N Goalstone, ML AF Pott, Gregory B. Tsurudome, Mark Bamfo, Nadia Goalstone, Marc L. TI ERK2 and Akt are negative regulators of insulin and Tumor Necrosis Factor-alpha stimulated VCAM-1 expression in rat aorta endothelial cells SO JOURNAL OF INFLAMMATION-LONDON LA English DT Article DE Atherosclerosis; Inflammation; ERK2; Akt; RNAi; Insulin; TNF alpha; VCAM-1 ID ADHESION MOLECULE-1 EXPRESSION; ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; CARDIOVASCULAR-DISEASE; SURFACE EXPRESSION; RESISTANCE; DIFFERENTIATION; INFLAMMATION; MONOCYTE AB Background: Diabetes is quickly becoming the most widespread disorder in the Western world. Among the most prevalent effects of diabetes is atherosclerosis, which in turn is driven in part by inflammation. Both insulin and Tumor Necrosis Factor-alpha (TNF alpha) increase the presence of Vascular Cellular Adhesion Molecule-1 (VCAM-1) expression. The aim of this study is to determine the effects of downregulating Extracellular signal-Regulated Kinase-2 (ERK2) and Akt on insulin and TNF alpha-stimulated VCAM-1 expression. Methods: Here we begin to define the relationships between ERK2 and Akt regulation of insulin and TNF alpha-stimulated VCAM-1 expression in Rat Arterial Endothelial Cells (RAEC) by transfecting RAEC with ERK2 and Akt RNA interference (RNAi) and then treating these cells with insulin (10 nM) or TNF alpha (10 ng/mL) alone or in combination. Results: Western blot analyses, flow cytometry and confocal microscopy were used to determine changes in VCAM-1 expression within the above-stated parameters. Cells transfected with ERK2 or Akt RNAi plasmids increased insulin and TNF alpha-stimulated VCAM-1 total protein expression significantly (P < 0.05) greater than that seen in mock transfected cells and expressed cell surface VCAM-1 greater than that seen in mock transfected cells as indicated by flow cytometry and confocal microscopy. Nevertheless, the decrease of both kinases did not increase insulin or TNF alpha-stimulated VCAM-1 expression above that seen when one or the other RNAi was present. Conclusions: Taken together, our results demonstrate that ERK2 and Akt may be negative regulators of insulin and TNF-alpha stimulated VCAM-1 and that their loss or down regulation might upregulate VCAM-1 expression and contribute to vascular disease. C1 [Pott, Gregory B.; Tsurudome, Mark; Bamfo, Nadia; Goalstone, Marc L.] Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, 12801 East 17th Ave Mail Stop 8106, Aurora, CO 80045 USA. [Goalstone, Marc L.] Eastern Colorado Hlth Care Syst, Denver VA Med Ctr, 1055 Clermont St Mail Stop 151, Denver, CO 80220 USA. RP Goalstone, ML (reprint author), Univ Colorado Anschutz Med Campus, Div Endocrinol Metab & Diabet, 12801 East 17th Ave Mail Stop 8106, Aurora, CO 80045 USA.; Goalstone, ML (reprint author), Eastern Colorado Hlth Care Syst, Denver VA Med Ctr, 1055 Clermont St Mail Stop 151, Denver, CO 80220 USA. EM Marc.Goalstone@va.gov FU Research Service of the Department of Veterans Affairs FX This work was supported by the Research Service of the Department of Veterans Affairs (to M.L.G.), in which Dr. Goalstone is a recipient of a VA Merit Review Award. We would like to thank Ron Bouchard for his excellent work in confocal microscopy and Harsh Pratap for his beneficial assistance with our flow cytometry measurements. The flow cytometer is equipment associated with the Mucosal and Vaccine Research Colorado (MAVRC). NR 25 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-9255 J9 J INFLAMM-LOND JI J. Inflamm.-Lond. PD FEB 25 PY 2016 VL 13 AR 6 DI 10.1186/s12950-016-0115-6 PG 9 WC Immunology SC Immunology GA DF1WR UT WOS:000371130600001 PM 26917991 ER PT J AU Paul-Emile, K Smith, AK Lo, B Fernandez, A AF Paul-Emile, Kimani Smith, Alexander K. Lo, Bernard Fernandez, Alicia TI Dealing with Racist Patients SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Paul-Emile, Kimani] Fordham Univ, Sch Law, New York, NY 10023 USA. [Lo, Bernard] Greenwall Fdn, New York, NY USA. [Smith, Alexander K.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94143 USA. [Fernandez, Alicia] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Paul-Emile, K (reprint author), Fordham Univ, Sch Law, New York, NY 10023 USA. NR 3 TC 2 Z9 2 U1 1 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 25 PY 2016 VL 374 IS 8 BP 708 EP 711 DI 10.1056/NEJMp1514939 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DE6BB UT WOS:000370716600004 PM 26933847 ER PT J AU Yang, N Friedl, A AF Yang, Ning Friedl, Andreas TI Syndecan-1-Induced ECM Fiber Alignment Requires Integrin alpha v beta 3 and Syndecan-1 Ectodomain and Heparan Sulfate Chains SO PLOS ONE LA English DT Article ID CELL-SURFACE PROTEOGLYCAN; BREAST-CARCINOMA CELLS; EXTRACELLULAR-MATRIX; FIBRONECTIN MATRIX; CANCER CELLS; 3-DIMENSIONAL MATRICES; BETA-3 INTEGRINS; ACTIN-FILAMENTS; NUCLEAR SHAPE; BINDING-SITE AB Expression of the cell surface proteoglycan syndecan-1 (Sdc1) is frequently induced in stromal fibroblasts of invasive breast carcinomas. We have recently identified a correlation between stromal Sdc1 expression and extracellular matrix (ECM) fiber alignment, both in vitro and in vivo. ECMs derived from Sdc1-positive human mammary fibroblasts (HMF) showed an aligned fiber architecture, which contrasted markedly with the more random fiber arrangement in the ECM produced by Sdc1-negative HMFs. We further demonstrated that aligned fiber architecture promotes the directional migration and invasion of breast carcinoma cells. To decipher the molecular mechanisms governing the formation of an aligned, invasion-permissive ECM, a series of Sdc1 mutants was introduced into HMF. We found that both the ectodomain and heparan sulfate chains of Sdc1 were required for full activity of Sdc1 in regulating ECM alignment, while transmembrane and cytoplasmic domains were dispensable. Sdc1 regulates the activities of several integrins via its ectodomain. Integrins are key players in the assembly of fibronectin-rich ECM. In addition, integrins are capable of regulating cell morphology and cell shape and orientation may affect ECM architecture. Therefore, we investigated the role of integrins in Sdc1-mediated ECM fiber alignment. Sdc1-overexpressing HMF gained an enhanced spindle-shaped morphology when cultured in an overconfluent state under conditions permissive for ECM production, which was partially reversed by siRNA-mediated silencing of beta 3 integrin expression. Moreover, suppression of alpha v beta 3 integrin activity by a function-blocking antibody or beta 3 knockdown largely abolished the aligned ECM fiber architecture and consequently the invasion-permissive properties of the ECM induced by Sdc1. The results suggest that Sdc1 may modulate fibronectin fibrillogenesis and/or alter cell morphology during ECM production through alpha v beta 3 integrin, thereby mediating ECM fiber alignment. Understanding the mechanisms governing ECM organization may lead to the development of novel stroma-targeted therapy for breast cancer, aiming at converting an invasion-permissive to an invasion-restrictive microenvironment. C1 [Yang, Ning; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. [Friedl, Andreas] UW Carbone Canc Ctr, Madison, WI USA. RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.; Friedl, A (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.; Friedl, A (reprint author), UW Carbone Canc Ctr, Madison, WI USA. EM afriedl@wisc.edu FU National Cancer Institute [R01 CA107012-06]; NIH/NCI [R01 CA107012] FX This work was supported by the National Cancer Institute, R01 CA107012-06 (http://www.cancer.gov). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by NIH/NCI grant R01 CA107012. The authors are grateful to other members of the Friedl lab, especially Kristy Key Meyer, for help with experiments. The authors also thank the University of Wisconsin Carbone Cancer Center (P30 CA014520 40) for use of its facilities and Flow Cytometry Laboratory. The contents do not represent the views of the Dept. of Veterans Affairs or the United States Government. NR 81 TC 1 Z9 1 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 24 PY 2016 VL 11 IS 2 AR e0150132 DI 10.1371/journal.pone.0150132 PG 25 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF2IA UT WOS:000371164700069 PM 26909794 ER PT J AU Chen, JS Sprague, BL Klabunde, CN Tosteson, ANA Bitton, A Onega, T MacLean, CD Harris, K Schapira, MM Haas, JS AF Chen, Jane S. Sprague, Brian L. Klabunde, Carrie N. Tosteson, Anna N. A. Bitton, Asaf Onega, Tracy MacLean, Charles D. Harris, Kimberly Schapira, Marilyn M. Haas, Jennifer S. CA PROSPR Population-Based Res Optim TI Take the money and run? Redemption of a gift card incentive in a clinician survey SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article DE Survey methods; Provider surveys ID SURVEY RESPONSE RATES; PHYSICIANS; BREAST AB Background: Clinician surveys provide critical information about many facets of health care, but are often challenging to implement. Our objective was to assess use by participants and non-participants of a prepaid gift card incentive that could be later reclaimed by the researchers if unused. Methods: Clinicians were recruited to participate in a mailed or online survey as part of a study to characterize women's primary health care provider attitudes towards breast and cervical cancer screening guidelines and practices (n = 177). An up-front incentive of a $50 gift card to a popular online retailer was included with the study invitation. Clinicians were informed that the gift card would expire if it went unused after 4 months. Outcome measures included use of gift cards by participants and non-participants and comparison of hypothetical costs of different incentive strategies. Results: 63.5 % of clinicians who responded to the survey used the gift card, and only one provider who didn't participate used the gift card (1.6 %). Many of those who participated did not redeem their gift cards (36.5 % of respondents). The price of the incentives actually claimed totaled $3700, which was less than half of the initial outlay. Since some of the respondents did not redeem their gift cards, the cost of incentives was less than it might have been if we had provided a conditional incentive of $50 to responders after they had completed the survey. Conclusions: Redeemable online gift card codes may provide an effective way to motivate clinicians to participate in surveys. C1 [Chen, Jane S.; Bitton, Asaf; Harris, Kimberly; Haas, Jennifer S.] Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. [Bitton, Asaf; Haas, Jennifer S.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Sprague, Brian L.; MacLean, Charles D.] Univ Vermont, Burlington, VT USA. [Tosteson, Anna N. A.; Onega, Tracy] Dartmouth & Norris Cotton Canc Ctr, Geisel Sch Med, Lebanon, NH USA. [Klabunde, Carrie N.] NIH, Off Director, Off Dis Prevent, Bethesda, MD USA. [Haas, Jennifer S.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Schapira, Marilyn M.] Univ Penn, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Chen, Jane S.] Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA.; Haas, JS (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM jhaas@partners.org FU [U54 CA163307]; [U54 CA 163313]; [U54 CA163303] FX The authors thank the participating PROSPR Research Centers for the data they have provided for this study. A list of the PROSPR investigators and contributing research staff are provided at: http://healthcaredelivery.cancer.gov/prospr/. (Grant numbers U54 CA163307, U54 CA 163313, U54 CA163303). NR 9 TC 1 Z9 1 U1 2 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD FEB 24 PY 2016 VL 16 AR 25 DI 10.1186/s12874-016-0126-2 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DE7SH UT WOS:000370836500002 PM 26911445 ER PT J AU Lau, KM Madden, E Neylan, TC Seal, KH Maguen, S AF Lau, Karen M. Madden, Erin Neylan, Thomas C. Seal, Karen H. Maguen, Shira TI Assessing for mild TBI among Iraq and Afghanistan veterans: Outcomes of injury severity and neurological factors SO BRAIN INJURY LA English DT Article DE veterans; injury severity markers; nausea; neurologic symptoms; Traumatic brain injury ID TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL SYMPTOM INVENTORY; POSTCONCUSSION SYNDROME; CLINICAL MANAGEMENT; HEAD-INJURY; MILITARY; DIAGNOSIS; MANIFESTATIONS; CLASSIFICATION; PERFORMANCE AB Objective: To investigate injury severity markers and neurological symptoms associated with clinician-confirmed mild traumatic brain injury (TBI) among Iraq and Afghanistan veterans. Setting: Department of Veterans Affairs (VA) medical centre and five affiliated community-based outpatient clinics. Participants: Three hundred and fifty Iraq and Afghanistan veterans with positive initial VA TBI screens between 1 April 2007 and 1 June 2010 and clinician-confirmed TBI status by 1 December 2010. Methods: Retrospective-cohort study of medical record data. Main measures included clinician-confirmed TBI status, injury severity markers (e.g. loss of consciousness (LOC), post-traumatic amnesia (PTA) or confusion/disorientation) and neurological symptoms. Results: Among veterans who screened positive on the initial VA TBI and then received a clinician evaluation, 60% were confirmed to have a TBI diagnosis. Veterans reporting at least one LOC, confusion or PTA were almost 18-times more likely to receive a confirmed TBI diagnosis. Odds of clinician-confirmed TBI were 2.5-3-times greater among those who endorsed dizziness, poor coordination, headaches, nausea, vision problems and/or irritability, compared to those not endorsing these symptoms. Nausea had greatest utility for confirming a TBI. Conclusions: Identification of neurologic symptoms that most contribute to a clinician-confirmed diagnosis of TBI has potential for streamlining detection of TBI and symptoms needed for treatment. C1 [Lau, Karen M.; Madden, Erin; Neylan, Thomas C.; Seal, Karen H.; Maguen, Shira] San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. [Neylan, Thomas C.; Seal, Karen H.; Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Seal, Karen H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Lau, KM (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM karen.lau2@va.gov FU Department of Defense Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program; VA Health Sciences Research and Development (HSR&D) Career Development 475 Award FX This research was supported by a Department of Defense Psychological Health and Traumatic Brain Injury (PH/TBI) Research Program (Maguen) and VA Health Sciences Research and Development (HSR&D) Career Development 475 Award (Maguen). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. NR 37 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD FEB 23 PY 2016 VL 30 IS 3 BP 287 EP 294 DI 10.3109/02699052.2015.1089601 PG 8 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DG9QM UT WOS:000372418900006 PM 26910483 ER PT J AU Anderson, RI Lopez, MF Becker, HC AF Anderson, Rachel I. Lopez, Marcelo F. Becker, Howard C. TI Stress-Induced Enhancement of Ethanol Intake in C57BL/6J Mice with a History of Chronic Ethanol Exposure: Involvement of Kappa Opioid Receptors SO FRONTIERS IN CELLULAR NEUROSCIENCE LA English DT Article DE ethanol; stress; kappa opioid receptor; dynorphin; mice ID CORTICOTROPIN-RELEASING-FACTOR; COCAINE PLACE PREFERENCE; ANXIETY-LIKE BEHAVIOR; CENTRAL AMYGDALA; ALCOHOL-DRINKING; INDUCED REINSTATEMENT; INDUCED INCREASES; CENTRAL NUCLEUS; SOCIAL STRESS; SALVINORIN-A AB Our laboratory has previously demonstrated that daily forced swim stress (FSS) prior to ethanol drinking sessions facilitates enhanced ethanol consumption in mice with a history of chronic intermittent ethanol (CIE) vapor exposure without altering ethanol intake in air -exposed controls. Because both stress and chronic ethanol exposure have been shown to activate the dynorphin/kappa opioid receptor (KOR) system, the present study was designed to explore a potential role for KORs in modulating stress effects on ethanol consumption in the CIE model of dependence and relapse drinking. After stable baseline ethanol intake was established in adult male C57BU6J mice, subjects received chronic intermittent exposure (16 h/day x 4 days/week) to ethanol vapor (CIE group) or air (CTL group). Weekly cycles of inhalation exposure were alternated with 5 -day limited access drinking tests (1 h access to 15% ethanol). Experiment 1 compared effects of daily FSS and KOR activation on ethanol consumption. CIE and CTL mice were either exposed to FSS (10 min), the KOR agonist U50,488 (5 mg/kg), or a vehicle injection (non stressedcondition) prior to each daily drinking session during test weeks. FSS selectively increased drinking in CIE mice. U50,488 mimicked this effect in CIE mice, but also increased drinking in CTL mice. Experiment 2 assessed effects of KOR blockade on stress induced drinking in CIE and CTL mice. Stressed and non stressed mice were administered the short -acting KOR antagonist LY2444296 (0 or 5 mg/kg) 30 min prior to each drinking session during test weeks. FSS selectively increased ethanol consumption in CIE mice, an effect that was abolished by LY2444296 pretreatment. In Experiment 3, CIE and CTL mice were administered one of four doses of U50,488 (0, 1.25, 2.5, 5.0 mg/kg) 1 h prior to each daily drinking test (in lieu of FSS). All doses of U50,488 increased ethanol consumption in both CIE and CTL mice. The U50,488 induced increase in drinking was blocked by LY2444296. Our results demonstrate that the KOR system contributes to the stress enhancement of ethanol intake in mice with a history of chronic ethanol exposure. C1 [Anderson, Rachel I.; Lopez, Marcelo F.; Becker, Howard C.] Med Univ S Carolina, Charleston, SC 29425 USA. [Anderson, Rachel I.; Lopez, Marcelo F.; Becker, Howard C.] Charleston Alcohol Res Ctr, Charleston, SC USA. [Becker, Howard C.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA. RP Anderson, RI (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.; Anderson, RI (reprint author), Charleston Alcohol Res Ctr, Charleston, SC USA. EM andersor@musc.edu OI Anderson, Rachel/0000-0002-6671-4810 FU NIH/NIAAA [U01 AA014095, P50 AA010761, U01 AA020929, T32 AA007474, F32 AA023700] FX This work was supported by NIH/NIAAA grants to HCB (U01 AA014095, P50 AA010761) and MFL (U01 AA020929). RIA was supported by NIH/NIAAA grants T32 AA007474 and F32 AA023700. Thanks to Chelsea Johnson, Rebecca Kritschil, and Anne Olsen for technical assistance. NR 60 TC 3 Z9 3 U1 1 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5102 J9 FRONT CELL NEUROSCI JI Front. Cell. Neurosci. PD FEB 23 PY 2016 VL 10 AR 45 DI 10.3389/fncel.2016.00045 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DE5FH UT WOS:000370656100001 PM 26941607 ER PT J AU Nagae, LM Honce, JM Tanabe, J Shelton, E Sillau, SH Berman, BD AF Nagae, Lidia M. Honce, Justin M. Tanabe, Jody Shelton, Erika Sillau, Stefan H. Berman, Brian D. TI Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes SO FRONTIERS IN NEUROANATOMY LA English DT Article DE Parkinson disease; motor subtypes; diffusion tensor imaging; basal ganglia ID SUBSTANTIA-NIGRA; MOTOR SUBTYPES AB Diffusion tensor imaging (DTI) of the substantia nigra has shown promise in detecting and quantifying neurodegeneration in Parkinson disease (PD). It remains unknown, however, whether differences in microstructural changes within the basal ganglia underlie PD motor subtypes. We investigated microstructural changes within the basal ganglia of mild to moderately affected PD patients using DTI and sought to determine if microstructural changes differ between the tremor dominant (TD) and postural instability/gait difficulty (PIGD) subtypes. Fractional anisotropy, mean diffusivity, radial, and axial diffusivity were obtained from bilateral caudate, putamen, globus pallidus, and substantia nigra of 21 PD patients (12 TD and 9 PIGD) and 20 age-matched healthy controls. T-tests and ANOVA methods were used to compare PD patients, subtypes, and controls, and Spearman correlations tested for relationships between DTI and clinical measures. We found our cohort of PD patients had reduced fractional anisotropy within the substantia nigra and increased mean and radial diffusivity within the substantia nigra and globus pallidus compared to controls, and that changes within those structures were largely driven by the PIGD subtype. Across all PD patients fractional anisotropy within the substantia nigra correlated with disease stage, while in PIGD patients increased diffusivity within the globus pallidus correlated with disease stage and motor severity. We conclude that PIGD patients have more severely affected microstructural changes within the substantia nigra compared to TD, and that microstructural changes within the globus pallidus may be particularly relevant for the manifestation of the PIGD subtype. C1 [Nagae, Lidia M.; Honce, Justin M.; Tanabe, Jody; Berman, Brian D.] Univ Colorado, Dept Biol, Anschutz Med Campus, Aurora, CO USA. [Shelton, Erika; Sillau, Stefan H.; Berman, Brian D.] Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO USA. [Berman, Brian D.] Denver VA Med Ctr, Neurol Sect, Denver, CO USA. RP Berman, BD (reprint author), Univ Colorado, Dept Biol, Anschutz Med Campus, Aurora, CO USA.; Berman, BD (reprint author), Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO USA.; Berman, BD (reprint author), Denver VA Med Ctr, Neurol Sect, Denver, CO USA. EM brian.berman@ucdenver.edu FU NIH/NCATS Colorado CTSI Grant [KL2 TR001080]; University of Colorado Department of Neurology; University of Colorado Center for NeuroScience FX This work was supported by NIH/NCATS Colorado CTSI Grant Number KL2 TR001080, the University of Colorado Department of Neurology, and the University of Colorado Center for NeuroScience. NR 30 TC 3 Z9 3 U1 0 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5129 J9 FRONT NEUROANAT JI Front. Neuroanat. PD FEB 23 PY 2016 VL 10 AR 17 DI 10.3389/fnana.2016.00017 PG 9 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA DE5AI UT WOS:000370642000001 PM 26941615 ER PT J AU Maertens, JA Raad, II Marr, KA Patterson, TF Kontoyiannis, DP Cornely, OA Bow, EJ Rahav, G Neofytos, D Aoun, M Baddley, JW Giladi, M Heinz, WJ Herbrecht, R Hope, W Karthaus, M Lee, DG Lortholary, O Morrison, VA Oren, I Selleslag, D Shoham, S Thompson, GR Lee, M Maher, RM Schmitt-Hoffmann, AH Zeiher, B Ullmann, AJ AF Maertens, Johan A. Raad, Issam I. Marr, Kieren A. Patterson, Thomas F. Kontoyiannis, Dimitrios P. Cornely, Oliver A. Bow, Eric J. Rahav, Galia Neofytos, Dionysios Aoun, Mickael Baddley, John W. Giladi, Michael Heinz, Werner J. Herbrecht, Raoul Hope, William Karthaus, Meinolf Lee, Dong-Gun Lortholary, Olivier Morrison, Vicki A. Oren, Ilana Selleslag, Dominik Shoham, Shmuel Thompson, George R., III Lee, Misun Maher, Rochelle M. Schmitt-Hoffmann, Anne-Hortense Zeiher, Bernhardt Ullmann, Andrew J. TI Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial SO LANCET LA English DT Article ID PHARMACODYNAMIC TARGET DETERMINATION; LIPOSOMAL AMPHOTERICIN-B; CELL TRANSPLANT PATIENTS; MYCOSES STUDY-GROUP; EUROPEAN-ORGANIZATION; PULMONARY ASPERGILLOSIS; CLINICAL-PRACTICE; THERAPY; INFECTIONS; CANCER AB Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. Methods This was a phase 3, double-blind, global multicentre, comparative-group study. Patients with suspected invasive mould disease were randomised in a 1: 1 ratio using an interactive voice-web response system, stratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malignant disease at baseline, to receive isavuconazonium sulfate 372 mg (prodrug; equivalent to 200 mg isavuconazole; intravenously three times a day on days 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards). We tested non-inferiority of the primary efficacy endpoint of all-cause mortality from first dose of study drug to day 42 in patients who received at least one dose of the study drug (intention-to-treat [ITT] population) using a 10% non-inferiority margin. Safety was assessed in patients who received the first dose of study drug. This study is registered with ClinicalTrials.gov, number NCT00412893. Findings 527 adult patients were randomly assigned (258 received study medication per group) between March 7, 2007, and March 28, 2013. All-cause mortality from first dose of study drug to day 42 for the ITT population was 19% with isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment difference of -1.0% (95% CI -7.8 to 5.7). Because the upper bound of the 95% CI (5.7%) did not exceed 10%, non-inferiority was shown. Most patients (247 [96%] receiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0.122); the most common were gastrointestinal disorders (174 [68%] vs 180 [69%]) and infections and infestations (152 [59%] vs 158 [61%]). Proportions of patients with treatment-emergent adverse events by system organ class were similar overall. However, isavuconazole-treated patients had a lower frequency of hepatobiliary disorders (23 [9%] vs 42 [16%]; p=0.016), eye disorders (39 [15%] vs 69 [27%]; p=0.002), and skin or subcutaneous tissue disorders (86 [33%] vs 110 [42%]; p=0.037). Drug-related adverse events were reported in 109 (42%) patients receiving isavuconazole and 155 (60%) receiving voriconazole (p<0.001). Interpretation Isavuconazole was non-inferior to voriconazole for the primary treatment of suspected invasive mould disease. Isavuconazole was well tolerated compared with voriconazole, with fewer study-drug-related adverse events. Our results support the use of isavuconazole for the primary treatment of patients with invasive mould disease. C1 [Maertens, Johan A.] Katholieke Univ Leuven, Univ Ziekenhuizen Leuven, Dept Hematol, Louvain, Belgium. [Raad, Issam I.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA. [Marr, Kieren A.; Shoham, Shmuel] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Marr, Kieren A.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD USA. [Neofytos, Dionysios] Johns Hopkins Univ, Div Infect Dis, Baltimore, MD USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA. [Cornely, Oliver A.] Univ Cologne, ZKS Koln Ctr Integrated Oncol CIO Koln Bonn, Cologne Excellence Cluster Cellular Stress Respon, Dept Internal Med,Clin Trials Ctr Cologne,German, D-50931 Cologne, Germany. [Bow, Eric J.] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada. [Bow, Eric J.] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada. [Bow, Eric J.] CancerCare Manitoba, Infect Control Serv, Winnipeg, MB, Canada. [Rahav, Galia] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel. [Rahav, Galia] Tel Aviv Univ, Sackler Sch Med, Ramat Gan, Israel. [Aoun, Mickael] Inst Jules Bordet, Div Infect Dis, B-1000 Brussels, Belgium. [Baddley, John W.] Univ Alabama Birmingham, Birmingham, AL USA. [Baddley, John W.] Vet Affairs Med Ctr, Birmingham, AL USA. [Giladi, Michael] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Infect Dis Unit, IL-69978 Tel Aviv, Israel. [Giladi, Michael] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Heinz, Werner J.] Univ Wurzburg, Med Ctr, D-97070 Wurzburg, Germany. [Herbrecht, Raoul] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France. [Herbrecht, Raoul] Univ Strasbourg, Strasbourg, France. [Hope, William] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England. [Karthaus, Meinolf] Klinikum Neuperlach, Klin Hamatol & Onkol, Munich, Germany. [Lee, Dong-Gun] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Infect Dis, Seoul, South Korea. [Lortholary, Olivier] Univ Paris 05, Ctr Infectiol Necker Pasteur, Hop Necker Enfants Malades, IHU Imagine, Paris, France. [Lortholary, Olivier] Inst Pasteur, Ctr Natl Reference Mycoses Invas & Antifong, Paris, France. [Morrison, Vicki A.] Univ Minnesota, Minneapolis, MN USA. [Morrison, Vicki A.] Vet Affairs Med Ctr, Minneapolis, MN USA. [Oren, Ilana] Rambam Hlth Care Campus, Infect Dis Unit, Haifa, Israel. [Oren, Ilana] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel. [Selleslag, Dominik] Algemeen Ziekenhuis St Jan, Brugge, Belgium. [Thompson, George R., III] Univ Calif Davis, Med Ctr, Davis, CA 95616 USA. [Lee, Misun; Maher, Rochelle M.; Zeiher, Bernhardt] Astellas Pharma Global Dev, Northbrook, IL USA. [Schmitt-Hoffmann, Anne-Hortense] Basilea Pharmaceut Int, Basel, Switzerland. [Ullmann, Andrew J.] Univ Wurzburg, Dept Internal Med 2, Infect Dis, Oderdurrbacher Str 6, D-97080 Wurzburg, Germany. RP Ullmann, AJ (reprint author), Univ Wurzburg, Dept Internal Med 2, Infect Dis, Oderdurrbacher Str 6, D-97080 Wurzburg, Germany. EM andrew.ullmann@uni-wuerzburg.de OI Patterson, Thomas /0000-0002-9513-7127; Heinz, Werner/0000-0002-7833-9202; Herbrecht, Raoul/0000-0002-9381-4876; Hope, William/0000-0001-6187-878X FU Astellas Pharma Global Development FX Isavuconazole was co-developed by Astellas Pharma US and Basilea Pharmaceutica International. We acknowledge the contributions of the medical director of the SECURE trial, Neddie Zadeikis (Astellas Pharma Global Development during the conduct of the study) in the design and conduct of the study. Editorial assistance was provided by Radhika Bhatia, of Envision Scientific Solutions, funded by Astellas Pharma Global Development. NR 32 TC 53 Z9 53 U1 15 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD FEB 20 PY 2016 VL 387 IS 10020 BP 760 EP 769 DI 10.1016/S0140-6736(15)01159-9 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DE1WU UT WOS:000370418000035 PM 26684607 ER PT J AU Baxi, SM Scherzer, R Greenblatt, RM Minkoff, H Sharma, A Cohen, M Young, MA Abraham, AG Shlipak, MG AF Baxi, Sanjiv M. Scherzer, Rebecca Greenblatt, Ruth M. Minkoff, Howard Sharma, Anjali Cohen, Mardge Young, Mary A. Abraham, Alison G. Shlipak, Michael G. CA Womens Interagency HIV Study TI Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV SO AIDS LA English DT Article DE adverse drug effect; HIV; kidney function; pharmacokinetics; tenofovir; Women's Interagency HIV Study ID DISOPROXIL FUMARATE; INFECTED PATIENTS; RENAL TOXICITY; INCOMPLETE REVERSIBILITY; ANTIRETROVIRAL ACTIVITY; PLASMA-CONCENTRATIONS; CLINICAL-TRIALS; PHASE I/II; PHARMACOKINETICS; ALAFENAMIDE AB Objective:Tenofovir disoproxil fumarate is a commonly used antiretroviral drug, but risk factors for tenofovir (TFV)-associated kidney disease are not fully understood. We used intensive pharmacokinetic studies in a cohort of HIV-infected women on TFV-based therapy to study the relationship between TFV exposure and subsequent kidney function.Design:This is a nested study within the Women's Interagency HIV Study, a multicenter, prospective cohort of HIV-infected women. Participants on TFV-based therapy underwent 24-h intensive pharmacokinetic sampling after witnessed dose. Kidney function was measured over the succeeding 7 years by serum creatinine [estimated glomerular filtration rate calculated by serum creatinine (eGFRcr)].Methods:Multivariable linear mixed models evaluated the relationship of baseline TFV area under the-time concentration curves (AUCs) with subsequent changes in kidney function. Covariates included age, diabetes, hypertension, race, BMI, ritonavir use, duration of TFV exposure, current CD4(+) cell count, and HIV viral load.Results:Of the 105 participants, persons within the highest baseline TFV AUC tertile had significantly lower eGFRcr compared with those in the lowest tertile (meanstandard error: 80 +/- 4.3 vs. 104 +/- 2.5ml/min per 1.73m(2), P<0.0001). By year 7, this difference widened (72 +/- 4.9 vs. 105 +/- 2.9, P<0.0001). After multivariable adjustment, TFV AUC in the highest tertile remained associated with lower eGFRcr relative to values in the lowest tertile at both baseline (-15ml/min per 1.73m(2), P=0.0047) and year 7 (-23ml/min per 1.73m(2), P=0.0002).Conclusion:Through intensive TFV pharmacokinetic sampling, we found a strong association between greater TFV exposure and subsequent decline in kidney function. Variations in TFV drug exposure may partially account for subsequent nephrotoxicity in persons infected with HIV. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Baxi, Sanjiv M.; Scherzer, Rebecca; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Baxi, Sanjiv M.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Scherzer, Rebecca; Shlipak, Michael G.] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA USA. [Greenblatt, Ruth M.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Greenblatt, Ruth M.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Minkoff, Howard] Suny Downstate Med Ctr, Div Infect Dis, Brooklyn, NY 11203 USA. [Sharma, Anjali] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Cohen, Mardge] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Div Infect Dis, Chicago, IL USA. [Young, Mary A.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Abraham, Alison G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Baxi, SM (reprint author), Univ Calif San Francisco, Div Infect Dis, 513 Parnassus Ave,Room S380, San Francisco, CA 94143 USA. EM sanjiv.baxi@ucsf.edu FU Bronx WIHS [U01-AI-035004]; Brooklyn WIHS [U01-AI-031834]; Chicago WIHS [U01-AI-034993]; Metropolitan Washington WIHS [U01-AI-034994]; Connie Wofsy Women's HIV Study, Northern California [U01-AI-034989, R01 AI 65233]; WIHS Data Management and Analysis Center [U01-AI-042590]; Southern California WIHS [U01-HD-032632]; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Cancer Institute (NCI); National Institute on Drug Abuse (NIDA); National Institute on Mental Health (NIMH); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute on Deafness and other Communication Disorders (NIDCD); NIH Office of Research on Women's Health; UCSF CTSA [UL1-TR000004]; UCSF Traineeship in AIDS Prevention Studies [US National Institutes of Health (NIH)] [T32 MH-19105]; National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR) [P30-AI027763]; US NIH National Institute on Aging [2R01AG03485306] FX WIHS (Principal Investigators): Bronx WIHS (Kathryn Anastos), U01-AI-035004; Brooklyn WIHS (Howard Minkoff and Deborah Gustafson), U01-AI-031834; Chicago WIHS (Mardge Cohen), U01-AI-034993; Metropolitan Washington WIHS (Mary Young), U01-AI-034994; Connie Wofsy Women's HIV Study, Northern California (Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien) U01-AI-034989; and R01 AI 65233 (NIAID/NIH, P.I. Greenblatt); WIHS Data Management and Analysis Center (Stephen Gange and Elizabeth Golub), U01-AI-042590; Southern California WIHS (Alexandra Levine and Marek Nowicki), U01-HD-032632 (WIHS I-WIHS IV). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA), and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD), and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA). S.M.B. is supported by the UCSF Traineeship in AIDS Prevention Studies [US National Institutes of Health (NIH) T32 MH-19105]. This research was also supported by a grant from the National Institutes of Health, University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR), P30-AI027763 (Principal Investigators Paul Volberding and Warner Greene). M.G.S. and R.S. by the US NIH National Institute on Aging grant 2R01AG03485306. NR 43 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD FEB 20 PY 2016 VL 30 IS 4 BP 609 EP 617 DI 10.1097/QAD.0000000000000958 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DC7ST UT WOS:000369421400009 PM 26558723 ER PT J AU Scheckel, C Drapeau, E Frias, MA Park, CY Fak, J Zucker-Scharff, I Kou, Y Haroutunian, V Ma'ayan, A Buxbaum, JD Darnell, RB AF Scheckel, Claudia Drapeau, Elodie Frias, Maria A. Park, Christopher Y. Fak, John Zucker-Scharff, Ilana Kou, Yan Haroutunian, Vahram Ma'ayan, Avi Buxbaum, Joseph D. Darnell, Robert B. TI Regulatory consequences of neuronal ELAV-like protein binding to coding and non-coding RNAs in human brain SO ELIFE LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; DIFFERENTIAL EXPRESSION ANALYSIS; GAP-43 GENE-EXPRESSION; RO 60-KDA AUTOANTIGEN; MESSENGER-RNA; ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; PC12 CELLS; HITS-CLIP; PARKINSON-DISEASE AB Neuronal ELAV-like (nELAVL) RNA binding proteins have been linked to numerous neurological disorders. We performed crosslinking-immunoprecipitation and RNAseq on human brain, and identified nELAVL binding sites on 8681 transcripts. Using knockout mice and RNAi in human neuroblastoma cells, we showed that nELAVL intronic and 3' UTR binding regulates human RNA splicing and abundance. We validated hundreds of nELAVL targets among which were important neuronal and disease-associated transcripts, including Alzheimer's disease (AD) transcripts. We therefore investigated RNA regulation in AD brain, and observed differential splicing of 150 transcripts, which in some cases correlated with differential nELAVL binding. Unexpectedly, the most significant change of nELAVL binding was evident on non-coding Y RNAs. nELAVL/Y RNA complexes were specifically remodeled in AD and after acute UV stress in neuroblastoma cells. We propose that the increased nELAVL/Y RNA association during stress may lead to nELAVL sequestration, redistribution of nELAVL target binding, and altered neuronal RNA splicing. C1 [Scheckel, Claudia; Frias, Maria A.; Park, Christopher Y.; Fak, John; Zucker-Scharff, Ilana; Darnell, Robert B.] Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA. [Scheckel, Claudia; Frias, Maria A.; Park, Christopher Y.; Fak, John; Zucker-Scharff, Ilana; Darnell, Robert B.] Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA. [Drapeau, Elodie; Kou, Yan; Buxbaum, Joseph D.] Seaver Autism Ctr Res & Treatment, New York, NY USA. [Drapeau, Elodie; Haroutunian, Vahram; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Park, Christopher Y.; Darnell, Robert B.] New York Genome Ctr, New York, NY USA. [Kou, Yan; Ma'ayan, Avi] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, LINCS Data Integrat & Coordinat Ctr BD2K, Mt Sinai Knowledge Management Ctr Illuminating Dr, New York, NY 10029 USA. [Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Haroutunian, Vahram] James J Peters VA Med Ctr, New York, NY USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth Inst, New York, NY 10029 USA. [Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. RP Darnell, RB (reprint author), Rockefeller Univ, Mol Neurooncol Lab, 1230 York Ave, New York, NY 10021 USA.; Darnell, RB (reprint author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.; Buxbaum, JD (reprint author), Seaver Autism Ctr Res & Treatment, New York, NY USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Darnell, RB (reprint author), New York Genome Ctr, New York, NY USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Mindich Child Hlth Inst, New York, NY 10029 USA.; Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. EM buxbaum@mssm.edu; darnelr@rockefeller.edu OI Buxbaum, Joseph/0000-0001-8898-8313 FU EMBO; SNF; Seaver Foundation; National Institutes of Health [ADRC AG005138, AG02219, HHSN27120130031C, R01GM098316, U54CA189201, U54HL127624, NS34389]; G Harold and Leila Y. Mathers Foundation; Simons Foundation; Howard Hughes Medical Institute FX EMBO Long-Term Fellowship Claudia Scheckel; SNF Early and Advanced Postdoc Mobility Fellowship Claudia Scheckel; Seaver Foundation Graduate Fellowship Yan Kou; National Institutes of Health ADRC AG005138 Vahram Haroutunian; National Institutes of Health AG02219 Vahram Haroutunian; National Institutes of Health HHSN27120130031C Vahram Haroutunian; National Institutes of Health R01GM098316 Avi Ma'ayan; National Institutes of Health U54CA189201 Avi Ma'ayan; National Institutes of Health U54HL127624 Avi Ma'ayan; G Harold and Leila Y. Mathers Foundation Joseph D Buxbaum; National Institutes of Health ADRC AG005138 Joseph D Buxbaum; National Institutes of Health NS081706 Robert B Darnell; Simons Foundation Robert B Darnell; National Institutes of Health NS34389 Robert B Darnell; Howard Hughes Medical Institute Robert B Darnell NR 112 TC 8 Z9 8 U1 0 U2 2 PU ELIFE SCIENCES PUBLICATIONS LTD PI CAMBRIDGE PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND SN 2050-084X J9 ELIFE JI eLife PD FEB 19 PY 2016 VL 5 AR e10421 DI 10.7554/eLife.10421 PG 35 WC Biology SC Life Sciences & Biomedicine - Other Topics GA DG2EX UT WOS:000371880400001 ER PT J AU Li, CW Menconi, F Osman, R Mezei, M Jacobson, EM Concepcion, E David, CS Kastrinsky, DB Ohlmeyer, M Tomer, Y AF Li, Cheuk Wun Menconi, Francesca Osman, Roman Mezei, Mihaly Jacobson, Eric M. Concepcion, Erlinda David, Chella S. Kastrinsky, David B. Ohlmeyer, Michael Tomer, Yaron TI Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE cell surface protein; endocrinology; major histocompatibility complex (MHC); peptides; small molecule; structural model; thyroid; thyroid hormone; thyroglobulin; thyroiditis ID MYELIN BASIC-PROTEIN; HLA-DR; TRANSGENIC MICE; GRAVES-DISEASE; HASHIMOTOS-THYROIDITIS; THYROGLOBULIN PEPTIDES; MULTIPLE-SCLEROSIS; UNITED-STATES; L-THYROXINE; CEPHARANTHINE AB We previously showed that an HLA-DR variant containing arginine at position 74 of the DR1 chain (DR1-Arg74) is the specific HLA class II variant conferring risk for autoimmune thyroid diseases (AITD). We also identified 5 thyroglobulin (Tg) peptides that bound to DR1-Arg74. We hypothesized that blocking the binding of these peptides to DR1-Arg74 could block the continuous T-cell activation in thyroiditis needed to maintain the autoimmune response to the thyroid. The aim of the current study was to identify small molecules that can block T-cell activation by Tg peptides presented within DR1-Arg74 pockets. We screened a large and diverse library of compounds and identified one compound, cepharanthine that was able to block peptide binding to DR1-Arg74. We then showed that Tg.2098 is the dominant peptide when inducing experimental autoimmune thyroiditis (EAT) in NOD mice expressing human DR1-Arg74. Furthermore, cepharanthine blocked T-cell activation by thyroglobulin peptides, in particular Tg.2098 in mice that were induced with EAT. For the first time we identified a small molecule that can block Tg peptide binding and presentation to T-cells in autoimmune thyroiditis. If confirmed cepharanthine could potentially have a role in treating human AITD. C1 [Li, Cheuk Wun; Menconi, Francesca; Jacobson, Eric M.; Concepcion, Erlinda; Tomer, Yaron] Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. [Osman, Roman; Mezei, Mihaly; Kastrinsky, David B.; Ohlmeyer, Michael] Icahn Sch Med Mt Sinai, Dept Struct & Chem Biol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. [David, Chella S.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA. [Tomer, Yaron] Bronx Vet Affairs Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Icahn Sch Med Mt Sinai, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu FU National Institutes of Health from NIDDK [DK061659, DK073681]; NIAID [T32 AI007605]; Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants DK061659 and DK073681 from the NIDDK (to Y. T.) and Grant T32 AI007605 from the NIAID (to C. W. L.). This material is based upon work supported in part by the Department of Veterans Affairs. The authors declare that they have no conflicts of interest with the contents of this article. NR 66 TC 1 Z9 1 U1 1 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 19 PY 2016 VL 291 IS 8 BP 4079 EP 4090 DI 10.1074/jbc.M115.694687 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DF4RQ UT WOS:000371338400033 PM 26703475 ER PT J AU Li, J Brock, J Jack, B Mittman, B Naylor, M Sorra, J Mays, G Williams, MV AF Li, Jing Brock, Jane Jack, Brian Mittman, Brian Naylor, Mary Sorra, Joanna Mays, Glen Williams, Mark V. CA Project ACHIEVE Team TI Project ACHIEVE - using implementation research to guide the evaluation of transitional care effectiveness SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Transitional care; Implementation research; Comparative effectiveness; Patient centered ID HOSPITAL READMISSIONS; PUBLIC-HEALTH; FRAMEWORK; DISCHARGE; INTERVENTION; QUALITY; TRIAL; REHOSPITALIZATION; PROGRAM; SCIENCE AB Background: Poorly managed hospital discharges and care transitions between health care facilities can cause poor outcomes for both patients and their caregivers. Unfortunately, the usual approach to health care delivery does not support continuity and coordination across the settings of hospital, doctors' offices, home or nursing homes. Though complex efforts with multiple components can improve patient outcomes and reduce 30-day readmissions, research has not identified which components are necessary. Also we do not know how delivery of core components may need to be adjusted based on patient, caregiver, setting or characteristics of the community, or how system redesign can be accelerated. Methods/design: Project ACHIEVE focuses on diverse Medicare populations such as individuals with multiple chronic diseases, patients with low health literacy/numeracy and limited English proficiency, racial and ethnic minority groups, low-income groups, residents of rural areas, and individuals with disabilities. During the first phase, we will use focus groups to identify the transitional care outcomes and components that matter most to patients and caregivers to inform development and validation of assessment instruments. During the second phase, we will evaluate the comparative effectiveness of multi-component care transitions programs occurring across the U.S. Using a mixed-methods approach for this evaluation, we will study historical (retrospective) and current and future (prospective) groups of patients, caregivers and providers using site visits, surveys, and clinical and claims data. In this natural experiment observational study, we use a fractional factorial study design to specify comparators and estimate the individual and combined effects of key transitional care components. Discussion: Our study will determine which evidence-based transitional care components and/or clusters most effectively produce patient and caregiver desired outcomes overall and among diverse patient and caregiver populations in different healthcare settings. Using the results, we will develop concrete, actionable recommendations regarding how best to implement these strategies. Finally, this work will provide tools for hospitals, community-based organizations, patients, caregivers, clinicians and other stakeholders to help them make informed decisions about which strategies are most effective and how best to implement them in their communities. C1 [Li, Jing] Univ Kentucky, Ctr Hlth Serv Res, Lexington, KY USA. [Li, Jing] Univ Kentucky, Internal Med, Lexington, KY USA. [Brock, Jane] Care Transit Theme Support Ctr, Englewood, CO USA. [Jack, Brian] Boston Univ, Sch Med, Family Med, Boston, MA 02118 USA. [Mittman, Brian] Kaiser Permanente, Res & Evaluat, Pasadena, CA USA. [Mittman, Brian] VA Ctr Implementat Practice & Res, US Dept Vet Affairs, Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mittman, Brian] Univ Calif Los Angeles, Sch Med, Clin Translat Sci Inst, Los Angeles, CA USA. [Naylor, Mary] Univ Penn, Sch Nursing, NewCourtland Ctr Transit & Hlth, Philadelphia, PA 19104 USA. [Sorra, Joanna] Westat Corp, Washington, DC USA. [Mays, Glen] Univ Kentucky, Natl Coordinating Ctr Publ Hlth Serv & Syst Res, Lexington, KY USA. [Williams, Mark V.] Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Kentucky Clin J525, Lexington, KY 40536 USA. RP Williams, MV (reprint author), Univ Kentucky, Dept Internal Med, Ctr Hlth Serv Res, Kentucky Clin J525, Lexington, KY 40536 USA. EM mark.will@uky.edu FU Patient Centered Outcomes Research Institute (PCORI), U.S [TC-1403-14049] FX Support for this research was provided by Contract No. TC-1403-14049, Patient Centered Outcomes Research Institute (PCORI), U.S. NR 33 TC 2 Z9 2 U1 6 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD FEB 19 PY 2016 VL 16 AR 70 DI 10.1186/s12913-016-1312-y PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DE1SK UT WOS:000370406500001 PM 26896024 ER PT J AU Asch, DA Pauly, MV Muller, RW AF Asch, David A. Pauly, Mark V. Muller, Ralph W. TI Asymmetric Thinking about Return on Investment SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Asch, David A.; Muller, Ralph W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.; Pauly, Mark V.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. RP Asch, DA (reprint author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.; Asch, DA (reprint author), Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.; Asch, DA (reprint author), Philadelphia VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 18 PY 2016 VL 374 IS 7 BP 606 EP 608 DI 10.1056/NEJMp1512297 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA DD9ER UT WOS:000370229000005 PM 26886519 ER PT J AU Keating, J Judy, R Newton, A Singhal, S AF Keating, Jane Judy, Ryan Newton, Andrew Singhal, Sunil TI Near-infrared operating lamp for intraoperative molecular imaging of a mediastinal tumor SO BMC MEDICAL IMAGING LA English DT Article DE Intraoperative imaging; Cancer; Near-infrared; Indocyanine green; Mediastinal tumors AB Background: Near-Infrared (NIR) intraoperative molecular imaging is a new diagnostic modality utilized during cancer surgery for the identification of tumors, metastases and lymph nodes. Surgeons typically use headlamps during an operation to increase visible light; however, these light sources are not adapted to function simultaneously with NIR molecular imaging technology. Here, we design a NIR cancelling headlamp and utilize it during surgery to assess whether intraoperative molecular imaging of mediastinal tumors is possible. Methods: A NIR cancelling headlamp was designed and tested using NIR spectroscopy preoperatively. Next, a 46 year-old-female was referred to the thoracic surgery clinic for a 5.8 cm mediastinal mass noted on chest x-ray. Prior to surgery, she was given intravenous indocyanine green (ICG). Then, the prototype headlamp was used in conjunction with our intraoperative molecular imaging device. The tumor was imaged both in vivo and following resection prior to pathological examination. Results: NIR spectroscopy confirmed NIR light excitation of the unfiltered headlamp and the absence of NIR emitted light after addition of the filter. Next, in vivo imaging confirmed fluorescence of the tumor, but also demonstrated a significant amount of NIR background fluorescence emanating from the unfiltered headlamp. During imaging with the filtered headlamp, we again demonstrated a markedly fluorescent tumor but with a reduced false positive NIR signal. Final pathology was well-differentiated thymoma with negative surgical margins. Conclusions: NIR intraoperative molecular imaging using a systemic injection of intravenous ICG was successful in localizing a thymoma. Additionally, a simple design and implementation of a NIR cancelling headlamp reduces false positive NIR fluorescence. C1 [Keating, Jane] Univ Penn, Dept Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. RP Keating, J (reprint author), Univ Penn, Dept Surg, 6 White Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM janejkeating@gmail.com FU [NIH R01 CA163256] FX Funding for the clinical trial in which this case report was involved was provided by grant NIH R01 CA163256. NR 11 TC 0 Z9 0 U1 4 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2342 J9 BMC MED IMAGING JI BMC Med. Imag. PD FEB 17 PY 2016 VL 16 AR 15 DI 10.1186/s12880-016-0120-5 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DE0LK UT WOS:000370316200001 PM 26883511 ER PT J AU Wang, J Bi, WN Zhao, W Varghese, M Koch, RJ Walker, RH Chandraratna, RA Sanders, ME Janesick, A Blumberg, B Ward, L Ho, L Pasinetti, GM AF Wang, Jun Bi, Weina Zhao, Wei Varghese, Merina Koch, Rick J. Walker, Ruth H. Chandraratna, Roshantha A. Sanders, Martin E. Janesick, Amanda Blumberg, Bruce Ward, Libby Ho, Lap Pasinetti, Giulio M. TI Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease SO ONCOTARGET LA English DT Article DE brain bioavailable; dopaminergic; nuclear receptor related-1 protein; Parkinson's disease; retinoid X receptor; Gero-target ID CILIARY NEUROTROPHIC FACTOR; ORPHAN NUCLEAR RECEPTOR; GENE-EXPRESSION; TYROSINE-HYDROXYLASE; CANCER PREVENTION; DOPAMINE CELLS; NEURONS; TRANSCRIPTION; SURVIVAL; ACID AB Parkinson's disease (PD) is one of the most common movement disorders, and currently there is no effective treatment that can slow disease progression. Preserving and enhancing DA neuron survival is increasingly regarded as the most promising therapeutic strategy for treating PD. IRX4204 is a second generation retinoid X receptor (RXR) agonist that has no cross reactivity with retinoic acid receptors, farnesoid X receptor, liver X receptors or peroxisome proliferator-activated receptor PPAR.. We found that IRX4204 promotes the survival and maintenance of nigral dopaminergic (DA) neurons in a dose-dependent manner in primary mesencephalic cultures. Brain bioavailability studies demonstrate that IRX4204 can cross the blood brain barrier and reach the brain at nM concentration. Oral administration of IRX4204 can activate nuclear receptor Nurr1 downstream signaling in the substantia nigra (SN) and attenuate neurochemical and motor deficits in a rat model of PD. Our study suggests that IRX4204 represents a novel, potent and selective pharmacological means to activate cellular RXR-Nurr1 signaling and promote SN DA neuron survival in PD prevention and/or treatment. C1 [Wang, Jun; Bi, Weina; Zhao, Wei; Varghese, Merina; Ward, Libby; Ho, Lap; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Pasinetti, Giulio M.] Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Koch, Rick J.; Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Chandraratna, Roshantha A.; Sanders, Martin E.] Io Therapeut Inc, Santa Ana, CA USA. [Janesick, Amanda; Blumberg, Bruce] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA USA. [Janesick, Amanda; Blumberg, Bruce] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.; Pasinetti, GM (reprint author), Geriatr Res Educ & Clin Ctr, Bronx, NY USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 FU Io Therapeutics, Inc. FX This study was funded by Io Therapeutics, Inc., and we thank Drs. Chandraratna and Sanders for providing the IRX4204 compound for the study herein described. NR 46 TC 1 Z9 1 U1 1 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 16 PY 2016 VL 7 IS 7 BP 7469 EP 7479 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DE0PD UT WOS:000370325900011 PM 26862735 ER PT J AU Edderkaoui, M Xu, SP Chheda, C Morvaridi, S Hu, RW Grippo, PJ Mascarinas, E Principe, DR Knudsen, B Xue, J Habtezion, A Uyeminami, D Pinkerton, KE Pandol, SJ AF Edderkaoui, Mouad Xu, Shiping Chheda, Chintan Morvaridi, Susan Hu, Robert W. Grippo, Paul J. Mascarinas, Emman Principe, Daniel R. Knudsen, Beatrice Xue, Jing Habtezion, Aida Uyeminami, Dale Pinkerton, Kent E. Pandol, Stephen J. TI HDAC3 mediates smoking-induced pancreatic cancer SO ONCOTARGET LA English DT Article DE smoking; HDAC; pancreatic cancer ID EPITHELIAL-MESENCHYMAL TRANSITION; STELLATE CELLS; HISTONE DEACETYLASES; STEM-CELLS; T-CELLS; DIFFERENTIATION; INTERLEUKIN-6; MACROPHAGES; PROGRESSION; STATISTICS AB Smoking is a major risk factor for developing pancreatic adenocarcinoma (PDAC); however, little is known about the mechanisms involved. Here we employed a genetic animal model of early stages of PDAC that overexpresses oncogenic Kras in the pancreas to investigate the mechanisms of smoking-induced promotion of the disease in vivo. We confirmed the regulation of the interactions between the tumor microenvironment cells using in vitro cellular systems. Aerial exposure to cigarette smoke stimulated development of pancreatic intraepithelial neaoplasia (PanIN) lesions associated with a tumor microenvironment-containing features of human PDAC including fibrosis, activated stellate cells, M2-macrophages and markers of epithelial-mesenchymal transition (EMT). The pro-cancer effects of smoking were prevented by Histone Deacetylase HDAC I/II inhibitor Saha. Smoking decreased histone acetylation associated with recruitment of and phenotypic changes in macrophages; which in turn, stimulated survival and induction of EMT of the pre-cancer and cancer cells. The interaction between the cancer cells and macrophages is mediated by IL-6 produced under the regulation of HDAC3 translocation to the nucleus in the cancer cells. Pharmacological and molecular inhibitions of HDAC3 decreased IL-6 levels in cancer cells. IL-6 stimulated the macrophage phenotype change through regulation of the IL-4 receptor level of the macrophage. This study demonstrates a novel pathway of interaction between cancer cells and tumor promoting macrophages involving HDAC3 and IL-6. It further demonstrates that targeting HDAC3 prevents progression of the disease and could provide a strategy for treating the disease considering that the HDAC inhibitor we used is FDA approved for a different disease. C1 [Edderkaoui, Mouad; Chheda, Chintan; Morvaridi, Susan; Hu, Robert W.; Knudsen, Beatrice; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Edderkaoui, Mouad; Chheda, Chintan; Morvaridi, Susan; Hu, Robert W.; Knudsen, Beatrice; Pandol, Stephen J.] Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA. [Edderkaoui, Mouad; Xu, Shiping; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Edderkaoui, Mouad; Xu, Shiping; Pandol, Stephen J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Xu, Shiping] Peoples Liberat Army Gen Hosp, Nanlou Div, Dept Gastroenterol, Beijing, Peoples R China. [Grippo, Paul J.; Mascarinas, Emman; Principe, Daniel R.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Grippo, Paul J.; Mascarinas, Emman; Principe, Daniel R.] Univ Illinois, Dept Med, Chicago, IL USA. [Xue, Jing; Habtezion, Aida] Stanford Univ, Dept Med, Sch Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA. [Uyeminami, Dale; Pinkerton, Kent E.] Univ Calif Davis, Ctr Hlth & Environm, Davis, CA 95616 USA. RP Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Edderkaoui, M (reprint author), Cedars Sinai Med Ctr, Dept Biol Sci, Los Angeles, CA 90048 USA.; Edderkaoui, M (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.; Edderkaoui, M (reprint author), Univ Calif Los Angeles, Los Angeles, CA USA. EM mouad.edderkaoui@cshs.org FU NIAAA [K01 AA019996, P50AA011999]; Hirshberg Foundation; NCI [P01CA163200]; Department of Veterans Affairs FX This work was supported by the NIAAA grant K01 AA019996 and the Hirshberg Foundation Award (to ME), the NCI grant P01CA163200, the NIAAA grant P50AA011999 and the Department of Veterans Affairs (to SJP). NR 41 TC 2 Z9 2 U1 2 U2 4 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 16 PY 2016 VL 7 IS 7 BP 7747 EP 7760 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DE0PD UT WOS:000370325900030 PM 26745602 ER PT J AU Prasad, R Kappes, JC Katiyar, SK AF Prasad, Ram Kappes, John C. Katiyar, Santosh K. TI Inhibition of NADPH oxidase 1 activity and blocking the binding of cytosolic and membrane-bound proteins by honokiol inhibit migratory potential of melanoma cells SO ONCOTARGET LA English DT Article DE honokiol; melanoma; NADPH oxidase; cell migration; imaging ID IN-VIVO; CANCER CELLS; PHOSPHORYLATION; GROWTH; NOX1; SRC; EPIDEMIOLOGY; ACTIVATION; TRANSITION; EXPRESSION AB Overexpression of NADPH oxidase 1 (Nox1) in melanoma cells is often associated with increased migration/metastasis rate. To develop effective treatment options, we have examined the effect of honokiol, a phytochemical from Magnolia plant, on the migratory potential of human melanoma cell lines (A375, Hs294t, SK-Mel119 and SK-Mel28) and assessed whether Nox1 is the target. Using an in vitro cell migration assay, we observed that treatment of different melanoma cell lines with honokiol for 24 h resulted in a dose-dependent inhibition of cell migration that was associated with reduction in Nox1 expression and reduced levels of oxidative stress. Treatment of cells with N-acetyl-L-cysteine, an anti-oxidant, also inhibited the migration of melanoma cells. Treatment of cells with diphenyleneiodonium chloride, an inhibitor of Nox1, significantly decreased the migration ability of Hs294t and SK-Mel28 cells. Further, we examined the effect of honokiol on the levels of core proteins (p22(phox) and p47(phox)) of the NADPH oxidase complex. Treatment of Hs294t and SK-Mel28 cells with honokiol resulted in accumulation of the cytosolic p47(phox) protein and decreased levels of the membrane-bound p22(phox) protein, thus blocking their interaction and inhibiting Nox1 activation. Our in vivo bioluminescence imaging data indicate that oral administration of honokiol inhibited the migration/extravasation and growth of intravenously injected melanoma cells in internal body organs, such as liver, lung and kidney in nude mice, and that this was associated with an inhibitory effect on Nox1 activity in these internal organs/tissues. C1 [Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Environm Hlth Sci, Birmingham, AL USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA. [Kappes, John C.; Katiyar, Santosh K.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA. [Kappes, John C.; Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Environm Hlth Sci, Birmingham, AL USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA.; Katiyar, SK (reprint author), Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA.; Katiyar, SK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. EM skatiyar@uab.edu FU National Institutes of Health (NIH,) National Cancer Institute [CA166883]; Veterans Administration Merit Review Award [1I01BX001410]; Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (CFAR) [P30-AI-27767] FX This work was supported by a grant from the National Institutes of Health (NIH, CA166883) National Cancer Institute (to S.K. Katiyar) and the Veterans Administration Merit Review Award (1I01BX001410) to S.K. Katiyar. The research also used the facilities supported by of the Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (CFAR), P30-AI-27767. NR 31 TC 1 Z9 2 U1 2 U2 6 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 16 PY 2016 VL 7 IS 7 BP 7899 EP 7912 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DE0PD UT WOS:000370325900041 PM 26760964 ER PT J AU Miglioretti, DL Lange, J van den Broek, JJ Lee, CI van Ravesteyn, NT Ritley, D Kerlikowske, K Fenton, JJ Melnikow, J de Koning, HJ Hubbard, RA AF Miglioretti, Diana L. Lange, Jane van den Broek, Jeroen J. Lee, Christoph I. van Ravesteyn, Nicolien T. Ritley, Dominique Kerlikowske, Karla Fenton, Joshua J. Melnikow, Joy de Koning, Harry J. Hubbard, Rebecca A. TI Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening A Modeling Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID UNITED-STATES; TOMOSYNTHESIS; RISK; ACCURACY; OBESITY; TRIAL AB Background: Estimates of risk for radiation-induced breast cancer from mammography screening have not considered variation in dose exposure or diagnostic work-up after abnormal screening results. Objective: To estimate distributions of radiation-induced breast cancer incidence and mortality from digital mammography screening while considering exposure from screening and diagnostic mammography and dose variation among women. Design: 2 simulation-modeling approaches. Setting: U.S. population. Patients: Women aged 40 to 74 years. Intervention: Annual or biennial digital mammography screening from age 40, 45, or 50 years until age 74 years. Measurements: Lifetime breast cancer deaths averted (benefits) and radiation-induced breast cancer incidence and mortality (harms) per 100 000 women screened. Results: Annual screening of 100 000 women aged 40 to 74 years was projected to induce 125 breast cancer cases (95% CI, 88 to 178) leading to 16 deaths (CI, 11 to 23), relative to 968 breast cancer deaths averted by early detection from screening. Women exposed at the 95th percentile were projected to develop 246 cases of radiation-induced breast cancer leading to 32 deaths per 100 000 women. Women with large breasts requiring extra views for complete examination (8% of population) were projected to have greater radiation-induced breast cancer risk (266 cancer cases and 35 deaths per 100 000 women) than other women (113 cancer cases and 15 deaths per 100 000 women). Biennial screening starting at age 50 years reduced risk for radiation-induced cancer 5-fold. Limitation: Life-years lost from radiation-induced breast cancer could not be estimated. Conclusion: Radiation-induced breast cancer incidence and mortality from digital mammography screening are affected by dose variability from screening, resultant diagnostic work-up, initiation age, and screening frequency. Women with large breasts may have a greater risk for radiation-induced breast cancer. C1 [Miglioretti, Diana L.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, One Shields Ave,Med Sci Bldg 1C,Room 144, Davis, CA 95616 USA. [Lange, Jane] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [van den Broek, Jeroen J.; van Ravesteyn, Nicolien T.; de Koning, Harry J.] Erasmus MC Univ, Med Ctr Rotterdam, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands. [Lee, Christoph I.] Univ Washington, Sch Med, Dept Radiol, 825 Eastlake Ave East,G3-200, Seattle, WA 98109 USA. [Ritley, Dominique; Fenton, Joshua J.; Melnikow, Joy] Univ Calif Davis, Ctr Hlth Care Policy & Res, 2103 Stockton Blvd, Sacramento, CA 95817 USA. [Kerlikowske, Karla] San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. [Hubbard, Rebecca A.] Univ Penn, Dept Biostat & Epidemiol, 604 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. RP Miglioretti, DL (reprint author), Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, One Shields Ave,Med Sci Bldg 1C,Room 144, Davis, CA 95616 USA. EM dmiglioretti@ucdavis.edu FU Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, National Cancer Institute FX Agency for Healthcare Research and Quality, U.S. Preventive Services Task Force, National Cancer Institute. NR 42 TC 9 Z9 9 U1 2 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2016 VL 164 IS 4 BP 205 EP + DI 10.7326/M15-1241 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA DD7WK UT WOS:000370135300011 PM 26756460 ER PT J AU Nelson, HD O'Meara, ES Kerlikowske, K Balch, S Miglioretti, D AF Nelson, Heidi D. O'Meara, Ellen S. Kerlikowske, Karla Balch, Steven Miglioretti, Diana TI Factors Associated With Rates of False-Positive and False -Negative Results From Digital Mammography Screening: An Analysis of Registry Data SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID SERVICES TASK-FORCE; BREAST-CANCER RISK; UNITED-STATES; COMMUNITY PRACTICE; HORMONE-THERAPY; WOMEN; TOMOSYNTHESIS; US; DENSITY; RECOMMENDATION AB Background: Women screened with digital mammography may receive false-positive and false-negative results and subsequent imaging and biopsies. How these outcomes vary by age, time since the last screening, and individual risk factors is unclear. Objective: To determine factors associated with false-positive and false-negative digital mammography results, additional imaging, and biopsies among a general population of women screened for breast cancer. Design: Analysis of registry data. Setting: Participating facilities at 5 U.S. Breast Cancer Surveillance Consortium breast imaging registries with linkages to pathology databases and tumor registries. Patients: 405 191 women aged 40 to 89 years screened with digital mammography between 2003 and 2011. A total of 2963 were diagnosed with invasive cancer or ductal carcinoma in situ within 12 months of screening. Measurements: Rates of false-positive and false-negative results and recommendations for additional imaging and biopsies from a single screening round; comparisons by age, time since the last screening, and risk factors. Results: Rates of false-positive results (121.2 per 1000 women [95% Cl, 105.6 to 138.7]) and recommendations for additional imaging (124.9 per 1000 women [Cl, 109.3 to 142.3]) were highest among women aged 40 to 49 years and decreased with increasing age. Rates of false-negative results (1.0 to 1.5 per 1000 women) and recommendations for biopsy (15.6 to 17.5 per 1000 women) did not differ greatly by age. Results did not differ by time since the last screening. False-positive rates were higher for women with risk factors, particularly family history of breast cancer; previous benign breast biopsy result; high breast density; and, for younger women, low body mass index. Limitations: Confounding by variation in patient-level characteristics and outcomes across registries and regions may have been present. Some factors, such as numbers of first- and second-degree relatives with breast cancer and diagnoses associated with previous benign biopsy results, were not examined. Conclusion: False-positive mammography results and additional imaging are common, particularly for younger women and those with risk factors, whereas biopsies occur less often. Rates of false-negative results are low. C1 [Nelson, Heidi D.] Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA. [O'Meara, Ellen S.; Balch, Steven] Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. [Kerlikowske, Karla] VAMC 111A1, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Miglioretti, Diana] Univ Calif Davis, 1 Shields Ave,Med Sci 1C,Room 145, Davis, CA 95616 USA. RP Nelson, HD (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA. EM nelsonh@ohsu.edu FU Agency for Healthcare Research and Quality; National Cancer Institute FX Agency for Healthcare Research and Quality and National Cancer Institute. NR 42 TC 12 Z9 12 U1 0 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2016 VL 164 IS 4 BP 226 EP + DI 10.7326/M15-0971 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA DD7WK UT WOS:000370135300013 PM 26756902 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP LeFevre, M AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. LeFevre, Michael CA US Preventive Serv Task Force TI Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement (Retracted article. See vol. 164, pg. 448, 2016) SO ANNALS OF INTERNAL MEDICINE LA English DT Article; Retracted Publication ID CARCINOMA IN-SITU; DIGITAL MAMMOGRAPHY; FILM MAMMOGRAPHY; TOMOSYNTHESIS; WOMEN; DENSITY; RISK; RACE; AGE; OVERDIAGNOSIS AB Description: Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for breast cancer. Methods: The USPSTF reviewed the evidence on the following: effectiveness of breast cancer screening in reducing breast cancer-specific and all-cause mortality, as well as the incidence of advanced breast cancer and treatment-related morbidity; harms of breast cancer screening; test performance characteristics of digital breast tomosynthesis as a primary screening strategy; and adjunctive screening in women with increased breast density. In addition, the USPSTF reviewed comparative decision models on optimal starting and stopping ages and intervals for screening mammography; how breast density, breast cancer risk, and comorbidity level affect the balance of benefit and harms of screening mammography; and the number of radiation-induced breast cancer cases and deaths associated with different screening mammography strategies over the course of a woman's lifetime. Population: This recommendation applies to asymptomatic women aged 40 years or older who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Recommendations: The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. (B recommendation) The decision to start screening mammography in women prior to age 50 years should be an individual one. Women who place a higher value on the potential benefit than the potential harms may choose to begin biennial screening between the ages of 40 and 49 years. (C recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years or older. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of digital breast tomosynthesis (DBT) as a primary screening method for breast cancer. (I statement) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography, magnetic resonance imaging (MRI), DBT, or other methods in women identified to have dense breasts on an otherwise negative screening mammogram. (I statement) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. [LeFevre, Michael] Univ Missouri, Columbia, MO USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. FU U.S. Congress mandates that the Agency for Healthcare Research and Quality FX The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF. NR 59 TC 68 Z9 69 U1 5 U2 22 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2016 VL 164 IS 4 BP 279 EP + DI 10.7326/M15-2886 PG 19 WC Medicine, General & Internal SC General & Internal Medicine GA DD7WK UT WOS:000370135300018 PM 26757170 ER PT J AU Hon, YY Lin, EE Tian, X Yang, Y Sun, H Swenson, ER Taveira-Dasilva, AM Gladwin, MT Machado, RF AF Hon, Yuen Yi Lin, Elaina E. Tian, Xin Yang, Yang Sun, He Swenson, Erik R. Taveira-Dasilva, Angelo M. Gladwin, Mark T. Machado, Roberto F. TI Increased consumption and vasodilatory effect of nitrite during exercise SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE nitrite store; incremental exercise test; pharmacokinetics; hemodynamics; vasodilation ID DIETARY NITRATE SUPPLEMENTATION; OXIDE PRODUCTION; BLOOD-FLOW; MITOCHONDRIAL RESPIRATION; XANTHINE-OXIDASE; OXYGEN-UPTAKE; O-2 COST; L-NAME; CAPACITY; HUMANS AB This study investigated the effects of aerobic-to-anaerobic exercise on nitrite stores in the human circulation and evaluated the effects of systemic nitrite infusion on aerobic and anaerobic exercise capacity and hemodynamics. Six healthy volunteers were randomized to receive sodium nitrite or saline for 70 min in two separate occasions in an exercise study. Subjects cycled on an upright electronically braked cycle ergometer 30 min into the infusion according to a ramp protocol designed to attain exhaustion in 10 min. They were allowed to recover for 30 min thereafter. The changes of whole blood nitrite concentrations over the 70-min study period were analyzed by pharmacokinetic modeling. Longitudinal measurements of hemodynamic and clinical variables were analyzed by fitting nonparametric regression spline models. During exercise, nitrite consumption/elimination rate was increased by similar to 137%. Cardiac output (CO), mean arterial pressure (MAP), and pulmonary artery pressure (PAP) were increased, but smaller elevation of MAP and larger increases of CO and PAP were found during nitrite infusion compared with placebo control. The higher CO and lower MAP during nitrite infusion were likely attributed to vasodilation and a trend toward decrease in systemic vascular resistance. In contrast, there were no significant changes in mean pulmonary artery pressures and pulmonary vascular resistance. These findings, together with the increased consumption of nitrite and production of iron-nitrosyl-hemoglobin during exercise, support the notion of nitrite conversion to release NO resulting in systemic vasodilatation. However, at the dosing used in this protocol achieving micromolar plasma concentrations of nitrite, exercise capacity was not enhanced, as opposed to other reports using lower dosing. C1 [Hon, Yuen Yi] Clin Ctr Pharm Dept, NIH, Bethesda, MD USA. [Lin, Elaina E.; Gladwin, Mark T.; Machado, Roberto F.] NHLBI, Vasc Med Branch, Bldg 10, Bethesda, MD 20892 USA. [Tian, Xin; Yang, Yang] NHLBI, Off Biostat Res, Bldg 10, Bethesda, MD 20892 USA. [Sun, He] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Taveira-Dasilva, Angelo M.] NHLBI, Cardiovasc & Pulm Branch, Bldg 10, Bethesda, MD 20892 USA. RP Machado, RF (reprint author), Univ Illinois, Sect Pulm Crit Care Med Sleep & Allergy, 840 S Wood St,Rm 920-N,Clin Sci Bldg,MC 719, Chicago, IL 60612 USA. EM machador@uic.edu FU Intramural Research Program of Clinical Center Pharmacy Department; National Heart, Lung, and Blood Institute, National Institutes of Health FX This work was supported by the Intramural Research Program of Clinical Center Pharmacy Department and the National Heart, Lung, and Blood Institute, National Institutes of Health. There was no commercial sponsorship. NR 43 TC 2 Z9 2 U1 5 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD FEB 15 PY 2016 VL 310 IS 4 BP 1354 EP 1364 DI 10.1152/ajplung.00081.2015 PG 11 WC Physiology; Respiratory System SC Physiology; Respiratory System GA DD7DU UT WOS:000370084700006 ER PT J AU Filson, CP Shelton, JB Tan, HJ Kwan, L Skolarus, TA Saigal, CS Litwin, MS AF Filson, Christopher P. Shelton, Jeremy B. Tan, Hung-Jui Kwan, Lorna Skolarus, Ted A. Saigal, Christopher S. Litwin, Mark S. TI Expectant management of veterans with early-stage prostate cancer SO CANCER LA English DT Article DE active surveillance; expectant management; prostate cancer; veterans' health; watchful waiting ID POPULATION-BASED COHORT; LOW-RISK; RADICAL PROSTATECTOMY; ACTIVE SURVEILLANCE; TRENDS; MEN; RECOMMENDATIONS; PREFERENCES; COMORBIDITY; SURVIVAL AB BACKGROUNDFor certain men with low-risk prostate cancer, aggressive treatment results in marginal survival benefits while exposing them to urinary and sexual side effects. Nevertheless, expectant management has been underused. In the current study, the authors evaluated the association between various factors and expectant management use among veterans diagnosed with prostate cancer. METHODSThe authors identified men diagnosed with prostate cancer in 2008. The outcome of interest was use of expectant management, based on documentation captured through an in-depth chart review. Multivariable regression models were fit to examine associations between use of expectant management and patient demographics, cancer severity, and facility characteristics. The authors assessed variation across 21 tertiary care regions and 52 facilities by generating predicted probabilities for receipt of expectant management. RESULTSExpectant management was more common among patients aged 75 years (40% vs 27% for those aged<55 years; odds ratio, 2.57) and those with low-risk tumors (49% vs 20% for patients with high-risk tumors; odds ratio, 5.35). There was no association noted between patient comorbidity and receipt of expectant management (P=.90). There were also no associations found between facility factors and use of expectant management (all P>.05). Among ideal candidates for expectant management, receipt of expectant management varied considerably across individual facilities (0%-85%; P<.001). CONCLUSIONSPatient age and tumor risk were found to be more strongly associated with use of expectant management than patient comorbidity. Although use of expectant management appears broadly appropriate, there was variation in expectant management noted between hospitals that was apparently not attributable to facility factors. Research determining the basis of this variation, with a focus on providers, will be critical to help optimize prostate cancer treatment for veterans. (c) 2015 American Cancer Society. C1 [Filson, Christopher P.] Emory Univ, Sch Med, Dept Urol, 1365 Clifton Rd NE,Bldg B,1st Fl,Ste 1400, Atlanta, GA 30322 USA. [Filson, Christopher P.; Shelton, Jeremy B.; Tan, Hung-Jui; Kwan, Lorna; Saigal, Christopher S.; Litwin, Mark S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Filson, Christopher P.] Vet Affairs Atlanta Healthcare Syst, Decatur, GA USA. [Shelton, Jeremy B.; Skolarus, Ted A.; Saigal, Christopher S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shelton, Jeremy B.; Saigal, Christopher S.] Vet Affairs Ann Arbor Healthcare Syst, Hlth Serv Res & Dev Serv, Ctr Clin Management Res, Ann Arbor, MI USA. [Skolarus, Ted A.] Univ Michigan, Dept Urol, Dow Div Hlth Serv Res, Ann Arbor, MI 48109 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Filson, CP (reprint author), Emory Univ, Sch Med, Dept Urol, 1365 Clifton Rd NE,Bldg B,1st Fl,Ste 1400, Atlanta, GA 30322 USA. EM cfilson@emory.edu FU American Cancer Society [PF-14-161-01-CPHPS]; Urology Care Foundation Research Scholars Program FX Christopher P. Filson was supported in part by postdoctoral fellowships from the American Cancer Society (PF-14-161-01-CPHPS) and the Urology Care Foundation Research Scholars Program for work performed as part of the current study. NR 27 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 15 PY 2016 VL 122 IS 4 BP 626 EP 633 DI 10.1002/cncr.29785 PG 8 WC Oncology SC Oncology GA DD5YA UT WOS:000369999600018 PM 26540451 ER PT J AU Cunningham, MA Wirth, JR Scott, JL Eudaly, J Collins, EL Gilkeson, GS AF Cunningham, Melissa A. Wirth, Jena R. Scott, Jennifer L. Eudaly, Jackie Collins, Erin L. Gilkeson, Gary S. TI Early Ovariectomy Results in Reduced Numbers of CD11c+/CD11b+Spleen Cells and Impacts Disease Expression in Murine Lupus SO FRONTIERS IN IMMUNOLOGY LA English DT Article DE systemic lupus erythematosus; mouse models; estrogen; ovariectomy; dendritic cells ID ESTROGEN-RECEPTOR-ALPHA; DENDRITIC CELLS; AUTOIMMUNE-DISEASE; B-CELLS; SEX-HORMONES; NITRIC-OXIDE; 17-BETA-ESTRADIOL; ERYTHEMATOSUS; DIFFERENTIATION; MACROPHAGES AB Ninety percent of those diagnosed with systemic lupus erythematosus are female, with peak incidence between the ages of 15 and 45, when women are most hormonally active. Despite significant research effort, the mechanisms underlying this sex bias remain unclear. We previously showed that a functional knockout of estrogen receptor alpha (ER alpha) resulted in significantly reduced renal disease and increased survival in murine lupus. Dendritic cell (DC) development, which requires both estrogen and ER alpha, is impacted, as is activation status and cytokine production. Since both estrogen and testosterone levels have immunomodulating effects, we presently studied the phenotype of NZM2410 lupus-prone mice following post- and prepubertal ovariectomy (OVX) +/- estradiol (E2) replacement to determine the impact of hormonal status on disease expression and DC development in these mice. We observed a trend toward survival benefit in addition to decreased proteinuria and improved renal histology in the early OVX, but not late OVX- or E2-repleted WT mice. Interestingly, there was also a significant difference in splenic DC subsets by flow cytometry. Spleens from NZM mice OVX'd early had a significant decrease in proinflammatory CD11c+CD11b+ DCs (vs. unmanipulated WTs, late OVX- and E2-repleted mice). These early OVX'd animals also had a significant increase in tolerogenic CD11c+CD8a+ DCs vs. WT. These data join a growing body of evidence that supports a role for hormone modulation of DCs that likely impacts the penetrance and severity of autoimmune diseases, such as lupus. C1 [Cunningham, Melissa A.; Wirth, Jena R.; Scott, Jennifer L.; Eudaly, Jackie; Collins, Erin L.; Gilkeson, Gary S.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Div Rheumatol & Immunol, Charleston, SC 29425 USA. RP Cunningham, MA (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Hosp, Div Rheumatol & Immunol, Charleston, SC 29425 USA. EM cunnima@musc.edu OI Cunningham, Melissa/0000-0002-9207-1986 FU South Carolina Clinical & Translational Research (SCTR) Institute; NUI/NCRR [UR1 RR029880, UL1 RR029882]; VA Medical Research Service Merit Award [1I01BX000470-01] FX This publication was supported by The South Carolina Clinical & Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, NUI/NCRR Grant number UR1 RR029880 and UL1 RR029882; and a VA Medical Research Service Merit Award 1I01BX000470-01. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCRR. NR 46 TC 0 Z9 0 U1 2 U2 4 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PD FEB 15 PY 2016 VL 7 AR 31 DI 10.3389/fimmu.2016.00031 PG 10 WC Immunology SC Immunology GA DD7RW UT WOS:000370122800001 PM 26913030 ER PT J AU Carreno, FR Frazer, A AF Carreno, Flavia R. Frazer, Alan TI The Allure of Transcutaneous Vagus Nerve Stimulation as a Novel Therapeutic Modality SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID TREATMENT-RESISTANT DEPRESSION; DELTA-FOSB IMMUNOREACTIVITY; BRAIN C1 [Carreno, Flavia R.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Carreno, Flavia R.; Frazer, Alan] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA. [Frazer, Alan] Audie L Murphy Mem Vet Adm Med Ctr, South Texas Vet Hlth Care Syst, San Antonio, TX 78284 USA. RP Carreno, FR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,Mail Code 7764, San Antonio, TX 78229 USA. EM Carrenof@uthscsa.edu NR 10 TC 0 Z9 0 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 15 PY 2016 VL 79 IS 4 BP 260 EP 261 DI 10.1016/j.biopsych.2015.11.016 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DA9BT UT WOS:000368102300002 PM 26796874 ER PT J AU Ritchie, C Andersen, R Eng, J Garrigues, SK Intinarelli, G Kao, H Kawahara, S Patel, K Sapiro, L Thibault, A Tunick, E Barnes, DE AF Ritchie, Christine Andersen, Robin Eng, Jessica Garrigues, Sarah K. Intinarelli, Gina Kao, Helen Kawahara, Suzanne Patel, Kanan Sapiro, Lisa Thibault, Anne Tunick, Erika Barnes, Deborah E. TI Implementation of an Interdisciplinary, Team-Based Complex Care Support Health Care Model at an Academic Medical Center: Impact on Health Care Utilization and Quality of Life SO PLOS ONE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; OUTPATIENT GERIATRIC EVALUATION; DWELLING OLDER-ADULTS; LOW-INCOME SENIORS; MANAGEMENT; RESOURCES; MORTALITY; PEOPLE AB Introduction The Geriatric Resources for the Assessment and Care of Elders (GRACE) program has been shown to decrease acute care utilization and increase patient self-rated health in lowincome seniors at community-based health centers. Aims To describe adaptation of the GRACE model to include adults of all ages (named Care Support) and to evaluate the process and impact of Care Support implementation at an urban academic medical center. Setting 152 high-risk patients (>= 5 ED visits or >= 2 hospitalizations in the past 12 months) enrolled from four medical clinics from 4/29/2013 to 5/31/2014. Program Description Patients received a comprehensive in-home assessment by a nurse practitioner/social worker (NP/SW) team, who then met with a larger interdisciplinary team to develop an individualized care plan. In consultation with the primary care team, standardized care protocols were activated to address relevant key issues as needed. Program Evaluation A process evaluation based on the Consolidated Framework for Implementation Research identified key adaptations of the original model, which included streamlining of standardized protocols, augmenting mental health interventions and performing some assessments in the clinic. A summative evaluation found a significant decline in the median number of ED visits (5.5 to 0, p = 0.015) and hospitalizations (5.5 to 0, p<0.001) 6 months before enrollment in Care Support compared to 6 months after enrollment. In addition, the percent of patients reporting better self-rated health increased from 31% at enrollment to 64% at 9 months (p = 0.002). Semi-structured interviews with Care Support team members identified patients with multiple, complex conditions; little community support; and mild anxiety as those who appeared to benefit the most from the program. Discussion It was feasible to implement GRACE/Care Support at an academic medical center by making adaptations based on local needs. Care Support patients experienced significant reductions in acute care utilization and significant improvements in self-rated health. C1 [Ritchie, Christine; Eng, Jessica; Garrigues, Sarah K.; Kawahara, Suzanne; Patel, Kanan; Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Ritchie, Christine; Garrigues, Sarah K.; Kawahara, Suzanne; Patel, Kanan; Barnes, Deborah E.] Univ Calif San Francisco, Div Geriatr, Tideswell UCSF, San Francisco, CA 94143 USA. [Andersen, Robin; Intinarelli, Gina; Kao, Helen; Sapiro, Lisa; Thibault, Anne; Tunick, Erika] Univ Calif San Francisco, UCSF Hlth, San Francisco, CA 94143 USA. [Eng, Jessica] San Francisco VA Med Ctr, Geriatr Palliat & Extended Care Serv, San Francisco, CA USA. [Barnes, Deborah E.] San Francisco VA Med Ctr, Res Serv, San Francisco, CA USA. RP Ritchie, C; Barnes, DE (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA USA.; Ritchie, C; Barnes, DE (reprint author), Univ Calif San Francisco, Div Geriatr, Tideswell UCSF, San Francisco, CA 94143 USA.; Barnes, DE (reprint author), San Francisco VA Med Ctr, Res Serv, San Francisco, CA USA. EM Christine.ritchie@ucsf.edu; Deborah.barnes@ucsf.edu FU S.D. Bechtel, Jr. Foundation; SCAN Foundation FX Evaluation of Care Support was supported by a grant to TideswellTM at UCSF from the S.D. Bechtel, Jr. Foundation. The SCAN Foundation provided support for the training and implementation assistance provided by the Indiana University Geriatrics GRACE Training and Resource Center to the UCSF Care Support program. The SCAN Foundation - advancing a coordinated and easily navigated system of high-quality services for older adults that preserve dignity and independence. For more information, please visit www.TheSCANFoundation.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 1 Z9 1 U1 8 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 12 PY 2016 VL 11 IS 2 AR e0148096 DI 10.1371/journal.pone.0148096 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD6SI UT WOS:000370054100017 PM 26871704 ER PT J AU Connolly, KR Thase, ME AF Connolly, K. Ryan Thase, Michael E. TI Vortioxetine: a New Treatment for Major Depressive Disorder SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs); Vortioxetine; antidepressants; major depressive disorder (MDD); multimodal serotonin modulator ID PLACEBO-CONTROLLED TRIAL; 5 MG VORTIOXETINE; DOUBLE-BLIND; LU AA21004; MULTIMODAL ANTIDEPRESSANT; 5-HT DEPLETION; OPEN-LABEL; EFFICACY; ADULTS; SAFETY AB Introduction: Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's effects from those of current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). Areas Covered: This article will review the basic clinical pharmacology of vortioxetine, summarize the major clinical trials that were performed prior to approval by the US Food and Drug Administration (FDA), discuss relevant post-marketing studies of this drug, and offer expert commentary on the significance of this new agent in clinical practice. Pre-approval studies were identified as all randomized, placebo-controlled studies of vortioxetine listed on clinicaltrials.gov. Other referenced studies were identified via a MEDLINE database literature search in August 2015 using the key search terms, vortioxetine and Lu AA21004, combined with additional terms that included pharmacological profile, pharmacokinetics, drug interactions, adverse effects, side effects, safety, major depression, and major depressive disorder. We identified relevant systematic reviews, meta-analyses, randomized trials and preclinical studies of importance. Expert Opinion: Results of placebo-controlled trials suggest efficacy and an overall safety profile comparable to existing first-line antidepressants. The most common side effects are nausea, vomiting and constipation. Results of several studies indicate that vortioxetine may have therapeutic effects on cognition (e.g., memory and executive functioning) that exceed that of standard antidepressants. Disadvantages include cost and the current paucity of long-term efficacy data from large clinical trials. The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option. C1 [Connolly, K. Ryan; Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Connolly, K. Ryan; Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Thase, ME (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.; Thase, ME (reprint author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu FU Agency for Healthcare Research and Quality; Alkermes; AssureRx; Avanir; Forest Pharmaceuticals; Janssen; National Institute of Mental Health; Otsuka Pharmaceuticals FX M E Thase has been an advisory/consultant for Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb Company, Cerecor, Inc., Eli Lilly & Co., Forest Laboratories, Gerson Lehrman Group, Fabre-Kramer Pharmaceuticals, Inc., GlaxoSmithKline, Guidepoint Global, H. Lundbeck A/S, MedAvante, Inc., Merck and Co. Inc. (formerly Schering Plough and Organon), Moksha8, Naurex, Inc., Neuronetics, Inc., Novartis, Ortho-McNeil Pharmaceuticals (Johnson & Johnson; Janssen), Otsuka, Pamlab, L.L.C. (Nestle) Pfizer (formerly Wyeth Ayerst Pharmaceuticals), Shire US Inc., Sunovion Pharmaceuticals, Inc., Trius Therapeutical, Inc. and Takeda. He has received grant support from Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest Pharmaceuticals, Janssen, National Institute of Mental Health and Otsuka Pharmaceuticals. M E Thase has equity holdings in MedAvante, Inc. and receives royalties from American Psychiatric Foundation, Guilford Publications, Herald House and W.W. Norton & Company, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 50 TC 3 Z9 3 U1 8 U2 21 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1465-6566 EI 1744-7666 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD FEB 11 PY 2016 VL 17 IS 3 BP 421 EP 431 DI 10.1517/14656566.2016.1133588 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DE0DD UT WOS:000370294100001 PM 26679430 ER PT J AU Erchegyi, J Wang, LX Gulyas, J Samant, M Perrin, MH Lewis, K Miller, C Vaughan, J Donaldson, C Fischer, W Low, W Yakabi, S Karasawa, H Tache, Y Rivier, C Rivier, J AF Erchegyi, Judit Wang, Lixin Gulyas, Jozsef Samant, Manoj Perrin, Marilyn H. Lewis, Kathy Miller, Charleen Vaughan, Joan Donaldson, Cynthia Fischer, Wolfgang Low, William Yakabi, Seiichi Karasawa, Hiroshi Tache, Yvette Rivier, Catherine Rivier, Jean TI Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins) SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID HORMONE-RECEPTOR ANTAGONIST; STRESS-RELATED ALTERATIONS; COLONIC MOTOR FUNCTION; COMPETITIVE ANTAGONISTS; SEQUENCE-ANALYSIS; RHESUS-MONKEY; RATS; SECRETION; INJECTION; SAUVAGINE AB CRF mediates numerous stress-related endocrine, autonomic, metabolic, and behavioral responses. We present the synthesis and chemical and biological properties of astressin B analogues {cydo(30-33)[D-Phe(12),Nle(21,38),C(alpha)MeLeu(27,40),Glu(30),Lys(33)]-acetyl-h/r-CRF(9-41)}. Out of 37 novel peptides, 17 (2, 4, 6-8, 10, 11, 16, 17, 27, 29, 30, 32-36) and 16 (3, 5, 9, 12-15, 18, 19, 22-26, 28, 31) had k(i) to CRF receptors in the high picomolar and low nanomole ranges, respectively. Peptides 1, 2, and 11 inhibited h/rCRF and urocortin 1-induced cAMP release from AtT20 and A7r5 cells. When Astressin C 2 was administered to adrenalectomized rats at 1.0 mg subcutaneously, it inhibited ACTH release for >7 d. Additional rat data based on the inhibitory effect of (2) on h/rCRF-induced stimulation of colonic secretory motor activity and urocortin 2-induced delayed gastric emptying also indicate a safe and long-lasting antagonistic effect. The overall properties of selected analogues may fulfill the criteria expected from clinical candidates. C1 [Erchegyi, Judit; Gulyas, Jozsef; Samant, Manoj; Perrin, Marilyn H.; Lewis, Kathy; Miller, Charleen; Vaughan, Joan; Donaldson, Cynthia; Fischer, Wolfgang; Low, William; Rivier, Catherine; Rivier, Jean] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Ctr, Div Digest Dis, Los Angeles, CA 90073 USA. [Wang, Lixin; Yakabi, Seiichi; Karasawa, Hiroshi; Tache, Yvette] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Rivier, J (reprint author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA. EM jrivier@salk.edu FU NIH [P01 DK026741-34, R01 DK057238]; VA Career Scientist Award; NIH (Animal Core) [DK041301] FX We thank D. Kirby for the synthesis of 11, Y. Haas for technical assistance, and D. Doan for manuscript preparation. J.R. is the Dr. Frederik Paulsen Chair in Neurosciences. This work was supported by NIH Grants P01 DK026741-34 (J.R, J.E., M.H.P., J.G., M.S., K.L., C.M., J.V., W.F., W.L.), DK041301 (Animal Core, Y.T., L.W.), R01 DK057238 (Y.T.), and VA Career Scientist Award (Y.T.). NR 38 TC 0 Z9 0 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 EI 1520-4804 J9 J MED CHEM JI J. Med. Chem. PD FEB 11 PY 2016 VL 59 IS 3 BP 854 EP 866 DI 10.1021/acs.jmedchem.5b00926 PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DD8YL UT WOS:000370212700005 PM 26789203 ER PT J AU Yueh, AE Payne, SN Leystra, AA Van De Hey, DR Foley, TM Pasch, CA Clipson, L Matkowskyj, KA Deming, DA AF Yueh, Alexander E. Payne, Susan N. Leystra, Alyssa A. Van De Hey, Dana R. Foley, Tyler M. Pasch, Cheri A. Clipson, Linda Matkowskyj, Kristina A. Deming, Dustin A. TI Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K SO PLOS ONE LA English DT Article ID COLORECTAL-CANCER; GENETIC ALTERATIONS; PIK3CA MUTATION; PATHWAY; INHIBITION AB The phosphoinositide 3-kinase (PI3K) signaling pathway is critical for multiple important cellular functions, and is one of the most commonly altered pathways in human cancers. We previously developed a mouse model in which colon cancers were initiated by a dominant active PI3K p110-p85 fusion protein. In that model, well-differentiated mucinous adenocarcinomas developed within the colon and initiated through a non-canonical mechanism that is not dependent on WNT signaling. To assess the potential relevance of PI3K mutations in human cancers, we sought to determine if one of the common mutations in the human disease could also initiate similar colon cancers. Mice were generated expressing the Pik3-ca(H1047R) mutation, the analog of one of three human hotspot mutations in this gene. Mice expressing a constitutively active PI3K, as a result of this mutation, develop invasive adenocarcinomas strikingly similar to invasive adenocarcinomas found in human colon cancers. These tumors form without a polypoid intermediary and also lack nuclear CTNNB1 (beta-catenin), indicating a non-canonical mechanism of tumor initiation mediated by the PI3K pathway. These cancers are sensitive to dual PI3K/mTOR inhibition indicating dependence on the PI3K pathway. The tumor tissue remaining after treatment demonstrated reduction in cellular proliferation and inhibition of PI3K signaling. C1 [Yueh, Alexander E.; Van De Hey, Dana R.; Foley, Tyler M.; Deming, Dustin A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Sch Med & Publ Hlth, Madison, WI USA. [Payne, Susan N.; Pasch, Cheri A.; Matkowskyj, Kristina A.; Deming, Dustin A.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Leystra, Alyssa A.; Clipson, Linda] Univ Wisconsin, Dept Oncol, Madison, WI USA. [Matkowskyj, Kristina A.] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth Madison, Madison, WI USA. [Matkowskyj, Kristina A.; Deming, Dustin A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Deming, DA (reprint author), Univ Wisconsin, Dept Med, Div Hematol & Oncol, Sch Med & Publ Hlth, Madison, WI USA.; Deming, DA (reprint author), Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.; Deming, DA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM ddeming@medicine.wisc.edu FU National Institutes of Health [P30 CA014520]; UW Carbone Cancer Center; UW Department of Medicine; UW School of Medicine and Public Health; UW Graduate School through the Wisconsin Alumni Research Foundation; Funk Out Cancer; UW Carbone Cancer Center Gastrointestinal Disease Oriented Working Group FX This project was supported by the National Institutes of Health (http://www.nih.gov/) P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center); start-up funds (D.A.D) from the UW Carbone Cancer Center, UW Department of Medicine, UW School of Medicine and Public Health, and the UW Graduate School through the Wisconsin Alumni Research Foundation; Funk Out Cancer (http://www.funkoutcancer.com/) and UW Carbone Cancer Center Gastrointestinal Disease Oriented Working Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 2 Z9 2 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 10 PY 2016 VL 11 IS 2 AR e0148730 DI 10.1371/journal.pone.0148730 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DD6PR UT WOS:000370046600102 PM 26863299 ER PT J AU Lee, JS Giesler, DL Gellad, WF Fine, MJ AF Lee, Jonathan S. Giesler, Daniel L. Gellad, Walid F. Fine, Michael J. TI Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia A Systematic Review SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID BETA-LACTAM MONOTHERAPY; QUALITY-OF-CARE; ELDERLY-PATIENTS; OUTCOMES; MORTALITY; METAANALYSIS; PATIENT; LACTAM/MACROLIDE; AZITHROMYCIN; ASSOCIATION AB IMPORTANCE Antibiotic therapy is the cornerstone of medical management for community-acquired pneumonia. OBJECTIVE To assess the associations between 3 key aspects of antibiotic therapy (optimal time to antibiotic initiation, initial antibiotic selection, and criteria for the transition from intravenous to oral therapy) and short-term mortality in adults hospitalized with community-acquired pneumonia. EVIDENCE REVIEW Bibliographic databases of MEDLINE, EMBASE, and the Cochrane Collaboration were searched for studies of adults hospitalized with radiographically confirmed community-acquired pneumonia published from January 1, 1995, until November 5, 2015. FINDINGS Twenty studies (17 observational and 3 randomized trials) met eligibility criteria. Among 8 observational studies identified, the 4 largest (study populations of 2878 to 1 170 022) found that antibiotic initiation within 4 to 8 hours of hospital arrival was associated with relative reductions of 5% to 43% in mortality; the 4 smallest studies (study populations of 451 to 2076) found no associations between the timing of antibiotic initiation and mortality. One cluster randomized trial (n = 1737) demonstrated noninferiority of beta-lactam monotherapy (n = 506) vs beta-lactam plus macrolide combination therapy (n = 566), with an absolute adjusted difference of 2.5%(90% CI, -0.6% to 5.2%) in 90-day mortality favoring beta-lactam monotherapy. A second randomized trial (n = 580) failed to demonstrate noninferiority of beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy, with an absolute difference of 7.6%(1-sided 90% CI upper limit, 13.0%) in attainment of clinical stability on hospital day 7 favoring beta-lactam plus macrolide combination therapy. Six of 8 observational studies (study populations of 1188 to 24 780) found that beta-lactam plus macrolide combination therapy was associated with relative reductions of 26% to 68% in short-term mortality and all 3 observational studies (study populations of 2068 to 24 780) reported that fluoroquinolone monotherapy was associated with relative reductions of 30% to 43% in mortality compared with beta-lactam monotherapy. One randomized trial (n = 302) reported significantly reduced hospital length of stay (absolute difference, 1.9 days; 95% CI, 0.6 to 3.2 days), but no differences in treatment failure when objective clinical criteria were used to decide when to transition patients from intravenous to oral therapy. CONCLUSIONS AND RELEVANCE In adults hospitalized with community-acquired pneumonia, antibiotic therapy consisting of beta-lactam plus macrolide combination therapy or fluoroquinolone monotherapy initiated within 4 to 8 hours of hospital arrival was associated with lower adjusted short-term mortality, supported predominantly by low-quality observational studies. One randomized trial supports the use of objective clinical criteria to guide the transition from intravenous to oral antibiotic therapy. C1 [Lee, Jonathan S.; Giesler, Daniel L.; Gellad, Walid F.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Lee, Jonathan S.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Gellad, Walid F.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Fine, MJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151C Univ Dr,Bldg 30, Pittsburgh, PA 15240 USA. EM michael.fine@va.gov NR 44 TC 14 Z9 15 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 9 PY 2016 VL 315 IS 6 BP 593 EP 602 DI 10.1001/jama.2016.0115 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DD0UJ UT WOS:000369635200018 PM 26864413 ER PT J AU Wong, SY Tan, MGK Banks, WA Wong, WSF Wong, PTH Lai, MKP AF Wong, Siew Ying Tan, Michelle G. K. Banks, William A. Wong, W. S. Fred Wong, Peter T. -H. Lai, Mitchell K. P. TI Andrographolide attenuates LPS-stimulated up-regulation of C-C and C-X-C motif chemokines in rodent cortex and primary astrocytes SO JOURNAL OF NEUROINFLAMMATION LA English DT Article DE Andrographolide; Cytokines; Chemokines; Astrocyte; Neuroinflammation ID NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; RECEPTOR MODULATORS DECREASE; CEREBRAL-ISCHEMIA; BACTERIAL-MENINGITIS; CEREBROSPINAL-FLUID; SPINAL-CORD; TNF-ALPHA; IN-VITRO; MULTIPLE-SCLEROSIS AB Background: Andrographolide is the major bioactive compound isolated from Andrographis paniculata, a native South Asian herb used medicinally for its anti-inflammatory properties. In this study, we aimed to assess andrographolide's potential utility as an anti-neuroinflammatory therapeutic. Methods: The effects of andrographolide on lipopolysaccharide (LPS)-induced chemokine up-regulation both in mouse cortex and in cultured primary astrocytes were measured, including cytokine profiling, gene expression, and, in cultured astrocytes, activation of putative signaling regulators. Results: Orally administered andrographolide significantly attenuated mouse cortical chemokine levels from the C-C and C-X-C subfamilies. Similarly, andrographolide abrogated a range of LPS-induced chemokines as well as tumor necrosis factor (TNF)-alpha in astrocytes. In astrocytes, the inhibitory actions of andrographolide on chemokine and TNF-alpha up-regulation appeared to be mediated by nuclear factor-kappa B (NF-kappa B) or c-Jun N-terminal kinase (JNK) activation. Conclusions: These results suggest that andrographolide may be useful as a therapeutic for neuroinflammatory diseases, especially those characterized by chemokine dysregulation. C1 [Wong, Siew Ying; Tan, Michelle G. K.; Wong, W. S. Fred; Wong, Peter T. -H.; Lai, Mitchell K. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, 16 Med Dr, Singapore 117600, Singapore. [Tan, Michelle G. K.] Singapore Gen Hosp, Dept Clin Res, Singapore, Singapore. [Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Banks, William A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Wong, W. S. Fred] Natl Univ Singapore, Immunol Program, Inst Life Sci, Singapore 117548, Singapore. RP Lai, MKP (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, 16 Med Dr, Singapore 117600, Singapore. EM mitchell.lai@dementia-research.org OI Lai, Mitchell K.P./0000-0001-7685-1424; Wong, Siew Ying/0000-0002-3152-9930 FU Yong Loo Lin School of Medicine, National University of Singapore [W184-000-223-133]; Singapore National Medical Research Council [NMRC/CBRG/0027/2012] FX This study was supported by the Yong Loo Lin School of Medicine, National University of Singapore (grant W184-000-223-133) to MKPL and the Singapore National Medical Research Council (NMRC/CBRG/0027/2012) to WSFW. We thank Y Zhu for the technical assistance. NR 72 TC 3 Z9 3 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-2094 J9 J NEUROINFLAMM JI J. Neuroinflamm. PD FEB 9 PY 2016 VL 13 AR 34 DI 10.1186/s12974-016-0498-6 PG 11 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DD5HN UT WOS:000369954000002 PM 26860080 ER PT J AU Peralta, CA McClure, LA Scherzer, R Odden, MC White, CL Shlipak, M Benavente, O Pergola, P AF Peralta, Carmen A. McClure, Leslie A. Scherzer, Rebecca Odden, Michelle C. White, Carole L. Shlipak, Michael Benavente, Oscar Pergola, Pablo TI Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial SO CIRCULATION LA English DT Article DE cerebrovascular disorders; hypertension; kidney; stroke ID GLOMERULAR-FILTRATION-RATE; CONVERTING ENZYME-INHIBITOR; TYPE-2 DIABETES-MELLITUS; STAGE RENAL-DISEASE; CLINICAL-TRIALS; GFR DECLINE; END-POINT; HYPERTENSION; PROGRESSION; OUTCOMES AB Background The effect of intensive blood pressure (BP) lowering on kidney function among individuals with established cerebrovascular disease and preserved estimated glomerular filtration rate (eGFR) is not established. Methods and Results- Among 2610 participants randomized to a lower (< 130 mm Hg) versus higher ( 130- 149 mm Hg) systolic BP target with repeated measures of serum creatinine, we evaluated differences by study arm in annualized eGFR decline and rapid decline ( eGFR decline > 30%) using linear mixed models and logistic regression, respectively. We assessed associations of both treatment and kidney function decline with stroke, major vascular events, and the composite of stroke, death, major vascular events, or myocardial infarction using multivariable Cox regression, separately and jointly including a test for interaction. Analyses were conducted by treatment arm. Mean age was 63 +/- 11 years; 949 participants ( 36%) were diabetic; and mean eGFR was 80 +/- 19 mL center dot min- 1 center dot 1.73 m- 2. At 9 months, achieved systolic BP was 137 +/- 15 versus 127 +/- 14 mm Hg in the higher versus lower BP group, and differences were maintained throughout follow- up ( mean, 3.2 years). Compared with the higher target, the lower BP target had a - 0.50- mL center dot min- 1 center dot 1.73 m- 2 per year ( 95% confidence interval [ CI], - 0.79 to - 0.21) faster eGFR decline. Differences were most pronounced during the first year (- 2.1 mL center dot min- 1 center dot 1.73 m- 2; 95% CI, - 0.97 to - 3.2), whereas rates of eGFR decline did not differ after year 1 (- 0.095; 95% CI, - 0.47 to 0.23). A total of 313 patients ( 24%) in the lower BP group had rapid kidney function decline compared with 247 ( 19%) in the higher BP group ( odds ratio, 1.4; 95% CI, 1.1- 1.6). Differences in rapid decline by treatment arm were apparent in the first year ( odds ratio, 1.4; 95% CI, 1.1- 1.8) but were not significant after year 1 ( odds ratio, 1.0; 95% CI, 0.73- 1.4). Rapid decline was associated with higher risk for stroke, major vascular events, and composite after full adjustment among individuals randomized to the higher BP target ( stroke hazard ratio, 1.93; 95% CI, 1.15- 3.21) but not the lower BP arm ( stroke hazard ratio, 0.93; 95% CI, 0.50- 1.75; all P for interaction < 0.06). Conclusions In patients with prior lacunar stroke and relatively preserved kidney function, intensive BP lowering was associated with a greater likelihood of rapid kidney function decline. Differences were observed primarily during the first year of antihypertensive treatment. Rapid kidney function decline was not associated with increased risk for clinical events among those undergoing intensive BP lowering. C1 [Peralta, Carmen A.; Scherzer, Rebecca; Shlipak, Michael] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94121 USA. [Peralta, Carmen A.; Scherzer, Rebecca; Shlipak, Michael] San Francisco VA Med Ctr, San Francisco, CA USA. [McClure, Leslie A.] Univ Alabama Birmingham, Birmingham, AL USA. [Odden, Michelle C.] Oregon State Univ, Corvallis, OR 97331 USA. [White, Carole L.; Pergola, Pablo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Benavente, Oscar] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. RP Peralta, CA (reprint author), Univ Calif San Francisco, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU Robert Wood Johnson Foundation Harold Amos Grant; [1R01AG046206-01A1]; [5R03DK095877-03] FX Dr Peralta was funded by grant 1R01AG046206-01A1, 5R03DK095877-03, and the Robert Wood Johnson Foundation Harold Amos Grant. NR 38 TC 9 Z9 9 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD FEB 9 PY 2016 VL 133 IS 6 BP 584 EP 591 DI 10.1161/CIRCULATIONAHA.115.019657 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DC8XV UT WOS:000369504400007 PM 26762524 ER PT J AU Abbott, RD Ross, GW Petrovitch, H Masaki, KH Launer, LJ Nelson, JS White, LR Tanner, CM AF Abbott, Robert D. Ross, G. Webster Petrovitch, Helen Masaki, Kamal H. Launer, Lenore J. Nelson, James S. White, Lon R. Tanner, Caroline M. TI Midlife milk consumption and substantia nigra neuron density at death SO NEUROLOGY LA English DT Article ID IDIOPATHIC PARKINSONS-DISEASE; CORONARY-HEART-DISEASE; ORGANOCHLORINE PESTICIDES; DAIRY-PRODUCTS; FUTURE RISK; LIFE-STYLE; MEN; CALIFORNIA; STROKE; HAWAII AB Objective:To examine the relationship between midlife milk intake and Parkinson disease (PD) incidence through associations with substantia nigra (SN) neuron density and organochlorine pesticide exposure in decedent brains from the Honolulu-Asia Aging Study.Methods:Milk intake data were collected from 1965 to 1968 in 449 men aged 45-68 years with postmortem examinations from 1992 to 2004. Neuron density (count/mm(2)) was measured in quadrants from a transverse section of the SN. Additional measures included brain residues of heptachlor epoxide, an organochlorine pesticide found at excessively high levels in the milk supply in Hawaii in the early 1980s.Results:Neuron density was lowest in nonsmoking decedents who consumed high amounts of milk (>16 oz/d). After removing cases of PD and dementia with Lewy bodies, adjusted neuron density in all but the dorsomedial quadrant was 41.5% lower for milk intake >16 oz/d vs intake that was less (95% confidence interval 22.7%-55.7%, p < 0.001). Among those who drank the most milk, residues of heptachlor epoxide were found in 9 of 10 brains as compared to 63.4% (26/41) for those who consumed no milk (p = 0.017). For those who were ever smokers, an association between milk intake and neuron density was absent.Conclusions:Milk intake is associated with SN neuron loss in decedent brains unaffected by PD. Whether contamination of milk with organochlorine pesticides has a role in SN neurodegeneration warrants further study. C1 [Abbott, Robert D.] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan. [Abbott, Robert D.; Ross, G. Webster; Petrovitch, Helen; Nelson, James S.; White, Lon R.] Pacific Hlth Res & Educ Inst, Honolulu, HI USA. [Ross, G. Webster] Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA. [Abbott, Robert D.; Ross, G. Webster; Petrovitch, Helen; Masaki, Kamal H.] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, John A Hartford Fdn Ctr Excellence Geriatr, Honolulu, HI 96822 USA. [Ross, G. Webster; Petrovitch, Helen; White, Lon R.] Vet Affairs Pacific Isl Hlth Care Syst, Honolulu, HI USA. [Masaki, Kamal H.] Kuakini Med Ctr, Honolulu, HI USA. [Launer, Lenore J.] NIA, Bethesda, MD 20892 USA. [Tanner, Caroline M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. RP Abbott, RD (reprint author), Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga 52021, Japan.; Abbott, RD (reprint author), Pacific Hlth Res & Educ Inst, Honolulu, HI USA.; Abbott, RD (reprint author), Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, John A Hartford Fdn Ctr Excellence Geriatr, Honolulu, HI 96822 USA. EM rda3e@virginia.edu FU National Institute on Aging [N01-AG-4-2149, 1 UO1 AG19349, 5 R01 AG017155]; National Heart, Lung, and Blood Institute [N01-HC-05102]; National Institute of Neurological Disorders and Stroke [5 R01 NS041265]; United States Department of the Army [DAMD17-98-1-8621]; Office of Research and Development, Medical Research Service, Department of Veterans Affairs; Kuakini Medical Center; National Institute on Aging FX Supported by a contract (N01-AG-4-2149) and grants (1 UO1 AG19349 and 5 R01 AG017155) from the National Institute on Aging, by a contract (N01-HC-05102) from the National Heart, Lung, and Blood Institute, by a grant (5 R01 NS041265) from the National Institute of Neurological Disorders and Stroke, by a grant from the United States Department of the Army (DAMD17-98-1-8621), by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs, by the Kuakini Medical Center, and in part by the Intramural Research Program of the National Institute on Aging. The information contained in this article does not necessarily reflect the position or the policy of the US Government, and no official endorsement should be inferred. NR 39 TC 4 Z9 4 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 9 PY 2016 VL 86 IS 6 BP 512 EP 519 DI 10.1212/WNL.0000000000002254 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DC9KT UT WOS:000369541200005 PM 26658906 ER PT J AU Vistamehr, A Kautz, SA Bowden, MG Neptune, RR AF Vistamehr, Arian Kautz, Steven A. Bowden, Mark G. Neptune, Richard R. TI Correlations between measures of dynamic balance in individuals with post-stroke hemiparesis SO JOURNAL OF BIOMECHANICS LA English DT Article DE Berg balance scale; Dynamic gait index; Margin of stability; Angular momentum; Biomechanics ID PLANE ANGULAR-MOMENTUM; HUMAN WALKING; STROKE REHABILITATION; LATERAL BALANCE; SUPPORT LIMB; OLDER-ADULTS; GAIT INDEX; STABILITY; FALLS; MARGINS AB Mediolateral balance control during walking is a challenging task in post-stroke hemiparetic individuals. To detect and treat dynamic balance disorders, it is important to assess balance using reliable methods. The Berg Balance Scale (BBS), Dynamic Gait Index (DGI), margin-of-stability (MoS), and peak-to-peak range of angular-momentum (H) are some of the most commonly used measures to assess dynamic balance and fall risk in clinical and laboratory settings. However, it is not clear if these measures lead to similar conclusions. Thus, the purpose of this study was to assess dynamic balance in post-stroke hemiparetic individuals using BBS, DGI, MoS and the range of H and determine if these measure are correlated. BBS and DGI were collected from 19 individuals post-stroke. Additionally, kinematic and kinetic data were collected while the same individuals walked at their self-selected speed. MoS and the range of H were calculated in the mediolateral direction for each participant. Correlation analyses revealed moderate associations between all measures. Overall, a higher range of angular-momentum was associated with a higher MoS, wider step width and lower BBS and DGI scores, indicating poor balance control. Further, only the MoS from the paretic foot placement, but not the nonparetic foot, correlated with the other balance measures. Although moderate correlations existed between all the balance measures, these findings do not necessarily advocate the use of a single measure as each test may assess different constructs of dynamic balance. These findings have important implications for the use and interpretation of dynamic balance assessments. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Vistamehr, Arian] Brooks Rehabil Hosp, Motion Anal Ctr, Jacksonville, FL USA. [Kautz, Steven A.; Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kautz, Steven A.; Bowden, Mark G.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Kautz, Steven A.; Bowden, Mark G.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu FU American Heart Association SouthWest Affiliate pre-doctoral fellowship [12PRE12030414]; Rehabilitation Research and Development Service of the Department of Veteran's Affairs [N0787-W]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20-GM109040] FX The authors would like to acknowledge Ms. Leah Carter for her valuable contributions to this study. This work was supported by an American Heart Association SouthWest Affiliate pre-doctoral fellowship (12PRE12030414), the Rehabilitation Research and Development Service of the Department of Veteran's Affairs (N0787-W) and an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant number P20-GM109040. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the AHA, the VA or the NIH. NR 37 TC 2 Z9 3 U1 7 U2 16 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0021-9290 EI 1873-2380 J9 J BIOMECH JI J. Biomech. PD FEB 8 PY 2016 VL 49 IS 3 BP 396 EP 400 DI 10.1016/j.jbiomech.2015.12.047 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA DF7PA UT WOS:000371548700012 PM 26795124 ER PT J AU Kristianto, J Litscher, SJ Johnson, MG Patel, F Patel, M Fisher, J Zastrow, RK Radcliff, AB Blank, RD AF Kristianto, Jasmin Litscher, Suzanne J. Johnson, Michael G. Patel, Forum Patel, Mital Fisher, Jacqueline Zastrow, Ryley K. Radcliff, Abigail B. Blank, Robert D. TI Congenic Strains Confirm the Pleiotropic Effect of Chromosome 4 QTL on Mouse Femoral Geometry and Biomechanical Performance SO PLOS ONE LA English DT Article ID QUANTITATIVE TRAIT LOCI; BONE-MINERAL DENSITY; CORTICAL BONE; SEX-DIFFERENCES; GENETIC COMPOSITION; CANDIDATE GENES; SKELETAL SIZE; BODY-SIZE; MICE; STRENGTH AB A pleiotropic quantitative trait locus (QTL) for bone geometry and mechanical performance in mice was mapped to distal chromosome 4 via an intercross of recombinant congenic mice HcB-8 and HcB-23. To study the QTL in isolation, we have generated C3H. B10-(rs6355453-rs13478087) (C. B. 4.3) and C3H. B10-(rs6369860-D4Mit170) (C. B. 4.2) congenic strains that harbor similar to 20 Mb and similar to 3 Mb, respectively, of chromosome 4 overlapping segments from C57BL/10ScSnA (B10) within the locus on a C3H/DiSnA (C3H) background. Using 3-point bend testing and standard beam equations, we phenotyped these mice for femoral mid-diaphyseal geometry and biomechanical performance. We analyzed the results via 2-way ANOVA, using sex and genotype as factors. In the C. B. 4.3 strain, we found that homozygous B10/B10 male mice had smaller cross sectional area (CSA) and reduced total displacement than homozygous C3H/C3H mice. Sex by genotype interaction was also observed for maximum load and stiffness for C3H/C3H and B10/B10 mice, respectively. In C. B. 4.2 strain, we found that homozygous B10/B10 mice had lower total displacement, post-yield displacement (PYD), stiffness, yield load and maximum load than mice harboring C3H allele. Sex by genotype interaction was observed in B10/B10 mice for perimeter, outer minor axis (OMA) and CSA. There were no significant differences in tissue level mechanical performance, which suggest that the QTL acts primarily on circumferential bone size. These data confirm the prior QTL mapping data and support other work demonstrating the importance of chromosome 4 QTL on bone modeling and bone responses to mechanical loading. C1 [Kristianto, Jasmin; Litscher, Suzanne J.; Johnson, Michael G.; Patel, Forum; Patel, Mital; Fisher, Jacqueline; Zastrow, Ryley K.; Radcliff, Abigail B.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Blank, Robert D.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Blank, Robert D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Blank, Robert D.] Milwaukee VA Med Ctr, Milwaukee, WI USA. RP Kristianto, J (reprint author), Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. EM jkristianto@medicine.wisc.edu OI Blank, Robert Daniel/0000-0003-2950-1944 FU Office of Research and Development, Rehabilitation Research and Development Service [I21 RX1440]; Merit Review Award from the Office of Research and Development, Biomedical and Laboratory Research and Development Service, the Department of Veterans Affairs; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health [NIH AR54753]; NIH [AR54753] FX We would like to thank Marc Drezner and Baozhi Yuan for helpful discussions. This material is based on work supported in part by award I21 RX1440, by the Office of Research and Development, Rehabilitation Research and Development Service, and a Merit Review Award from the Office of Research and Development, Biomedical and Laboratory Research and Development Service, the Department of Veterans Affairs, and performed in the Geriatrics Research, Education, and Clinical Center at the William S. Middleton Memorial Veterans Hospital. The views expressed here are those of the authors, and the contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.; Research reported in this publication was supported in part by National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health under Award Number NIH AR54753. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.; Funded by NIH AR54753. www.nih.gov. (Robert Blank). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 52 TC 2 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 5 PY 2016 VL 11 IS 2 AR e0148571 DI 10.1371/journal.pone.0148571 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9PR UT WOS:000369554000127 PM 26849124 ER PT J AU Zaynagetdinov, R Sherrill, TP Gleaves, LA Hunt, P Han, W McLoed, AG Saxon, JA Tanjore, H Gulleman, PM Young, LR Blackwell, TS AF Zaynagetdinov, Rinat Sherrill, Taylor P. Gleaves, Linda A. Hunt, Pierre Han, Wei McLoed, Allyson G. Saxon, Jamie A. Tanjore, Harikrishna Gulleman, Peter M. Young, Lisa R. Blackwell, Timothy S. TI Chronic NF-kappa B activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs SO ONCOTARGET LA English DT Article DE NF-kappa B; COPD; lung cancer; macrophage; tregs ID OBSTRUCTIVE PULMONARY-DISEASE; REGULATORY T-CELLS; RETINOIC ACID; BRONCHIAL BIOPSIES; MACROPHAGES; CARCINOGENESIS; EXPRESSION; BETA; TUMORIGENESIS; INFLAMMATION AB Nuclear Factor (NF)-kappa B is positioned to provide the interface between COPD and carcinogenesis through regulation of chronic inflammation in the lungs. Using a tetracycline-inducible transgenic mouse model that conditionally expresses activated I kappa B kinase beta (IKK beta) in airway epithelium (IKTA), we found that sustained NF-kappa B signaling results in chronic inflammation and emphysema by 4 months. By 11 months of transgene activation, IKTA mice develop lung adenomas. Investigation of lung inflammation in IKTA mice revealed a substantial increase in M2-polarized macrophages and CD4(+)/CD25(+)/FoxP3(+) regulatory T lymphocytes (Tregs). Depletion of alveolar macrophages in IKTA mice reduced Tregs, increased lung CD8(+) lymphocytes, and reduced tumor numbers following treatment with the carcinogen urethane. Alveolar macrophages from IKTA mice supported increased generation of inducible Foxp3(+) Tregs ex vivo through expression of TGF beta and IL-10. Targeting of TGF beta and IL-10 reduced the ability of alveolar macrophages from IKTA mice to induce Foxp3 expression on T cells. These studies indicate that sustained activation of NF-kappa B pathway links COPD and lung cancer through generation and maintenance of a pro-tumorigenic inflammatory environment consisting of alternatively activated macrophages and regulatory T cells. C1 [Zaynagetdinov, Rinat; Sherrill, Taylor P.; Gleaves, Linda A.; Hunt, Pierre; Han, Wei; Tanjore, Harikrishna; Young, Lisa R.; Blackwell, Timothy S.] Vanderbilt Univ, Dept Med, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. [McLoed, Allyson G.; Saxon, Jamie A.; Blackwell, Timothy S.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA. [Blackwell, Timothy S.] US Dept Vet Affairs, Nashville, TN 37232 USA. [Gulleman, Peter M.; Young, Lisa R.] Vanderbilt Univ, Dept Pediat, Sch Med, Div Pulm Med, Nashville, TN 37232 USA. RP Zaynagetdinov, R (reprint author), Vanderbilt Univ, Dept Med, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA. EM rinat.z.zaynagetdinov@vanderbilt.edu FU Lung Cancer Initiative of North Carolina; National Institutes of Health [T32HL094296, R01 HL119503]; Department of Veterans Affairs Merit Review Award [1101BX002378]; Vanderbilt-Ingram Cancer Center Spore Grant; Free to Breathe FX This work was supported by a Grant from the Lung Cancer Initiative of North Carolina and Free to Breathe (R.Z.), by National Institutes of Health Grants T32HL094296 (R.Z.) and R01 HL119503 (L.R.Y), by the Department of Veterans Affairs Merit Review Award 1101BX002378 (T.S.B), and by a Vanderbilt-Ingram Cancer Center Spore Grant 2010 (T.S.B). NR 30 TC 2 Z9 2 U1 3 U2 5 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD FEB 2 PY 2016 VL 7 IS 5 BP 5470 EP 5482 PG 13 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DD5HD UT WOS:000369952800028 PM 26756215 ER PT J AU Hassan, A Ahlskog, JE Matsumoto, JY Milber, JM Bower, JH Wilkinson, JR AF Hassan, Anhar Ahlskog, J. Eric Matsumoto, Joseph Y. Milber, Joshua M. Bower, James H. Wilkinson, Jayne R. TI Orthostatic tremor Clinical, electrophysiologic, and treatment findings in 184 patients SO NEUROLOGY LA English DT Article ID MYOCLONUS AB Objective:To evaluate the clinical, electrophysiologic, and treatment outcome features of orthostatic tremor (OT) in a large case series.Methods:We performed medical record review of 184 patients who met clinical and electrodiagnostic criteria for OT from 1976 to 2013 at the Mayo Clinic. Demographic, clinical, electrophysiologic, and treatment data were extracted.Results:The majority of OT cases were female (63.6%) and mean age at onset was 59.3 years (range 13-85 years). Diagnosis was delayed by a mean of 7.2 years (range 0-44 years). The average tremor frequency was 15.7 Hz (range 12.5-20 Hz), and transmitted to the arms on weight-bearing (95.5%). Patients reported a spectrum of progressive orthostatic leg symptoms, relieved by sitting or leaning. Falls were reported in 24.1%. Coexistent neurologic disorders included essential tremor (22.8%), other tremor (4.9%), and parkinsonism (8.7%). Family history of OT was noted in 4.9%. Of 46 medications trialed, 24 failed to provide any benefit. Benzodiazepines provided at least mild benefit in 55.9%, and moderate to marked benefit in 31.5%; -blockers (31.0%) and anticonvulsants (25.0%) provided mild benefit, and the remainder were largely ineffective. Medication benefit waned over time. Deep brain stimulation (DBS) was effective in 2 cases.Conclusion:OT predominantly affects female seniors, and the diagnosis should be considered with any orthostatic-induced leg symptoms, and confirmed by surface EMG. Benzodiazepines are the most efficacious treatment, followed by -blockers and anticonvulsants. DBS should be further explored for treatment. C1 [Hassan, Anhar; Ahlskog, J. Eric; Matsumoto, Joseph Y.; Bower, James H.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Milber, Joshua M.] SUNY Downstate Coll Med, Brooklyn, NY USA. [Wilkinson, Jayne R.] Univ Penn, Philadelphia, PA 19104 USA. [Wilkinson, Jayne R.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. RP Hassan, A (reprint author), Mayo Clin, Dept Neurol, Rochester, MN USA. EM hassan.anhar@mayo.edu NR 15 TC 7 Z9 8 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD FEB 2 PY 2016 VL 86 IS 5 BP 458 EP 464 DI 10.1212/WNL.0000000000002328 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DD1HZ UT WOS:000369673200010 PM 26747880 ER PT J AU Boutin, M Sun, Y Shacka, JJ Auray-Blais, C AF Boutin, Michel Sun, Ying Shacka, John J. Auray-Blais, Christiane TI Tandem Mass Spectrometry Multiplex Analysis of Glucosylceramide and Galactosylceramide Isoforms in Brain Tissues at Different Stages of Parkinson Disease SO ANALYTICAL CHEMISTRY LA English DT Article ID NEURONOPATHIC GAUCHER-DISEASE; ALPHA-SYNUCLEIN; GLUCOCEREBROSIDASE; ACCUMULATION; QUANTITATION; DEFICIENCY; QUADRUPOLE; BIOMARKERS; PLASMA; MODEL AB Previous studies demonstrated that Parkinson disease (PD) is associated with a decreased activity of the glucocerebrosidase (GCase) enzyme in brain tissues. The objective of this study was to determine if GCase deficiency is associated with the accumulation of its glucosylceramide (GluCer) substrate in PD brain tissues. An ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed, optimized, and validated for the multiplex analysis of GluCer isoforms (C18:0, C20:0, C22:0, C24:1, and C24:0) in brain tissue samples. These molecules were chromatographically separated from their isobaric galactosylceramide (GalCer) counterparts using normal phase chromatography. The analysis was performed by tandem mass spectrometry in the multiple reaction monitoring (MRM) acquisition mode. Limits of detection ranging from 0.4 to 1.1 nmol/g brain tissue were established for the different GluCer isoforms analyzed. For the first time, GluCer isoform levels were analyzed in temporal cortex brain tissue samples from 26 PD patients who were divided into three PD disease stages (IIa, III, and IV) according to the Unified Staging System for Lewy Body Disorders. These specimens were compared with brain tissue samples from 12 controls and 6 patients with Incidental Lewy Body Disease. No significant GluCer concentration differences were observed between the 5 sample groups. The GluCer isoform levels were also normalized with their matching GalCer isoforms. The normalized results showed a trend for GluCer levels which increased with PD severity. However, the differences observed between the groups were not significant, owing likely to the high standard deviations measured. C1 [Boutin, Michel; Auray-Blais, Christiane] Univ Sherbrooke, Div Med Genet, Dept Pediat, Ctr Rech,CHUS,Fac Med & Hlth Sci, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada. [Sun, Ying] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, R Bldg Room 1401,3333 Burnet Ave, Cincinnati, OH 45229 USA. [Shacka, John J.] Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Pathol Div, 1670 Univ Blvd,VH G019H, Birmingham, AL 35294 USA. [Shacka, John J.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Auray-Blais, C (reprint author), Univ Sherbrooke, Div Med Genet, Dept Pediat, Ctr Rech,CHUS,Fac Med & Hlth Sci, 3001,12th Ave North, Sherbrooke, PQ J1H 5N4, Canada. EM christiane.auray-blais@usherbrooke.ca FU Michael J. Fox Foundation for Parkinson's Research FX This research was funded by the Michael J. Fox Foundation for Parkinson's Research. We are grateful to Waters Corporation for their continued scientific support and partnership. We would like to thank Michael P. Nelson, Ph.D. at University of Alabama at Birmingham for his support in preparing the brain tissue samples. We would like to sincerely thank Dr. Joe T. R. Clarke for his expertise and insight and Marie-Pierre Garant for statistical analysis support. NR 25 TC 4 Z9 4 U1 5 U2 18 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD FEB 2 PY 2016 VL 88 IS 3 BP 1856 EP 1863 DI 10.1021/acs.analchem.5b04227 PG 8 WC Chemistry, Analytical SC Chemistry GA DC8LM UT WOS:000369471100053 PM 26735924 ER PT J AU Merrins, MJ Poudel, C McKenna, JP Ha, J Sherman, A Bertram, R Satin, LS AF Merrins, Matthew J. Poudel, Chetan McKenna, Joseph P. Ha, Joon Sherman, Arthur Bertram, Richard Satin, Leslie S. TI Phase Analysis of Metabolic Oscillations and Membrane Potential in Pancreatic Islet beta-Cells SO BIOPHYSICAL JOURNAL LA English DT Article ID PULSATILE INSULIN-SECRETION; PURINE NUCLEOTIDE CYCLE; GLYCOLYTIC PATHWAY; CA2+; GLUCOSE; CALCIUM; MODEL; DEHYDROGENASE; ACTIVATION; MECHANISMS AB Metabolism in islet beta-cells displays oscillations that can trigger pulses of electrical activity and insulin secretion. There has been a decades-long debate among islet biologists about whether metabolic oscillations are intrinsic or occur in response to oscillations in intracellular Ca2+ that result from bursting electrical activity. In this article, the dynamics of oscillatory metabolism were investigated using five different optical reporters. Reporter activity was measured simultaneously with membrane potential bursting to determine the phase relationships between the metabolic oscillations and electrical activity. Our experimental findings suggest that Ca2+ entry into beta-cells stimulates the rate of mitochondrial metabolism, accounting for the depletion of glycolytic intermediates during each oscillatory burst. We also performed Ca2+ clamp tests in which we clamped membrane potential with the K-ATP channel-opener diazoxide and KCl to fix Ca2+ at an elevated level. These tests confirm that metabolic oscillations do not require Ca2+ oscillations, but show that Ca2+ plays a larger role in shaping metabolic oscillations than previously suspected. A dynamical picture of the mechanisms of oscillations emerged that requires the restructuring of contemporary mathematical beta-cell models, including our own dual oscillator model. In the companion article, we modified our model to account for these new data. C1 [Merrins, Matthew J.; Poudel, Chetan] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Endocrinol Diabet & Metab, Madison, WI USA. [Merrins, Matthew J.; Poudel, Chetan] Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, Madison, WI USA. [Merrins, Matthew J.; Poudel, Chetan] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Dept Math, Tallahassee, FL 32306 USA. [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA. [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Program Mol Biophys, Tallahassee, FL 32306 USA. [Ha, Joon; Sherman, Arthur] NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA. [Satin, Leslie S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA. [Satin, Leslie S.] Univ Michigan, Brehm Diabet Ctr, Ann Arbor, MI 48109 USA. RP Satin, LS (reprint author), Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA.; Satin, LS (reprint author), Univ Michigan, Brehm Diabet Ctr, Ann Arbor, MI 48109 USA. EM lsatin@umich.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK46409, K01-DK101683]; NIH FX This work was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases, including grants R01-DK46409 to L.S.S. and K01-DK101683 to M.J.M. A.S. and J.H. were supported by the Intramural Research Program of the NIH. NR 39 TC 4 Z9 4 U1 0 U2 6 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD FEB 2 PY 2016 VL 110 IS 3 BP 691 EP 699 DI 10.1016/j.bpj.2015.12.029 PG 9 WC Biophysics SC Biophysics GA DC8KH UT WOS:000369467800018 PM 26840733 ER PT J AU McKenna, JP Ha, J Merrins, MJ Satin, LS Sherman, A Bertram, R AF McKenna, Joseph P. Ha, Joon Merrins, Matthew J. Satin, Leslie S. Sherman, Arthur Bertram, Richard TI Ca2+ Effects on ATP Production and Consumption Have Regulatory Roles on Oscillatory Islet Activity SO BIOPHYSICAL JOURNAL LA English DT Article ID PANCREATIC BETA-CELLS; PULSATILE INSULIN-SECRETION; METABOLIC OSCILLATIONS; GLYCOLYTIC OSCILLATIONS; ELECTRICAL-ACTIVITY; GLUCOSE-METABOLISM; CALCIUM; PHOSPHOFRUCTOKINASE; MODEL; MEMBRANE AB Pancreatic islets respond to elevated blood glucose by secreting pulses of insulin that parallel oscillations in beta-cell metabolism, intracellular Ca2+ concentration, and bursting electrical activity. The mechanisms that maintain an oscillatory response are not fully understood, yet several models have been proposed. Only some can account for experiments supporting that metabolism is intrinsically oscillatory in beta-cells. The dual oscillator model (DOM) implicates glycolysis as the source of oscillatory metabolism. In the companion article, we use recently developed biosensors to confirm that glycolysis is oscillatory and further elucidate the coordination of metabolic and electrical signals in the insulin secretory pathway. In this report, we modify the DOM by incorporating an established link between metabolism and intracellular Ca2+ to reconcile model predictions with experimental observations from the companion article. With modification, we maintain the distinguishing feature of the DOM, oscillatory glycolysis, but introduce the ability of Ca2+ influx to reshape glycolytic oscillations by promoting glycolytic efflux. We use the modified model to explain measurements from the companion article and from previously published experiments with islets. C1 [McKenna, Joseph P.; Bertram, Richard] Florida State Univ, Dept Math, Tallahassee, FL 32306 USA. [Ha, Joon; Sherman, Arthur] NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA. [Merrins, Matthew J.] Univ Wisconsin, Dept Med, Div Endocrinol Diabet & Metab, Sch Med & Publ Hlth, Madison, WI USA. [Merrins, Matthew J.] Univ Wisconsin, Dept Biomol Chem, Sch Med & Publ Hlth, Madison, WI USA. [Merrins, Matthew J.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Satin, Leslie S.] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA. [Satin, Leslie S.] Univ Michigan, Brehm Diabet Ctr, Ann Arbor, MI 48109 USA. [Bertram, Richard] Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA. [Bertram, Richard] Florida State Univ, Program Mol Biophys, Tallahassee, FL 32306 USA. RP Bertram, R (reprint author), Florida State Univ, Dept Math, Tallahassee, FL 32306 USA.; Bertram, R (reprint author), Florida State Univ, Program Neurosci, Tallahassee, FL 32306 USA.; Bertram, R (reprint author), Florida State Univ, Program Mol Biophys, Tallahassee, FL 32306 USA. EM bertram@math.fsu.edu FU National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK46409, K01-DK101683]; Intramural Research Program of the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases) FX This work was partially supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (grant No. R01-DK46409 to L.S.S. and grant No. K01-DK101683 to M.J.M.). A.S. and J.H. were supported by the Intramural Research Program of the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases). NR 46 TC 2 Z9 2 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0006-3495 EI 1542-0086 J9 BIOPHYS J JI Biophys. J. PD FEB 2 PY 2016 VL 110 IS 3 BP 733 EP 742 DI 10.1016/j.bpj.2015.11.3526 PG 10 WC Biophysics SC Biophysics GA DC8KH UT WOS:000369467800022 PM 26840737 ER PT J AU Bradley, SM O'Donnell, CI Grunwald, GK Liu, CF Hebert, PL Maddox, TM Jesse, RL Fihn, SD Rumsfeld, JS Ho, PM AF Bradley, Steven M. O'Donnell, Colin I. Grunwald, Gary K. Liu, Chuan-Fen Hebert, Paul L. Maddox, Thomas M. Jesse, Robert L. Fihn, Stephan D. Rumsfeld, John S. Ho, P. Michael TI Facility Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short- Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program Response SO CIRCULATION LA English DT Letter C1 [Bradley, Steven M.; O'Donnell, Colin I.; Grunwald, Gary K.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA. [O'Donnell, Colin I.; Grunwald, Gary K.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA. [Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Jesse, Robert L.; Fihn, Stephan D.] US Dept Vet Affairs, Vet Hlth Adm, Washington, DC USA. RP Bradley, SM (reprint author), VA Eastern Colorado Hlth Care Syst, Denver, CO USA.; Bradley, SM (reprint author), Univ Colorado, Sch Med, Aurora, CO USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD FEB 2 PY 2016 VL 133 IS 5 BP E377 EP E377 DI 10.1161/CIRCULATIONAHA.115.019552 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DD1IC UT WOS:000369673500005 PM 26831442 ER PT J AU Chen-Scarabelli, C Scarabelli, TM AF Chen-Scarabelli, Carol Scarabelli, Tiziano M. TI Cyclosporine A Prior to Primary PCI in STEMI Patients The Coup de Grace to Post-Conditioning? SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material DE cardioprotection; coronary occlusion; infarct size; mitochondrial permeability transition pores; myocardial reperfusion injury ID ELEVATION MYOCARDIAL-INFARCTION; REPERFUSION; INJURY; TRIAL; CARDIOPROTECTION C1 [Chen-Scarabelli, Carol; Scarabelli, Tiziano M.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Scarabelli, Tiziano M.] Univ Alabama Birmingham, Div Cardiovasc Dis, 1530 3rd Ave,South Tinsley Harrison Tower, Birmingham, AL 35294 USA. RP Scarabelli, TM (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, 1530 3rd Ave,South Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM tscarabelli@uabmc.edu NR 14 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 2 PY 2016 VL 67 IS 4 BP 375 EP 378 DI 10.1016/j.jacc.2015.11.024 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DB6HO UT WOS:000368615600004 PM 26821624 ER PT J AU Carson, AP Muntner, P Selvin, E Carnethon, MR Li, XL Gross, MD Garvey, WT Lewis, CE AF Carson, April P. Muntner, Paul Selvin, Elizabeth Carnethon, Mercedes R. Li, Xuelin Gross, Myron D. Garvey, W. Timothy Lewis, Cora E. TI Do glycemic marker levels vary by race? Differing results from a cross-sectional analysis of individuals with and without diagnosed diabetes SO BMJ OPEN DIABETES RESEARCH & CARE LA English DT Article ID HEMOGLOBIN A(1C) LEVELS; GLYCATED ALBUMIN; ALTERNATIVE MARKERS; BLOOD-GLUCOSE; RISK; 1,5-ANHYDROGLUCITOL; FRUCTOSAMINE; ADULTS; ASSOCIATION; MELLITUS AB Objective: It is well known that A1c varies by race. However, racial differences in other biomarkers of hyperglycemia are less well characterized. The objective of this study was to determine whether average levels of glycemic markers differ by race in adults with and without diagnosed diabetes, before and after accounting for postchallenge glucose. Research design and methods: This cross-sectional study included 2692 middle-aged men and women (5.5% with diagnosed diabetes; 44% African-American; and 56% white) from the Coronary Artery Risk Development in Young Adults Study (2005-2006) who had fasting glucose, 2-hour postchallenge glucose, A1c, glycated albumin, fructosamine, and 1,5-anhydroglucitol (1,5-AG) measured. Multiple linear regression was used to evaluate racial differences in mean levels of each glycemic marker stratified by the diabetes status and adjusted for sociodemographics, cardiovascular factors, and postchallenge glucose. Results: Among those with diagnosed diabetes, racial differences were not observed for any of the glycemic markers. In contrast, among those without diagnosed diabetes, African-Americans had higher mean levels than whites of A1c (beta=0.19% points; 95% CI 0.14 to 0.24), glycated albumin (beta=0.82% points; 95% CI 0.68 to 0.97), fructosamine (beta=8.68 mu mol/L; 95% CI 6.68 to 10.68), and 2-hour glucose (beta=3.50 mg/dL; 95% CI 0.10 to 6.90) after multivariable adjustment, whereas there were no statistically significant racial difference in 1,5-AG. The racial differences observed for A1c, glycated albumin, and fructosamine persisted after further adjustment for fasting and 2-hour glucose and were of similar magnitude (SD units). Conclusions: Racial differences in glycemic marker levels were evident among middle-aged adults without diagnosed diabetes even after adjustment for postchallenge glucose. Whether these racial differences in biomarkers of hyperglycemia affect the risk of complications warrants additional study. C1 [Carson, April P.; Muntner, Paul] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. [Selvin, Elizabeth] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Carnethon, Mercedes R.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. [Li, Xuelin; Lewis, Cora E.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. [Gross, Myron D.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Sch Hlth Profess, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Carson, AP (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA. EM apcarson@uab.edu FU NCATS NIH HHS [UL1 TR000165, UL1 TR001417]; NHLBI NIH HHS [HHSN268201300027C, HHSN268200900041C, HHSN268201300025C, HHSN268201300026C, HHSN268201300028C, HHSN268201300029C, R01 HL053560]; NIDDK NIH HHS [F32 DK009528, K01 DK095928, K24 DK106414, P30 DK079626] NR 33 TC 3 Z9 3 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2052-4897 J9 BMJ OPEN DIAB RES CA JI BMJ Open Diab. Res. Care PD FEB PY 2016 VL 4 IS 1 AR e000213 DI 10.1136/bmjdrc-2016-000213 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA1DQ UT WOS:000386333100047 PM 27335652 ER PT J AU Berry, ABL Butler, KA Harrington, C Braxton, MO Walker, AJ Pete, N Johnson, T Oberle, MW Haselkorn, J Nichol, WP Haselkorn, M AF Berry, Andrew B. L. Butler, Keith A. Harrington, Craig Braxton, Melissa O. Walker, Amy J. Pete, Nikki Johnson, Trevor Oberle, Mark W. Haselkorn, Jodie Nichol, W. Paul Haselkorn, Mark TI Using conceptual work products of health care to design health IT SO JOURNAL OF BIOMEDICAL INFORMATICS LA English DT Article DE Model-based design; Health IT; Electronic health record; Workflow; Conceptual work products; Case management; Information architecture; User interface; Human-computer interaction ID TASK-ANALYSIS; FRAMEWORK AB This paper introduces a new, model -based design method for interactive health information technology (IT) systems. This method extends workflow models with models of conceptual work products. When the health care work being modeled is substantially cognitive, tacit, and complex in nature, graphical workflow models can become too complex to be useful to deigners. Conceptual models complement and simplify workflows by providing an explicit specification for the information product they must produce. We illustrate how conceptual work products can be modeled using standard software modeling language, which allows them to provide fundamental requirements for what the workflow must accomplish and the information that a new system should provide. Developers can use these specifications to envision how health IT could enable an effective cognitive strategy as a workflow with precise information requirements. We illustrate the new method with a study conducted in an outpatient multiple sclerosis (MS) clinic. This study shows specifically how the different phases of the method can be carried out, how the method allows for iteration across phases, and how the method generated a health IT design for case management of MS that is efficient and easy to use. (C) 2015 Elsevier Inc. All rights reserved. C1 [Berry, Andrew B. L.; Butler, Keith A.; Braxton, Melissa O.; Pete, Nikki; Johnson, Trevor; Haselkorn, Mark] Univ Washington, Dept Human Ctr Design & Engn, Coll Engn, Campus Box 352315, Seattle, WA 98195 USA. [Harrington, Craig] Univ Texas Houston, Sch Biomed Informat, 7000 Fannin St,Suite 600, Houston, TX 77030 USA. [Walker, Amy J.] Univ Washington, Sch Nursing, 1959 NE Pacific St, Seattle, WA 98195 USA. [Oberle, Mark W.] Univ Washington, Sch Publ Hlth, Box 357230, Seattle, WA 98195 USA. [Haselkorn, Jodie; Nichol, W. Paul] Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. RP Butler, KA (reprint author), Univ Washington, Dept Human Ctr Design & Engn, Coll Engn, Campus Box 352315, Seattle, WA 98195 USA. EM ablberry@uw.edu; Keith.A.Butler@gmail.com; craig.j.harrington@uth.tmc.edu; braxtm@uw.edu; walkeraj@uw.edu; peten@uw.edu; trevorj@uw.edu; moberle@uw.edu; Jodie.Haselkorn@va.gov; Paul.Nichol@va.gov; markh@uw.edu FU Agency for Healthcare Research and Quality [R01HS021233]; VA Puget Sound Health Care System, Seattle, Washington FX This project was supported by Grant Number R01HS021233 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. We gratefully acknowledge participation by the VHA MS COE West and VHA Office of Informatics and Analytics. The research with human subjects was conducted in accordance with UW IRB 40065, VA IRB MIRB0553, and UT-Houston IRB HSC-SBMI-14-0136. We would like to thank Dr. Lucas McCarthy for his analysis of data feasibility, Dr. Chris Esposito for programming P-CMS, Christina Chung for assistance with data collection and analysis, Yi-Chen Sung for assistance designing prototypes and figures, and Tongfang Sun for assistance with manuscript preparation. NR 36 TC 1 Z9 1 U1 1 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1532-0464 EI 1532-0480 J9 J BIOMED INFORM JI J. Biomed. Inform. PD FEB PY 2016 VL 59 BP 15 EP 30 DI 10.1016/j.jbi.2015.10.014 PG 16 WC Computer Science, Interdisciplinary Applications; Medical Informatics SC Computer Science; Medical Informatics GA DX9HJ UT WOS:000384703900002 PM 26528606 ER PT J AU Wecht, JM Weir, JP Radulovic, M Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Radulovic, Miroslav Bauman, William A. TI Effects of midodrine and L-NAME on systemic and cerebral hemodynamics during cognitive activation in spinal cord injury and intact controls SO PHYSIOLOGICAL REPORTS LA English DT Article DE Blood pressure; cerebral blood flow; cognition; L-NAME; Midodrine; NOS inhibition; spinal cord injury; tetraplegia ID BLOOD-PRESSURE ABNORMALITIES; OXIDE SYNTHASE INHIBITION; ORTHOSTATIC HYPOTENSION; HEART-RATE; SERIAL 7S; FLOW; TETRAPLEGIA; PERFORMANCE; HYDROCHLORIDE; RESPONSES AB We previously showed that increases in mean arterial pressure (MAP) following administration of midodrine hydrochloride (MH) and nitro-L-arginine methyl ester (L-NAME) resulted in increased mean cerebral blood flow velocity (MFV) during head-up tilt in hypotensive individuals with spinal cord injury (SCI) and question if this same association was evident during cognitive activation. Herein, we report MAP and MFV during two serial subtraction tasks (SSt) given before (predrug) and after (postdrug) administration of MH; (10 mg), L-NAME (1 mg/kg) or no drug (ND) in 15 subjects with SCI compared to nine able-bodied (AB) controls. Three-way factorial analysis of variance (ANOVA) models were used to determine significant main and interaction effects for group (SCI, AB), visit (MH, L-NAME, ND), and time (predrug, postdrug) for MAP and MFV during the two SSt. The three-way interaction was significant for MAP (F = 4.262; P = 0.020); both MH (30 +/- 26 mmHg; P < 0.05) and L-NAME (27 +/- 22 mmHg; P < 0.01) significantly increased MAP in the SCI group, but not in the AB group. There was a significant visit by time interaction for MFV suggesting an increase from predrug to postdrug following L-NAME (6 +/- 8 cm/sec; P < 0.05) and MH (4 +/- 7 cm/sec; P < 0.05), regardless of study group, with little change following ND (3 +/- 3 cm/sec). The relationship between change in MAP and MFV was significant in the SCI group following administration of MH (r(2) = 0.38; P < 0.05) and L-NAME (r(2) = 0.32; P < 0.05). These antihypotensive agents, at the doses tested, raised MAP, which was associated with an increase MFV during cognitive activation in hypotensive subjects with SCI. C1 [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] James J Peters VAMC, VA RR&D Natl Ctr Med Consequences Spinal Cord Inj, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] James J Peters VAMC, Med Serv, Bronx, NY USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Radulovic, Miroslav; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. RP Wecht, JM (reprint author), James J Peters VAMC, VA RR&D Natl Ctr Med Consequences Spinal Cord Inj, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM jm.wecht@va.gov NR 30 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2051-817X J9 PHYSIOL REP JI PHYSIOL. REP. PD FEB PY 2016 VL 4 IS 3 AR e12683 DI 10.14814/phy2.12683 PG 9 WC Physiology SC Physiology GA DR9SI UT WOS:000380236000002 ER PT J AU Nguyen, KL Tian, X Alam, S Mehari, A Leung, SW Seamon, C Allen, D Minniti, CP Sachdev, V Arai, AE Kato, GJ AF Kim-Lien Nguyen Tian, Xin Alam, Shoaib Mehari, Alem Leung, Steve W. Seamon, Catherine Allen, Darlene Minniti, Caterina P. Sachdev, Vandana Arai, Andrew E. Kato, Gregory J. TI Elevated transpulmonary gradient and cardiac magnetic resonance-derived right ventricular remodeling predict poor outcomes in sickle cell disease SO HAEMATOLOGICA LA English DT Letter DE pulmonary hypertension; magnetic resonance imaging; right ventricle; cardiomyopathy; sickle cell disease ID RIGHT HEART CATHETERIZATION; PULMONARY-HYPERTENSION; MORTALITY; ANEMIA; ADULTS C1 [Alam, Shoaib; Sachdev, Vandana] Lung & Blood Inst, Cardiovasc & Pulm Branch, Bethesda, MD USA. [Mehari, Alem; Seamon, Catherine; Allen, Darlene; Minniti, Caterina P.; Kato, Gregory J.] Lung & Blood Inst, Sickle Cell Vasc Dis Sect, Hematol Branch, Bethesda, MD USA. [Tian, Xin] NHLBI, Off Biostat Res, Bethesda, MD USA. [Kim-Lien Nguyen; Mehari, Alem; Leung, Steve W.; Arai, Andrew E.] Howard Univ, Coll Med, Washington, DC USA. [Kim-Lien Nguyen] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA USA. [Kim-Lien Nguyen] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Kato, Gregory J.] Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA. [Kato, Gregory J.] Univ Pittsburgh, Adult Sickle Cell Ctr Excellence, Pittsburgh, PA USA. [Minniti, Caterina P.] Montefiore Med Ctr, Sickle Cell Ctr, Div Hematol Oncol, New York, NY USA. [Leung, Steve W.] Univ Kentucky, Div Cardiovasc Med, Lexington, KY USA. RP Kato, GJ (reprint author), Lung & Blood Inst, Sickle Cell Vasc Dis Sect, Hematol Branch, Bethesda, MD USA.; Kato, GJ (reprint author), Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA USA.; Kato, GJ (reprint author), Univ Pittsburgh, Adult Sickle Cell Ctr Excellence, Pittsburgh, PA USA. EM katogj@upmc.edu RI Kato, Gregory/I-7615-2014; Leung, Steve/E-5624-2011 OI Kato, Gregory/0000-0003-4465-3217; Leung, Steve/0000-0003-2832-2258; Nguyen, Kim-Lien/0000-0002-8854-2976 FU NHLBI NIH HHS [ZIA HL004607, ZIA HL006011, ZIA HL006012, ZIA HL006015, ZIA HL006137, ZID HL006140, ZIE HL006139]; PHS HHS [1ZIAHL004607, 1ZIAHL006012, 1ZIAHL006015, 1ZIAHL006137, 1ZIDHL006140, 1ZIEHL006139, 1ZIAHL006011] NR 15 TC 2 Z9 2 U1 1 U2 2 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD FEB PY 2016 VL 101 IS 2 BP E40 EP E43 DI 10.3324/haematol.2015.125229 PG 4 WC Hematology SC Hematology GA DQ4EI UT WOS:000379156300001 PM 26589907 ER PT J AU Erickson, ZD Mena, SJ Pierre, JM Blum, LH Martin, E Hellemann, GS Aragaki, DR Firestone, L Lee, C Lee, P Kunkel, CF Ames, D AF Erickson, Zachary D. Mena, Shirley J. Pierre, Joseph M. Blum, Lisa H. Martin, Eda Hellemann, Gerhard S. Aragaki, Dixie R. Firestone, Lisa Lee, Catherine Lee, Paul Kunkel, Charles F. Ames, Donna TI Behavioral Interventions for Antipsychotic Medication-Associated Obesity: A Randomized, Controlled Clinical Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID LIFE-STYLE INTERVENTION; WEIGHT-GAIN; MENTAL-ILLNESS; PROGRAM; SCHIZOPHRENIA; PSYCHOTHERAPY; MAINTENANCE; PREDICTORS; REDUCTION; METFORMIN AB Objective: To demonstrate the effectiveness of a Diabetes Prevention Program-inspired 12-month behavioral intervention for patients with severe mental illness (SMI) and medication-associated obesity. Method: This randomized, controlled, parallel, superiority study screened 225 volunteers from November 2005 to August 2008 at the VA Greater Los Angeles Healthcare System. 122 outpatients with DSM-IV-diagnosed SMI taking antipsychotic medications who had >= 7% weight gain or body mass index (BMI) > 25 were randomized by computer-generated number to Lifestyle Balance treatment intervention (n = 60) or usual care control (n = 62) groups. Clinical raters were masked to randomization. Treatment intervention included weekly classes and individual counseling for 8 weeks, food and exercise diaries, rewards, caregiver consultations, and monthly booster classes and counseling for 1 year. Controls received self-help materials and visited at equivalent intervals without formal classes or counseling. Outcomes were changes in anthropometric measurements, psychiatric symptoms, health knowledge, and glucose, hemoglobin A1c, and lipid levels. Results: Our intention-to-treat analysis found significant differences in predicted trajectory of mean weight change between the groups over 12 months (P < .01), with treatment participants expected to lose an average 4.6 kg, while control participants would gain an average 0.6 kg. BMI and body fat percentage followed the same pattern. Both groups demonstrated statistically significant improvements in health knowledge quiz scores over time (P = .006), without significant difference between groups. Conclusions: Treatment was more effective than usual care control in treating medication-associated obesity, independent of SMI diagnosis, antipsychotic medication, and knowledge gained, suggesting that behavioral interventions are effective in SMI patients. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Erickson, Zachary D.; Mena, Shirley J.; Blum, Lisa H.; Martin, Eda] VA Greater Los Angeles Healthcare Syst, Res Dept, Los Angeles, CA USA. [Pierre, Joseph M.; Ames, Donna] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Aragaki, Dixie R.; Firestone, Lisa; Lee, Catherine; Lee, Paul; Kunkel, Charles F.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA. [Pierre, Joseph M.; Aragaki, Dixie R.; Firestone, Lisa; Lee, Catherine; Lee, Paul; Kunkel, Charles F.; Ames, Donna] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Hellemann, Gerhard S.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. RP Ames, D (reprint author), 11301 Wilshire Blvd,B151H, Los Angeles, CA 90073 USA. EM donna.ames@va.gov FU Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development; Veterans Affairs Merit Review Rehabilitation Research and Development Service (Washington, DC) [D3925-R] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development. Funded by Veterans Affairs Merit Review Rehabilitation Research and Development Service (Washington, DC; project number D3925-R). NR 28 TC 0 Z9 0 U1 8 U2 11 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD FEB PY 2016 VL 77 IS 2 BP E183 EP E189 DI 10.4088/JCP.14m09552 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MJ UT WOS:000379249200009 PM 26930534 ER PT J AU Cooper, SA Desjardins, PJ Turk, DC Dworkin, RH Katz, NP Kehlet, H Ballantyne, JC Burke, LB Carragee, E Cowan, P Croll, S Dionne, RA Farrar, JT Gilron, I Gordon, DB Iyengar, S Jay, GW Kalso, EA Kerns, RD McDermott, MP Raja, SN Rappaport, BA Rauschkolb, C Royal, MA Segerdahl, M Stauffer, JW Todd, KH Vanhove, GF Wallace, MS West, C White, RE Wu, C AF Cooper, Stephen A. Desjardins, Paul J. Turk, Dennis C. Dworkin, Robert H. Katz, Nathaniel P. Kehlet, Henrik Ballantyne, Jane C. Burke, Laurie B. Carragee, Eugene Cowan, Penney Croll, Scott Dionne, Raymond A. Farrar, John T. Gilron, Ian Gordon, Debra B. Iyengar, Smriti Jay, Gary W. Kalso, Eija A. Kerns, Robert D. McDermott, Michael P. Raja, Srinivasa N. Rappaport, Bob A. Rauschkolb, Christine Royal, Mike A. Segerdahl, Marta Stauffer, Joseph W. Todd, Knox H. Vanhove, Geertrui F. Wallace, Mark S. West, Christine White, Richard E. Wu, Christopher TI Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations SO PAIN LA English DT Review DE Randomized clinical trials; Acute pain; Research design; Assay sensitivity; Proof-of-concept trials; Clinical trial methods ID POSTOPERATIVE DENTAL PAIN; INDIVIDUAL PATIENT METAANALYSIS; PLACEBO-CONTROLLED TRIALS; ACTIVE-CONTROL TRIALS; MOVEMENT-EVOKED PAIN; DOUBLE-BLIND; RATING-SCALES; PARECOXIB SODIUM; MISSING DATA; EFFICACY AB This article summarizes the results of a meeting convened by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) on key considerations and best practices governing the design of acute pain clinical trials. We discuss the role of early phase clinical trials, including pharmacokinetic-pharmacodynamic (PK-PD) trials, and the value of including both placebo and active standards of comparison in acute pain trials. This article focuses on single-dose and short-duration trials with emphasis on the perioperative and study design factors that influence assay sensitivity. Recommendations are presented on assessment measures, study designs, and operational factors. Although most of the methodological advances have come from studies of postoperative pain after dental impaction, bunionectomy, and other surgeries, the design considerations discussed are applicable to many other acute pain studies conducted in different settings. C1 [Cooper, Stephen A.] Stephen A Cooper LLC, Palm Beach Gardens, FL USA. [Desjardins, Paul J.] Tufts Univ, Desjardins Associates LLC, Boston, MA 02111 USA. [Desjardins, Paul J.] Tufts Univ, Dept Oral & Maxillofacial Surg, Boston, MA 02111 USA. [Turk, Dennis C.; Ballantyne, Jane C.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Dworkin, Robert H.; McDermott, Michael P.] Univ Rochester, Dept Anesthesiol, Rochester, NY USA. [Dworkin, Robert H.; McDermott, Michael P.] Univ Rochester, Dept Neurol, Rochester, NY USA. [Dworkin, Robert H.; McDermott, Michael P.] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA. [Katz, Nathaniel P.] Analges Solut, Needham, MA USA. [Kehlet, Henrik] Rigshosp, Sect Surg Pathophysiol, Copenhagen, Denmark. [Burke, Laurie B.] Univ Maryland, Dept Hlth Serv Res, Baltimore, MD 21201 USA. [Burke, Laurie B.] LORA Grp LLC, Royal Oak, MD USA. [Carragee, Eugene] Stanford Univ, Dept Orthoped Surg, Palo Alto, CA 94304 USA. [Cowan, Penney] Amer Chron Pain Assoc, Rocklin, CA USA. [Croll, Scott] Walter Reed Army Med Ctr, Washington, DC 20307 USA. [Dionne, Raymond A.] E Carolina Univ, Dept Pharmacol, Greenville, NC USA. [Dionne, Raymond A.] E Carolina Univ, Dept Toxicol, Greenville, NC USA. [Dionne, Raymond A.] E Carolina Univ, Dept Foundat Sci, Greenville, NC USA. [Farrar, John T.] Univ Penn, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Gilron, Ian] Queens Univ, Dept Anesthesiol, Kingston, ON, Canada. [Gordon, Debra B.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA USA. [Iyengar, Smriti] Eli Lilly & Co, Indianapolis, IN 46285 USA. [Jay, Gary W.] Advise Clin, Raleigh, NC USA. [Kalso, Eija A.] Univ Helsinki, Dept Anaesthesia Intens Care & Pain Med, Helsinki, Finland. [Kalso, Eija A.] Helsinki Univ Hosp, Helsinki, Finland. [Kerns, Robert D.] US Dept Vet Affairs, New Haven, CT USA. [Raja, Srinivasa N.; Wu, Christopher] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA. [Rappaport, Bob A.] Analges Concepts LLC, Arlington, VA USA. [Rauschkolb, Christine] Johnson & Johnson Pharmaceut Res & Dev, Titusville, NY USA. [Royal, Mike A.] Sorrento Therapeut, San Diego, CA USA. [Segerdahl, Marta] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden. [Stauffer, Joseph W.] Johns Hopkins Univ, Baltimore, MD USA. [Stauffer, Joseph W.] Cara Therapeut, Shelton, CT USA. [Todd, Knox H.] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA. [Vanhove, Geertrui F.] NeurogesX, San Carlos, CA USA. [Wallace, Mark S.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA. [West, Christine] Pfizer Inc, Groton, CT 06340 USA. [White, Richard E.] Endo Pharmaceut, Chadds Ford, PA USA. RP Cooper, SA (reprint author), 40 Durand Rd, Maplewood, NJ 07040 USA. EM paul.j.desjardins@gmail.com FU Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); FDA; US Department of Veteran Affairs; US National Institutes of Health FX Preparation of the background literature reviews and draft manuscripts was supported by the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); public-private partnership with the US Food and Drug Administration (FDA) ACTTION has received research contracts, grants, and other revenue from the FDA, multiple pharmaceutical and device companies, and other sources. No official endorsement by the FDA, US Department of Veteran Affairs, US National Institutes of Health, or the pharmaceutical and medical devices companies that have provided unrestricted grants to support the activities of IMMPACT and ACTTION should be inferred. NR 74 TC 3 Z9 3 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD FEB PY 2016 VL 157 IS 2 BP 288 EP 301 DI 10.1097/j.pain.0000000000000375 PG 14 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA DP1NV UT WOS:000378257600004 PM 26683233 ER PT J AU Hwang, YC Fujimoto, WY Hayashi, T Kahn, SE Leonetti, DL Boyko, EJ AF Hwang, You-Cheol Fujimoto, Wilfred Y. Hayashi, Tomoshige Kahn, Steven E. Leonetti, Donna L. Boyko, Edward J. TI Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; METABOLIC RISK-FACTORS; JAPANESE-AMERICAN MEN; INCIDENT HYPERTENSION; INSULIN SENSITIVITY; FAT DISTRIBUTION; OBESE ADULTS; BODY-FAT; PLASMA; PREVALENCE AB Context: Atherogenic dyslipidemia is frequently observed in persons with a greater amount of visceral adipose tissue (VAT). However, it is still uncertain whether VAT is independently associated with the future development of atherogenic dyslipidemia. Objectives: The aim of this study was to determine whether baseline and changes in VAT and subcutaneous adipose tissue (SAT) are associated with future development of atherogenic dyslipidemia independent of baseline lipid levels and standard anthropometric indices. Design and Setting: Community-based prospective cohort study with 5 years of follow-up. Participants: A total of 452 Japanese Americans (240 men, 212 women), aged 34-75 years were assessed at baseline and after 5 years of follow-up. Main Outcome Measures: Abdominal fat areas were measured by computed tomography. Atherogenic dyslipidemia was defined as one or more abnormalities in high-density lipoprotein (HDL) cholesterol, triglycerides, or non-HDL cholesterol levels. Results: Baseline VAT and change in VAT over 5 years were independently associated with log-transformed HDL cholesterol, log-transformed triglyceride, and non-HDL cholesterol after 5 years (standardized beta = -0.126, 0.277, and 0.066 for baseline VAT, respectively, and -0.095, 0.223, and 0.090 for change in VAT, respectively). However, baseline and change in SAT were not associated with any future atherogenic lipid level. In multivariate logistic regression analysis, incremental change in VAT (odds ratio [95% confidence interval], 1.73 [1.20-2.48]; P = .003), triglycerides (4.01 [1.72-9.33]; P < .001), HDL cholesterol (0.32 [0.18-0.58]; P < .001), and non-HDL cholesterol (7.58 [4.43-12.95]; P < .001) were significantly associated with the future development of atherogenic dyslipidemia independent of age, sex, diastolic blood pressure, homeostasis model assessment insulin resistance, body mass index (BMI), change in BMI, SAT, and baseline atherogenic lipid levels. Conclusion: Baseline and change in VAT were independent predictors for future development of atherogenic dyslipidemia. However, BMI, waist circumference, and SAT were not associated with future development of atherogenic dyslipidemia. C1 [Hwang, You-Cheol; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. [Hwang, You-Cheol] Kyung Hee Univ, Sch Med, Kyung Hee Univ Hosp Gangdong, Div Endocrinol & Metab,Dept Med, Seoul 134727, South Korea. [Fujimoto, Wilfred Y.; Kahn, Steven E.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98105 USA. [Hayashi, Tomoshige] Osaka City Univ, Grad Sch Med, Dept Prevent Med & Environm Hlth, Osaka 3-3-138, Osaka, Japan. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Seattle, WA 98108 USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. RP Boyko, EJ (reprint author), VA Puget Sound, S-123-PCC,1660 South Columbian Way, Seattle, WA 98108 USA. EM eboyko@uw.edu OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU King County Japanese American community FX We dedicate this manuscript to the memory of Marguerite J. McNeely who for many years played an important role as investigator in the Japanese American Community Diabetes Study. Her critical contributions will be missed. We are grateful to the King County Japanese American community for support and cooperation. NR 35 TC 4 Z9 4 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2016 VL 101 IS 2 BP 678 EP 685 DI 10.1210/jc.2015-3246 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP6XI UT WOS:000378642700038 PM 26636177 ER PT J AU Duca, LM Maahs, DM Schauer, IE Bergman, BC Nadeau, KJ Bjornstad, P Rewers, M Snell-Bergeon, JK AF Duca, Lindsey M. Maahs, David M. Schauer, Irene E. Bergman, Bryan C. Nadeau, Kristen J. Bjornstad, Petter Rewers, Marian Snell-Bergeon, Janet K. TI Development and Validation of a Method to Estimate Insulin Sensitivity in Patients With and Without Type 1 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID CORONARY-ARTERY CALCIFICATION; CARDIOVASCULAR-DISEASE; PITTSBURGH EPIDEMIOLOGY; GLUCOSE CLAMP; RESISTANCE; HYPERTENSION; COMPLICATION; NEPHROPATHY; ADOLESCENTS; OBESITY AB Context: People with type 1 diabetes (T1D) have markedly reduced insulin sensitivity (IS) compared to their nondiabetic counterparts, and reduced IS is linked to higher cardiovascular risk. Objective: This study aimed to develop and validate an improved method for estimating IS in people with T1D. Design: Prospective cohort. Setting: Adults (36 with T1D, 41 nondiabetic) were recruited from the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study for measurement of IS by hyperinsulinemic-euglycemic clamp to develop a clinically useful IS prediction equation (eIS) for T1D and nondiabetic individuals. These equations were then compared with previously published equations from the SEARCH and Pittsburgh Epidemiology of Diabetes Complications studies for the ability to predict measured IS in test sets of adults and adolescents from independent clamp studies. Intervention: None. Main Outcome Measure: Comparison of clamp-measured IS to estimated IS. Results: The best-fit prediction model (eIS) differed by diabetes status and included waist circumference, triglycerides, adiponectin, and diastolic blood pressure in all CACTI adults and insulin dose in adults with T1D (adjusted R-2 = 0.64) or fasting glucose and hemoglobin A1c (HbA1c) in nondiabetic adults (adjusted R-2 = 0.63). The eIS highly correlated with clamp-measured IS in all of the non-CACTI comparison populations (r = 0.83, P = .0002 in T1D adults; r = 0.71, P = .01 in nondiabetic adults; r = 0.44, P = .008 in T1D adolescents; r = 0.44, P = .006 in nondiabetic adolescents). Conclusions: eIS performed better than previous equations for estimating IS in individuals with and without T1D. These equations could simplify point-of-care assessment of IS to identify patients who could benefit from targeted intervention. C1 [Duca, Lindsey M.; Maahs, David M.; Bjornstad, Petter; Rewers, Marian; Snell-Bergeon, Janet K.] Univ Colorado, Sch Med, Barbara Davis Ctr Diabet, Aurora, CO 80045 USA. [Duca, Lindsey M.; Maahs, David M.; Snell-Bergeon, Janet K.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [Schauer, Irene E.; Bergman, Bryan C.] Univ Colorado, Div Endocrinol Metab & Diabet, Dept Med, Sch Med, Aurora, CO 80045 USA. [Nadeau, Kristen J.] Univ Colorado, Sch Med, Div Pediat Endocrinol, Dept Pediat, Aurora, CO 80045 USA. [Schauer, Irene E.] Denver VA Med Ctr, Denver, CO 80220 USA. RP Duca, LM (reprint author), Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Sch Med, Box A-140,1775 Aurora Court, Aurora, CO 80045 USA. EM Lindsey.Duca@ucdenver.edu OI Bergman, Bryan/0000-0002-9561-1052; Bjornstad, Petter/0000-0002-5160-2947 FU National Institutes of Health (NIH) [M01 RR000051]; Colorado Clinical and Translational Sciences Institute (CCTSI) [UL1 TR000154]; NIH National Heart, Lung and Blood Institute [R01 HL61753, R01 HL079611, R01 HL11309]; American Diabetes Association [1-10-JF-50, 7-13-CD-10, 7-11-CD-08]; Juvenile Diabetes Research Foundation [11-2010-343, 17-2013-313]; NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) [K12 5K12HD057022-04]; National Center for Research Resources [K23 RR020038-01]; NIH [R56 DK088971]; Office of Research in Women's Health BIRCWH K12 Program; Diabetes Endocrinology Research Center Clinical Investigation Core Grant [P30 DK57516] FX The study was performed at the Barbara Davis Center for Childhood Diabetes in Denver, Colorado, and at the Clinical Translational Research Centers (CTRC) at the University of Colorado and Children's Hospital Colorado and was supported by the National Institutes of Health (NIH) Grant M01 RR000051 and Colorado Clinical and Translational Sciences Institute (CCTSI) Grant UL1 TR000154. Support was provided by the NIH National Heart, Lung and Blood Institute Grants R01 HL61753, R01 HL079611, and R01 HL11309; the American Diabetes Association Junior Faculty Award 1-10-JF-50 and 7-13-CD-10 (to J.K.S.-B.), American Diabetes Association Grant 7-11-CD-08, the Juvenile Diabetes Research Foundation Grant 11-2010-343 and 17-2013-313, NIH Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Grant K12 5K12HD057022-04, the National Center for Research Resources Grant K23 RR020038-01, NIH Grant R56 DK088971 (to K.J.N.), Office of Research in Women's Health BIRCWH K12 Program (to I.E.S.), and Diabetes Endocrinology Research Center Clinical Investigation Core Grant P30 DK57516. NR 28 TC 1 Z9 1 U1 1 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2016 VL 101 IS 2 BP 686 EP 695 DI 10.1210/jc.2015-3272 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP6XI UT WOS:000378642700039 PM 26672636 ER PT J AU Abe, J Alop-Mabuti, A Burger, P Button, J Ellsberry, M Hitzeman, J Morgenstern, D Nunies, K Strother, M Darling-Munson, J Chan, YL Cassady, R Vasconcellos, SMK Iseman, MD Chan, ED Honda, JR AF Abe, Jonathan Alop-Mabuti, Aleena Burger, Peyton Button, Jackson Ellsberry, Madeline Hitzeman, Jaycinth Morgenstern, David Nunies, Kasey Strother, Mara Darling-Munson, Jared Chan, Yvonne L. Cassady, Robert Vasconcellos, Sarah Maile K. Iseman, Michael D. Chan, Edward D. Honda, Jennifer R. TI Comparing the temporal colonization and microbial diversity of showerhead biofilms in Hawai'i and Colorado SO FEMS MICROBIOLOGY LETTERS LA English DT Article DE microbial biofilms; environmental health; water quality; citizen science; microbiology education ID MYCOBACTERIAL LUNG-DISEASE; WATER DISTRIBUTION-SYSTEMS; NONTUBERCULOUS MYCOBACTERIA; PULMONARY-DISEASE; HOUSEHOLD; INFECTION; AVIUM; INTRACELLULARE; EPIDEMIOLOGY; PATHOGENS AB The household is a potential source of opportunistic pathogens to humans, a particularly critical issue for immunodeficient individuals. An important human-microbe interface is the biofilm that develops on showerhead surfaces. Once microbe-laden biofilms become aerosolized, they can potentially be inhaled into the lungs. Understanding how quickly a new showerhead becomes colonized would provide useful information to minimize exposure to potentially pathogenic environmental microbes. High school scientists sampled the inner surfaces of pre-existing and newly fitted showerheads monthly over a nine-month period and applied standard microbiologic culture techniques to qualitatively assess microbial growth. Water chemistry was also monitored using commercial test strips. Sampling was performed in households on Oahu, Hawai'i and Denver, Colorado, representing warm/humid and cold/arid environments, respectively. Pre-existing showerheads in Hawai'i showed more diverse microbial growth and significantly greater microbial numbers than a comparable showerhead from Colorado. New, chrome-plated or plastic showerheads in Hawai'i showed diverse and abundant growth one month after installment compared to new showerheads from Colorado. The pH, total chlorine and water hardness levels varied significantly between the Hawai'i and Colorado samples. Enthusiastic student and teacher participation allowed us to answer long-standing questions regarding the temporal colonization of microbial biofilms on pre-existing and new showerhead surfaces. C1 [Abe, Jonathan; Chan, Yvonne L.] Iolani Sch, Honolulu, HI 96826 USA. [Alop-Mabuti, Aleena; Button, Jackson; Hitzeman, Jaycinth; Nunies, Kasey; Vasconcellos, Sarah Maile K.] Isl Pacific Acad, Kapolei, HI 96707 USA. [Burger, Peyton; Ellsberry, Madeline; Morgenstern, David; Strother, Mara; Cassady, Robert] Standley Lake High Sch, Denver, CO 80021 USA. [Darling-Munson, Jared; Iseman, Michael D.; Chan, Edward D.; Honda, Jennifer R.] Natl Jewish Hlth, 1400 Jackson St,Neustadt Bldg,Room D509, Denver, CO 80206 USA. [Chan, Edward D.; Honda, Jennifer R.] Univ Colorado, Dept Med, Pulm & Crit Care Med Div, Anschutz Med Campus, Aurora, CO 80045 USA. [Chan, Edward D.; Honda, Jennifer R.] Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Honda, JR (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, Anschutz Med Campus,RC2,Box C272, Aurora, CO 80045 USA. EM Jennifer.Honda@ucdenver.edu FU Randall/Maciver Trust; University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Medicine Division; Shoot for the Cure Foundation FX Dr Jennifer R. Honda is supported by the Randall/Maciver Trust, The University of Colorado Anschutz Medical Campus Pulmonary and Critical Care Medicine Division, and The Shoot for the Cure Foundation. NR 29 TC 1 Z9 1 U1 5 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0378-1097 EI 1574-6968 J9 FEMS MICROBIOL LETT JI FEMS Microbiol. Lett. PD FEB PY 2016 VL 363 IS 4 AR fnw005 DI 10.1093/femsle/fnw005 PG 8 WC Microbiology SC Microbiology GA DO7MI UT WOS:000377966300010 ER PT J AU Radomski, TR Good, CB Thorpe, CT Zhao, XH Marcum, ZA Glassman, PA Lowe, J Mor, MK Fine, MJ Gellad, WF AF Radomski, Thomas R. Good, Chester B. Thorpe, Carolyn T. Zhao, Xinhua Marcum, Zachary A. Glassman, Peter A. Lowe, John Mor, Maria K. Fine, Michael J. Gellad, Walid F. TI Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY LA English DT Article ID MEDICAL-CENTER; NATIONAL FORMULARY; THERAPY; PHARMACY; COST; LOVASTATIN; BREAKING; PROGRAM; IMPACT; SWITCH AB BACKGROUND: All Department of Veterans Affairs Medical Centers (VAMCs) operate under a single national drug formulary, yet substantial variation in prescribing and spending exists across facilities. Local management of the national formulary may differ across VAMCs and may be one cause of this variation. OBJECTIVE: To characterize variation in the management of nonformulary medication requests and pharmacy and therapeutics (P&T) committee member perceptions of the formulary environment at VAMCs nationwide. METHODS: We performed an online survey of the chief of pharmacy and an additional staff pharmacist and physician on the P&T committee at all VAMCs. Respondents were asked questions regarding criteria for use for nonformulary medications, specific procedures for ordering nonformulary medications in general and specific lipid-lowering and diabetes agents, the appeals. process, and the formulary environment at their VAMCs. We compared responses across facilities and between chiefs of pharmacy, pharmacists, and physicians. RESULTS: A total of 212 chief pharmacists (n=80), staff pharmacists (n=78), and physicians (n=54) responded, for an overall response rate of 49%. In total, 107/143 (75%) different VAMCs were represented. The majority of VAMCs reported adhering to national criteria for use, with 38 (36%) being very adherent and 69 (65%) being mostly adherent. There was substantial variation between VAMCs regarding how nonformulary drugs were ordered, evaluated, and appealed. The nonformulary lipid-lowering drugs ezetimibe, rosuvastatin, and atorvastatin were viewable to providers in the order entry screen at 67 (63%), 67 (63%), and 64 (60%) VAMCs, respectively. The nonformulary diabetes medication pioglitazone was only viewable at 58 (55%) VAMCs. In the remaining VAMCs, providers could not order these nonformulary drugs through the normal order-entry process. For questions about the formulary environment, physician respondent perceptions differed from those of staff pharmacists and chief pharmacists. Compared with pharmacy chiefs and staff pharmacists, physicians were less likely to agree that providers at their VAMC prescribed too many nonformulary medications (47% and 44% vs. 12%, P<0.001), more likely to agree that providers must jump through too many hoops to prescribe nonformulary medication (5% and 3% vs. 25%, P<0.001), and more likely to agree that providers make an effort to convert new patients from non-formulary to formulary lipid-lowering (65% and 73% vs. 94%, P<0.02) and diabetic medications (49% and 50% vs. 88%, P<0.001). CONCLUSIONS: Although the Department of Veterans Affairs (VA) operates under a single national formulary, we found significant differences among VAMCs regarding their management of nonformulary medication requests. We also found differences among formulary leaders regarding their perception of the environment in which their VAMC's formulary is managed. These findings have important implications not just for VA, but for any organization that develops, implements, and manages drug formularies across multiple facilities. Copyright (C) 2016, Academy of Managed Care Pharmacy. All rights reserved. C1 [Gellad, Walid F.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Univ Dr 151c, Pittsburgh, PA 15240 USA. [Radomski, Thomas R.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med,Clin Instructor, Pittsburgh, PA USA. [Radomski, Thomas R.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity REs & Promotion, Clin Res Fellow, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Hines, IL USA. [Good, Chester B.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Core Investigator, Pittsburgh, PA USA. [Good, Chester B.] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA USA. [Good, Chester B.] US Dept Vet Affairs, Pharm Benefits Management Serv, VA Ctr Medication Safety, Med Advisory Panel, Hines, IL USA. [Thorpe, Carolyn T.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Core Investigator, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 718 Salk Hall, Pittsburgh, PA USA. [Zhao, Xinhua] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Statistic, Pittsburgh, PA USA. [Marcum, Zachary A.] Univ Pittsburgh, Sch Med, Dept Med, Dept Geriatr Med, Pittsburgh, PA USA. [Glassman, Peter A.] Calif State Univ Los Angeles, David Geffen Sch Med, Dept Med,Staff Phys, Clin Med,VA Greater Los Angles Hlthcare Syst, Los Angeles, CA USA. [Glassman, Peter A.] US Dept Vet Affairs, VA Ctr Med Safety Pharm Benefits Management Serv, Hines, IL USA. [Lowe, John] US Dept Vet Affairs, Pharm Benefits Management Serv, Pharm Compliance & Efficiency, Hines, IL USA. [Mor, Maria K.] VA Pittsburgh Hlthcare Syst, Biostat & Informat Core, Ctr Hlth Equtiy Res & Promotion, Pittsburgh, PA USA. [Mor, Maria K.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. [Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Pittsburgh, PA USA. RP Gellad, WF (reprint author), VA Pittsburgh Hlthcare Syst, Ctr Hlth Equity Res & Promotion, Pittsburgh, PA USA. EM walid.gellad@va.gov FU Health Resources and Services Administration T32 Training Grant; VA HSR&D Career Development Award FX Radomski is funded by a Health Resources and Services Administration T32 Training Grant. Gellad is funded by a VA HSR&D Career Development Award. The authors have no other conflicts of interest to disclose. NR 26 TC 2 Z9 2 U1 0 U2 0 PU ACAD MANAGED CARE PHARMACY PI ALEXANDRIA PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA SN 2376-0540 EI 2376-1032 J9 J MANAG CARE SPEC PH JI J. Manag. Care Spec. Pharm. PD FEB PY 2016 VL 22 IS 2 BP 114 EP U113 PG 9 WC Health Care Sciences & Services; Pharmacology & Pharmacy SC Health Care Sciences & Services; Pharmacology & Pharmacy GA DN1BU UT WOS:000376802100003 PM 27015250 ER PT J AU Liu, XR Liu, J Zhao, SF Zhang, HY Cai, W Cai, MF Ji, XM Leak, RK Gao, YQ Chen, J Hu, XM AF Liu, Xiangrong Liu, Jia Zhao, Shangfeng Zhang, Haiyue Cai, Wei Cai, Mengfei Ji, Xunming Leak, Rehana K. Gao, Yanqin Chen, Jun Hu, Xiaoming TI Interleukin-4 Is Essential for Microglia/Macrophage M2 Polarization and Long-Term Recovery After Cerebral Ischemia SO STROKE LA English DT Article DE flow cytometry; interleukin-4; macrophages; neurological function; stroke ID BRAIN-INJURY; CNS REMYELINATION; SEX-DIFFERENCES; WHITE-MATTER; MICROGLIA; IL-4; STROKE; MICE; MACROPHAGES; DYNAMICS AB Background and Purpose-Interleukin-4 (IL-4) is a unique cytokine that may contribute to brain repair by regulating microglia/macrophage functions. Thus, we examined the effect of IL-4 on long-term recovery and microglia/macrophage polarization in 2 well-established stroke models. Methods-Transient middle cerebral artery occlusion or permanent distal middle cerebral artery occlusion was induced in wild-type and IL-4 knockout C57/BL6 mice. In a separate cohort of wild-type animals, IL-4 (60 ng/d for 7 days) or vehicle was infused into the cerebroventricle after transient middle cerebral artery occlusion. Behavioral outcomes were assessed by the Rotarod, corner, foot fault, and Morris water maze tests. Neuronal tissue loss was verified by 2 independent neuron markers. Markers of classically activated (M1) and alternatively activated (M2) microglia were assessed by real-time polymerase chain reaction, immunofluorescence, and flow cytometry. Results-Loss of IL-4 exacerbated sensorimotor deficits and impaired cognitive functions <= 21 days post injury. In contrast to the delayed deterioration of neurological functions, IL-4 deficiency increased neuronal tissue loss only in the acute phase (5 days) after stroke and had no impact on neuronal tissue loss 14 or 21 days post injury. Loss of IL-4 promoted expression of M1 microglia/macrophage markers and impaired expression of M2 markers at 5 and 14 days post injury. Administration of IL-4 into the ischemic brain also enhanced long-term functional recovery. Conclusions-The cytokine IL-4 improves long-term neurological outcomes after stroke, perhaps through M2 phenotype induction in microglia/macrophages. These results are the first to suggest that immunomodulation with IL-4 is a promising approach to promote long-term functional recovery after stroke. C1 [Liu, Xiangrong; Zhao, Shangfeng; Zhang, Haiyue; Cai, Wei; Chen, Jun; Hu, Xiaoming] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Liu, Xiangrong; Ji, Xunming] Capital Med Univ, Xuanwu Hosp, Cerebrovasc Dis Res Inst, Beijing, Peoples R China. [Liu, Jia; Cai, Mengfei; Gao, Yanqin; Chen, Jun; Hu, Xiaoming] Fudan Univ, Inst Brain Sci, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Chen, Jun; Hu, Xiaoming] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hu, XM (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM hux2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819 FU National Institutes of Health [NS092618, NS095671, NS089534]; American Heart Association [13SDG14570025]; Chinese Natural Science Foundation [81471209, 81171149, 81371306, 81228008]; Veteran's Affairs research career scientist award FX This work was supported by the National Institutes of Health grants NS092618 (to Dr Hu), NS095671 and NS089534 (to Dr Chen), grant 13SDG14570025 from the American Heart Association (to Dr Hu), the Chinese Natural Science Foundation grants 81471209 (to Dr Liu), 81171149, 81371306 (to Dr Gao), and 81228008 (to Dr Chen). Dr Chen is also supported by a Veteran's Affairs research career scientist award. NR 30 TC 8 Z9 9 U1 10 U2 21 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD FEB PY 2016 VL 47 IS 2 BP 498 EP + DI 10.1161/STROKEAHA.115.012079 PG 11 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA DN4MD UT WOS:000377040200042 PM 26732561 ER PT J AU Wang, T Ren, Z Ding, Y Fang, Z Sun, Z MacDonald, ML Sweet, RA Wang, JR Chen, W AF Wang, Ting Ren, Zhao Ding, Ying Fang, Zhou Sun, Zhe MacDonald, Matthew L. Sweet, Robert A. Wang, Jieru Chen, Wei TI FastGGM: An Efficient Algorithm for the Inference of Gaussian Graphical Model in Biological Networks SO PLOS COMPUTATIONAL BIOLOGY LA English DT Article ID EXPRESSION DATA; ASTHMA; LASSO; DISCOVERY; SELECTION AB Biological networks provide additional information for the analysis of human diseases, beyond the traditional analysis that focuses on single variables. Gaussian graphical model (GGM), a probability model that characterizes the conditional dependence structure of a set of random variables by a graph, has wide applications in the analysis of biological networks, such as inferring interaction or comparing differential networks. However, existing approaches are either not statistically rigorous or are inefficient for high-dimensional data that include tens of thousands of variables for making inference. In this study, we propose an efficient algorithm to implement the estimation of GGM and obtain p-value and confidence interval for each edge in the graph, based on a recent proposal by Ren et al., 2015. Through simulation studies, we demonstrate that the algorithm is faster by several orders of magnitude than the current implemented algorithm for Ren et al. without losing any accuracy. Then, we apply our algorithm to two real data sets: transcriptomic data from a study of childhood asthma and proteomic data from a study of Alzheimer's disease. We estimate the global gene or protein interaction networks for the disease and healthy samples. The resulting networks reveal interesting interactions and the differential networks between cases and controls show functional relevance to the diseases. In conclusion, we provide a computationally fast algorithm to implement a statistically sound procedure for constructing Gaussian graphical model and making inference with high-dimensional biological data. The algorithm has been implemented in an R package named "FastGGM". C1 [Wang, Ting; Wang, Jieru; Chen, Wei] Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh UPMC, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA. [Ren, Zhao] Univ Pittsburgh, Dept Stat, Pittsburgh, PA USA. [Ding, Ying; Fang, Zhou; Sun, Zhe; Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. [MacDonald, Matthew L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Chen, Wei] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. RP Chen, W (reprint author), Univ Pittsburgh, Dept Pediat, Childrens Hosp Pittsburgh UPMC, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA.; Chen, W (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.; Chen, W (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. EM wei.chen@chp.edu OI Ding, Ying/0000-0003-1352-1000 FU VAPHS [BX000542]; UPMC Competitive Medical Research Fund; [MH16804]; [AG05133]; [AG027224]; [HG007358]; [P30CA047904] FX This work is supported by grants MH16804 (MLM), AG05133 (RAS), AG027224 (RAS), VAPHS grant BX000542 (RAS), UPMC Competitive Medical Research Fund (YD) and HG007358 (WC). The Biomedical Mass Spectrometry Center and UPCI Cancer Proteomics Facility are supported in part by award P30CA047904. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 2 Z9 2 U1 3 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-734X EI 1553-7358 J9 PLOS COMPUT BIOL JI PLoS Comput. Biol. PD FEB PY 2016 VL 12 IS 2 AR e1004755 DI 10.1371/journal.pcbi.1004755 PG 16 WC Biochemical Research Methods; Mathematical & Computational Biology SC Biochemistry & Molecular Biology; Mathematical & Computational Biology GA DM8AL UT WOS:000376582900026 PM 26872036 ER PT J AU Padula, CB Weitlauf, JC Rosen, AC Reiber, G Cochrane, BB Naughton, MJ Li, WJ Rissling, M Yaffe, K Hunt, JR Stefanick, ML Goldstein, MK Espeland, MA AF Padula, Claudia B. Weitlauf, Julie C. Rosen, Allyson C. Reiber, Gayle Cochrane, Barbara B. Naughton, Michelle J. Li, Wenjun Rissling, Michelle Yaffe, Kristine Hunt, Julie R. Stefanick, Marcia L. Goldstein, Mary K. Espeland, Mark A. TI Longitudinal Cognitive Trajectories of Women Veterans from the Women's Health Initiative Memory Study SO GERONTOLOGIST LA English DT Article DE Women; Veterans; Cognition; Cognitive decline; Risk factors ID RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; RISK-FACTORS; CARDIOVASCULAR-DISEASE; HORMONE-THERAPY; IMPAIRMENT; DEMENTIA; DECLINE; DYSLIPIDEMIA AB Purpose of the Study: A comparison of longitudinal global cognitive functioning in women Veteran and non-Veteran participants in the Women's Health Initiative (WHI). Design and Methods: We studied 7,330 women aged 65-79 at baseline who participated in the WHI Hormone Therapy Trial and its ancillary Memory Study (WHIMS). Global cognitive functioning (Modified Mini-Mental State Examination [3MSE]) in Veterans (n = 279) and non-Veterans (n = 7,051) was compared at baseline and annually for 8 years using generalized linear modeling methods. Results: Compared with non-Veterans, Veteran women were older, more likely to be Caucasian, unmarried, and had higher rates of educational and occupational attainment. Results of unadjusted baseline analyses suggest 3MSE scores were similar between groups. Longitudinal analyses, adjusted for age, education, ethnicity, and WHI trial assignment revealed differences in the rate of cognitive decline between groups over time, such that scores decreased more in Veterans relative to non-Veterans. This relative difference was more pronounced among Veterans who were older, had higher educational/occupational attainment and greater baseline prevalence of cardiovascular risk factors (e.g., smoking) and cardiovascular disease (e.g., angina, stroke). Implications: Veteran status was associated with higher prevalence of protective factors that may have helped initially preserve cognitive functioning. However, findings ultimately revealed more pronounced cognitive decline among Veteran relative to non-Veteran participants, likely suggesting the presence of risks that may impact neuropathology and the effects of which were initially masked by Veterans' greater cognitive reserve. C1 [Padula, Claudia B.; Weitlauf, Julie C.; Rosen, Allyson C.] VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, 3801 Miranda Ave, Palo Alto, CA 94304 USA. [Padula, Claudia B.; Weitlauf, Julie C.; Rosen, Allyson C.] Stanford Univ, Dept Psychiat & Behav Sci, 3801 Miranda Ave, Palo Alto, CA 94304 USA. [Weitlauf, Julie C.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Reiber, Gayle] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Cochrane, Barbara B.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Naughton, Michelle J.] Ohio State Univ, Coll Med, Div Populat Sci, Columbus, OH 43210 USA. [Li, Wenjun] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Li, Wenjun] Univ Massachusetts, Sch Med, Dept Prevent & Behav Med, Worcester, MA USA. [Rissling, Michelle] Mid Atlantic MIRECC, Durham VA Med Ctr, Durham, NC USA. [Yaffe, Kristine] Sierra Pacif MIRECC, San Francisco VA Med Ctr, UCSF Dept Psychiat Neurol & Epidemiol & Biostat, San Francisco, CA USA. [Hunt, Julie R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Stanford Ctr Prevent Res, Dept Med, Stanford, CA 94305 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA. [Goldstein, Mary K.] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, GRECC,Dept Med,Ctr Primary Care & Outcomes Res, Palo Alto, CA 94304 USA. [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, One Med Ctr Blvd, Winston Salem, NC USA. RP Padula, CB (reprint author), VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, 3801 Miranda Ave, Palo Alto, CA 94304 USA.; Padula, CB (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM padula@stanford.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health; U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health; and the U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. NR 46 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 IS 1 SI SI BP 115 EP 125 DI 10.1093/geront/gnv663 PG 11 WC Gerontology SC Geriatrics & Gerontology GA DJ5AW UT WOS:000374220200013 PM 26615021 ER PT J AU Karel, MJ Teri, L McConnell, E Visnic, S Karlin, BE AF Karel, Michele J. Teri, Linda McConnell, Eleanor Visnic, Stephanie Karlin, Bradley E. TI Effectiveness of Expanded Implementation of STAR-VA for Managing Dementia-Related Behaviors Among Veterans SO GERONTOLOGIST LA English DT Article DE Interdisciplinary training; Dementia; Challenging behaviors; Veterans; Nursing homes ID LONG-TERM-CARE; NEUROPSYCHIATRIC SYMPTOMS; HEALTH; MANAGEMENT; TOOLKIT; ANXIETY; HOMES AB Purpose of the Study: Nonpharmacological, psychosocial approaches are first-line treatments for managing behavioral symptoms in dementia, but they can be challenging to implement in long-term care settings. The Veterans Health Administration implemented STAR-VA, an interdisciplinary behavioral approach for managing challenging dementia-related behaviors in its Community Living Center (CLCs, nursing home care) settings. This study describes how the program was implemented and provides an evaluation of Veteran clinical outcomes and staff feedback on the intervention. Design and Methods: One mental health professional and registered nurse team from 17 CLCs completed STAR-VA training, which entailed an experiential workshop followed by 6 months of expert consultation as they worked with their teams to implement STAR-VA with Veterans identified to have challenging dementia-related behaviors. The frequency and severity of target behaviors and symptoms of depression, anxiety, and agitation were evaluated at baseline and at intervention completion. Staff provided feedback regarding STAR-VA feasibility and impact. Results: Seventy-one Veterans completed the intervention. Behaviors clustered into 6 types: care refusal or resistance, agitation, aggression, vocalization, wandering, and other. Frequency and severity of target behaviors and symptoms of depression, anxiety, and agitation all significantly decreased, with overall effect sizes of 1 or greater. Staff rated both benefits for Veterans and program feasibility favorably. Implications: This evaluation supports the feasibility and effectiveness of STAR-VA, an interdisciplinary, behavioral intervention for managing challenging behaviors among residents with dementia in CLCs. C1 [Karel, Michele J.] US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC USA. [Teri, Linda] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [McConnell, Eleanor] Durham VA Geriatr Res Educ & Clin Ctr, Durham, NC USA. [McConnell, Eleanor] Duke Univ, Sch Med, Durham, NC USA. [Visnic, Stephanie] Vet Affairs Ann Arbor Healthcare Syst, Serious Mental Illness Treatment Resource & Evalu, Ann Arbor, MI USA. [Karlin, Bradley E.] Educ Dev Ctr Inc, New York, NY USA. [Karlin, Bradley E.] Northeastern Univ, Bouve Coll Hlth Sci, Sch Nursing, Boston, MA 02115 USA. RP Karel, MJ (reprint author), VA Cent Off, Mental Hlth Serv 10P4M, 1575 1 St NW, Washington, DC 20420 USA. EM Michele.Karel@va.gov FU Mental Health Services, U. S. Department of Veterans Affairs (VA) Central Office FX This project was supported by Mental Health Services, U. S. Department of Veterans Affairs (VA) Central Office. NR 36 TC 4 Z9 4 U1 3 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 IS 1 SI SI BP 126 EP 134 DI 10.1093/geront/gnv068 PG 9 WC Gerontology SC Geriatrics & Gerontology GA DJ5AW UT WOS:000374220200014 PM 26185155 ER PT J AU Kopacz, MS Rasmussen, KA Searle, RF Wozniak, BM Titus, CE AF Kopacz, Marek S. Rasmussen, Kathy A. Searle, Robert F. Wozniak, Barbara M. Titus, Caitlin E. TI Veterans, guilt, and suicide risk: An opportunity to collaborate with chaplains? SO CLEVELAND CLINIC JOURNAL OF MEDICINE LA English DT Editorial Material ID PASTORAL CARE SERVICES; MOOD DISORDERS; DEPRESSION; FORGIVENESS; PERSONNEL; IDEATION; THERAPY; COMBAT; SHAME C1 [Kopacz, Marek S.; Rasmussen, Kathy A.; Titus, Caitlin E.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. [Rasmussen, Kathy A.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Searle, Robert F.] US Dept Vet Affairs, Canandaigua VA Med Ctr, Canandaigua, NY USA. [Wozniak, Barbara M.] Jagiellonian Univ, Coll Med, Dept Med Sociol, Epidemiol & Prevent Med, Krakow, Poland. RP Kopacz, MS (reprint author), US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov NR 40 TC 1 Z9 1 U1 1 U2 1 PU CLEVELAND CLINIC PI CLEVELAND PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA SN 0891-1150 EI 1939-2869 J9 CLEV CLIN J MED JI Clevel. Clin. J. Med. PD FEB PY 2016 VL 83 IS 2 BP 101 EP 105 DI 10.3949/ccjm.83a.15070 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DK3TR UT WOS:000374840800006 PM 26871385 ER PT J AU Patel, AM Lee, JXW Pham, AQ Yusin, JS AF Patel, Anil M. Lee, Joyce X. W. Pham, Andrew Q. Yusin, Joseph S. TI Self-Injectable Epinephrine Adherence Survey Amongst Veterans SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Patel, Anil M.; Lee, Joyce X. W.; Pham, Andrew Q.; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 602 BP AB184 EP AB184 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403048 ER PT J AU Pham, AQ Lee, JXW Lin, C Liang, E Yusin, JS AF Pham, Andrew Q. Lee, Joyce Xiang Wu Lin, Connie Liang, Emily Yusin, Joseph S. TI Characterization of Patients with Low Ige Levels SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Pham, Andrew Q.; Lee, Joyce Xiang Wu; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Lin, Connie; Liang, Emily] Cedars Sinai Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 573 BP AB174 EP AB174 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005403019 ER PT J AU Philipp, AT Jones, AH Zeitz, H Yusin, JS AF Philipp, Ami Thakor Jones, Alesia Hawkins Zeitz, Howard Yusin, Joseph S. TI Adolescent Asthmatics' Use of the Internet and Other Management Strategies SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology (AAAAI) CY MAR 04-07, 2016 CL Los Angeles, CA SP Amer Acad Allergy, Asthma & Immunol C1 [Philipp, Ami Thakor; Yusin, Joseph S.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Jones, Alesia Hawkins] Univ Illinois, Coll Med, Rockford, IL 61107 USA. [Zeitz, Howard] Univ Illinois, Coll Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2016 VL 137 IS 2 SU S MA 322 BP AB99 EP AB99 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA DK6BI UT WOS:000375005402013 ER PT J AU Kirkwood, CM MacDonald, ML Schempf, TA Vatsavayi, AV Ikonomovic, MD Koppel, JL Ding, Y Sun, M Kofler, JK Lopez, OL Yates, NA Sweet, RA AF Kirkwood, Caitlin M. MacDonald, Matthew L. Schempf, Tadhg A. Vatsavayi, Anil V. Ikonomovic, Milos D. Koppel, Jeremy L. Ding, Ying Sun, Mai Kofler, Julia K. Lopez, Oscar L. Yates, Nathan A. Sweet, Robert A. TI Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer disease; Frontotemporal lobar degeneration; Human postmortem brain tissue; Visinin-like 1 protein (Vilip-1) ID CEREBROSPINAL-FLUID; COGNITIVE DECLINE; TANGLE FORMATION; BRAIN-INJURY; LEWY BODIES; BIOMARKER; DEMENTIA; CONSORTIUM; PATHOLOGY; VILIP-1 AB Recent studies have implicated the neuronal calcium-sensing protein visinin-like 1 protein (Vilip-1) as a peripheral biomarker in Alzheimer disease (AD), but little is known about expression of Vilip-1 in the brains of patients with AD. We used targeted and quantitative mass spectrometry to measure Vilip-1 peptide levels in the entorhinal cortex (ERC) and the superior frontal gyrus (SF) from cases with early to moderate stage AD, frontotemporal lobar degeneration (FTLD), and cognitively and neuropathologically normal elderly controls. We found that Vilip-1 levels were significantly lower in the ERC, but not in SF, of AD subjects compared to normal controls. In FTLD cases, Vilip-1 levels in the SF were significantly lower than in normal controls. These findings suggest a unique role for cerebrospinal fluid Vilip-1 as a biomarker of ERC neuron loss in AD. C1 [Kirkwood, Caitlin M.; MacDonald, Matthew L.; Schempf, Tadhg A.; Sweet, Robert A.] Univ Pittsburgh, Sch Hlth Sci, Translat Neurosci Program, Pittsburgh, PA USA. [Kirkwood, Caitlin M.; MacDonald, Matthew L.; Schempf, Tadhg A.; Ikonomovic, Milos D.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Sch Hlth Sci, Pittsburgh, PA USA. [Ikonomovic, Milos D.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Sch Hlth Sci, Pittsburgh, PA 15260 USA. [Kofler, Julia K.] Univ Pittsburgh, Dept Pathol, Sch Hlth Sci, Pittsburgh, PA USA. [MacDonald, Matthew L.; Ding, Ying; Sun, Mai; Yates, Nathan A.] Univ Pittsburgh, Biomed Mass Spectrometry Ctr, Sch Hlth Sci, Pittsburgh, PA USA. [Kirkwood, Caitlin M.; Yates, Nathan A.] Univ Pittsburgh, Dept Cell Biol, Sch Hlth Sci, Pittsburgh, PA USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Vatsavayi, Anil V.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01655 USA. [Koppel, Jeremy L.] Litwin Zucker Res Ctr Study Alzheimers Dis, Manhasset, NY USA. [Koppel, Jeremy L.] Feinstein Inst Med Res, Manhasset, NY USA. [Koppel, Jeremy L.] North Shore LIJ Hlth Syst, Zucker Hillside Hosp, Glen Oaks, NY USA. RP Sweet, RA (reprint author), 3811 OHara St,BST W1645, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu OI Ding, Ying/0000-0003-1352-1000 FU VAPHS [BX000542]; [MH16804]; [AG05133]; [AG014449]; [AG027224]; [P30CA047904] FX This work was supported by grants MH16804 (MLM), AG05133 (OLL), AG014449 (MDI), AG027224 (RAS), and VAPHS grant BX000542 (RAS). The Biomedical Mass Spectrometry Center and UPCI Cancer Proteomics Facility are supported in part by award P30CA047904. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 41 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD FEB PY 2016 VL 75 IS 2 BP 175 EP 182 DI 10.1093/jnen/nlv018 PG 8 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA DK9DN UT WOS:000375230800008 PM 26769253 ER PT J AU Burgio, KL Williams, BR Dionne-Odom, JN Redden, DT Noh, H Goode, PS Kvale, E Bakitas, M Bailey, FA AF Burgio, Kathryn L. Williams, Beverly R. Dionne-Odom, J. Nicholas Redden, David T. Noh, Hyunjin Goode, Patricia S. Kvale, Elizabeth Bakitas, Marie Bailey, F. Amos TI Racial Differences in Processes of Care at End of Life in VA Medical Centers: Planned Secondary Analysis of Data from the BEACON Trial SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID SMALL-SAMPLE ADJUSTMENTS; NURSING-HOME RESIDENTS; IN-HOSPITAL DEATH; ADVANCE DIRECTIVES; ETHNIC DISPARITIES; HEALTH EQUITY; OLDER-ADULTS; VETERANS; SYSTEM; CANCER AB Background: Racial differences exist for a number of health conditions, services, and outcomes, including end-of-life (EOL) care. Objective: The aim of the study was to examine differences in processes of care in the last 7 days of life between African American and white inpatients. Methods: Secondary analysis was conducted of data collected in the Best Practices for End-of-Life Care for Our Nation's Veterans (BEACON) trial (conducted 2005-2011). Subjects were 4891 inpatient decedents in six Veterans Administration Medical Centers. Data were abstracted from decedents' medical records. Multi-variable analyses were conducted to examine the relationship between race and each of 18 EOL processes of care controlling for patient characteristics, study site, year of death, and whether the observation was pre- or post-intervention. Results: The sample consisted of 1690 African American patients (34.6%) and 3201 white patients (65.4%). African Americans were less likely to have: do not resuscitate (DNR) orders (odds ratio [ OR]: 0.67; p = 0.004), advance directives (OR: 0.71; p = 0.023), active opioid orders (OR: 0.64, p = 0.0008), opioid medications administered (OR: 0.61, p = 0.004), benzodiazepine orders (OR: 0.68, p < 0.0001), benzodiazepines administered (OR: 0.61, p < 0.0001), antipsychotics administered (OR: 0.73, p = 0.004), and steroids administered (OR: 0.76, p = 0.020). Racial differences were not found for other processes of care, including palliative care consultation, pastoral care, antipsychotic and steroid orders, and location of death. Conclusions: Racial differences exist in some but not all aspects of EOL care. Further study is needed to understand the extent to which racial differences reflect different patient needs and preferences and whether interventions are needed to reduce disparities in patient/family education or access to quality EOL care. C1 [Burgio, Kathryn L.; Williams, Beverly R.; Redden, David T.; Goode, Patricia S.; Kvale, Elizabeth; Bakitas, Marie; Bailey, F. Amos] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Birmingham, AL USA. [Burgio, Kathryn L.; Williams, Beverly R.; Redden, David T.; Goode, Patricia S.; Kvale, Elizabeth; Bakitas, Marie; Bailey, F. Amos] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Atlanta, GA USA. [Burgio, Kathryn L.; Williams, Beverly R.; Goode, Patricia S.; Kvale, Elizabeth; Bailey, F. Amos] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Dionne-Odom, J. Nicholas; Bakitas, Marie] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [Redden, David T.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. [Noh, Hyunjin] Univ Alabama, Tuscaloosa, AL USA. [Bailey, F. Amos] Univ Colorado, Dept Med, Denver, CO USA. RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, 11G 700 South 19th St, Birmingham, AL 35233 USA. EM kburgio@uabmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service ("Intervention to Improve Care at Life's End in VA Medical Centers'') [IIR 03-126]; University of Alabama at Birmingham Cancer Prevention and Control Training Program [5R25CA047888]; National Palliative Care Research Center Career Development Award FX This research was supported by a Merit Review grant from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (IIR 03-126, "Intervention to Improve Care at Life's End in VA Medical Centers''; PI: K.L. Burgio, Co-PI: F.A. Bailey). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Kathryn Burgio, PhD, is director of the Deep South Resource Center for Minority Aging Research (RCMAR; P30AG031054). J. Nicholas Dionne-Odom, PhD, is a post-doctoral fellow supported by the University of Alabama at Birmingham Cancer Prevention and Control Training Program (5R25CA047888) and by a National Palliative Care Research Center Career Development Award. Hyunjin Noh, PhD, is a scholar with the Deep South Resource Center for Minority Aging Research (RCMAR; P30AG031054). NR 56 TC 2 Z9 2 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2016 VL 19 IS 2 SI SI BP 157 EP 163 DI 10.1089/jpm.2015.0311 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DK9SA UT WOS:000375270400009 PM 26840851 ER PT J AU Huang, CHS Crowther, M Allen, RS DeCoster, J Kim, G Azuero, C Ang, XY Kvale, E AF Huang, Chao-Hui Sylvia Crowther, Martha Allen, Rebecca S. DeCoster, Jamie Kim, Giyeon Azuero, Casey Ang, Xinying Kvale, Elizabeth TI A Pilot Feasibility Intervention to Increase Advance Care Planning among African Americans in the Deep South SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID OF-LIFE CARE; RANDOMIZED CONTROLLED-TRIAL; HEALTH LITERACY; DECISION-MAKING; PALLIATIVE CARE; END; DISPARITIES; COMMUNITY; BARRIERS; PREFERENCES AB Background: Despite growing efforts to facilitate advance care planning (ACP) to decrease health disparities in palliative care, low completion rates of advance directives (AD) have been consistently found among African Americans. Objective: The objective was to examine the feasibility of a multicomponent ACP intervention program that integrates motivational interviewing, evidence-based ACP facilitation program (Respecting Choices (R)), and health-literacy adjusted AD. This pilot study aims to address the unique barriers to ACP engagement among African Americans in the Deep South. Methods: The design was a mixed-method randomized controlled trial design. Analysis of covariance (ANCOVA) and thematic content analysis (TCA) were conducted to identify barriers and facilitators for ACP engagement and to assess feasibility, knowledge, and intention to complete an AD. Thirty community-dwelling African Americans (mean age M=55.43, SD = 6.71, range = 47-73) were recruited from the Deep South and randomly assigned to receive intervention (n = 15) or educational material (n = 15) at a local university medical center. Results: All participants (n = 30) reported high satisfaction (M= 4.81, SD = 0.44, max score = 5) and increased intent to complete an AD at postintervention. A significant increase in knowledge on AD from baseline to postintervention was observed in the intervention group-t(14)=-3.06, p = 0.01, d = 1.67); no significant change was found for control. Lack of information, mistrust of doctors, and avoidance of discussing death were primary barriers to ACP discussions. Facilitators include ACP education, decreased mistrust, and proactive initiation of ongoing ACP discussions. Conclusions: Feasibility data revealed successful implementation of a brief intervention to increase ACP engagement and willingness to complete an AD among southern African Americans. C1 [Huang, Chao-Hui Sylvia; Azuero, Casey; Kvale, Elizabeth] Univ Alabama Birmingham, Dept Med, Ctr Palliat & Support Care, CH-19 Suite 219 933 19th St South, Birmingham, AL 35205 USA. [Huang, Chao-Hui Sylvia; Crowther, Martha; Allen, Rebecca S.; Kim, Giyeon; Azuero, Casey] Univ Alabama, Alabama Inst Aging, Tuscaloosa, AL USA. [Crowther, Martha; Allen, Rebecca S.; Kim, Giyeon; Azuero, Casey; Ang, Xinying] Univ Alabama, Dept Psychol, Box 870348, Tuscaloosa, AL 35487 USA. [DeCoster, Jamie] Univ Virginia, Ctr Adv Study Teaching & Learning, Charlottesville, VA USA. [Ang, Xinying] East Virginia Med Sch, Dept Psychiat & Behav Sci, Nortolk, VA USA. [Azuero, Casey; Kvale, Elizabeth] Birmingham VA Med Ctr, Birmingham, AL USA. RP Huang, CHS (reprint author), Univ Alabama Birmingham, Dept Med, Ctr Palliat & Support Care, CH-19 Suite 219 933 19th St South, Birmingham, AL 35205 USA. EM chhuang@uabmc.edu OI Allen, Rebecca Sue/0000-0002-2563-4996 NR 40 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD FEB PY 2016 VL 19 IS 2 SI SI BP 164 EP 173 DI 10.1089/jpm.2015.0334 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DK9SA UT WOS:000375270400010 PM 26840852 ER PT J AU Bastian, LA Gray, KE DeRycke, E Mirza, S Gierisch, JM Haskell, SG Magruder, KM Wakelee, HA Wang, AG Ho, GYF LaCroix, AZ AF Bastian, Lori A. Gray, Kristen E. DeRycke, Eric Mirza, Shireen Gierisch, Jennifer M. Haskell, Sally G. Magruder, Kathryn M. Wakelee, Heather A. Wang, Ange Ho, Gloria Y. F. LaCroix, Andrea Z. TI Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Lung cancer; Smoking; Tobacco; Women Veterans ID NEVER-SMOKERS; CIGARETTE-SMOKING; RISK-FACTORS; US MILITARY; TOBACCO USE; MORTALITY; PREVALENCE; PROMOTION; BEHAVIORS; TRENDS AB Introduction: Women Veterans may have higher rates of both active and passive tobacco exposure than their civilian counterparts, thereby increasing their risk for lung cancer. Purpose of the Study: To compare differences in active and passive smoking exposure and lung cancer incidence among women Veterans and non-Veterans using prospective data from the Women's Health Initiative (WHI). Design and Methods: We used data from the WHI, which collected longitudinal demographic, clinical, and laboratory data on 161,808 postmenopausal women. We employed linear and multinomial regression and generalized linear models to compare active and passive smoking exposure between Veterans and non-Veterans and Cox proportional hazards models to estimate differences in lung cancer incidence rates. Results: After adjustment, Veterans had 2.54 additional pack years of smoking compared with non-Veterans (95% confidence interval [CI] 1.68, 3.40). Veterans also had a 1% increase in risk of any passive smoking exposure (95% CI 1.00, 1.02) and a 9% increase in risk of any workplace exposure (95% CI 1.07, 1.11) compared with non-Veterans. After adjustment for age and smoking exposures, Veterans did not have a higher risk of lung cancer compared with non-Veterans (relative risk = 1.06 95% CI 0.86, 1.30). Implications: Women Veterans had higher rates of tobacco use and exposure to passive smoking, which were associated with a higher risk for lung cancer compared with non-Veterans. Clinicians who care for Veterans need to be aware that older women Veterans have more exposures to risk factors for lung cancer. C1 [Bastian, Lori A.; DeRycke, Eric; Mirza, Shireen] VA Connecticut, 555 Willard Ave, Newington, CT 06111 USA. [Bastian, Lori A.] Univ Connecticut, Div Gen Internal Med, Farmington, CT USA. [Gray, Kristen E.] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Gray, Kristen E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Mirza, Shireen] Univ Connecticut, Dept Med, Newington, CT USA. [Gierisch, Jennifer M.] Durham VA Med Ctr, Durham, NC USA. [Gierisch, Jennifer M.] Duke Univ, Dept Med, Durham, NC USA. [Haskell, Sally G.] Womens Hlth Serv, VA Off Patient Care, Washington, DC USA. [Haskell, Sally G.] VA Connecticut Hlth Care Syst, West Haven, CT USA. [Haskell, Sally G.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Magruder, Kathryn M.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. [Magruder, Kathryn M.] VA Med Ctr, Charleston, SC USA. [Wakelee, Heather A.] Stanford Univ, Dept Med, Oncol, Stanford, CA 94305 USA. [Wang, Ange] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Ho, Gloria Y. F.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA. RP Bastian, LA (reprint author), VA Connecticut, 555 Willard Ave, Newington, CT 06111 USA. EM lori.bastian@va.gov FU National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C]; U.S. Department of Veterans Affairs; Health Service Research Development [CRE 12-008]; VA Health Services Research and Development (HSRD) [TPP 61-029]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [FOP14-439]; VA Office of Women's Health FX The Women's Health Initiative programs are funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services through contracts, HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C. Dr. Bastian was supported by the U.S. Department of Veterans Affairs; Health Service Research & Development CRE 12-008. Dr. Gray was supported by VA Health Services Research and Development (HSR&D) Postdoctoral Fellowship (TPP 61-029). This research was also supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FOP14-439 and the VA Office of Women's Health. NR 36 TC 1 Z9 1 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S102 EP S111 DI 10.1093/geront/gnv664 PG 10 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500011 PM 26768384 ER PT J AU Bastian, LA Hayes, PM Haskell, SG Atkins, D Reiber, GE LaCroix, AZ Yano, EM AF Bastian, Lori A. Hayes, Patricia M. Haskell, Sally G. Atkins, David Reiber, Gayle E. LaCroix, Andrea Z. Yano, Elizabeth M. TI Improving Our Understanding of Health Issues in Older Women Veterans SO GERONTOLOGIST LA English DT Editorial Material ID CARE C1 [Bastian, Lori A.; Haskell, Sally G.] Vet Affairs VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. [Hayes, Patricia M.; Haskell, Sally G.] Vet Hlth Adm, Womens Hlth Serv, Washington, DC USA. [Haskell, Sally G.] Yale Univ, Dept Med, New Haven, CT 06520 USA. [Atkins, David] Hlth Serv Res & Dev Serv, Dept Vet Affairs, Washington, DC USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, La Jolla, CA 92093 USA. [Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, VA HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. RP Bastian, LA (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave Mail Code 151, West Haven, CT 06516 USA. EM lori.bastian@va.gov FU National Heart, Lung and Blood Institute, National Institute of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Department of Veterans Affairs Health Services Research and Development VA HSRD FOP [FOP 14-439, SDR 10-012]; VA Women's Health Services; VA HSR&D VA Senior Research Career Scientist Awards [RCS 98-353, RCS 05-195] FX The WHI program is funded by the National Heart, Lung and Blood Institute, National Institute of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.; This work was also supported by the Department of Veterans Affairs Health Services Research and Development VA HSR&D FOP 14-439 and SDR 10-012, and the VA Women's Health Services. Dr. Reiber's and Yano's efforts were supported by VA HSR&D VA Senior Research Career Scientist Awards (Reiber Project RCS 98-353 and Yano Project RCS 05-195). NR 19 TC 2 Z9 2 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S10 EP S13 DI 10.1093/geront/gnv672 PG 4 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500003 PM 26768383 ER PT J AU Gray, KE Katon, JG Rillamas-Sun, E Bastian, LA Nelson, KM LaCroix, AZ Reiber, GE AF Gray, Kristen E. Katon, Jodie G. Rillamas-Sun, Eileen Bastian, Lori A. Nelson, Karin M. LaCroix, Andrea Z. Reiber, Gayle E. TI Association Between Chronic Conditions and Physical Function Among Veteran and Non-Veteran Women With Diabetes SO GERONTOLOGIST LA English DT Article DE Physical function; Diabetes; Veterans; Women's issues; Chronic illness ID POSTTRAUMATIC-STRESS-DISORDER; LOWER-EXTREMITY DISABILITY; CENTERED MEDICAL HOME; QUALITY-OF-LIFE; OLDER WOMEN; MILITARY SERVICE; UNITED-STATES; HEALTH SURVEY; SELF-REPORTS; MELLITUS AB Purpose of the Study: To compare the number of chronic conditions among a list of 12 and their association with physical function among postmenopausal non-Veteran and Veteran women with diabetes. Design and Methods: Among women with diabetes from the Women's Health Initiative, we compared the average number of chronic conditions between non-Veterans and Veterans and the association between total number of chronic conditions on subsequent RAND-36 physical function. To examine associations between each condition and subsequent physical function, we compared women with diabetes plus one chronic condition to women with diabetes alone using linear regression in separate models for each condition and for non-Veterans and Veterans. Results: Both non-Veterans (N = 23,542) and Veterans (N = 618) with diabetes had a median of 3 chronic conditions. Decreases in physical function for each additional condition were larger among Veterans than non-Veterans (-6.3 vs. -4.1 points). Decreases in physical function among women with diabetes plus one chronic condition were greater than that reported for diabetes alone for all combinations and were more pronounced among Veterans (non-Veterans: -11.1 to -24.2, Veterans: -16.6 to -40.4 points). Hip fracture, peripheral artery disease, cerebrovascular disease, and coronary disease in combination with diabetes were associated with the greatest decreases in physical function. Implications: Chronic conditions were common among postmenopausal women with diabetes and were associated with large declines in physical function, particularly among Veterans. Interventions to prevent and reduce the impact of these conditions and facilitate coordination of care among women with diabetes may help them maintain physical function. C1 [Gray, Kristen E.; Katon, Jodie G.; Rillamas-Sun, Eileen; Nelson, Karin M.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Gray, Kristen E.; Katon, Jodie G.; Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Katon, Jodie G.] Womens Hlth Serv, VA Off Patient Care, Washington, DC USA. [Rillamas-Sun, Eileen] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Bastian, Lori A.] VA Connecticut Healthcare Syst, PRIME Ctr, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, Div Gen Internal Med, Farmington, CT USA. [Nelson, Karin M.] VA Puget Sound Hlth Care Syst, Gen Internal Med Serv, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. [Nelson, Karin M.] Univ Washington, Dept Med, Seattle, WA USA. [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, San Diego, CA 92103 USA. [Reiber, Gayle E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP Gray, KE (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way S-152, Seattle, WA 98108 USA. EM kristen.gray2@va.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201 100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; U.S. Department of Veterans Affairs Health Services Research & Development Program [TPP 61-029]; U.S. Department of Veterans Affairs Office of Patient Care, Women's Health Services; VA Puget Sound Center of Innovation for Veteran-Centered and Value-Driven Care; Department of Veterans Affairs Health Services Research and Development VA HSRD [FOP 14-439]; VA Office of Women's Health; VA HSR&D Senior Research Career Scientist Award [RCS 98-353] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services (grant numbers HHSN268201100046C, HHSN268201100001C, HHSN268201 100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C).; WHI Investigators-Program Office: Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford, and Nancy Geller (National Heart, Lung, and Blood Institute, Bethesda, MD). Clinical Coordinating Center: Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg (Fred Hutchinson Cancer Research Center, Seattle, WA). Investigators and Academic Centers: JoAnn E. Manson (Brigham and Women's Hospital, Harvard Medical School, Boston, MA); Barbara V. Howard (MedStar Health Research Institute/Howard University, Washington, DC); Marcia L. Stefanick (Stanford Prevention Research Center, Stanford, CA); Rebecca Jackson (The Ohio State University, Columbus, OH); Cynthia A. Thomson (University of Arizona, Tucson/Phoenix, AZ); Jean Wactawski-Wende (University at Buffalo, Buffalo, NY); Marian Limacher (University of Florida, Gainesville/Jacksonville, FL); Robert Wallace (University of Iowa, Iowa City/Davenport, IA); Lewis Kuller (University of Pittsburgh, Pittsburgh, PA); and Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, NC). Women's Health Initiative Memory Study: Sally Shumaker (Wake Forest University School of Medicine, Winston-Salem, NC). For a list of all the investigators who have contributed to WHI science, please visit: https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20I nvestigator%20Long%20List.pdf This work was also supported by the U.S. Department of Veterans Affairs Health Services Research & Development Program (Postdoctoral Fellowship TPP 61-029 to K. E. Gray); U.S. Department of Veterans Affairs Office of Patient Care, Women's Health Services; and the VA Puget Sound Center of Innovation for Veteran-Centered and Value-Driven Care (to J. G. Katon). This work was also supported by the Department of Veterans Affairs Health Services Research and Development VA HSR&D FOP 14-439; the VA Office of Women's Health; and a VA HSR&D Senior Research Career Scientist Award (Project RCS 98-353 to G. E. Reiber). NR 75 TC 0 Z9 0 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S112 EP S125 DI 10.1093/geront/gnv675 PG 14 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500012 PM 26768385 ER PT J AU LaCroix, AZ Rillamas-Sun, E Woods, NF Weitlauf, J Zaslavsky, O Shih, R LaMonte, MJ Bird, C Yano, EM LeBoff, M Washington, D Reiber, G AF LaCroix, Andrea Z. Rillamas-Sun, Eileen Woods, Nancy F. Weitlauf, Julie Zaslavsky, Oleg Shih, Regina LaMonte, Michael J. Bird, Chloe Yano, Elizabeth M. LeBoff, Meryl Washington, Donna Reiber, Gayle TI Aging Well Among Women Veterans Compared With Non-Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Healthy aging; disability; Quality of life; Women Veterans ID QUALITY-OF-LIFE; CARE UTILIZATION; SOCIAL SUPPORT; OLDER WOMEN; RESILIENCE; OUTCOMES; THERAPY; STRESS; SCALE; USERS AB Purpose of the Study: To examine whether Veteran status influences (a) women's survival to age 80 years without disease and disability and (b) indicators of successful, effective, and optimal aging at ages 80 years and older. Design and Methods: The Women's Health Initiative (WHI) enrolled 161,808 postmenopausal women aged 50-79 years from 1993 to 1998. We compared successful aging indicators collected in 2011-2012 via mailed questionnaire among 33,565 women (921 Veterans) who reached the age of 80 years and older, according to Veteran status. A second analysis focused on women with intact mobility at baseline who could have reached age 80 years by December 2013. Multinominal logistic models examined Veteran status in relation to survival to age 80 years without major disease or mobility disability versus having prevalent or incident disease, having mobility disability, or dying prior to age 80 years. Results: Women Veterans aged 80 years and older reported significantly lower perceived health, physical function, life satisfaction, social support, quality of life, and purpose in life scale scores compared with non-Veterans. The largest difference was in physical function scores (53.0 for Veterans vs 59.5 for non-Veterans; p < .001). Women Veterans were significantly more likely to die prior to age 80 years than non-Veteran WHI participants (multivariate adjusted odds ratio = 1.20; 95% confidence interval, 1.04-1.38). In both Veteran and non-Veteran women, healthy survival was associated with not smoking, higher physical activity, healthy body weight, and fewer depressive symptoms. C1 [LaCroix, Andrea Z.] Univ Calif San Diego, Dept Family Med & Publ Hlth, Div Epidemiol, San Diego, CA 92103 USA. [Rillamas-Sun, Eileen] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Woods, Nancy F.] Univ Washington, Seattle WHI Clin Ctr, Biobehav Nursing, Seattle, WA 98195 USA. [Weitlauf, Julie] VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA USA. [Weitlauf, Julie] Ctr Innovat Implementat, La Jolla, CA USA. [Weitlauf, Julie] Stanford Univ, Dept Psychiat & Behav Sci, Stanford Canc Inst, Palo Alto, CA 94304 USA. [Zaslavsky, Oleg] Univ Haifa, Fac Hlth Sci & Social Welf, IL-31999 Haifa, Israel. [Shih, Regina] RAND Corp, Arlington, VA USA. [LaMonte, Michael J.] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Bird, Chloe] RAND Corp, Santa Monica, CA USA. [Yano, Elizabeth M.; Washington, Donna] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [LeBoff, Meryl] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens,Dept Med, Boston, MA USA. [Reiber, Gayle] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. RP LaCroix, AZ (reprint author), Univ Calif San Diego, Div Epidemiol, Dept Family Med & Publ Hlth, 9500 Gilman Dr 0725, La Jolla, CA 92093 USA. EM alacroix@ucsd.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (HSRD) Service [FOP14-439]; VA Office of Women's Health; VA HSR&D Senior Research Career Scientist awards [98-353, 05-195] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.; This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (HSR&D) Service FOP14-439 and the VA Office of Women's Health. Drs. Reiber and Yano were funded through VA HSR&D Senior Research Career Scientist awards (RCS # 98-353 and RCS # 05-195, respectively). NR 44 TC 1 Z9 1 U1 1 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S14 EP S26 DI 10.1093/geront/gnv124 PG 13 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500004 PM 26768388 ER PT J AU Washington, DL Gray, K Hoerster, KD Katon, JG Cochrane, BB LaMonte, MJ Weitlauf, JC Groessl, E Bastian, L Vitolins, MZ Tinker, L AF Washington, Donna L. Gray, Kristen Hoerster, Katherine D. Katon, Jodie G. Cochrane, Barbara B. LaMonte, Michael J. Weitlauf, Julie C. Groessl, Erik Bastian, Lori Vitolins, Mara Z. Tinker, Lesley TI Trajectories in Physical Activity and Sedentary Time Among Women Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Women Veterans; Health behavior; Physical activity; Sedentary lifestyle; Sedentary behavior; Health trajectory; Longitudinal Study; Postmenopausal ID LONGITUDINAL DATA-ANALYSIS; OLDER-ADULTS; CARDIOVASCULAR-DISEASE; POPULATION HEALTH; UNITED-STATES; PREVALENCE; BEHAVIOR; PREVENTION; QUESTIONNAIRE; MORTALITY AB Purpose of the Study: Trajectories of physical activity (PA) and sedentary time (ST) after military separation are likely important determinants of women's health outcomes later in life, because low PA and high ST are known contributors to premature mortality risk. Our objective was to compare longitudinal trajectories of recreational PA and ST between Veteran and non-Veteran postmenopausal women from the Women's Health Initiative (WHI). Design and Methods: Women Veteran (n = 3,719) and non-Veteran (n = 141,800) WHI participants were included. Self-reported participation in recreational PA, converted to metabolic equivalent (MET)-hours/week, was prospectively assessed over 8 years. Self-reported ST, defined as hours/day sitting or lying down, was collected at baseline and at Years 3 and 6. Generalized estimating equations were used to compare trajectories of PA and ST between Veterans and non-Veterans, adjusted for demographics and lifestyle behaviors. Results: Veterans had higher baseline PA than non-Veterans (13.2 vs 12.5 MET-hours/week, p = .03). PA declined for both groups, with a steeper decline among Veterans (change/visit year -0.19 vs -0.02 MET-hours/week; interaction p < .001). At baseline, Veterans and non-Veterans had similar levels of ST (107.2 vs 105.9 hours/week, p = 0.42). Over time, ST remained stable among Veterans but declined slightly among non-Veterans (change/visit year -0.19 vs -0.49 hours/week; interaction p = .01). C1 [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, VA Hlth Serv Res & Dev HSR&D, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA. [Gray, Kristen; Hoerster, Katherine D.; Katon, Jodie G.] VA Puget Sound Hlth Care Syst Hlth Serv Res & Dev, Seattle, WA USA. [Gray, Kristen; Katon, Jodie G.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA. [Katon, Jodie G.] VA Off Patient Care, Womens Hlth Serv, Seattle, WA USA. [Cochrane, Barbara B.; Tinker, Lesley] Univ Washington, Sch Nursing, Seattle, WA USA. [Cochrane, Barbara B.; Tinker, Lesley] Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [LaMonte, Michael J.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Weitlauf, Julie C.] VA Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA USA. [Weitlauf, Julie C.] Ctr Innovat Implementat, Seattle, WA USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Groessl, Erik] VA San Diego Hlth Serv Res & Dev Unit, San Diego, CA USA. [Groessl, Erik] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA. [Bastian, Lori] VA Connecticut Healthcare Syst, New Haven, CT USA. [Vitolins, Mara Z.] Wake Forest Univ Hlth Sci, Dept Epidemiol & Prevent, Winston Salem, NC USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@va.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [FOP14-439]; VA Office of Women's Health FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C.r This research was also supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FOP14-439 and the VA Office of Women's Health. NR 49 TC 0 Z9 0 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S27 EP S39 DI 10.1093/geront/gnv676 PG 13 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500005 PM 26768390 ER PT J AU Washington, DL Bird, CE LaMonte, MJ Goldstein, KM Rillamas-Sun, E Stefanick, ML Woods, NF Bastian, LA Gass, M Weitlauf, JC AF Washington, Donna L. Bird, Chloe E. LaMonte, Michael J. Goldstein, Karen M. Rillamas-Sun, Eileen Stefanick, Marcia L. Woods, Nancy F. Bastian, Lori A. Gass, Margery Weitlauf, Julie C. TI Military Generation and Its Relationship to Mortality in Women Veterans in the Women's Health Initiative SO GERONTOLOGIST LA English DT Article DE Women Veterans; Mortality; Cohort effect; Longitudinal study ID UNITED-STATES; WAR; SERVICE; CANCER; RISK; LIFE AB Purpose of the Study: Women's military roles, exposures, and associated health outcomes have changed over time. However, mortality risk-within military generations or compared with non-Veteran women-has not been assessed. Using data from the Women's Health Initiative (WHI), we examined all-cause and cause-specific mortality by Veteran status and military generation among older women. Design and Methods: WHI participants (3,719 Veterans; 141,802 non-Veterans), followed for a mean of 15.2 years, were categorized into pre-Vietnam or Vietnam/after generations based on their birth cohort. We used cox proportional hazards models to examine the association between Veteran status and mortality by generation. Results: After adjusting for sociodemographic characteristics and WHI study arm, all-cause mortality hazard rate ratios (HRs) for Veterans relative to non-Veterans were 1.16 (95% CI: 1.09-1.23) for pre-Vietnam and 1.16 (95% CI: 0.99-1.36) for Vietnam/after generations. With additional adjustment for health behaviors and risk factors, this excess mortality rate persisted for pre-Vietnam but attenuated for Vietnam/after generations. After further adjustment for medical morbidities, across both generations, Veterans and non-Veterans had similar all-cause mortality rates. Relative to non-Veterans, adjusting for sociodemographics and WHI study arm, pre-Vietnam generation Veterans had higher cancer, cardiovascular, and trauma-related morality rates; Vietnam/after generation Veterans had the highest trauma-related mortality rates (HR = 2.93, 1.64-5.23). Implications: Veterans' higher all-cause mortality rates were limited to the pre-Vietnam generation, consistent with diminution of the healthy soldier effect over the life course. Mechanisms underlying Vietnam/after generation Veteran trauma-related mortality should be elucidated. Efforts to modify salient health risk behaviors specific to each military generation are needed. C1 [Washington, Donna L.] VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, VA Hlth Serv Res & Dev HSR&D, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Bird, Chloe E.] RAND Corp, Pardee Rand Grad Sch, Santa Monica, CA USA. [LaMonte, Michael J.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY USA. [Goldstein, Karen M.] Durham VA Hlth Care Syst, Durham, NC USA. [Rillamas-Sun, Eileen] Fred Hutchinson Canc Res Ctr, Seatle, WA USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Stanford Ctr Hlth Res Women & Sex Differences Med, Stanford, CA 94305 USA. [Woods, Nancy F.] Univ Washington, Sch Nursing, Div Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Bastian, Lori A.] VA Connecticut, West Haven, CT USA. [Bastian, Lori A.] Univ Connecticut, Ctr Hlth, West Haven, CT USA. [Gass, Margery] North Amer Menopause Soc, Mayfield Hts, OH USA. [Weitlauf, Julie C.] Sierra Pacific MIRECC, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Weitlauf, Julie C.] Ctr Innovat Implementat, San Diego, CA USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. EM donna.washington@va.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [FOP14-439]; VA Office of Women's Health FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. The research reported here was supported by Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service FOP14-439 and the VA Office of Women's Health. NR 40 TC 0 Z9 0 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S126 EP S137 DI 10.1093/geront/gnv669 PG 12 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500013 PM 26768386 ER PT J AU Weitlauf, JC Washington, DL Stefanick, ML AF Weitlauf, Julie C. Washington, Donna L. Stefanick, Marcia L. TI Who Are the Women Veterans in the Women's Health Initiative? SO GERONTOLOGIST LA English DT Editorial Material ID MILITARY SERVICE; MORTALITY; CANCER C1 [Weitlauf, Julie C.] Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA 94304 USA. [Weitlauf, Julie C.] Stanford Univ, Sch Med, Ctr Implementat Innovat Ci2i, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Washington, Donna L.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90095 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Stefanick, Marcia L.] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford Prevent Res Ctr Stanford, Stanford, CA 94305 USA. RP Weitlauf, JC (reprint author), Stanford Univ, Sch Med, Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific MIRECC, Palo Alto, CA 94304 USA.; Weitlauf, JC (reprint author), Stanford Univ, Sch Med, Ctr Implementat Innovat Ci2i, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. EM wjulie1@stanford.edu FU Women's Mental Health and Aging Core of the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC); VA Office of Women's Health and VA Health Services Research and Development [VA HSRD FOP 14-439] FX This editorial was supported, in part, by the Women's Mental Health and Aging Core of the Sierra Pacific Mental Illness, Research, Education and Clinical Center (MIRECC) and the VA Office of Women's Health and VA Health Services Research and Development (VA HSR&D FOP 14-439). NR 22 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD FEB PY 2016 VL 56 SU 1 BP S6 EP S9 DI 10.1093/geront/gnv674 PG 4 WC Gerontology SC Geriatrics & Gerontology GA DJ5BJ UT WOS:000374221500002 PM 26768392 ER PT J AU Ramage, AE Litz, BT Resick, PA Woolsey, MD Dondanville, KA Young-McCaughan, S Borah, AM Borah, EV Peterson, AL Fox, PT AF Ramage, Amy E. Litz, Brett T. Resick, Patricia A. Woolsey, Mary D. Dondanville, Katherine A. Young-McCaughan, Stacey Borah, Adam M. Borah, Elisa V. Peterson, Alan L. Fox, Peter T. CA STRONG STAR Consortium TI Regional cerebral glucose metabolism differentiates danger- and non-danger-based traumas in post-traumatic stress disorder SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE post-traumatic stress disorder; FDG PET; glucose metabolism; fear ID FUNCTIONAL CONNECTIVITY; BRAIN NETWORKS; PSYCHOMETRIC PROPERTIES; CINGULATE CORTEX; AMYGDALA VOLUME; WAR VETERANS; METAANALYSIS; PTSD; RELIABILITY; ANXIETY AB Post-traumatic stress disorder (PTSD) is presumably the result of life threats and conditioned fear. However, the neurobiology of fear fails to explain the impact of traumas that do not entail threats. Neuronal function, assessed as glucose metabolism with 18fluoro-deoxyglucose positron emission tomography, was contrasted in active duty, treatment-seeking US Army Soldiers with PTSD endorsing either danger-(n = 19) or non-danger-based (n = 26) traumas, and was compared with soldiers without PTSD (Combat Controls, n = 26) and Civilian Controls (n = 24). Prior meta-analyses of regions associated with fear or trauma script imagery in PTSD were used to compare glucose metabolism across groups. Danger-based traumas were associated with higher metabolism in the right amygdala than the control groups, while non-danger-based traumas associated with heightened precuneus metabolism relative to the danger group. In the danger group, PTSD severity was associated with higher metabolismin precuneus and dorsal anterior cingulate and lower metabolismin left amygdala (R-2 = 0.61). In the non-danger group, PTSD symptom severity was associated with higher precuneus metabolismand lower right amygdala metabolism( R-2 = 0.64). These findings suggest a biological basis to consider subtyping PTSD according to the nature of the traumatic context. C1 [Ramage, Amy E.; Dondanville, Katherine A.; Young-McCaughan, Stacey; Borah, Elisa V.; Peterson, Alan L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Ramage, Amy E.; Woolsey, Mary D.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 7703 Floyd Curl Dr,MSC 6240, San Antonio, TX 78229 USA. [Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Washington, DC USA. [Litz, Brett T.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02215 USA. [Resick, Patricia A.] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC USA. [Borah, Adam M.] Carl R Darnall Army Med Ctr, Ft Hood, TX USA. [Peterson, Alan L.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pok Fu Lam, Hong Kong, Peoples R China. RP Ramage, AE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 7703 Floyd Curl Dr,MSC 6240, San Antonio, TX 78229 USA. EM ramagea@uthscsa.edu FU Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-02-109, W81XWH-08-02-0112, W81XWH-08-02-0114, W81XWH-08-02-0116]; U.S. Department of Defense, Defense Health Program; U.S. Department of Veterans Affairs, Office of Research & Development through the Psychological Health and Traumatic Brain Injury Research Program (PH/TBI RP), Consortium to Alleviate PTSD (CAP) [W81XWH-13-2-0065] FX The data collection for this study was conducted with support to the STRONG STAR Multidisciplinary PTSD Research Consortium from the U.S. Department of Defense through the U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-02-109 (Alan Peterson), W81XWH-08-02-0112 (Peter Fox), W81XWH-08-02-0114 (Brett Litz), and W81XWH-08-02-0116 (Patricia Resick). The analysis and interpretation of data for this study was supported by the U.S. Department of Defense, Defense Health Program and the U.S. Department of Veterans Affairs, Office of Research & Development through the Psychological Health and Traumatic Brain Injury Research Program (PH/TBI RP), Consortium to Alleviate PTSD (CAP) award W81XWH-13-2-0065. NR 58 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD FEB PY 2016 VL 11 IS 2 BP 234 EP 242 DI 10.1093/scan/nsv102 PG 9 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA DJ5DL UT WOS:000374226900005 PM 26373348 ER PT J AU Day, MA Ehde, DM Ward, LC Hartoonian, N Alschuler, KN Turner, AP Kraft, GH Jensen, MP AF Day, Melissa A. Ehde, Dawn M. Ward, L. Charles Hartoonian, Narineh Alschuler, Kevin N. Turner, Aaron P. Kraft, George H. Jensen, Mark P. TI An Empirical Investigation of a Biopsychosocial Model of Pain in Multiple Sclerosis SO CLINICAL JOURNAL OF PAIN LA English DT Article DE multiple sclerosis; biopsychosocial model; structural equation model; pain ID QUALITY-OF-LIFE; LARGE COMMUNITY SAMPLE; MAJOR DEPRESSION; MEDIATING ROLE; PRIMARY-CARE; FATIGUE; PREVALENCE; SEVERITY; OUTCOMES; IMPACT AB Objectives: Pain is a significant problem for many individuals with multiple sclerosis (MS). Pain is often associated with other MS symptoms (eg, physical, sensorimotor, cognitive declines), and both pain and MS symptoms are hypothesized to contribute to psychosocial problems (eg, depression), other symptoms (eg, fatigue, sleep disturbance), and functional impairments (eg, pain interference). On the basis of a biopsychosocial model, we sought to: (1) examine the associations between pain, MS symptoms, depression, psychosocial, and functional variables and (2) identify possible risk and protective factors associated with pain in MS. Materials and Methods: A cross-sectional survey was completed by 424 individuals with MS. Pain, MS symptoms, demographics, MS diagnostic factors, and psychosocial and functional variables were assessed. Data were analyzed by structural equation models. Results: Participants were predominantly white (92%), middle-aged (mean=50.7 y), and female (80%). Results indicated that pain severity and depression accounted for > 50% of the variance in pain interference. Although pain contributed minimally to fatigue and sleep quality, depression and MS symptoms predicted 49% of the variance in fatigue, and depression was largely responsible for the 40% of predicted variance in sleep quality. Identified risk factors for pain were low educational attainment and lack of a committed/marital relationship, even while controlling for diagnostic and other key demographic variables. Discussion: Results highlight the importance of targeting interventions toward improving coping skills and social support within the context of pain and MS. Research is needed to determine whether effectively targeting depression in MS results in improvements of other critical psychosocial and physical functioning domains. C1 [Day, Melissa A.] Univ Queensland, Sch Psychol, 1100 Nudgee Rd, Brisbane, Qld 4014, Australia. [Ehde, Dawn M.; Hartoonian, Narineh; Alschuler, Kevin N.; Turner, Aaron P.; Kraft, George H.; Jensen, Mark P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hartoonian, Narineh; Turner, Aaron P.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Ward, L. Charles] VA Med Ctr, Psychol Serv, Tuscaloosa, AL USA. [Hartoonian, Narineh; Turner, Aaron P.] VA MS Ctr Excellence, Seattle, WA USA. RP Day, MA (reprint author), Univ Queensland, Sch Psychol, 1100 Nudgee Rd, Brisbane, Qld 4014, Australia. EM Melissa.Day@acu.edu.au FU Department of Education, NIDRR, Washington, DC [H133B080025]; National Institutes of Health, Bethesda, Maryland [5U01AR052171-03]; National Multiple Sclerosis Society, New York City, NY [MB 0026, MB 0008] FX Supported by grants from the Department of Education, NIDRR grant number H133B080025, Washington, DC; National Institutes of Health, Grant 5U01AR052171-03, Bethesda, Maryland; and the National Multiple Sclerosis Society, Grants MB 0026 and MB 0008, New York City, NY. The authors declare no conflict of interest. NR 42 TC 1 Z9 2 U1 5 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0749-8047 EI 1536-5409 J9 CLIN J PAIN JI Clin. J. Pain PD FEB PY 2016 VL 32 IS 2 BP 155 EP 163 DI 10.1097/AJP.0000000000000240 PG 9 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA DI9MW UT WOS:000373828000009 PM 26741742 ER PT J AU Robbins, J Humpal, NS Banaszynski, K Hind, J Rogus-Pulia, N AF Robbins, JoAnne Humpal, Naomi S. Banaszynski, Kelsey Hind, Jacqueline Rogus-Pulia, Nicole TI Age-Related Differences in Pressures Generated During Isometric Presses and Swallows by Healthy Adults SO DYSPHAGIA LA English DT Article DE Swallowing; Dysphagia; Tongue strength; Aging; Deglutition; Deglutition disorders ID TONGUE STRENGTH; OLDER-ADULTS; RISK-FACTOR; DYSPHAGIA; PREVALENCE; SARCOPENIA; MUSCLES; IMPACT AB The aim of this prospective observational study was to determine the associations among age, maximum lingual isometric pressures, and maximum swallow pressures in specific regions of the tongue. Individuals 21 years and older who reported normal swallowing were enrolled. Seventy-one healthy adults were stratified by age into young (21-40 years), middle (41-60), and old (61-82) groups. Maximum pressures were measured for each individual during isometric tongue press tasks as well as saliva, 5, and 10 mL thin liquid bolus swallows at 5 sensors located on the hard palate: front, middle, left, right, and back. Lower maximum lingual pressures for all tasks were associated with increased age (p < 0.04). Saliva pressures exhibited a different pressure pattern than bolus swallows with pressures higher than bolus swallows on middle (p < 0.03) and back (p < 0.05) tongue sensors but not in the front. Diminished swallow pressure reserve (maximum isometric pressure-maximum swallow pressure) also was found with increased age (p < 0.03). Isometric pressures were greater than swallow pressures in young and middle age groups at both the front (p < 0.04) and back (p < 0.03) sensors, but only significantly greater at the front sensor for the oldest group (p < 0.04). Older healthy adults have lower lingual isometric pressures and lower swallow pressures than younger healthy adults. Elders have a decreased swallow pressure reserve to draw upon during occasions of physiological stress. While the exact mechanisms for age-related decline in lingual pressures remain unclear, they are likely due, at least in part, to sarcopenia. Saliva, 5, and 10 mL thin boluses also exhibit different age-related declines in pressure at specific sensors, indicating they may elicit different muscle activation patterns. C1 [Robbins, JoAnne; Rogus-Pulia, Nicole] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison GRECC, 2500 Overlook Terrace,Room D4220, Madison, WI 53705 USA. [Robbins, JoAnne; Rogus-Pulia, Nicole] Univ Wisconsin, Dept Med, SMPH, Madison, WI 53706 USA. [Humpal, Naomi S.] Univ Wisconsin, Coll Engn, Dept Biomed Engn, Madison, WI 53706 USA. [Banaszynski, Kelsey] WhiteWave Foods, 1900 Cherry St, Louisville, CO USA. [Hind, Jacqueline] Swallow Solut LLC, 401 Charmany Dr, Madison, WI 53719 USA. RP Rogus-Pulia, N (reprint author), William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison GRECC, 2500 Overlook Terrace,Room D4220, Madison, WI 53705 USA.; Rogus-Pulia, N (reprint author), Univ Wisconsin, Dept Med, SMPH, Madison, WI 53706 USA. EM npulia@wisc.edu NR 26 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD FEB PY 2016 VL 31 IS 1 BP 90 EP 96 DI 10.1007/s00455-015-9662-x PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DI8IP UT WOS:000373745000010 PM 26525059 ER PT J AU Maier, MM Ross, DB Chartier, M Belperio, PS Backus, LI AF Maier, Marissa M. Ross, David B. Chartier, Maggie Belperio, Pamela S. Backus, Lisa I. TI Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID GENOTYPE 1 INFECTION; UNITED-STATES; PLUS RIBAVIRIN; AFFAIRS CARE; PREVALENCE; SOFOSBUVIR; LEDIPASVIR AB Objectives. We measured the quality of HCV care using a cascade of HCV care model. Methods. We estimated the number of patients diagnosed with chronic HCV, linked to HCV care, treated with HCV antivirals, and having achieved a sustained virologic response (SVR) in the electronic medical record data from the Veterans Health Administration's Corporate Data Warehouse and the HCV Clinical Case Registry in 2013. Results. Of the estimated 233 898 patients with chronic HCV, 77% (181 168) were diagnosed, 69% (160 794) were linked to HCV care, 17% (39 388) were treated with HCV antivirals, and 7% (15 983) had achieved SVR. Conclusions. This Cascade of HCV Care provides a clinically relevant model to measure the quality of HCV care within a health care system and to compare HCV care across health systems. C1 [Maier, Marissa M.] Vet Hlth Adm, VA Portland Hlth Care Syst, Portland, OR USA. [Maier, Marissa M.; Ross, David B.; Chartier, Maggie] VHA, Off Publ Hlth, HIV Hepatitis & Publ Hlth Pathogens Programs, Washington, DC USA. [Ross, David B.] VA Washington DC Hlth Care Syst, Washington, DC USA. [Chartier, Maggie] VHA, VA San Francisco Hlth Care Syst, San Francisco, CA USA. [Belperio, Pamela S.] VHA, VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA. [Belperio, Pamela S.; Backus, Lisa I.] VHA, Off Publ Hlth Populat Hlth, Washington, DC USA. [Backus, Lisa I.] VHA, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. RP Maier, MM (reprint author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,Mail Code P3ID, Portland, OR 97239 USA. EM Marissa.Maier@va.gov NR 18 TC 2 Z9 2 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2016 VL 106 IS 2 BP 353 EP 358 DI 10.2105/AJPH.2015.302927 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DI3VY UT WOS:000373429000043 PM 26562129 ER PT J AU Hagiwara, Y Healy, J Ghannam, S Lee, S Sanchez-Reilly, S AF Hagiwara, Yuya Healy, Jennifer Ghannam, Sammar Lee, Shuko Sanchez-Reilly, Sandra TI Development and Validation of a Family Meeting OSCE Assessment Tool (FMOSCEAT) SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Hagiwara, Yuya] Avera Med Grp Palliat Med, San Antonio, TX USA. [Healy, Jennifer; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Ghannam, Sammar] Univ Texas San Antonio, San Antonio, TX USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA TH331A BP 332 EP 333 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900084 ER PT J AU Mireles, C Healy, J Lee, S Sanchez-Reilly, S Kapp, B AF Mireles, Christina Healy, Jennifer Lee, Shuko Sanchez-Reilly, Sandra Kapp, Bethany TI Nurses Have the Magic Touch: Determining the Effect of Embedding a Palliative Care Nurse Within the MICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Mireles, Christina; Healy, Jennifer; Sanchez-Reilly, Sandra; Kapp, Bethany] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA FR420A BP 354 EP 355 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900127 ER PT J AU Amdur, S Seetharama, A Lee, S Ross, J Sanchez-Reilly, S AF Amdur, Shira Seetharama, Aparna Lee, Shuko Ross, Jeanette Sanchez-Reilly, Sandra TI Good Mourning, YouTube! Grieving and Bereaving on the World's Most Popular Video Sharing Website SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Amdur, Shira; Seetharama, Aparna; Ross, Jeanette; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Seetharama, Aparna; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA FR461D BP 373 EP 374 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900162 ER PT J AU Petrillo, L McMahan, R Sudore, R AF Petrillo, Laura McMahan, Ryan Sudore, Rebecca TI What Is a Serious Medical Decision? Patients' And Surrogates' Perceptions of Serious Decisions and What Is Important in Making Them SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Petrillo, Laura] San Francisco Dept Vet Affairs, San Francisco, CA USA. [Petrillo, Laura; McMahan, Ryan; Sudore, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sudore, Rebecca] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S766 BP 443 EP 444 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900289 ER PT J AU Veeder, H Stowers, K Linden, J Lee, S Sanchez-Reilly, S AF Veeder, Heather Stowers, Katie Linden, James Lee, Shuko Sanchez-Reilly, Sandra TI Protecting Our Vulnerable Population: Screening for Mistreatment in Palliative Care SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Veeder, Heather; Stowers, Katie; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Linden, James] Univ Hawaii Manoa, Honolulu, HI 96822 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S776 BP 449 EP 450 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900299 ER PT J AU Williams, S Lee, S Healy, J Sanchez-Reilly, S AF Williams, Sherry Lee, Shuko Healy, Jennifer Sanchez-Reilly, Sandra TI How Come They Don't Come? Identifying Reasons of No-Shows Among a Palliative Care Outpatient Clinic SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Williams, Sherry; Healy, Jennifer; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Williams, Sherry; Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S775 BP 449 EP 449 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900298 ER PT J AU Kapp, B Mireles, C Sanchez-Reilly, S Healy, J Lee, S AF Kapp, Bethany Mireles, Christina Sanchez-Reilly, Sandra Healy, Jennifer Lee, Shuko TI Benefits of Palliative Care in the MICU SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Kapp, Bethany; Mireles, Christina; Sanchez-Reilly, Sandra; Healy, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S781 BP 452 EP 453 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900304 ER PT J AU May, L Sanchez-Reilly, S Frausto, E Lee, S Garcia, J AF May, Linda Sanchez-Reilly, Sandra Frausto, Edggar Lee, Shuko Garcia, Jessica TI Yes, I Can Live with Less Pain: A Pain Educational Intervention Improving Patient-Centered Care and Attitudes Among Older Adults SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [May, Linda; Sanchez-Reilly, Sandra; Frausto, Edggar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Garcia, Jessica] Symptom Management Consultants, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S784 BP 454 EP 454 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900307 ER PT J AU Klein, D Dinardo, D Hwa, S Superson, J Chang, V Olson, E AF Klein, David Dinardo, Daniel Hwa, Stephanie Superson, Jennifer Chang, Victor Olson, Ellen TI Comparison of Symptoms in Patients with Lung Cancer and Hepatocellular Cancer Referred for Palliative Care at a VA Medical Center SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Klein, David] Hosp New York, Queens, NY USA. [Dinardo, Daniel] St Johns Episcopal Hosp, Merrick, NY USA. [Hwa, Stephanie] James J Peters VA Med Ctr, New York, NY USA. [Superson, Jennifer] James J Peters VA Med Ctr, Brooklyn, NY USA. [Chang, Victor] VA New Jersey Hlth Care Syst, E Orange, NJ USA. [Olson, Ellen] James J Peters Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S791 BP 458 EP 458 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900314 ER PT J AU Monskaya, M Pruskowski, J Garcia, Y Chang, V Olson, E AF Monskaya, Milena Pruskowski, Jennifer Garcia, Yleana Chang, Victor Olson, Ellen TI Dosing of Analgesics for Patients with Liver Cancer or Lung Cancer SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Meeting Abstract CT Annual Assembly of the American-Academy-of-Hospice-and-Palliative-Medicine and the Hospice-and-Palliative-Nurses-Association CY MAR 09-12, 2016 CL Chicago, IL SP Amer Acad Hosp & Palliat Med, Hosp & Palliat Nurses Assoc C1 [Monskaya, Milena] JJPMC, Brooklyn, NY USA. [Pruskowski, Jennifer] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Garcia, Yleana] Kaweah Delta Hlth Care Dist, Visalia, CA USA. [Chang, Victor] Vet Adm New Jersey Hlth Care Syst, E Orange, NJ USA. [Olson, Ellen] James J Peters Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD FEB PY 2016 VL 51 IS 2 MA S792 BP 458 EP 459 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA DI4MB UT WOS:000373472900315 ER PT J AU Apelo, SIA Neuman, JC Baar, EL Syed, FA Cummings, NE Brar, HK Pumper, CP Kimple, ME Lamming, DW AF Apelo, Sebastian I. Arriola Neuman, Joshua C. Baar, Emma L. Syed, Faizan A. Cummings, Nicole E. Brar, Harpreet K. Pumper, Cassidy P. Kimple, Michelle E. Lamming, Dudley W. TI Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system SO AGING CELL LA English DT Article DE aging; mechanistic target of rapamycin; mice; rapamycin ID MAMMALIAN LIFE-SPAN; INSULIN-RESISTANCE; T-CELLS; MICE; MTORC2; EXPRESSION; RICTOR; RESPONSES; QUALITY; TISSUE AB Inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway by the FDA-approved drug rapamycin has been shown to promote lifespan and delay age-related diseases in model organisms including mice. Unfortunately, rapamycin has potentially serious side effects in humans, including glucose intolerance and immunosuppression, which may preclude the long-term prophylactic use of rapamycin as a therapy for age-related diseases. While the beneficial effects of rapamycin are largely mediated by the inhibition of mTOR complex 1 (mTORC1), which is acutely sensitive to rapamycin, many of the negative side effects are mediated by the inhibition of a second mTOR-containing complex, mTORC2, which is much less sensitive to rapamycin. We hypothesized that different rapamycin dosing schedules or the use of FDA-approved rapamycin analogs with different pharmacokinetics might expand the therapeutic window of rapamycin by more specifically targeting mTORC1. Here, we identified an intermittent rapamycin dosing schedule with minimal effects on glucose tolerance, and we find that this schedule has a reduced impact on pyruvate tolerance, fasting glucose and insulin levels, beta cell function, and the immune system compared to daily rapamycin treatment. Further, we find that the FDA-approved rapamycin analogs everolimus and temsirolimus efficiently inhibit mTORC1 while having a reduced impact on glucose and pyruvate tolerance. Our results suggest that many of the negative side effects of rapamycin treatment can be mitigated through intermittent dosing or the use of rapamycin analogs. C1 [Apelo, Sebastian I. Arriola; Baar, Emma L.; Syed, Faizan A.; Cummings, Nicole E.; Brar, Harpreet K.; Pumper, Cassidy P.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI USA. [Apelo, Sebastian I. Arriola; Neuman, Joshua C.; Baar, Emma L.; Syed, Faizan A.; Cummings, Nicole E.; Brar, Harpreet K.; Pumper, Cassidy P.; Kimple, Michelle E.; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. [Neuman, Joshua C.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Interdisciplinary Grad Program Nutr Sci, Madison, WI USA. [Cummings, Nicole E.; Kimple, Michelle E.; Lamming, Dudley W.] Univ Wisconsin, Endocrinol & Reprod Physiol Grad Training Program, Madison, WI USA. [Lamming, Dudley W.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu OI Lamming, Dudley/0000-0002-0079-4467 FU National Institute of Health/National Institute on Aging [AG041765]; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; American Diabetes Association [1-14-BS-115]; NIH/NIDDK [R01 DK102598]; University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520]; UW Institute on Aging [NIA T32 AG000213] FX The Lamming lab is supported by a K99/R00 Pathway to Independence Award to D.W.L. from the National Institute of Health/National Institute on Aging (AG041765), as well as startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. This work was also supported by grants from the American Diabetes Association (1-14-BS-115) and the NIH/NIDDK (R01 DK102598) to M.E.K. D.W.L. is a member of the UW-Carbone Cancer Center (UWCCC), and use of the UWCCC Flow Cytometry Laboratory, a Shared Service of the UWCCC, was supported in part by the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520. J.C.N. is supported in part by a training grant from the UW Institute on Aging (NIA T32 AG000213). This work was supported using facilities and resources at the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 42 TC 6 Z9 6 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD FEB PY 2016 VL 15 IS 1 BP 28 EP 38 DI 10.1111/acel.12405 PG 11 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6CQ UT WOS:000372879000004 ER PT J AU Martin, SA DeMuth, TM Miller, KN Pugh, TD Polewski, MA Colman, RJ Eliceiri, KW Beasley, TM Johnson, SC Anderson, RM AF Martin, Stephen A. DeMuth, Tyler M. Miller, Karl N. Pugh, Thomas D. Polewski, Michael A. Colman, Ricki J. Eliceiri, Kevin W. Beasley, Timothy Mark Johnson, Sterling C. Anderson, Rozalyn M. TI Regional metabolic heterogeneity of the hippocampus is nonuniformly impacted by age and caloric restriction SO AGING CELL LA English DT Article DE aging; metabolism; caloric restriction; hippocampus; mitochondria; neuroprotection ID GLYCOGEN-SYNTHASE KINASE-3; RHESUS-MONKEYS; ALZHEIMERS-DISEASE; OXIDATIVE-METABOLISM; ENERGY-METABOLISM; CELLS; FLUORESCENCE; NADH; PGC-1-ALPHA; BRAIN AB The hippocampus is critical for cognition and memory formation and is vulnerable to age-related atrophy and loss of function. These phenotypes are attenuated by caloric restriction (CR), a dietary intervention that delays aging. Here, we show significant regional effects in hippocampal energy metabolism that are responsive to age and CR, implicating metabolic pathways in neuronal protection. In situ mitochondrial cytochrome c oxidase activity was region specific and lower in aged mice, and the impact of age was region specific. Multiphoton laser scanning microscopy revealed region- and age-specific differences in nicotinamide adenine dinucleotide (NAD)-derived metabolic cofactors. Age-related changes in metabolic parameters were temporally separated, with early and late events in the metabolic response to age. There was a significant regional impact of age to lower levels of PGC-1 alpha, a master mitochondrial regulator. Rather than reversing the impact of age, CR induced a distinct metabolic state with decreased cytochrome c oxidase activity and increased levels of NAD(P) H. Levels of hippocampal PGC-1 alpha were lower with CR, as were levels of GSK3 beta, a key regulator of PGC-1 alpha turnover and activity. Regional distribution and colocalization of PGC-1 alpha and GSK3 beta in mouse hippocampus was similar in monkeys. Furthermore, the impact of CR to lower levels of both PGC-1 alpha and GSK3 beta was also conserved. The studies presented here establish the hippocampus as a highly varied metabolic environment, reveal cell-type and regional specificity in the metabolic response to age and delayed aging by CR, and suggest that PGC-1 alpha and GSK3 beta play a role in implementing the neuroprotective program induced by CR. C1 [Martin, Stephen A.; DeMuth, Tyler M.; Miller, Karl N.; Pugh, Thomas D.; Polewski, Michael A.; Johnson, Sterling C.; Anderson, Rozalyn M.] SMPH, Dept Med, Div Geriatr, Madison, WI 53705 USA. [Colman, Ricki J.] Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA. [Eliceiri, Kevin W.] Univ Wisconsin, Lab Opt & Computat Instrumentat, Madison, WI 53706 USA. [Beasley, Timothy Mark] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Beasley, Timothy Mark] Birmingham Atlanta Vet Adm Hosp, GRECC, Birmingham, AL 35294 USA. [Johnson, Sterling C.; Anderson, Rozalyn M.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI 53705 USA. RP Anderson, RM (reprint author), William S Middleton VA Hosp, GRECC D5214,2500 Overlook Terrace, Madison, WI 53705 USA. EM rmanderson@medicine.wisc.edu FU NIH/NIA R01 [AG037000, AG043125]; ADRC [AG033514]; UW Institute on Aging [AG000213]; UW Department of Nutritional Sciences [DK007665] FX This work was supported by NIH/NIA R01 grants AG037000, AG043125, and ADRC grant AG033514. SAM and KNM are supported by T32 fellowships from the UW Institute on Aging AG000213 and the UW Department of Nutritional Sciences DK007665, respectively. The study was conducted with the use of resources and facilities at the William S. Middleton Memorial Veterans Hospital, Madison, WI. NR 47 TC 3 Z9 3 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD FEB PY 2016 VL 15 IS 1 BP 100 EP 110 DI 10.1111/acel.12418 PG 11 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6CQ UT WOS:000372879000011 PM 26521867 ER PT J AU Baar, EL Carbajal, KA Ong, IM Lamming, DW AF Baar, Emma L. Carbajal, Kathryn A. Ong, Irene M. Lamming, Dudley W. TI Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice SO AGING CELL LA English DT Article DE aging; mice; mTOR; mTORC1; mTORC2; rapamycin; sexual dimorphism ID LIFE-SPAN; CALORIC RESTRICTION; DIETARY RESTRICTION; S6 KINASE; RAPAMYCIN; LONGEVITY; EXPRESSION; RESVERATROL; SENSITIVITY; INHIBITION AB Inhibition of the mTOR (mechanistic Target Of Rapamycin) signaling pathway robustly extends the lifespan of model organisms including mice. The precise molecular mechanisms and physiological effects that underlie the beneficial effects of rapamycin are an exciting area of research. Surprisingly, while some data suggest that mTOR signaling normally increases with age in mice, the effect of age on mTOR signaling has never been comprehensively assessed. Here, we determine the age-associated changes in mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2) signaling in the liver, muscle, adipose, and heart of C57BL/6J. Nia mice, the lifespan of which can be extended by rapamycin treatment. We find that the effect of age on several different readouts of mTORC1 and mTORC2 activity varies by tissue and sex in C57BL/6J. Nia mice. Intriguingly, we observed increased mTORC1 activity in the liver and heart tissue of young female mice compared to male mice of the same age. Tissue and substrate-specific results were observed in the livers of HET3 and DBA/2 mouse strains, and in liver, muscle and adipose tissue of F344 rats. Our results demonstrate that aging does not result in increased mTOR signaling in most tissues and suggest that rapamycin does not promote lifespan by reversing or blunting such an effect. C1 [Baar, Emma L.; Carbajal, Kathryn A.; Lamming, Dudley W.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Baar, Emma L.; Carbajal, Kathryn A.; Lamming, Dudley W.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. [Ong, Irene M.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA. [Ong, Irene M.; Lamming, Dudley W.] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI USA. RP Lamming, DW (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room C3127 Res 151, Madison, WI 53705 USA. EM dlamming@medicine.wisc.edu FU National Institute of Health/NIA [AG041765]; UW-Madison School of Medicine and Public Health; UW-Madison Department of Medicine; Research Supplement to Promote Diversity in Health-Related Research [AG041765-04S1]; University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520]; Clinical and Translational Science Award (CTSA) program through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427] FX The Lamming lab is supported by a K99/R00 Pathway to Independence Award to DWL from the National Institute of Health/NIA (AG041765), as well as startup funds from the UW-Madison School of Medicine and Public Health and the UW-Madison Department of Medicine. KAC was supported in part by a Research Supplement to Promote Diversity in Health-Related Research (AG041765-04S1). IO is supported by the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520 and the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427. This work was supported using facilities and resources from the William S. Middleton Memorial Veterans Hospital. This work does not represent the views of the Department of Veterans Affairs or the United States Government. NR 45 TC 11 Z9 11 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1474-9718 EI 1474-9726 J9 AGING CELL JI Aging Cell PD FEB PY 2016 VL 15 IS 1 BP 155 EP 166 DI 10.1111/acel.12425 PG 12 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA DH6CQ UT WOS:000372879000017 PM 26695882 ER PT J AU Chidi, AP Rogal, S Bryce, CL Fine, MJ Good, CB Myaskovsky, L Rustgi, VK Tsung, A Smith, KJ AF Chidi, Alexis P. Rogal, Shari Bryce, Cindy L. Fine, Michael J. Good, Chester B. Myaskovsky, Larissa Rustgi, Vinod K. Tsung, Allan Smith, Kenneth J. TI Cost-Effectiveness of New Antiviral Regimens for Treatment-Naive US Veterans with Hepatitis C SO HEPATOLOGY LA English DT Article ID GENOTYPE 1 INFECTION; UNITED-STATES VETERANS; ALL-CAUSE MORTALITY; VIRUS-INFECTION; CHRONIC HCV; COMPENSATED CIRRHOSIS; LIVER-TRANSPLANTATION; PEGYLATED INTERFERON; VIROLOGICAL RESPONSE; SOFOSBUVIR AB Recently approved, interferon-free medication regimens for treating hepatitis C are highly effective, but extremely costly. We aimed to identify cost-effective strategies for managing treatment-naive U.S. veterans with new hepatitis C medication regimens. We developed a Markov model with 1-year cycle length for a cohort of 60-year-old veterans with untreated genotype 1 hepatitis C seeking treatment in a typical year. We compared using sofosbuvir/ledipasvir or ombitasvir/ritonavir/paritaprevir/dasabuvir to treat: (1) any patient seeking treatment; (2) only patients with advanced fibrosis or cirrhosis; or (3) patients with advanced disease first and healthier patients 1 year later. The previous standard of care, sofosbuvir/simeprevir or sofosbuvir/pegylated interferon/ribavirin, was included for comparison. Patients could develop progressive fibrosis, cirrhosis, or hepatocellular carcinoma, undergo transplantation, or die. Complications were less likely after sustained virological response. We calculated the incremental cost per quality-adjusted life year (QALY) and varied model inputs in one-way and probabilistic sensitivity analyses. We used the Veterans Health Administration perspective with a lifetime time horizon and 3% annual discounting. Treating any patient with ombitasvir-based therapy was the preferred strategy ($ 35,560; 14.0 QALYs). All other strategies were dominated (greater costs/QALY gained than more effective strategies). Varying treatment efficacy, price, and/or duration changed the preferred strategy. In probabilistic sensitivity analysis, treating any patient with ombitasvir-based therapy was cost-effective in 70% of iterations at a $ 50,000/QALY threshold and 65% of iterations at a $ 100,000/QALY threshold. Conclusion: Managing any treatment-naive genotype 1 hepatitis C patient with ombitasvir-based therapy is the most economically efficient strategy, although price and efficacy can impact cost-effectiveness. It is economically unfavorable to restrict treatment to patients with advanced disease or use a staged treatment strategy. C1 [Chidi, Alexis P.; Rogal, Shari; Bryce, Cindy L.; Fine, Michael J.; Good, Chester B.; Myaskovsky, Larissa; Smith, Kenneth J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, 3471 Fifth Ave,Suite 300, Pittsburgh, PA 15213 USA. [Chidi, Alexis P.; Rogal, Shari; Fine, Michael J.; Good, Chester B.; Myaskovsky, Larissa; Smith, Kenneth J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Chidi, Alexis P.; Tsung, Allan] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA. [Bryce, Cindy L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15213 USA. [Good, Chester B.] US Dept Vet Affairs, VA Ctr Medicat Safety, Hines, IL USA. [Rustgi, Vinod K.] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. RP Chidi, AP (reprint author), Univ Pittsburgh, Sch Med, Div Gen Internal Med, 3471 Fifth Ave,Suite 300, Pittsburgh, PA 15213 USA. EM apc10@pitt.edu OI Bryce, Cindy/0000-0001-6356-6675 FU National Center for Advancing Translational Sciences of the National Institutes of Health [TL1TR000145] FX AC was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR000145. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the VA Healthcare Systems. NR 56 TC 7 Z9 7 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD FEB PY 2016 VL 63 IS 2 BP 428 EP 436 DI 10.1002/hep.28327/suppinfo PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DI1ZZ UT WOS:000373296800001 PM 26524695 ER PT J AU Bachhuber, MA Maughan, BC Mitra, N Feingold, J Starrels, JL AF Bachhuber, Marcus A. Maughan, Brandon C. Mitra, Nandita Feingold, Jordyn Starrels, Joanna L. TI Prescription monitoring programs and emergency department visits involving benzodiazepine misuse: Early evidence from 11 United States metropolitan areas SO INTERNATIONAL JOURNAL OF DRUG POLICY LA English DT Article DE Benzodiazepines; Prescription drug misuse; Health policy; Public policy; Public health ID PHARMACOLOGICAL-TREATMENT; OPIOID ANALGESICS; ABUSE; DISORDERS; ANXIETY; ASSOCIATION; GUIDELINES; IMPACT AB Background: Emergency department (ED) visits involving benzodiazepines have increased in the United States. Most states have created prescription monitoring programs (PMPs) to improve drug prescribing safety. To determine the association between PMP implementation and ED visits involving benzodiazepine misuse, we conducted a retrospective analysis of data from 11 metropolitan areas in the United States from 2004 to 2011. Methods: We estimated rates of ED visits per 100,000 residents involving benzodiazepine misuse from the Drug Abuse Warning Network dataset. Dates of PMP implementation were obtained from program administrators. We used linear regression models to assess whether PMP implementation was associated with a change in ED visits involving benzodiazepines. Models were adjusted for calendar quarter, metropolitan area, and metropolitan area-specific linear time trends. Results: Rates of ED visits involving benzodiazepine misuse increased in all metropolitan areas during the study period. PMP implementation was not associated with a change in ED visits (mean difference: 0.9 [95% CI:-0.09 to 1.9] visits per 100,000 population per quarter; p = 0.08). When analyzed by number of years after implementation, PMPs were associated with a higher visit rate in year one (0.8 [95% CI: 0.2-1.5]; p = 0.011), but not in year two (0.3 [95% CI: 2.1-2.81; p = 0.78) or year three or later (2.1 [95% CI: 0.4-4.7]; p = 0.10). Conclusion: We did not find evidence that PMP implementation was associated with reductions in ED visits involving benzodiazepine misuse. Future work should identify PMP features and capabilities that improve benzodiazepine safety. Published by Elsevier B.V. C1 [Bachhuber, Marcus A.; Maughan, Brandon C.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bachhuber, Marcus A.; Maughan, Brandon C.; Mitra, Nandita] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Bachhuber, Marcus A.; Maughan, Brandon C.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Mitra, Nandita] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Feingold, Jordyn] Univ Penn, Philadelphia, PA 19104 USA. [Starrels, Joanna L.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA. RP Bachhuber, MA (reprint author), 1303-A Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM marcus.bachhuber@gmail.com; bmaughan@gmail.com; nanditam@mail.med.upenn.edu; jordyn.feingold@gmail.com; jostarre@montefiore.org OI Bachhuber, Marcus/0000-0002-5610-8382 FU National Institute on Drug Abuse [K23DA027719]; Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania FX This study was supported by funding from the National Institute on Drug Abuse (K23DA027719) and a Matt Slap Pilot Research Award from the Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania. The funding bodies had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. NR 32 TC 3 Z9 3 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0955-3959 EI 1873-4758 J9 INT J DRUG POLICY JI Int. J. Drug Policy PD FEB PY 2016 VL 28 BP 120 EP 123 DI 10.1016/j.drugpo.2015.08.005 PG 4 WC Substance Abuse SC Substance Abuse GA DH3LJ UT WOS:000372688200015 PM 26345658 ER PT J AU Kasckow, J Youk, A Anderson, SJ Dew, MA Butters, MA Marron, MM Begley, AE Szanto, K Dombrovski, AY Mulsant, BH Lenze, EJ Reynolds, CF AF Kasckow, John Youk, Ada Anderson, Stewart J. Dew, Mary Amanda Butters, Meryl A. Marron, Megan M. Begley, Amy E. Szanto, Katalin Dombrovski, Alexander Y. Mulsant, Benoit H. Lenze, Eric J. Reynolds, Charles F., III TI Trajectories of suicidal ideation in depressed older adults undergoing antidepressant treatment SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Suicide; Trajectory; Antidepressant; Depression; Late life ID NEUROPSYCHOLOGICAL STATUS; PSYCHIATRIC OUTPATIENTS; REPEATABLE BATTERY; SAS PROCEDURE; RISK-FACTORS; ATTEMPTERS; SCALE; BEHAVIOR AB Suicide is a public health concern in older adults. Recent cross sectional studies suggest that impairments in executive functioning, memory and attention are associated with suicidal ideation in older adults. It is unknown whether these neuropsychological features predict persistent suicidal ideation. We analyzed data from 468 individuals >= age 60 with major depression who received venlafaxine XR monotherapy for up to 16 weeks. We used latent class growth modeling to classify groups of individuals based on trajectories of suicidal ideation. We also examined whether cognitive dysfunction predicted suicidal ideation while controlling for time-dependent variables including depression severity, and age and education. The optimal model using a zero inflated Poisson link classified individuals into four groups, each with a distinct temporal trajectory of suicidal ideation: those with 'minimal suicidal ideation' across time points; those with 'low suicidal ideation'; those with 'rapidly decreasing suicidal ideation'; and those with 'high and persistent suicidal ideation'. Participants in the 'high and persistent suicidal ideation' group had worse scores relative to those in the "rapidly decreasing suicidal ideation" group on the Color-Word 'inhibition/switching' subtest from the Delis-Kaplan Executive Function Scale, worse attention index scores on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and worse total RBANS index scores. These findings suggest that individuals with poorer ability to switch between inhibitory and non-inhibitory responses as well as worse attention and worse overall cognitive status are more likely to have persistently higher levels of suicidal ideation. Clinicaltrial.gov number: NCF00892047. Published by Elsevier Ltd. C1 [Kasckow, John] Univ DR C, VA Pittsburgh Hlth Care Syst, Behav Hlth, Pittsburgh, PA 15240 USA. [Kasckow, John] Univ DR C, VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA 15240 USA. [Kasckow, John] Univ DR C, VA Pittsburgh Hlth Care Syst, CHERP, Pittsburgh, PA 15240 USA. [Kasckow, John; Dew, Mary Amanda; Butters, Meryl A.; Begley, Amy E.; Szanto, Katalin; Dombrovski, Alexander Y.; Mulsant, Benoit H.; Reynolds, Charles F., III] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Kasckow, John; Youk, Ada; Anderson, Stewart J.; Dew, Mary Amanda] Univ Pittsburgh, Grad Sch Publ Hlth, Biostat, Pittsburgh, PA 15213 USA. [Dew, Mary Amanda; Marron, Megan M.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol, Pittsburgh, PA 15213 USA. [Mulsant, Benoit H.] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Mulsant, Benoit H.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Lenze, Eric J.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. RP Kasckow, J (reprint author), Univ DR C, VA Pittsburgh Hlth Care Syst, Behav Hlth, Pittsburgh, PA 15240 USA. EM kasckowjw@upmc.edu OI Youk, Ada/0000-0001-6912-9759 FU NIH [R01-MH083660, P30 MH090333]; UPMC Endowment in Geriatric Psychiatry; Taylor Family Institute for Innovative Psychiatric Research; National Center for Advancing Translational Sciences; Campbell Family Mental Health Research Institute FX Supported by NIH grant R01-MH083660, P30 MH090333, the UPMC Endowment in Geriatric Psychiatry, Taylor Family Institute for Innovative Psychiatric Research, National Center for Advancing Translational Sciences and the Campbell Family Mental Health Research Institute. NR 40 TC 1 Z9 1 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD FEB PY 2016 VL 73 BP 96 EP 101 DI 10.1016/j.jpsychires.2015.11.004 PG 6 WC Psychiatry SC Psychiatry GA DI1JD UT WOS:000373251500012 PM 26708830 ER PT J AU Sacks, GD Lawson, EH Dawes, AJ Weiss, RE Russell, MM Brook, RH Zingmond, DS Ko, CY AF Sacks, Greg D. Lawson, Elise H. Dawes, Aaron J. Weiss, Robert E. Russell, Marcia M. Brook, Robert H. Zingmond, David S. Ko, Clifford Y. TI Variation in Hospital Use of Postacute Care After Surgery and the Association With Care Quality SO MEDICAL CARE LA English DT Article DE hospital quality; variation in care; care coordination; surgery; post-acute care ID POST-ACUTE CARE; GEOGRAPHIC-VARIATION; SURGICAL QUALITY; HEALTH-CARE; IMPROVEMENT PROGRAM; AMERICAN-COLLEGE; MEDICARE; DISCHARGE; REHABILITATION; PREFERENCES AB Background: Little is known about hospital use of postacute care after surgery and whether it is related to measures of surgical quality. Research Design: We used data merged between a national surgery registry, Medicare inpatient claims, the Area Resource File, and the American Hospital Association Annual Survey (2005-2008). Using bivariate and multivariate analyses, we calculated hospital-level, risk-adjusted rates of postacute care use for both inpatient facilities (IF) and home health care (HHC), and examined the association of these rates with hospital quality measures, including mortality, complications, readmissions, and length of stay. Results: Of 112,620 patients treated at 217 hospitals, 18.6% were discharged to an IF, and 19.9% were discharged with HHC. Even after adjusting for differences in patient and hospital characteristics, hospitals varied widely in their use of both IF (mean, 20.3%; range, 2.7%-39.7%) and HHC (mean, 22.3%; range, 3.1%-57.8%). A hospital's risk-adjusted postoperative mortality rate or complication rate was not significantly associated with its use of postacute care, but higher 30-day readmission rates were associated with higher use of IF (24.1% vs. 21.2%, P=0.03). Hospitals with longer average length of stay used IF less frequently (19.4% vs. 24.4%, P < 0.01). Conclusions: Hospitals vary widely in their use of postacute care. Although hospital use of postacute care was not associated with risk-adjusted complication or mortality rates, hospitals with high readmission rates and shorter lengths of stay used inpatient postacute care more frequently. To reduce variations in care, better criteria are needed to identify which patients benefit most from these services. C1 [Sacks, Greg D.; Lawson, Elise H.; Dawes, Aaron J.; Russell, Marcia M.; Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. [Sacks, Greg D.; Dawes, Aaron J.; Russell, Marcia M.; Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Weiss, Robert E.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Brook, Robert H.] RAND Corp, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA. [Brook, Robert H.; Zingmond, David S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Sacks, GD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave 72-215 CHS, Los Angeles, CA 90095 USA. EM gsacks@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 NR 34 TC 1 Z9 1 U1 5 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2016 VL 54 IS 2 BP 172 EP 179 DI 10.1097/MLR.0000000000000463 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DH6XI UT WOS:000372935000010 PM 26595222 ER PT J AU Sada, Y Hou, J Richardson, P El-Serag, H Davila, J AF Sada, Yvonne Hou, Jason Richardson, Peter El-Serag, Hashem Davila, Jessica TI Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing SO MEDICAL CARE LA English DT Article DE hepatocellular cancer; natural language processing; pathology; radiology ID UNITED-STATES; CARCINOMA; VETERANS; SYSTEM AB Background:Accurate identification of hepatocellular cancer (HCC) cases from automated data is needed for efficient and valid quality improvement initiatives and research. We validated HCC International Classification of Diseases, 9th Revision (ICD-9) codes, and evaluated whether natural language processing by the Automated Retrieval Console (ARC) for document classification improves HCC identification.Methods:We identified a cohort of patients with ICD-9 codes for HCC during 2005-2010 from Veterans Affairs administrative data. Pathology and radiology reports were reviewed to confirm HCC. The positive predictive value (PPV), sensitivity, and specificity of ICD-9 codes were calculated. A split validation study of pathology and radiology reports was performed to develop and validate ARC algorithms. Reports were manually classified as diagnostic of HCC or not. ARC generated document classification algorithms using the Clinical Text Analysis and Knowledge Extraction System. ARC performance was compared with manual classification. PPV, sensitivity, and specificity of ARC were calculated.Results:A total of 1138 patients with HCC were identified by ICD-9 codes. On the basis of manual review, 773 had HCC. The HCC ICD-9 code algorithm had a PPV of 0.67, sensitivity of 0.95, and specificity of 0.93. For a random subset of 619 patients, we identified 471 pathology reports for 323 patients and 943 radiology reports for 557 patients. The pathology ARC algorithm had PPV of 0.96, sensitivity of 0.96, and specificity of 0.97. The radiology ARC algorithm had PPV of 0.75, sensitivity of 0.94, and specificity of 0.68.Conclusions:A combined approach of ICD-9 codes and natural language processing of pathology and radiology reports improves HCC case identification in automated data. C1 [Sada, Yvonne; Hou, Jason; Richardson, Peter; El-Serag, Hashem; Davila, Jessica] Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA. [Sada, Yvonne; Hou, Jason; Richardson, Peter; El-Serag, Hashem; Davila, Jessica] Baylor Coll Med, Houston, TX 77030 USA. [Sada, Yvonne; Hou, Jason; Richardson, Peter; El-Serag, Hashem; Davila, Jessica] Baylor Coll Med, Hlth Serv Res & Dev Sect, Houston, TX 77030 USA. [Sada, Yvonne] Baylor Coll Med, Dept Oncol, Houston, TX 77030 USA. [Hou, Jason; El-Serag, Hashem] Baylor Coll Med, Dept Gastroenterol, Houston, TX 77030 USA. RP Sada, Y (reprint author), Michael E DeBakey Vet Adm Med Ctr, HSR&D Ctr Excellence 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM yhlam@bcm.edu FU National Cancer Institute [R01 CA160738]; Michael E. DeBakey Veterans Affairs Medical Center; Dan Duncan Cancer Center, Houston, TX FX Supported in part by the National Cancer Institute (R01 CA160738, PI: J.D.), the facilities and resources of the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020), Michael E. DeBakey Veterans Affairs Medical Center, and the Dan Duncan Cancer Center, Houston, TX. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veteran Affairs. NR 14 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD FEB PY 2016 VL 54 IS 2 BP E9 EP E14 DI 10.1097/MLR.0b013e3182a30373 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DH6XJ UT WOS:000372935100001 PM 23929403 ER PT J AU Fouts, DE Matthias, MA Adhikarla, H Adler, B Amorim-Santos, L Berg, DE Bulach, D Buschiazzo, A Chang, YF Galloway, RL Haake, DA Haft, DH Hartskeerl, R Ko, AI Levett, PN Matsunaga, J Mechaly, AE Monk, JM Nascimento, ALT Nelson, KE Palsson, B Peacock, SJ Picardeau, M Ricaldi, JN Thaipandungpanit, J Wunder, EA Yang, XF Zhang, JJ Vinetz, JM AF Fouts, Derrick E. Matthias, Michael A. Adhikarla, Haritha Adler, Ben Amorim-Santos, Luciane Berg, Douglas E. Bulach, Dieter Buschiazzo, Alejandro Chang, Yung-Fu Galloway, Renee L. Haake, David A. Haft, Daniel H. Hartskeerl, Rudy Ko, Albert I. Levett, Paul N. Matsunaga, James Mechaly, Ariel E. Monk, Jonathan M. Nascimento, Ana L. T. Nelson, Karen E. Palsson, Bernhard Peacock, Sharon J. Picardeau, Mathieu Ricaldi, Jessica N. Thaipandungpanit, Janjira Wunder, Elsio A., Jr. Yang, X. Frank Zhang, Jun-Jie Vinetz, Joseph M. TI What Makes a Bacterial Species Pathogenic?: Comparative Genomic Analysis of the Genus Leptospira SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID COMPLEMENT REGULATOR C4BP; FAINEI SEROVAR HURSTBRIDGE; VIRULENCE-ASSOCIATED GENES; OUTER-MEMBRANE PROTEINS; LPS BIOSYNTHETIC LOCI; DNA-DNA HYBRIDIZATION; SIGNAL PEPTIDASE-II; L-GLUTAMATE OXIDASE; ESCHERICHIA-COLI; BORRELIA-BURGDORFERI AB Leptospirosis, caused by spirochetes of the genus Leptospira, is a globally widespread, neglected and emerging zoonotic disease. While whole genome analysis of individual pathogenic, intermediately pathogenic and saprophytic Leptospira species has been reported, comprehensive cross-species genomic comparison of all known species of infectious and non-infectious Leptospira, with the goal of identifying genes related to pathogenesis and mammalian host adaptation, remains a key gap in the field. Infectious Leptospira, comprised of pathogenic and intermediately pathogenic Leptospira, evolutionarily diverged from non-infectious, saprophytic Leptospira, as demonstrated by the following computational biology analyses: 1) the definitive taxonomy and evolutionary relatedness among all known Leptospira species; 2) genomically-predicted metabolic reconstructions that indicate novel adaptation of infectious Leptospira to mammals, including sialic acid biosynthesis, pathogen-specific porphyrin metabolism and the first-time demonstration of cobalamin (B12) autotrophy as a bacterial virulence factor; 3) CRISPR/Cas systems demonstrated only to be present in pathogenic Leptospira, suggesting a potential mechanism for this clade's refractoriness to gene targeting; 4) finding Leptospira pathogen-specific specialized protein secretion systems; 5) novel virulence-related genes/gene families such as the Virulence Modifying (VM) (PF07598 paralogs) proteins and pathogen-specific adhesins; 6) discovery of novel, pathogen-specific protein modification and secretion mechanisms including unique lipoprotein signal peptide motifs, Sec-independent twin arginine protein secretion motifs, and the absence of certain canonical signal recognition particle proteins from all Leptospira; and 7) and demonstration of infectious Leptospira-specific signal-responsive gene expression, motility and chemotaxis systems. By identifying large scale changes in infectious (pathogenic and intermediately pathogenic) vs. non-infectious Leptospira, this work provides new insights into the evolution of a genus of bacterial pathogens. This work will be a comprehensive roadmap for understanding leptospirosis pathogenesis. More generally, it provides new insights into mechanisms by which bacterial pathogens adapt to mammalian hosts. C1 [Fouts, Derrick E.; Haft, Daniel H.; Nelson, Karen E.] J Craig Venter Inst, Rockville, MD USA. [Matthias, Michael A.; Berg, Douglas E.; Vinetz, Joseph M.] Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Med, La Jolla, CA 92093 USA. [Adhikarla, Haritha; Amorim-Santos, Luciane; Ko, Albert I.; Wunder, Elsio A., Jr.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Adler, Ben] Monash Univ, Dept Microbiol, Australian Res Council, Ctr Excellence Struct & Funct Microbial Gen, Clayton, Vic 3168, Australia. [Amorim-Santos, Luciane; Ko, Albert I.; Wunder, Elsio A., Jr.] Fundacao Oswaldo Cruz MS, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil. [Bulach, Dieter] Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic, Australia. [Buschiazzo, Alejandro; Mechaly, Ariel E.] Inst Pasteur, Lab Mol & Struct Microbiol, Montevideo, Uruguay. [Buschiazzo, Alejandro] Inst Pasteur, Dept Struct Biol & Chem, Paris, France. [Chang, Yung-Fu] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY 14853 USA. [Galloway, Renee L.] Ctr Dis Control & Prevent, BSPB, DHCPP, NCEZID,OID,CDC,DHHS, Atlanta, GA USA. [Haake, David A.; Matsunaga, James] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Haake, David A.; Matsunaga, James] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hartskeerl, Rudy] Royal Trop Inst KIT, WHO FAO OIE, Amsterdam, Netherlands. [Hartskeerl, Rudy] Royal Trop Inst KIT, Natl Collaborating Ctr Reference & Res Leptospiro, KIT Biomed Res, Amsterdam, Netherlands. [Levett, Paul N.] Govt Saskatchewan, Dis Control Lab Regina, Saskatoon, SK, Canada. [Monk, Jonathan M.; Palsson, Bernhard] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA. [Nascimento, Ana L. T.] Inst Butantan, Ctr Biotecnol, Sao Paulo, SP, Brazil. [Nascimento, Ana L. T.] Univ Sao Paulo, Programa Interunidades Biotecnol, Inst Ciencias Biomed, Sao Paulo, SP, Brazil. [Peacock, Sharon J.] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England. [Picardeau, Mathieu] Inst Pasteur, Biol Spirochetes Unit, Natl Reference Ctr, Paris, France. [Picardeau, Mathieu] WHO Collaborating Ctr Leptospirosis, Paris, France. [Ricaldi, Jessica N.; Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Fac Med Alberto Hurtado, Lima, Peru. [Thaipandungpanit, Janjira] Mahidol Univ, Fac Trop Med, Bangkok, Thailand. [Yang, X. Frank; Zhang, Jun-Jie] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA. [Vinetz, Joseph M.] Univ Peruana Cayetano Heredia, Inst Med Alexander von Humboldt, Lima, Peru. RP Fouts, DE (reprint author), J Craig Venter Inst, Rockville, MD USA.; Fouts, DE; Vinetz, JM (reprint author), Univ Calif San Diego, Sch Med, Div Infect Dis, Dept Med, La Jolla, CA 92093 USA.; Vinetz, JM (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Fac Med Alberto Hurtado, Lima, Peru.; Vinetz, JM (reprint author), Univ Peruana Cayetano Heredia, Inst Med Alexander von Humboldt, Lima, Peru. EM dfouts@jcvi.org; jvinetz@ucsd.edu RI Ko, Albert/P-2343-2015; Wunder, Elsio/C-2733-2013; zhang, junjie/P-2376-2015 OI Ko, Albert/0000-0001-9023-2339; zhang, junjie/0000-0002-5108-2072; Nascimento, Ana Lucia /0000-0003-4851-0870; Mechaly, Ariel/0000-0002-5305-7495 FU federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200900007C]; U.S. Public Health Service [U19AI115658, R01AI108276, D43TW007120, K24AI068903, R21AI115273, R01AI052473, R25TW009338, U01AI088752, R01TW009504, R01AI121207]; ANII (Uruguay) [FSA_1_2013_1_12557, ALI_1_2014_1_4982] FX This project has been funded in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Contract Number HHSN272200900007C. This work was also supported in part by the following U.S. Public Health Service grants: U19AI115658 (JMV), R01AI108276 (JMV), D43TW007120 (JMV), K24AI068903 (JMV), R21AI115273 (MAM), R01AI052473 (AIK), U01AI088752 (AIK), R25TW009338 (AIK), R01TW009504 (AIK), and R01AI121207 (AIK). In addition, support to the A. Buschiazzo team was provided in part by grants FSA_1_2013_1_12557 and ALI_1_2014_1_4982 from ANII (Uruguay). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 214 TC 13 Z9 13 U1 8 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2016 VL 10 IS 2 AR e0004403 DI 10.1371/journal.pntd.0004403 PG 57 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA DH1TH UT WOS:000372567300024 PM 26890609 ER PT J AU Aghagolzadeh, M Truccolo, W AF Aghagolzadeh, Mehdi Truccolo, Wilson TI Inference and Decoding of Motor Cortex Low-Dimensional Dynamics via Latent State-Space Models SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Brain-machine interfaces (BMI); collective dynamics; neural encoding; point processes ID NEURAL POPULATION-DYNAMICS; GRASP; REACH; VARIABILITY AB Motor cortex neuronal ensemble spiking activity exhibits strong low-dimensional collective dynamics (i.e., coordinated modes of activity) during behavior. Here, we demonstrate that these low-dimensional dynamics, revealed by unsupervised latent state-space models, can provide as accurate or better reconstruction of movement kinematics as direct decoding from the entire recorded ensemble. Ensembles of single neurons were recorded with triple microelectrode arrays (MEAs) implanted in ventral and dorsal premotor (PMv, PMd) and primary motor (M1) cortices while nonhuman primates performed 3-D reach-to-grasp actions. Low-dimensional dynamics were estimated via various types of latent state-space models including, for example, Poisson linear dynamic system (PLDS) models. Decoding from low-dimensional dynamics was implemented via point process and Kalman filters coupled in series. We also examined decoding based on a predictive subsampling of the recorded population. In this case, a supervised greedy procedure selected neuronal subsets that optimized decoding performance. When comparing decoding based on predictive subsampling and latent state-space models, the size of the neuronal subset was set to the same number of latent state dimensions. Overall, our findings suggest that information about naturalistic reach kinematics present in the recorded population is preserved in the inferred low-dimensional motor cortex dynamics. Furthermore, decoding based on unsupervised PLDS models may also outperform previous approaches based on direct decoding from the recorded population or on predictive subsampling. C1 [Aghagolzadeh, Mehdi; Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA. [Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02912 USA. RP Aghagolzadeh, M; Truccolo, W (reprint author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.; Truccolo, W (reprint author), Brown Univ, Inst Brain Sci, Providence, RI 02912 USA.; Truccolo, W (reprint author), US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI 02912 USA. EM Mehdi_Aghagolzadeh@Brown.edu; Wilson_Truccolo@Brown.edu FU National Institute of Neurological Disorders and Stroke (NINDS) [NS057389, R01 NS25074]; Defense Advanced Research Projects Agency [DARPA REPAIR N66001-10-C-2010]; Pablo J. Salame'88 Goldman Sachs endowed Assistant Professorship in Computational Neuroscience FX This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS), K01 Career Award NS057389 and R01 NS25074, by the Defense Advanced Research Projects Agency (DARPA REPAIR N66001-10-C-2010), and by the Pablo J. Salame'88 Goldman Sachs endowed Assistant Professorship in Computational Neuroscience. NR 28 TC 4 Z9 4 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 EI 1558-0210 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD FEB PY 2016 VL 24 IS 2 BP 272 EP 282 DI 10.1109/TNSRE.2015.2470527 PG 11 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA DG4FP UT WOS:000372027300008 PM 26336135 ER PT J AU Schoenfeld, AJ Grady, D AF Schoenfeld, Adam Jacob Grady, Deborah TI Adverse Effects Associated With Proton Pump Inhibitors SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID METAANALYSIS; IMPACT; RISK C1 [Schoenfeld, Adam Jacob; Grady, Deborah] Univ Calif San Francisco, 3333 Calif St,Ste 265,POB 0936, San Francisco, CA 94118 USA. [Grady, Deborah] San Francisco VA Med Ctr, Med, San Francisco, CA USA. RP Schoenfeld, AJ (reprint author), Univ Calif San Francisco, 3333 Calif St,Ste 265,POB 0936, San Francisco, CA 94118 USA. EM Adam.Schoenfeld@ucsf.edu NR 12 TC 13 Z9 14 U1 4 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 172 EP 174 DI 10.1001/jamainternmed.2015.7927 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600007 PM 26751904 ER PT J AU Wong, SPY Vig, EK Taylor, JS Burrows, NR Liu, CF Williams, DE Hebert, PL O'Hare, AM AF Wong, Susan P. Y. Vig, Elizabeth K. Taylor, Janelle S. Burrows, Nilka R. Liu, Chuan-Fen Williams, Desmond E. Hebert, Paul L. O'Hare, Ann M. TI Timing of Initiation of Maintenance Dialysis A Qualitative Analysis of the Electronic Medical Records of a National Cohort of Patients From the Department of Veterans Affairs SO JAMA INTERNAL MEDICINE LA English DT Article ID DECISION-MAKING; HEALTH-CARE; KIDNEY-DISEASE; SURVIVAL; COMORBIDITY; MORTALITY; HARMFUL; TRENDS; START; AGE AB IMPORTANCE There is often considerable uncertainty about the optimal time to initiate maintenance dialysis in individual patients and little medical evidence to guide this decision. OBJECTIVE To gain a better understanding of the factors influencing the timing of initiation of dialysis in clinical practice. DESIGN, SETTING, AND PARTICIPANTS A qualitative analysis was conducted using the electronic medical records from the Department of Veterans Affairs (VA) of a national random sample of 1691 patients for whom the decision to initiate maintenance dialysis occurred in the VA between January 1, 2000, and December 31, 2009. Data analysis took place from June 1 to November 30, 2014. MAIN OUTCOMES AND MEASURES Central themes related to the timing of initiation of dialysis as documented in patients' electronic medical records. RESULTS Of the 1691 patients, 1264 (74.7%) initiated dialysis as inpatients and 1228 (72.6%) initiated dialysis with a hemodialysis catheter. Cohort members met with a nephrologist during an outpatient clinic visit a median of 3 times (interquartile range, 0-6) in the year prior to initiation of dialysis. The mean (SD) estimated glomerular filtration rate at the time of initiation for cohort members was 10.4 (5.7) mL/min/1.73m(2). The timing of initiation of dialysis reflected the complex interplay of at least 3 interrelated and dynamic processes. The first was physician practices, which ranged from practices intended to prepare patients for dialysis to those intended to forestall the need for dialysis by managing the signs and symptoms of uremia with medical interventions. The second process was sources of momentum. Initiation of dialysis was often precipitated by clinical events involving acute illness or medical procedures. In these settings, the imperative to treat often seemed to override patient choice. The third process was patient-physician dynamics. Interactions between patients and physicians were sometimes adversarial, and physician recommendations to initiate dialysis sometimes seemed to conflict with patient priorities. CONCLUSIONS AND RELEVANCE The initiation of maintenance dialysis reflects the care practices of individual physicians, sources of momentum for initiation of dialysis, interactions between patients and physicians, and the complex interplay of these dynamic processes over time. Our findings suggest opportunities to improve communication between patients and physicians and to better align these processes with patients' values, goals, and preferences. C1 [Wong, Susan P. Y.; Vig, Elizabeth K.; O'Hare, Ann M.] Univ Washington, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. [Vig, Elizabeth K.; O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Dept Med, Seattle, WA USA. [Taylor, Janelle S.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [Burrows, Nilka R.] Ctr Dis Control & Prevent, Chron Kidney Dis Initiat, Div Diabet Translat, Atlanta, GA USA. [Liu, Chuan-Fen; Hebert, Paul L.] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Innovat, Washington, DC USA. [Liu, Chuan-Fen; Hebert, Paul L.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Williams, Desmond E.] Ctr Dis Control & Prevent, Liberia Country Off, Div Global Hlth Protect, Atlanta, GA USA. RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,POB 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU United States Department of Veterans Affairs [VA IIR 09-094]; VA Puget Sound Healthcare System [IAA 15FED1505101-0001]; Centers for Disease Control and Prevention [IAA 15FED1505101-0001]; Clinical Scientist in Nephrology Fellowship from the American Kidney Fund; Department of Veterans Affairs Health Services Research and Development Service; National Institutes of Health FX This study was supported by grant VA IIR 09-094 from the United States Department of Veterans Affairs and by Interagency Agreement IAA 15FED1505101-0001 between the VA Puget Sound Healthcare System and the Centers for Disease Control and Prevention. Dr Wong is supported by the Clinical Scientist in Nephrology Fellowship from the American Kidney Fund. Drs O'Hare, Hebert, and Liu reported having received research funding from the Department of Veterans Affairs Health Services Research and Development Service. Dr O'Hare also reported having received research funding from the National Institutes of Health and an honorarium from the American Society of Nephrology. NR 36 TC 9 Z9 9 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 228 EP 235 DI 10.1001/jamainternmed.2015.7412 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600017 PM 26809745 ER PT J AU Good, CB McConnell, M Downs, JR AF Good, Chester B. McConnell, Mark Downs, John R. TI Finding the Balance of Less Is More SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Good, Chester B.] Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Med, Pittsburgh, PA USA. [McConnell, Mark] Oscar G Johnson Vet Affairs Med Clin, Primary Care, Iron Mt, MI USA. [Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Med, San Antonio, TX 78229 USA. RP Good, CB (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Med, Univ Dr C, Pittsburgh, PA 15240 USA. EM chester.good@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD FEB PY 2016 VL 176 IS 2 BP 282 EP 283 DI 10.1001/jamainternmed.2015.8089 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA DD0RR UT WOS:000369627600045 PM 26830244 ER PT J AU Harris, JP Struzyna, LA Murphy, PL Adewole, DO Kuo, E Cullen, DK AF Harris, J. P. Struzyna, L. A. Murphy, P. L. Adewole, D. O. Kuo, E. Cullen, D. K. TI Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain SO JOURNAL OF NEURAL ENGINEERING LA English DT Article DE neurotransplantation; transplantation; bioengineering; cell replacement; axonal tracts; tissue engineering; biomaterials ID LONG-TERM SURVIVAL; STEM-CELL TRANSPLANTATION; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; IN-VITRO; CARBOXYMETHYL CELLULOSE; FUNCTIONAL RECOVERY; PARKINSONS-DISEASE; CHONDROITINASE ABC; NEURITE OUTGROWTH AB Objective. Connectome disruption is a hallmark of many neurological diseases and trauma with no current strategies to restore lost long-distance axonal pathways in the brain. We are creating transplantable micro-tissue engineered neural networks (micro-TENNs), which are preformed constructs consisting of embedded neurons and long axonal tracts to integrate with the nervous system to physically reconstitute lost axonal pathways. Approach. We advanced micro-tissue engineering techniques to generate micro-TENNs consisting of discrete populations of mature primary cerebral cortical neurons spanned by long axonal fascicles encased in miniature hydrogel micro-columns. Further, we improved the biomaterial encasement scheme by adding a thin layer of low viscosity carboxymethylcellulose (CMC) to enable needle-less insertion and rapid softening for mechanical similarity with brain tissue. Main results. The engineered architecture of cortical micro-TENNs facilitated robust neuronal viability and axonal cytoarchitecture to at least 22 days in vitro. Micro-TENNs displayed discrete neuronal populations spanned by long axonal fasciculation throughout the core, thus mimicking the general systems-level anatomy of gray matter-white matter in the brain. Additionally, micro-columns with thin CMC-coating upon mild dehydration were able to withstand a force of 893 +/- 457 mN before buckling, whereas a solid agarose cylinder of similar dimensions was predicted to withstand less than 150 mu N of force. This thin CMC coating increased the stiffness by three orders of magnitude, enabling needle-less insertion into brain while significantly reducing the footprint of previous needle-based delivery methods to minimize insertion trauma. Significance. Our novel micro-TENNs are the first strategy designed for minimally invasive implantation to facilitate nervous system repair by simultaneously providing neuronal replacement and physical reconstruction of long-distance axon pathways in the brain. The micro-TENN approach may offer the ability to treat several disorders that disrupt the connectome, including Parkinson's disease, traumatic brain injury, stroke, and brain tumor excision. C1 [Harris, J. P.; Struzyna, L. A.; Murphy, P. L.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA. [Harris, J. P.; Struzyna, L. A.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Struzyna, L. A.; Adewole, D. O.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. RP Cullen, DK (reprint author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.; Cullen, DK (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM dkacy@mail.med.upenn.edu FU Penn Medicine Neuroscience Center; National Science Foundation [DGE-1321851]; National Institutes of Health [T32-NS043126, T32-GM007517]; Department of Veterans Affairs (RRD Merit Review) [B1097-I]; US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-207 004] FX Financial support was provided by the Penn Medicine Neuroscience Center, National Science Foundation (Graduate Research Fellowship DGE-1321851), National Institutes of Health (T32-NS043126 & T32-GM007517), Department of Veterans Affairs (RR&D Merit Review #B1097-I), and the US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-207 004). The authors would like to thank Rob Mauck and Mike Hast in the Penn Center for Musculoskeletal Disorders Core for help in mechanical testing. Additional thanks go to Vincent Wu, Norma Alexis Brown, Alan He, Camila Robles-Oteiza, and Parker Schabel for technical contributions. NR 83 TC 2 Z9 3 U1 5 U2 24 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 EI 1741-2552 J9 J NEURAL ENG JI J. Neural Eng. PD FEB PY 2016 VL 13 IS 1 AR 016019 DI 10.1088/1741-2560/13/1/016019 PG 19 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA DF7XD UT WOS:000371570200020 PM 26760138 ER PT J AU Ly, M Adluru, N Destiche, DJ Lu, SY Oh, JM Hoscheidt, SM Alexander, AL Okonkwo, OC Rowley, HA Sager, MA Johnson, SC Bendlin, BB AF Ly, Martina Adluru, Nagesh Destiche, Daniel J. Lu, Sharon Y. Oh, Jennifer M. Hoscheidt, Siobhan M. Alexander, Andrew L. Okonkwo, Ozioma C. Rowley, Howard A. Sager, Mark A. Johnson, Sterling C. Bendlin, Barbara B. TI Fornix Microstructure and Memory Performance Is Associated with Altered Neural Connectivity during Episodic Recognition SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Aging; Task-related functional connectivity; fMRI; gPPI; Fractional anisotropy; Episodic recognition ID WHITE-MATTER MICROSTRUCTURE; AGE-RELATED DIFFERENCES; ALZHEIMERS-DISEASE; FUNCTIONAL CONNECTIVITY; ENTORHINAL CORTEX; WORKING-MEMORY; OLDER-ADULTS; PREFRONTAL CORTEX; COGNITIVE DECLINE; BRAIN ACTIVITY AB Objectives: The purpose of this study was to assess whether age-related differences in white matter microstructure are associated with altered task-related connectivity during episodic recognition. Methods: Using functional magnetic resonance imaging and diffusion tensor imaging from 282 cognitively healthy middle-to-late aged adults enrolled in the Wisconsin Registry for Alzheimer's Prevention, we investigated whether fractional anisotropy (FA) within white matter regions known to decline with age was associated with task-related connectivity within the recognition network. Results: There was a positive relationship between fornix FA and memory performance, both of which negatively correlated with age. Psychophysiological interaction analyses revealed that higher fornix FA was associated with increased task-related connectivity amongst the hippocampus, caudate, precuneus, middle occipital gyrus, and middle frontal gyrus. In addition, better task performance was associated with increased task-related connectivity between the posterior cingulate gyrus, middle frontal gyrus, cuneus, and hippocampus. Conclusions: The findings indicate that age has a negative effect on white matter microstructure, which in turn has a negative impact on memory performance. However, fornix microstructure did not significantly mediate the effect of age on performance. Of interest, dynamic functional connectivity was associated with better memory performance. The results of the psychophysiological interaction analysis further revealed that alterations in fornix microstructure explain-at least in part-connectivity among cortical regions in the recognition memory network. Our results may further elucidate the relationship between structural connectivity, neural function, and cognition. C1 [Ly, Martina; Oh, Jennifer M.; Hoscheidt, Siobhan M.; Okonkwo, Ozioma C.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Ly, Martina; Oh, Jennifer M.; Hoscheidt, Siobhan M.; Okonkwo, Ozioma C.; Rowley, Howard A.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53792 USA. [Ly, Martina; Hoscheidt, Siobhan M.; Okonkwo, Ozioma C.; Sager, Mark A.; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI 53792 USA. [Ly, Martina] Univ Wisconsin, Neurosci Training Program, Madison, WI 53792 USA. [Ly, Martina; Adluru, Nagesh; Destiche, Daniel J.; Lu, Sharon Y.; Alexander, Andrew L.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Psychiat, Madison, WI 53792 USA. [Alexander, Andrew L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, Madison, WI 53792 USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Alzheimers Dis Res Ctr, Madison, WI 53792 USA.; Bendlin, BB (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu FU National Institutes of Health [R01 AG037639, R01 AG027161, ADRC P50 AG033514, R01 AG021155, T32 GM007507, T32 AG000213]; Veterans Administration Merit Review Grant [I01CX000165]; Waisman Center Core Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [P30 HD003352-45] FX This work was supported by the National Institutes of Health (B.B.B., R01 AG037639), (S.C.J., R01 AG027161), (ADRC P50 AG033514), (S.C.J., R01 AG021155), (T32 GM007507), (T32 AG000213); Veterans Administration Merit Review Grant (S.C.J., I01CX000165); and the Waisman Center Core Grant (P30 HD003352-45) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The project was also facilitated by the facilities and resources at the Geriatric Research, Education, and Clinical Center (GRECC) of the William S. Middleton Memorial Veterans Hospital, Madison, WI. The authors gratefully acknowledge Nancy Davenport, Amy Hawley, Sandra Harding, Caitlin Cleary, Jay Fruehling, Chuck Illingworth, and the support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where imaging data were collected. Above all, we thank our dedicated volunteers for their participation in this research. Ly, Adluru, Destiche, Lu, Oh, Hoscheidt, Okonkwo, Sager, Johnson, and Bendlin report no conflicts of interest. Rowley has provided consultation to and/or received honoraria from GE Healthcare, Bracco, Lundbeck, HL Gore, and Eli Lilly. Alexander is part owner and Chief Operating Officer of inSERT, Inc. NR 89 TC 0 Z9 0 U1 0 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD FEB PY 2016 VL 22 IS 2 SI SI BP 191 EP 204 DI 10.1017/S1355617715001216 PG 14 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA DF8TE UT WOS:000371631200007 PM 26888616 ER PT J AU Hugos, CL Chen, YY Chen, ZQ Turner, A Haselkorn, JK Chiara, T McCoy, SC Bever, C Bourdette, D AF Hugos, Cinda L. Chen, Yiyi Chen, Zunqiu Turner, Aaron Haselkorn, Jodie K. Chiara, Toni McCoy, Sean C. Bever, Christopher Bourdette, Dennis TI A multicenter randomized controlled trial in people with multiple sclerosis comparing the effects of two group programs on fatigue and self-efficacy SO MULTIPLE SCLEROSIS JOURNAL LA English DT Meeting Abstract CT ACTRIMS Forum CY FEB 18-20, 2016 CL New Orleans, LA SP ACTRIMS C1 [Hugos, Cinda L.; Bourdette, Dennis] VA Portland Hlth Care Syst, Portland, OR USA. [Chen, Yiyi; Chen, Zunqiu] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Chen, Zunqiu; Turner, Aaron; Haselkorn, Jodie K.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Chiara, Toni; McCoy, Sean C.] North Florida South Georgia Vet Hlth Syst, Gainesville, FL USA. [Bever, Christopher] VA Maryland Hlth Care Syst, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD FEB PY 2016 VL 22 SU 1 MA P065 BP 33 EP 34 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DF9CE UT WOS:000371657100077 ER PT J AU Durazzo, TC Mattsson, N Weiner, MW AF Durazzo, Timothy C. Mattsson, Niklas Weiner, Michael W. CA Alzheimer's Dis Neuroimaging TI Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; PROCESSING-SPEED; RISK-FACTORS; IMPAIRMENT; DEMENTIA; BIOMARKERS; BETA AB Introduction: Chronic cigarette smoking is associated with increased risk for Alzheimer's disease (AD). The goal of this study was to determine if smoking history moderated the associations of age and APOE genotype (the most robust risk factors for AD) on brain amyloid deposition, glucose metabolism, and neurocognition in cognitively-normal elders. Methods: Participants (n = 264) were grouped according to their APOE epsilon 4 carrier status (epsilon 4 carrier: APOE4+; non-epsilon 4 carrier: APOE4-) and smoking status (smokers: at least 1 year of smoking during lifetime; never-smokers: no history of smoking). Approximately 89% of the smoking sample was former-smokers. We specifically tested for interactions of smoking status with APOE epsilon 4 carrier status and age on measures of cortical amyloid deposition, glucose metabolism, and neurocognition. Results: (1) smoking status interacted with APOE epsilon 4 carrier status, where smoker APOE4+ showed lower glucose metabolism and poorer auditory-verbal learning and memory than never-smoking APOE4-, never-smoking APOE4+, and smoking APOE4-; (2) smoking status interacted with age on measures of semantic fluency, processing speed/set-shifting and global neurocognition; smokers, irrespective of APOE epsilon 4 carrier status, demonstrated poorer performance with increasing age than never-smokers; and (3) smoking APOE4+ and never-smoking APOE4+ showed greater cortical amyloid deposition than never-smoking APOE4-and smoking APOE4-. Conclusions: The findings indicate consideration of smoking history is essential to both better understand the factors associated with neurobiological and neurocognitive abnormalities in elders, and the risk for development of AD-related neuropathology. C1 [Durazzo, Timothy C.; Mattsson, Niklas; Weiner, Michael W.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Durazzo, Timothy C.; Mattsson, Niklas; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Mattsson, Niklas] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu OI Preda, Adrian /0000-0003-3373-2438 FU National Institutes of Health [NIH DA24136]; National Institute on Aging [U01 AG024904]; National Institute of Biomedical Imaging and Bioengineering; NIH [P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435]; Dana Foundation FX The study sponsors had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. This work was supported by the National Institutes of Health (NIH DA24136 to TCD) and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. All data collection and sharing for this project was supported by ADNI. ADNI is funded by the National Institute on Aging (U01 AG024904 to MWW), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co, Medpace, Inc, Merck and Co, Inc, Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc, and Wyeth, as well as nonprofit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University Southern California. This research was also supported by NIH grants P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435, and The Dana Foundation. The above funding agencies had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript. Original data used in preparation of this article were obtained from the ADNI database (www.loni.usc.edu/ADNI). As such, the investigators within ADNI contributed to the design and implementation of ADNI and/or provided data, but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Authorship _List.pdf. NR 51 TC 4 Z9 4 U1 2 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2016 VL 18 IS 2 BP 204 EP 211 DI 10.1093/ntr/ntv075 PG 8 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA DE0FV UT WOS:000370301200013 PM 25847292 ER PT J AU Belalcazar, LM Papandonatos, GD Erar, B Peter, I Alkofide, H Balasubramanyam, A Brautbar, A Kahn, SE Knowler, WC Ballantyne, CM McCaffery, JM Huggins, GS AF Belalcazar, L. Maria Papandonatos, George D. Erar, Bahar Peter, Inga Alkofide, Hadeel Balasubramanyam, Ashok Brautbar, Ariel Kahn, Steven E. Knowler, William C. Ballantyne, Christie M. McCaffery, Jeanne M. Huggins, Gordon S. CA Look AHEAD Study TI Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE lifestyle; GCKR; behavioral intervention; triglycerides; C-reactive protein; obesity; diabetes mellitus ID C-REACTIVE PROTEIN; FASTING PLASMA-GLUCOSE; TYPE-2 DIABETES RISK; CARDIOVASCULAR-DISEASE; TRIGLYCERIDE LEVELS; REDUCING LIPIDS; INDIVIDUALS; HOMEOSTASIS; ASSOCIATION; PREVALENCE AB Background- Glucokinase regulatory protein (GCKR) inhibitors offer a novel treatment approach for glucose control in diabetes mellitus; however, their cardiometabolic effects, particularly in relation to increased triglycerides and C-reactive protein (CRP) levels, are of concern. GCKR Leu446Pro is a common variant associated with reduced GCKR function, increased triglycerides, and CRP. Methods and Results- We investigated whether a 1-year intensive lifestyle intervention (ILI) for weight loss would avert the unfavorable cardiometabolic effects associated with GCKR Leu446Pro when compared with a diabetes mellitus support and education arm in overweight/obese individuals with type 2 diabetes mellitus with triglyceride (n=3214) and CRP (n=1411) data participating in a randomized lifestyle intervention study for weight loss, Action for Health in Diabetes Mellitus (Look AHEAD). Once demographics, medication use and baseline adiposity, and fitness were accounted for, ILI did not modify the baseline association of GCKR-Leu446Pro with elevated triglycerides (beta +/- SE=0.067 +/- 0.013, P=1.5x10(-7) and beta +/- SE=0.052 +/- 0.015, P=5x10(-4)) or with elevated CRP (beta +/- SE=0.136 +/- 0.034, P=5.1x10(-5)and beta +/- SE=0.903 +/- 0.038, P=0.015) in the overall sample and Non-Hispanic Whites, respectively. The lack of a protective effect from ILI at 1 year when compared with diabetes mellitus support and education (ILI versus diabetes mellitus support and education interaction for triglyceride and CRP change, respectively: P=0.64 and 0.37 in the overall sample; P=0.27 and 0.05 in Non-Hispanic Whites) persisted after additional adjustment for changes in adiposity and fitness. Conclusions- Moderate improvements in adiposity and fitness with ILI did not mitigate the adverse cardiometabolic effects of GCKR inhibition in overweight/obese individuals with diabetes mellitus. C1 [Belalcazar, L. Maria; Ballantyne, Christie M.] Univ Texas Med Branch, Dept Internal Med, Div Endocrinol & Metab, Galveston, TX 77555 USA. [Papandonatos, George D.; Erar, Bahar] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA. [Peter, Inga] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Alkofide, Hadeel] Tufts Univ, Sackler Sch Biomed Res, Clin Translat Sci Program, Boston, MA 02111 USA. [Balasubramanyam, Ashok] Baylor Coll Med, Div Endocrinol Diabet & Metab, Diabet Res Ctr, Translat Metab Unit, Houston, TX 77030 USA. [Brautbar, Ariel] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, Phoenix, AZ USA. [Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA. [McCaffery, Jeanne M.] Miriam Hosp, Dept Psychiat & Human Behav, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA. [McCaffery, Jeanne M.] Brown Med Sch, Providence, RI USA. [Huggins, Gordon S.] Tufts Med Ctr, Ctr Translat Genom, Mol Cardiol Res Inst, Boston, MA 02111 USA. [Huggins, Gordon S.] Tufts Univ, Boston, MA 02111 USA. RP Huggins, GS (reprint author), Tufts Med Ctr, MCRI Ctr Translat Genom, Boston, MA 02111 USA.; Huggins, GS (reprint author), Tufts Univ, Sch Med, Boston, MA 02111 USA. EM ghuggins@tuftsmedicalcenter.org OI Papandonatos, George/0000-0001-6770-932X; Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services from the National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; National Institutes of Health (NIH) Office of Research on Women's Health; Centers for Disease Control and Prevention; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center [M01RR000056 44]; NIH [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center [M01RR01346]; [DK090043-02]; [X01 HG006659]; [HL09051401] FX This study was funded by DK090043-02 and X01 HG006659 (Drs Papandonatos, McCaffery, Huggins) and HL09051401 (Drs Belalcazar and Ballantyne). Look AHEAD was supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; National Institutes of Health (NIH) Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the IHS or other funding sources. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (M01RR000056 44) and NIH grant (DK 046204); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346). The following organizations have committed to make major contributions to Look AHEAD: Federal Express; Health Management Resources; Johnson & Johnson, LifeScan Inc; Optifast-Novartis Nutrition; Roche Pharmaceuticals; Ross Product Division of Abbott Laboratories; Slim-Fast Foods Company; and Unilever. NR 32 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1942-325X EI 1942-3268 J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2016 VL 9 IS 1 BP 71 EP 78 DI 10.1161/CIRCGENETICS.115.001192 PG 8 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA DF0FI UT WOS:000371014100010 PM 26578543 ER PT J AU Bansal, N Simmons, KD Epstein, AJ Morris, JB Kelz, RR AF Bansal, Neha Simmons, Kristina D. Epstein, Andrew J. Morris, Jon B. Kelz, Rachel R. TI Using Patient Outcomes to Evaluate General Surgery Residency Program Performance SO JAMA SURGERY LA English DT Article ID QUALITY-OF-CARE; TRAINING-PROGRAMS; COST-EFFECTIVENESS; MORTALITY-RATES; FAILURE; RESCUE; STAY AB IMPORTANCE To evaluate and financially reward general surgery residency programs based on performance, performance must first be defined and measureable. OBJECTIVE To assess general surgery residency program performance using the objective clinical outcomes of patients operated on by program graduates. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study was conducted of discharge records from 349 New York and Florida hospitals between January 1, 2008, and December 31, 2011. The records comprised 230 769 patients undergoing 1 of 24 general surgical procedures performed by 454 surgeons from 73 general surgery residency programs. Analysis was conducted from June 4, 2014, to June 16, 2015. MAIN OUTCOMES AND MEASURES In-hospital death; development of 1 or more postoperative complications before discharge; prolonged length of stay, defined as length of stay greater than the 75th percentile when compared with patients undergoing the same procedure type at the same hospital; and failure to rescue, defined as in-hospital death after the development of 1 or more postoperative complications. RESULTS Patients operated on by surgeons trained in residency programs that were ranked in the top tertile were significantly less likely to experience an adverse event than were patients operated on by surgeons trained in residency programs that were ranked in the bottom tertile. Adjusted adverse event rates for patients operated on by surgeons trained in programs that were ranked in the top tertile and those who were operated on by surgeons trained in programs that were ranked in the bottom tertile were, respectively, 0.483% vs 0.476% for death, 9.68% vs 10.79% for complications, 16.76% vs 17.60% for prolonged length of stay, and 2.68% vs 2.98% for failure to rescue (all P < .001). The differences remained significant in procedure-specific subset analyses. The rankings were significantly correlated among some but not all outcome measures. The magnitude of the effect of the residency program on the outcomes achieved by the graduates decreased with increasing years of practice. Within the analyses of surgeons within 20, 10, and 5 years of practice, the relative difference in adjusted adverse event rates across the individual models between the top and bottom tertiles ranged from 1.5% to 12.3%(20 years), 9.1% to 33.8% (10 years), and 8.0% to 44.4%(5 years). CONCLUSIONS AND RELEVANCE Objective data were successfully used to rank the clinical outcomes achieved by graduates of general surgery residency programs. Program rankings differed by the outcome measured. The magnitude of differences across programs was small. Careful consideration must be used when identifying potential targets for payment-for-performance initiatives in graduate medical education. C1 [Bansal, Neha; Epstein, Andrew J.; Morris, Jon B.; Kelz, Rachel R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Bansal, Neha; Simmons, Kristina D.; Morris, Jon B.; Kelz, Rachel R.] Univ Penn Hlth Syst, Dept Surg, Ctr Surg & Hlth Econ, 3400 Spruce St,4 Silverstein Bldg, Philadelphia, PA 19104 USA. [Epstein, Andrew J.; Kelz, Rachel R.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Epstein, Andrew J.] Philadelphia Vet Affairs Med Ctr, Dept Vet Affairs, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Kelz, RR (reprint author), Univ Penn Hlth Syst, Dept Surg, Ctr Surg & Hlth Econ, 3400 Spruce St,4 Silverstein Bldg, Philadelphia, PA 19104 USA. EM rachel.kelz@uphs.upenn.edu NR 33 TC 2 Z9 2 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2016 VL 151 IS 2 BP 111 EP 119 DI 10.1001/jamasurg.2015.3637 PG 9 WC Surgery SC Surgery GA DF4LH UT WOS:000371319200003 PM 26510131 ER PT J AU Sobel, M Tang, GL AF Sobel, Michael Tang, Gale L. TI Inflammation, Endoleaks, and Aortic Remodeling-The Chicken or the Egg SO JAMA SURGERY LA English DT Editorial Material C1 VA Puget Sound Hlth Care Syst, Dept Surg, Div Vasc Surg, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Sobel, M (reprint author), Univ Washington, Div Vasc Surg, Dept Surg, VA Puget Sound Hlth Care Syst, 1660 Columbian Way S, Seattle, WA 98108 USA. EM sobelm@uw.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD FEB PY 2016 VL 151 IS 2 BP 154 EP 154 DI 10.1001/jamasurg.2015.3246 PG 1 WC Surgery SC Surgery GA DF4LH UT WOS:000371319200012 PM 26502236 ER PT J AU Zaman, T Boyd, JW AF Zaman, Tauheed Boyd, J. Wesley TI The Authors Reply to Cannabis Use Disorders and ADHD SO JOURNAL OF ADDICTION MEDICINE LA English DT Letter C1 [Zaman, Tauheed] UCSF, San Francisco VA Med Ctr, Addict & Recovery Treatment Serv, San Francisco, CA USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Ctr Bioeth, Cambridge, MA 02138 USA. RP Boyd, JW (reprint author), Cambridge Hlth Alliance, 26 Cent St, Somerville, MA 02143 USA. EM jwboyd@cha.harvard.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD FEB PY 2016 VL 10 IS 1 BP 70 EP 71 DI 10.1097/ADM.0000000000000185 PG 2 WC Substance Abuse SC Substance Abuse GA DE0CS UT WOS:000370293000013 ER PT J AU Shen, Q Huang, SL Duong, TQ AF Shen, Qiang Huang, Shiliang Duong, Timothy Q. TI T-2*-weighted fMRI time-to-peak of oxygen challenge in ischemic stroke SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE Functional MRI; focal ischemia; perfusion-weighted MRI; diffusion-weighted MRI; BOLD contrast ID PERFUSION MRI; POSTISCHEMIC HYPERPERFUSION; QUANTITATIVE PERFUSION; FUNCTIONAL MRI; TISSUE FATE; DIFFUSION; PENUMBRA; REPERFUSION; RAT; STIMULATION AB T-2*-weighted MRI of transient oxygen challenge (OC) showed exaggerated OC percent changes in the ischemic tissue at risk compared to normal tissue. One ambiguity is that regions with high vascular density also showed exaggerated OC percent changes. This study explored time-to-peak (TTP) of the OC percent changes to improve the utility of T-2*-weighted OC MRI. Experiments were performed longitudinally at 30 min, 150 min and 24 h after transient (60-min) stroke in rats. Ischemic core, normal, and mismatch tissue were classified pixel-by-pixel based on apparent diffusion coefficient and cerebral blood flow. Major findings were: (i) Delayed OC TTP was localized to and corresponded well with the perfusion-diffusion mismatch. (ii) By contrast, the exaggerated OC percent changes were less localized, with changes not only in the at-risk tissue but also in some areas of the contralesional hemisphere with venous vessel origins. (iii) The OC time-course of the mismatch tissue was biphasic, with a faster initial increase followed by a slower increase. (iv) At-risk tissue with delayed TTP and exaggerated OC was normal after reperfusion and the at-risk tissue was mostly (83 +/- 18%) rescued by reperfusion as indicated by normal 24-h T-2. OC TTP offers unique information toward better characterization of at-risk tissue in ischemic stroke. C1 [Shen, Qiang; Huang, Shiliang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Shen, Q; Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM shenq3@uthscsa.edu; duongt@uthscsa.edu FU NIH [R01-NS45879]; American Heart Association [EIA 0940104N, SDG 0830293N, 12BGIA9300047] FX This work was supported by the NIH (grant no. R01-NS45879) and the American Heart Association (grant nos. EIA 0940104N, SDG 0830293N and 12BGIA9300047). NR 24 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2016 VL 36 IS 2 BP 283 EP 291 DI 10.1177/0271678X15606461 PG 9 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA DF4EG UT WOS:000371299800004 PM 26661164 ER PT J AU Gellad, WF AF Gellad, Walid F. TI The Veterans Choice Act and Dual Health System Use SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID CARE C1 [Gellad, Walid F.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr,151C, Pittsburgh, PA 15240 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr,151C, Pittsburgh, PA 15240 USA. EM walid.gellad@va.gov FU HSRD VA [I01 HX001765] NR 3 TC 3 Z9 3 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2016 VL 31 IS 2 BP 153 EP 154 DI 10.1007/s11606-015-3492-2 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA DF2GQ UT WOS:000371161000008 PM 26289922 ER PT J AU Beben, T Ix, JH Shlipak, MG Sarnak, MJ Fried, LF Hoofnagle, AN Chonchol, M Kestenbaum, BR de Boer, IH Rifkin, DE AF Beben, Tomasz Ix, Joachim H. Shlipak, Michael G. Sarnak, Mark J. Fried, Linda F. Hoofnagle, Andrew N. Chonchol, Michel Kestenbaum, Bryan R. de Boer, Ian H. Rifkin, Dena E. TI Fibroblast Growth Factor-23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE fibroblast growth factor 23; frailty; mortality ID LOW VITAMIN-D; OLDER-ADULTS; PARATHYROID-HORMONE; 25-HYDROXYVITAMIN D; MUSCLE STRENGTH; CYSTATIN-C; DISEASE; MEN; INFLAMMATION; ASSOCIATION AB ObjectivesTo evaluate whether fibroblast growth factor 23 (FGF-23) is related to frailty and to characterize the nature of their joint association with mortality. DesignCross-sectional analysis for frailty and longitudinal cohort analysis for mortality. SettingCardiovascular Health Study. ParticipantsCommunity-dwelling individuals (N= 2,977; mean age 77.94.7, 40% male, 83% white). MeasurementsThe predictor was serum FGF-23 concentration (C-terminal enzyme-linked immunosorbent assay), and the outcomes were frailty status (determined according to frailty phenotype criteria of weight loss, weakness, exhaustion, slowness, and low physical activity) and mortality. Multinomial logistic regression was used to assess the cross-sectional association between FGF-23 and frailty and prefrailty, adjusting for demographic characteristics, cardiovascular disease and risk factors, and kidney markers. Proportional hazards Cox proportional hazards regression was used to assess the association between FGF-23, frailty, and all-cause mortality. ResultsMean estimated glomerular filtration rate (eGFR) was 64 +/- 17mL/min per 1.73m(2). Median FGF-23 was 70.3RU/mL (interquartile range 53.4-99.2); 52% were prefrail, and 13% were frail. After multivariate adjustment, each doubling in FGF-23 concentration was associated with 38% (95% confidence interval (CI)=17-62%) higher odds of frailty than of nonfrailty and 16% (95% CI=3-30%) higher odds of prefrailty. FGF-23 (hazard ratio (HR)=1.16, 95% CI=1.10-1.23) and frailty (HR=1.82, 95% CI=1.57-2.12) were independently associated with mortality, but neither association was meaningfully attenuated when adjusted for the other. ConclusionIn a large cohort of older adults, higher FGF-23 was independently associated with prevalent frailty and prefrailty. FGF-23 and frailty were independent and additive risk factors for mortality. FGF-23 may be a marker for functional outcomes. C1 [Beben, Tomasz; Ix, Joachim H.; Rifkin, Dena E.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Beben, Tomasz; Ix, Joachim H.; Rifkin, Dena E.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Sarnak, Mark J.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Fried, Linda F.] Veteran Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Nephrol Sect, Pittsburgh, PA USA. [Hoofnagle, Andrew N.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Denver, CO 80202 USA. [Kestenbaum, Bryan R.; de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Kestenbaum, Bryan R.; de Boer, Ian H.] Univ Washington, Kidney Res Inst, Dept Med, Seattle, WA 98195 USA. RP Beben, T (reprint author), 9500 Gilman Dr 9111H, La Jolla, CA 92093 USA. EM tbeben@ucsd.edu FU National Heart, Lung, and Blood Institute (NHLBI) [HHSN268201200036C, HHSN268200800007C, N01HC 55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295]; National Institute on Aging [R01AG 023629]; American Heart Association [14EIA18560026]; National Institutes of Health [T32 HL007261, RO1 HL096851, R01 HL096851, K23 DK091521, R01 HL073208, R01 AG027002, R01 DK087726] FX The CHS was supported by Contracts HHSN268201200036C, HHSN268200800007C, N01HC 55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and Grant U01HL080295 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by R01AG 023629 from the National Institute on Aging. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, NHLBI, or CHS. Dr. Beben was supported by Grant T32 HL007261, Dr. Ix by Grant RO1 HL096851, Dr. Ix by Grant R01 HL096851 and an American Heart Association Established Investigator Award 14EIA18560026, Dr. Rifkin by Grant K23 DK091521, Dr. Shlipak by Grant R01 HL073208, Dr. Sarnak by Grant R01 AG027002, and Dr. De Boer by Grant R01 DK087726 all from the National Institutes of Health, except where otherwise noted. NR 33 TC 0 Z9 0 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 270 EP 276 DI 10.1111/jgs.13951 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000003 PM 26889836 ER PT J AU Wang, SY Aldridge, MD Gross, CP Canavan, M Cherlin, E Johnson-Hurzeler, R Bradley, E AF Wang, Shi-Yi Aldridge, Melissa D. Gross, Cary P. Canavan, Maureen Cherlin, Emily Johnson-Hurzeler, Rosemary Bradley, Elizabeth TI Transitions Between Healthcare Settings of Hospice Enrollees at the End of Life SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospice; transitions in care; end-of-life care ID MARKET-STRUCTURE; HEART-FAILURE; NURSING-HOME; CANCER; POPULATION; INDICATORS; FACILITIES; INPATIENT; VARIABLES; PATTERNS AB ObjectivesTo characterize the number and types of care transitions in the last 6months of life of individuals who used hospice and to examine factors associated with having multiple transitions in care. DesignRetrospective cohort study. SettingOne hundred percent fee-for-service Medicare decedent claims data. ParticipantsMedicare beneficiaries aged 66 and older who died between July 1, 2011, and December 31, 2011, and were enrolled in hospice at some time during the last 6months of life. MeasurementsHierarchical generalized linear modeling was used to identify individual, hospice, and regional factors associated with transitions. The sequence of transitions across healthcare settings was described. Healthcare transitions after hospice enrollment included from and to the hospital, skilled nursing facility, home health agency program, hospice, or home without receiving any service in these four healthcare settings. ResultsOf 311,090 hospice decedents, 31,675 (10.2%) had at least one transition after hospice enrollment, and this varied substantially across the United States; 6.6% of all decedents had more than one transition in care after hospice enrollment (range 2-19 transitions). Of hospice users with transitions, 53.4% were admitted to hospitals, 17.7% were admitted to skilled nursing facilities, 9.6% used home health agencies, and 25.8% had transitions to home without receiving the services from the healthcare settings examined. In adjusted analyses, decedents who were younger, nonwhite, enrolled in a for-profit or small hospice program, or had less access to hospital-based palliative care had significantly higher odds of having at least one transition. ConclusionA notable proportion of hospice users experience at least one transition in care in the last 6months of life, suggesting that further research on the effect of transitions on users and families is warranted. C1 [Wang, Shi-Yi] Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St New, New Haven, CT 06520 USA. [Wang, Shi-Yi; Gross, Cary P.] Yale Univ, Yale Canc Ctr, Canc Outcomes Publ Policy & Effectiveness Res Ctr, New Haven, CT 06520 USA. [Aldridge, Melissa D.] Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Aldridge, Melissa D.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT 06520 USA. [Canavan, Maureen; Cherlin, Emily; Bradley, Elizabeth] Yale Univ, Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT 06520 USA. [Johnson-Hurzeler, Rosemary] John D Thompson Hosp Inst Educ Training & Res In, Branford, CT USA. RP Wang, SY (reprint author), Yale Univ, Sch Publ Hlth, Dept Chron Dis Epidemiol, 60 Coll St New, New Haven, CT 06520 USA. EM shiyi.wang@yale.edu FU Medtronic, Inc.; Johnson Johnson, Inc.; 21st Century Oncology; National Cancer Institute [1R01CA116398-01A2]; National Institute of Nursing Research [1R01NR013499-01A1] FX Dr. Gross receives support from Medtronic, Inc., Johnson & Johnson, Inc., and 21st Century Oncology. These sources of support were not used for any portion of the current manuscript. None of the other coauthors have conflicts to report.; This study was supported by Grant 1R01CA116398-01A2 from the National Cancer Institute (Drs. Aldridge and Bradley), the John D. Thompson Foundation (Dr. Bradley), and Grant 1R01NR013499-01A1 from the National Institute of Nursing Research (Dr. Aldridge). NR 41 TC 3 Z9 3 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 314 EP 322 DI 10.1111/jgs.13939 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000009 PM 26889841 ER PT J AU Naples, JG Hanlon, JT Schmader, KE Semla, TP AF Naples, Jennifer G. Hanlon, Joseph T. Schmader, Kenneth E. Semla, Todd P. TI Recent Literature on Medication Errors and Adverse Drug Events in Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE medication errors; adverse drug events; literature ID RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; ADVANCED DEMENTIA; CLINICAL-TRIAL; CARE; PEOPLE; INTERVENTION; FALLS; POLYPHARMACY; PHARMACIST AB Medication errors and adverse drug events are common in older adults, but locating literature addressing these issues is often challenging. The objective of this article is to summarize recent studies addressing medication errors and adverse drug events in a single location to improve accessibility for individuals working with older adults. A comprehensive literature search for studies published in 2014 was conducted, and 51 potential articles were identified. After critical review, 17 studies were selected for inclusion based on innovation; rigorous observational or experimental study designs; and use of reliable, valid measures. Four articles characterizing potentially inappropriate prescribing and interventions to optimize medication regimens were annotated and critiqued in detail. The authors hope that health policy-makers and clinicians find this information helpful in improving the quality of care for older adults. C1 [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Naples, Jennifer G.; Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Sch Med, Div Geriatr,Dept Med, Durham, NC 27710 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Semla, Todd P.] Pharm Benefits Management Serv, Dept Vet Affairs, Hines, IL USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Semla, Todd P.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Semla, TP (reprint author), Pharm Benefits Management 10P4P, Hines, IL 60141 USA. EM t-semla@northwestern.edu FU National Institute of Aging (NIA) [T32-AG021885]; NIA [P30AG024827, K07AG033174, R01AG037451, P30AG028716]; Donoghue Foundation; Agency for Healthcare Research and Quality [R18 HS023779]; Veterans Affairs Health Services Research and Development Service Merit Awards [IIR 12-379, IIR 14-297] FX Dr. Naples's fellowship is supported by National Institute of Aging (NIA) Grant T32-AG021885. Dr. Hanlon is supported by NIA Grants P30AG024827, K07AG033174, and R01AG037451; a grant from the Donoghue Foundation; grant R18 HS023779 from the Agency for Healthcare Research and Quality, and Veterans Affairs Health Services Research and Development Service Merit Awards IIR 12-379 and IIR 14-297. Dr. Schmader is supported by NIA Grant P30AG028716. NR 35 TC 1 Z9 1 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 401 EP 408 DI 10.1111/jgs.13922 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000022 PM 26804210 ER PT J AU Rogus-Pulia, N Rusche, N Hind, JA Zielinski, J Gangnon, R Safdar, N Robbins, J AF Rogus-Pulia, Nicole Rusche, Nicole Hind, Jacqueline A. Zielinski, Jill Gangnon, Ronald Safdar, Nasia Robbins, JoAnne TI Effects of Device-Facilitated Isometric Progressive Resistance Oropharyngeal Therapy on Swallowing and Health-Related Outcomes in Older Adults with Dysphagia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dysphagia; oropharyngeal; lingual; strengthening; pneumonia ID PENETRATION-ASPIRATION SCALE; LINGUAL EXERCISE; STROKE PATIENTS; PNEUMONIA; PERFORMANCE; STRENGTH; PEOPLE; COST AB Swallowing disorders (dysphagia) are associated with malnutrition, aspiration pneumonia, and mortality in older adults. Strengthening interventions have shown promising results, but the effectiveness of treating dysphagia in older adults remains to be established. The Swallow STRengthening OropharyNGeal (Swallow STRONG) Program is a multidisciplinary program that employs a specific approach to oropharyngeal strengtheningdevice-facilitated (D-F) isometric progressive resistance oropharyngeal (I-PRO) therapywith the goal of reducing health-related sequelae in veterans with dysphagia. Participants completed 8 weeks of D-F I-PRO therapy while receiving nutritional counseling and respiratory status monitoring. Assessments were completed at baseline, 4, and 8 weeks. At each visit, videofluoroscopic swallowing studies were performed. Dietary and swallowing-related quality of life questionnaires were administered. Long-term monitoring for 6-17 months after enrollment allowed for comparison of pneumonia incidence and hospitalizations to the 6-17 months before the program. Veterans with dysphagia confirmed with videofluoroscopy (N = 56; 55 male, 1 female; mean age 70) were enrolled. Lingual pressures increased at anterior (effect estimate = 92.5, P < .001) and posterior locations (effect estimate = 85.4, P < .001) over 8 weeks. Statistically significant improvements occurred on eight of 11 subscales of the Quality of Life in Swallowing Disorders (SWAL-QOL) Questionnaire (effect estimates = 6.5-19.5, P < .04) and in self-reported sense of effort (effect estimate = -18.1, P = .001). Higher Functional Oral Intake Scale scores (effect estimate = 0.4, P = .02) indicated that participants were able to eat less-restrictive diets. There was a 67% reduction in pneumonia diagnoses, although the difference was not statistically significant. The number of hospital admissions decreased significantly (effect estimate = 0.96; P = .009) from before to after enrollment. Findings suggest that the Swallow STRONG multidisciplinary oropharyngeal strengthening program may be an effective treatment for older adults with dysphagia. C1 [Rogus-Pulia, Nicole] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Div Gastroenterol, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Div Hepatol, Madison, WI USA. [Rogus-Pulia, Nicole; Robbins, JoAnne] Univ Wisconsin, Speech Swallowing & Dining Enhancement Program, Madison, WI USA. [Rusche, Nicole] Swallow STRengthening OropharyNGeal Program, Madison, WI USA. [Hind, Jacqueline A.] Swallow Solut LLC, Clin Affairs, Madison, WI USA. [Zielinski, Jill] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Div Infect Dis, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Dept Med, Madison, WI USA. [Gangnon, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Safdar, Nasia; Robbins, JoAnne] Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Rogus-Pulia, N (reprint author), 2500 Overlook Terrace,Madison GRECC 11G, Madison, WI 53705 USA. EM npulia@wisc.edu FU Geriatrics and Extended Care division of the VA through a T21 Non-Institutional Long Term Care grant FX Funding was provided by the Geriatrics and Extended Care division of the VA through a T21 Non-Institutional Long Term Care grant. The authors would like to acknowledge Sue McCartney, MS, RD, for providing nutritional support and counseling and Kevin Bjork, MS, NP, for monitoring participants' respiratory health. NR 20 TC 1 Z9 1 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2016 VL 64 IS 2 BP 417 EP 424 DI 10.1111/jgs.13933 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DF2FX UT WOS:000371159000024 PM 26804715 ER PT J AU Forman, DE AF Forman, Daniel E. TI Cardiac Rehabilitation: The Mandate Grows SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material ID AMERICAN-HEART-ASSOCIATION; PREVENTION; EXERCISE; DELIVERY C1 [Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA. [Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Div Cardiol, Pittsburgh, PA USA. [Forman, Daniel E.] Univ Pittsburgh, Med, Pittsburgh, PA USA. RP Forman, DE (reprint author), Univ Pittsburgh, Med Ctr, Sect Geriatr Cardiol, 3471 Fifth Ave,Ste 500, Pittsburgh, PA 15213 USA. EM formand@pitt.edu NR 20 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD FEB PY 2016 VL 91 IS 2 BP 125 EP 128 DI 10.1016/j.mayocp.2015.12.009 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DF3MN UT WOS:000371248500004 PM 26847999 ER PT J AU Thakore, NP Samantaray, S Park, S Nozaki, K Smith, JA Cox, A Krause, J Banik, NL AF Thakore, Nakul P. Samantaray, Supriti Park, Sookyoung Nozaki, Kenkichi Smith, Joshua A. Cox, April Krause, James Banik, Naren L. TI Molecular Changes in Sub-lesional Muscle Following Acute Phase of Spinal Cord Injury SO NEUROCHEMICAL RESEARCH LA English DT Article DE Spinal cord injury; Muscle atrophy; Protein degradation; Protein synthesis; Inflammation; E3-ubiquitin ligases ID CROSS-SECTIONAL AREA; SKELETAL-MUSCLE; PROTEIN-METABOLISM; MESSENGER-RNA; RAT SOLEUS; EXPRESSION; CALPAIN; ATROPHY; STIMULATION; HUMANS AB To clarify the molecular changes of sublesional muscle in the acute phase of spinal cord injury (SCI), a moderately severe injury (40 g cm) was induced in the spinal cord (T10 vertebral level) of adult male Sprague-Dawley rats (injury) and compared with sham (laminectomy only). Rats were sacrificed at 48 h (acute) post injury, and gastrocnemius muscles were excised. Morphological examination revealed no significant changes in the muscle fiber diameter between the sham and injury rats. Western blot analyses performed on the visibly red, central portion of the gastrocnemius muscle showed significantly higher expression of muscle specific E3 ubiquitin ligases (muscle ring finger-1 and muscle atrophy f-box) and significantly lower expression of phosphorylated Akt-1/2/3 in the injury group compared to the sham group. Cyclooxygenase 2, tumor necrosis factor alpha (TNF-alpha), and caspase-1, also had a significantly higher expression in the injury group; although, the mRNA levels of TNF-alpha and IL-6 did not show any significant difference between the sham and injury groups. These results suggest activation of protein degradation, deactivation of protein synthesis, and development of inflammatory reaction occurring in the sublesional muscles in the acute phase of SCI before overt muscle atrophy is seen. C1 [Thakore, Nakul P.; Samantaray, Supriti; Park, Sookyoung; Nozaki, Kenkichi; Smith, Joshua A.; Cox, April; Banik, Naren L.] Med Univ S Carolina, Dept Neurosurg & Neurol, 96 Jonathan Lucas St,309 CSB,MSC 606, Charleston, SC 29425 USA. [Park, Sookyoung] Kyungnam Univ, Dept Phys Therapy, Chang Won, South Korea. [Krause, James] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA. [Nozaki, Kenkichi] Univ Alabama Birmingham, Dept Neurol, Div Neuromuscular Dis, UAB Stn, Birmingham, AL 35294 USA. [Banik, Naren L.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Banik, NL (reprint author), Med Univ S Carolina, Dept Neurosurg & Neurol, 96 Jonathan Lucas St,309 CSB,MSC 606, Charleston, SC 29425 USA.; Banik, NL (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM baniknl@musc.edu FU National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS-NIH) [NS031622]; Ralph H. Johnson Veterans Administration Medical Center [1IOBX001262, 1IOBX002349-01]; State of South Carolina Spinal Cord Injury Research Foundation [SCIRF 2012-001]; National Institutes of Health from the Extramural Research Facilities Program of the National Center for Research Resources [C06 RR015455] FX We would like to acknowledge Ms. Margaret Romonov for her assistance in the muscle biopsy slicing and H&E staining and Dr. Varduhi H. Knaryan for valuable discourse. The funding for this project was provided in part by R01 Grants from National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NINDS-NIH; NS031622), Ralph H. Johnson Veterans Administration Medical Center (1IOBX001262 and 1IOBX002349-01) and the State of South Carolina Spinal Cord Injury Research Foundation (SCIRF 2012-001). This work was conducted in a facility constructed with support from the National Institutes of Health, Grant Number C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. NR 44 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-3190 EI 1573-6903 J9 NEUROCHEM RES JI Neurochem. Res. PD FEB PY 2016 VL 41 IS 1-2 SI SI BP 44 EP 52 DI 10.1007/s11064-015-1696-9 PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA DF5SO UT WOS:000371412800006 PM 26290268 ER PT J AU Tackett, MJ Nash, L Stucky, KJ Nierenberg, B AF Tackett, M. Jan Nash, Laurie Stucky, Kirk Jeffrey Nierenberg, Barry TI Supervision in Rehabilitation Psychology: Application of Beatrice Wright's Value-Laden Beliefs and Principles SO REHABILITATION PSYCHOLOGY LA English DT Article DE supervision; rehabilitation; mentoring; clinical training; residency training ID COMPETENCE AB Clinical supervision is of critical importance for training subsequent generations of psychologists. Specialty training in rehabilitation psychology requires exposure to specific knowledge, skills, and attitudes related to disability and specialized supervision and mentorship. In the literature to date, minimal guidance exists regarding supervision training and methods specifically for rehabilitation psychologists. This article aims to provoke discussion regarding supervision practice and dissemination of the values fundamental to our specialty. The foundational wisdom of Dr. Beatrice Wright (1983) is applied for the purposes of this endeavor. Examples of clinical supervision scenarios are presented as teaching vignettes to demonstrate ways in which supervisors and mentors can incorporate this content, promote discussion, and apply it to real-world practice. Impact and Implications This article describes the importance of specialty clinical supervision in rehabilitation psychology. In addition, a model is advanced for providing supervision and values clarification based on foundational rehabilitation psychology literature. This article suggests ongoing dissemination of core rehabilitation psychology values through supervision and mentoring relationships, as well as processes for improving supervision practice in the specialty. C1 [Tackett, M. Jan] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. [Tackett, M. Jan] Univ Washington, Seattle, WA 98195 USA. [Nash, Laurie] Shepherd Ctr, Atlanta, GA USA. [Stucky, Kirk Jeffrey] Hurley Med Ctr, Flint, MI USA. [Nierenberg, Barry] Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA. RP Tackett, MJ (reprint author), Univ Washington, Seattle Div, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM meredith.tackett@va.gov NR 16 TC 2 Z9 2 U1 0 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 EI 1939-1544 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD FEB PY 2016 VL 61 IS 1 BP 74 EP 81 DI 10.1037/rep0000070 PG 8 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA DF4EZ UT WOS:000371302000008 PM 26881309 ER PT J AU Liu, Y Mallampalli, RK AF Liu, Yuan Mallampalli, Rama K. TI Small molecule therapeutics targeting F-box proteins in cancer SO SEMINARS IN CANCER BIOLOGY LA English DT Review DE Ubiquitin; E3 ligase; F-box protein; Small molecule inhibitor; Cancer ID SCF UBIQUITIN-LIGASE; NF-KAPPA-B; CELL-CYCLE ARREST; PHOSPHORYLATION-DEPENDENT UBIQUITINATION; ANAPHASE PROMOTING COMPLEX/CYCLOSOME; TUMOR-SUPPRESSOR; BETA-TRCP; C-MYC; MEDIATED DEGRADATION; SKP2 PROTEIN AB The ubiquitin proteasome system (UPS) plays vital roles in maintaining protein equilibrium mainly through proteolytic degradation of targeted substrates. The archetypical SCF ubiquitin E3 ligase complex contains a substrate recognition subunit F-box protein that recruits substrates to the catalytic ligase core for its polyubiquitylation and subsequent proteasomal degradation. Several well-characterized F-box proteins have been demonstrated that are tightly linked to neoplasia. There is mounting information characterizing F-box protein-substrate interactions with the rationale to develop unique therapeutics for cancer treatment. Here we review that how F-box proteins function in cancer and summarize potential small molecule inhibitors for cancer therapy. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Liu, Yuan; Mallampalli, Rama K.] Univ Pittsburgh, Ctr Excellence, Acute Lung Injury, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, UPMC Montefiore, Pulm Allergy & Crit Care Med, Dept Med, NW628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US National Institutes of Health [HL096376, P01 HL114453]; United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; United States Department of Veterans Affairs FX The authors apologize for the omission of many colleagues' work owing to space constraints. Work in the Mallampalli laboratory is partly supported by the US National Institutes of Health R01 Grant HL096376 and P01 HL114453 (to R.K.M.), and is partly supported by the United States Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and by a Merit Review award from the United States Department of Veterans Affairs (to R.K.M.). NR 177 TC 3 Z9 3 U1 1 U2 5 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1044-579X J9 SEMIN CANCER BIOL JI Semin. Cancer Biol. PD FEB PY 2016 VL 36 BP 105 EP 119 DI 10.1016/j.semcancer.2015.09.014 PG 15 WC Oncology SC Oncology GA DF7QY UT WOS:000371553900011 PM 26427329 ER PT J AU Zaman, T Boyd, JW AF Zaman, Tauheed Boyd, J. Wesley TI The Authors Reply to Cannabis Use Disorders and ADHD SO JOURNAL OF ADDICTION MEDICINE LA English DT Letter C1 [Zaman, Tauheed] UCSF, San Francisco VA Med Ctr, Addict & Recovery Treatment Serv, San Francisco, CA USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA. [Boyd, J. Wesley] Harvard Univ, Sch Med, Ctr Bioeth, Cambridge, MA 02138 USA. RP Boyd, JW (reprint author), Cambridge Hlth Alliance, 26 Cent St, Somerville, MA 02143 USA. EM jwboyd@cha.harvard.edu NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD FEB PY 2016 VL 10 IS 1 BP 70 EP 71 DI 10.1097/ADM.0000000000000185 PG 2 WC Substance Abuse SC Substance Abuse GA DE0CV UT WOS:000370293300002 ER PT J AU McCutchan, PK Liu, X LeardMann, CA Smith, TC Boyko, EJ Gore, KL Freed, MC Engel, CC AF McCutchan, Phoebe K. Liu, Xian LeardMann, Cynthia A. Smith, Tyler C. Boyko, Edward J. Gore, Kristie L. Freed, Michael C. Engel, Charles C. TI Deployment, combat, and risk of multiple physical symptoms in the US military: a prospective cohort study SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Signs and symptoms; Military medicine; Military personnel; Veterans health; Cohort studies ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CLINICAL-TRIAL; PERSIAN-GULF-WAR; SOMATIC SYMPTOMS; MILLENNIUM COHORT; PRIMARY-CARE; CHRONIC PAIN; IRAQ WAR; SERVICE MEMBERS; HEALTH OUTCOMES AB Purpose: Multiple physical symptoms (MPS) have historically been observed after deployment to a combat zone and are often disabling in nature. This study examined longitudinal trends in MPS status and its relationship to deployment in U.S. military service members. Methods: Using longitudinal data from panel 1 participants in the Millennium Cohort Study (n = 76,924), MPS status was assessed at three time points (2001-2008) using the 15 -item Patient Health Questionnaire. Probability of reporting MPS was analyzed using mixed-effects multinomial logit regression, with time and deployment experience as main explanatory variables. Results: After adjustment for demographic, military, and health characteristics, service members who deployed with combat were significantly more likely to report MPS at each time point compared with those not deployed (odds ratio [OR] and 95% confidence interval [CI] for wave 1 =1.49 [1.47-1.52], wave 2 = 1.73 [1.69-1.78], wave 3 = 2.08 [2.03-2.12]), and those who deployed without combat (OR and CI for wave 1 = 2.66 [2.59-2.74], wave 2 = 1.81 [1.75-1.87]; wave 3 = 1.68 [1.63-1.74]). Conclusions: Longitudinal trends indicate that the probability of reporting MPS has increased consistently over time only for those deployed, regardless of combat experience. (C) 2016 Elsevier Inc. All rights reserved. C1 [McCutchan, Phoebe K.; Liu, Xian; Freed, Michael C.] Def Ctr Excellence Psychol Hlth, Deployment Hlth Clin Ctr, Silver Spring, MD USA. [McCutchan, Phoebe K.; Liu, Xian; Freed, Michael C.] Def Ctr Traumat Brain Injury, Deployment Hlth Clin Ctr, Silver Spring, MD USA. [McCutchan, Phoebe K.; Liu, Xian; LeardMann, Cynthia A.] Henry M Jackson Fdn Adv Mil Med Inc, Bethesda, MD USA. [Liu, Xian; Freed, Michael C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA. [LeardMann, Cynthia A.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA USA. [Smith, Tyler C.] Natl Univ, Sch Hlth & Human Serv, Dept Community Hlth, San Diego, CA USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Gore, Kristie L.; Engel, Charles C.] RAND Corp, Behav & Policy Sci, Arlington, VA USA. [McCutchan, Phoebe K.] Amer Univ, Dept Psychol, 4400 Massachusetts Ave NW, Washington, DC 20016 USA. [Freed, Michael C.] NIMH, Div Serv & Intervent Res, Serv Res & Clin Epidemiol Branch, 6001 Execut Blvd, Bethesda, MD 20892 USA. [Engel, Charles C.] RAND Corp, Behav & Policy Sci, 20 Pk Plaza,Suite 920, Boston, MA 02116 USA. RP McCutchan, PK (reprint author), Amer Univ, Dept Psychol, 4400 Massachusetts Ave NW, Washington, DC 20016 USA. EM phoebe.mccutchan@gmail.com OI Boyko, Edward/0000-0002-3695-192X FU Management Information Division, U.S. Defense Manpower Data Center (Seaside, CA); Military Operational Medicine Research Program; U.S. Army Medical Research and Materiel Command (Fort Detrick, MD); Military Operational Medicine Research Program of the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland - Department of Defense [60002]; Deployment Health Clinical Center; VA Puget Sound Health Care System FX In addition to the authors, the Millennium Cohort Study team includes Richard Armenta, PhD, Lauren Bauer, MPH, Madeline Cross, James Davies, CPT Carrie Donoho, PhD, CDR Dennis Faix, MD, Lt Col Susan Farrish, MD, Toni Geronimo, Kathleen Gunn, William Lee, Hector Lemus, PhD, Gordon Lynch, Denise Lovec-Jenkins, David Luxton PhD, Danielle Mitchell, Kristin Motylinski, Anna Nagel, MPH, Chiping Nieh, PhD, Chris O'Malley, MPH, Serguey Parkhomovsky, Anet Petrosyan, Christopher Phillips, MD, MPH, Teresa Powell, MPH, Ben Porter, PhD, Rudy Rull, PhD, Kari Sausedo, MA, Beverly Sheppard, Steven Speigle, Evelyn Sun, MPH, Valerie Stander, PhD, Laura Tobin, MPH, Daniel Trone, PhD, Jennifer Walstrom, from the Deployment Health Research Department, Naval Health Research Center, San Diego, CA. We thank Hector Lemus, PhD (Naval Health Research Center, San Diego, CA) for his contribution in providing statistical support and consultation for this study. In addition, we thank Michelle LeWark from the Naval Health Research Center (San Diego, CA) for her technical review and editing of this article. We appreciate the support from the Management Information Division, U.S. Defense Manpower Data Center (Seaside, CA); Military Operational Medicine Research Program and U.S. Army Medical Research and Materiel Command (Fort Detrick, MD).; The Millennium Cohort Study is funded through the Military Operational Medicine Research Program of the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland (supported by the Department of Defense, under work unit no. 60002). The Deployment Health Clinical Center provided funding for P.K.M., X.L., K.L.G, and M.C.F.'s efforts in this project. VA Puget Sound Health Care System provided support for E.J.B's participation in this research. The funding organizations had no role in the design and conduct of the study; collection, analysis, or preparation of data; or preparation, review, or approval of the article. NR 58 TC 1 Z9 1 U1 5 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD FEB PY 2016 VL 26 IS 2 BP 122 EP 128 DI 10.1016/j.annepidem.2015.12.001 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DE8MG UT WOS:000370889500006 PM 26781443 ER PT J AU Villatte, JL Vilardaga, R Villatte, M Vilardaga, JCP Atkins, DC Hayes, SC AF Villatte, Jennifer L. Vilardaga, Roger Villatte, Matthieu Vilardaga, Jennifer C. Plumb Atkins, David C. Hayes, Steven C. TI Acceptance and Commitment Therapy modules: Differential impact on treatment processes and outcomes SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Acceptance and commitment therapy; Component analysis; Modular design; Single case experimental design; Acceptance; Values; Mindfulness; Therapy process ID RANDOMIZED EFFECTIVENESS TRIAL; PSYCHOTHERAPY PROCESS; ANXIETY DISORDERS; TREATMENT DESIGNS; MENTAL-ILLNESS; METAANALYSIS; COMPONENT; INTERVENTIONS; MINDFULNESS; ATTITUDES AB A modular, transdiagnostic approach to treatment design and implementation may increase the public health impact of evidence-based psychosocial interventions. Such an approach relies on algorithms for selecting and implementing treatment components intended to have a specific therapeutic effect, yet there is little evidence for how components function independent of their treatment packages when employed in clinical service settings. This study aimed to demonstrate the specificity of treatment effects for two components of Acceptance and Commitment Therapy (ACT), a promising candidate for modularization. A randomized, nonconcurrent, multiple-baseline across participants design was used to examine component effects on treatment processes and outcomes in 15 adults seeking mental health treatment. The ACT OPEN module targeted acceptance and cognitive defusion; the ACT ENGAGED module targeted values-based activation and persistence. According to Tau-U analyses, both modules produced significant improvements in psychiatric symptoms, quality of life, and targeted therapeutic processes. ACT ENGAGED demonstrated greater improvements in quality of life and values-based activation. ACT OPEN showed greater improvements in symptom severity, acceptance, and defusion. Both modules improved awareness and non-reactivity, which were mutually targeted, though using distinct intervention procedures. Both interventions demonstrated high treatment acceptability, completion, and patient satisfaction. Treatment effects were maintained at 3-month follow up. ACT components should be considered for inclusion in a modular approach to implementing evidence-based psychosocial interventions for adults. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Villatte, Jennifer L.; Vilardaga, Roger; Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. [Villatte, Matthieu] Evidence Based Practice Inst, Seattle, WA USA. [Vilardaga, Jennifer C. Plumb] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA. [Hayes, Steven C.] Univ Nevada, Dept Psychol, Reno, NV 89557 USA. RP Villatte, JL (reprint author), Univ Washington, Dept Psychiat & Behav Sci, 1959 NE Pacific St,Box 356560, Seattle, WA 98195 USA. EM villatte@uw.edu; vilardag@uw.edu; matt@ebpi.org; jennifer.plumbvilardaga@va.gov; datkins@uw.edu; hayes@unr.edu OI Atkins, David/0000-0002-5781-9880; Hayes, Steven/0000-0003-4399-6859 FU National Institute of Mental Health [F31MH096341]; [T32MH096341] FX First author J.L.V. was assisted in the preparation of this manuscript by grant number F31MH096341 from the National Institute of Mental Health. First author J.L.V. and second author R.V. were assisted in preparation of this manuscript by grant number T32MH096341. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health, who had no involvement in the design or execution of the study. NR 59 TC 3 Z9 3 U1 6 U2 20 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD FEB PY 2016 VL 77 BP 52 EP 61 DI 10.1016/j.brat.2015.12.001 PG 10 WC Psychology, Clinical SC Psychology GA DE8PR UT WOS:000370899200007 PM 26716932 ER PT J AU Singh, J Ramachandaran, R AF Singh, Jasvinder A. Ramachandaran, Rekha TI Does rural residence impact total ankle arthroplasty utilization and outcomes? SO CLINICAL RHEUMATOLOGY LA English DT Article DE Outcomes; Residence; Rural; Total ankle arthroplasty; Urban; Utilization ID INPATIENT SAMPLE NIS; OPEN APPENDECTOMY; REPLACEMENT; POPULATION; DATABASE AB The objective of this study was to compare total ankle arthroplasty (TAA) utilization and outcomes by patient residence. We used the Nationwide Inpatient Sample (NIS) from 2003 to 2011 to compare utilization and outcomes (post-arthroplasty discharge disposition, length of hospitalization, and mortality) by rural vs. urban residence. Ten thousand eight hundred thirty-three patients in urban and 3,324 patients in rural area underwent TAA. Compared to rural residents, urban residents had: lower mean age, 62.4 vs. 61.8 years (p < 0.0001); higher percent of women, 49 vs. 56 % (p = 0.0008); and lower proportion of Whites, 93 vs. 86 % (p = 0.0005). There were rural-urban disparities in TAA utilization in 2003 (0.32 vs. 0.39/100,000; p = 0.021), but not in 2011 (1.19 vs. 1.17/100,00; p = 0.80). TAA outcomes did not differ by rural vs. urban residence: (1) 11.3 % rural vs. 14.2 % urban residents were discharged to an inpatient facility (p = 0.098); (2) length of hospital stay above the median stay, was 44.8 vs. 42.2 % (p = 0.30); and (3) mortality was 0.2 vs. 0.1 %, respectively (p = 0.81). Multivariable-adjusted logistic regression models did not show any significant differences in discharge to home, length of stay, or mortality, by residence. Our study demonstrated an absence of any evidence of rural-urban differences in TAA outcomes. The rural-urban differences in TAA utilization noted in 2003 were no longer significant in 2011. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit SMART C, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Ramachandaran, Rekha] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, J (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.; Singh, J (reprint author), Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit SMART C, Birmingham, AL USA. EM Jasvinder.md@gmail.com FU Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) [U19 HS021110]; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) [P50 AR060772, U34 AR062891]; National Institute of Aging (NIA) [U01 AG018947]; National Cancer Institute (NCI) [U10 CA149950]; Patient Centered Outcomes Research Institute (PCORI) [CE-1304-6631] FX JAS is supported by grants from the Agency for Health Quality and Research Center for Education and Research on Therapeutics (AHRQ CERTs) U19 HS021110; National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) P50 AR060772 and U34 AR062891; National Institute of Aging (NIA) U01 AG018947; National Cancer Institute (NCI) U10 CA149950; and research contract CE-1304-6631 from the Patient Centered Outcomes Research Institute (PCORI). JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD FEB PY 2016 VL 35 IS 2 BP 381 EP 386 DI 10.1007/s10067-015-2908-z PG 6 WC Rheumatology SC Rheumatology GA DE7MN UT WOS:000370821300014 PM 25771850 ER PT J AU Annapureddy, N Elsallabi, O Baker, J Sreih, AG AF Annapureddy, Narender Elsallabi, Osama Baker, Joshua Sreih, Antoine G. TI Patient-reported outcomes in ANCA-associated vasculitis. A comparison between Birmingham Vasculitis Activity Score and routine assessment of patient index data 3 SO CLINICAL RHEUMATOLOGY LA English DT Article DE ANCA-associated Vasculitis; Disease activity measures; Patient-Reported Outcomes; RAPID3; Validation of measures ID QUALITY-OF-LIFE; HEALTH-ASSESSMENT QUESTIONNAIRE; PRIMARY SYSTEMIC VASCULITIS; GRANULOMATOSIS; WEGENERS; DISEASE; MDHAQ AB The objective of this study was to determine health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) as measured by the "routine assessment of patient index data 3" (RAPID3) and whether RAPID3 is correlated with disease activity as determined by the Birmingham Vasculitis Activity Score (BVAS). Data from patients at an academic institution vasculitis clinic seen between Jan 2010 and Jan 2012 were collected using chart review. BVAS and RAPID3 scores were calculated at each patient visit. RAPID3 was compared between patients in remission (BVAS = 0) and patients with active disease (BVAS > =1) at all visits for four consecutive visits, when data available, at least 3 months apart during the period mentioned. Robust generalized estimating equations (GEE) in linear regression models evaluated associations between the RAPID3 and BVAS over all available observations, adjusting for intra-subject correlations. Thirty-four patients were included in the study, 26 had granulomatosis with polyangiitis (GPA), five microscopic polyangiitis (MPA), and three eosinophilic granulomatosis with polyangiitis (EGPA). Patients at first visit had impaired HRQoL as measured by RAPID3 [6.8 (3.1-12.6)]. The median RAPID3 scores were higher in patients with active disease as compared to patients in remission (7.0 vs. 3.0, p = 0.115; 8.8 vs. 1.0, p = 0.011; 6.1 vs. 2.0, p = 0.032; and 11.7 vs. 2.0, p = 0.128 for visits 1, 2, 3, and 4, respectively). In longitudinal GEE models incorporating all observations there was a strong association between the RAPID3 (per 1 unit) and BVAS (per 1 unit) [beta 0.21 (0.10, 0.32) p < 0.001]. RAPID3 can be used to measure HRQoL in patients with AAV. RAPID3 correlated significantly with BVAS. RAPID3 can discriminate between disease states in AAV. This instrument may help document patient experience and add to clinical decisions. C1 [Annapureddy, Narender] Vanderbilt Univ, Div Rheumatol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Elsallabi, Osama] Creighton Univ, Dept Med, Omaha, NE 68178 USA. [Baker, Joshua] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Baker, Joshua; Sreih, Antoine G.] Univ Penn, Div Rheumatol, 3400 Spruce St,1407 Penn Tower, Philadelphia, PA 19104 USA. [Baker, Joshua] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Annapureddy, Narender; Sreih, Antoine G.] Rush Univ, Div Rheumatol, Chicago, IL 60612 USA. RP Sreih, AG (reprint author), Univ Penn, Div Rheumatol, 3400 Spruce St,1407 Penn Tower, Philadelphia, PA 19104 USA.; Sreih, AG (reprint author), Rush Univ, Div Rheumatol, Chicago, IL 60612 USA. EM antoine.sreih@uphs.upenn.edu OI Annapureddy, Narender/0000-0002-4012-3406 NR 18 TC 2 Z9 2 U1 3 U2 3 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0770-3198 EI 1434-9949 J9 CLIN RHEUMATOL JI Clin. Rheumatol. PD FEB PY 2016 VL 35 IS 2 BP 395 EP 400 DI 10.1007/s10067-015-2921-2 PG 6 WC Rheumatology SC Rheumatology GA DE7MN UT WOS:000370821300016 PM 25822996 ER PT J AU Buttner, MM Bormann, JE Weingart, K Andrews, T Ferguson, M Afari, N AF Buttner, Melissa M. Bormann, Jill E. Weingart, Kimberly Andrews, Taylor Ferguson, Marjorie Afari, Niloofar TI Multi-site evaluation of a complementary, spiritually-based intervention for Veterans: The Mantram Repetition Program SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE LA English DT Article DE Complementary therapies; Dissemination; Mindfulness; Program evaluation; Relaxation techniques; Veterans ID WELL-BEING SCALE; POSTTRAUMATIC-STRESS-DISORDER; ALTERNATIVE MEDICINE USE; FUNCTIONAL ASSESSMENT; TRIAL; PTSD; CARE AB Background: Mental and physical symptoms affect Veterans' quality of life. Despite available conventional treatments, an increasing number of Veterans are seeking complementary approaches to symptom management. Research on the Mantram Repetition Program (MRP), a spiritually-based intervention, has shown significant improvements in psychological distress and spiritual well-being in randomized trials. However, these findings have not been replicated in real-world settings. Methods: In this naturalistic study, we analyzed outcomes from 273 Veterans who participated in MRP at six sites and explored outcomes based on facilitator training methods. Measures included satisfaction and symptoms of anxiety, depression, and somatization using the Brief Symptom Inventory-18; Functional Assessment of Chronic Illness Therapy-Spiritual Well-being questionnaire; and the Mindfulness Attention Awareness Scale. Results: There were significant improvements in all outcomes ( p's <.001) regardless of how facilitators were trained. Patient satisfaction was high. Conclusion: The MRP was disseminated successfully yielding improvements in psychological distress, spiritual well-being, and mindfulness. Published by Elsevier Ltd. C1 [Buttner, Melissa M.; Bormann, Jill E.; Afari, Niloofar] VA San Diego Ctr Excellence Stress & Mental Hlth, San Diego, CA USA. [Buttner, Melissa M.; Bormann, Jill E.; Weingart, Kimberly; Andrews, Taylor; Afari, Niloofar] VA San Diego Healthcare Syst, San Diego, CA USA. [Buttner, Melissa M.; Afari, Niloofar] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Buttner, Melissa M.; Ferguson, Marjorie] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bormann, Jill E.] Univ San Diego, Hahn Sch Nursing & Hlth Sci, San Diego, CA 92110 USA. RP Bormann, JE (reprint author), San Diego Healthcare Syst, 3350 La Jolla Village Dr 111n-1, San Diego, CA 92161 USA. EM Jill.Bormann@va.gov FU Department of Veterans Affairs; VA San Diego Healthcare System; Center of Excellence for Stress and Mental Health (CESAMH) FX This material is based upon work supported by the Department of Veterans Affairs, VA San Diego Healthcare System, and the Center of Excellence for Stress and Mental Health (CESAMH). We thank Ms. Jan Wong and Ms. Suzanne Milligan from VA Employee Education Services (EES) for their assistance in implementing the 2-Day Facilitator Trainings. We especially thank all of the clinicians who brought the Mantram Repetition Program to their facilities and especially all the Veterans who participated in this project. None of the authors have any conflicts of interest to declare. The views expressed in this paper are those of the authors only and do not reflect the official policy or position of the institutions with which the authors are affiliated, nor the Department of Veteran's Affairs, or the United States Government. NR 28 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1744-3881 EI 1873-6947 J9 COMPLEMENT THER CLIN JI Complement. Ther. Clin. Pract. PD FEB PY 2016 VL 22 BP 74 EP 79 DI 10.1016/j.ctcp.2015.12.008 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DE7YW UT WOS:000370854000015 PM 26850810 ER PT J AU Kopacz, MS Connery, AL Bishop, TM Bryan, CJ Drescher, KD Currier, JM Pigeon, WR AF Kopacz, Marek S. Connery, April L. Bishop, Todd M. Bryan, Craig J. Drescher, Kent D. Currier, Joseph M. Pigeon, Wilfred R. TI Moral injury: A new challenge for complementary and alternative medicine SO COMPLEMENTARY THERAPIES IN MEDICINE LA English DT Article DE Moral injury; Pastoral care; Mindfulness; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH; SUICIDAL IDEATION; PSYCHOMETRIC EVALUATION; INTEGRATIVE MEDICINE; MINDFULNESS PROGRAM; MILITARY PERSONNEL; SERVICE MEMBERS; PASTORAL CARE AB Moral injury represents an emerging clinical construct recognized as a source of morbidity in current and former military personnel. Finding effective ways to support those affected by moral injury remains a challenge for both biomedical and complementary and alternative medicine. This paper introduces the concept of moral injury and suggests two complementary and alternative medicine, pastoral care and mindfulness, which may prove useful in supporting military personnel thought to be dealing with moral injury. Research strategies for developing an evidence-base for applying these, and other, complementary and alternative medicine modalities to moral injury are discussed. Published by Elsevier Ltd C1 [Kopacz, Marek S.; Bishop, Todd M.; Pigeon, Wilfred R.] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Connery, April L.] US Dept Vet Affairs, Canandaigua VA Med Ctr, Canandaigua, NY USA. [Bishop, Todd M.; Pigeon, Wilfred R.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Bryan, Craig J.] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT USA. [Drescher, Kent D.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Disseminat & Training Div, Menlo Pk, CA USA. [Currier, Joseph M.] Univ S Alabama, Dept Psychol, CCP, Mobile, AL 36688 USA. RP Kopacz, MS (reprint author), Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM marek.kopacz@va.gov OI Bishop, Todd/0000-0001-8551-2117; Bryan, Craig/0000-0002-9714-0733 FU Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention; VA's VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, NY FX Dr. Bishop is supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention. This work was funded, in part, by the VA's VISN 2 Center of Excellence for Suicide Prevention in Canandaigua, NY. The views expressed are those of the authors and do not reflect the official policy or position of the Department of Veterans Affairs or the U.S. Government. The authors gratefully acknowledge the contribution of Jeffrey Millegan, MD, MPH, FAPA, and Constance M. Cass, MPA, to the development of this paper. NR 79 TC 2 Z9 2 U1 2 U2 9 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0965-2299 EI 1873-6963 J9 COMPLEMENT THER MED JI Complement. Ther. Med. PD FEB PY 2016 VL 24 BP 29 EP 33 DI 10.1016/j.ctim.2015.11.003 PG 5 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DE8NY UT WOS:000370894100006 PM 26860798 ER PT J AU Chiang, SR Levin, HS Wilde, E Haneef, Z AF Chiang, Sharon Levin, Harvey S. Wilde, Elisabeth Haneef, Zulfi TI White matter structural connectivity changes correlate with epilepsy duration in temporal lobe epilepsy SO EPILEPSY RESEARCH LA English DT Article DE Temporal lobe epilepsy; Diffusion tensor imaging; Progression; Mean diffusivity; Fractional anisotropy ID DIFFUSION-TENSOR MRI; HIPPOCAMPAL SCLEROSIS; QUANTITATIVE MRI; AUTOMATED SEGMENTATION; ABNORMALITIES; NETWORKS; BRAIN; FEATURES; VOLUMES; CORTEX AB Purpose: Temporal lobe epilepsy (TLE) is thought to be a network disease and structural changes using diffusion tensor imaging (DTI) have been shown. However, lateralized differences in the structural integrity of TLE, as well as changes in structural integrity with longer disease duration, have not been well defined. Methods: We examined the fractional anisotropy (FA) and mean diffusivity (MD) in the hippocampus, as well as its primary (cingulum and fornix) and remote (uncinate and external capsule) connections in both right and left TLE. Changes in diffusion measures over the disease course were examined by correlating FA and MD in the various structures with epilepsy duration. The potential for each measure of anisotropy and diffusivity as a marker of TLE laterality was investigated using random forest (RF) analysis. Results: MD was increased in the bilateral hippocampus, cingulum, fornix and the right external capsule in both left and right TLE compared to controls. In addition, left TLE exhibited an increased MD in the ipsilateral uncinate fasciculus and bilateral external capsules. A decrease in FA was seen in the left cingulum in left TLE. RF analysis demonstrated that MD of the right hippocampus and FA of the left external capsule were important predictors of TLE laterality. An association of increased MD with epilepsy duration was seen in the left hippocampus in left TLE. Conclusion: Evidence of disrupted white matter architecture in the hippocampus and its primary and remote connections were demonstrated in TLE. While changes in the hippocampus and cingulum were more prominent in right TLE, remote changes were more prominent in left TLE. MD of the right hippocampus and FA of the left external capsule were found to be the strongest structural predictors of TLE laterality. Changes associated with duration of epilepsy indicated that changes in structural integrity may be progressive over the disease course. This study illustrates the potential of structural diffusion tensor imaging in elucidating pathophysiology, enhancing diagnosis and assisting prognostication. (C) 2015 Elsevier B.V. All rights reserved. C1 [Chiang, Sharon] Rice Univ, Dept Stat, Houston, TX 77251 USA. [Levin, Harvey S.; Wilde, Elisabeth] Baylor Coll Med, Dept Phys Med, Houston, TX 77030 USA. [Haneef, Zulfi] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Haneef, Zulfi] Michael E DeBakey VA Med Ctr, Neurol Care Line, Houston, TX USA. [Levin, Harvey S.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA. RP Chiang, SR (reprint author), Rice Univ, Dept Stat, Houston, TX 77251 USA. EM sc4712@rice.edu; hlevin@bcm.edu; ewilde@bcm.edu; zulfi.haneef@bcm.edu FU National Library of Medicine Training Fellowship in Biomedical Informatics, Gulf Coast Consortia for Quantitative Biomedical Sciences [2T15LM007093-21]; National Institutes of Health [5T32CA096520-07]; Moody Foundation; Epilepsy Foundation of America; Baylor College of Medicine Computational and Integrative Biomedical Research Center Seed Grant Awards FX Sharon Chiang's contributions to this article include study concept or design, statistical analysis, drafting/revising the manuscript for content, and analysis/interpretation of data. Harvey S. Levin's contributions to this article include revising the manuscript for content. Elisabeth Wilde's contributions to this article include revising the manuscript for content. Zulfi Haneef's contributions to this article include study concept or design, drafting/revising the manuscript for content, analysis/interpretation of data, study supervision, and obtaining funding. The authors acknowledge Raja Muthupillai, Claudio Arenas, Cynthia Calija, Sikawat Thanaviratananich, and Christina Thomas for help with methodology, recruitment, and data collection. Funding for the design and conduct of this study; for the collection, management, analysis, and interpretation of the data; and for the preparation, review, and approval of the manuscript was provided by the Epilepsy Foundation of America. Support for this publication was provided by the National Library of Medicine Training Fellowship in Biomedical Informatics, Gulf Coast Consortia for Quantitative Biomedical Sciences (Grant #2T15LM007093-21) (SC); the National Institutes of Health (Grant #5T32CA096520-07) (SC); the Moody Foundation (HSL); Epilepsy Foundation of America (Research Grants Program) (ZH); and the Baylor College of Medicine Computational and Integrative Biomedical Research Center Seed Grant Awards (ZH). NR 58 TC 5 Z9 6 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2016 VL 120 BP 37 EP 46 DI 10.1016/j.eplepsyres.2015.12.002 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DE9ZQ UT WOS:000370998800007 PM 26709881 ER PT J AU Torolira, D Suchomelova, L Wasterlain, CG Niquet, J AF Torolira, Daniel Suchomelova, Lucie Wasterlain, Claude G. Niquet, Jerome TI Widespread neuronal injury in a model of cholinergic status epilepticus in postnatal day 7 rat pups SO EPILEPSY RESEARCH LA English DT Article DE Immature brain; Seizures; Fluoro-Jade B; Active caspase-3; Neonate; Hippocampus ID RECURRENT NEONATAL SEIZURES; EARLY-LIFE SEIZURES; LONG-TERM CONSEQUENCES; NERVE AGENT EXPOSURE; MEDIODORSAL NUCLEUS; EXCITATORY ACTIONS; BRAIN-DEVELOPMENT; 12-DAY-OLD RATS; IMMATURE RATS; HIPPOCAMPUS AB Objective: Status Epilepticus (SE) is common in neonates and infants, and is associated with neuronal injury and adverse developmental outcomes. However, the role of SE in this injury is uncertain. Until now, we have lacked an animal model in which seizures result in neuronal injury in rodent models at ages below postnatal day 12 (P12) unless seizures are combined with inflammatory stressors. Methods: We induced SE with high-dose lithium and pilocarpine in P7 rats, which are developmentally close to human neonates. Several EEG measures and O-2 saturation were recorded during the 6 h following initiation of SE. We assessed neuronal injury at 6 and 24 h post-SE onset using Fluoro-Jade B staining (FJB) and caspase-3a immunoreactivity (IR). Results: EEGs showed continuous polyspikes activity for 54.3 +/- 6.7 min, while O-2 saturation showed no significant hypoxemia. By 24 h after SE onset, significant neuronal injury was observed in CA1/subiculum, CA3, dentate gyrus, thalamus, neocortex, amygdala, piriform cortex, lateral entorhinal cortex, hypothalamus, caudate putamen, globus pallidus, ventral pallidum, and nucleus accumbens. At 24 h post-SE, caspase-3a IR was significantly increased in CA1/subiculum, thalamus, and neocortex compared to sham, and caspase-3a IR neurons had fragmented nuclei, suggesting that SE triggered an irreversible form of cell injury. Significance: In conclusion, we have developed a model of cholinergic SE in P7 rat pups, which combines high survival (69.9% survival at 24 h) and widespread brain injury. These studies suggest that the immature brain is vulnerable to severe forms of SE. Published by Elsevier B.V. C1 [Torolira, Daniel; Suchomelova, Lucie; Wasterlain, Claude G.; Niquet, Jerome] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA 90073 USA. [Wasterlain, Claude G.; Niquet, Jerome] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, Los Angeles, CA 90073 USA. EM jniquet@ucla.edu FU Merit Review Award from the United States (U.S.) Department of Veterans Affairs (Biomedical Laboratory Research and Development Service) [I01 BX000273-07]; NINDS [UO1 NS074926] FX This work was supported in part by Merit Review Award # I01 BX000273-07 from the United States (U.S.) Department of Veterans Affairs (Biomedical Laboratory Research and Development Service) and NINDS (grant UO1 NS074926; CW). NR 42 TC 1 Z9 1 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD FEB PY 2016 VL 120 BP 47 EP 54 DI 10.1016/j.eplepsyres.2015.11.005 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DE9ZQ UT WOS:000370998800008 PM 26709882 ER PT J AU Chen, S Whitson, H Quinones, A Thielke, S AF Chen, Sunny Whitson, Heather Quinones, Ana Thielke, Stephen TI Comparative health and self-rated health are equivalently associated with health indicators among older adults SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Letter ID MORTALITY; ASSESSMENTS C1 [Chen, Sunny; Thielke, Stephen] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. [Whitson, Heather] Duke Univ, Med Ctr, Dept Med Geriatr & Ophthalmol, DUMC Box 3003, Durham, NC 27710 USA. [Whitson, Heather] Duke Univ, Med Ctr, Aging Ctr, DUMC Box 3003, Durham, NC 27710 USA. [Whitson, Heather] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 508 Fulton St,3rd Floor GRECC, Durham, NC 27705 USA. [Quinones, Ana] Oregon Hlth & Sci Univ, Sch Publ Hlth, 3181 SW Sam Jackson Pk Rd,Mail Code CB669, Portland, OR 97239 USA. [Quinones, Ana] Oregon Hlth & Sci Univ, Portland VA Med Ctr, 3181 SW Sam Jackson Pk Rd,Mail Code CB669, Portland, OR 97239 USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, 1959 Pacific St,Box 356560, Seattle, WA 98195 USA. RP Thielke, S (reprint author), Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA.; Thielke, S (reprint author), Univ Washington, Dept Psychiat & Behav Sci, 1959 Pacific St,Box 356560, Seattle, WA 98195 USA. EM sthielke@u.washington.edu OI Quinones, Ana/0000-0001-6554-7734 FU NHLBI NIH HHS [R25 HL105430, R25HL105430]; NIA NIH HHS [K23-AG-032867, K23 AG032867, P30 AG028716, P30-AG-028716, R01 AG043438]; NIMH NIH HHS [K23 MH093591] NR 8 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0895-4356 EI 1878-5921 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD FEB PY 2016 VL 70 BP 279 EP 280 DI 10.1016/j.jclinepi.2015.08.022 PG 2 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DE5NE UT WOS:000370676900041 PM 26386324 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI Ambulatory blood pressure monitoring to diagnose hypertension-an idea whose time has come SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Editorial Material C1 [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Med, Reno, NV 89557 USA. [Bloch, Michael J.] Renown Inst Heart & Vasc Hlth, Vasc Care, Reno, NV USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Bloch, MJ (reprint author), Univ Nevada, Sch Med, Dept Internal Med, Vasc Care,Renown Heart & Vasc Inst, Reno, NV 89557 USA. EM Michael@bluesprucemed.com NR 7 TC 4 Z9 4 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD FEB PY 2016 VL 10 IS 2 BP 89 EP 91 DI 10.1016/j.jash.2015.10.010 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DE8MB UT WOS:000370889000001 PM 26654344 ER PT J AU Ibrahim-Verbaas, CA Bressler, J Debette, S Schuur, M Smith, AV Bis, JC Davies, G Trompet, S Smith, JA Wolf, C Chibnik, LB Liu, Y Vitart, V Kirin, M Petrovic, K Polasek, O Zgaga, L Fawns-Ritchie, C Hoffmann, P Karjalainen, J Lahti, J Llewellyn, DJ Schmidt, CO Mather, KA Chouraki, V Sun, Q Resnick, SM Rose, LM Oldmeadow, C Stewart, M Smith, BH Gudnason, V Yang, Q Mirza, SS Jukema, JW Dejager, PL Harris, TB Liewald, DC Amin, N Coker, LH Stegle, O Lopez, OL Schmidt, R Teumer, A Ford, I Karbalai, N Becker, JT Jonsdottir, MK Au, R Fehrmann, RSN Herms, S Nalls, M Zhao, W Turner, ST Yaffe, K Lohman, K van Swieten, JC Kardia, SLR Knopman, DS Meeks, WM Heiss, G Holliday, EG Schofield, PW Tanaka, T Stott, DJ Wang, J Ridker, P Gow, AJ Pattie, A Starr, JM Hocking, LJ Armstrong, NJ McLachlan, S Shulman, JM Pilling, LC Eiriksdottir, G Scott, RJ Kochan, NA Palotie, A Hsieh, YC Eriksson, JG Penman, A Gottesman, RF Oostra, BA Yu, L DeStefano, AL Beiser, A Garcia, M Rotter, JI Nothen, MM Hofman, A Slagboom, PE Westendorp, RGJ Buckley, BM Wolf, PA Uitterlinden, AG Psaty, BM Grabe, HJ Bandinelli, S Chasman, DI Grodstein, F Roikkonen, K Lambert, JC Porteous, DJ Price, JF Sachdev, PS Ferrucci, L Attia, JR Rudan, I Hayward, C Wright, AF Wilson, JF Cichon, S Franke, L Schmidt, H Ding, J de Craen, AJM Fornage, M Bennett, DA Deary, IJ Ikram, MA Launer, LJ Fitzpatrick, AL Seshadri, S van Duijn, CM Mosley, TH AF Ibrahim-Verbaas, C. A. Bressler, J. Debette, S. Schuur, M. Smith, A. V. Bis, J. C. Davies, G. Trompet, S. Smith, J. A. Wolf, C. Chibnik, L. B. Liu, Y. Vitart, V. Kirin, M. Petrovic, K. Polasek, O. Zgaga, L. Fawns-Ritchie, C. Hoffmann, P. Karjalainen, J. Lahti, J. Llewellyn, D. J. Schmidt, C. O. Mather, K. A. Chouraki, V. Sun, Q. Resnick, S. M. Rose, L. M. Oldmeadow, C. Stewart, M. Smith, B. H. Gudnason, V. Yang, Q. Mirza, S. S. Jukema, J. W. Dejager, P. L. Harris, T. B. Liewald, D. C. Amin, N. Coker, L. H. Stegle, O. Lopez, O. L. Schmidt, R. Teumer, A. Ford, I. Karbalai, N. Becker, J. T. Jonsdottir, M. K. Au, R. Fehrmann, R. S. N. Herms, S. Nalls, M. Zhao, W. Turner, S. T. Yaffe, K. Lohman, K. van Swieten, J. C. Kardia, S. L. R. Knopman, D. S. Meeks, W. M. Heiss, G. Holliday, E. G. Schofield, P. W. Tanaka, T. Stott, D. J. Wang, J. Ridker, P. Gow, A. J. Pattie, A. Starr, J. M. Hocking, L. J. Armstrong, N. J. McLachlan, S. Shulman, J. M. Pilling, L. C. Eiriksdottir, G. Scott, R. J. Kochan, N. A. Palotie, A. Hsieh, Y-C Eriksson, J. G. Penman, A. Gottesman, R. F. Oostra, B. A. Yu, L. DeStefano, A. L. Beiser, A. Garcia, M. Rotter, J. I. Noethen, M. M. Hofman, A. Slagboom, P. E. Westendorp, R. G. J. Buckley, B. M. Wolf, P. A. Uitterlinden, A. G. Psaty, B. M. Grabe, H. J. Bandinelli, S. Chasman, D. I. Grodstein, F. Roikkonen, K. Lambert, J-C Porteous, D. J. Price, J. F. Sachdev, P. S. Ferrucci, L. Attia, J. R. Rudan, I. Hayward, C. Wright, A. F. Wilson, J. F. Cichon, S. Franke, L. Schmidt, H. Ding, J. de Craen, A. J. M. Fornage, M. Bennett, D. A. Deary, I. J. Ikram, M. A. Launer, L. J. Fitzpatrick, A. L. Seshadri, S. van Duijn, C. M. Mosley, T. H. CA Generation Scotland TI GWAS for executive function and processing speed suggests involvement of the CADM2 gene SO MOLECULAR PSYCHIATRY LA English DT Article ID ONSET ALZHEIMERS-DISEASE; GENOME-WIDE ASSOCIATION; COGNITIVE FUNCTION; LINKAGE ANALYSIS; COMMON VARIANTS; LOCI; INTELLIGENCE; EXPRESSION; DISORDER; SCHIZOPHRENIA AB To identify common variants contributing to normal variation in two specific domains of cognitive functioning, we conducted a genome-wide association study (GWAS) of executive functioning and information processing speed in non-demented older adults from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium. Neuropsychological testing was available for 5429-32 070 subjects of European ancestry aged 45 years or older, free of dementia and clinical stroke at the time of cognitive testing from 20 cohorts in the discovery phase. We analyzed performance on the Trail Making Test parts A and B, the Letter Digit Substitution Test (LDST), the Digit Symbol Substitution Task (DSST), semantic and phonemic fluency tests, and the Stroop Color and Word Test. Replication was sought in 1311-21860 subjects from 20 independent cohorts. A significant association was observed in the discovery cohorts for the single-nucleotide polymorphism (SNP) rs17518584 (discovery P-value = 3.12 x 10(-8)) and in the joint discovery and replication meta-analysis (P-value = 3.28 x 10(-9) after adjustment for age, gender and education) in an intron of the gene cell adhesion molecule 2 (CADM2) for performance on the LDST/DSST. Rs17518584 is located about 170 kb upstream of the transcription start site of the major transcript for the CADM2 gene, but is within an intron of a variant transcript that includes an alternative first exon. The variant is associated with expression of CADM2 in the cingulate cortex (P-value= 4x10(-4)). The protein encoded by CADM2 is involved in glutamate signaling (P-value = 7.22 x 10(-15)), gamma-aminobutyric acid (GABA) transport (P-value = 1.36 x 10(-11)) and neuron cell-cell adhesion (P-value = 1.48 x 10(-13)). Our findings suggest that genetic variation in the CADM2 gene is associated with individual differences in information processing speed. C1 [Ibrahim-Verbaas, C. A.; Schuur, M.; Amin, N.; Oostra, B. A.; van Duijn, C. M.] Erasmus Univ, Med Ctr, Dept Epidemiol, Genet Epidemiol Unit, Rotterdam, Netherlands. [Ibrahim-Verbaas, C. A.; Schuur, M.; van Swieten, J. C.; Ikram, M. A.] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands. [Bressler, J.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Human Genet Ctr, Houston, TX 77030 USA. [Debette, S.; Au, R.; DeStefano, A. L.; Beiser, A.; Wolf, P. A.; Seshadri, S.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Debette, S.] Univ Bordeaux, Epidemiol & Biostat, U897, INSERM, Bordeaux, France. [Debette, S.] Bordeaux Univ Hosp, Dept Neurol, Bordeaux, France. [Smith, A. V.; Gudnason, V.; Eiriksdottir, G.] Iceland Heart Assoc, Kopavogur, Iceland. [Smith, A. V.; Gudnason, V.] Univ Iceland, Fac Med, Reykjavik, Iceland. [Bis, J. C.; Psaty, B. M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Davies, G.; Fawns-Ritchie, C.; Liewald, D. C.; Gow, A. J.; Pattie, A.; Starr, J. M.; Deary, I. J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland. [Trompet, S.; Jukema, J. W.] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands. [Trompet, S.; de Craen, A. J. M.] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands. [Smith, J. A.; Zhao, W.; Kardia, S. L. R.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Wolf, C.; Karbalai, N.] Max Planck Inst Psychiat, RG Stat Genet, Munich, Germany. [Chibnik, L. B.; Dejager, P. L.] Brigham & Womens Hosp, Div Neurol, Program Translat Neuropsychiat Gen, Boston, MA 02115 USA. [Liu, Y.; Lohman, K.] Wake Forest Sch Med, Dept Epidemiol, Winston Salem, NC USA. [Petrovic, K.; Schmidt, R.; Schmidt, H.] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland. [Kirin, M.; Stewart, M.; McLachlan, S.; Price, J. F.; Rudan, I.; Wilson, J. F.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland. [Petrovic, K.; Schmidt, R.; Schmidt, H.] Med Univ & Gen Hosp Graz, Dept Neurol, Graz, Austria. [Polasek, O.] Univ Split, Dept Publ Hlth, Split, Croatia. [Zgaga, L.] Trintiy Coll Dublin, Dept Publ Hlth & Primary Care, Dublin, Ireland. [Hoffmann, P.; Cichon, S.] Res Ctr Juelich, Inst Neurosci & Med INM1, Julich, Germany. [Hoffmann, P.; Herms, S.; Cichon, S.] Univ Basel, Dept Biomed, Div Med Genet, Basel, Switzerland. [Hoffmann, P.; Herms, S.; Noethen, M. M.; Cichon, S.] Univ Bonn, Inst Human Genet, Life & Brain Res Ctr, Dept Genom, Bonn, Germany. [Karjalainen, J.; Fehrmann, R. S. N.; Franke, L.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands. [Lahti, J.; Roikkonen, K.] Univ Helsinki, Inst Behav Sci, Helsinki, Finland. [Lahti, J.; Eriksson, J. G.] Folkhalsan Res Ctr, Helsinki, Finland. [Llewellyn, D. J.] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Exeter, Devon, England. [Schmidt, C. O.] Univ Med Greifswald, Inst Community Med, Greifswald, Germany. [Mather, K. A.; Armstrong, N. J.; Kochan, N. A.; Sachdev, P. S.] Univ New S Wales, UNSW Med, Sch Psychiat, Ctr Hlth Brain Ageing, Sydney, NSW, Australia. [Chouraki, V.; Lambert, J-C] Univ Lille Nord France, Inst Pasteur Lille, U1167, INSERM, Lille, France. [Sun, Q.; Grodstein, F.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Sun, Q.; Grodstein, F.] Harvard Univ, Sch Med, Boston, MA USA. [Resnick, S. M.] NIA, Lab Behav Neurosci, NIH, Baltimore, MD 21224 USA. [Rose, L. M.; Ridker, P.; Chasman, D. I.] Brigham & Womens Hosp, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Oldmeadow, C.; Holliday, E. G.; Scott, R. J.; Attia, J. R.] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2300, Australia. [Oldmeadow, C.; Holliday, E. G.; Scott, R. J.; Attia, J. R.] Univ Newcastle, Fac Hlth, Newcastle, NSW 2300, Australia. [Smith, B. H.] Univ Dundee, Med Res Inst, Dundee, Scotland. [Yang, Q.; Au, R.; DeStefano, A. L.; Beiser, A.; Wolf, P. A.; Seshadri, S.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Yang, Q.; Wang, J.; DeStefano, A. L.; Beiser, A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Mirza, S. S.; Hofman, A.; Uitterlinden, A. G.; Ikram, M. A.] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Mirza, S. S.; Hofman, A.; Uitterlinden, A. G.; Ikram, M. A.; van Duijn, C. M.] Netherlands Consortium Hlth Ageing, Leiden, Netherlands. [Harris, T. B.; Garcia, M.; Launer, L. J.] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA. [Liewald, D. C.; Gow, A. J.; Deary, I. J.] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland. [Coker, L. H.] Wake Forest Sch Med, Div Publ Hlth Sci & Neurol, Winston Salem, NC USA. [Stegle, O.] Max Planck Inst Intelligent Syst, Max Planck Inst Dev Biol, Tubingen, Germany. [Lopez, O. L.; Becker, J. T.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Teumer, A.] Univ Med Greifswald, Interfaculty Inst Genet & Funct Genom, Greifswald, Germany. [Ford, I.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland. [Becker, J. T.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Becker, J. T.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Jonsdottir, M. K.] Landspitali Hosp, Reykjavik, Iceland. [Nalls, M.] NIA, Lab Neurogenet, Bethesda, MD 20892 USA. [Turner, S. T.] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA. [Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Knopman, D. S.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Meeks, W. M.] Univ Mississippi, Med Ctr, Dept Med, Div Geriatr, Jackson, MS 39216 USA. [Heiss, G.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Schofield, P. W.] Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Tanaka, T.; Ferrucci, L.] NIA, Translat Gerontol Branch, Baltimore, MD 21224 USA. [Stott, D. J.] Univ Glasgow, Dept Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. [Starr, J. M.] Alzheimer Scotland Res Ctr, Edinburgh, Midlothian, Scotland. [Hocking, L. J.] Univ Aberdeen, Div Appl Med, Aberdeen, Scotland. [Armstrong, N. J.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia. [Armstrong, N. J.] Univ New S Wales, Sch Math & Stat, Sydney, NSW, Australia. [Armstrong, N. J.] Univ New S Wales, Prince Wales Clin Sch, Sydney, NSW, Australia. [Shulman, J. M.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Shulman, J. M.] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Dept Mol & Human Genet, Houston, TX 77030 USA. [Pilling, L. C.] Univ Exeter, Sch Med, Epidemiol & Publ Hlth Grp, Exeter, Devon, England. [Kochan, N. A.; Sachdev, P. S.] Prince Wales Hosp, Neuropsychiat Inst, Sydney, NSW, Australia. [Palotie, A.] Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge, England. [Palotie, A.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland. [Palotie, A.] Univ Helsinki, Dept Med Genet, Helsinki, Finland. [Palotie, A.] Univ Cent Hosp, Helsinki, Finland. [Hsieh, Y-C] Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan. [Eriksson, J. G.] Univ Helsinki, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland. [Eriksson, J. G.] Natl Inst Hlth & Welf, Helsinki, Finland. [Eriksson, J. G.] Univ Helsinki, Cent Hosp, Unit Gen Practice, Helsinki, Finland. [Eriksson, J. G.] Vasa Cent Hosp, Vaasa, Finland. [Penman, A.] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA. [Gottesman, R. F.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Yu, L.; Bennett, D. A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Rotter, J. I.] Cedars Sinai Med Ctr, Med Genet Inst, Los Angeles, CA 90048 USA. [Rotter, J. I.] Harbor UCLA Med Ctr, Angeles BioMed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA. [Rotter, J. I.] Harbor UCLA Med Ctr, Dept Pediat, Div Genet Outcomes, Torrance, CA 90509 USA. [Noethen, M. M.] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany. [Slagboom, P. E.] Leiden Univ, Med Ctr, Dept Mol Epidemiol, Leiden, Netherlands. [Westendorp, R. G. J.] Leiden Acad Vital & Ageing, Leiden, Netherlands. [Buckley, B. M.] Univ Coll Cork, Dept Pharmacol & Therapeut, Cork, Ireland. [Uitterlinden, A. G.] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands. [Psaty, B. M.; Fitzpatrick, A. L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Psaty, B. M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Psaty, B. M.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA. [Grabe, H. J.] HELIOS Hosp Stralsund, Univ Med Greifswald, Dept Psychiat & Psychotherapy, Stralsund, Germany. [Ibrahim-Verbaas, C. A.; Bressler, J.; Debette, S.; Schuur, M.; Smith, A. V.; Bis, J. C.; Davies, G.; Bandinelli, S.] Azienda Sanitaria Firenze, Geriatr Unit, Florence, Italy. [Porteous, D. J.] Univ Edinburgh, Inst Genet & Mol Med, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland. [Ding, J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA. [Fornage, M.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA. [Fornage, M.] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Ikram, M. A.] Erasmus Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands. [Mosley, T. H.] Univ Mississippi, Med Ctr, Dept Med & Neurol, Jackson, MS 39216 USA. RP Mosley, TH (reprint author), Univ Mississippi, Med Ctr, Dept Med Geriatr, 2500 North State St, Jackson, MS 39216 USA. EM tmosley@umc.edu RI ; Lambert, jean-charles/A-9553-2014; Franke, Lude/P-7036-2016; Karjalainen, Juha/P-8624-2016; Slagboom, P. Eline/R-4790-2016; Fehrmann, Rudolf/E-2551-2011; Polasek, Ozren/B-6002-2011; Gudnason, Vilmundur/K-6885-2015 OI van Swieten, John /0000-0001-6278-6844; Lahti, Jari/0000-0002-4310-5297; Sachdev, Perminder/0000-0002-9595-3220; Smith, Blair/0000-0002-5362-9430; Beiser, Alexa/0000-0001-8551-7778; Smith, Jennifer/0000-0002-3575-5468; Raikkonen, Katri/0000-0003-3124-3470; Gow, Alan/0000-0002-3320-4531; Nothen, Markus/0000-0002-8770-2464; Smith, Albert Vernon/0000-0003-1942-5845; Lambert, jean-charles/0000-0003-0829-7817; Franke, Lude/0000-0002-5159-8802; Slagboom, P. Eline/0000-0002-2875-4723; Fehrmann, Rudolf/0000-0002-7516-315X; Polasek, Ozren/0000-0002-5765-1862; Stegle, Oliver/0000-0002-8818-7193; Zgaga, Lina/0000-0003-4089-9703; Hocking, Lynne J/0000-0002-2414-2826; Gudnason, Vilmundur/0000-0001-5696-0084 FU National Foundation for Alzheimer's disease and related disorders; Institut Pasteur de Lille; Centre National de Genotypage; Inserm; FRC (fondation pour la recherche sur le cerveau); Rotary; LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease); MEDIALZ Project - ERDF (European Regional Development Fund) [11001003]; Conseil Regional Nord Pas de Calais; Fondation pour la Recherche Medicale; Caisse Nationale Maladie des Travailleurs Salaries; Direction Generale de la Sante; MGEN; Institut de la Longevite; Agence Francaise de Securite Sanitaire des Produits de Sante; Aquitaine and Bourgogne Regional Councils; Fondation de France; joint French Ministry of Research/INSERM 'Cohortes et collections de donnees biologiques' program; Eisai; Wellcome Trust; British Heart Foundation; Chief Scientist Office of the Scottish Executive; NIA [N01-AG-12100]; National Heart, Lung and Blood Institute Contracts [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL70825, R01HL087641, R01HL59367, R01HL086694]; National Human Genome Research Institute [U01HG004402]; NIH Roadmap for Medical Research; Austrian Science Fond (FWF) [P20545-P05, P13180]; Intramural Research Program of the NIH, National Institute on Aging; NHLBI [HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC850863, U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393]; National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) [R01AG023629, R01AG15928, R01AG20098, R01AG027058]; National Center for Advancing Translational Sciences; CTSI [UL1TR000124]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) [DK063491]; Medical Research Council (UK); European Commission Framework 6 project EUROSPAN [LSHG-CT-2006-018947]; Republic of Croatia Ministry of Science, Education and Sports [108-1080315-0302]; Netherlands Organization for Scientific Research (NWO); Internationale Stichting Alzheimer Onderzoek (ISAO); Hersenstichting Nederland (HSN); Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI); Russian Foundation for Basic Research (RFBR); National Heart, Lung and Blood Institute's Framingham Heart Study [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278, U01 HL096917, R01 HL093029]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center; National Institute of Neurological Disorders and Stroke [NS17950]; National Institute of Aging [U01 AG049505, AG033193, AG008122, AG16495]; Agence National de la Recherche; Leducq Foundation; National Heart, Lung and Blood Institute [HL054464, HL054457, HL054481, HL071917, HL87660, HL043851, HL080467]; National Institute of Neurological Disorders and Stroke of the National Institutes of Health [NS041558]; Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6]; Scottish Funding Council [HR03006]; Academy of Finland; Finnish Diabetes Research Society; Folkhalsan Research Foundation; Novo Nordisk Foundation; Finska Lakaresallskapet; Signe and Ane Gyllenberg Foundation; University of Helsinki; Ministry of Education; Ahokas Foundation; Emil Aaltonen Foundation; Juho Vainio Foundation; Wellcome Trust [WT089062]; University of Newcastle's Strategic Initiative Fund; Vincent Fairfax Family Foundation; Hunter Medical Research Institute; Italian Ministry of Health [ICS 110.1RS97.71]; US National Institute on Aging [N01[AG]916413, N01[AG]821336, 263 MD 9164 13, 263 MD 821336]; Intramural Research Program, National Institute on Aging, National Institutes of Health; BBSRC; Royal Society; Chief Scientist Office of the Scottish Government; Research Into Ageing; UK Biotechnology and Biological Sciences Research Council (BBSRC); Engineering and Physical Sciences Research Council (EPSRC); Economic and Social Research Council (ESRC); MRC; NHMRC [401184]; Australian National Health & Medical Research Council [350833, 568969]; Capacity Building Grant [568940]; NHMRC Project [525453]; National Institutes of Health [CA87969, CA49449, HL34594, U01HG004399, DK058845, CA65725, CA67262, CA50385, 5UO1CA098233, EY09611, EY015473, HG004728, HL35464, CA55075, CA134958, DK070756]; MRC Human Genetics Unit; Arthritis Research UK; European Union [LSHG-CT-2006-018947]; Bristol-Myers Squibb; Netherlands Heart Foundation [2001 D 032]; European commission [223004]; Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging) [050-060-810]; Netherlands Organisation of Scientific Research NWO Investments [175.010.2005.011, 911-03-012]; Research Institute for Diseases in the Elderly [014-93-015]; Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project [050-060-810]; Erasmus Medical Center; Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry of Education, Culture and Science; Ministry for Health, Welfare and Sports; European Commission 49 (DG XII); Municipality of Rotterdam; ZonMW Veni Grant [916.13.054]; NIA Grants [P30AG10161, R01AG15819, R01AG17917, R01AG30146, K08AG34290, K25AG41906]; Federal Ministry of Education and Research [01ZZ9603, 01ZZ0103, 01ZZ0403]; Ministry of Cultural Affairs; Social Ministry of the Federal State of Mecklenburg-West Pomerania; National Cancer Institute [CA047988]; Donald W Reynolds Foundation; Fondation Leducq; Amgen FX CS: The work was made possible by the generous participation of the control subjects and their families. This work was supported by the National Foundation for Alzheimer's disease and related disorders, the Institut Pasteur de Lille, the Centre National de Genotypage, Inserm, FRC (fondation pour la recherche sur le cerveau) and Rotary. This work has been developed and supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease). JCL was funded by the MEDIALZ Project (Grant 11001003) financed by ERDF (European Regional Development Fund) and Conseil Regional Nord Pas de Calais. The Three-City Study was performed as part of a collaboration between the Institut National de la Sante et de la Recherche Medicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthelabo. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, MGEN, Institut de la Longevite, Agence Francaise de Securite Sanitaire des Produits de Sante, the Aquitaine and Bourgogne Regional Councils, Fondation de France and the joint French Ministry of Research/INSERM 'Cohortes et collections de donnees biologiques' program. Lille Genopole received an unconditional grant from Eisai.; AAA: We thank the cohort participants and team members who contributed to this study. Phenotype collection and DNA extraction were supported by the Wellcome Trust, the British Heart Foundation and the Chief Scientist Office of the Scottish Executive. The AAA Trial was performed and the database is maintained by members of the University of Edinburgh Molecular Epidemiology Research Group in the Centre for Population Health Sciences. We also thank staff at the Wellcome Trust Clinical Research Facility in Edinburgh where some of the research clinics and genotyping were undertaken.; AGES: Aging Gene-Environment Susceptibility-Reykjavik Study: The research has been funded by NIA Contract N01-AG-12100 with contributions from NEI, NIDCD and NHLBI, the NIA Intramural Research Program, Hjartavernd (the Icelandic Heart Association) and the Althingi (the Icelandic Parliament).; ARIC: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung and Blood Institute Contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and HHSN268201100012C), R01HL70825, R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute Contract U01HG004402; and National Institutes of Health Contract HHSN268200625226C. We thank the staff and participants of the ARIC study for their important contributions. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research.; ASPS: We thank Ing. Johann Semmler and Irmgard Polzl for creating the DNA bank and for supervising the quality management of the biobanking and DNA analyses. The ASPS is funded by the Austrian Science Fond (FWF) Grant Number P20545-P05 and P13180.; BLSA: Baltimore Longitudinal Study of Aging (BLSA): The Baltimore Longitudinal Study of Aging is supported by the Intramural Research Program of the NIH, National Institute on Aging.; Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG15928, R01AG20098, and R01AG027058 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHSNHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; CROATIA-Korcula: The CROATIA-Korcula study was funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN (Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to IR (108-1080315-0302). We would like to acknowledge the invaluable contributions of the recruitment team in Korcula, the administrative teams in Croatia and Edinburgh and the people of Korcula. The SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum Munchen, Neuherberg, Germany.; CROATIA-Vis: The CROATIA-Vis study was funded by grants from the Medical Research Council (UK) and Republic of Croatia Ministry of Science, Education and Sports research grants to IR (108-1080315-0302). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of Split and Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Vis cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research Facility at the Western General Hospital, Edinburgh, Scotland.; ERF: This study was financially supported by the Netherlands Organization for Scientific Research (NWO), the Internationale Stichting Alzheimer Onderzoek (ISAO), the Hersenstichting Nederland (HSN) and the Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI) and by the Russian Foundation for Basic Research (RFBR). We thank the participants from the Genetic Research in Isolated Populations, Erasmus Rucphen Family, who made this work possible. Also, we thank Petra Veraart for collecting all genealogical data.; FHS: This work was supported by the National Heart, Lung and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278) and Grants (U01 HL096917 and R01 HL093029). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This study was also supported by grants from the National Institute of Neurological Disorders and Stroke (NS17950) and the National Institute of Aging (U01 AG049505, AG033193, AG008122, AG16495). The content is solely the responsibility of the authors and does not necessarily represent the official views of NINDS, NHLBI, NIA, NIH or AHA. Dr. Debette is a recipient of a Chaire d'Excellence grant from the Agence National de la Recherche and a grant from the Leducq Foundation.; GENOA: Support for the Genetic Epidemiology Network of Arteriopathy (GENOA) was provided by the National Heart, Lung and Blood Institute (HL054464, HL054457, HL054481, HL071917 and HL87660) and the National Institute of Neurological Disorders and Stroke (NS041558) of the National Institutes of Health. Genotyping was performed at the Mayo Clinic (S.T.T., Mariza de Andrade, Julie Cunningham) and was made possible by the University of Texas Health Sciences Center (Eric Boerwinkle, Megan L Grove-Gaona). We would also like to thank the families that participated in the GENOA study.; GS: We are grateful to the GS Executive Committee Professors Blair H. Smith, David J. Porteous, Sandosh Padmanabhan and Dr. Lynne J. Hocking, and all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006].; HBCS: We thank all study participants as well as everybody involved in the Helsinki Birth Cohort Study. Helsinki Birth Cohort Study has been supported by grants from the Academy of Finland, the Finnish Diabetes Research Society, Folkhalsan Research Foundation, Novo Nordisk Foundation, Finska Lakaresallskapet, Signe and Ane Gyllenberg Foundation, University of Helsinki, Ministry of Education, Ahokas Foundation, Emil Aaltonen Foundation, Juho Vainio Foundation and Wellcome Trust (Grant Number WT089062).; Health ABC: This research was supported by NIA Contracts N01AG62101, N01AG62103 and N01AG62106. The genome-wide association study was funded by NIA Grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, Contract Number HHSN268200782096C. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging.; Hunter: The authors would like to thank the men and women participating in the HCS as well as all the staff, investigators and collaborators who have supported or been involved in the project to date. The cohort was made possible with support from the University of Newcastle's Strategic Initiative Fund, the Vincent Fairfax Family Foundation and the Hunter Medical Research Institute.; InCHIANTI: The Invechhiare in Chianti (InCHIANTI) Study was supported as a targeted project (ICS 110.1RS97.71) by the Italian Ministry of Health, by the US National Institute on Aging (Contracts N01[AG]916413, N01[AG]821336, 263 MD 9164 13, and 263 MD 821336), and, in part, by the Intramural Research Program, National Institute on Aging, National Institutes of Health.; LBC1921/LBC1936: We thank the cohort participants and team members who contributed to these studies. Phenotype collection in the Lothian Birth Cohort 1921 was supported by the BBSRC, The Royal Society and The Chief Scientist Office of the Scottish Government. Phenotype collection in the Lothian Birth Cohort 1936 was supported by Research Into Ageing (continues as part of Age UK The Disconnected Mind project). Genotyping of the cohorts was funded by the UK Biotechnology and Biological Sciences Research Council (BBSRC). The work was undertaken by The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698). Funding from the BBSRC, Engineering and Physical Sciences Research Council (EPSRC), Economic and Social Research Council (ESRC) and MRC is gratefully acknowledged.; MAS: We would like to acknowledge and thank the Sydney MAS participants and the Research Team for their contributions and assistance. We would like to specifically acknowledge the support and contributions of Professor Henry Brodaty (Chief Investigator), Dr Simone Reppermund (Study Co-ordinator), Professor Peter Schofield, Dr Arezoo Assareh and Dr John Kwok to this work. DNA was extracted by Genetic Repositories Australia, an Enabling Facility supported by NHMRC Grant 401184. DNA sample preparation was undertaken in the laboratory of Professor Peter Schofield and Dr John Kwok, Neuroscience Research Australia, with the assistance of Dr Arezoo Assareh. Genotyping was performed by the Ramaciotti Centre, University of New South Wales. Sydney MAS is supported by the Australian National Health & Medical Research Council Program Grants 350833 and 568969. Karen Mather is supported by the Capacity Building Grant 568940. Nicola Armstrong is supported by the NHMRC Project Grant 525453.; Hippocampal eQTL: The hippocampal gene expression study was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Genome Research Network (IG) MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia, under the auspices of the National Genome Research Network plus (NGFNplus)).; NHS: This study was supported by research Grants CA87969, CA49449, HL34594, U01HG004399, DK058845, CA65725, CA67262, CA50385, 5UO1CA098233, EY09611, EY015473, HG004728, HL35464, CA55075, CA134958 and DK070756 from the National Institutes of Health. The genotyping was partly supported by an unrestricted grant from Merck Research Laboratories. Dr Sun is supported by career development award K99HL098459 from the National Heart, Lung and Blood Institute. Supported in part by NIH.; ORCADES: ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (Contract No. LSHG-CT-2006-018947). DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the invaluable contributions of Lorraine Anderson and the research nurses in Orkney, the administrative team in Edinburgh and the people of Orkney.; PROSPER: The PROSPER study was supported by an investigator initiated grant obtained from Bristol-Myers Squibb. Prof. Dr JW Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (Grant 2001 D 032). Support for genotyping was provided by the seventh framework program of the European commission (Grant 223004) and by the Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging Grant 050-060-810).; RS: The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS database, and Karol Estrada and Maksim V. Struchalin for their support in creation and analysis of imputed data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission 49 (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. Dr Ikram was supported by a ZonMW Veni Grant: 916.13.054.; RUSH: Supported in part by NIA Grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, K08AG34290 and K25AG41906.; SHIP: SHIP is part of the Community Medicine Research net of the University Medicine of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. The SHIP authors are grateful to Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum Munchen) for the genotyping of the SHIP-TREND cohort.; WGHS: The WGHS is supported by HL043851 and HL080467 from the National Heart, Lung and Blood Institute and CA047988 from the National Cancer Institute, the Donald W Reynolds Foundation and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen. NR 59 TC 4 Z9 5 U1 6 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD FEB PY 2016 VL 21 IS 2 BP 189 EP 197 DI 10.1038/mp.2015.37 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA DE7LI UT WOS:000370817800005 PM 25869804 ER PT J AU Lu, AT Hannon, E Levine, ME Hao, K Crimmins, EM Lunnon, K Kozlenkov, A Mill, J Dracheva, S Horvath, S AF Lu, Ake T. Hannon, Eilis Levine, Morgan E. Hao, Ke Crimmins, Eileen M. Lunnon, Katie Kozlenkov, Alexey Mill, Jonathan Dracheva, Stella Horvath, Steve TI Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum SO NATURE COMMUNICATIONS LA English DT Article ID GENOME-WIDE ASSOCIATION; DNA METHYLATION AGE; HUMAN LONGEVITY; HUMAN BRAIN; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; LIFE-SPAN; HUMAN TISSUES; CELL-TYPES; CLOCK AB DNA methylation (DNAm) levels lend themselves for defining an epigenetic biomarker of aging known as the 'epigenetic clock'. Our genome-wide association study (GWAS) of cerebellar epigenetic age acceleration identifies five significant (P<5.0 x 10(-8)) SNPs in two loci: 2p22.1 (inside gene DHX57) and 16p13.3 near gene MLST8 (a subunit of mTOR complex 1 and 2). We find that the SNP in 16p13.3 has a cis-acting effect on the expression levels of MLST8 (P = 6.9 x 10(-18)) in most brain regions. In cerebellar samples, the SNP in 2p22.1 has a cis-effect on DHX57 (P = 4.4 x 10(-5)). Gene sets found by our GWAS analysis of cerebellar age acceleration exhibit significant overlap with those of Alzheimer's disease (P = 4.4 x 10(-15)), age-related macular degeneration (P = 6.4 x 10(-6)), and Parkinson's disease (P = 2.6 x 10(-4)). Overall, our results demonstrate the utility of a new paradigm for understanding aging and age-related diseases: it will be fruitful to use epigenetic tissue age as endophenotype in GWAS. C1 [Lu, Ake T.; Levine, Morgan E.; Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA. [Hannon, Eilis; Lunnon, Katie; Mill, Jonathan] Univ Exeter, Sch Med, Exeter EX2 5DW, Devon, England. [Hao, Ke] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Genet & Genom Sci, New York, NY 10029 USA. [Crimmins, Eileen M.] Univ So Calif, Davis Sch Gerontol, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA. [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Kozlenkov, Alexey; Dracheva, Stella] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Kozlenkov, Alexey; Dracheva, Stella] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Mill, Jonathan] Kings Coll London, Inst Psychiat, London SE5 8AF, England. [Horvath, Steve] Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA. RP Horvath, S (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.; Horvath, S (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Biostat, Los Angeles, CA 90095 USA. EM shorvath@mednet.ucla.edu RI ; Mill, Jonathan/B-3276-2010 OI Hannon, Eilis/0000-0001-6840-072X; Mill, Jonathan/0000-0003-1115-3224; Lunnon, Katie/0000-0001-7570-6065 FU National Institutes of Health [NIA/NIH 5R01AG042511-02] FX The study was supported by the National Institutes of Health (NIA/NIH 5R01AG042511-02). NR 56 TC 5 Z9 5 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD FEB PY 2016 VL 7 AR 10561 DI 10.1038/ncomms10561 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DF0FM UT WOS:000371014500003 PM 26830004 ER PT J AU Griffis, HM Band, RA Ruther, M Harhay, M Asch, DA Hershey, JC Hill, S Nadkarni, L Kilaru, A Branas, CC Shofer, F Nichol, G Becker, LB Merchant, RM AF Griffis, Heather M. Band, Roger A. Ruther, Matthew Harhay, Michael Asch, David A. Hershey, John C. Hill, Shawndra Nadkarni, Lindsay Kilaru, Austin Branas, Charles C. Shofer, Frances Nichol, Graham Becker, Lance B. Merchant, Raina M. TI Employment and residential characteristics in relation to automated external defibrillator locations SO AMERICAN HEART JOURNAL LA English DT Article ID HOSPITAL CARDIAC-ARREST; PUBLIC-ACCESS DEFIBRILLATION; AMERICAN-HEART-ASSOCIATION; UNITED-STATES; SURVIVAL; NEIGHBORHOOD; RESOURCES; PLACEMENT; CPR AB Background Survival from out-of-hospital cardiac arrest (OHCA) is generally poor and varies by geography. Variability in automated external defibrillator (AED) locations may be a contributing factor. To inform optimal placement of AEDs, we investigated AED access in a major US city relative to demographic and employment characteristics. Methods and Results This was a retrospective analysis of a Philadelphia AED registry (2,559 total AEDs). The 2010 US Census and the Local Employment Dynamics database by ZIP code was used. Automated external defibrillator access was calculated as the weighted areal percentage of each ZIP code covered by a 400-m radius around each AED. Of 47 ZIP codes, only 9% (4) were high-AED-service areas. In 26% (12) of ZIP codes, less than 35% of the area was covered by AED service areas. Higher-AED-access ZIP codes were more likely to have a moderately populated residential area (P = .032), higher median household income (P = .006), and higher paying jobs (P =. 008). Conclusions The locations of AEDs vary across specific ZIP codes; select residential and employment characteristics explain some variation. Further work on evaluating OHCA locations, AED use and availability, and OHCA outcomes could inform AED placement policies. Optimizing the placement of AEDs through this work may help to increase survival. C1 [Griffis, Heather M.; Band, Roger A.; Nadkarni, Lindsay; Kilaru, Austin; Branas, Charles C.; Shofer, Frances; Becker, Lance B.; Merchant, Raina M.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA. [Ruther, Matthew] Univ Colorado, Dept Geog, Boulder, CO 80309 USA. [Harhay, Michael; Branas, Charles C.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Asch, David A.; Merchant, Raina M.] Univ Penn, Penn Med Ctr Innovat, Philadelphia, PA 19104 USA. [Asch, David A.; Hershey, John C.; Hill, Shawndra] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Nichol, Graham] Univ Washington, Harborview Ctr Prehospital Emergency Care, Dept Med, Seattle, WA 98195 USA. RP Merchant, RM (reprint author), Univ Penn, Perelman Sch Med, 423 Guardian St,1022 Blockley, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu OI Harhay, Michael/0000-0002-0553-674X FU National Institutes of Health (NTH), K23 Grant [10714038]; Physio-Control Seattle, Washington; Zoll Medical, Boston MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington; Medtronic Foundation Heart Rescue Project; Penn University Research Fund; McCabe Fund, American Heart Association Beginning; NIH; Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, WA; Medtronic Foundation, Minnesota; Resuscitation Outcomes Consortium (NIH) [U01 HL077863-05]; Evaluation of Video Self-Instruction in Compressions-Only CPR; Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest (NHLBI) [R21 HL093641-01A1]; Randomized Field Trial of Cold Saline IV After Resuscitation from Cardiac Arrest (NHLBI) [R01 HL089554-03]; Resychronization/Defibrillation for Advanced Heart Failure Trial (RAF) [200211UCT-110607]; Novel Methods of Measuring Health Disparities [1RC2HL101759-01]; Cascade Cardiac Resuscitation System (Medtronic Foundation); Gambro Renal Inc, Lakewood, CO; Sotera Wireless, San Diego, CA; Lifebridge Medizintechnik AG; Ampfing, Germany; American Heart Association (AHA) Executive Database Steering Committee; Lifeline EMS Task. Force; AHA Resuscitation Science Symposium Planning Committee; AHA Advanced Cardiac Life Support Subcommittee; AHA Epidemiology and Statistics Committee; Pacific Mountain Affiliate Board of Directors, AHA FX R.M.M. has received grant/research support from the National Institutes of Health (NTH), K23 Grant 10714038, and pilot funding from Physio-Control Seattle, Washington; Zoll Medical, Boston MA; Cardiac Science, Bothell, Washington; Philips Medical Seattle, Washington; The Medtronic Foundation Heart Rescue Project; The Penn University Research Fund; and the McCabe Fund, American Heart Association Beginning Grant in Aid. R.A.B., J.C., O.S., H.G., A.L., J.M.A., K.L., L.N., E.S., L.S., and F.S. have no disclosures. C.C.B. has received grant/research support from NIH. D.A.A. has received grant/research support from NIH and is a consultant to VAL Health. G.N. discloses the following: Resuscitation Outcomes Consortium (NIH U01 HL077863-05) 2004-2015; co-principal investigator (co-PI), Evaluation of Video Self-Instruction in Compressions-Only CPR (Asmund S. Laerdal Foundation for Acute Medicine) 2007-2010; PI, Randomized Trial of Hemofiltration After Resuscitation from Cardiac Arrest (NHLBI R21 HL093641-01A1) 2009-2011; PI, Randomized Field Trial of Cold Saline IV After Resuscitation from Cardiac Arrest (NHLBI R01 HL089554-03) 2007-2012: co-investigator (Co-I), Resychronization/Defibrillation for Advanced Heart Failure Trial (RAF 200211UCT-110607) 2003-2010; Co-I, Novel Methods of Measuring Health Disparities (1RC2HL101759-01) 2009-2011; Co-I, Cascade Cardiac Resuscitation System (Medtronic Foundation) 2010-2015; PI, Research Collaborator: Gambro Renal Inc, Lakewood, CO; Sotera Wireless, San Diego, CA; Lifebridge Medizintechnik AG; Ampfing, Germany; Other Chair, American Heart Association (AHA) Executive Database Steering Committee; Chair, Mission: Lifeline EMS Task. Force; Co-Chair, AHA Resuscitation Science Symposium Planning Committee; Member, AHA Advanced Cardiac Life Support Subcommittee; Member, AHA Epidemiology and Statistics Committee; Member, Pacific Mountain Affiliate Board of Directors, AHA. He also received travel reimbursement from AHA. L.B.B. has received grant/research support from Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, WA; and Medtronic Foundation, Minnesota. He also received speaker honoraria/consultant fees from Philips Healthcare, Seattle, WA. NR 30 TC 2 Z9 2 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD FEB PY 2016 VL 172 BP 185 EP 191 DI 10.1016/j.ahj.2015.09.022 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DD1CS UT WOS:000369659400024 PM 26856232 ER PT J AU Graff, JN Baciarello, G Armstrong, AJ Higano, CS Iversen, P Flaig, TW Forer, D Parli, T Phung, D Tombal, B Beer, TM Sternberg, CN AF Graff, J. N. Baciarello, G. Armstrong, A. J. Higano, C. S. Iversen, P. Flaig, T. W. Forer, D. Parli, T. Phung, D. Tombal, B. Beer, T. M. Sternberg, C. N. TI Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL SO ANNALS OF ONCOLOGY LA English DT Article DE metastatic castration-resistant prostate cancer; enzalutamide; PREVAIL trial; elderly patients ID QUALITY-OF-LIFE; DOCETAXEL-BASED CHEMOTHERAPY; ABIRATERONE ACETATE; ELDERLY-PATIENTS; TRIAL; PAIN; MEN; SURVIVAL; IMPACT; FALLS AB Background: Prostate cancer disproportionately affects older men. Because age affects treatment decisions, it is important to understand the efficacy and tolerability of therapies for advanced prostate cancer in elderly men. This analysis describes efficacy and safety outcomes in men aged >= 75 years who received enzalutamide, an androgen receptor inhibitor, in the phase III PREVAIL trial. Patients and methods: PREVAIL was a randomised, double-blind, multinational study of oral enzalutamide 160 mg/day (N = 872) versus placebo (N = 845) in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Overall survival (OS) and radiographic progression-free survival (rPFS) were coprimary end points. Subgroup analysis of men aged = 75 years (elderly) and men aged <75 years was pre-specified for the coprimary end points and adverse events (AEs). Results: Among 609 elderly patients (35%) who participated in PREVAIL, median treatment duration was 16.6 and 5.0 months in the enzalutamide and placebo arms, respectively. In the elderly subgroup, OS was greater with enzalutamide than with placebo [32.4 months (95% confidence interval (CI) 27.7-not yet reached] versus 25.1 months (95% CI 22.6-28.0); hazard ratio (HR) = 0.61 (95% CI 0.47-0.79); P = 0.0001], as was rPFS [not yet reached (95% CI 12.3-not yet reached) versus 3.7 months (95% CI 3.6-5.3); HR = 0.17 (95% CI 0.12-0.24); P < 0.0001]. Irrespective of treatment assignment, incidence of AEs was similar between the two age groups, except for an overall higher incidence of falls among elderly patients than younger patients [84/609 (13.8%) versus 62/1106 (5.6%)] and among elderly patients receiving enzalutamide than those receiving placebo [61/317 (19.2%) versus 23/292 (7.9%)]. Conclusions: Elderly men benefited from treatment with enzalutamide in terms of OS and rPFS. Enzalutamide was well tolerated in the elderly subgroup and those aged <75 years. Age and enzalutamide treatment were associated with a higher incidence of falls. C1 [Graff, J. N.; Beer, T. M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Graff, J. N.] Portland VA Med Ctr, Div Oncol, Portland, OR USA. [Baciarello, G.; Sternberg, C. N.] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy. [Armstrong, A. J.] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27706 USA. [Armstrong, A. J.] Duke Univ, Med Ctr, Div Urol, Durham, NC 27706 USA. [Armstrong, A. J.] Duke Canc Inst, Durham, England. [Higano, C. S.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. [Higano, C. S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Iversen, P.] Univ Copenhagen, Rigshosp, Copenhagen Prostate Canc Ctr, Copenhagen, Denmark. [Flaig, T. W.] Univ Colorado, Ctr Canc, Dept Med Oncol, Aurora, CO USA. [Forer, D.; Parli, T.] Medivat Inc, San Francisco, CA USA. [Phung, D.] Astellas Pharma Global Dev Inc, Leiden, Netherlands. [Tombal, B.] Clin Univ St Luc, Dept Urol, Brussels, Belgium. RP Graff, JN (reprint author), Oregon Hlth & Sci Univ, Knight Canc Ctr, Portland VA Med Ctr, Div Oncol, MC CH14R,3303 SW Bond Ave, Portland, OR 97239 USA. EM graffj@ohsu.edu FU Medivation, Inc.; Astellas Pharma Global Development, Inc. FX Medivation, Inc., and Astellas Pharma Global Development, Inc., funded the PREVAIL trial, provided the study drug and collaborated with the investigators on protocol design, data analysis and interpretation, and preparation of this report, including the support of medical writing and editorial services (no grant number). NR 24 TC 7 Z9 7 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD FEB PY 2016 VL 27 IS 2 BP 286 EP 294 DI 10.1093/annonc/mdv542 PG 10 WC Oncology SC Oncology GA DD8TF UT WOS:000370199100013 PM 26578735 ER PT J AU Cohen, ME Liu, YM Ko, CY Hall, BL AF Cohen, Mark E. Liu, Yaoming Ko, Clifford Y. Hall, Bruce L. TI Improved Surgical Outcomes for ACS NSQIP Hospitals Over Time Evaluation of Hospital Cohorts With up to 8 Years of Participation SO ANNALS OF SURGERY LA English DT Article DE ACS NSQIP; profiling; risk adjustment; surgical quality improvement; time trends ID SURVEILLANCE BIAS; AMERICAN-COLLEGE; SITE INFECTIONS; QUALITY; PROGRAM AB Background:The American College of Surgeons, National Surgical Quality Improvement Program (ACS NSQIP) surgical quality feedback models are recalibrated every 6 months, and each hospital is given risk-adjusted, hierarchical model, odds ratios that permit comparison to an estimated average NSQIP hospital at a particular point in time. This approach is appropriate for relative benchmarking, and for targeting quality improvement efforts, but does not permit evaluation of hospital or program-wide changes in quality over time. We report on long-term improvement in surgical outcomes associated with participation in ACS NSQIP.Study Design:ACS NSQIP data (2006-2013) were used to create prediction models for mortality, morbidity (any of several distinct adverse outcomes), and surgical site infection (SSI). For each model, for each hospital, and for year of first participation (hospital cohort), hierarchical model observed/expected (O/E) ratios were computed. The primary performance metric was the within-hospital trend in logged O/E ratios over time (slope) for mortality, morbidity, and SSI.Results:Hospital-averaged log O/E ratio slopes were generally negative, indicating improving performance over time. For all hospitals, 62%, 70%, and 65% of hospitals had negative slopes for mortality, morbidity, and any SSI, respectively. For hospitals currently in the program for at least 3 years, 69%, 79%, and 71% showed improvement in mortality, morbidity, and SSI, respectively. For these hospitals, we estimate 0.8%, 3.1%, and 2.6% annual reductions (with respect to prior year's rates) for mortality, morbidity, and SSI, respectively.Conclusions:Participation in ACS NSQIP is associated with reductions in adverse events after surgery. The magnitude of quality improvement increases with time in the program. C1 [Cohen, Mark E.; Liu, Yaoming; Ko, Clifford Y.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] BJC Healthcare, St Louis, MO USA. RP Cohen, ME (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL USA. EM markcohen@facs.org NR 14 TC 24 Z9 24 U1 4 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2016 VL 263 IS 2 BP 267 EP 273 DI 10.1097/SLA.0000000000001192 PG 7 WC Surgery SC Surgery GA DD8TP UT WOS:000370200100012 PM 25723845 ER PT J AU Chidi, AP Bryce, CL Myaskovsky, L Fine, MJ Geller, DA Landsittel, DP Tsung, A AF Chidi, Alexis P. Bryce, Cindy L. Myaskovsky, Larissa Fine, Michael J. Geller, David A. Landsittel, Douglas P. Tsung, Allan TI Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma A Retrospective Cohort Study SO ANNALS OF SURGERY LA English DT Article DE access to care; HCC; health care disparities; liver cancer; socioeconomic status ID STAGE BREAST-CANCER; UNITED-STATES; GEOGRAPHIC DISPARITIES; TREATMENT CHOICES; TRAVEL-TIME; CARE; ACCESS; SURVIVAL; THERAPY; OUTCOMES AB Objective:To determine whether sociodemographic and geographic factors are associated with referral for surgery and receipt of recommended surgical intervention.Background:Surgical interventions confer survival advantages compared with palliative therapies for hepatocellular carcinoma (HCC), but disparities exist in use of surgical intervention. Few have investigated referral for surgery as a potential barrier to surgical intervention, and little is known about the effects of patient geographic factors, including proximity to surgical centers.Methods:Data were abstracted from the Pennsylvania Cancer Registry for patients with a diagnosis of HCC from 2006 to 2011. Using hospital procedure volume data from the Pennsylvania Health Care Cost Containment Council, we calculated proximity to a surgical center. We used multivariable logistic regression to determine whether geographic, racial, socioeconomic, and clinical factors were associated with referral for surgery and receipt of a recommended surgical intervention.Results:Of 3576 patients with HCC, 41.0% were referred for surgery. Patients who lived closer to a surgical center were less likely to be referred for surgery (adjusted odds ratio=0.79; 95% confidence interval, 0.68-0.92). Surgical referral was less likely among older, male patients with Medicaid insurance and advanced tumor stage at diagnosis. Of those referred, 1276 (87.0%) underwent surgical intervention. Proximity to a surgical center was not associated with receipt of surgical intervention (P=0.27). Patients with distant tumor stage at diagnosis were less likely to receive recommended surgical intervention (adjusted odds ratio=0.27; 95% confidence interval, 0.15-0.50).Conclusions:Geographic and sociodemographic disparities in referral for surgery may be major barriers to surgical intervention for patients with HCC. C1 [Chidi, Alexis P.; Geller, David A.; Tsung, Allan] Univ Pittsburgh, Dept Surg, Div Hepatobiliary & Pancreat Surg, Pittsburgh, PA USA. [Chidi, Alexis P.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bryce, Cindy L.; Myaskovsky, Larissa; Fine, Michael J.; Landsittel, Douglas P.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Bryce, Cindy L.; Myaskovsky, Larissa; Fine, Michael J.] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA. RP Tsung, A (reprint author), UPMC Liver Canc Ctr, Montefiore Hosp, Div Hepatobiliary & Pancreat Surg, 3459 Fifth Ave,7 South, Pittsburgh, PA 15213 USA. EM tsunga@upmc.edu OI Bryce, Cindy/0000-0001-6356-6675 FU National Institutes of Health [T35DK065521, TL1TR000145, UL1TR000005] FX Supported by the National Institutes of Health (T35DK065521, TL1TR000145, UL1TR000005). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no conflicts of interest. NR 31 TC 1 Z9 1 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD FEB PY 2016 VL 263 IS 2 BP 362 EP 368 DI 10.1097/SLA.0000000000001111 PG 7 WC Surgery SC Surgery GA DD8TP UT WOS:000370200100025 PM 25563883 ER PT J AU Soble, JR Osborn, KE Mattingly, ML Vale, FL Benbadis, SR Rodgers-Neame, NT Schoenberg, MR AF Soble, Jason R. Osborn, Katie E. Mattingly, Michelle L. Vale, Fernando L. Benbadis, Selim R. Rodgers-Neame, Nancy T. Schoenberg, Mike R. TI Utility of Green's Word Memory Test Free Recall Subtest as a Measure of Verbal Memory: Initial Evidence from a Temporal Lobe Epilepsy Clinical Sample SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Epilepsy; Assessment; Learning and memory; Lateralization ID SYMPTOM VALIDITY TEST; SURGERY CANDIDATES; NEUROPSYCHOLOGICAL ASSESSMENT; EXTERNAL INCENTIVES; AMERICAN-ACADEMY; TEST-PERFORMANCE; BRAIN-INJURY; RELIABILITY; SENSITIVITY; IMPAIRMENT AB This study investigated the Word Memory Test (WMT) Free Recall (FR) subtest as a conventional memory measure. Nineteen participants with pharmacoresistant left temporal lobe epilepsy (LTLE) and 16 with right temporal lobe epilepsy (RTLE) completed the WMT, Rey Auditory Verbal Learning Test (RAVLT), and Wechsler Memory Scale-Fourth Edition Logical Memory (LM) subtest during presurgical evaluation. LTLE participants performed significantly worse on FR subtest (p < .05, eta(2)(p) = 0.17) and RAVLT Trial 7 (p < .01, eta(2)(p) = 0.25), but not on LM subtest. Age was a significant covariate for FR (p < .01, eta(2)(p) = 0.22). Logistic regression revealed FR plus age and RAVLT age-adjusted T-scores both yielded 77.1% classification accuracy and respective diagnostic odds ratios of 11.36 and 11.84. Receiver operating characteristic curves to classify seizure laterality found that RAVLT and FR were significant (area under the curve [AUC] = 0.82 and 0.74), whereas LM was nonsignificant (AUC = 0.67). Cut scores and positive/negative predictive values were established for improved clinical classification. C1 [Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Osborn, Katie E.; Mattingly, Michelle L.; Schoenberg, Mike R.] Univ S Florida, Dept Psychiat & Behav Neurosci, Morsani Coll Med, Tampa, FL USA. [Vale, Fernando L.; Schoenberg, Mike R.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL USA. [Benbadis, Selim R.; Schoenberg, Mike R.] Univ S Florida, Dept Neurol, Morsani Coll Med, Tampa, FL 33620 USA. [Rodgers-Neame, Nancy T.] Florida Comprehens Epilepsy & Seizure Disorders C, Tampa, FL USA. RP Schoenberg, MR (reprint author), 3515 E Fletcher Ave,MDC Box 14, Tampa, FL 33613 USA. EM mschoenb@health.usf.edu NR 54 TC 0 Z9 0 U1 1 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2016 VL 31 IS 1 BP 79 EP 87 DI 10.1093/arclin/acv084 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA DD8QQ UT WOS:000370192400011 PM 26663824 ER PT J AU Torrence, ND John, SE Gavett, BE O'Bryant, SE AF Torrence, Nicole D. John, Samantha E. Gavett, Brandon E. O'Bryant, Sid E. TI An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Validity; Factor analysis; Statistical model; Cognition; Neuropsychology ID ITEM BIFACTOR ANALYSIS; CLOCK DRAWING TASK; FIT INDEXES; DEMENTIA; VALIDITY; MODELS; CRITERIA; SAMPLE; RBANS AB The original factor structure of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) has received little empirical support, but at least eight alternative factor structures have been identified in the literature. The current study used confirmatory factor analysis to compare the original RBANS model with eight alternatives, which were adjusted to include a general factor. Participant data were obtained from Project FRONTIER, an epidemiological study of rural health, and comprised 341 adults (229 women, 112 men) with mean age of 61.2 years (SD = 12.1) and mean education of 12.4 years (SD = 3.3). A bifactor version of the model proposed by Duff and colleagues provided the best fit to the data (CFI = 0.98; root-mean-squared error of approximation = 0.07), but required further modification to produce appropriate factor loadings. The results support the inclusion of a general factor and provide partial replication of the Duff and colleagues RBANS model. C1 [Torrence, Nicole D.; John, Samantha E.; Gavett, Brandon E.] Univ Colorado, Dept Psychol, 1420 Austin Bluffs Pkwy, Colorado Springs, CO 80907 USA. [O'Bryant, Sid E.] Univ N Texas, Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX USA. [O'Bryant, Sid E.] Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzheimers Dis Res, Ft Worth, TX USA. [Torrence, Nicole D.] VA Puget Sound Hlth Care Syst, Amer Lake, VA USA. RP Gavett, BE (reprint author), Univ Colorado, Dept Psychol, 1420 Austin Bluffs Pkwy, Colorado Springs, CO 80907 USA. EM bgavett@uccs.edu OI O'Bryant, Sid/0000-0003-0582-5266; John, Samantha/0000-0003-1347-4865; Gavett, Brandon/0000-0003-1938-1854 FU National Institute on Aging (NIA); National Institute on Minority Health and Health Disparities(NIMHD) of the National Institutes of Health [R01AG039389, P30AG12300, L60MD001849]; Hogg Foundation for Mental Health [JRG-040, JRG-149]; Environmental Protection Agency [RD834794]; National Academy of Neuropsychology; Texas Tech University Health Sciences Center F. Marie Hall Institute for Rural & Community Health; Garrison Institute on Aging FX Research reported in this publication was supported by the National Institute on Aging (NIA) and National Institute on Minority Health and Health Disparities(NIMHD) of the National Institutes of Health under Award Numbers R01AG039389, P30AG12300, and L60MD001849. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This research was also funded in part by grants from the Hogg Foundation for Mental Health (JRG-040 & JRG-149), the Environmental Protection Agency (RD834794), and the National Academy of Neuropsychology. Project FRONTIER is supported by Texas Tech University Health Sciences Center F. Marie Hall Institute for Rural & Community Health and the Garrison Institute on Aging. The researchers would also like to thank the Project FRONTIER participants and research staff. NR 35 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD FEB PY 2016 VL 31 IS 1 BP 88 EP 96 DI 10.1093/arclin/acv057 PG 9 WC Psychology, Clinical; Psychology SC Psychology GA DD8QQ UT WOS:000370192400012 PM 26429558 ER PT J AU O'Brien, CM Flanagan, ME Bergman, AA Ebright, PR Frankel, RM AF O'Brien, Colleen M. Flanagan, Mindy E. Bergman, Alicia A. Ebright, Patricia R. Frankel, Richard M. TI "Anybody on this list that you're more worried about?" Qualitative analysis exploring the functions of questions during end of shift handoffs SO BMJ QUALITY & SAFETY LA English DT Article ID EMERGENCY-DEPARTMENT; HANDOVER; CARE; COMMUNICATION; DISCOURSE; DOCTORS AB Background Shift change handoffs are known to be a point of vulnerability in the quality, safety and outcomes of healthcare. Despite numerous efforts to improve handoff reliability, few interventions have produced lasting change. Although the opportunity to ask questions during patient handoff has been required by some regulatory bodies, the function of questions during handoff has been less well explored and understood. Objective To investigate questions and the functions they serve in nursing and medicine handoffs. Research design Qualitative thematic analysis based on audio recordings of nurse-to-nurse, medical resident-to-resident and surgical intern-to-intern handoffs. Subjects Twenty-seven nurse handoff dyads and 18 medical resident and surgical intern handoff dyads at one VA Medical Center. Results Our analysis revealed that the vast majority of questions were asked by the Incoming Providers. Although topics varied widely, the bulk of Incoming Provider questions requested information that would best help them understand individual patient conditions and plan accordingly. Other question types sought consensus on clinical reasoning or framing and alignment between the two professionals. Conclusions Handoffs are a type of socially constructed work. Questions emerge with some frequency in virtually all handoffs but not in a linear or predictable way. Instead, they arise in the moment, as necessary, and without preplanning. A checklist cannot model this process element because it is a static memory aid and questions occur in a relational context that is emergent. Studying the different functions of questions during end of shift handoffs provides insights into the interface between the technical context in which information is transferred and the social context in which meaning is created. C1 [O'Brien, Colleen M.; Frankel, Richard M.] Indiana Univ Sch Med, 340 W 10th St 6200, Indianapolis, IN 46202 USA. [O'Brien, Colleen M.] Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA. [O'Brien, Colleen M.; Flanagan, Mindy E.; Bergman, Alicia A.; Frankel, Richard M.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Bergman, Alicia A.] VA Greater Los Angeles Healthcare Syst, VA HSR&D Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA. [Ebright, Patricia R.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [Frankel, Richard M.] Mary Margaret Walther Ctr Res & Educ Palliat Care, Indianapolis, IN USA. RP O'Brien, CM (reprint author), Indiana Univ Sch Med, 340 W 10th St 6200, Indianapolis, IN 46202 USA. EM colmobri@iupui.edu FU VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana; VA Health Services Research Grant [IIR 7-241] FX The project reported here was supported by the VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana, and VA Health Services Research Grant No. IIR 7-241. NR 36 TC 2 Z9 2 U1 1 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2016 VL 25 IS 2 BP 76 EP 83 DI 10.1136/bmjqs-2014-003853 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD6GH UT WOS:000370022200004 PM 26217038 ER PT J AU Bergman, AA Flanagan, ME Ebright, PR O'Brien, CM Frankel, RM AF Bergman, Alicia A. Flanagan, Mindy E. Ebright, Patricia R. O'Brien, Colleen M. Frankel, Richard M. TI "Mr Smith's been our problem child today...": anticipatory management communication (AMC) in VA end of shift medicine and nursing handoffs SO BMJ QUALITY & SAFETY LA English DT Article ID SIGN-OUT; CARE; DISCONTINUITY; STRATEGIES AB Background Tools and procedures designed to improve end-of-shift handoffs through standardisation of processes and reliance on technology may miss contextually sensitive information about anticipated events that emerges during face-to-face handoff interactions. Such information, what we refer to as anticipatory management communication (AMC), is necessary to ensure timely and safe patient care, but has been little studied and understood. Objective To investigate AMC and the role it plays in nursing and medicine handoffs. Research design Qualitative thematic analysis based on audio recordings of nurse-to-nurse, medical resident-to-resident and surgical intern to-intern handoffs. Subjects 27 nurse handoff dyads and 18 medical resident and surgical intern handoff dyads at one VA Medical Center. Results Heads-up information was the most frequent type of AMC across all handoff dyads (N=257; 108 resident and 149 nursing). Indirect instructions AMC was used in a little over half the resident handoff dyads, but occurred in all nursing dyads (292 instances). Direct instructions AMC occurred in roughly equal proportion across all dyads but at a modest frequency (N=45; 28 resident and 17 nursing). Direct (if/then) contingency AMC occurred in resident handoffs more frequently than in nursing handoffs (N=32; 30 resident and 2 nursing). Conclusions The different frequencies for types of AMC likely reflect differences in how residents and nurses work and disparate professional cultures. But, verbal communication in both groups included important information unlikely to be captured in written handoff tools or the electronic medical record, underscoring the importance of direct communication to ensure safe handoffs. C1 [Bergman, Alicia A.] VA Greater Los Angeles, Ctr Study Healthcare Innovat Implementat & Policy, 16111 Plummer St,Bldg 25, North Hills, CA 91343 USA. [Flanagan, Mindy E.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Indianapolis, IN 46204 USA. [Bergman, Alicia A.; Flanagan, Mindy E.; Frankel, Richard M.] Richard L Roudebush VA Med Ctr, HSR&D Ctr Hlth Informat & Commun, Indianapolis, IN USA. [Ebright, Patricia R.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [O'Brien, Colleen M.] Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA. [Frankel, Richard M.] Indiana Univ, Dept Med, Indianapolis, IN 46204 USA. RP Bergman, AA (reprint author), VA Greater Los Angeles, Ctr Study Healthcare Innovat Implementat & Policy, 16111 Plummer St,Bldg 25, North Hills, CA 91343 USA. EM alicia.bergman@va.gov FU VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana [IIR 07-241-2] FX VA Health Services Research and Development (HSR&D) Center of Excellence in Implementing Evidence-Based Practice, Indianapolis, Indiana, IIR 07-241-2. NR 26 TC 1 Z9 1 U1 1 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD FEB PY 2016 VL 25 IS 2 BP 84 EP 91 DI 10.1136/bmjqs-2014-003694 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA DD6GH UT WOS:000370022200005 PM 26221029 ER PT J AU Liang, PS Dominitz, JA AF Liang, Peter S. Dominitz, Jason A. TI Striving for Efficient, Patient-centered Endoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID COLORECTAL-CANCER; OUTPATIENT ENDOSCOPY; NON-ATTENDANCE; COLONOSCOPY; RATES; NONATTENDANCE; CAPACITY; DEMAND C1 [Liang, Peter S.; Dominitz, Jason A.] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. [Dominitz, Jason A.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA. RP Liang, PS (reprint author), Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. OI Liang, Peter/0000-0002-4160-421X FU NIDDK NIH HHS [NIH T32 DK007742] NR 19 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2016 VL 14 IS 2 BP 268 EP 270 DI 10.1016/j.cgh.2015.10.004 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1GY UT WOS:000370376300020 PM 26484705 ER PT J AU Cadoni, S Falt, P Leung, FW AF Cadoni, Sergio Falt, Premysl Leung, Felix W. TI Some Clarifications About Water-Aided Colonoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Letter ID UNSEDATED COLONOSCOPY; CECAL INTUBATION; CONTROLLED-TRIAL; INSUFFLATION; INFUSION; EXCHANGE C1 [Cadoni, Sergio] St Barbara Hosp, Digest Endoscopy Unit, Iglesias, Carbonia Iglesi, Italy. [Falt, Premysl] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Czech Republic. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Iglesias, Carbonia Iglesi, Italy. NR 8 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2016 VL 14 IS 2 BP 323 EP 323 DI 10.1016/j.cgh.2015.09.003 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DE1GY UT WOS:000370376300030 PM 26375611 ER PT J AU Carroll, WW O'Connell, BP Schlosser, RJ Gudis, DA Karnezis, TT Lawrence, LA Soler, ZM Mulligan, JK AF Carroll, William W. O'Connell, Brendan P. Schlosser, Rodney J. Gudis, David A. Karnezis, Tom T. Lawrence, Lauren A. Soler, Zachary M. Mulligan, Jennifer K. TI Fibroblast levels are increased in chronic rhinosinusitis with nasal polyps and are associated with worse subjective disease severity SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE chronic rhinosinusitis; endoscopic sinus surgery; SNOT-22; quality of life; sinusitis ID ALLERGIC FUNGAL RHINOSINUSITIS; SINONASAL OUTCOME TEST; QUALITY-OF-LIFE; MESENCHYMAL TRANSITION; INFLAMMATORY MEDIATORS; AIRWAY RESPONSIVENESS; COLLAGEN DEPOSITION; LUNG-DISEASE; SINUSITIS; ASTHMA AB BackgroundFibroblasts are implicated in tissue remodeling and recruitment of inflammatory cells in chronic rhinosinusitis (CRS). Populations of fibroblasts remain unquantified in CRS subtypes. The objectives of this study were to measure fibroblast populations in subtypes of CRS, and to investigate the association between fibroblasts and disease severity. MethodsPatients undergoing endoscopic sinus surgery (ESS) for CRS were prospectively enrolled from January 2011 to December 2014. Control subjects included patients undergoing endoscopic surgery for non-inflammatory conditions such as cerebrospinal fluid leak repair or non-hormone-secreting pituitary tumors. Patients completed 22-item Sino-Nasal Outcome Test (SNOT-22) questionnaires prior to surgery. Blood and tissue biopsies were taken during surgery. Percent of sinonasal fibroblasts was determined via flow cytometry by selecting fibroblast-specific protein (FSP)-positive and Mucin 1 (MUC1)-negative cells. ResultsA total of 69 patients were enrolled: control (n = 24), CRS without nasal polyps (CRSsNP) (n = 13), CRS with nasal polyps (CRSwNP) (n = 22), and allergic fungal rhinosinusitis (AFRS) (n = 10). Patients with CRSwNP had significantly more fibroblasts than both control (p < 0.001) and CRSsNP (p < 0.01). Patients with AFRS had the most fibroblasts when compared to control (p < 0.0001), CRSsNP (p < 0.0001), and CRSwNP (p < 0.05). Atopy and asthma were not associated with increased fibroblasts in CRSwNP (p = 0.21, p = 0.26, respectively). Increased fibroblasts correlated with subjective disease severity as measured by SNOT-22 for CRSwNP (p = 0.003) and AFRS (p = 0.048). ConclusionSinonasal fibroblasts are increased in CRSwNP and AFRS compared to control and CRSsNP. Increased fibroblasts correlated with worse quality of life in CRSwNP and AFRS. C1 [Carroll, William W.; O'Connell, Brendan P.; Schlosser, Rodney J.; Gudis, David A.; Karnezis, Tom T.; Lawrence, Lauren A.; Soler, Zachary M.; Mulligan, Jennifer K.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.; Mulligan, Jennifer K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA. RP Mulligan, JK (reprint author), 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM konopa@musc.edu FU American Academy of Otolaryngic Allery; Flight Attendant Medical Research Institute; Department of Veterans Affairs FX American Academy of Otolaryngic Allery (to B.P.O.); Flight Attendant Medical Research Institute (to J.K.M.); Department of Veterans Affairs (to R.J.S.). NR 61 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD FEB PY 2016 VL 6 IS 2 BP 162 EP 168 DI 10.1002/alr.21636 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DD8SR UT WOS:000370197700010 PM 26370180 ER PT J AU Lawrence, LA Baker, AB Nguyen, SA Karnezis, TT Soler, ZM Schlosser, RJ AF Lawrence, Lauren A. Baker, Andrew B. Nguyen, Shaun A. Karnezis, Tom T. Soler, Zachary M. Schlosser, Rodney J. TI Predictors of 30-day morbidity and mortality in transnasal microscopic pituitary tumor excision SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE anterior skull base; postoperative; endonasal approach to the pituitary; NSQIP; outcomes; adverse events ID ENDONASAL TRANSSPHENOIDAL SURGERY; ADENOMAS; COMPLICATIONS; READMISSION; EXPERIENCE; SERIES; STAY AB BackgroundThere is a lack of population-based, multi-institutional analyses of factors associated with morbidity and mortality following pituitary tumor excision. MethodsThe American College of Surgeons National Surgical Quality Improvement Project files were used to compile information on patients that had undergone transnasal microscopic pituitary tumor resection from 2006 to 2012. Patient demographics, comorbidities, operative characteristics, and morbidity and mortality in the 30 days following surgery were included. Multivariate logistic regression was used for categorical variables and multivariate linear regression was used for continuous variables to evaluate factors leading to adverse events. ResultsA total of 658 patients were included, of which 58 (8.81%) experienced a complication, reoperation or death in the 30 days following surgery. The most common complications were reoperation (3.37%), followed by unplanned reintubation (1.99%), urinary tract infection (1.68%), and transfusion (1.68%). Predictors of any complication, reoperation, or death include preoperative sepsis (odds ratio [OR] = 7.596) and lower preoperative serum albumin (OR = 6.667). Younger age predicted surgical complications (OR = 1.105). Predictors of medical complications include higher body mass index (OR = 1.112), chronic steroid use (OR = 6.568), preoperative sepsis (OR = 15.297), and lower preoperative serum hematocrit (OR = 1.225). Predictors of increased total length of hospital stay were older age ( = 0.146), higher body mass index ( = 0.188), chronic steroid use ( = 0.142), preoperative sepsis ( = 0.489), and lower preoperative serum albumin ( = -0.213). ConclusionAlthough adverse events following pituitary tumor excision are low, awareness of factors associated with morbidity and mortality in the early postoperative period may allow for improved patient monitoring and outcomes. C1 [Lawrence, Lauren A.; Baker, Andrew B.; Nguyen, Shaun A.; Karnezis, Tom T.; Soler, Zachary M.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge,MSC 550, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Lawrence, LA (reprint author), Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge,MSC 550, Charleston, SC 29425 USA. EM lawre194@gmail.com OI Baker, Andrew/0000-0002-2041-5225 FU Optinose (Yardley, PA); Intersect ENT FX R.J.S. is a consultant for Olympus (Center Valley, PA) and has been provided grant support from Optinose (Yardley, PA) and Intersect ENT; none of these provided support for this investigation. Z.M.S. is also consultant for Olympus, but no support was provided for this investigation. NR 29 TC 3 Z9 3 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD FEB PY 2016 VL 6 IS 2 BP 206 EP 213 DI 10.1002/alr.21641 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA DD8SR UT WOS:000370197700016 PM 26370600 ER PT J AU Riemer, C Doctor, M Dellavalle, RP AF Riemer, Christie Doctor, Monica Dellavalle, Robert P. TI Analysis of Online Ratings of Dermatologists SO JAMA DERMATOLOGY LA English DT Letter C1 [Riemer, Christie] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Doctor, Monica] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA. RP Dellavalle, RP (reprint author), Eastern Colorado Hlth Care Syst, US Dept Vet Affairs, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. NR 3 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD FEB PY 2016 VL 152 IS 2 BP 218 EP 220 DI 10.1001/jamadermatol.2015.4991 PG 4 WC Dermatology SC Dermatology GA DE4AT UT WOS:000370572300021 PM 26677133 ER PT J AU Cohen, AS Mitchell, KR Docherty, NM Horan, WP AF Cohen, Alex S. Mitchell, Kyle R. Docherty, Nancy M. Horan, William P. TI Vocal Expression in Schizophrenia: Less Than Meets the Ear SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE schizophrenia; negative; alogia; blunted affect; computer ID PSYCHIATRIC RATING-SCALE; NEGATIVE SYMPTOMS; ACOUSTIC ANALYSIS; MENTAL-ILLNESS; SPEECH FLUENCY; METAANALYSIS; DEPRESSION; DISORDERS; PROSODY; DEFICIT AB Abnormalities in nonverbal communication are a hallmark of schizophrenia. Results from studies using symptom rating scales suggest that these abnormalities are profound (i.e., 3-5 SDs) and occur across virtually every channel of vocal expression. Computerized acoustic analytic technologies, used to overcome practical and psychometric limitations with symptom rating scales, have found much more benign and isolated abnormalities. To better understand vocal deficits in schizophrenia and to advance acoustic analytic technologies for clinical and research applications, we examined archived speech samples from 5 separate studies, each using different speaking tasks (patient N = 309; control N = 117). We sought to: (a) use Principal Component Analysis (PCA) to identify independent vocal expression measures from a large set of variables, (b) quantify how patients with schizophrenia are abnormal with respect to these variables, (c) evaluate the impact of demographic and contextual factors (e.g., study site, speaking task), and (d) examine the relationship between clinically-rated psychiatric symptoms and vocal variables. PCA identified 7 independent markers of vocal expression. Most of these vocal variables varied considerably as a function of context and many were associated with demographic factors. After controlling for context and demographics, there were no meaningful differences in vocal expression between patients and controls. Within patients, vocal variables were associated with a range of psychiatric symptoms-though only pause length was significantly associated with clinically rated negative symptoms. The discussion centers on explaining the apparent discordance between clinical and computerized speech measures. C1 [Cohen, Alex S.; Mitchell, Kyle R.] Louisiana State Univ, Dept Psychol, 236 Audubon Hall, Baton Rouge, LA 70803 USA. [Docherty, Nancy M.] Kent State Univ, Dept Psychol, Kent, OH USA. [Horan, William P.] Univ Calif Los Angeles, VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Cohen, AS (reprint author), Louisiana State Univ, Dept Psychol, 236 Audubon Hall, Baton Rouge, LA 70803 USA. EM acohen@lsu.edu FU National Institute of Mental Health [R03MH092622] FX This project was funded by Grant R03MH092622 from the National Institute of Mental Health to AC. We thank the patients and subjects who volunteered their time to participate in the study. We are also grateful to Matt Calamia for his statistical advice and consultation. NR 55 TC 2 Z9 2 U1 2 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD FEB PY 2016 VL 125 IS 2 BP 299 EP 309 DI 10.1037/abn0000136 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA DD8GJ UT WOS:000370163500014 PM 26854511 ER PT J AU Aplin, AC Kohler, T Nicosia, R AF Aplin, Alfred C. Kohler, Ted Nicosia, Roberto TI Human Plaque-Aortic Ring Co-Culture: A Novel Assay for the Study of Atherosclerosis-Induced Angiogenesis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound HCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2016 VL 29 SU 2 MA 316 BP 81A EP 81A PG 1 WC Pathology SC Pathology GA DE0GI UT WOS:000370302500317 ER PT J AU David, SN Arnold, S Goyal, R Goldstein, J Gellert, LL Clark, PE Hameed, O Giannico, GA AF David, Stephanie N. Arnold, Shanna Goyal, Rajen Goldstein, Jeffery Gellert, Lan L. Clark, Peter E. Hameed, Omar Giannico, Giovanna A. TI MAGI-2 is Associated with Biochemical Recurrence in Prostate Cancer SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Vanderbilt Univ, Med Ctr, Nashville, TN USA. US Dept Vet Affairs, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 EI 1530-0285 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2016 VL 29 SU 2 MA 892 BP 224A EP 225A PG 2 WC Pathology SC Pathology GA DE0GI UT WOS:000370302501376 ER PT J AU Flickinger, TE Saha, S Roter, D Korthuis, PT Sharp, V Cohn, J Eggly, S Moore, RD Beach, MC AF Flickinger, Tabor E. Saha, Somnath Roter, Debra Korthuis, P. Todd Sharp, Victoria Cohn, Jonathan Eggly, Susan Moore, Richard D. Beach, Mary Catherine TI Clinician empathy is associated with differences in patient-clinician communication behaviors and higher medication self-efficacy in HIV care SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE HIV/AIDS; Patient-clinician communication; Empathy; Self-efficacy; Medication adherence ID PHYSICIAN EMPATHY; PROVIDER COMMUNICATION; HEALTH OUTCOMES; SATISFACTION; QUALITY; ADHERENCE; DISEASE; PARTNERSHIP; MULTICENTER; ASSESSMENTS AB Objective: We examined associations of clinicians' empathy with patient-clinician communication behaviors, patients' rating of care, and medication self-efficacy. Methods: We analyzed 435 adult patients and 45 clinicians at four outpatient HIV care sites in the United States. Negative binomial regressions investigated associations between clinician empathy and patient-clinician communication, assessed using the Roter Interaction Analysis System (RIAS). Logistic regressions investigated associations between clinician empathy and patient ratings of clinician communication, overall satisfaction, and medication self-efficacy. Results: Clinicians in the highest vs. lowest empathy tertile engaged in less explicitly emotional talk (IRR 0.79, p < 0.05), while clinicians in the middle vs. lowest engaged in more positive talk (IRR 1.31, p < 0.05), more questions (IRR 1.42, p < 0.05), and more patient activating talk (IRR 1.43, p < 0.05). Patients of higher empathy clinicians disclosed more psychosocial and biomedical information. Patients of clinicians in both the middle and highest (vs. lowest) empathy tertiles had greater odds of reporting highest medication self-efficacy (OR 1.80, 95% CI 1.16-2.80; OR 2.13, 95% CI 1.37-3.32). Conclusions: Clinician empathy may be expressed through addressing patient engagement in care, by fostering cognitive, rather than primarily emotional, processing. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Flickinger, Tabor E.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Saha, Somnath] Portland VA Med Ctr, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Roter, Debra; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Baltimore, MD USA. [Sharp, Victoria] St Lukes Roosevelt, New York, NY USA. [Cohn, Jonathan; Eggly, Susan] Wayne State Univ, Detroit, MI USA. RP Flickinger, TE (reprint author), Univ Virginia, Sch Med, Div Gen Geriatr Palliat & Hosp Med, POB 800901, Charlottesville, VA 22908 USA. EM TES3J@hscmail.mcc.virginia.edu OI Eggly, Susan/0000-0002-8137-6098; Flickinger, Tabor/0000-0001-8820-2536 FU Health Resources Service Administration; National Institute of Drug Abuse [K23 DA019808]; Agency for Healthcare Research and Quality [K08HS013903-05, AHRQ 290-01-0012]; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019808). Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. The funding sources had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. NR 51 TC 2 Z9 2 U1 3 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2016 VL 99 IS 2 BP 220 EP 226 DI 10.1016/j.pec.2015.09.001 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DE7GU UT WOS:000370804700006 PM 26395313 ER PT J AU Flickinger, TE Saha, S Roter, D Korthuis, PT Sharp, V Cohn, J Moore, RD Ingersoll, KS Beach, MC AF Flickinger, Tabor E. Saha, Somnath Roter, Debra Korthuis, P. Todd Sharp, Victoria Cohn, Jonathan Moore, Richard D. Ingersoll, Karen S. Beach, Mary Catherine TI Respecting patients is associated with more patient-centered communication behaviors in clinical encounters SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE HIV/AIDS; Patient-clinician communication; Respect ID HIV CARE; PHYSICIAN COMMUNICATION; PROVIDER COMMUNICATION; RACIAL DISPARITIES; HEALTH-CARE; SEXUAL-BEHAVIOR; WHITE PATIENTS; SUBSTANCE USE; ADHERENCE; SATISFACTION AB Objective: Attitudes towards patients may influence how clinicians interact. We investigated whether respect for patients was associated with communication behaviors during HIV care encounters. Methods: We analyzed audio-recordings of visits between 413 adult HIV-infected patients and 45 primary HIV care providers. The independent variable was clinician-reported respect for the patient and outcomes were clinician and patient communication behaviors assessed by the Roter Interaction Analysis System (RIAS). We performed negative binomial regressions for counts outcomes and linear regressions for global outcomes. Results: When clinicians had higher respect for a patient, they engaged in more rapport-building, social chitchat, and positive talk. Patients of clinicians with higher respect for them engaged in more rapport-building, social chitchat, positive talk, and gave more psychosocial information. Encounters between patients and clinicians with higher respect for them had more positive clinician emotional tone [regression coefficient 2.97 (1.92-4.59)], more positive patient emotional tone [2.71 (1.75-4.21)], less clinician verbal dominance [0.81 (0.68-0.96)] and more patient-centeredness [1.28 (1.09-1.51)]. Conclusions: Respect is associated with positive and patient-centered communication behaviors during encounters. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Flickinger, Tabor E.; Ingersoll, Karen S.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA. [Saha, Somnath] Portland VA Med Ctr, Dept Med, Portland, OR USA. [Saha, Somnath; Korthuis, P. Todd] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Roter, Debra; Moore, Richard D.; Beach, Mary Catherine] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Sharp, Victoria] St Lukes Roosevelt, Dept Med, New York, NY USA. [Cohn, Jonathan] Wayne State Univ, Dept Med, Detroit, MI 48202 USA. RP Flickinger, TE (reprint author), Univ Virginia, Sch Med, Div Gen Geriatr Palliat & Hosp Med, POB 800901, Charlottesville, VA 22908 USA. EM TES3J@hscmail.mcc.virginia.edu OI Flickinger, Tabor/0000-0001-8820-2536 FU Health Resources Service Administration; Agency for Healthcare Research and Quality [AHRQ 290-01-0012, K08HS013903-05]; National Institute of Drug Abuse [K23 DA019808]; Robert Wood Johnson Generalist Physician Faculty Scholars Awards FX This research was supported by a contract from the Health Resources Service Administration and the Agency for Healthcare Research and Quality (AHRQ 290-01-0012). In addition, Dr. Korthuis was supported by the National Institute of Drug Abuse (K23 DA019808). Dr. Beach was supported by the Agency for Healthcare Research and Quality (K08HS013903-05) and both Drs. Beach and Saha were supported by Robert Wood Johnson Generalist Physician Faculty Scholars Awards. Preliminary findings of this manuscript were presented at the National Meeting of the Society of General Internal Medicine, San Diego, California, April 2014, and the International Conference on Communication in Healthcare, Amsterdam, The Netherlands, October 2014. NR 42 TC 3 Z9 3 U1 2 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD FEB PY 2016 VL 99 IS 2 BP 250 EP 255 DI 10.1016/j.pec.2015.08.020 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DE7GU UT WOS:000370804700010 PM 26320821 ER PT J AU Wen, JC Yeh, CK Sun, YY AF Wen, Jianchuan Yeh, Chih-Ko Sun, Yuyu TI Functionalized Denture Resins as Drug Delivery Biomaterials to Control Fungal Biofilms SO ACS BIOMATERIALS SCIENCE & ENGINEERING LA English DT Article DE denture; poly(2-hydroxyethyl methacrylate); drug delivery; fungal; biofilm-controlling ID IN-VITRO; POLY(2-HYDROXYETHYL METHACRYLATE); ANTIFUNGAL ACTIVITY; SILVER NANOPARTICLES; CANDIDA-ALBICANS; STOMATITIS; PLASMA; ETIOLOGY; SURFACE; DEVICE AB Colonization and biofilm-formation of Candida species on denture surfaces cause Candida-associated denture stomatitis (CADS), a recurring fungal infection that affects up to 67% of denture wearers. We grafted poly(2-hydroxyethyl methacrylate) (PHEMA) onto poly(methyl methacrylate) (PMMA)-based denture resins through plasma-initiated grafting polymerization. The effects of reaction conditions on grafting and the physical properties of the resulting resins were evaluated. The grafted resins showed significantly increased drug binding capability toward clotrimazole, one of the most widely used antifungal drugs. The mechanisms for the enhancement in drug binding were discussed. The new clotrimazole-containing resins provided sustained drug release for longer than 28 days, and the released drugs demonstrated potent, long-term biofilm-controlling effects against Candida, pointing to an attractive strategy in controlling CADS and related fungal infections. C1 [Wen, Jianchuan; Sun, Yuyu] Univ Massachusetts, Dept Chem, 1 Univ Ave, Lowell, MA 01854 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. RP Sun, YY (reprint author), Univ Massachusetts, Dept Chem, 1 Univ Ave, Lowell, MA 01854 USA. EM yuyu_sun@uml.edu FU NIDCR, NIH [R01 DE021084]; VA Merit Review [1I01BX001103] FX This study was partly supported by NIDCR, NIH (R01 DE021084), and VA Merit Review (1I01BX001103). NR 43 TC 1 Z9 1 U1 3 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 2373-9878 J9 ACS BIOMATER SCI ENG JI ACS Biomater. Sci. Eng. PD FEB PY 2016 VL 2 IS 2 BP 224 EP 230 DI 10.1021/acsbiomaterials.5b00416 PG 7 WC Materials Science, Biomaterials SC Materials Science GA DD4FA UT WOS:000369876700010 ER PT J AU Wecht, JM Weir, JP Martinez, S Eraifej, M Bauman, WA AF Wecht, Jill M. Weir, Joseph P. Martinez, Stephanie Eraifej, Mastanna Bauman, William A. TI Orthostatic hypotension and orthostatic hypertension in American veterans SO CLINICAL AUTONOMIC RESEARCH LA English DT Article DE Orthostatic hypotension; Orthostatic hypertension; American veterans; Prevalence; Prescription medications; Age ID CARDIOVASCULAR RISK-FACTOR; MALMO PREVENTIVE PROJECT; BLOOD-PRESSURE RESPONSE; ELDERLY HYPERTENSIVES; ATHEROSCLEROSIS RISK; EXTREME DIPPERS; MORTALITY; DISEASE; PREVALENCE; ADULTS AB Abnormal blood pressure (BP) response to orthostatic maneuvers may predict adverse health outcomes. Orthostatic hypotension (OH) is defined as a fall in BP of a parts per thousand yen20/10 mmHg, and orthostatic hypertension (OHTN) is defined as an increase in systolic BP (SBP) of a parts per thousand yen20 mmHg, with standing. Herein, we document the prevalence of OH and OHTN in American veterans. The influence of demographic characteristics, life habits, co-incident medical conditions, and prescription medication use on these prevalence rates and associations between abnormal orthostatic BP responses and severity of self-reported symptoms of fatigue, dizziness, trouble concentrating, and head and neck discomfort were determined. 286 veterans participated; 14 % were classified with OH, 22 % with OHTN, and 64 % with normal BP responses to standing (reference group). An increased prevalence of the diagnosis of diabetes mellitus (27 %) and hypertension (63 %) was noted, which did not differ by orthostatic BP classification. Veterans with OH were older than the reference group and were prescribed more antihypertensive medications than the reference and OHTN groups. While the prevalence of OH increased with age, the prevalence of OHTN was comparable in young (20-30 years) and old (70+ years) veterans (17 vs. 19 %, respectively). The severity of fatigue and dizziness was increased in veterans with OH and OHTN compared to the reference group. These data suggest a relatively high prevalence of OH and OHTN, which is associated with increased self-reported severity of fatigue and dizziness in American veterans, findings which may adversely impact long-term health outcomes. C1 [Wecht, Jill M.; Martinez, Stephanie; Eraifej, Mastanna; Bauman, William A.] James J Peters VA Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Bauman, William A.] James J Peters VA Med Ctr, Med Serv, Bronx, NY 10468 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Wecht, Jill M.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Weir, Joseph P.] Univ Kansas, Dept Hlth Sport & Exercise Sci, Lawrence, KS 66045 USA. RP Wecht, JM (reprint author), James J Peters VA Med Ctr, Med Consequences Spinal Cord Injury, Ctr Excellence, Rm 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Wecht, JM (reprint author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.; Wecht, JM (reprint author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. EM JM.Wecht@va.gov FU Veterans Affairs Rehabilitation Research and Development Service: Center of Excellence for the Medical Consequences of Spinal Cord Injury [B9212C] FX This research was supported by the Veterans Affairs Rehabilitation Research and Development Service: Center of Excellence for the Medical Consequences of Spinal Cord Injury (Grant # B9212C). NR 51 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0959-9851 EI 1619-1560 J9 CLIN AUTON RES JI Clin. Auton. Res. PD FEB PY 2016 VL 26 IS 1 BP 49 EP 58 DI 10.1007/s10286-015-0328-4 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DD5WL UT WOS:000369995300007 PM 26695397 ER PT J AU Dai, DW Singh, I Hershman, JM AF Dai, David W. Singh, Ishita Hershman, Jerome M. TI Lozenge-Induced Hypermineralcorticoid State--A Unique Case of Licorice Lozenges Resulting in Hypertension and Hypokalemia SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CORTISOL; RECEPTOR C1 [Singh, Ishita] Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Singh, I (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Dept Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Singh, I (reprint author), West Los Angeles VA Med Ctr, VA Greater Los Angeles Healthcare Syst, Endocrinol 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM isingh@mednet.ucla.edu NR 13 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2016 VL 18 IS 2 BP 159 EP 160 DI 10.1111/jch.12633 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DD5SQ UT WOS:000369985100013 PM 26212733 ER PT J AU Hochman, M Briggs-Malonson, M Wilkes, E Bergman, J Daskivich, LP Moin, T Brook, I Ryan, GW Brook, RH Mangione, CM AF Hochman, Michael Briggs-Malonson, Medell Wilkes, Erin Bergman, Jonathan Daskivich, Lauren Patty Moin, Tannaz Brook, Ilanit Ryan, Gery W. Brook, Robert H. Mangione, Carol M. TI Fostering a Commitment to Quality: Best Practices in Safety-net Hospitals SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Quality improvement; safety-net; community ID HEALTH REFORM; OF-CARE; 1990S AB In 2007, the Martin Luther King, Jr.-Harbor Hospital (MLK-Harbor), which served a large safety-net population in South Los Angeles, closed due to quality challenges. Shortly thereafter, an agreement was made to establish a new hospital, Martin Luther King, Jr. Community Hospital (MLKCH), to serve the unmet needs of the community. To assist the newly appointed MLKCH Board of Directors in building a culture of quality, we conducted a series of interviews with five high-performing hospital systems. In this report, we describe our findings. The hospitals we interviewed achieved a culture of quality by: 1) developing guiding principles that foster quality; 2) hiring and retaining personnel who are stewards of quality; 3) promoting efficient resource utilization; 4) developing a well-organized quality improvement infrastructure; and 5) cultivating integrated, patient-centric care. The institutions highlighted in this report provide important lessons for MLKCH and other safety-net institutions. C1 [Hochman, Michael; Bergman, Jonathan; Daskivich, Lauren Patty; Brook, Robert H.; Mangione, Carol M.] Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA. [Hochman, Michael; Daskivich, Lauren Patty] US Dept Vet Affairs, Los Angeles, CA USA. [Hochman, Michael] AltaMed Hlth Serv, 2040 Camfield Ave, Los Angeles, CA 90040 USA. [Briggs-Malonson, Medell] Univ Calif Los Angeles, David Geffen Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90095 USA. [Briggs-Malonson, Medell] Martin Luther King Jr Community Hosp, Los Angeles, CA USA. [Wilkes, Erin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wilkes, Erin; Daskivich, Lauren Patty] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Bergman, Jonathan] US Dept Vet Affairs, Vet Hlth Affairs, Los Angeles, CA USA. [Bergman, Jonathan] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA. [Moin, Tannaz] Univ Calif Los Angeles, David Geffen Sch Med, Vet Hlth Affairs, Los Angeles, CA USA. [Brook, Ilanit] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA. [Ryan, Gery W.] Pardee RAND Grad Sch, Santa Monica, CA USA. [Brook, Robert H.] Univ Calif Los Angeles, David Geffen Sch Med, US Dept Vet Affairs, Pardee RAND Grad Sch, Los Angeles, CA 90095 USA. [Brook, Robert H.; Mangione, Carol M.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Hochman, M (reprint author), Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA USA.; Hochman, M (reprint author), US Dept Vet Affairs, Los Angeles, CA USA.; Hochman, M (reprint author), AltaMed Hlth Serv, 2040 Camfield Ave, Los Angeles, CA 90040 USA. EM meh1979@gmail.com FU Robert Wood Johnson Foundation Clinical Scholars Program; U.S. Department of Veterans Affairs; National Research Award Program, National Institutes of Health FX We would like to thank the numerous people who helped us with this project including, but not limited to, Ken Wells, MD, MPH; Loretta Jones, MA; the original Martin Luther King, Jr. Community Hospital Board of Directors (Manuel A. Abascal, JD; Elaine Batchlor, MD, MPH; Linda Griego, BA; Paul King, MHA; Michael Madden, MA; Robert Margolis, MD and James Yoshioka, BS); those who graciously allowed us to interview them at Denver Health, Grady Health, Harlem Hospital Center, Mount Sinai Health System, and Virginia Mason Medical Center; and the Robert Wood Johnson Foundation Clinical Scholars Program, the U.S. Department of Veterans Affairs, and the National Research Award Program, National Institutes of Health, for supporting our efforts. NR 23 TC 0 Z9 0 U1 2 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2016 VL 27 IS 1 BP 293 EP 307 DI 10.1353/hpu.2016.0008 PG 15 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DC9BD UT WOS:000369514400024 PM 27763471 ER PT J AU Armour, C Contractor, A Shea, T Elhai, JD Pietrzak, RH AF Armour, Cherie Contractor, Ateka Shea, Tracie Elhai, Jon D. Pietrzak, Robert H. TI Factor Structure of the PTSD Checklist for DSM-5 Relationships Among Symptom Clusters, Anger, and Impulsivity SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE PTSD; PCL-5; anger; impulsivity; DSM-5; confirmatory factor analysis ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE DEPENDENT INPATIENTS; CONFIRMATORY FACTOR-ANALYSIS; CLINIC-REFERRED YOUTH; 5 FACTOR MODEL; UNDERLYING DIMENSIONS; EARTHQUAKE SURVIVORS; MALE VETERANS; PSYCHOMETRIC PROPERTIES; EMOTION DYSREGULATION AB Scarce data are available regarding the dimensional structure of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) posttraumatic stress disorder (PTSD) symptoms and how factors relate to external constructs. We evaluated six competing models of DSM-5 PTSD symptoms, including Anhedonia, Externalizing Behaviors, and Hybrid models, using confirmatory factor analyses in a sample of 412 trauma-exposed college students. We then examined whether PTSD symptom clusters were differentially related to measures of anger and impulsivity using Wald chi-square tests. The seven-factor Hybrid model was deemed optimal compared with the alternatives. All symptom clusters were associated with anger; the strongest association was between externalizing behaviors and anger (r = 0.54). All symptom clusters, except reexperiencing and avoidance, were associated with impulsivity, with the strongest association between externalizing behaviors and impulsivity (r = 0.49). A seven-factor Hybrid model provides superior fit to DSM-5 PTSD symptom data, with the externalizing behaviors factor being most strongly related to anger and impulsivity. C1 [Armour, Cherie] Univ Ulster, Sch Psychol, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland. [Contractor, Ateka; Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH USA. [Contractor, Ateka; Shea, Tracie] Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Shea, Tracie] Vet Affairs Med Ctr, Providence, RI USA. [Elhai, Jon D.] Univ Toledo, Dept Psychiat, Toledo, OH USA. [Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA. RP Armour, C (reprint author), Univ Ulster, Sch Psychol, Coleraine Campus, Coleraine BT52 1SA, Londonderry, North Ireland. EM armour.cherie@gmail.com OI Armour, Cherie/0000-0001-7649-3874 NR 68 TC 4 Z9 4 U1 5 U2 18 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD FEB PY 2016 VL 204 IS 2 BP 108 EP 115 DI 10.1097/NMD.0000000000000430 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DD5NP UT WOS:000369971100006 PM 26669984 ER PT J AU Murphey, MD Roberts, CC Bencardino, JT Appel, M Arnold, E Chang, EY Dempsey, ME Fox, MG Fries, IB Greenspan, BS Hochman, MG Jacobson, JA Mintz, DN Newman, JS Rosenberg, ZS Rubin, DA Small, KM Weissman, BN AF Murphey, Mark D. Roberts, Catherine C. Bencardino, Jenny T. Appel, Marc Arnold, Erin Chang, Eric Y. Dempsey, Molly E. Fox, Michael G. Fries, Ian Blair Greenspan, Bennett S. Hochman, Mary G. Jacobson, Jon A. Mintz, Douglas N. Newman, Joel S. Rosenberg, Zehava S. Rubin, David A. Small, Kirstin M. Weissman, Barbara N. TI ACR Appropriateness Criteria Osteonecrosis of the Hip SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness criteria; osteonecrosis; adult; child; MRI; radiograph ID CALVE-PERTHES-DISEASE; FEMORAL-HEAD OSTEONECROSIS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; SUBCHONDRAL INSUFFICIENCY FRACTURE; CONTRAST-ENHANCED MRI; SICKLE-CELL-DISEASE; BONE-MARROW EDEMA; AVASCULAR NECROSIS; ASYMPTOMATIC OSTEONECROSIS; CORE DECOMPRESSION AB Osteonecrosis of the hip (Legg-Calve-Perthes) is a common disease, with 10,000-20,000 symptomatic cases annually in the United States. The disorder affects both adults and children and is most frequently associated with trauma and corticosteroid usage. The initial imaging evaluation of suspected hip osteonecrosis is done using radiography. MRI is the most sensitive and specific imaging modality for diagnosis of osteonecrosis of the hip. The clinical significance of hip osteonecrosis is dependent on its potential for articular collapse. The likelihood of articular collapse is significantly increased with involvement of greater than 30%-50% of the femoral head area, which is optimally evaluated by MRI, often in the sagittal plane. Contrast-enhanced MRI may be needed to detect early osteonecrosis of the hip in pediatric patients, revealing hypoperfusion. In patients with a contraindication for MRI, use of either CT or bone scintigraphy with SPECT (single-photon emission CT) are alternative radiologic methods of assessment. Imaging helps guide treatment, which may include core decompression, osteotomy, and ultimately, need for joint replacement. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. C1 [Murphey, Mark D.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. [Roberts, Catherine C.] Mayo Clin, Phoenix, AZ USA. [Bencardino, Jenny T.] NYU Radiol Associates, New York, NY USA. [Appel, Marc] Amer Acad Orthopaed Surgeons, James J Peters VA Med Ctr, Bronx, NY USA. [Arnold, Erin] Amer Coll Rheumatol, Orthopaed & Rheumatol North Shore, Skokie, IL USA. [Chang, Eric Y.] VA San Diego Healthcare Syst, San Diego, CA USA. [Dempsey, Molly E.] Texas Scottish Rite Hosp Children, Dallas, TX 75219 USA. [Fox, Michael G.] Univ Virginia Hlth Syst, Charlottesville, VA USA. [Fries, Ian Blair] Amer Acad Orthopaed Surgeons, Bone Spine & Hand Surg, Chartered, Brick, NJ USA. [Greenspan, Bennett S.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Hochman, Mary G.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Jacobson, Jon A.] Univ Michigan, Med Ctr, Ann Arbor, MI USA. [Mintz, Douglas N.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Newman, Joel S.] New England Baptist Hosp, Boston, MA USA. [Rosenberg, Zehava S.] Hosp Joint Dis & Med Ctr, New York, NY USA. [Rubin, David A.] Washington Univ, Sch Med, St Louis, MO USA. [Small, Kirstin M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Murphey, MD (reprint author), 1010 Wayne Ave Ste 320, Silver Spring, MD 20910 USA. EM mmurphey@acr.org OI Jacobson, Jon/0000-0002-3676-6628; Rosenberg MD, Zehava/0000-0003-1902-6350 NR 68 TC 1 Z9 1 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD FEB PY 2016 VL 13 IS 2 BP 147 EP 155 DI 10.1016/j.jacr.2015.10.033 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DD4FL UT WOS:000369877800014 PM 26846390 ER PT J AU Menon, MC Ross, MJ AF Menon, Madhav C. Ross, Michael J. TI Epithelial-to-mesenchymal transition of tubular epithelial cells in renal fibrosis: a new twist on an old tale SO KIDNEY INTERNATIONAL LA English DT Editorial Material ID TISSUE GROWTH-FACTOR; KIDNEY FIBROSIS; DISEASE AB Recent publications have questioned whether epithelial-to-mesenchymal transition of tubular epithelial cells is an important contributor to renal fibrosis. Two recent publications describe an intratubular epithelial-to-mesenchymal transition-like program of epithelial cell dedifferentiation that may contribute to the recruitment or proliferation of interstitial myofibroblasts after kidney injury. C1 [Menon, Madhav C.] Icahn Sch Med Mt Sinai, Dept Med, Div Nephrol, New York, NY 10029 USA. [Ross, Michael J.] James J Peters VA Med Ctr, Bronx, NY USA. RP Ross, MJ (reprint author), Icahn Sch Med Mt Sinai, Div Nephrol, One Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM michael.ross@mssm.edu NR 11 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2016 VL 89 IS 2 BP 263 EP 266 DI 10.1016/j.kint.2015.12.025 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA DD2TO UT WOS:000369775300004 PM 26806826 ER PT J AU Heatwole, C Bode, R Johnson, NE Dekdebrun, J Dilek, N Eichinger, K Hilbert, JE Logigian, E Luebbe, E Martens, W Mcdermott, MP Pandya, S Puwanant, A Rothrock, N Thornton, C Vickrey, BG Victorson, D Moxley, RT AF Heatwole, Chad Bode, Rita Johnson, Nicholas E. Dekdebrun, Jeanne Dilek, Nuran Eichinger, Katy Hilbert, James E. Logigian, Eric Luebbe, Elizabeth Martens, William Mcdermott, Michael P. Pandya, Shree Puwanant, Araya Rothrock, Nan Thornton, Charles Vickrey, Barbara G. Victorson, David Moxley, Richard T., III TI MYOTONIC DYSTROPHY HEALTH INDEX: CORRELATIONS WITH CLINICAL TESTS AND PATIENT FUNCTION SO MUSCLE & NERVE LA English DT Article DE muscle disease; myotonic dystrophy Type-1; patient-relevant; patient-reported outcome measure; quality of life; therapeutic trial ID QUALITY-OF-LIFE; FACIOSCAPULOHUMERAL MUSCULAR-DYSTROPHY; ACTIVITY RATING-SCALES; ADULT MUSCLE DISEASE; NATURAL-HISTORY; THERAPEUTIC TRIALS; DUCHENNE DYSTROPHY; ACTUALLY MEASURE; CTG REPEAT; RELIABILITY AB Introduction: The Myotonic Dystrophy Health Index (MDHI) is a disease-specific patient-reported outcome measure. Here, we examine the associations between the MDHI and other measures of disease burden in a cohort of individuals with myotonic dystrophy type-1 (DM1). Methods: We conducted a cross-sectional study of 70 patients with DM1. We examined the associations between MDHI total and subscale scores and scores from other clinical tests. Participants completed assessments of strength, myotonia, motor and respiratory function, ambulation, and body composition. Participants also provided blood samples, underwent physician evaluations, and completed other patient-reported outcome measures. Results: MDHI total and subscale scores were strongly associated with muscle strength, myotonia, motor function, and other clinical measures. Conclusions: Patient-reported health status, as measured by the MDHI, is associated with alternative measures of clinical health. These results support the use of the MDHI as a valid tool to measure disease burden in DM1 patients. C1 [Heatwole, Chad; Dekdebrun, Jeanne; Dilek, Nuran; Eichinger, Katy; Hilbert, James E.; Logigian, Eric; Luebbe, Elizabeth; Martens, William; Mcdermott, Michael P.; Pandya, Shree; Thornton, Charles; Moxley, Richard T., III] Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA. [Bode, Rita] Psychometr Consultant, Chicago, IL USA. [Johnson, Nicholas E.] Univ Utah, Salt Lake City, UT USA. [Mcdermott, Michael P.] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA. [Puwanant, Araya] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Rothrock, Nan; Victorson, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Med Ctr, Los Angeles, CA 90095 USA. [Vickrey, Barbara G.] Greater Los Angeles VA HealthCare Syst, Los Angeles, CA USA. RP Heatwole, C (reprint author), Univ Rochester, Med Ctr, Dept Neurol, 601 Elmwood Ave,Box 673, Rochester, NY 14642 USA. EM chad_heatwole@urmc.rochester.edu FU Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center [NINDS U54NS48843]; Muscular Dystrophy Association; Saunders Family Fund; Abrams Family Fund for Myotonic Dystrophy Research; University of Rochester CTSA award from the National Center for Research Resources [UL1 RR024160]; National Center for Advancing Translational Sciences of the National Institutes of Health FX Support for this research was provided by the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (NINDS U54NS48843), the Muscular Dystrophy Association, the Saunders Family Fund, and the Abrams Family Fund for Myotonic Dystrophy Research. The project described in this publication was also supported by the University of Rochester CTSA award number UL1 RR024160 from the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional information regarding the MDHI is available at the Neuromuscular Institute of Quality-of-Life Studies and Outcome Measure Development website www.QOLINSTITUTE.com and MDHI licensing opportunities can be reviewed at: www.urmc.rochester.edu/techtransfer. NR 47 TC 2 Z9 2 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD FEB PY 2016 VL 53 IS 2 BP 183 EP 190 DI 10.1002/mus.24725 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DD3RE UT WOS:000369839500003 PM 26044513 ER PT J AU Jemielita, TO Leonard, MB Baker, J Sayed, S Zemel, BS Shults, J Herskovitz, R Denburg, MR AF Jemielita, T. O. Leonard, M. B. Baker, J. Sayed, S. Zemel, B. S. Shults, J. Herskovitz, R. Denburg, M. R. TI Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bone mineral density; Parathyroid hormone; Vitamin D; Vitamin D-binding protein ID RANDOMIZED-CONTROLLED-TRIALS; NUTRITION EXAMINATION SURVEY; D SUPPLEMENTATION; AFRICAN-AMERICAN; WHITE WOMEN; SERUM 25-HYDROXYVITAMIN-D; FRACTURE PREVENTION; NATIONAL-HEALTH; CALCIUM; MEN AB A comparison of the association of different forms of 25-hydroxyvitamin D [25(OH)D] with parathyroid hormone (PTH) and with areal and volumetric bone mineral density (BMD) demonstrated that bioavailable and free 25(OH)D do not provide a better index of vitamin D status in terms of bone health compared to total 25(OH)D. Introduction This study aims to compare measures of vitamin D-binding protein (DBP) using a monoclonal versus polyclonal ELISA and assess correlations of total versus estimated free and bioavailable 25(OH)D with BMD and PTH concentrations. Methods DXA and peripheral quantitative CT (pQCT) scans were obtained in 304 adults (158 black, 146 white), ages 21-80 years. Free and bioavailable 25(OH)D were calculated from total 25(OH)D, DBP, and albumin concentrations. Multivariable linear regression with standardized beta coefficients was used to evaluate associations of bone measures and PTH with total, free, and bioavailable 25(OH)D. Results Measures of DBP obtained using a monoclonal versus polyclonal ELISA were not correlated (r (s) = 0.02, p = 0.76). Free and bioavailable 25(OH)D based on the polyclonal assay were lower in black versus white participants (p < 0.0001); this race difference was not evident using the monoclonal assay. Adjusted for age, sex, calcium intake, and race, all forms of 25(OH)D were negatively associated with PTH, but the absolute coefficient was greatest for total 25(OH)D (-0.34, p < 0.001) versus free/bioavailable 25(OH)D (-0.18/-0.24 depending on DBP assay, p <= 0.003). In analyses stratified on race, none of the measures of 25(OH)D were associated with BMD across DXA and pQCT sites. Conclusions The monoclonal versus polyclonal ELISA yielded highly discrepant measures of DBP, particularly among black individuals, likely related to established race differences in DBP polymorphisms. Contrary to prior studies, our findings indicate that using DBP to estimate bioavailable and free 25(OH)D does not provide a better index of vitamin D status in terms of bone health. C1 [Jemielita, T. O.; Baker, J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Leonard, M. B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Baker, J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Sayed, S.; Herskovitz, R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Zemel, B. S.; Shults, J.; Denburg, M. R.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. RP Denburg, MR (reprint author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM denburgm@email.chop.edu FU NIH [K23 DK093556, K24 DK076808, R01DK064966, T32DK060455]; Nephcure Foundation-American Society of Nephrology Research Grant; Veterans Affairs Clinical Science Research & Development Career Development Award FX This project was supported by NIH Grants K23 DK093556 (MRD), K24 DK076808 (MBL and JS), R01DK064966 (MBL), and T32DK060455 (TJ). Dr. Denburg was also funded by The Nephcure Foundation-American Society of Nephrology Research Grant. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr. Baker is supported by a Veterans Affairs Clinical Science Research & Development Career Development Award. The contents of this work do not represent the views of the Department of Veterans Affairs or the United States Government. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, and approval of the manuscript. NR 53 TC 7 Z9 7 U1 1 U2 4 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2016 VL 27 IS 2 BP 617 EP 626 DI 10.1007/s00198-015-3296-6 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DD6PN UT WOS:000370046200020 PM 26359185 ER PT J AU McMains, KC AF McMains, Kevin Christopher TI Response to "A Beacon of Emotional Resilience in a Storm of Mistreatment?" SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Letter C1 [McMains, Kevin Christopher] South Texas Vet Hlth Care Syst, Surg, San Antonio, TX USA. RP McMains, KC (reprint author), South Texas Vet Hlth Care Syst, Surg, San Antonio, TX USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2016 VL 154 IS 2 BP 398 EP 399 DI 10.1177/0194599815621529 PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA DD5VB UT WOS:000369991600035 PM 26833650 ER PT J AU Axon, RN Cole, L Moonan, A Foster, R Cawley, P Long, L Turley, CB AF Axon, R. Neal Cole, Laura Moonan, Aunyika Foster, Richard Cawley, Patrick Long, Laura Turley, Christine B. TI Evolution and Initial Experience of a Statewide Care Transitions Quality Improvement Collaborative: Preventing Avoidable Readmissions Together SO POPULATION HEALTH MANAGEMENT LA English DT Article ID HOSPITAL READMISSION; HEART-FAILURE; REHOSPITALIZATIONS; RISK AB Increasing scrutiny of hospital readmission rates has spurred a wide variety of quality improvement initiatives. The Preventing Avoidable Readmissions Together (PART) initiative is a statewide quality improvement learning collaborative organized by stakeholder organizations in South Carolina. This descriptive report focused on initial interventions with hospitals. Eligible participants included all acute care hospitals plus home health organizations, nursing facilities, hospices, and other health care organizations. Measures were degree of statewide participation, curricular engagement, adoption of evidence-based improvement strategies, and readmission rate changes. Fifty-nine of 64 (92%) acute care hospitals and 9 of 10 (90%) hospital systems participated in collaborative events. Curricular engagement included: webinars and coaching calls (49/59, 83%), statewide in-person meetings (35/59, 59%), regional in-person meetings (44/59, 75%), and individualized consultations (46/59, 78%). Among 34 (58%) participating hospitals completing a survey at the completion of Year 1, respondents indicated complete implementation of multidisciplinary rounding (58%), post-discharge telephone calls (58%), and teach-back (32%), and implementation in process of high-quality transition records (52%), improved discharge summaries (45%), and timely follow-up appointments (39%). A higher proportion of hospitals had significant decreases (10% relative change) in all-cause readmission rates for acute myocardial infarction (55.6% vs. 30.4%, P=0.01), heart failure (54.2% vs. 31.7%, P=0.09), and chronic obstructive pulmonary disease (41.7% vs. 33.3%, P=0.83) between 2011-2013 compared to earlier (2009-2011) trends. Focus on reducing readmissions is driving numerous, sometimes competing, quality improvement initiatives. PART successfully engaged the majority of acute care facilities in one state to harmonize and accelerate adoption of evidence-based care transitions strategies. (Population Health Management 2016;19:4-10) C1 [Axon, R. Neal] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Axon, R. Neal; Cawley, Patrick] Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA. [Cole, Laura; Moonan, Aunyika; Foster, Richard] South Carolina Hosp Assoc, Columbia, SC USA. [Long, Laura] BlueCross BlueShield South Carolina, Columbia, SC USA. [Turley, Christine B.] Hlth Sci S Carolina, Columbia, SC USA. [Turley, Christine B.] Univ S Carolina, Sch Med, Columbia, SC USA. RP Axon, RN (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA.; Axon, RN (reprint author), Med Univ S Carolina, Dept Med, Div Gen Internal Med, Charleston, SC 29425 USA.; Axon, RN (reprint author), 109 Bee St,Mail Code 111, Charleston, SC 29401 USA. EM axon@musc.edu NR 19 TC 1 Z9 1 U1 3 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1942-7891 EI 1942-7905 J9 POPUL HEALTH MANAG JI Popul. Health Manag. PD FEB 1 PY 2016 VL 19 IS 1 BP 4 EP 10 DI 10.1089/pop.2014.0182 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DD4DO UT WOS:000369872900002 PM 26102592 ER PT J AU Yu, LL Rodriguez, RA Chen, LL Chen, LY Perry, G McHardy, SF Yeh, CK AF Yu, Lili Rodriguez, Roberto A. Chen, L. Laurie Chen, Liao Y. Perry, George McHardy, Stanton F. Yeh, Chih-Ko TI 1,3-propanediol binds deep inside the channel to inhibit water permeation through aquaporins SO PROTEIN SCIENCE LA English DT Article DE ligand-protein interaction; aquaporin inhibitor; molecular dynamics ID X-RAY-STRUCTURE; NEPHROGENIC DIABETES-INSIPIDUS; PLASMODIUM-FALCIPARUM; MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; FREE-ENERGY; BRAIN; MICE; AQUAGLYCEROPORIN; TRAFFICKING AB Aquaporins and aquaglyceroporins (AQPs) are membrane channel proteins responsible for transport of water and for transport of glycerol in addition to water across the cell membrane, respectively. They are expressed throughout the human body and also in other forms of life. Inhibitors of human AQPs have been sought for therapeutic treatment for various medical conditions including hypertension, refractory edema, neurotoxic brain edema, and so forth. Conducting all-atom molecular dynamics simulations, we computed the binding affinity of acetazolamide to human AQP4 that agrees closely with in vitro experiments. Using this validated computational method, we found that 1,3-propanediol (PDO) binds deep inside the AQP4 channel to inhibit that particular aquaporin efficaciously. Furthermore, we used the same method to compute the affinities of PDO binding to four other AQPs and one aquaglyceroporin whose atomic coordinates are available from the protein data bank (PDB). For bovine AQP1, human AQP2, AQP4, AQP5, and Plasmodium falciparum PfAQP whose structures were resolved with high resolution, we obtained definitive predictions on the PDO dissociation constant. For human AQP1 whose PDB coordinates are less accurate, we estimated the dissociation constant with a rather large error bar. Taking into account the fact that PDO is generally recognized as safe by the US FDA, we predict that PDO can be an effective diuretic which directly modulates water flow through the protein channels. It should be free from the serious side effects associated with other diuretics that change the hydro-homeostasis indirectly by altering the osmotic gradients. C1 [Yu, Lili; Rodriguez, Roberto A.; Chen, Liao Y.] Univ Texas San Antonio, Dept Phys, One UTSA Circle, San Antonio, TX 78249 USA. [Chen, L. Laurie] Univ Texas SW Med Ctr Dallas, Sch Med, Dallas, TX 75390 USA. [Perry, George] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA. [McHardy, Stanton F.] Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA. [Yeh, Chih-Ko] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. [Yeh, Chih-Ko] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX 78229 USA. [Yu, Lili] Yancheng Vocat Inst Hlth Sci, Dept Lab Med, Yancheng 224006, Jiangsu, Peoples R China. RP Chen, LY (reprint author), Univ Texas San Antonio, Dept Phys, One UTSA Circle, San Antonio, TX 78249 USA. EM Liao.chen@utsa.edu RI Chen, Liao/B-8037-2009; Perry, George/A-8611-2009 OI Chen, Liao/0000-0003-1911-8634; Perry, George/0000-0002-6547-0172; Rodriguez, Roberto/0000-0002-3303-9564 FU NIH [GM 084834] FX Grant sponsor: NIH; Grant number: GM 084834. NR 62 TC 1 Z9 1 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0961-8368 EI 1469-896X J9 PROTEIN SCI JI Protein Sci. PD FEB PY 2016 VL 25 IS 2 BP 433 EP 441 DI 10.1002/pro.2832 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DD3JW UT WOS:000369819500012 PM 26481430 ER PT J AU Stewart, RW Tuerk, PW Metzger, IW Davidson, TM Young, J AF Stewart, Regan W. Tuerk, Peter W. Metzger, Isha W. Davidson, Tatiana M. Young, John TI A Decision-Tree Approach to the Assessment of Posttraumatic Stress Disorder: Engineering Empirically Rigorous and Ecologically Valid Assessment Measures SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; assessment; screening; decision-tree analysis; veterans ID ADMINISTERED PTSD SCALE; MENTAL-HEALTH; TREATMENT SEEKING; VIETNAM VETERANS; ASSESSMENT TOOLS; PRIMARY-CARE; CLINICIAN; CLASSIFICATION; SAMPLE; ADOLESCENTS AB Structured diagnostic interviews are widely considered to be the optimal method of assessing symptoms of posttraumatic stress; however, few clinicians report using structured assessments to guide clinical practice. One commonly cited impediment to these assessment approaches is the amount of time required for test administration and interpretation. Empirically keyed methods to reduce the administration time of structured assessments may be a viable solution to increase the use of standardized and reliable diagnostic tools. Thus, the present research conducted an initial feasibility study using a sample of treatment-seeking military veterans (N = 1,517) to develop a truncated assessment protocol based on the Clinician-Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS). Decision-tree analysis was utilized to identify a subset of predictor variables among the CAPS items that were most predictive of a diagnosis of PTSD. The algorithm-driven, atheoretical sequence of questions reduced the number of items administered by more than 75% and classified the validation sample at 92% accuracy. These results demonstrated the feasibility of developing a protocol to assess PTSD in a way that imposes little assessment burden while still providing a reliable categorization. C1 [Stewart, Regan W.; Tuerk, Peter W.; Metzger, Isha W.; Davidson, Tatiana M.; Young, John] Med Univ S Carolina, Dept Psychol & Behav Sci, 67 President St,2nd Floor,South Bldg,MSC 861, Charleston, SC 29425 USA. [Tuerk, Peter W.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. [Young, John] Univ Mississippi, Dept Psychol, University, MS 38677 USA. RP Stewart, RW (reprint author), Med Univ S Carolina, Dept Psychol & Behav Sci, 67 President St,2nd Floor,South Bldg,MSC 861, Charleston, SC 29425 USA. EM stewartr@musc.edu FU Career Development Award from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [CDA-2] FX Peter W. Tuerk's contribution to this article was partially supported by a Career Development Award (CDA-2) from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (principal investigator: Peter W. Tuerk). NR 70 TC 1 Z9 1 U1 2 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2016 VL 13 IS 1 BP 1 EP 9 DI 10.1037/ser0000069 PG 9 WC Psychology, Clinical SC Psychology GA DD0FJ UT WOS:000369595500001 PM 26654473 ER PT J AU Keller, SM Tuerk, PW AF Keller, Stephanie M. Tuerk, Peter W. TI Evidence-Based Psychotherapy (EBP) Non-Initiation Among Veterans Offered an EBP for Posttraumatic Stress Disorder SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; treatment initiation; veterans; evidence-based psychotherapy ID PROLONGED EXPOSURE THERAPY; COGNITIVE PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; TRAUMATIC BRAIN-INJURY; PTSD TREATMENT; AFGHANISTAN VETERANS; IRAQ; CARE; IMPLEMENTATION; ADHERENCE AB Current efforts to disseminate evidence-based psychotherapies (EBPs) for posttraumatic stress disorder (PTSD) in Veterans Affairs Medical Centers (VAMCs) have made effective treatment options more available throughout the system. Yet many veterans identified as likely to benefit from such services choose not to utilize them. The evidence base retarding factors that contribute to treatment initiation among those offered EBPs is still in its early-stages. The present study investigated clinical presentation, patient demographics, and environment of care factors as potential predictors of EBP treatment initiation among veterans offered such care,. The sample consisted of 324 Veterans (62% Operation Enduring Freedom [OEF]/Operation Iraqi Freedom [OM; 77% male; age M = 42.95 SD = 12.57 years), who attended an intake evaluation at a VAMC outpatient PTSD Clinical Team, were diagnosed with PTSD, and offered a course of EBP. Overall, 720 of veterans (11 = 232) who were offered an FOP initiated such treatment, and 28% of veterans (n = 92) did not initiate treatment. Veterans who initiated treatment were significantly older. Treatment initiation did not significantly differ by ethnicity, gender, or baseline PTSD severity. Significantly more veterans referred from mental health clinics initiated treatment than did veterans referred from primary care. This study examined treatment initiation among veterans who were offered FOP for PTSD. Rates of initiation differed across subgroups of veterans. Clinically, this suggests the need to tailor outreach efforts to younger veterans, OEF/OLF veterans, and veterans referred from primary care, and potentially including programming and education aimed at primary care referrers, to increase help-seeking. C1 [Keller, Stephanie M.; Tuerk, Peter W.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC 29401 USA. [Keller, Stephanie M.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Keller, SM (reprint author), Ralph H Johnson VA Med Ctr, Menhil Hlth, 109 Bee St,116, Charleston, SC 29401 USA. EM smp28@case.edu FU CDA-2 award from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development [NCT01031979] FX Peter W. Tuerk's contribution to his research was supported in part by funding from a CDA-2 award from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (principal investigator: Peter W. Tuerk; NCT01031979). NR 40 TC 0 Z9 0 U1 1 U2 3 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD FEB PY 2016 VL 13 IS 1 BP 42 EP 48 DI 10.1037/ser0000064 PG 7 WC Psychology, Clinical SC Psychology GA DD0FJ UT WOS:000369595500005 PM 26654474 ER PT J AU Jahn, DR Bennett, ME Park, SG Gur, RE Horan, WP Kring, AM Blanchard, JJ AF Jahn, Danielle R. Bennett, Melanie E. Park, Stephanie G. Gur, Raquel E. Horan, William P. Kring, Ann M. Blanchard, Jack J. TI The interactive effects of negative symptoms and social role functioning on suicide ideation in individuals with schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Social anhedonia; Social closeness; Belonging; Moderation; Protective factors ID PSYCHIATRIC RATING-SCALE; RISK-FACTORS; DEPRESSIVE SYMPTOMS; COMPLETED SUICIDE; DISORDERS; ANHEDONIA; LIFE; MOTIVATION; COMMUNITY; SPECTRUM AB Findings regarding the protective effect of social role functioning on suicide ideation in individuals with schizophrenia have been mixed. One reason for such inconsistencies in the literature may be that individuals with prominent negative symptoms of schizophrenia may not experience a desire for social closeness, and therefore social role functioning may not influence suicide risk in these individuals. The aim of this study was to examine the moderating effects of self-reported desire for social closeness and interviewer-rated negative symptoms on the relationship between social role functioning and suicide ideation. Our sample consisted of 162 individuals who had been diagnosed with schizophrenia-spectrum disorders; all participants completed self-report questionnaires and clinician-administered interviews, and moderation hypotheses were tested with a non parametric procedure. The results indicated that motivation and pleasure-related negative symptoms moderated the relationship between social role functioning and suicide ideation; self-reported desire for social closeness and negative symptoms related to expression did not have such a moderating effect. Specifically, better social role functioning was associated with less suicide ideation only in those individuals who had low motivation and pleasure-related negative symptoms; no significant relationship was observed between social role functioning and suicide ideation among those with elevated motivation and pleasure-related negative symptoms. These findings suggest that assessing for negative symptoms and social role functioning may inform suicide risk assessments in individuals with schizophrenia, and improving social role functioning may reduce suicide ideation among those with few motivation and pleasure-related negative symptoms. (c) 2015 Elsevier B.V. All rights reserved. C1 [Jahn, Danielle R.; Bennett, Melanie E.; Park, Stephanie G.] VA Maryland Hlth Care Syst, VA Capitol Hlth Care Network VISN 5, Mental Illness Res Educ & Clin Ctr, 10 N Greene St Annex Room 723A, Baltimore, MD 21201 USA. [Jahn, Danielle R.; Bennett, Melanie E.; Park, Stephanie G.] Univ Maryland, Sch Med, Dept Psychiat, 737 W Lombard St,Suite 551, Baltimore, MD 21201 USA. [Gur, Raquel E.] Univ Penn, Perelman Sch Med, Dept Psychiat, 10th Floor Gates Bldg, Philadelphia, PA 19104 USA. [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Jane & Terry Semel Inst Neurosci & Human Behav, 760 Westwood Plaza, Los Angeles, CA 90095 USA. [Horan, William P.] VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 210,Mail Code 210A, Los Angeles, CA 90073 USA. [Kring, Ann M.] Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA. [Blanchard, Jack J.] Univ Maryland, Dept Psychol, 1147 Biol Psychol Bldg, College Pk, MD 20742 USA. RP Blanchard, JJ (reprint author), Univ Maryland, 1147 Biol Psychol Bldg, College Pk, MD 20742 USA. EM danielle.jahn@va.gov; mbennett@p.sych.umaryland.edu; stephanie.park3@va.gov; raquel@upenn.edu; horan@ucla.edu; kring@berkeley.edu; jblancha@umd.edu FU NIH [1R01MH082839]; Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs FX This work was supported by NIH grant (1R01MH082839) to Dr. Blanchard. Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs (Dr. Jahn and Dr. Park's time). The funding sources had no role in study design or in the collection, analysis and interpretation of data, or in the writing of this report. NR 43 TC 0 Z9 0 U1 2 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD FEB PY 2016 VL 170 IS 2-3 BP 271 EP 277 DI 10.1016/j.schres.2015.12.011 PG 7 WC Psychiatry SC Psychiatry GA DD0LS UT WOS:000369612100006 PM 26746862 ER PT J AU Suri, P Pashova, H Heagerty, PJ Jarvik, JG Turner, JA Bauer, Z Annaswamy, M Nedeljkovic, SS Wasan, AD Friedly, JL AF Suri, Pradeep Pashova, Hristina Heagerty, Patrick J. Jarvik, Jeffrey G. Turner, Judith A. Bauer, Zoya Annaswamy, M. Nedeljkovic, Srdjan S. Wasan, Ajay D. Friedly, Janna L. TI Short-term Improvements in Disability Mediate Patient Satisfaction After Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal Stenosis Reply SO SPINE LA English DT Letter ID TRIAL C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Dallas VA Med Ctr, Dallas, TX USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM pradeep.suri@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD FEB PY 2016 VL 41 IS 3 BP E183 EP E184 DI 10.1097/BRS.0000000000001142 PG 2 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA DD5VS UT WOS:000369993400002 ER PT J AU Suri, P Pashova, H Heagerty, PJ Jarvik, JG Turner, JA Bauer, Z Annaswamy, TM Nedeljkovic, SS Wasan, AD Friedly, JL AF Suri, Pradeep Pashova, Hristina Heagerty, Patrick J. Jarvik, Jeffrey G. Turner, Judith A. Bauer, Zoya Annaswamy, Thiru M. Nedeljkovic, Srdjan S. Wasan, Ajay D. Friedly, Janna L. TI Re: Suri, P. et al. Short-term Improvements in Disability Mediate Patient Satisfaction After Epidural Corticosteroid Injections for Symptomatic Lumbar Spinal Stenosis. Spine (Phila Pa 1976) 2015 May 22. Reply SO SPINE LA English DT Letter ID TRIAL C1 [Suri, Pradeep] VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Dallas VA Med Ctr, Dallas, TX USA. Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Suri, P (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM pradeep.suri@va.gov NR 4 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD FEB PY 2016 VL 41 IS 3 BP E183 EP E184 DI 10.1097/BRS.0000000000001142 PG 2 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA DD5VR UT WOS:000369993300013 ER PT J AU Monteith, LL Menefee, DS Forster, JE Bahraini, NH AF Monteith, Lindsey L. Menefee, Deleene S. Forster, Jeri E. Bahraini, Nazanin H. TI A Closer Examination of Sexual Trauma During Deployment: Not all Sexual Traumas are Associated with Suicidal Ideation SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-DIFFERENCES; MENTAL-HEALTH; MILITARY PERSONNEL; OEF/OIF VETERANS; FOLLOW-UP; ASSAULT; HARASSMENT; EXPERIENCES; AFGHANISTAN AB Military personnel can be exposed to a wide range of sexual traumawhile deployed, including sexual harassment and sexual assault. We examined whether different types of sexual trauma during deployment associated with recent suicidal ideation among previously deployed OEF/OIF/OND veterans admitted to trauma-focused treatment (n=199). More severe forms of sexual trauma (e.g., sexual assault) were significantly and positively associated with suicidal ideation. In contrast, sexual trauma involving verbal remarks (e.g., sexual harassment) was not associated with suicidal ideation. Our findings suggest that sexual harassment and sexual assault during deployment may be differentially associated with suicidal ideation. C1 [Monteith, Lindsey L.; Forster, Jeri E.; Bahraini, Nazanin H.] VISN 19 MIRECC, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA. [Monteith, Lindsey L.; Bahraini, Nazanin H.] Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA. [Menefee, Deleene S.] VISN 16 MIRECC, Michael F DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Menefee, Deleene S.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Forster, Jeri E.] Colorado Sch Publ Hlth, Aurora, CO USA. RP Monteith, LL (reprint author), VISN 19 MIRECC, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO USA. EM lindsey.monteith@va.gov FU Denver Veterans Affairs Medical Center; MEDVAMC; VISN 19 MIRECC in Denver, Colorado; VISN 16 MIRECC in Houston, Texas FX This material is the result of work supported with resources and the use of facilities at the Denver Veterans Affairs Medical Center and VISN 19 MIRECC in Denver, Colorado, and the MEDVAMC and VISN 16 MIRECC in Houston, Texas. The views expressed are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. Government. NR 26 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD FEB PY 2016 VL 46 IS 1 BP 46 EP 54 DI 10.1111/sltb.12171 PG 9 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DD7WS UT WOS:000370136200005 PM 26096625 ER PT J AU Saxena, V Kim, M Keah, NM Neuwirth, AL Stoeckl, BD Bickard, K Restle, DJ Salowe, R Wang, MY Steinberg, DR Mauck, RL AF Saxena, Vishal Kim, Minwook Keah, Niobra M. Neuwirth, Alexander L. Stoeckl, Brendan D. Bickard, Kevin Restle, David J. Salowe, Rebecca Wang, Margaret Ye Steinberg, David R. Mauck, Robert L. TI Anatomic Mesenchymal Stem Cell-Based Engineered Cartilage Constructs for Biologic Total Joint Replacement SO TISSUE ENGINEERING PART A LA English DT Article ID HYALURONIC-ACID HYDROGELS; ARTICULAR-CARTILAGE; POROUS TANTALUM; NUTRIENT CHANNELS; TISSUE; KNEE; REPAIR; BONE; REGENERATION; GROWTH AB Cartilage has a poor healing response, and few viable options exist for repair of extensive damage. Hyaluronic acid (HA) hydrogels seeded with mesenchymal stem cells (MSCs) polymerized through UV crosslinking can generate functional tissue, but this crosslinking is not compatible with indirect rapid prototyping utilizing opaque anatomic molds. Methacrylate-modified polymers can also be chemically crosslinked in a cytocompatible manner using ammonium persulfate (APS) and N,N,N,N-tetramethylethylenediamine (TEMED). The objectives of this study were to (1) compare APS/TEMED crosslinking with UV crosslinking in terms of functional maturation of MSC-seeded HA hydrogels; (2) generate an anatomic mold of a complex joint surface through rapid prototyping; and (3) grow anatomic MSC-seeded HA hydrogel constructs using this alternative crosslinking method. Juvenile bovine MSCs were suspended in methacrylated HA (MeHA) and crosslinked either through UV polymerization or chemically with APS/TEMED to generate cylindrical constructs. Minipig porcine femoral heads were imaged using microCT, and anatomic negative molds were generated by three-dimensional printing using fused deposition modeling. Molded HA constructs were produced using the APS/TEMED method. All constructs were cultured for up to 12 weeks in a chemically defined medium supplemented with TGF-3 and characterized by mechanical testing, biochemical assays, and histologic analysis. Both UV- and APS/TEMED-polymerized constructs showed increasing mechanical properties and robust proteoglycan and collagen deposition over time. At 12 weeks, APS/TEMED-polymerized constructs had higher equilibrium and dynamic moduli than UV-polymerized constructs, with no differences in proteoglycan or collagen content. Molded HA constructs retained their hemispherical shape in culture and demonstrated increasing mechanical properties and proteoglycan and collagen deposition, especially at the edges compared to the center of these larger constructs. Immunohistochemistry showed abundant collagen type II staining and little collagen type I staining. APS/TEMED crosslinking can be used to produce MSC-seeded HA-based neocartilage and can be used in combination with rapid prototyping techniques to generate anatomic MSC-seeded HA constructs for use in filling large and anatomically complex chondral defects or for biologic joint replacement. C1 [Saxena, Vishal; Kim, Minwook; Keah, Niobra M.; Neuwirth, Alexander L.; Stoeckl, Brendan D.; Bickard, Kevin; Restle, David J.; Salowe, Rebecca; Wang, Margaret Ye; Steinberg, David R.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. [Saxena, Vishal; Kim, Minwook; Keah, Niobra M.; Neuwirth, Alexander L.; Stoeckl, Brendan D.; Steinberg, David R.; Mauck, Robert L.] Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA. [Kim, Minwook; Bickard, Kevin; Restle, David J.; Salowe, Rebecca; Wang, Margaret Ye; Mauck, Robert L.] Univ Penn, Dept Bioengn, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. RP Mauck, RL (reprint author), Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA.; Mauck, RL (reprint author), Philadelphia Vet Affairs Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA USA.; Mauck, RL (reprint author), Univ Penn, Dept Bioengn, Stemmler Hall 36th St & Hamilton Walk, Philadelphia, PA 19104 USA. EM lemauck@mail.med.upenn.edu FU National Institutes of Health [R01 EB008722]; Department of Veterans Affairs [I01 RX000700]; Penn Center for Musculoskeletal Disorders [P30 AR050950] FX This work was funded by the National Institutes of Health (R01 EB008722), the Department of Veterans Affairs (I01 RX000700), and the Penn Center for Musculoskeletal Disorders (P30 AR050950). NR 55 TC 1 Z9 1 U1 3 U2 14 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3341 EI 1937-335X J9 TISSUE ENG PT A JI Tissue Eng. Part A PD FEB 1 PY 2016 VL 22 IS 3-4 BP 386 EP 395 DI 10.1089/ten.tea.2015.0384 PG 10 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA DD5TS UT WOS:000369987900020 PM 26871863 ER PT J AU Ismail, Z Smith, EE Geda, Y Sultzer, D Brodaty, H Smith, G Aguera-Ortiz, L Sweet, R Miller, D Lyketsos, CG AF Ismail, Zahinoor Smith, Eric E. Geda, Yonas Sultzer, David Brodaty, Henry Smith, Gwenn Agueera-Ortiz, Luis Sweet, Rob Miller, David Lyketsos, Constantine G. CA ISTAART Neuropsychiat Symptoms Pro TI Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment SO ALZHEIMERS & DEMENTIA LA English DT Article DE Dementia; FTD; Alzheimer's disease; MCI; MBI; Neuropsychiatric symptoms of dementia; NPS; Behavior; Behaviour; Agitation; Psychosis; Disinhibition; Apathy; Depression; BPSD ID ALZHEIMERS ASSOCIATION WORKGROUPS; COGNITIVE IMPAIRMENT; FRONTOTEMPORAL DEMENTIA; NATIONAL INSTITUTE; CACHE COUNTY; RISK-FACTORS; DISEASE; PROGRESSION; AGITATION; PREDICTORS AB Neuropsychiatric symptoms (NPS) are common in dementia and in predementia syndromes such as mild cognitive impairment (MCI). NPS in MCI confer a greater risk for conversion to dementia in comparison to MCI patients without NPS. NPS in older adults with normal cognition also confers a greater risk of cognitive decline in comparison to older adults without NPS. Mild behavioral impairment (MBI) has been proposed as a diagnostic construct aimed to identify patients with an increased risk of developing dementia, but who may or may not have cognitive symptoms. We propose criteria that include MCI in the MBI framework, in contrast to prior definitions of MBI. Although MBI and MCI can co-occur, we suggest that they are different and that both portend a higher risk of dementia. These MBI criteria extend the previous literature in this area and will serve as a template for validation of the MBI construct from epidemiologic, neurobiological, treatment, and prevention perspectives. (C) 2016 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved. C1 [Ismail, Zahinoor] Univ Calgary, Dept Psychiat, Calgary, AB, Canada. [Ismail, Zahinoor; Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Ismail, Zahinoor] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada. [Ismail, Zahinoor; Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. [Geda, Yonas] Mayo Clin, Dept Psychiat, Scottsdale, AZ USA. [Geda, Yonas] Mayo Clin, Dept Neurol, Scottsdale, AZ USA. [Sultzer, David] VA Greater Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Brodaty, Henry] Univ New S Wales, Ctr Hlth Brain Ageing, Sydney, NSW, Australia. [Brodaty, Henry] Univ New S Wales, Dementia Collaborat Res Ctr, Sydney, NSW, Australia. [Smith, Gwenn] Johns Hopkins Sch Med, Alzheimers Dis Res Ctr, Baltimore, MD USA. [Agueera-Ortiz, Luis] Carlos III Inst Hlth, Alzheimer Ctr Reina Sofia Fdn, Res Unit, Madrid, Spain. [Agueera-Ortiz, Luis] CIBERSAM, Madrid, Spain. [Sweet, Rob] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Rob] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Rob] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Miller, David] Bracket Global, Wayne, PA USA. [Lyketsos, Constantine G.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. RP Ismail, Z (reprint author), Univ Calgary, Dept Psychiat, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Calgary, AB, Canada.; Ismail, Z (reprint author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. EM zahinoor@gmail.com FU Veterans Health Administration [BX000452]; NIH [MH071533, AG05133, AG027224, P50AG005146]; Department of Veterans Affairs FX The authors acknowledge The Alzheimer's Association ISTAART group for reading and supporting these criteria. Article supported in part by Veterans Health Administration Grant BX000452, and NIH grants MH071533, AG05133, AG027224 (R.S.), and P50AG005146 to the Johns Hopkins Alzheimer's Disease Research Center (C.G.L.) and by the Department of Veterans Affairs (D.S. and R.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 52 TC 22 Z9 22 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD FEB PY 2016 VL 12 IS 2 BP 195 EP 202 DI 10.1016/j.jalz.2015.05.017 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DC9EI UT WOS:000369523500011 PM 26096665 ER PT J AU Feemster, LC Curtis, JR AF Feemster, Laura C. Curtis, J. Randall TI "We Understand the Prognosis, but We Live with Our Heads in the Clouds": Understanding Patient and Family Outcome Expectations and Their Influence on Shared Decision Making SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID ADVANCED CANCER; COMMUNICATION; PREFERENCES C1 [Feemster, Laura C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA. [Feemster, Laura C.; Curtis, J. Randall] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Curtis, J. Randall] Univ Washington, Cambia Palliat Care Ctr Excellence, Seattle, WA 98195 USA. RP Feemster, LC (reprint author), VA Puget Sound Hlth Care Syst, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.; Feemster, LC (reprint author), Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. FU NHLBI NIH HHS [HL111116, K23 HL111116] NR 14 TC 0 Z9 0 U1 4 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2016 VL 193 IS 3 BP 239 EP 241 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DC6UR UT WOS:000369355600008 PM 26829423 ER PT J AU Kellum, JA Chawla, LS Keener, C Singbartl, K Palevsky, PM Pike, FL Yealy, DM Huang, DT Angus, DC AF Kellum, John. A. Chawla, Lakhmir S. Keener, Christopher Singbartl, Kai Palevsky, Paul M. Pike, Francis L. Yealy, Donald M. Huang, David T. Angus, Derek C. CA ProCESS & ProGReSS-AKI Investigato TI The Effects of Alternative Resuscitation Strategies on Acute Kidney Injury in Patients with Septic Shock SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE sepsis; septic shock; resuscitation; early goal-directed therapy; acute kidney injury ID CRITICALLY-ILL PATIENTS; CREATININE; MORTALITY; RECOVERY; CRITERIA; TRIAL; CARE AB Rationale: Septic shock is a common cause of acute kidney injury (AKI), and fluid resuscitation is a major part of therapy. Objectives: To determine if structured resuscitation designed to alter fluid, blood, and vasopressor use affects the development or severity of AKI or outcomes. Methods: Ancillary study to the ProCESS (Protocolized Care for Early Septic Shock) trial of alternative resuscitation strategies (two protocols vs. usual care) for septic shock. Measurements and Main Results: We studied 1,243 patients and classified AKI using serum creatinine and urine output. We determined recovery status at hospital discharge, examined rates of renal replacement therapy and fluid overload, and measured biomarkers of kidney damage. Among patients without evidence of AKI at enrollment, 37.6% of protocolized care and 38.1% of usual care patients developed kidney injury (P = 0.90). AKI duration (P = 0.59) and rates of renal replacement therapy did not differ between study arms (6.9% for protocolized care and 4.3% for usual care; P = 0.08). Fluid overload occurred in 8.3% of protocolized care and 6.3% of usual care patients (P = 0.26). Among patients with severe AKI, complete and partial recovery was 50.7 and 13.2% for protocolized patients and 49.1 and 13.4% for usual care patients (P = 0.93). Sixty-day hospital mortality was 6.2% for patients without AKI, 16.8% for those with stage 1, and 27.7% for stages 2 to 3. Conclusions: In patients with septic shock, AKI is common and associated with adverse outcomes, but it is not influenced by protocolized resuscitation compared with usual care. C1 [Kellum, John. A.; Pike, Francis L.; Huang, David T.; Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA 15261 USA. [Kellum, John. A.; Chawla, Lakhmir S.; Singbartl, Kai; Palevsky, Paul M.] Univ Pittsburgh, Ctr Crit Care Nephrol, Pittsburgh, PA 15261 USA. [Keener, Christopher] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Palevsky, Paul M.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, 930 Scaife Hall, Pittsburgh, PA 15261 USA. [Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA. [Chawla, Lakhmir S.] Vet Affairs Med Ctr, Dept Med, Div Intens Care Med, 50 Irving St NW, Washington, DC 20422 USA. [Chawla, Lakhmir S.] Vet Affairs Med Ctr, Div Nephrol, 50 Irving St NW, Washington, DC 20422 USA. [Singbartl, Kai] Penn State Hershey Med Ctr, Dept Anesthesia, Hershey, PA USA. [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Med Serv, Renal Sect, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,604 Scaife Hall, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 FU National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases grant [R01 DK083961]; NIH/National Institute of General Medical Sciences grant [P50 GM076659] FX Supported by National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases grant R01 DK083961 and NIH/National Institute of General Medical Sciences grant P50 GM076659. NR 19 TC 11 Z9 11 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD FEB 1 PY 2016 VL 193 IS 3 BP 281 EP 287 DI 10.1164/rccm.201505-0995OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA DC6UR UT WOS:000369355600013 PM 26398704 ER PT J AU Sevy, S Sher, L AF Sevy, Serge Sher, Leo TI Gender differences in the dosing of antipsychotic medications SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY LA English DT Letter C1 [Sevy, Serge; Sher, Leo] James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. [Sher, Leo] Mt Sinai Sch Med, New York, NY USA. RP Sevy, S (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, New York, NY 10468 USA. EM sevymd@gmail.com NR 3 TC 0 Z9 0 U1 1 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0004-8674 EI 1440-1614 J9 AUST NZ J PSYCHIAT JI Aust. N. Z. J. Psych. PD FEB PY 2016 VL 50 IS 2 SI SI BP 185 EP 186 DI 10.1177/0004867415609426 PG 3 WC Psychiatry SC Psychiatry GA DC5FQ UT WOS:000369247300022 PM 26450940 ER PT J AU Cowan, AJ Stevenson, PA Cassaday, RD Graf, SA Fromm, JR Wu, D Holmberg, LA Till, BG Chauncey, TR Smith, SD Philip, M Orozco, JJ Shustov, AR Green, DJ Libby, EN Bensinger, WI Shadman, M Maloney, DG Press, OW Gopal, AK AF Cowan, Andrew J. Stevenson, Philip A. Cassaday, Ryan D. Graf, Solomon A. Fromm, Jonathan R. Wu, David Holmberg, Leona A. Till, Brian G. Chauncey, Thomas R. Smith, Stephen D. Philip, Mary Orozco, Johnnie J. Shustov, Andrei R. Green, Damian J. Libby, Edward N., III Bensinger, William I. Shadman, Mazyar Maloney, David G. Press, Oliver W. Gopal, Ajay K. TI Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Mantle cell lymphoma; Transplantation; Minimal residual disease; Predictors; Survival ID INTERNATIONAL PROGNOSTIC INDEX; PROGRESSION-FREE SURVIVAL; NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; FLOW-CYTOMETRY; MOLECULAR REMISSION; RESPONSE ASSESSMENT; IMMUNOCHEMOTHERAPY; TOMOGRAPHY; CLASSIFICATION AB Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission after induction chemotherapy, with the best results for patients in complete remission (CR). We hypothesized that evaluation of minimal residual disease (MRD) before ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011 with pretransplantation MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11; 14) by PCR or positive flow cytometry from blood or bone marrow, was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached, with 82% survival at 5 years, whereas for the MRD-positive patients, median OS was 3.01 years (hazard ratio [HR], 4.04; P = .009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75% PFS at 5 years, whereas for MRD-positive patients, it was 238 years (HR, 3.69; P = .002). MRD positivity is independently associated with poor outcomes after ASCT for MCL patients in CR. (C) 2016 American Society for Blood and Marrow Transplantation. C1 [Cowan, Andrew J.; Stevenson, Philip A.; Cassaday, Ryan D.; Graf, Solomon A.; Holmberg, Leona A.; Till, Brian G.; Chauncey, Thomas R.; Smith, Stephen D.; Philip, Mary; Orozco, Johnnie J.; Shustov, Andrei R.; Green, Damian J.; Bensinger, William I.; Shadman, Mazyar; Press, Oliver W.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Fromm, Jonathan R.; Wu, David] Univ Washington, Dept Lab Med, Marrow Transplant Unit, Seattle, WA 98195 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Libby, Edward N., III] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA. [Maloney, David G.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Transplantat Biol Dept, 1124 Columbia St, Seattle, WA 98104 USA. RP Gopal, AK (reprint author), 825 Eastlake Ave E,MS G3-200, Seattle, WA 98109 USA. EM agopal@u.washington.edu FU NIH [P01CA044991, K24CA184039]; Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative Clinical Scholar Award by the Leukemia and Lymphoma Society; Mary Aileen Wright Memorial Fund; David and Patricia Giuliani Family Foundation; [5T32 CA009515-30] FX A.J.C. is supported by 5T32 CA009515-30. This work was supported by research funding from NIH P01CA044991 and K24CA184039; Lymphoma Research Foundation Mantle Cell Lymphoma Research Initiative Clinical Scholar Award by the Leukemia and Lymphoma Society, to A.K.G.; the Mary Aileen Wright Memorial Fund; the David and Patricia Giuliani Family Foundation; and philanthropic gifts from Frank and Betty Vandermeer and Don and Debbie Hunkins. NR 34 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2016 VL 22 IS 2 BP 380 EP 385 DI 10.1016/j.bbmt.2015.08.035 PG 6 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA DC2JD UT WOS:000369042100027 PM 26348890 ER PT J AU ter Maaten, JM Valente, MAE Metra, M Bruno, N O'Connor, CM Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JG Givertz, MM Bloomfield, DM Dittrich, HC van Veldhuisen, DJ Hillege, HL Damman, K Voors, AA AF ter Maaten, Jozine M. Valente, Mattia A. E. Metra, Marco Bruno, Noemi O'Connor, Christopher M. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. van Veldhuisen, Dirk J. Hillege, Hans L. Damman, Kevin Voors, Adriaan A. TI A combined clinical and biomarker approach to predict diuretic response in acute heart failure SO CLINICAL RESEARCH IN CARDIOLOGY LA English DT Article DE Diuretic response; Heart failure; Biomarkers; Prediction ID BLOOD UREA NITROGEN; PROGNOSTIC VALUE; THERAPY; ATHEROSCLEROSIS; TRANSPORT; CHLORIDE; RECEPTOR AB Poor diuretic response in acute heart failure is related to poor clinical outcome. The underlying mechanisms and pathophysiology behind diuretic resistance are incompletely understood. We evaluated a combined approach using clinical characteristics and biomarkers to predict diuretic response in acute heart failure (AHF). We investigated explanatory and predictive models for diuretic response-weight loss at day 4 per 40 mg of furosemide-in 974 patients with AHF included in the PROTECT trial. Biomarkers, addressing multiple pathophysiological pathways, were determined at baseline and after 24 h. An explanatory baseline biomarker model of a poor diuretic response included low potassium, chloride, hemoglobin, myeloperoxidase, and high blood urea nitrogen, albumin, triglycerides, ST2 and neutrophil gelatinase-associated lipocalin (r (2) = 0.086). Diuretic response after 24 h (early diuretic response) was a strong predictor of diuretic response (beta = 0.467, P < 0.001; r (2) = 0.523). Addition of diuretic response after 24 h to biomarkers and clinical characteristics significantly improved the predictive model (r (2) = 0.586, P < 0.001). Biomarkers indicate that diuretic unresponsiveness is associated with an atherosclerotic profile with abnormal renal function and electrolytes. However, predicting diuretic response is difficult and biomarkers have limited additive value. Patients at risk of poor diuretic response can be identified by measuring early diuretic response after 24 h. C1 [ter Maaten, Jozine M.; Valente, Mattia A. E.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Damman, Kevin; Voors, Adriaan A.] Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. [Metra, Marco] Univ Brescia, Brescia, Italy. [Bruno, Noemi] Univ Roma La Sapienza, Dept Cardiovasc Sci, Piazzale Aldo Moro 5, I-00185 Rome, Italy. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. RP Voors, AA (reprint author), Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016 FU NovaCardia, Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Alere and Singulex kindly provided assays and performed biomarker measurements. NR 27 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1861-0684 EI 1861-0692 J9 CLIN RES CARDIOL JI Clin. Res. Cardiol. PD FEB PY 2016 VL 105 IS 2 BP 145 EP 153 DI 10.1007/s00392-015-0896-2 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DC5IM UT WOS:000369254700006 PM 26280875 ER PT J AU Hall, GM Shanmugan, S Bleier, JIS Jeganathan, AN Epstein, AJ Paulson, EC AF Hall, G. M. Shanmugan, S. Bleier, J. I. S. Jeganathan, A. N. Epstein, A. J. Paulson, E. C. TI Colorectal specialization and survival in colorectal cancer SO COLORECTAL DISEASE LA English DT Article DE Colon cancer; rectal cancer; specialization; survival ID II COLON-CANCER; HOSPITAL VOLUME; RECTAL-CANCER; UNITED-STATES; STAGE-II; ADJUVANT THERAPY; SURGERY; OUTCOMES; PREDICTORS; RECURRENCE AB AimIt is recognized that higher surgeon volume is associated with improved survival in colorectal cancer. However, there is a paucity of national studies that have evaluated the relationship between surgical specialization and survival. MethodWe used the Surveillance, Epidemiology, and End Results Medicare cancer registry to examine the association between colorectal specialization (CRS) and disease-specific survival (DSS) between 2001 and 2009. A total of 21432 colon cancer and 5893 rectal cancer patients who underwent elective surgical resection between 2001 and 2009 were evaluated. Univariate and multivariate Cox survival analysis was used to identify the association between surgical specialization and cancer-specific survival. ResultsColorectal specialists performed 16.3% of the colon and 27% of the rectal resections. On univariate analysis, specialization was associated with improved survival in Stage II and Stage III colon cancer and Stage II rectal cancer. In multivariate analysis, however, CRS was associated with significantly improved DSS only in Stage II rectal cancer [hazard ratio (HR) 0.70, P=0.03]. CRS was not significantly associated with DSS in either Stage I (colon HR 1.14, P=0.39; rectal HR 0.1.26, P=0.23) or Stage III (colon HR 1.06, P=0.52; rectal HR 1.08, P=0.55) disease. When analysis was limited to high volume surgeons only, the relationship between CRS and DSS was unchanged. ConclusionsCRS is associated with improved DSS following resection of Stage II rectal cancer. A combination of factors may contribute to long-term survival in these patients, including appropriate surgical technique, multidisciplinary treatment decisions and guideline-adherent surveillance. CRS probably contributes positively to these factors resulting in improved survival. C1 [Hall, G. M.; Shanmugan, S.; Bleier, J. I. S.; Paulson, E. C.] Univ Penn, Dept Gen Surg, Div Colon & Rectal Surg, Philadelphia, PA 19104 USA. [Jeganathan, A. N.] Univ Penn, Dept Gen Surg, Philadelphia, PA 19104 USA. [Epstein, A. J.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Epstein, A. J.] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Paulson, E. C.] Philadelphia VA Med Ctr, Dept Gen Surg, Philadelphia, PA 19104 USA. RP Paulson, EC (reprint author), Philadelphia VA Med Ctr, Surg Business Off, 3900 Woodland Ave,5th Floor, Philadelphia, PA 19104 USA. EM paulsone@uphs.upenn.edu NR 26 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1462-8910 EI 1463-1318 J9 COLORECTAL DIS JI Colorectal Dis. PD FEB PY 2016 VL 18 IS 2 BP O51 EP O60 DI 10.1111/codi.13246 PG 10 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA DD2GH UT WOS:000369740200001 PM 26708838 ER PT J AU Meya, DB Manabe, YC Boulware, DR Janoff, EN AF Meya, David B. Manabe, Yukari C. Boulware, David R. Janoff, Edward N. TI The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE cryptococcus; cryptococcal meningitis; HIV; immunopathogenesis; immune reconstitution inflammatory syndrome ID ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; HIV-INFECTED PATIENTS; RESOURCE-LIMITED SETTINGS; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; RESTORATION DISEASE; FUNGAL-INFECTIONS; PRIMARY IMMUNODEFICIENCIES AB Purpose of reviewCryptococcal meningitis causes significant mortality among HIV-infected patients, despite antifungal therapy and use of antiretroviral therapy (ART). In patients with cryptococcal meningitis, ART is often complicated by immune reconstitution inflammatory syndrome (IRIS), manifesting as unmasking of previously unrecognized subclinical infection (unmasking CM-IRIS) or paradoxical worsening of symptoms in the central nervous system after prior improvement with antifungal therapy (paradoxical CM-IRIS). We review our current understanding of the pathogenesis of this phenomenon, focusing on unifying innate and adaptive immune mechanisms leading to the development of this often fatal syndrome.Recent findingsWe propose that HIV-associated CD4(+) T-cell depletion, chemokine-driven trafficking of monocytes into cerebrospinal fluid in response to cryptococcal meningitis, and poor localized innate cytokine responses lead to inadequate cryptococcal killing and clearance of the fungus. Subsequent ART-associated recovery of T-cell signaling and restored cytokine responses, characterized by IFN- production, triggers an inflammatory response. The inflammatory response triggered by ART is dysregulated because of impaired homeostatic and regulatory mechanisms, culminating in the development of CM-IRIS.SummaryDespite our incomplete understanding of the immunopathogenesis of CM-IRIS, emerging data exploring innate and adaptive immune responses could be exploited to predict, prevent and manage CM-IRIS and associated morbid consequences. C1 [Meya, David B.] Makerere Univ, Infect Dis Inst, Kampala 22418, Uganda. [Meya, David B.; Boulware, David R.] Univ Minnesota, Dept Med, Ctr Infect Dis & Microbiol Translat Res, Box 736 UMHC, Minneapolis, MN 55455 USA. [Meya, David B.] Makerere Univ, Sch Med, Coll Hlth Sci, Kampala 22418, Uganda. [Manabe, Yukari C.] Johns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USA. [Janoff, Edward N.] Univ Colorado, Mucosal & Vaccine Res Program Colorado MAVRC, Denver, CO 80202 USA. [Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Meya, DB (reprint author), Makerere Univ, Infect Dis Inst, Coll Hlth Sci, Kampala 22418, Uganda. EM david.meya@gmail.com OI Boulware, David/0000-0002-4715-0060 FU National Institutes of Health [R01AI078934, U01AI089244, R21NS065713, R01AI108479, T32AI055433, K24AI096925]; Welcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa [087540, AI108479]; Veterans Affairs Research Service FX This work supported by the National Institutes of Health (R01AI078934, U01AI089244, R21NS065713, R01AI108479, T32AI055433) to D.M. and D.B.; K24AI096925 to P.B.; the Welcome Trust Training Health Researchers into Vocational Excellence (THRiVE) in East Africa, grant number 087540 to D.M.; AI108479 to E.J.; and the Veterans Affairs Research Service. NR 108 TC 2 Z9 2 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0951-7375 EI 1473-6527 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD FEB PY 2016 VL 29 IS 1 BP 10 EP 22 DI 10.1097/QCO.0000000000000224 PG 13 WC Infectious Diseases SC Infectious Diseases GA DC9NZ UT WOS:000369549600002 PM 26658650 ER PT J AU Jensen, DM Ohning, GV Kovacs, TOG Jutabha, R Ghassemi, K Dulai, GS Machicado, GA AF Jensen, Dennis M. Ohning, Gordon V. Kovacs, Thomas O. G. Jutabha, Rome Ghassemi, Kevin Dulai, Gareth S. Machicado, Gustavo A. TI Natural history of definitive diverticular hemorrhage based on stigmata of recent hemorrhage and colonoscopic Doppler blood flow monitoring for risk stratification and definitive hemostasis SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID BLEEDING COLONIC DIVERTICULA; ENDOSCOPIC HEMOSTASIS; URGENT COLONOSCOPY; SEVERE HEMATOCHEZIA; MASSIVE HEMORRHAGE; DIAGNOSIS; MANAGEMENT; VESSEL; INJECTION; THERAPY AB Background and Aims: Few prospective reports describe the short-term natural history of colon diverticular hemorrhage based on stigmata of recent hemorrhage, and none include blood flow detection for risk stratification or as a guide to definitive hemostasis. Our purposes were to report the 30-day natural history of definitive diverticular hemorrhage based on stigmata and to describe Doppler probe blood flow detection as a guide to definitive hemostasis. Methods: Different cohorts of patients with severe diverticular bleeding and stigmata on urgent colonoscopy are reported. For 30-day natural history, patients were treated medically. If severe rebleeding occurred, they had surgical or angiographic treatment. We report natural history with major stigmata (active bleeding, visible vessel, or adherent clot) and no stigmata or flat spots after clots were washed away. We also report Doppler probe detection of arterial blood flow underneath stigmata before and after hemostasis in a recent cohort. Results: For natural history, patients with major stigmata treated medically had 65.8% (25/38) rebleeding rates, and 44.7% (17/38) had intervention for hemostasis. Patients with spots or clean bases had no rebleeding. A Doppler probe detected arterial blood flow in 92% of major stigmatadnone after hemostasisdand there was no rebleeding. Conclusions: (1) Patients with major stigmata treated medically had high rates of rebleeding and intervention for hemostasis. (2) Patients with clean diverticula or only flat spots had no rebleeding. (3) High rates of arterial blood flow were detected under major stigmata with a Doppler probe, but with obliteration by hemostasis no rebleeding occurred. C1 [Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Ulcer Res & Educ,Dept Med Ronald Reagan UCLA, Digest Dis Res Ctr,Vet Affairs Greater Los Angele, Los Angeles, CA 90095 USA. Vet Affairs West Los Angeles Med Ctr, Los Angeles, CA USA. RP Jensen, DM (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr DDRC, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU Clinical Veterans Affairs Merit Review Grant, NIH [P30 AM41301]; Center for Ulcer Research and Education Digestive Diseases Research Center core grant; Vascular Technologies Incorporated (VTI) FX These studies were supported partially by a Clinical Veterans Affairs Merit Review Grant (D. Jensen, PI), NIH P30 AM41301, a Center for Ulcer Research and Education Digestive Diseases Research Center core grant (human studies core), and by Vascular Technologies Incorporated (VTI), who donated colon Doppler endoscopic probes. D. Jensen is a consultant for VTI and is a speaker for BSC. All other authors disclosed no financial relationships relevant to this publication. NR 33 TC 3 Z9 3 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 EI 1097-6779 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2016 VL 83 IS 2 BP 416 EP 423 DI 10.1016/j.gie.2015.07.033 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC5AK UT WOS:000369232000021 PM 26227931 ER PT J AU Sethi, S Anzueto, A Miravitlles, M Arvis, P Alder, J Haverstock, D Trajanovic, M Wilson, R AF Sethi, S. Anzueto, A. Miravitlles, M. Arvis, P. Alder, J. Haverstock, D. Trajanovic, M. Wilson, R. TI Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease SO INFECTION LA English DT Article DE Bacteriological outcomes; Beta-lactams; Exacerbation of chronic obstructive pulmonary disease; Fluoroquinolones; Risk factors; Systemic corticosteroids ID CHRONIC-BRONCHITIS; HAEMOPHILUS-INFLUENZAE; CONTROLLED-TRIAL; GENE-EXPRESSION; COPD; MOXIFLOXACIN; INFLAMMATION; ANTIBIOTICS; INFECTIONS; COLONIZATION AB Changes in sputum microbiology following antibiotic treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), including patterns of bacteriological relapse and superinfection are not well understood. Sputum microbiology at exacerbation is not routinely performed, but pathogen presence and species are determinants of outcomes. Therefore, we determined whether baseline clinical factors could predict the presence of bacterial pathogens at exacerbation. Bacterial eradication at end of treatment (EOT) is associated with clinical resolution of exacerbation. We determined the clinical, microbiological and therapeutic factors that were associated with bacteriological eradication in AECOPD at EOT and in the following 8 weeks. Sputum bacteriological outcomes (i.e., eradication, persistence, superinfection, reinfection) from AECOPD patients (N = 1352) who were randomized to receive moxifloxacin or amoxicillin/clavulanate in the MAESTRAL study were compared. Independent predictors of bacterial presence in sputum at exacerbation and determinants for bacteriological eradication were analyzed by logistic regression and receiver operating characteristic (ROC) analyses. Significantly greater bacteriological eradication with moxifloxacin was mainly driven by superior Haemophilus influenzae eradication (P = 0.002, EOT). Baseline clinical factors were a weak predictor of the presence of pathogens in sputum (AUC(ROC) = 0.593). On multivariate analysis, poorer bacterial eradication was associated with antibiotic resistance (P = 0.0001), systemic steroid use (P = 0.0024) and presence of P. aeruginosa (P = 0.0282). Since clinical prediction of bacterial presence in sputum at AECOPD is poor, sputum microbiological analysis should be considered for guiding antibiotic therapy in moderate-to-severe AECOPD, particularly in those who received concomitant systemic corticosteroids or are at risk for infection with antibiotic-resistant bacteria. C1 [Sethi, S.] SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA. [Sethi, S.] VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Miravitlles, M.] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain. [Arvis, P.] Bayer HealthCare, Loos, France. [Alder, J.; Haverstock, D.] Bayer HealthCare Pharmaceut, Whippany, NJ USA. [Trajanovic, M.] Bayer Inc, Toronto, ON, Canada. [Wilson, R.] Royal Brompton Hosp, Host Def Unit, London SW3 6LY, England. RP Sethi, S (reprint author), SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA.; Sethi, S (reprint author), VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA. EM ssethi@buffalo.edu OI Miravitlles, Marc/0000-0002-9850-9520 FU Bayer HealthCare AG, Germany FX Highfield Communication (Oxford, United Kingdom) provided editorial assistance in preparation of this manuscript. This work was supported by Bayer HealthCare AG, Germany. NR 36 TC 1 Z9 1 U1 0 U2 8 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0300-8126 EI 1439-0973 J9 INFECTION JI Infection PD FEB PY 2016 VL 44 IS 1 BP 65 EP 76 DI 10.1007/s15010-015-0833-3 PG 12 WC Infectious Diseases SC Infectious Diseases GA DC5ZJ UT WOS:000369299000008 PM 26370552 ER PT J AU Zhu, JM Hamel, D Dhaliwal, G Glass, M Sharpe, B Kim, B Monash, B AF Zhu, Jane M. Hamel, David Dhaliwal, Gurpreet Glass, Marcia Sharpe, Bradley Kim, Benjamin Monash, Bradley TI Breakdown SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID HEMOLYTIC-ANEMIA C1 [Zhu, Jane M.; Hamel, David; Dhaliwal, Gurpreet; Glass, Marcia; Sharpe, Bradley; Kim, Benjamin; Monash, Bradley] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Hamel, David; Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Monash, B (reprint author), 533 Parnassus Ave,Box 0131, San Francisco, CA 94143 USA. EM bradley.monash@ucsf.edu NR 9 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD FEB PY 2016 VL 11 IS 2 BP 126 EP 129 DI 10.1002/jhm.2530 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DC5VB UT WOS:000369287500008 PM 26800656 ER PT J AU Aplin, AC Kohler, T Nicosia, R AF Aplin, Alfred C. Kohler, Ted Nicosia, Roberto TI Human Plaque-Aortic Ring Co-Culture: A Novel Assay for the Study of Atherosclerosis-Induced Angiogenesis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 105th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 12-18, 2016 CL Seattle, WA SP US & Canadian Acad Pathol C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound HCS, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 EI 1530-0307 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2016 VL 96 SU 1 MA 316 BP 81A EP 81A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA DC5OQ UT WOS:000369270700317 ER PT J AU Sidani, JE Shensa, A Shiffman, S Switzer, GE Primack, BA AF Sidani, Jaime E. Shensa, Ariel Shiffman, Saul Switzer, Galen E. Primack, Brian A. TI Behavioral associations with waterpipe tobacco smoking dependence among US young adults SO ADDICTION LA English DT Article DE Addiction; dependence; hookah; measurement; scale; tobacco; waterpipe ID HOOKAH SMOKING; UNITED-STATES; UNIVERSITY-STUDENTS; CIGARETTE-SMOKING; NICOTINE EXPOSURE; PUFF TOPOGRAPHY; SMOKERS; PREVALENCE; ATTITUDES; ADDICTION AB Background and AimsWaterpipe tobacco smoking (WTS) is increasingly prevalent in the United States, especially among young adults. We aimed to (1) adapt items from established dependence measures into a WTS dependence scale for US young adults (the US Waterpipe Dependence Scale), (2) determine the factor structure of the items and (3) assess associations between scale values and behavioral use characteristics known to be linked to dependence. DesignCross-sectional survey. SettingUnited States. ParticipantsA total of 436 past-year waterpipe tobacco users ages 18-30years selected at random from a national probability-based panel. MeasurementsParticipants responded to six tobacco dependence items adapted for WTS in US populations. Behavioral use characteristics included factors such as frequency of use and age of initiation. FindingsPrincipal components analysis yielded an unambiguous one-factor solution. Approximately half (52.9%) of past-year waterpipe tobacco users received a score of 0, indicating that none of the six WTS dependence items were endorsed. Approximately one-quarter (25.4%) endorsed one dependence item and 22.7% endorsed two or more items. Higher WTS dependence scores were associated significantly with all five behavioral use characteristics. For example, compared with those who endorsed no dependence items, those who endorsed two or more had an adjusted odds ratio (AOR) of 3.90 [95% confidence interval (CI)=1.56-9.78] for having had earlier age of initiation and an AOR of 32.75 (95% CI=9.76-109.86) for more frequent WTS sessions. ConclusionsScores on a six-item waterpipe tobacco smoking dependence scale (the US Waterpipe Dependence Scale) correlate with measures that would be expected to be related to dependence, such as amount used and age of initiation. C1 [Sidani, Jaime E.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, UPMCMontefiore Hosp,Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Sidani, Jaime E.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Ctr Res Media Technol & Hlth, Pittsburgh, PA USA. [Shiffman, Saul] Pinney Associates, Pittsburgh, PA USA. [Switzer, Galen E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Psychiat Med, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Clin, Pittsburgh, PA USA. [Switzer, Galen E.] Univ Pittsburgh, Dept Translat Sci, Pittsburgh, PA USA. [Primack, Brian A.] Univ Pittsburgh, Dept Pediat, Sch Med, Div Adolescent Med, 3420 Fifth Ave, Pittsburgh, PA 15260 USA. RP Sidani, JE (reprint author), Ctr Res Media Technol & Hlth, 230 McKee Pl Suite 600, Pittsburgh, PA 15213 USA. EM sidanije@upmc.edu FU National Cancer Institute at the National Institutes of Health [R01-CA140150]; Steven Manners Memorial Fund at the University of Pittsburgh Center for Social and Urban Research FX This work was supported by the National Cancer Institute at the National Institutes of Health (R01-CA140150) and the Steven Manners Memorial Fund at the University of Pittsburgh Center for Social and Urban Research, both awarded to B.A.P. The funding agencies had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. NR 44 TC 6 Z9 6 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD FEB PY 2016 VL 111 IS 2 BP 351 EP 359 DI 10.1111/add.13163 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA DC0XE UT WOS:000368940500020 PM 26417942 ER PT J AU Dupre, TV Doll, MA Shah, PP Sharp, CN Kiefer, A Scherzer, MT Saurabh, K Saforo, D Siow, D Casson, L Arteel, GE Jenson, AB Megyesi, J Schnellmann, RG Beverly, LJ Siskind, LJ AF Dupre, Tess V. Doll, Mark A. Shah, Parag P. Sharp, Cierra N. Kiefer, Alex Scherzer, Michael T. Saurabh, Kumar Saforo, Doug Siow, Deanna Casson, Lavona Arteel, Gavin E. Jenson, Alfred Bennett Megyesi, Judit Schnellmann, Rick G. Beverly, Levi J. Siskind, Leah J. TI Suramin protects from cisplatin-induced acute kidney injury SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE cisplatin; acute kidney injury; suramin; renoprotective strategies ID ACUTE-RENAL-FAILURE; EPITHELIAL-CELLS; PROXIMAL TUBULE; ER STRESS; NEPHROTOXICITY; RECEPTORS; APOPTOSIS; FIBROSIS; LIVER; MICE AB Cisplatin, a commonly used cancer chemotherapeutic, has a dose-limiting side effect of nephrotoxicity. Approximately 30% of patients administered cisplatin suffer from kidney injury, and there are limited treatment options for the treatment of cisplatin-induced kidney injury. Suramin, which is Federal Drug Administration-approved for the treatment of trypanosomiasis, improves kidney function after various forms of kidney injury in rodent models. We hypothesized that suramin would attenuate cisplatin-induced kidney injury. Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury. Furthermore, suramin attenuated cisplatin-induced expression of inflammatory cytokines and chemokines, endoplasmic reticulum stress, and apoptosis in the kidney cortex. Treatment of mice with suramin 24 h after cisplatin also improved kidney function, suggesting that the mechanism of protection is not by inhibition of tubular cisplatin uptake or its metabolism to nephrotoxic species. If suramin is to be used in the context of cancer, then it cannot prevent cisplatin-induced cytotoxicity of cancer cells. Suramin did not alter the dose-response curve of cisplatin in lung adenocarcinoma cells in vitro. In addition, suramin pretreatment of mice harboring lung adenocarcinomas did not alter the initial cytotoxic effects of cisplatin (DNA damage and apoptosis) on tumor cells. These results provide evidence that suramin has potential as a renoprotective agent for the treatment/prevention of cisplatin-induced acute kidney injury and justify future long-term preclinical studies using cotreatment of suramin and cisplatin in mouse models of cancer. C1 [Dupre, Tess V.; Doll, Mark A.; Sharp, Cierra N.; Saforo, Doug; Siow, Deanna; Arteel, Gavin E.; Beverly, Levi J.; Siskind, Leah J.] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA. [Shah, Parag P.; Kiefer, Alex; Scherzer, Michael T.; Saurabh, Kumar; Casson, Lavona; Beverly, Levi J.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Jenson, Alfred Bennett; Beverly, Levi J.; Siskind, Leah J.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA. [Megyesi, Judit] Univ Arkansas Med Sci, Dept Internal Med, Div Nephrol, Little Rock, AR 72205 USA. [Megyesi, Judit] Cent Arkansas & Vet Healthcare Syst, Little Rock, AR USA. [Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Siskind, LJ (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, James Graham Brown Canc Ctr, 505 S Hancock St,CTRB 204, Louisville, KY 40202 USA. EM leah.siskind@louisville.edu FU National Institutes of Health (NIH) Grant [R01-DK-093462]; NIH [R01-GM-084147, UL1-RR-029882]; Small Business Innovation Research/Small Business Technology Transfer Grant [ES-023767]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs Grant [1BX000851]; South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina FX This work was supported by National Institutes of Health (NIH) Grant R01-DK-093462 (to L. J. Siskind). This work was also supported by NIH Grants R01-GM-084147 (to R. G. Schnellmann), Grant UL1-RR-029882 (to R. G. Schnellmann), and Small Business Innovation Research/Small Business Technology Transfer Grant ES-023767 (to R. G. Schnellmann), Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs Grant 1BX000851 (to R. G. Schnellmann), and the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina (to R. G. Schnellmann). NR 46 TC 1 Z9 1 U1 3 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD FEB 1 PY 2016 VL 310 IS 3 BP F248 EP F258 DI 10.1152/ajprenal.00433.2015 PG 11 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA DC2TU UT WOS:000369070400007 PM 26661653 ER PT J AU Navarro-Millan, I Yang, S DuVall, SL Chen, L Baddley, J Cannon, GW Delzell, ES Zhang, J Safford, MM Patkar, NM Mikuls, TR Singh, JA Curtis, JR AF Navarro-Millan, Iris Yang, Shuo DuVall, Scott L. Chen, Lang Baddley, John Cannon, Grant W. Delzell, Elizabeth S. Zhang, Jie Safford, Monika M. Patkar, Nivedita M. Mikuls, Ted R. Singh, Jasvinder A. Curtis, Jeffrey R. TI Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE PROTEIN; FOLLOW-UP; MORTALITY; POLYARTHRITIS; EVENTS; COHORT; VALIDATION; DATABASES AB Objective To examine the association of serum lipids, inflammation and seropositivity on coronary heart disease (CHD) and stroke in patients with rheumatoid arthritis (RA). Methods The incidence of hospitalised myocardial infarction (MI) or stroke was calculated in a cohort of patients with RA receiving care within the national Veterans Health Administration from 1998 to 2011. Cox proportional hazard models were used to examine the association between these outcomes and low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as time-varying variables, divided into quintiles. Results There were 37 568 patients with RA in the cohort with mean age of 63 years (SD 12.1); 90% were men. There was a no clear association between LDL-C and CHD/stroke. Compared with lower HDL-C (<34 mg/dL), higher HDL-C (>= 54 mg/dL) was inversely associated with MI (hazard ratio (HR)=0.68, 95% CI 0.55 to 0.85) and stroke (HR=0.69, 95% CI 0.50 to 0.96). Higher CRP >2.17 mg/dL (vs CRP <0.26 mg/dL) was associated with increased risk (HR=2.43, 95% CI 1.77 to 3.33) for MI and 2.02 (95% CI 1.32 to 3.08) for stroke. ESR >47 mm/h compared with <8 mm/h had an HR 1.87 (95% CI 1.39 to 2.52) for MI and 2.00 (95% CI 1.26 to 3.18) for stroke. The association between MI was significant for RA seropositivity (HR=1.23, 95% CI 1.03 to 1.48). Conclusions In this predominantly older male RA cohort, there was no clear association between LDL-C and CHD, whereas higher HDL-C was inversely associated with MI and stroke. CRP and ESR were similarly associated with increase MI risk and stroke, reflecting the prominent role of inflammation in CHD risk in RA. C1 [Navarro-Millan, Iris; Yang, Shuo; Chen, Lang; Baddley, John; Singh, Jasvinder A.; Curtis, Jeffrey R.] Birmingham VA Med Ctr, Birmingham, AL USA. [Navarro-Millan, Iris; Yang, Shuo; Chen, Lang; Baddley, John; Delzell, Elizabeth S.; Zhang, Jie; Safford, Monika M.; Patkar, Nivedita M.; Singh, Jasvinder A.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 802D, Birmingham, AL 35294 USA. [DuVall, Scott L.; Cannon, Grant W.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA. [DuVall, Scott L.; Cannon, Grant W.] Univ Utah, Sch Med, Salt Lake City, UT USA. [Mikuls, Ted R.] Omaha VA, Omaha, NE USA. [Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. RP Curtis, JR (reprint author), Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, 510 20th St S,Fac Off Tower 802D, Birmingham, AL 35294 USA. EM jcurtis@uab.edu FU Agency for Healthcare Research and Quality (AHRQ) [R01HS018517]; NIH [AR 053351, R01 AR062376-S1]; Arthritis Foundation [5561] FX This work was supported by the Agency for Healthcare Research and Quality (AHRQ) (R01HS018517). Dr Curtis receives support from the NIH (AR 053351). Dr Navarro-Millan received support from the Arthritis Foundation (5561) and NIH (R01 AR062376-S1). NR 37 TC 6 Z9 7 U1 0 U2 5 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD FEB PY 2016 VL 75 IS 2 BP 341 EP 347 DI 10.1136/annrheumdis-2013-204987 PG 7 WC Rheumatology SC Rheumatology GA DC1CZ UT WOS:000368955700004 PM 25609412 ER PT J AU Ward, MM Deodhar, A Akl, EA Lui, A Ermann, J Gensler, LS Smith, JA Borenstein, D Hiratzka, J Weiss, PF Inman, RD Majithia, V Haroon, N Maksymowych, WP Joyce, J Clark, BM Colbert, RA Figgie, MP Hallegua, DS Prete, PE Rosenbaum, JT Stebulis, JA Van Den Bosch, F Yu, DTY Miller, AS Reveille, JD Caplan, L AF Ward, Michael M. Deodhar, Atul Akl, Elie A. Lui, Andrew Ermann, Joerg Gensler, Lianne S. Smith, Judith A. Borenstein, David Hiratzka, Jayme Weiss, Pamela F. Inman, Robert D. Majithia, Vikas Haroon, Nigil Maksymowych, Walter P. Joyce, Janet Clark, Bruce M. Colbert, Robert A. Figgie, Mark P. Hallegua, David S. Prete, Pamela E. Rosenbaum, James T. Stebulis, Judith A. Van Den Bosch, Filip Yu, David T. Y. Miller, Amy S. Reveille, John D. Caplan, Liron TI American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; CLASSIFICATION CRITERIA; PSORIATIC-ARTHRITIS; MANAGEMENT; EFFICACY; SAFETY; INJECTIONS; THERAPY; DRUGS; GRADE AB ObjectiveTo provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). MethodsA core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework. ResultsIn patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS. ConclusionThese recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas. C1 [Ward, Michael M.; Colbert, Robert A.] NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. [Deodhar, Atul; Hiratzka, Jayme; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Akl, Elie A.] Amer Univ Beirut, Beirut, Lebanon. [Akl, Elie A.] McMaster Univ, Hamilton, ON, Canada. [Lui, Andrew; Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ermann, Joerg] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Smith, Judith A.] Univ Wisconsin, Madison, WI 53706 USA. [Borenstein, David] Arthrit & Rheumatism Assoc, Washington, DC USA. [Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Weiss, Pamela F.] Univ Penn, Philadelphia, PA 19104 USA. [Inman, Robert D.; Haroon, Nigil] Univ Toronto, Toronto, ON, Canada. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA. [Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada. [Joyce, Janet; Miller, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA. [Clark, Bruce M.] RPT, Vancouver, BC, Canada. [Figgie, Mark P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Hallegua, David S.] Cedars Sinai Med Ctr, Beverly Hills, CA USA. [Prete, Pamela E.] VA Long Beach Med Ctr, Long Beach, CA USA. [Prete, Pamela E.] Univ Calif Irvine, Irvine, CA USA. [Rosenbaum, James T.] Legacy Devers Eye Inst, Portland, OR USA. [Stebulis, Judith A.] Univ Massachusetts, Worcester, MA 01605 USA. [Van Den Bosch, Filip] Univ Ghent, B-9000 Ghent, Belgium. [Yu, David T. Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. RP Ward, MM (reprint author), NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. EM wardm1@mail.nih.gov FU American College of Rheumatology; Spondylitis Association of America FX This work was supported by the American College of Rheumatology and the Spondylitis Association of America. We thank our patient representative for adding valuable perspectives. We thank Laurie Savage and Charlotte Howard of the Spondylitis Association of America for their partnership on this project. We thank Regina Parker for administrative assistance and Tamara Rader, who with Janet Joyce, developed and reviewed the literature search strategies. We appreciate the contributions of Drs. Robert Hart, Siba Raychaudhuri, and James Witter to the literature review. NR 29 TC 4 Z9 4 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2016 VL 68 IS 2 BP 151 EP 166 DI 10.1002/acr.22708 PG 16 WC Rheumatology SC Rheumatology GA DB9RT UT WOS:000368855100001 PM 26401907 ER PT J AU Ward, MM Deodhar, A Akl, EA Lui, A Ermann, J Gensler, LS Smith, JA Borenstein, D Hiratzka, J Weiss, PF Inman, RD Majithia, V Haroon, N Maksymowych, WP Joyce, J Clark, BM Colbert, RA Figgie, MP Hallegua, DS Prete, PE Rosenbaum, JT Stebulis, JA van den Bosch, F Yu, DTY Miller, AS Reveille, JD Caplan, L AF Ward, Michael M. Deodhar, Atul Akl, Elie A. Lui, Andrew Ermann, Joerg Gensler, Lianne S. Smith, Judith A. Borenstein, David Hiratzka, Jayme Weiss, Pamela F. Inman, Robert D. Majithia, Vikas Haroon, Nigil Maksymowych, Walter P. Joyce, Janet Clark, Bruce M. Colbert, Robert A. Figgie, Mark P. Hallegua, David S. Prete, Pamela E. Rosenbaum, James T. Stebulis, Judith A. van den Bosch, Filip Yu, David T. Y. Miller, Amy S. Reveille, John D. Caplan, Liron TI American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; CLASSIFICATION CRITERIA; PSORIATIC-ARTHRITIS; MANAGEMENT; EFFICACY; SAFETY; INJECTIONS; THERAPY; DRUGS; GRADE AB Objective. To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA). Methods. A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework. Results. In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS. Conclusion. These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas. C1 [Ward, Michael M.; Colbert, Robert A.] NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. [Deodhar, Atul; Hiratzka, Jayme; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Akl, Elie A.] Amer Univ Beirut, Beirut, Lebanon. [Akl, Elie A.] McMaster Univ, Hamilton, ON, Canada. [Lui, Andrew; Gensler, Lianne S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ermann, Joerg] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Smith, Judith A.] Univ Wisconsin, Madison, WI 53706 USA. [Borenstein, David] Arthrit & Rheumatism Associates, Washington, DC USA. [Weiss, Pamela F.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Weiss, Pamela F.] Univ Penn, Philadelphia, PA 19104 USA. [Inman, Robert D.; Haroon, Nigil] Univ Toronto, Toronto, ON, Canada. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS USA. [Maksymowych, Walter P.] Univ Alberta, Edmonton, AB, Canada. [Joyce, Janet; Miller, Amy S.] Amer Coll Rheumatol, 60 Execut Pk S,Suite 150, Atlanta, GA 30329 USA. [Clark, Bruce M.] RPT, Vancouver, BC, Canada. [Figgie, Mark P.] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. [Hallegua, David S.] Cedars Sinai Med Ctr, Beverly Hills, CA USA. [Prete, Pamela E.] VA Long Beach Med Ctr, Long Beach, CA USA. [Prete, Pamela E.] Univ Calif Irvine, Irvine, CA USA. [Rosenbaum, James T.] Legacy Devers Eye Inst, Portland, OR USA. [Stebulis, Judith A.] Univ Massachusetts, Worcester, MA 01605 USA. [van den Bosch, Filip] Univ Ghent, B-9000 Ghent, Belgium. [Yu, David T. Y.] Univ Calif Los Angeles, Los Angeles, CA USA. [Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Caplan, Liron] Univ Colorado, Aurora, CO USA. RP Ward, MM (reprint author), NIAMSD, NIH, Bldg 10 CRC,Room 4-1339,10 Ctr Dr, Bethesda, MD 20892 USA. EM wardm1@mail.nih.gov FU Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH; Abbott; Amgen; Pfizer; Novartis; AbbVie; UCB; Johnson Johnson; Celgene; Iroko; Janssen; Amgen/Pfizer; GlaxoSmithKline; Janssen/Johnson & Johnson/Centocor/Ortho Biotech Products; Janssen Biotech; Augurex; Bristol-Myers Squibb; Medtronic; Ethicon; Q-Med AB; Centocor; IDEC; Xoma; Roche; Isis; Pharmacia; La Jolla Pharma; Genentech; Proctor Gamble; Genelabs; MedImmune; Human Genome Sciences; Array Biopharma; Cipher; Regeneron; Lux Biosciences; Elan; Allergan; Santen; Teva; Sanofi; Janssen/Johnson Johnson FX Drs. Ward and Colbert's work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH.; Dr. Deodhar has received consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Pfizer, and Novartis (less than $10,000 each) and from AbbVie and UCB (more than $10,000 each), and research grants from Novartis, UCB, Johnson & Johnson, and Amgen. Dr. Ermann has received honoraria from AbbVie (less than $10,000) for Advisory Board service. Dr. Gensler has received consulting fees, speaking fees, and/or honoraria from AbbVie, UCB, and Amgen (less than $10,000 each) and research grants from Celgene and AbbVie. Dr. Borenstein has received consulting fees, speaking fees, and/or honoraria from Iroko and Abbott (less than $10,000 each) and honoraria from Clinical Care Options (more than $10,000). Dr. Inman has received consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott, Janssen, Amgen/Pfizer, UCB, Novartis, and Celgene (less than $10,000 each). Dr. Majithia has received consulting fees, speaking fees, and/or honoraria from GlaxoSmithKline (less than $10,000). Dr. Haroon has received consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott, Amgen, Janssen/Johnson & Johnson/Centocor/Ortho Biotech Products, Janssen Biotech, Celgene, UCB, and Pfizer (less than $10,000 each). Dr. Maksymowych has received consulting fees, speaking fees, and/or honoraria from AbbVie, UCB, Pfizer, Amgen, Janssen, and Augurex (less than $10,000 each) and receives licensing fees and royalties from Augurex for the 14-3-3 biomarker. Mr. Clark has received consulting fees, speaking fees, and/or honoraria from AbbVie, Abbott, Amgen, Janssen, and Bristol-Myers Squibb (less than $10,000 each). Dr. Figgie has received consulting fees, speaking fees, and/or honoraria from Medtronic and Ethicon (less than $10,000 each). Dr. Hallegua has received consulting fees, speaking fees, and/or honoraria from AbbVie, Q-Med AB, UCB, Bristol-Myers Squibb, Centocor, Amgen, IDEC, Xoma, Novartis, Roche, Isis, Pharmacia, La Jolla Pharma, Genentech, Proctor & Gamble, Genelabs, MedImmune, Human Genome Sciences, Array Biopharma, and Cipher (less than $10,000 each). Dr. Prete has received consulting fees, speaking fees, and/or honoraria from Abbott (less than $10,000). Dr. Rosenbaum has received consulting fees, speaking fees, and/or honoraria from UCB, Regeneron, Xoma, Lux Biosciences, Elan, Allergan, Santen, Teva, Novartis, Sanofi, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, and Genentech (less than $10,000 each) and is a contributor to UpToDate. Dr. van den Bosch has received consulting fees, speaking fees, and/or honoraria from AbbVie, Bristol-Myers Squibb, Celgene, Janssen/Johnson & Johnson, Pfizer, and UCB (less than $10,000 each). Dr. Reveille has received consulting fees, speaking fees, and/or honoraria from Abbott and UCB (less than $10,000 each). NR 29 TC 26 Z9 28 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2016 VL 68 IS 2 BP 282 EP 298 DI 10.1002/art.39298 PG 17 WC Rheumatology SC Rheumatology GA DC0XY UT WOS:000368942500005 PM 26401991 ER PT J AU Baker, JF Ibrahim, S Billig, E Michaud, K Caplan, L Cannon, GW Stokes, A Majithia, V Mikuls, TR AF Baker, Joshua F. Ibrahim, Said Billig, Erica Michaud, Kaleb Caplan, Liron Cannon, Grant W. Stokes, Andrew Majithia, Vikas Mikuls, Ted R. TI Weight loss, the obesity paradox in rheumatoid arthritis: is it a paradox? Comment on the article by Baker et al Reply SO ARTHRITIS & RHEUMATOLOGY LA English DT Letter ID OLDER-ADULTS C1 [Baker, Joshua F.; Ibrahim, Said] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.; Ibrahim, Said; Billig, Erica] Univ Penn, Philadelphia, PA 19104 USA. [Michaud, Kaleb; Mikuls, Ted R.] Nebraska Western Iowa VA Med Ctr, Omaha, NE USA. [Michaud, Kaleb; Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Michaud, Kaleb] Natl Data Bank Rheumat Dis, Wichita, KS USA. [Caplan, Liron] Denver VA Med Ctr, Denver, CO USA. [Cannon, Grant W.] Salt Lake City VA Med Ctr, Salt Lake City, UT USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT USA. [Stokes, Andrew] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Majithia, Vikas] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA. [Majithia, Vikas] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. RP Baker, JF (reprint author), Philadelphia VA Med Ctr, Philadelphia, PA USA. FU CSRD VA [IK2 CX000955] NR 4 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD FEB PY 2016 VL 68 IS 2 BP 553 EP 554 PG 2 WC Rheumatology SC Rheumatology GA DC0XY UT WOS:000368942500035 PM 26555220 ER PT J AU Jaffa, MA Luttrell, D Schmaier, AH Klein, RL Lopes-Virella, M Luttrell, LM Jaffa, AA AF Jaffa, Miran A. Luttrell, Deirdre Schmaier, Alvin H. Klein, Richard L. Lopes-Virella, Maria Luttrell, Louis M. Jaffa, Ayad A. CA DCC EDIC Res Grp TI Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes SO DIABETES LA English DT Article ID KALLIKREIN-KININ SYSTEM; VASCULAR SMOOTH-MUSCLE; MACROVASCULAR COMPLICATIONS; CONTACT ACTIVATION; ENDOTHELIAL-CELLS; PROLYLCARBOXYPEPTIDASE; INFLAMMATION; NEPHROPATHY; PROGRESSION; MECHANISM AB The hypothesis that plasma prekallikrein (PK) is a risk factor for the development of vascular complications was assessed in a study using the Diabetes Control and Complications Trial (DCCT)/Epidemiology and Diabetes Interventions and Complications (EDIC) cohort of subjects with type 1 diabetes. The circulating levels of plasma PK activity were measured in the plasma of 636 subjects with type 1 diabetes (EDIC years 3-5). Common and internal carotid intima-media thickness (IMT) were measured by B-mode ultrasonography in EDIC years 1 and 6. Plasma PK levels were positively and significantly associated with BMI, hemoglobin A(1c), systolic blood pressure, total cholesterol, LDL cholesterol, and triglycerides but not with age, sex, duration of diabetes, or HDL cholesterol. Univariate and multivariable statistical models after controlling for other risk factors consistently demonstrated a positive association between plasma PK and progression of internal carotid IMT. Multivariate analysis using a general linear model showed plasma PK to be significantly associated with progression of both internal and combined IMT (Wilks Lambda P value of 0.005). In addition, the mean internal carotid IMT levels were higher in subjects with plasma PK levels in the highest 10th percentile compared with subjects with plasma PK levels in the lower 10th percentile (P = 0.048). These novel findings implicate plasma PK as a risk factor for vascular disease in type 1 diabetes. C1 [Jaffa, Miran A.] Amer Univ Beirut, Fac Hlth Sci, Epidemiol & Populat Hlth Dept, Beirut, Lebanon. [Luttrell, Deirdre; Klein, Richard L.; Lopes-Virella, Maria; Luttrell, Louis M.; Jaffa, Ayad A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Schmaier, Alvin H.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29403 USA. [Jaffa, Ayad A.] Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon. RP Jaffa, AA (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.; Jaffa, AA (reprint author), Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon. EM aj24@aub.edu.lb FU National Institutes for Health [HL-052779, HL-055782, HL-077192, HL-087986]; Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health FX This work was supported by National Institutes for Health research grants HL-052779 (to A.H.S.), HL-055782 (to M.L.-V.), and HL-077192 and HL-087986 (to A.A.J.). The DCCT/EDIC was sponsored through research contracts from the Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health. NR 24 TC 1 Z9 1 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD FEB PY 2016 VL 65 IS 2 BP 498 EP 502 DI 10.2337/db15-0930 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DC1HS UT WOS:000368968000020 PM 26603531 ER PT J AU Kaunitz, JD AF Kaunitz, Jonathan D. TI The Doppler Effect: A Century from Red Shift to Red Spot SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material ID BLOOD-FLOW; ULTRASOUND C1 [Kaunitz, Jonathan D.] VA Greater Los Angeles Healthcare Syst, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. RP Kaunitz, JD (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.; Kaunitz, JD (reprint author), Univ Calif Los Angeles, Sch Med, Bldg 114-217E,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU BLRD VA [I01 BX001245]; Intramural VA [VA999999]; NIDDK NIH HHS [R01 DK054221] NR 12 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2016 VL 61 IS 2 BP 340 EP 341 DI 10.1007/s10620-015-3998-9 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DC1XR UT WOS:000369012100006 PM 26745970 ER PT J AU Schoenfeld, P Dominitz, JA AF Schoenfeld, Philip Dominitz, Jason A. TI No Polyp Left Behind: Defining Bowel Preparation Adequacy to Avoid Missed Polyps SO GASTROENTEROLOGY LA English DT Editorial Material ID SOCIETY-TASK-FORCE; ADENOMA DETECTION RATE; AVERAGE-RISK PATIENTS; COLORECTAL-CANCER; PREPARATION SCALE; COLONOSCOPY; RECOMMENDATIONS; IMPACT; SURVEILLANCE; CLEANLINESS C1 [Schoenfeld, Philip] Univ Michigan, Sch Med, Ann Arbor Vet Hlth Care Syst, Ann Arbor, MI USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Schoenfeld, P (reprint author), Univ Michigan, Sch Med, Med, Room 111-D,2215 Fuller Rd, Ann Arbor, MI USA. NR 23 TC 0 Z9 0 U1 1 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2016 VL 150 IS 2 BP 303 EP 306 DI 10.1053/j.gastro.2015.12.024 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6MU UT WOS:000368629900010 PM 26713765 ER PT J AU Su, F Yu, L Berry, K Liou, IW Landis, CS Rayhill, SC Reyes, JD Ioannou, GN AF Su, Feng Yu, Lei Berry, Kristin Liou, Iris W. Landis, Charles S. Rayhill, Stephen C. Reyes, Jorge D. Ioannou, George N. TI Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit SO GASTROENTEROLOGY LA English DT Article DE Waitlist Outcomes; Post-Transplantation Outcomes; Transplant-Related Survival Benefit ID C VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; WAITING-LIST; NONALCOHOLIC STEATOHEPATITIS; CANDIDATES; MORTALITY; OLDER; AGE; DISEASE AB BACKGROUND & AIMS: Epidemiologic factors have generated increased demand for liver transplantation among older patients. We aimed to describe trends in age among liver transplant registrants and recipients and the effect of age on waitlist and post-transplantation outcomes and on transplant-related survival benefit. METHODS: We obtained data from the United Network for Organ Sharing on adults who were listed for liver transplantation (N = 122,606) or underwent liver transplantation (N = 60,820) from 2002 to 2014 in the United States. Competing risks analysis was used to model waitlist outcomes and Cox proportional hazards analysis to model post-transplantation survival. These models were also used to estimate 5-year transplant-related survival benefit for different age groups, calculated as the difference between waitlist and post-transplantation life expectancy. RESULTS: Between 2002 and 2014, the mean age of liver transplant registrants increased from 51.2 to 55.7 years, with a more prominent increase in hepatitis C virus-positive (50.9 - 57.9 years) than hepatitis C virus-negative (51.3 - 54.3 years) registrants. The proportion of registrants aged >= 60 years increased from 19% to 41%. In hepatitis C virus-negative patients, aging trends were driven by increasing proportions of patients with hepatocellular carcinoma or nonalcoholic steatohepatitis. Among transplant registrants, increasing age was associated with increasing mortality before transplantation and decreasing likelihood of transplantation. Among transplant recipients, increasing age was associated with increasing post-transplantation mortality. There was little difference in 5-year transplant-related survival benefit between different age groups who had the same Model for EndStage Liver Disease score. CONCLUSIONS: Dramatic aging of liver transplant registrants and recipients occurred from 2002 to 2014, driven by aging of the hepatitis C virus - positive cohort and increased prevalence of nonalcoholic steatohepatitis and hepatocellular carcinoma. Increasing age does not affect transplant-related survival benefit substantially because age diminishes both post-transplantation survival and waitlist survival approximately equally. C1 [Su, Feng] Univ Washington, Dept Med, Div Internal Med, Seattle, WA USA. [Yu, Lei; Liou, Iris W.; Landis, Charles S.; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Yu, Lei; Liou, Iris W.; Landis, Charles S.; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Berry, Kristin] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Rayhill, Stephen C.; Reyes, Jorge D.] Univ Washington, Dept Surg, Div Transplant Surg, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Gastroenterol, S-111 Gastro 1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Research and Development, Veterans Affairs Puget Sound Healthcare System; Health Resources and Services Administration [231-00-0115] FX This study was funded byResearch and Development, Veterans Affairs Puget Sound Healthcare System. This work was supported in part by Health Resources and Services Administration contract 231-00-0115. NR 42 TC 4 Z9 4 U1 3 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2016 VL 150 IS 2 BP 441 EP + DI 10.1053/j.gastro.2015.10.043 PG 19 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6MU UT WOS:000368629900031 PM 26522262 ER PT J AU Berry, K Ioannou, GN AF Berry, Kristin Ioannou, George N. TI Estimation of Liver Transplant Related Survival Benefit: the Devil Is in The Details Reply SO GASTROENTEROLOGY LA English DT Letter ID HEPATOCELLULAR-CARCINOMA C1 [Berry, Kristin; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. RP Berry, K (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD FEB PY 2016 VL 150 IS 2 BP 535 EP 537 DI 10.1053/j.gastro.2015.12.030 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DB6MU UT WOS:000368629900042 PM 26718174 ER PT J AU Knapp, AA Blumenthal, H Mischel, ER Badour, CL Leen-Feldner, EW AF Knapp, Ashley A. Blumenthal, Heidemarie Mischel, Emily R. Badour, Christal L. Leen-Feldner, Ellen W. TI Anxiety Sensitivity and Its Factors in Relation to Generalized Anxiety Disorder among Adolescents SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY LA English DT Article DE Anxiety sensitivity; Worry; Generalized anxiety disorder; Adolescents ID REVISED CHILD ANXIETY; DSM-IV ANXIETY; EMOTIONAL DISORDERS; DEPRESSION SCALE; UNIFIED PROTOCOL; NEGATIVE AFFECT; PANIC-ATTACKS; SYMPTOMS; INDEX; WORRY AB Anxiety psychopathology, one of the most prevalent classes of disorder among youth, is linked to detrimental outcomes. Accordingly, identifying factors that influence vulnerability to anxiety disorders is important. One promising factor, given emerging evidence for its transdiagnostic nature, is anxiety sensitivity (AS); however, relatively little is known about the linkage between AS and indicators of generalized anxiety disorder (GAD), particularly among youth. The aim of the current investigation was to address this gap in the literature using a community-based sample of adolescents aged 10-17 years (n = 165; M (age) = 14.49 years, SD = 2.26). Results indicated global AS and the AS-physical concerns dimension were significantly associated with worry, generalized anxiety symptoms, and GAD diagnosis assessed via a structured clinical interview, above and beyond key theoretically-relevant covariates. These findings add to a growing body of work underscoring the relevance of AS for multiple types of anxiety-related disorders among youth. C1 [Knapp, Ashley A.; Mischel, Emily R.; Leen-Feldner, Ellen W.] Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA. [Blumenthal, Heidemarie] Univ N Texas, Dept Psychol, 155 Union Circle 311280, Denton, TX 76203 USA. [Badour, Christal L.] Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861,2nd Fl IOP South Bldg, Charleston, SC 29425 USA. [Badour, Christal L.] Ralph H Johnson VA Med Ctr, Dept Psychiat, 109 Bee St, Charleston, SC 29401 USA. RP Knapp, AA (reprint author), Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA. EM aaknapp@uark.edu NR 70 TC 2 Z9 2 U1 6 U2 17 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0627 EI 1573-2835 J9 J ABNORM CHILD PSYCH JI J. Abnorm. Child Psychol. PD FEB PY 2016 VL 44 IS 2 BP 233 EP 244 DI 10.1007/s10802-015-9991-0 PG 12 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA DC1ZF UT WOS:000369016300003 PM 25724327 ER PT J AU Walter, ND Miller, MA Vasquez, J Weiner, M Chapman, A Engle, M Higgins, M Quinones, AM Rosselli, V Canono, E Yoon, C Cattamanchi, A Davis, JL Phang, T Stearman, RS Datta, G Garcia, BJ Daley, CL Strong, M Kechris, K Fingerlin, TE Reves, R Geraci, MW AF Walter, Nicholas D. Miller, Mikaela A. Vasquez, Joshua Weiner, Marc Chapman, Adam Engle, Melissa Higgins, Michael Quinones, Amy M. Rosselli, Vanessa Canono, Elizabeth Yoon, Christina Cattamanchi, Adithya Davis, J. Lucian Phang, Tzu Stearman, Robert S. Datta, Gargi Garcia, Benjamin J. Daley, Charles L. Strong, Michael Kechris, Katerina Fingerlin, Tasha E. Reves, Randall Geraci, Mark W. TI Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SIGNATURES; EXPRESSION; MEDICINE; AFRICA AB Blood transcriptional signatures are promising for tuberculosis (TB) diagnosis but have not been evaluated among U.S. patients. To be used clinically, transcriptional classifiers need reproducible accuracy in diverse populations that vary in genetic composition, disease spectrum and severity, and comorbidities. In a prospective case-control study, we identified novel transcriptional classifiers for active TB among U.S. patients and systematically compared their accuracy to classifiers from published studies. Blood samples from HIV-uninfected U.S. adults with active TB, pneumonia, or latent TB infection underwent whole-transcriptome microarray. We used support vector machines to classify disease state based on transcriptional patterns. We externally validated our classifiers using data from sub-Saharan African cohorts and evaluated previously published transcriptional classifiers in our population. Our classifier distinguishing active TB from pneumonia had an area under the concentration-time curve (AUC) of 96.5% (95.4% to 97.6%) among U.S. patients, but the AUC was lower (90.6% [89.6% to 91.7%]) in HIV-uninfected Sub-Saharan Africans. Previously published comparable classifiers had AUC values of 90.0% (87.7% to 92.3%) and 82.9% (80.8% to 85.1%) when tested in U.S. patients. Our classifier distinguishing active TB from latent TB had AUC values of 95.9% (95.2% to 96.6%) among U.S. patients and 95.3% (94.7% to 96.0%) among Sub-Saharan Africans. Previously published comparable classifiers had AUC values of 98.0% (97.4% to 98.7%) and 94.8% (92.9% to 96.8%) when tested in U.S. patients. Blood transcriptional classifiers accurately detected active TB among U.S. adults. The accuracy of classifiers for active TB versus that of other diseases decreased when tested in new populations with different disease controls, suggesting additional studies are required to enhance generalizability. Classifiers that distinguish active TB from latent TB are accurate and generalizable across populations and can be explored as screening assays. C1 [Walter, Nicholas D.] Vet Adm Med Ctr, Pulm Sect, Denver, CO 80220 USA. [Walter, Nicholas D.; Chapman, Adam; Phang, Tzu; Stearman, Robert S.; Geraci, Mark W.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Walter, Nicholas D.; Miller, Mikaela A.; Rosselli, Vanessa; Kechris, Katerina; Fingerlin, Tasha E.; Reves, Randall] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Vasquez, Joshua; Yoon, Christina; Cattamanchi, Adithya; Davis, J. Lucian] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA. [Weiner, Marc; Engle, Melissa] Vet Adm Med Ctr, Dept Med, San Antonio, TX USA. [Higgins, Michael; Reves, Randall] Denver Metro TB Control Program, Denver, CO USA. [Quinones, Amy M.] Denver Hlth Med Ctr, Denver, CO USA. [Canono, Elizabeth] Natl Jewish Hlth, Clin Translat Res Ctr, Denver, CO USA. [Datta, Gargi; Garcia, Benjamin J.; Strong, Michael] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA. [Daley, Charles L.] Natl Jewish Hlth, Div Mycobacterial & Resp Infect, Denver, CO USA. [Davis, J. Lucian] Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA. [Stearman, Robert S.] Indiana Univ, Dept Med, Indianapolis, IN USA. [Fingerlin, Tasha E.] Natl Jewish Hlth, Ctr Genes Environm & Hlth, Denver, CO USA. [Geraci, Mark W.] Indiana Univ, Dept Med, Indianapolis, IN USA. RP Walter, ND (reprint author), Vet Adm Med Ctr, Pulm Sect, Denver, CO 80220 USA.; Walter, ND (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Aurora, CO USA.; Walter, ND (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. EM nicholas.walter@ucdenver.edu OI Garcia, Benjamin/0000-0001-5524-6946 FU Veteran's Administration Career Development Award Colorado Clinical and Translational Sciences Institute, Mucosal and Vaccine Research Colorado [CDA 1IK2CX000914-01A1]; University of Colorado Denver Division of Pulmonary Sciences and Critical Care Medicine FX The Veteran's Administration Career Development Award (CDA 1IK2CX000914-01A1) Colorado Clinical and Translational Sciences Institute, Mucosal and Vaccine Research Colorado and the University of Colorado Denver Division of Pulmonary Sciences and Critical Care Medicine provided funding. NR 24 TC 2 Z9 2 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2016 VL 54 IS 2 BP 274 EP 282 DI 10.1128/JCM.01990-15 PG 9 WC Microbiology SC Microbiology GA DC3YD UT WOS:000369155100006 PM 26582831 ER PT J AU Zhang, Y Jenkins, AJ Basu, A Stoner, JA Lopes-Virella, MF Klein, RL Lyons, TJ AF Zhang, Ying Jenkins, Alicia J. Basu, Arpita Stoner, Julie A. Lopes-Virella, Maria F. Klein, Richard L. Lyons, Timothy J. CA DCCT EDIC Res Grp TI Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes SO JOURNAL OF LIPID RESEARCH LA English DT Article DE intensive diabetes treatment; dyslipidemia; atherosclerosis; clinical trial; high density lipoprotein; low density lipoprotein; nuclear magnetic resonance ID MAGNETIC-RESONANCE-SPECTROSCOPY; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; COMPLICATIONS TRIAL; HEART-DISEASE; CARDIOVASCULAR-DISEASE; DCCT/EDIC COHORT; FOLLOW-UP; CAROTID ATHEROSCLEROSIS; PARTICLE CONCENTRATIONS AB Our objective is to define differences in circulating lipoprotein subclasses between intensive versus conventional management of type 1 diabetes during the randomization phase of the Diabetes Control and Complications Trial (DCCT). NMR-determined lipoprotein subclass profiles (NMR-LSPs), which estimate molar subclass concentrations and mean particle diameters, were determined in 1,294 DCCT subjects after a median of 5 years (interquartile range: 4-6 years) of randomization to intensive or conventional diabetes management. In cross-sectional analyses, we compared standard lipids and NMR-LSPs between treatment groups. Standard total, LDL, and HDL cholesterol levels were similar between randomization groups, while triglyceride levels were lower in the intensively treated group. NMR-LSPs showed that intensive therapy was associated with larger LDL diameter (20.7 vs. 20.6 nm, P = 0.01) and lower levels of small LDL (median: 465 vs. 552 nmol/l, P = 0.007), total IDL/LDL (mean: 1,000 vs. 1,053 nmol/l, P = 0.01), and small HDL (mean: 17.3 vs. 18.6 mu mol/l, P < 0.0001), the latter accounting for reduced total HDL (mean: 33.8 vs. 34.8 mu mol/l, P = 0.01). In conclusion, intensive diabetes therapy was associated with potentially favorable changes in LDL and HDL subclasses in sera. Further research will determine whether these changes contribute to the beneficial effects of intensive diabetes management on vascular complications. C1 [Zhang, Ying; Stoner, Julie A.] Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK USA. [Lyons, Timothy J.] Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA. [Jenkins, Alicia J.] Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW 2006, Australia. [Jenkins, Alicia J.; Lyons, Timothy J.] Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland. [Basu, Arpita] Oklahoma State Univ, Dept Nutr Sci, Stillwater, OK 74078 USA. [Lopes-Virella, Maria F.; Klein, Richard L.] Med Univ S Carolina, Div Endocrinol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.; Klein, Richard L.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Lyons, TJ (reprint author), Univ Oklahoma, Hlth Sci Ctr, Sect Endocrinol & Diabet, Oklahoma City, OK USA.; Lyons, TJ (reprint author), Queens Univ Belfast, Ctr Med Expt, Belfast BT7 1NN, Antrim, North Ireland. EM t.lyons@qub.ac.uk FU National Institutes of Health [R01DK080043]; American Diabetes Association [7-12-CT-46]; Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases; National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical Research Centers Program; National Eye Institute, the National Institute of Neurologic Disorders and Stroke, Clinical Translational Science Center Program FX This project was supported by grants from the National Institutes of Health (R01DK080043) and the American Diabetes Association (7-12-CT-46). DCCT/EDIC has been supported by U01 Cooperative Agreement grants (1982-1993, 2011-2016) and contracts (1982-2011) from the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases, and through support by the National Eye Institute, the National Institute of Neurologic Disorders and Stroke, the General Clinical Research Centers Program (1993-2007), and Clinical Translational Science Center Program (2006-present). The authors have no relevant conflicts of interest to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 52 TC 2 Z9 2 U1 2 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 EI 1539-7262 J9 J LIPID RES JI J. Lipid Res. PD FEB PY 2016 VL 57 IS 2 BP 310 EP 317 DI 10.1194/jlr.P060657 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DC3AN UT WOS:000369091600014 PM 26658239 ER PT J AU Vanderberg, RH Farkas, AH Miller, E Sucato, GS Akers, AY Borrero, SB AF Vanderberg, Rachel H. Farkas, Amy H. Miller, Elizabeth Sucato, Gina S. Akers, Aletha Y. Borrero, Sonya B. TI Racial and/or Ethnic Differences in Formal Sex Education and Sex Education by Parents among Young Women in the United States SO JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY LA English DT Article DE Contraception; Disparities; Parents; Race; Sex education ID REPRODUCTIVE HEALTH COMMUNICATION; UNINTENDED PREGNANCY; ADOLESCENT WOMEN; DISPARITIES; PERSPECTIVES; KNOWLEDGE; ATTITUDES AB Study Objective: We sought to investigate the associations between race and/or ethnicity and young women's formal sex education and sex education by parents. Design, Setting, and Participants: Cross-sectional analysis of a nationally representative sample of 1768 women aged 15-24 years who participated in the 2011-2013 National Survey of Family Growth. Interventions and Main Outcome Measures: We assessed 6 main outcomes: participants' report of: (1) any formal sex education; (2) formal contraceptive education; (3) formal sexually transmitted infection (STI) education; (4) any sex education by parents; (5) contraceptive education by parents; and (6) STI education by parents. The primary independent variable was self-reported race and/or ethnicity. Results: Nearly all of participants (95%) reported any formal sex education, 68% reported formal contraceptive education, and 92% reported formal STI education. Seventy-five percent of participants reported not having any sex education by parents and only 61% and 56% reported contraceptive and STI education by parents, respectively. US-born Hispanic women were more likely than white women to report STI education by parents (adjusted odds ratio = 1.87; 95% confidence interval, 1.17-2.99). No other significant racial and/or ethnic differences in sex education were found. Conclusion: There are few racial and/or ethnic differences in formal sex education and sex education by parents among young women. C1 [Vanderberg, Rachel H.; Farkas, Amy H.; Borrero, Sonya B.] Univ Pittsburgh, Med Ctr, Div Gen Internal Med, Pittsburgh, PA USA. [Miller, Elizabeth; Sucato, Gina S.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Div Adolescent & Young Adult Med,Dept Pediat, Pittsburgh, PA 15213 USA. [Akers, Aletha Y.] Childrens Hosp Philadelphia, Craig Dalsimer Div Adolescent Med, Philadelphia, PA 19104 USA. [Borrero, Sonya B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Borrero, SB (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu FU NIH [UL1-TR-000005]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [1R21HD068736-01A1] FX The authors thank Dan Winger, at the Clinical and Translation Science Institute, University of Pittsburgh, supported by NIH Grant UL1-TR-000005, for his assistance with statistical analysis. This work was also supported by Dr. Sonya Borrero's Grant 1R21HD068736-01A1 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 24 TC 0 Z9 0 U1 18 U2 32 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-3188 EI 1873-4332 J9 J PEDIATR ADOL GYNEC JI J. Pediatr Adolesc. Gynecol. PD FEB PY 2016 VL 29 IS 1 BP 69 EP 73 DI 10.1016/j.jpag.2015.06.011 PG 5 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA DC1IS UT WOS:000368970600014 PM 26143556 ER PT J AU Deo, R Shou, HC Soliman, EZ Yang, W Arkin, JM Zhang, XM Townsend, RR Go, AS Shlipak, MG Feldman, HI AF Deo, Rajat Shou, Haochang Soliman, Elsayed Z. Yang, Wei Arkin, Joshua M. Zhang, Xiaoming Townsend, Raymond R. Go, Alan S. Shlipak, Michael G. Feldman, Harold I. TI Electrocardiographic Measures and Prediction of Cardiovascular and Noncardiovascular Death in CKD SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID HEART-ASSOCIATION ELECTROCARDIOGRAPHY; OF-CARDIOLOGY-FOUNDATION; LEFT-VENTRICULAR HYPERTROPHY; SUDDEN CARDIAC DEATH; SERVICES TASK-FORCE; ARRHYTHMIAS COMMITTEE; SCIENTIFIC STATEMENT; CLINICAL CARDIOLOGY; RHYTHM-SOCIETY; AHA/ACCF/HRS RECOMMENDATIONS AB Limited studies have assessed the resting 12-lead electrocardiogram (ECG) as a screening test in intermediate risk populations. We evaluated whether a panel of common ECG parameters are independent predictors of mortality risk in a prospective cohort of participants with CKD. The Chronic Renal Insufficiency Cohort (CRIC) study enrolled 3939 participants with eGFR<70 ml/min per 1.73 m(2) from June 2003 to September 2008. Over a median follow-up of 7.5 years, 750 participants died. After adjudicating the initial 497 deaths, we identified 256 cardiovascular and 241 noncardiovascular deaths. ECG metrics were independent risk markers for cardiovascular death (hazard ratio, 95% confidence interval): PR interval >= 200 ms (1.62, 1.19-2.19); QRS interval 100-119 ms (1.64, 1.20-2.25) and >= 120 ms (1.75, 1.17-2.62); corrected QT (QTc) interval >= 450 ms in men or >= 460 ms in women (1.72, 1.19-2.49); and heart rate 60-90 beats per minute (1.21, 0.89-1.63) and >= 90 beats per minute (2.35, 1.03-5.33). Most ECG measures were stronger markers of risk for cardiovascular death than for all-cause mortality or noncardiovascular death. Adding these intervals to a comprehensive model of cardiorenal risk factors increased the C-statistic for cardiovascular death from 0.77 to 0.81 (P<0.001). Furthermore, adding ECG metrics to the model adjusted for standard risk factors resulted in a net reclassification of 12.1% (95% confidence interval 8.1%-16.0%). These data suggest common ECG metrics are independent risk factors for cardiovascular death and enhance the ability to predict death events in a population with CKD. C1 [Deo, Rajat; Arkin, Joshua M.] Univ Penn, Cardiac Electrophysiol Sect, Div Cardiovasc Med, Dept Med,Perelman Sch Med, Philadelphia, PA 19104 USA. [Shou, Haochang; Yang, Wei; Zhang, Xiaoming; Feldman, Harold I.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Shou, Haochang; Yang, Wei; Zhang, Xiaoming; Feldman, Harold I.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Soliman, Elsayed Z.] Wake Forest Univ, Bowman Gray Sch Med, Epidemiol Cardiol Res Ctr EPICARE, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA. [Soliman, Elsayed Z.] Wake Forest Univ, Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27109 USA. [Townsend, Raymond R.; Feldman, Harold I.] Univ Penn, Renal Electrolyte & Hypertens Div, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Go, Alan S.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Go, Alan S.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Go, Alan S.; Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol Biostat & Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Dept Gen Internal Med, San Francisco, CA USA. RP Deo, R (reprint author), 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19146 USA. EM Rajat.Deo@uphs.upenn.edu FU National Institutes of Health (NIH) [K23-DK089118]; National Institute of Diabetes and Digestive and Kidney Diseases [U01-DK060990, U01-DK060984, U01-DK061022, U01-DK061021, U01-DK061028, U01-DK060980, U01-DK060963, U01-DK060902]; Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/ National Center for Advancing Translational Sciences (NCATS) [UL1-TR000003]; Johns Hopkins University [UL1-TR000424]; University of Maryland [M01-RR16500]; Clinical and Translational Science Collaborative of Cleveland from the NCATS component of the NIH and NIH roadmap for Medical Research [UL1-TR000439]; Michigan Institute for Clinical and Health Research Grant [UL1-TR000433]; University of Illinois at Chicago CTSA Grant [UL1-RR029879]; Tulane University Translational Research in Hypertension and Renal Biology Grant [P30-GM103337]; Kaiser Permanente NIH/NCRR UCSF-CTSI Grant [UL1-RR024131] FX We appreciate the support of the other CRIC Study Investigators including Lawrence J. Appel, Jiang He, John W. Kusek, James P. Lash, Akinlolu Ojo, and Mahboob Rahman. The CRIC ancillary study was supported by the National Institutes of Health (NIH) grant K23-DK089118 (to R.D.). The CRIC study is supported by cooperative agreement project grants from the National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK060990, U01-DK060984, U01-DK061022, U01-DK061021, U01-DK061028, U01-DK060980, U01-DK060963, and U01-DK060902).; In addition, this work was supported in part by the Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/ National Center for Advancing Translational Sciences (NCATS) Grant UL1-TR000003, Johns Hopkins University Grant UL1-TR000424, University of Maryland GCRC Grant M01-RR16500, Clinical and Translational Science Collaborative of Cleveland Grant UL1-TR000439 from the NCATS component of the NIH and NIH roadmap for Medical Research, Michigan Institute for Clinical and Health Research Grant UL1-TR000433, University of Illinois at Chicago CTSA Grant UL1-RR029879, Tulane University Translational Research in Hypertension and Renal Biology Grant P30-GM103337, and Kaiser Permanente NIH/NCRR UCSF-CTSI Grant UL1-RR024131. NR 33 TC 4 Z9 4 U1 2 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2016 VL 27 IS 2 BP 559 EP 569 DI 10.1681/ASN.2014101045 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA DC1DS UT WOS:000368957600025 PM 26160896 ER PT J AU Gin, JL Kranke, D Saia, R Dobalian, A AF Gin, June L. Kranke, Derrick Saia, Rebecca Dobalian, Aram TI Disaster Preparedness in Homeless Residential Organizations in Los Angeles County: Identifying Needs, Assessing Gaps SO NATURAL HAZARDS REVIEW LA English DT Article DE Disasters; Residential organizations; Disaster planning; Preparedness; Homeless persons; Emergency management; Vulnerable populations ID HEALTH-CARE; COMMUNITY AB Community-based organizations (CBOs) are essential to supporting homeless populations during disasters, yet little is known about their preparedness and ability to support their vulnerable clients. This qualitative study evaluated the perceptions of Los Angeles nonprofit homeless residential service providers regarding the likely impacts of a disaster on their clients and operations, the barriers they face in disaster planning, and their suggested solutions to facilitate preparedness within their sector. Twelve semistructured interviews were conducted with executive staff and emergency planners from six organizations serving people experiencing homelessness. Respondents reported significant barriers to both postdisaster services and collaboration with emergency management. They indicated both a need for and interest in technical assistance and training to develop their disaster capabilities. These concerns suggest that a multisector effort, including homeless-service organizations, their funders, and emergency managers, is needed to strengthen the resilience of safety-net CBOs serving homeless populations. This work is made available under the terms of the Creative Commons Attribution 4.0 International license, http://creativecommons. org/licenses/by/4.0/. C1 [Gin, June L.; Kranke, Derrick; Saia, Rebecca; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, North Hills, CA 91343 USA. [Dobalian, Aram] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. RP Gin, JL (reprint author), US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, North Hills, CA 91343 USA. EM June.Gin@va.gov; Derrick.Kranke@va.gov; Rebecca.Saia@va.gov; Aram.Dobalian@va.gov NR 46 TC 0 Z9 0 U1 5 U2 8 PU ASCE-AMER SOC CIVIL ENGINEERS PI RESTON PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA SN 1527-6988 EI 1527-6996 J9 NAT HAZARDS REV JI Nat. Hazards Rev. PD FEB PY 2016 VL 17 IS 1 AR 04015022 DI 10.1061/(ASCE)NH.1527-6996.0000208 PG 8 WC Engineering, Civil; Environmental Studies; Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences; Water Resources SC Engineering; Environmental Sciences & Ecology; Geology; Meteorology & Atmospheric Sciences; Water Resources GA DB9LK UT WOS:000368837300016 ER PT J AU Guo, FJ Garvey, WT AF Guo, Fangjian Garvey, W. Timothy TI Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults SO OBESITY LA English DT Article ID BODY-MASS INDEX; TREATMENT PANEL-III; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; MYOCARDIAL-INFARCTION; NORMAL-WEIGHT; IMPACT; WOMEN; POPULATION; OVERWEIGHT AB ObjectiveTo assess the stability of metabolic status and body mass index (BMI) status and their relative contribution to risk of diabetes, cardiovascular events, and mortality. MethodsA total of 14,685 participants from the Atherosclerosis Risk in Communities Study and 4,990 from the Coronary Artery Risk Development in Young Adults Study were included. People with healthy obesity (HO) are defined as those meeting all three indices of blood pressure, blood glucose, and blood lipids. People with unhealthy obesity crossed the risk threshold for all three criteria. ResultsIn both healthy and unhealthy subgroups, risks for coronary heart disease (CHD), stroke, and mortality were comparable among BMI status during a mean 18.7-year follow-up. When compared with HO, hazard ratios were increased for diabetes (5.56, 95% confidence interval [CI] 4.12-7.48), CHD (5.60, 95% CI 3.14-9.98), stroke (4.84, 95% CI 2.13-10.97), and mortality (2.6, 95% CI 1.88-3.61) in people with unhealthy obesity. BMI only moderately increased the risks for diabetes among healthy subjects. In the Coronary Artery Risk Development in Young Adults Study over 20 years, 17.5% of lean subjects and 67.3% of overweight subjects at baseline developed obesity during follow-up. Despite rising BMI, metabolic status remained relatively stable. ConclusionsMetabolic status is relatively stable despite rising BMI. HO had lower risks for diabetes, CHD, stroke, and mortality than unhealthy subjects but increased diabetes risks than healthy lean people. Cardiometabolic risk factors confer much higher risk than obesity per se. C1 [Guo, Fangjian] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA. [Guo, Fangjian] Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC, Birmingham, AL USA. RP Guo, FJ (reprint author), Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA.; Guo, FJ (reprint author), Univ Texas Med Branch, Ctr Interdisciplinary Res Womens Hlth, Galveston, TX 77555 USA.; Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr GRECC, Birmingham, AL USA. EM faguo@utmb.edu; garveyt@uab.edu OI Guo, Fangjian/0000-0003-3729-2724 FU Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the National Institutes of Health (NIH) [T32HD055163]; U.S. Department of Veterans Affairs, National Institutes of Health [DK-038765, DK-083562]; University of Alabama at Birmingham Diabetes Research Center [P60-DK079626] FX Dr. Guo is currently a postdoctoral fellow supported by an institutional training grant (National Research Service Award T32HD055163) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) at the National Institutes of Health (NIH). This study is supported by the Merit Review program of the U.S. Department of Veterans Affairs, National Institutes of Health (DK-038765 and DK-083562), and the University of Alabama at Birmingham Diabetes Research Center (P60-DK079626). NR 34 TC 9 Z9 9 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD FEB PY 2016 VL 24 IS 2 BP 516 EP 525 DI 10.1002/oby.21344 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA DC3SQ UT WOS:000369139500034 PM 26719125 ER PT J AU Golier, JA Caramanica, K Michaelides, AC Makotkine, I Schmeidler, J Harvey, PD Yehuda, R AF Golier, Julia A. Caramanica, Kimberly Michaelides, Andreas C. Makotkine, Iouri Schmeidler, James Harvey, Philip D. Yehuda, Rachel TI A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Gulf War; Mifepristone; CMI; Dexamethasone; ACTH; Cortisol; Verbal learning ID POSTTRAUMATIC-STRESS-DISORDER; OPEN-LABEL TRIAL; PSYCHOTIC DEPRESSION; COGNITIVE DYSFUNCTION; ALZHEIMERS-DISEASE; HIPPOCAMPAL; MEMORY; DEXAMETHASONE; NEUROGENESIS; RU-486 AB No pharmacological treatments have been demonstrated to effectively treat chronic multisymptom illness (CMI) in Gulf War veterans (GWV). This study assessed the effect of the glucocorticoid receptor antagonist mifepristone in GWV with CMI. A randomized, double-blind, cross-over trial of mifepristone, with two six-week treatment phases separated by a one-month washout period, was conducted at a Veterans Affairs (VA) hospital between 2008 and 2011. Participants were randomized to receive either 200 mg of mifepristone per day or matched placebo first. The primary clinical outcome measure was change in self-reported physical health. Neurocognitive functioning and self-reported measures of depression, PTSD, and fatigue were secondary outcomes. Sixty-five participants enrolled, of whom 36 were randomized and 32 (mean age, 49.1 (7.2) years) completed the study. Physical and mental health status and neurocognitive functioning were poor at baseline. Mifepristone treatment was not associated with improvement in self-reported physical health (p = 0.838) or in other self-reported measures of mental health. Mifepristone treatment was significantly associated with improvements in verbal learning (p = 0.008, d = 0.508), in the absence of improvement in other cognitive measures (working memory (p = 0.914), visual learning (p = 0.643) and a global composite measure (p = 0.937). Baseline morning cortisol levels and lysozyme IC50-DEX, a measure of peripheral glucocorticoid sensitivity, displayed a significant relationship with endpoint verbal learning scores (p = 0.012 and p = 0.007, respectively). The magnitude of cortisol change during treatment mediated the improvement in verbal learning. This study was negative for the primary and secondary clinical outcomes. However, the data suggest a moderate dose of mifepristone may have circumscribed cognitive-enhancing effects in CMI. Further study is warranted to determine whether and through which mechanisms mifepristone treatment can yield clinically meaningful improvement in cognitive function in CMI or other neuropsychiatric conditions associated with HPA axis dysregulation. (C) Published by Elsevier Ltd. C1 [Golier, Julia A.; Caramanica, Kimberly; Michaelides, Andreas C.; Makotkine, Iouri; Yehuda, Rachel] James J Peters VA Med Ctr, OOMH 526,130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Golier, Julia A.; Makotkine, Iouri; Schmeidler, James; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, 1428 Madison Ave, New York, NY 10029 USA. [Harvey, Philip D.] Univ Miami, Miller Sch Med, 1600 NW 10th Ave 1140, Miami, FL 33136 USA. RP Golier, JA (reprint author), James J Peters VA Med Ctr, OOMH 526,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM julia.golier@va.gov FU Department of Defense (DoD) FX This study is registered with ClinicalTrials.gov (NCT00691067) and was solely funded by the Department of Defense (DoD). The DoD did not influence any aspects of the study design or manuscript preparation. The authors declare no conflicts of interests. The authors also acknowledge the assistance of Ahmed El-Razi, B.A. in the revising of the manuscript. NR 44 TC 2 Z9 2 U1 3 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD FEB PY 2016 VL 64 BP 22 EP 30 DI 10.1016/j.psyneuen.2015.11.001 PG 9 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA DB9WF UT WOS:000368867700003 PM 26600007 ER PT J AU Kline, CE Reboussin, DM Foster, GD Rice, TB Strotmeyer, ES Jakicic, JM Millman, RP Pi-Sunyer, X Newman, AB Wadden, TA Zammit, G Kuna, ST AF Kline, Christopher E. Reboussin, David M. Foster, Gary D. Rice, Thomas B. Strotmeyer, Elsa S. Jakicic, John M. Millman, Richard P. Pi-Sunyer, Xavier Newman, Anne B. Wadden, Thomas A. Zammit, Gary Kuna, Samuel T. CA Look AHEAD Res Grp TI The Effect of Changes in Cardiorespiratory Fitness and Weight on Obstructive Sleep Apnea Severity in Overweight Adults with Type 2 Diabetes SO SLEEP LA English DT Article DE apnea-hypopnea index; cardiorespiratory fitness; obstructive sleep apnea; physical activity; weight loss ID LIFE-STYLE INTERVENTION; CARDIOVASCULAR-DISEASE RISK; RANDOMIZED CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE; HEART-RATE RECOVERY; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; OBESE-PATIENTS; FOLLOW-UP; METABOLIC SYNDROME AB Study Objectives: To examine the effect of changes in cardiorespiratory fitness on obstructive sleep apnea (OSA) severity prior to and following adjustment for changes in weight over the course of a 4-y weight loss intervention. Methods: As secondary analyses of a randomized controlled trial, 263 overweight/obese adults with type 2 diabetes and OSA participated in an intensive lifestyle intervention or education control condition. Measures of OSA severity, cardiorespiratory fitness, and body weight were obtained at baseline, year 1, and year 4. Change in the apnea-hypopnea index (AHI) served as the primary outcome. The percentage change in fitness (submaximal metabolic equivalents [METs]) and change in weight (kg) were the primary independent variables. Primary analyses collapsed intervention conditions with statistical adjustment for treatment group and baseline METs, weight, and AHI among other relevant covariates. Results: At baseline, greater METs were associated with lower AHI (B [SE] = -1.48 [0.71], P = 0.038), but this relationship no longer existed (B [SE] = -0.24 [0.73], P = 0.75) after adjustment for weight (B [SE] = 0.31 [0.07], P < 0.0001). Fitness significantly increased at year 1 (+16.53 +/- 28.71% relative to baseline), but returned to near-baseline levels by year 4 (+1.81 +/- 24.48%). In mixed-model analyses of AHI change over time without consideration of weight change, increased fitness at year 1 (B [SE] = -0.15 [0.04], P < 0.0001), but not at year 4 (B [SE] = 0.04 [0.05], P = 0.48), was associated with AHI reduction. However, with weight change in the model, greater weight loss was associated with AHI reduction at years 1 and 4 (B [SE] = 0.81 [0.16] and 0.60 [0.16], both P < 0.0001), rendering the association between fitness and AHI change at year 1 nonsignificant (B [SE] = -0.04 [0.04], P = 0.31). Conclusions: Among overweight/obese adults with type 2 diabetes, fitness change did not influence OSA severity change when weight change was taken into account. C1 [Kline, Christopher E.; Rice, Thomas B.; Strotmeyer, Elsa S.; Jakicic, John M.; Newman, Anne B.] Univ Pittsburgh, Pittsburgh, PA USA. [Reboussin, David M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Foster, Gary D.] Temple Univ, Philadelphia, PA 19122 USA. [Foster, Gary D.] Weight Watchers Int, New York, NY USA. [Millman, Richard P.] Brown Univ, Providence, RI 02912 USA. [Pi-Sunyer, Xavier] Columbia Univ, New York, NY USA. [Wadden, Thomas A.; Kuna, Samuel T.] Univ Penn, Philadelphia, PA 19104 USA. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kline, CE (reprint author), Univ Pittsburgh, Dept Hlth & Phys Act, 32 Oak Hill Court,Room 227, Pittsburgh, PA 15261 USA. EM chriskline@pitt.edu OI Strotmeyer, Elsa/0000-0002-4093-6036; Newman, Anne B./0000-0002-0106-1150 FU Abbott; Abbvie; Actelion; Ancile; Apnex; Arena; Aptalis; Astra-Zeneca; Aventis; Banyu; Biomarin; BMS; Catalyst; Celgene; Cephalon; CHDI; Edgemont; Elan; Epix; Eisai; Elminda; Evotec; Forest; Fresca; Galderma; Genentech; Gilead; Glaxo Smith Kline; H. Lundbeck A/S; Janssen; Jazz; Johnson Johnson; King; Merck and Co.; National Institutes of Health (NIH); Neurim; Neurocrine Biosciences; Naurex; Neurogen; Novo Nordisk; Organon; Orphan Medical; Otsuka; Pfizer; Predix; Respironics; Roxane; Saladax; Sanofi-Aventis; Sanofi-Synthelabo; Schering-Plough; Sepracor; Sunovion; Shire; Somaxon; Takeda; Takeda Pharmaceuticals North America; Targacept; Teva; Thymon; Transcept; UCB; USWorldmeds; Pharma; Ultragenyx; Vanda; Wyeth-Ayerst Research; Orexigen; Nutrisystem; Weight Watchers; Jawbone; [HL070301]; [DK60426]; [DK56992]; [DK057135]; [HL118318] FX This was not an industry supported study. Financial support was provided by HL070301, DK60426, DK56992, DK057135, HL118318. Dr. Zammit is a consultant for Acorda, Actelion, Alexza, Arena, Aventis, Biovail, Boehringer-Ingelheim, Cephalon, Elan, Eli Lilly, Evotec, Forest, Glaxo Smith Kline, Jazz, King Pharmaceuticals, Ligand, McNeil, Merck, Neurocrine Biosciences, Organon, Pfizer, Purdue, Renovis, Sanofi-Aventis, Select Comfort, Sepracor, Shire, Somnus, Takeda Pharmaceuticals, Vela, and Wyeth; has grant support from Abbott, Abbvie, Actelion, Ancile, Apnex, Arena, Aptalis, Astra-Zeneca, Aventis, Banyu, Biomarin, BMS, Catalyst, Celgene, Cephalon, CHDI, Edgemont, Elan, Epix, Eisai, Elminda, Evotec, Forest, Fresca, Galderma, Genentech, Gilead, Glaxo Smith Kline, Gilead, H. Lundbeck A/S, Janssen, Jazz, Johnson & Johnson, King, Merck and Co., National Institutes of Health (NIH), Neurim, Neurocrine Biosciences, Naurex, Neurim, Neurogen, Novo Nordisk, Organon, Orphan Medical, Otsuka, Pfizer, Predix, Respironics, Roxane, Saladax, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Sepracor, Sunovion, Shire, Somaxon, Takeda, Takeda Pharmaceuticals North America, Targacept, Teva, Thymon, Transcept, UCB, USWorldmeds, Pharma, Ultragenyx, Predix, Vanda, and Wyeth-Ayerst Research; and has received honoraria from King Pharmaceuticals, McNeil, Merck, Neurocrine Biosciences, Sanofi-Aventis, Sanofi-Synthelabo, Sepracor, Takeda Pharmaceuticals, Vela Pharmaceuticals, and Wyeth-Ayerst Research. Dr. Wadden serves on Scientific Advisory Boards for Orexigen, Novo Nordisk, Nutrisystem, and Weight Watchers and has received grant support, on behalf of the University of Pennsylvania, from Orexigen, Novo Nordisk, Nutrisystem, and Weight Watchers. Dr. Jakicic is a member of Weight Watchers International Scientific Advisory Board and has served as the Principal Investigator on a research grant received from Jawbone that was awarded to the University of Pittsburgh. Dr. Foster is the Chief Scientific Officer for Weight Watchers International. The other authors have indicated no financial conflicts of interest. The work was performed at: Brown University, Providence, RI; St. Luke's-Roosevelt Hospital/Clinilabs, New York, NY; Temple University, Philadelphia, PA; University of Pennsylvania, Philadelphia, PA; and University of Pittsburgh, Pittsburgh, PA. NR 62 TC 1 Z9 1 U1 2 U2 9 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD FEB 1 PY 2016 VL 39 IS 2 BP 317 EP 325 DI 10.5665/sleep.5436 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DC0WH UT WOS:000368938100008 PM 26446118 ER PT J AU Ioannou, GN AF Ioannou, George N. TI The Role of Cholesterol in the Pathogenesis of NASH SO TRENDS IN ENDOCRINOLOGY AND METABOLISM LA English DT Review ID FATTY LIVER-DISEASE; HEPATIC STELLATE CELLS; LOW-DENSITY-LIPOPROTEIN; ENDOPLASMIC-RETICULUM STRESS; NONALCOHOLIC STEATOHEPATITIS; LIPID DROPLETS; INSULIN-RESISTANCE; OXIDIZED LDL; HEPATOCELLULAR-CARCINOMA; CARDIOVASCULAR-DISEASE AB Lipotoxicity drives the development of progressive hepatic inflammation and fibrosis in a subgroup of patients with nonalcoholic fatty liver disease (NAFLD), causing nonalcoholic steatohepatitis (NASH) and even progression to cirrhosis and hepatocellular carcinoma (HCC). While the underlying molecular mechanisms responsible for the development of inflammation and fibrosis that characterize progressive NASH remain unclear, emerging evidence now suggests that hepatic free cholesterol (FC) is a major lipotoxic molecule critical in the development of experimental and human NASH. In this review, we examine the effects of excess FC in hepatocytes, Kupffer cells (KCs), and hepatic stellate cells (HSCs), and the subcellular mechanisms by which excess FC can induce cellular toxicity or proinflammatory and profibrotic effects in these cells. C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA.; Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA.; Ioannou, GN (reprint author), Univ Washington, Seattle, WA 98195 USA. EM georgei@medicine.washington.edu NR 99 TC 11 Z9 12 U1 4 U2 12 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 1043-2760 J9 TRENDS ENDOCRIN MET JI Trends Endocrinol. Metab. PD FEB PY 2016 VL 27 IS 2 BP 84 EP 95 DI 10.1016/j.tem.2015.11.008 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DC1DE UT WOS:000368956200003 PM 26703097 ER PT J AU Kearney, DJ Simpson, TL Malte, CA Felleman, B Martinez, ME Hunt, SC AF Kearney, David J. Simpson, Tracy L. Malte, Carol A. Felleman, Benjamin Martinez, Michelle E. Hunt, Stephen C. TI Mindfulness-based Stress Reduction in Addition to Usual Care Is Associated with Improvements in Pain, Fatigue, and Cognitive Failures Among Veterans with Gulf War Illness SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Complementary and alternative medicine; Gulf War illness; Mindfulness; Veterans ID QUALITY-OF-LIFE; HEALTH-STATUS; THEORETICAL CONSIDERATIONS; ALTERNATIVE MEDICINE; PHYSICAL SYMPTOMS; FOLLOW-UP; THERAPY; QUESTIONNAIRE; DEPRESSION; DISORDER AB BACKGROUND: Many Gulf War I veterans report ongoing negative health consequences. The constellation of pain, fatigue, and concentration/memory disturbances is referred to as "Gulf War illness." Prior research suggests that mindfulness-based stress reduction may be beneficial for these symptoms, but mindfulness-based stress reduction has not been studied for veterans with Gulf War illness. The objective of this trial was to conduct a pilot study of mindfulness-based stress reduction for veterans with Gulf War illness. METHODS: Veterans (N = 55) with Gulf War illness were randomly assigned to treatment as usual plus mindfulness-based stress reduction or treatment as usual only. Mindfulness-based stress reduction was delivered in 8 weekly 2.5-hour sessions plus a single 7-hour weekend session. Pain, fatigue, and cognitive failures were the primary outcomes, assessed at baseline, after mindfulness-based stress reduction, and 6 months follow-up. Secondary outcomes included symptoms of posttraumatic stress disorder and depression. RESULTS: In intention-to-treat analyses, at 6-month follow-up, veterans randomized to mindfulness-based stress reduction plus treatment as usual reported greater reductions in pain (f = 0.33; P = .049), fatigue (f = 0.32; P = .027), and cognitive failures (f = 0.40; P < .001). Depressive symptoms showed a greater decline after mindfulness-based stress reduction (f = 0.22; P = .050) and at 6 months (f = 0.27; P = .031) relative to treatment as usual only. Veterans with posttraumatic stress disorder at baseline randomized to mindfulness-based stress reduction plus treatment as usual experienced significantly greater reductions in symptoms of posttraumatic stress disorder after mindfulness-based stress reduction (f = 0.44; P = .005) but not at 6 months follow-up (f = 0.31; P = .082). CONCLUSIONS: Mindfulness-based stress reduction in addition to treatment as usual is associated with significant improvements in self-reported symptoms of Gulf War illness, including pain, fatigue, cognitive failures, and depression. Published by Elsevier Inc. C1 [Kearney, David J.; Hunt, Stephen C.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Kearney, David J.; Hunt, Stephen C.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Simpson, Tracy L.; Malte, Carol A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Substance Abuse Treatment & Educ C, Seattle, WA USA. [Simpson, Tracy L.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Felleman, Benjamin; Martinez, Michelle E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Kearney, DJ (reprint author), Seattle VAMC 111GI,1660 S Columbian Way, Seattle, WA 98108 USA. EM david.kearney@va.gov FU VA Office of Research and Development [5I01CX000313-02] FX This trial was funded by a grant from the VA Office of Research and Development (5I01CX000313-02). NR 70 TC 3 Z9 3 U1 6 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 EI 1555-7162 J9 AM J MED JI Am. J. Med. PD FEB PY 2016 VL 129 IS 2 BP 204 EP 214 DI 10.1016/j.amjmed.2015.09.015 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DB2MG UT WOS:000368342300039 PM 26519614 ER PT J AU Matioc, AA AF Matioc, Adrian A. TI An Anesthesiologist's Perspective on the History of Basic Airway Management The "Preanesthetic" Era-1700 to 1846 SO ANESTHESIOLOGY LA English DT Article ID RESUSCITATION AB Basic airway management modern history starts in the early 18th century in the context of resuscitation of the apparently dead. History saw the rise and fall of the mouth-to-mouth and then of the instrumental positive-pressure ventilation generated by bellows. Pulmonary ventilation had a secondary role to external and internal organ stimulation in resuscitation of the apparently dead. Airway access for the extraglottic technique was to the victim's nose. The bellows-to-nose technique was the basic airway management technique applicable by both medical and nonmedical personnel. Although the techniques had been described at the time, very few physicians practiced glottic (intubation) and subglottic (tracheotomy) techniques. Before the anesthetic era, positive-pressure ventilation was discredited and replaced by manual negative-pressure techniques. In the middle of the 19th century, physicians who would soon administer anesthetic gases were unfamiliar with the positive-pressure ventilation concept. C1 [Matioc, Adrian A.] Univ Wisconsin, Dept Anesthesiol, Sch Med & Publ Hlth, Madison, WI USA. [Matioc, Adrian A.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room A8030, Madison, WI 53705 USA. RP Matioc, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room A8030, Madison, WI 53705 USA. EM aamatioc@wisc.edu FU Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois FX Support was provided by departmental sources and by a 2013 Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois, awarded in the author name for this topic. NR 61 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2016 VL 124 IS 2 BP 301 EP 311 DI 10.1097/ALN.0000000000000955 PG 11 WC Anesthesiology SC Anesthesiology GA DB5FP UT WOS:000368540300008 PM 26580835 ER PT J AU Lee, SM Takemoto, S Wallace, AW AF Lee, Susan M. Takemoto, Steven Wallace, Arthur W. TI Early Postoperative Withholding Angiotensin Receptor Blockers and 30-day Mortality after Noncardiac Surgery Reply SO ANESTHESIOLOGY LA English DT Letter ID SYSTEMS C1 [Lee, Susan M.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. RP Lee, SM (reprint author), Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. EM susan.lee5@va.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD FEB PY 2016 VL 124 IS 2 BP 513 EP 514 DI 10.1097/ALN.0000000000000965 PG 2 WC Anesthesiology SC Anesthesiology GA DB5FP UT WOS:000368540300032 PM 26785436 ER PT J AU Lee, CH Verma, P Lee, J Klaustermeyer, WB AF Lee, Christina H. Verma, Prashant Lee, Joyce Klaustermeyer, William B. TI Cost analysis of asthma maintenance medications in a veteran population SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter C1 [Lee, Christina H.; Verma, Prashant; Lee, Joyce; Klaustermeyer, William B.] Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. RP Klaustermeyer, WB (reprint author), Univ Calif Los Angeles, Dept Med, Div Allergy & Immunol, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. EM william.klaustermeyer@va.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD FEB PY 2016 VL 116 IS 2 BP 165 EP 166 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA DB5SD UT WOS:000368573000016 PM 26702545 ER PT J AU Taylor, BE McClave, SA Martindale, RG Warren, MM Johnson, DR Braunschweig, C McCarthy, MS Davanos, E Rice, TW Cresci, GA Gervasio, JM Sacks, GS Roberts, PR Compher, C AF Taylor, Beth E. McClave, Stephen A. Martindale, Robert G. Warren, Malissa M. Johnson, Debbie R. Braunschweig, Carol McCarthy, Mary S. Davanos, Evangelia Rice, Todd W. Cresci, Gail A. Gervasio, Jane M. Sacks, Gordon S. Roberts, Pamela R. Compher, Charlene CA Soc Critical Care Med Amer Soc Parenteral Enteral Nutr TI Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN) SO CRITICAL CARE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SEVERE ACUTE-PANCREATITIS; RESTING ENERGY-EXPENDITURE; MECHANICALLY VENTILATED PATIENTS; GAMMA-LINOLENIC ACID; INFLAMMATORY RESPONSE SYNDROME; INTENSIVE INSULIN THERAPY; PLACEBO-CONTROLLED TRIAL; MILD ACUTE-PANCREATITIS; TRAUMATIC BRAIN-INJURY C1 [Taylor, Beth E.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [McClave, Stephen A.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Martindale, Robert G.] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA. [Warren, Malissa M.] Portland VA Med Ctr, Portland, OR USA. [Johnson, Debbie R.] UW Hlth Univ, Wisconsin Hosp & Clin, Wound Skin Ost, Madison, WI USA. [Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA. [Braunschweig, Carol] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA. [McCarthy, Mary S.] Madigan Healthcare Syst, Ctr Nursing Sci & Clin Inquiry, Tacoma, WA USA. [Davanos, Evangelia] Brooklyn Hosp Ctr, Nutr Support, Brooklyn, NY USA. [Rice, Todd W.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Med, Nashville, TN 37212 USA. [Cresci, Gail A.] Inst Digest Dis, Gastroenterol & Pathobiol, Cleveland, OH USA. [Gervasio, Jane M.] Butler Univ, Coll Pharm & Hlth Sci, Pharm Practice, Indianapolis, IN 46208 USA. [Sacks, Gordon S.] Auburn Univ, Dept Pharm Practice, Harrison Sch Pharm, Auburn, AL 36849 USA. [Roberts, Pamela R.] Univ Oklahoma, Hlth Sci Ctr, Dept Anesthesiol, Oklahoma City, OK 73190 USA. [Compher, Charlene] Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA. RP Taylor, BE (reprint author), Barnes Jewish Hosp, St Louis, MO 63110 USA. EM bet1217@bjc.org FU Metagenics; Kabi USA, LLC; A.S.P.E.N. Rhoads Research Foundation - Board of Advisors; Fresenius Kabi USA, LLC; March of Dimes Foundation FX Dr. Taylor disclosed serving as an A.S.P.E.N. committee member and DNS past chair. Dr. McClave disclosed other relationships with Nestle (consulting), Abbott (Speaker), Metagenics (consulting), Covidien (consultant), and A.S.P.E.N. Dr. Martindale disclosed other relationships with Davol, LifeCell, and Metagenics (consultant) and received funding from Metagenics (research grant recipient). Dr. Warren disclosed serving as Co-chair for the Veterans Health Administration Dietary Supplement Committee and as a Chair for the Dietitians in Nutrition Support webinar planning committee. Dr. Braunschweig disclosed serving as the A.S.P.E.N. editor for clinical guidelines. Dr. McCarthy disclosed serving as an A.S.P.E.N. Committee Member for Research Committee and Abstract Review Committee, A.S.P.E.N. Nursing Section Member, and SCCM Nursing Section Member. Dr. Davanos disclosed other relationships with Baxter Healthcare (Medical Science Liaison and employee) and NY/LISPEN chapter (President Elect). Dr. Cresci disclosed other relatiosnhips with Metagenics, Advocare, and Covidien. She received funding from Metagenics (research grant, speaker) and served as a research committee member for A.S.P.E.N. and DNS (Chair - symposium planning committee). Dr. Rice disclosed other relationships with Avisa, LLC (Consultant) and GSK (DSMB). Dr. Roberts disclosed other relationships as ASA Committee Member (critical care) and as an A.S.P.E.N. Committee member (abstract reviews). Dr. Gervasio disclosed serving as an A.S.P.E.N. committee member. Dr. Sacks disclosed other relationships with Kabi USA, LLC (research grant recipient) and A.S.P.E.N. (President and member of Board of Directors, A.S.P.E.N. Rhoads Research Foundation - Board of Advisors); received funding (Research grant recipient, related to parenteral nutrition); and received funding from Fresenius Kabi USA, LLC (research grant recipient). Dr. Rice served as expert witness. Dr. Compher received funding from the March of Dimes Foundation (Research grant recipient) and disclosed other relationships with A.S.P.E.N. (Board of directors and President elect). Dr. Johnson disclosed that she does not have any potential conflicts of interest. NR 484 TC 23 Z9 30 U1 14 U2 37 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0090-3493 EI 1530-0293 J9 CRIT CARE MED JI Crit. Care Med. PD FEB PY 2016 VL 44 IS 2 BP 390 EP 438 DI 10.1097/CCM.0000000000001525 PG 49 WC Critical Care Medicine SC General & Internal Medicine GA DB4SO UT WOS:000368503700020 PM 26771786 ER PT J AU Post, RM Altshuler, LL Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, Robert M. Altshuler, Lori L. Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E. Leverich, Gabriele S. Nolen, Willem A. TI More illness in offspring of bipolar patients from the US compared to Europe SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Review DE Depression; Substance abuse; Anxiety disorder; Family history; Suicide attempt ID UNITED-STATES; EARLY-ONSET; N-ACETYLCYSTEINE; EARLY AGE; DISORDER; RISK; TRIAL; ADOLESCENTS; GENERATIONS; STRATEGIES AB Background: Evidence suggests that patients with bipolar disorder from the United States have an earlier age of onset and a more difficult course of illness than those from Germany and the Netherlands. These characteristics were related to a greater family burden of psychiatric illness and the experience of more psychosocial adversity in childhood. We hypothesized that this greater illness burden would extend to the offspring of the US patients. Methods: 968 outpatients (average age 41) with bipolar illness gave informed consent for participation in a treatment outcome network and filled out a detailed questionnaire about their illness and family history of illness, including whether their offspring had a diagnosis of depression, bipolar disorder, alcohol or substance abuse, suicide attempt or "other" illness. Of those with children, 356 were from the US and 132 were from Europe. Results: Compared to the Europeans, offspring of patients from the US had significantly (p < 0.001) more depression, bipolar disorder, drug abuse, and "other" illnesses. The number of illnesses in the offspring was related to the bipolar parent being from the US, having had childhood adversity, more than 20 prior episodes, and more parental psychiatric illness. Conclusions: While the findings are limited by their basis on self report, the distribution of the percentages in the US offspring are similar to those of Axelson et al. (2015) who used direct interviews. The higher burden of illness in the offspring and their in direct progenitors from the US compared to Europe warrant new attempts at better treatment and prevention. (c) 2016 The Authors. Published by Elsevier B.V. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA. [Kupka, Ralph; Keck, Paul E.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.; Keck, Paul E.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Altshuler, Lori L.] UCLA Mood Disorders Res Program, Mood Disorders Res, Los Angeles, CA USA. RP Post, RM (reprint author), Bipolar Collaborat Network, Bethesda, MD 20814 USA. EM Robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 NR 44 TC 6 Z9 6 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD FEB PY 2016 VL 191 BP 180 EP 186 DI 10.1016/j.jad.2015.11.038 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA DB1FL UT WOS:000368253400025 PM 26655863 ER PT J AU Halbert, CH Melvin, C Briggs, V Delmoor, E Rice, LJ Lynch, C Jefferson, M Johnson, JC AF Halbert, Chanita Hughes Melvin, Cathy Briggs, Vanessa Delmoor, Ernestine Rice, LaShanta J. Lynch, Cheryl Jefferson, Melanie Johnson, Jerry C. TI Neighborhood Satisfaction and Colorectal Cancer Screening in a Community Sample of African Americans SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Neighborhood satisfaction; Social determinants; Colorectal cancer screening; African Americans ID HEALTH; COLONOSCOPY; VALIDATION; VEGETABLES; KNOWLEDGE; COLLEGE; ACCESS; FRUITS; WOMEN AB Social determinants are important to cancer screening among African Americans. To evaluate the association between social determinants (e.g., psychological characteristics, perceived social environment, cultural beliefs such as present temporal orientation) and colorectal cancer (CRC) screening among African Americans. African American adults (n = 262) ages 50-75 completed a telephone interview. Multivariate logistic regression analysis was used to identify factors having significant independent associations with CRC screening. Only 57 % of respondents reported having CRC screening. The likelihood of screening increased with greater neighborhood satisfaction (OR = 1.38, 95 % CI = 1.01, 1.90, p = 0.04), older age (OR = 1.75, 95 % CI = 1.24, 2.48, p = 0.002), greater self-efficacy (OR = 2.73, 95 % CI = 1.40, 5.35, p = 0.003), and health care provider communication (OR = 10.78, 95 % CI = 4.85, 29.94, p = 0.0001). Community resources are important precursors to CRC screening and outcomes among African Americans. In addition to addressing psychological factors and patient-provider communication, efforts to ensure the availability of quality health care facilities that provide CRC screening in the neighborhoods where African Americans live are needed. C1 [Halbert, Chanita Hughes; Rice, LaShanta J.; Jefferson, Melanie] Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Populat Hlth & Outcomes, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Halbert, Chanita Hughes] Ralph H Johnson Vet Adm Med Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Melvin, Cathy] Med Univ S Carolina, Hollings Canc Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Melvin, Cathy] Med Univ S Carolina, Dept Publ Hlth Sci, 68 President St,Suite BE103, Charleston, SC 29425 USA. [Briggs, Vanessa] Public Hlth Management Corp, Hlth Promot Serv, 260 South Broad St, Philadelphia, PA 19102 USA. [Delmoor, Ernestine] Natl Black Leadership Initiat Canc, Philadelphia Chapter, 1415 N Broad St,Suite 221B, Philadelphia, PA 19122 USA. [Lynch, Cheryl] Med Univ S Carolina, Div Gen Internal Med, Dept Med, 135 Rutledge Ave, Charleston, SC 29425 USA. [Lynch, Cheryl] Ralph H Johnson Vet Adm Med Ctr, 135 Rutledge Ave, Charleston, SC 29425 USA. [Johnson, Jerry C.] Univ Penn, Dept Med, Div Geriatr, 3615 Chestnut St, Philadelphia, PA 19104 USA. RP Halbert, CH (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Ctr Populat Hlth & Outcomes, 68 President St,Suite BE103, Charleston, SC 29425 USA.; Halbert, CH (reprint author), Ralph H Johnson Vet Adm Med Ctr, 68 President St,Suite BE103, Charleston, SC 29425 USA. EM hughesha@musc.edu FU National Cancer Institute [R01CA100254]; National Institute on Minority Health and Health Disparities Grant [R24MD001594] FX This research was supported by National Cancer Institute Grant No. R01CA100254 and National Institute on Minority Health and Health Disparities Grant No. R24MD001594. We would like to Benita Weathers, MPH for project management, Aliya Collier, BA for data management, Stacey Brown, MSW for data collection and administration, and Brenda Bryant, BA for community outreach and relations. We are very appreciative to all of the women and men who participated in this research. NR 35 TC 2 Z9 2 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD FEB PY 2016 VL 41 IS 1 BP 38 EP 45 DI 10.1007/s10900-015-0062-9 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DB6PY UT WOS:000368638400006 PM 26184107 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Review of cardiovascular literature SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 306,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2016 VL 23 IS 1 BP 8 EP 10 DI 10.1007/s12350-015-0343-9 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DB6CQ UT WOS:000368601300004 PM 26626784 ER PT J AU Iskandrian, AE Roth, CP Hage, FG AF Iskandrian, Ami E. Roth, Christopher P. Hage, Fadi G. TI Serial imaging and outcome prediction SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID CORONARY-ARTERY-DISEASE; LEFT-VENTRICULAR PERFUSION; MYOCARDIAL-PERFUSION; QUANTITATIVE-ANALYSIS; ASYMPTOMATIC PATIENTS; TRIAL; ISCHEMIA; ADENOSINE; NUCLEAR; SPECT C1 [Iskandrian, Ami E.; Roth, Christopher P.; Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ BLVD, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Iskandrian, AE (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, 318 LHRB,1900 Univ BLVD, Birmingham, AL 35294 USA. EM aiskand@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 21 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2016 VL 23 IS 1 BP 117 EP 121 DI 10.1007/s12350-015-0312-3 PG 5 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DB6CQ UT WOS:000368601300019 PM 26514576 ER PT J AU AlJaroudi, WA Hage, FG AF AlJaroudi, Wael A. Hage, Fadi G. TI Review of cardiovascular imaging in the journal of nuclear cardiology in 2015. Part 1 of 2: Plaque imaging, positron emission tomography, computed tomography, and magnetic resonance SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Review DE Vulnerable atherosclerotic plaque; myocardial perfusion imaging: PET; fluorodeoxyglucose (FDG); computed tomography (CT); magnetic resonance imaging ID CORONARY-ARTERY-DISEASE; SCREENING ASYMPTOMATIC PATIENTS; MYOCARDIAL-ISCHEMIA; CARDIAC AMYLOIDOSIS; HIV-INFECTION; MR-IMPACT; PET; ATHEROSCLEROSIS; INFLAMMATION; TRIAL AB In 2015, many original articles pertaining to cardiovascular imaging with impressive quality were published in the Journal of Nuclear Cardiology. In a set of 2 articles, we provide an overview of these contributions to facilitate for the interested reader a quick review of the advancements that occurred in the field over this year. In this first article, we focus on arterial plaque imaging, cardiac positron emission tomography, computed tomography, and magnetic resonance imaging. C1 [AlJaroudi, Wael A.] Clemenceau Med Ctr, Cardiovasc Imaging, Div Cardiovasc Med, Beirut, Lebanon. [Hage, Fadi G.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1720 2nd AVE S, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Lyons Harrison Res Bldg 314,1720 2nd AVE S, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 NR 43 TC 1 Z9 1 U1 1 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 EI 1532-6551 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD FEB PY 2016 VL 23 IS 1 BP 122 EP 130 DI 10.1007/s12350-015-0319-9 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA DB6CQ UT WOS:000368601300020 PM 26542991 ER PT J AU Steverson, D Tian, L Fu, YC Zhang, W Ma, E Garvey, WT AF Steverson, Dennis, Jr. Tian, Ling Fu, Yuchang Zhang, Wei Ma, Elizabeth Garvey, William Timothy TI Tribbles Homolog 3 Promotes Foam Cell Formation Associated with Decreased Proinflammatory Cytokine Production in Macrophages: Evidence for Reciprocal Regulation of Cholesterol Uptake and Inflammation SO METABOLIC SYNDROME AND RELATED DISORDERS LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; CARDIOVASCULAR-DISEASE; NLRP3 INFLAMMASOMES; INSULIN-RESISTANCE; METABOLIC SYNDROME; DEFICIENT MICE; ATHEROSCLEROSIS; PLAQUES; TRB3 AB Background: Insulin resistance is central in the pathophysiology of cardiometabolic disease; however, common mechanisms that explain the parallel development of both type 2 diabetes and atherosclerosis have not been elucidated. We have previously shown that tribbles homolog 3 (TRB3) can exert a chronic pathophysiological role in promoting insulin resistance and also has an acute physiological role to alternatively regulate glucose uptake in fat and muscle during short-term fasting and nutrient excess. Since TRB3 is expressed in human atherosclerotic plaques, we explored its role in foam cell formation to assess its potential contribution to atherogenesis. Methods: We have used human THP-1 monocytes, which transition to lipid-laden macrophage foam cells when exposed to oxidized low-density lipoprotein (ox-LDL). Results: We first observed that TRB3 was upregulated by more than twofold (P<0.01) within 24hr of treatment with ox-LDL. To determine whether TRB3 actively participated in foam cell formation, we overexpressed TRB3 in THP-1 monocytes and found that this led to a 1.5-fold increase in cholesterol accumulation after 48hr (P<0.01), compared with controls. At the same time, TRB3 overexpression suppressed inflammation in macrophages as evidenced by reduced expression and secretion of tumor necrosis factor alpha (TNF-) and interleukin-1 beta (IL-1) (both P<0.01). Conclusions: (1) TRB3 is upregulated in macrophages upon treatment with ox-LDL; (2) TRB3 promotes lipid accumulation and suppresses cytokine expression; and (3) inflammation and foam cell formation can be reciprocally regulated, and TRB3 orients the macrophage to assume a more primary role for lipid accumulation while maintaining a secondary role as an inflammatory immune cell. C1 [Steverson, Dennis, Jr.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Steverson, Dennis, Jr.; Tian, Ling; Fu, Yuchang; Zhang, Wei; Ma, Elizabeth; Garvey, William Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, William Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Steverson, D (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, 1675 Univ Blvd, Birmingham, AL 35294 USA. EM dsteversonjr@gmail.com FU National Institutes of Health [DK-038765, DK-083562]; Merit Review program of the Department of Veterans Affairs FX This work was supported by grants from the National Institutes of Health (DK-038765, DK-083562) and by the Merit Review program of the Department of Veterans Affairs. The authors also acknowledge support from core facilities of the UAB Diabetes Research Center (P30 DK079626). NR 39 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-4196 EI 1557-8518 J9 METAB SYNDR RELAT D JI Metab. Syndr. Relat. Disord. PD FEB 1 PY 2016 VL 14 IS 1 BP 7 EP 15 DI 10.1089/met.2015.0037 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DB4XT UT WOS:000368517600003 PM 26584255 ER PT J AU McGrath, JM Fisher, V Krejci-Manwaring, J AF McGrath, John M. Fisher, Valerie Krejci-Manwaring, Jennifer TI Skin Cancer Warnings and the Need for New Preventive Campaigns A Pilot Study SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID PREVALENCE C1 [McGrath, John M.] Trinity Univ, Dept Human Commun, San Antonio, TX 78212 USA. [McGrath, John M.; Krejci-Manwaring, Jennifer] Audie L Murphy Vet Hosp, San Antonio, TX USA. [Fisher, Valerie; Krejci-Manwaring, Jennifer] Univ Texas Hlth Sci Ctr San Antonio, Div Dermatol & Cutaneous Surg, San Antonio, TX 78229 USA. RP McGrath, JM (reprint author), Trinity Univ, Dept Human Commun, One Trinity Pl, San Antonio, TX 78212 USA. EM jmcgrath@trinity.edu NR 10 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2016 VL 50 IS 2 BP E62 EP E63 DI 10.1016/j.amepre.2015.10.009 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA DB1DG UT WOS:000368247600004 PM 26657182 ER PT J AU Banks, WA Dohi, K Hansen, K Thompson, HJ AF Banks, William A. Dohi, Kenji Hansen, Kim Thompson, Hilaire J. TI Assessing blood granulocyte colony-stimulating factor as a potential biomarker of acute traumatic brain injury in mice and humans SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE G-CSF; Traumatic brain injury; Biomarker; Neuroinflammation; Blood brain barrier ID INTRACEREBROVENTRICULAR INJECTION; SEVERITY SCORE; RATS; INTERLEUKIN-1-BETA; CYTOKINES; BARRIER; IMMUNE; MODEL; CARE AB Previous work has found that serum G-CSF was acutely elevated in mice 24 h but not one week after controlled cortical impact (CCI). The purpose of this study was to investigate whether blood G-CSF correlates with the elevated brain cytokines in mice after CCI and also if it correlates with traumatic brain injury (TBI) in humans. Here, we found in mice undergoing CCI, a procedure that induces direct injury to the brain, that serum G-CSF correlated directly or indirectly with several brain cytokines, indicating it is a useful marker for the neuroinflammation of TBI. A pilot study in humans (phase I, n = 19) confirmed that plasma G-CSF is acutely elevated on day I (p < 0.001) of TBI and has returned to baseline by one week. In a second human sample (phase II) (n = 80), we found plasma G-CSF peaks about 12 h after arriving in the emergency department (41.6 +/ 5.4 pg/ml). Aging was weakly associated (p < 0.05) with a less robust elevation in serum G-CSF, but there was no difference with gender. ISS, a measure of total severity of injury, correlated with the degree of elevation in serum G-CSF (r = .419; p < 0.05), but severity of head injury (via AIS) did not. The latter may have been because of the statistically narrow range of head injuries among our cases and the high number of cases diagnosed with closed head injury (a non-codable diagnosis). In conclusion, plasma G-CSF may be a useful biomarker of TBI, correlating with neuroinflammation in the animal model and in the human studies with time since injury and total severity of injury. As such, it may be useful in determining whether TBI has occurred within the last 24 h. Published by Elsevier Inc. C1 [Banks, William A.; Dohi, Kenji; Hansen, Kim; Thompson, Hilaire J.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Banks, William A.; Dohi, Kenji; Hansen, Kim] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA. [Dohi, Kenji] Jikei Univ, Sch Med, Dept Emergency Med, Tokyo, Japan. [Thompson, Hilaire J.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Thompson, Hilaire J.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA. RP Banks, WA (reprint author), VAPSHCS, Rm 1-810A,1660 S Columbian Way, Seattle, WA 98108 USA. EM wabanks1@uw.edu; kdoppy@jikei.ac.jp; nesnah@u.washington.edu; hilairet@uw.edu FU National Institutes of Health, National Center for Research Resources [KL2RR025015]; National Institute of Neurologic Diseases and Stroke [R01NS077913]; Department of Veterans Affairs; National Institute on Aging [R01AG029839, R01AG046619] FX Supported by grants from the National Institutes of Health, National Center for Research Resources KL2RR025015 (HT), the National Institute of Neurologic Diseases and Stroke R01NS077913 (HT), the Department of Veterans Affairs (WAB), and the National Institute on Aging R01AG029839 (WAB) and R01AG046619 (WAB). NR 30 TC 1 Z9 1 U1 2 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD FEB PY 2016 VL 52 BP 81 EP 87 DI 10.1016/j.bbi.2015.10.002 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA DB2DB UT WOS:000368317400011 PM 26441136 ER PT J AU Seltman, HJ Mitchell, S Sweet, RA AF Seltman, Howard J. Mitchell, Shaina Sweet, Robert A. TI A Bayesian model of psychosis symptom trajectory in Alzheimer's disease SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Alzheimer's disease; cognitive impairment; neuropsychiatric symptoms ID LAST 2 DECADES; CARDIOVASCULAR HEALTH; COGNITIVE IMPAIRMENT; DIAGNOSIS AB ObjectivePsychosis, like other neuropsychiatric symptoms of dementia, has many features that make predictive modeling of its onset difficult. For example, psychosis onset is associated with both the absolute degree of cognitive impairment and the rate of cognitive decline. Moreover, psychotic symptoms, while more likely than not to persist over time within individuals, may remit and recur. To facilitate predictive modeling of psychosis for personalized clinical decision making, including evaluating the role of risk genes in its onset, we have developed a novel Bayesian model of the dual trajectories of cognition and psychosis symptoms. MethodsCognition was modeled as a four-parameter logistic curve with random effects for all four parameters and possible covariates for the rate and time of fall. Psychosis was modeled as a continuous-time hidden Markov model with a latent never-psychotic class and states for pre-psychotic, actively psychotic and remitted psychosis. Covariates can affect the probability of being in the never-psychotic class. Covariates and the level of cognition can affect the transition rates for the hidden Markov model. ResultsThe model characteristics were confirmed using simulated data. Results from 434 AD patients show that a decline in cognition is associated with an increased rate of transition to the psychotic state. ConclusionsThe model allows declining cognition as an input for psychosis prediction, while incorporating the full uncertainty of the interpolated cognition values. The techniques used can be used in future genetic studies of AD and are generalizable to the study of other neuropsychiatric symptoms in dementia. Copyright (c) 2015 John Wiley & Sons, Ltd. C1 [Seltman, Howard J.] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. [Mitchell, Shaina] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. RP Seltman, HJ (reprint author), Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA. EM hseltman@stat.cmu.edu FU National Institutes of Health [AG 027224] FX This work was supported in part by the National Institutes of Health grant AG 027224. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 19 TC 1 Z9 1 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD FEB PY 2016 VL 31 IS 2 BP 204 EP 210 DI 10.1002/gps.4326 PG 7 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA DA8BU UT WOS:000368030100013 PM 26216660 ER PT J AU McClave, SA Taylor, BE Martindale, RG Warren, MM Johnson, DR Braunschweig, C McCarthy, MS Davanos, E Rice, TW Cresci, GA Gervasio, JM Sacks, GS Roberts, PR Compher, C AF McClave, Stephen A. Taylor, Beth E. Martindale, Robert G. Warren, Malissa M. Johnson, Debbie R. Braunschweig, Carol McCarthy, Mary S. Davanos, Evangelia Rice, Todd W. Cresci, Gail A. Gervasio, Jane M. Sacks, Gordon S. Roberts, Pamela R. Compher, Charlene CA Soc Critical Care Med Amer Soc Parenteral Enteral Nutr TI Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN) SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE nutrition; critical care; intensive care unit; enteral; parenteral; evidence-based medicine; Grading of Recommendations, Assessment, Development, and Evaluation criteria; guidelines ID RANDOMIZED CONTROLLED-TRIAL; SEVERE ACUTE-PANCREATITIS; RESTING ENERGY-EXPENDITURE; MECHANICALLY VENTILATED PATIENTS; GAMMA-LINOLENIC ACID; INFLAMMATORY RESPONSE SYNDROME; INTENSIVE INSULIN THERAPY; PLACEBO-CONTROLLED TRIAL; MILD ACUTE-PANCREATITIS; TRAUMATIC BRAIN-INJURY C1 [McClave, Stephen A.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. [Taylor, Beth E.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Martindale, Robert G.] Oregon Hlth & Sci Univ, Div Gen Surg, Portland, OR 97201 USA. [Warren, Malissa M.] Portland VA Med Ctr, Portland, OR USA. [Johnson, Debbie R.] Univ Wisconsin Hosp & Clin, UW Hlth, Wound Skin Ost, Madison, WI 53792 USA. [Braunschweig, Carol] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA. [Braunschweig, Carol] Univ Illinois, Div Epidemiol & Biostat, Chicago, IL USA. [McCarthy, Mary S.] Madigan Healthcare Syst, Ctr Nursing Sci & Clin Inquiry, Tacoma, WA USA. [Davanos, Evangelia] Brooklyn Hosp Ctr, Nutr Support, Brooklyn, NY USA. [Rice, Todd W.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Med, Nashville, TN 37235 USA. [Cresci, Gail A.] Inst Digest Dis, Gastroenterol & Pathobiol, Cleveland, OH USA. [Gervasio, Jane M.] Butler Univ, Coll Pharm & Hlth Sci, Indianapolis, IN 46208 USA. [Sacks, Gordon S.] Auburn Univ, Harrison Sch Pharm, Dept Pharm Practice, Auburn, AL 36849 USA. [Roberts, Pamela R.] Res John A Moffitt Endowed Chair, Dept Anesthesiol, Div Chief Crit Care Med, Oklahoma City, OK USA. [Compher, Charlene] Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA. RP Compher, C (reprint author), Univ Penn, Sch Nursing, Nutr Sci, Philadelphia, PA 19104 USA. EM stephen.mcclave@louisville.edu; compherc@nursing.upenn.edu FU Metagenics; Fresenius Kabi USA, LLC; March of Dimes Foundation FX Dr Taylor disclosed serving as an A.S.P.E.N. committee member and Dietitians in Nutrition Support past chair. Dr McClave disclosed other relationships with Nestle (consulting), Abbott (speaker), Metagenics (consulting), Covidien (consultant), and A.S.P.E.N. Dr Martindale disclosed other relationships with Davol, LifeCell, and Metagenics (consultant) and received funding from Metagenics (research grant recipient). Dr Warren disclosed serving as cochair for the Veterans Health Administration Dietary Supplement Committee and as a chair for the Dietitians in Nutrition Support Webinar Planning Committee. Dr Johnson disclosed that she does not have any potential conflicts of interest. Dr Braunschweig disclosed serving as the A.S.P.E.N. editor for clinical guidelines. Dr McCarthy disclosed serving as an A.S.P.E.N. committee member for the Research Committee and the Abstract Review Committee, an A.S.P.E.N. Nursing Section member, and a SCCM Nursing Section member. Dr Davanos disclosed other relationships with Baxter Healthcare (medical science liaison and employee) and NY/LISPEN chapter (president-elect). Dr Rice disclosed other relationships with Avisa, LLC (consultant) and GSK (Data and Safety Monitoring Board) and served as an expert witness. Dr Cresci disclosed other relationships with Metagenics, Advocare, and Covidien; received funding from Metagenics (research grant, speaker); and served as a Research Committee member for A.S.P.E.N. and Dietitians in Nutrition Support (chair of the Symposium Planning Committee). Dr Gervasio disclosed serving as an A.S.P.E.N. committee member. Dr Sacks disclosed other relationships with Fresenius Kabi USA, LLC (research grant recipient) and A.S.P.E.N. (president and member of Board of Directors, A.S.P.E.N. Rhoads Research Foundation-Board of Advisors). Dr Roberts disclosed other relationships as an American Society of Anesthesiologists committee member (critical care) and as an A.S.P.E.N. committee member (abstract reviews). Dr Compher received funding from the March of Dimes Foundation (research grant recipient) and disclosed other relationships with A.S.P.E.N. (Board of Directors and president-elect). NR 481 TC 70 Z9 90 U1 12 U2 41 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD FEB PY 2016 VL 40 IS 2 BP 159 EP 211 DI 10.1177/0148607115621863 PG 53 WC Nutrition & Dietetics SC Nutrition & Dietetics GA DB1TS UT WOS:000368292500002 PM 26773077 ER PT J AU Newcomb, LF Thompson, IM Boyer, HD Brooks, JD Carroll, PR Cooperberg, MR Dash, A Ellis, WJ Fazli, L Feng, ZD Gleave, ME Kunju, P Lance, RS McKenney, JK Meng, MV Nicolas, MM Sanda, MG Simko, J So, A Tretiakova, MS Troyer, DA True, LD Vakar-Lopez, F Virgin, J Wagner, AA Wei, JT Zheng, YY Nelson, PS Lin, DW AF Newcomb, Lisa F. Thompson, Ian M., Jr. Boyer, Hilary D. Brooks, James D. Carroll, Peter R. Cooperberg, Matthew R. Dash, Atreya Ellis, William J. Fazli, Ladan Feng, Ziding Gleave, Martin E. Kunju, Priya Lance, Raymond S. McKenney, Jesse K. Meng, Maxwell V. Nicolas, Marlo M. Sanda, Martin G. Simko, Jeffry So, Alan Tretiakova, Maria S. Troyer, Dean A. True, Lawrence D. Vakar-Lopez, Funda Virgin, Jeff Wagner, Andrew A. Wei, John T. Zheng, Yingye Nelson, Peter S. Lin, Daniel W. CA Canary PASS Investigators TI Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort SO JOURNAL OF UROLOGY LA English DT Article DE prostatic neoplasms; prospective studies; watchful waiting ID RADICAL PROSTATECTOMY; RISK-ASSESSMENT; DISEASE RECURRENCE; PREDICTION; ANTIGEN; TRENDS; VALIDATION; MANAGEMENT; PATHOLOGY; MEN AB Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance. Materials and Methods: We studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance. Results: At a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p = 0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p = 0.76). Conclusions: Most men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome. C1 [Newcomb, Lisa F.; Boyer, Hilary D.; Feng, Ziding; Zheng, Yingye; Nelson, Peter S.; Lin, Daniel W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Newcomb, Lisa F.; Ellis, William J.; Tretiakova, Maria S.; True, Lawrence D.; Vakar-Lopez, Funda; Lin, Daniel W.] Univ Washington, Seattle, WA 98195 USA. [Dash, Atreya; Virgin, Jeff; Lin, Daniel W.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Brooks, James D.] Stanford Univ, Stanford, CA 94305 USA. [Carroll, Peter R.; Cooperberg, Matthew R.; Meng, Maxwell V.; Simko, Jeffry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Fazli, Ladan; Gleave, Martin E.; So, Alan] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Thompson, Ian M., Jr.; Nicolas, Marlo M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Sanda, Martin G.; Wagner, Andrew A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Lance, Raymond S.; Troyer, Dean A.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA. [McKenney, Jesse K.] Cleveland Clin, Cleveland, OH 44106 USA. [Kunju, Priya; Wei, John T.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Lin, DW (reprint author), Univ Washington, Dept Urol, 1959 NE Pacific St,Box 356510, Seattle, WA 98195 USA. EM dlin@uw.edu FU Canary Foundation; National Cancer Institute at the National Institutes of Health Early Detection Research Network [U01 CA086402]; National Institutes of Health [P30 CA054174]; National Institutes of Health (Pacific Northwest Prostate Cancer SPORE) [P50 CA097186] FX Supported by the Canary Foundation; the National Cancer Institute at the National Institutes of Health Early Detection Research Network (Grant U01 CA086402); and the National Institutes of Health (Grant P30 CA054174, and the Pacific Northwest Prostate Cancer SPORE P50 CA097186). NR 27 TC 17 Z9 17 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD FEB PY 2016 VL 195 IS 2 BP 313 EP 320 DI 10.1016/j.juro.2015.08.087 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DA8KZ UT WOS:000368054800023 PM 26327354 ER PT J AU Hunsberger, JG Rao, M Kurtzberg, J Bulte, JWM Atala, A LaFerla, FM Greely, HT Sawa, A Gandy, S Schneider, LS Doraiswamy, PM AF Hunsberger, Joshua G. Rao, Mahendra Kurtzberg, Joanne Bulte, Jeff W. M. Atala, Anthony LaFerla, Frank M. Greely, Henry T. Sawa, Akira Gandy, Sam Schneider, Lon S. Doraiswamy, P. Murali TI Accelerating stem cell trials for Alzheimer's disease SO LANCET NEUROLOGY LA English DT Article ID UMBILICAL-CORD BLOOD; IPSC-DERIVED NEURONS; PARKINSONS-DISEASE; A-BETA; REGENERATIVE MEDICINE; PEDIATRIC-PATIENTS; INFORMED-CONSENT; DRUG-DEVELOPMENT; MOUSE MODELS; AMYLOID-BETA AB At present, no effective cure or prophylaxis exists for Alzheimer's disease. Symptomatic treatments are modestly effective and off er only temporary benefit. Advances in induced pluripotent stem cell (iPSC) technology have the potential to enable development of so-called disease-in-a-dish personalised models to study disease mechanisms and reveal new therapeutic approaches, and large panels of iPSCs enable rapid screening of potential drug candidates. Different cell types can also be produced for therapeutic use. In 2015, the US Food and Drug Administration granted investigational new drug approval for the first phase 2A clinical trial of ischaemia-tolerant mesenchymal stem cells to treat Alzheimer's disease in the USA. Similar trials are either underway or being planned in Europe and Asia. Although safety and ethical concerns remain, we call for the acceleration of human stem cell-based translational research into the causes and potential treatments of Alzheimer's disease. C1 [Hunsberger, Joshua G.; Atala, Anthony] Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA. [Rao, Mahendra] New York Stem Cell Fdn, New York, NY USA. [Kurtzberg, Joanne] Duke Univ, Med Ctr, Robertson Clin & Translat Cell Therapy Program, Durham, NC USA. [Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA. [Bulte, Jeff W. M.] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD USA. [Sawa, Akira] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA. [LaFerla, Frank M.] Univ Calif Irvine, Inst Memory Impairment & Neurol Disorders, Irvine, CA USA. [Greely, Henry T.] Stanford Univ, Ctr Law & Biosci, Stanford, CA 94305 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Ctr Cognit Hlth, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Natl Football League Neurol Care, New York, NY 10029 USA. [Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY USA. [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Alzheimers Dis Res Ctr, Los Angeles, CA 90033 USA. [Doraiswamy, P. Murali] Duke Univ, Duke Inst Brain Sci, Durham, NC USA. [Doraiswamy, P. Murali] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. RP Hunsberger, JG (reprint author), Wake Forest Univ, Wake Forest Inst Regenerat Med, Winston Salem, NC 27109 USA. FU Accelerated Medicines Partnership [U01 AG046170]; David Werber Family Trust; Cure Alzheimer's Fund; Veterans Affairs [I01RX000684]; US National Institutes of Health; National Multiple Sclerosis Society; ALS Association; Maryland Stem Cell Research Fund; Brain & Behavior Research Foundation; Stanley Foundation; RUSK Foundation; Maryland Stem Cell Research Funds FX We acknowledge the contributions of all faculty members and participants at our meeting for the valuable discussions. We are especially grateful for the support of Marjorie Bekaert Thomas, Trustee for the Karen L Wrenn Trust, whose vision led to this conference. The meeting on stem cells and Alzheimer's disease, and the writing of this Personal View, was funded by a gift from the Karen L Wrenn Trust to PMD through Duke University. The Trust had no input in the content of this Personal View. We also acknowledge support from Accelerated Medicines Partnership/U01 AG046170, the David Werber Family Trust, the Cure Alzheimer's Fund, and Veterans Affairs (grant I01RX000684) (all to SG). JWMB, PMD, and AS have been supported by grants from the US National Institutes of Health. JWMB is also supported by the National Multiple Sclerosis Society, the ALS Association, and the Maryland Stem Cell Research Fund. AS reports receiving grants from the Brain & Behavior Research Foundation (formerly the NARSAD), Stanley Foundation, RUSK Foundation, and Maryland Stem Cell Research Funds during the writing of the manuscript. Figure 1 is courtesy of Piotr Walczak and Miroslaw Janowski, Johns Hopkins University, Baltimore, MD, USA. NR 92 TC 3 Z9 4 U1 8 U2 55 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD FEB PY 2016 VL 15 IS 2 BP 219 EP 230 DI 10.1016/S1474-4422(15)00332-4 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA DA9GC UT WOS:000368116000019 PM 26704439 ER PT J AU Sher, L AF Sher, Leo TI SSRIs have a smaller benefit in paediatric when compared to adult major depressive disorder SO EVIDENCE-BASED MENTAL HEALTH LA English DT Editorial Material ID BRAIN C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, New York, NY USA.; Sher, L (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA. EM Leo.Sher@mssm.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1362-0347 EI 1468-960X J9 EVID-BASED MENT HEAL JI Evid.-Based Ment. Health PD FEB PY 2016 VL 19 IS 1 BP 26 EP 26 DI 10.1136/eb-2015-102216 PG 1 WC Psychiatry SC Psychiatry GA ET1BF UT WOS:000400000200015 PM 26729796 ER PT J AU Gardner, RC Rabinovici, GD AF Gardner, Raquel C. Rabinovici, Gil D. TI Evaluating and treating neurobehavioral symptoms in professional American football players: Lessons from a case series Respond SO NEUROLOGY-CLINICAL PRACTICE LA English DT Letter C1 [Gardner, Raquel C.; Rabinovici, Gil D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Gardner, Raquel C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU American Academy of Neurology; Alzheimer's Association; Department of Veterans Affairs; NIH/NIA; UCSF Pepper Center Research Career Development Core; GE Healthcare; Rockpointe; Tau Consortium; Medscape; Avid Radiopharmaceuticals/Eli Lilly; John Douglas French Alzheimer's Foundation; Hellman Family Foundation FX R.C. Gardner has received funding for travel from the American Academy of Neurology and the Alzheimer's Association and has received research support from the Department of Veterans Affairs, NIH/NIA, and UCSF Pepper Center Research Career Development Core. G.D. Rabinovici has received funding for travel and/or speaker honoraria from Alzheimer's Association, GE Healthcare, Rockpointe, Tau Consortium, and Medscape and receives research support from Avid Radiopharmaceuticals/Eli Lilly, NIH/NIA, Alzheimer's Association, John Douglas French Alzheimer's Foundation, Hellman Family Foundation, and Tau Consortium. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD FEB PY 2016 VL 6 IS 1 BP 7 EP 8 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EI6IT UT WOS:000392599600006 ER PT J AU Kraakevik, J AF Kraakevik, Jeff TI Crafting a positive professional digital profile to augment your practice SO NEUROLOGY-CLINICAL PRACTICE LA English DT Editorial Material AB A digital profile is the sum content about a person on the Internet. A digital profile can be composed of personal or professional information shared on public Web sites posted personally or by others. One of the most effective ways to build a positive professional digital profile is through social media. It is increasingly important to maintain a positive digital profile as others mine the Internet to find out about a professional prior to meeting him or her. As the digital environment continues to grow, it will become increasingly difficult to neglect a professional digital profile without potential negative consequences. There are many benefits to creating a digital presence and using the tools available to learn about neurology and interact with other professionals and patients in ways that were not possible in the past. The spread of social media to a large part of the population makes it unlikely to go away. C1 [Kraakevik, Jeff] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. EM kraakevik@ohsu.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD FEB PY 2016 VL 6 IS 1 BP 87 EP 93 DI 10.1212/CPJ.0000000000000211 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EI6IT UT WOS:000392599600024 ER PT J AU Albergotti, WG Byrd, JK Nance, M Choi, EC Koh, YW Kim, S Duvvuri, U AF Albergotti, William G. Byrd, James K. Nance, Melonie Choi, Eun Chang Koh, Yoon Woo Kim, Seungwon Duvvuri, Umamaheswar TI Robot-Assisted Neck Dissection Through a Modified Facelift Incision SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE head and neck squamous cell carcinoma; head and neck surgery; neck dissection; surgical outcomes; treatment of head and neck tumors ID SQUAMOUS-CELL-CARCINOMA; POSTOPERATIVE MORBIDITY; RETROAURICULAR APPROACH; ORAL-CAVITY; HEAD; SURGERY; CANCER; LYMPHEDEMA; PAROTIDECTOMY; EXPERIENCE AB Objectives: The aim of this study is to describe the feasibility as well as oncologic outcomes of robot-assisted neck dissection (RAND) through a modified facelift incision in an American population. Study Design: Retrospective case series. Setting: University tertiary care hospital. Methods: All patients who underwent RAND between November 2012 and December 2014 were included. Medical records were reviewed for demographics, medical histories, staging, operative information, postoperative hospital course and complications, and oncologic outcomes. Results: There were 11 RANDs identified among 10 patients. Five patients had known nodal metastasis at the time of surgery. Two patients had been previously irradiated. The average time of surgery was 284.4 72.3 minutes, including other associated procedures. The average lymph node yield was 28.5 +/- 9.3 nodes. There were no major complications. Average follow-up was 19.4 months. There was 1 supraclavicular recurrence in a previously irradiated patient. All patients are currently alive and without evidence of disease. Conclusions: Robot-assisted neck dissection is a safe and feasible procedure that can be performed by surgeons with familiarity with neck dissection and robot-assisted surgery and who have been trained in RAND. Appropriate oncologic outcomes can be obtained in a patient wishing to avoid a noticeable scar. C1 [Albergotti, William G.; Byrd, James K.; Nance, Melonie; Kim, Seungwon; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Nance, Melonie; Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. [Choi, Eun Chang; Koh, Yoon Woo] Yonsei Univ, Dept Otorhinolaryngol, Coll Med, Seoul, South Korea. RP Duvvuri, U (reprint author), Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Med Ctr, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA. EM duvuriu@upmc.edu FU Intuitive Surgical, Inc.; Department of Veterans Affairs BLRD; PNC Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Byrd was funded by a clinical robotics training and research grant from Intuitive Surgical, Inc. This work was supported in part by a Career Development Award from the Department of Veterans Affairs BLR&D and the PNC Foundation (U.D). NR 29 TC 0 Z9 0 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0003-4894 EI 1943-572X J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD FEB PY 2016 VL 125 IS 2 BP 123 EP 129 DI 10.1177/0003489415601127 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DA5NM UT WOS:000367849800004 PM 26282589 ER PT J AU Browne, KC Wray, TB Stappenbeck, CA Krenek, M Simpson, TL AF Browne, Kendall C. Wray, Tyler B. Stappenbeck, Cynthia A. Krenek, Marketa Simpson, Tracy L. TI Alcohol Consumption, Craving, and Craving Control Efforts Assessed Daily in the Context of Readiness to Change Among Individuals with Alcohol Dependence and PTSD SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Alcohol; PTSD; Craving; Motivation to change ID POSTTRAUMATIC-STRESS-DISORDER; ECOLOGICAL MOMENTARY ASSESSMENT; COMPULSIVE DRINKING SCALE; SUBSTANCE USE; CUE-REACTIVITY; PREDICTOR; DRINKERS; VALIDITY; TRAUMA; MODEL AB Research has demonstrated the positive association between alcohol craving and alcohol use and has identified craving as a central component of alcohol use disorders (AUD). Despite potential clinical implications, few studies have examined the relationship between craving and alcohol use in individuals with AUD and common psychiatric comorbidities or explored possible moderators of the craving-alcohol use relationship. The current study used daily monitoring data to: 1) replicate previous findings detecting a positive relationship between craving and alcohol use in individuals with AUD and co-occurring posttraumatic stress disorder (PTSD) and 2) extend these findings by examining the influence of initial change motivation on the craving-use relationship and within-day associations among craving, efforts to control craving, and alcohol consumption. Participants were 84 individuals with alcohol dependence and PTSD enrolled in an intervention study. Generalized estimating equations using pre-treatment baseline daily data revealed significant main effects for craving, craving control, and motivation to change alcohol use. Daily craving was positively related to alcohol use. Greater change motivation and craving control (i.e., efforts to resist craving, avoidance of thoughts and feelings related to craving) were negatively related to alcohol use. A significant interaction was detected between baseline change motivation and daily craving indicating that the association between craving and alcohol use was significantly stronger for those with low baseline change motivation. A significant interaction was also detected between craving control and daily craving, suggesting that participants were more likely to consume alcohol when experiencing high levels of craving if they reported low levels of craving control. Findings bolster the idea that efforts to prevent or ameliorate craving are critical to treatment success for individuals with AUD and PTSD who are seeking to reduce or quit drinking. Published by Elsevier Inc. C1 [Browne, Kendall C.; Krenek, Marketa; Simpson, Tracy L.] VA Puget Sound Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98018 USA. [Wray, Tyler B.; Simpson, Tracy L.] VA Puget Sound Healthcare Syst, Seattle, WA 98018 USA. [Browne, Kendall C.; Stappenbeck, Cynthia A.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98018 USA. RP Simpson, TL (reprint author), VA Puget Sound Healthcare Syst, 1660 S Columbian Way,CESATE-116, Seattle, WA 98018 USA. EM tracy.simpson@va.gov FU NIH/NIAAA [R21 AA17130-01, R01 AA020252-01] FX This material is the result of work supported by NIH/NIAAA awards (GRANT R21 AA17130-01; R01 AA020252-01) to Dr. Tracy Simpson and by resources from the Center of Excellence in Substance Abuse Treatment and Education (CESATE), the Mental Illness Research, Education, and Clinical Center (MIRECC), the US Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, and the VA Puget Sound Health Care System, Seattle, WA. The views expressed in this article are those of the authors and do not represent the views of the Department of Veteran Affairs or the United States government. Dr. Tyler Wray is now affiliated with the Department of Behavioral and Social Sciences, Brown University, School of Public Health, 121 South Main St., Providence RI 02912. NR 58 TC 1 Z9 1 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD FEB PY 2016 VL 61 BP 34 EP 41 DI 10.1016/j.jsat.2015.09.005 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DA4HP UT WOS:000367761200005 PM 26597623 ER PT J AU Serafini, K Shipley, L Stewart, DG AF Serafini, Kelly Shipley, Leandra Stewart, David G. TI Motivation and substance use outcomes among adolescents in a school-based intervention SO ADDICTIVE BEHAVIORS LA English DT Article DE Stages of change; Adolescence; Substance use; Alcohol; Marijuana; Motivation; Transtheoretical Model of Change ID ALCOHOL PROBLEM INDEX; ABUSE TREATMENT; TRANSTHEORETICAL MODEL; COLLEGE-STUDENTS; DRINKING; READINESS; CONSEQUENCES; SAMPLE; SCALE; STAGE AB The stages of change (Precontemplation, Contemplation, Preparation, Action, and Maintenance) have been well studied in adult populations. However, fewer studies have examined how the stages of change are related to adolescent substance use. Furthermore, there have been no studies that have examined how the stages of change relate to outcomes in a school-based intervention. To better capture adolescent motivation, we added an additional group to the Transtheoretical Model of Change, which we titled Coerced Action, to represent adolescents that made changes to their substance use despite low problem recognition (representing the internal motivation of Precontemplation and the change behaviors of the Action group). We then examined how the stages of change were related to a thorough assessment of substance use at baseline and corresponding treatment outcomes. Our sample consisted of 264 adolescents (mean age: 16.1,44.5% Caucasian, 37.5% female) who participated in an 8-week, school-based Motivational Enhancement intervention. Results indicated significant group differences across the stages of change in substance use patterns (alcohol use, negative consequences, affective dysregulation), as well as treatment outcomes (alcohol use and negative consequences). For instance, adolescents in the Action group demonstrated more negative consequences at 16 weeks follow-up than those in Precontemplation and Coerced Action, F(1, 3) = 8.23,p <.001. The Coerced Action group reported the most alcohol use at 16 weeks follow-up, although the finding was not significant when post-hoc tests were conducted. This study provides meaningful support for the assessment of motivation among adolescent substance users within school-based settings. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Serafini, Kelly] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. [Shipley, Leandra] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Stewart, David G.] Seattle Pacific Univ, Dept Clin Psychol, Seattle, WA 98119 USA. RP Serafini, K (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06511 USA. EM kelly.serafini@yale.edu FU National Institute on Drug Abuse (NIDA) [T32DA007238-23, R03DA12974-01] FX This research was supported in part through a National Institute on Drug Abuse (NIDA) grantT32DA007238-23 (Petrakis) and R03DA12974-01 (Project READY; PI: Stewart). We wish to acknowledge Michael Toohey, Ph.D., who provided feedback on this project. We also wish to thank the participants, research staff, and colleagues who participated in the original clinical trial. NR 35 TC 5 Z9 5 U1 5 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2016 VL 53 BP 74 EP 79 DI 10.1016/j.addbeh.2015.10.004 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CZ7KR UT WOS:000367278800012 PM 26458191 ER PT J AU Hiraoka, R Cook, AJ Bivona, JM Meyer, EC Morissette, SB AF Hiraoka, Regina Cook, Andrew J. Bivona, Jenny M. Meyer, Eric C. Morissette, Sandra B. TI Acceptance and Commitment Therapy in the Treatment of Depression Related to Military Sexual Trauma in a Woman Veteran: A Case Study SO CLINICAL CASE STUDIES LA English DT Article DE acceptance and commitment therapy; military sexual trauma; depression; Veterans ID AFGHANISTAN; OUTCOMES; ANXIETY; IRAQ AB Depression is commonly reported by Veterans who have experienced military sexual trauma (MST). An increasing body of literature supports the use of Acceptance and Commitment Therapy (ACT) for the treatment of depression among civilians and military Veterans; however, additional research is needed, particularly among people exposed to trauma. This clinical case study describes the application of ACT with a 21-year-old woman Veteran who sought treatment for depression related to MST. The Veteran's depression symptoms decreased substantially over the course of therapy. Moreover, she demonstrated increased ability to attend to the present moment, tolerate feelings of uncertainty, and make decisions consistent with her chosen values. Treatment implications of these findings are discussed, with an emphasis on the unique aspects of using ACT in the treatment of MST-related depression among Veterans. C1 [Hiraoka, Regina; Cook, Andrew J.; Bivona, Jenny M.; Meyer, Eric C.; Morissette, Sandra B.] Cent Texas Vet Hlth Care Syst, Waco, TX 76711 USA. [Hiraoka, Regina; Cook, Andrew J.; Meyer, Eric C.; Morissette, Sandra B.] US Dept Vet Affairs, Washington, DC USA. [Cook, Andrew J.; Meyer, Eric C.; Morissette, Sandra B.] Texas A&M Hlth Sci Ctr, Coll Med, Bryan, TX USA. RP Hiraoka, R (reprint author), Cent Texas Vet Hlth Care Syst, 4800 Mem Dr, Waco, TX 76711 USA. EM regina.hiraoka@va.gov FU Veterans Health Administration FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Veterans Health Administration. NR 26 TC 0 Z9 0 U1 3 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-6501 EI 1552-3802 J9 CLIN CASE STUD JI Clin. Case Stud. PD FEB PY 2016 VL 15 IS 1 BP 84 EP 97 DI 10.1177/1534650115594004 PG 14 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DA0FJ UT WOS:000367472400006 ER PT J AU Szot, P Franklin, A Miguelez, C Wang, YQ Vidaurrazaga, I Ugedo, L Sikkema, C Wilkinson, CW Raskind, MA AF Szot, Patricia Franklin, Allyn Miguelez, Cristina Wang, Yangqing Vidaurrazaga, Igor Ugedo, Luisa Sikkema, Carl Wilkinson, Charles W. Raskind, Murray A. TI Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine SO NEUROPHARMACOLOGY LA English DT Article DE Locus coeruleus; 6-Hydroxydopamine; Forced swim test; Electrophysiology; Depression ID MILD COGNITIVE IMPAIRMENT; NORADRENERGIC NERVOUS-SYSTEM; DOPAMINE-BETA-HYDROXYLASE; WISTAR-KYOTO RATS; ALZHEIMERS-DISEASE; ANTIDEPRESSANT DRUGS; PARKINSONS-DISEASE; ANIMAL-MODEL; SENILE DEMENTIA; DEFICIENT MICE AB Depression is a common co-morbid condition most often observed in subjects with mild cognitive impairment (MCI) and during the early stages of Alzheimer's disease (AD). Dysfunction of the central noradrenergic nervous system is an important component in depression. In AD, locus coeruleus (LC) noradrenergic neurons are significantly reduced pathologically and the reduction of LC neurons is hypothesized to begin very early in the progression of the disorder; however, it is not known if dysfunction of the noradrenergic system due to early LC neuronal loss is involved in mediating depression in early AD. Therefore, the purpose of this study was to determine in an animal model if a loss of noradrenergic LC neurons results in depressive-like behavior. The LC noradrenergic neuronal population was reduced by the bilateral administration of the neurotoxin 6-hydroxydopamine (6-OHDA) directly into the LC. Forced swim test (FST) was performed three weeks after the administration of 6-OHDA (5, 10 and 14 mu g/mu l), animals administered the 5 mu g/mu l of 6-OHDA demonstrated a significant increase in immobility, indicating depressive-like behavior. This increase in immobility at the 5 mu g/mu l dose was observed with a minimal loss of LC noradrenergic neurons as compared to LC neuronal loss observed at 10 and 14 mu g/mu l dose. A significant positive correlation between the number of surviving LC neurons after 6-OHDA and FST immobile time was observed, suggesting that in animals with a minimal loss of LC neurons (or a greater number of surviving LC neurons) following 6-OHDA demonstrated depressive-like behavior. As the 6-OHDA-induced loss of LC neurons is increased, the time spent immobile is reduced. Depressive-like behavior was also observed with the 5 mu g/mu l dose of 6-OHDA with a second behavior test, sucrose consumption. FST increased immobility following 6-OHDA (5 mu g/mu l) was reversed by the administration of a single dose of L-1-3-4-dihydroxyphenylalanine (DOPA) or t-threo-3,4-dihydroxyphenylserine (DOPS) prior to behavioral assessment. Surviving LC neurons 3 weeks after 6-OHDA (5 mu g/mu l) demonstrated compensatory changes of increased firing frequency, a more irregular firing pattern, and a higher percentage of cells firing in bursts. These results indicate that depressive-like behavior in mice is observed following the administration of 6-OHDA and the loss of LC noradrenergic neurons; however, the depressive-like behavior correlates positively with the number of surviving LC neurons with 6-OHDA administration. This data suggests the depression observed in MCI subjects and in the early stages of AD may due to the hypothesized early, minimal loss of LC neurons with remaining LC neurons being more active than normal. Published by Elsevier Ltd. C1 [Szot, Patricia; Franklin, Allyn; Wang, Yangqing; Raskind, Murray A.] Vet Adm Puget Sound Hlth Care Syst, Educ & Clin Ctr, Mental Illness Res, Seattle, WA USA. [Szot, Patricia; Wilkinson, Charles W.; Raskind, Murray A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Miguelez, Cristina; Vidaurrazaga, Igor; Ugedo, Luisa] Univ Basque Country, UPV EHU, Dept Pharmacol, Leioa, Spain. [Sikkema, Carl; Wilkinson, Charles W.] Vet Adm Puget Sound Hlth Care Syst, Educ & Clin Ctr, Geriatr Res, Seattle, WA USA. [Miguelez, Cristina] Univ Basque Country, UPV EHU, Dept Pharmacol, Vitoria, Spain. RP Szot, P (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM szot@uw.edu RI Ugedo, Luisa/H-4244-2015 OI Ugedo, Luisa/0000-0001-5993-0606; Miguelez, Cristina/0000-0001-6624-2932 FU Department of Veterans Affairs VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC); Geriatric Research, Education, and Clinical Center (GRECC); University of Washington Department of Psychiatry and Behavioral Science; Basque Government [UFI 11/32]; Spanish Government [FIS PI12/00613] FX This work was supported by Department of Veterans Affairs VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC; Patricia Szot, Allyn Franklin, Murray A Raskind), Geriatric Research, Education, and Clinical Center (GRECC; Carl Sikkema, Charles Wilkinson), University of Washington Department of Psychiatry and Behavioral Science (Patricia Szsot, Murray A Raskind) and grants form the Basque Government (UFI 11/32) and the Spanish Government (FIS PI12/00613) (Cristiria Miguelez, Luisa Ugedo). These institutions had no further competing financial interest in relation to the work described. The authors declare no conflict of interest. NR 62 TC 1 Z9 1 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3908 EI 1873-7064 J9 NEUROPHARMACOLOGY JI Neuropharmacology PD FEB PY 2016 VL 101 BP 76 EP 86 DI 10.1016/j.neuropharm.2015.09.003 PG 11 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DA0JQ UT WOS:000367483800008 PM 26362360 ER PT J AU Demissei, BG Cleland, JG O'Connor, CM Metra, M Ponikowski, P Teerlink, JR Davison, B Givertz, MM Bloomfield, DM Dittrich, H van Veldhuisen, DJ Hillege, HL Voors, AA Cotter, G AF Demissei, Biniyam G. Cleland, John G. O'Connor, Christopher M. Metra, Marco Ponikowski, Piotr Teerlink, John R. Davison, Beth Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard van Veldhuisen, Dirk J. Hillege, Hans L. Voors, Adriaan A. Cotter, Gad TI Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Acute heart failure; Procalcitonin; Bacterial infection; Prognosis ID C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED PNEUMONIA; TERM PROGNOSIS; DIAGNOSIS; TRIAL; OUTCOMES; ADULTS; ROLOFYLLINE; ANTAGONIST; BACTEREMIA AB Background: Bacterial infections in patients hospitalized with acute heart failure are related to worse prognosis, but they can be difficult to diagnose. In this study we evaluated the prevalence, clinical correlates and association with outcomes of significantly elevated procalcitonin levels in patients hospitalized for acute heart failure without clear signs of bacterial infection. Methods: 1781 patients from the PROTECT trial were included. Patients with a body temperature >38 degrees C, sepsis or active infection requiring IV antibiotics were excluded. Significant elevation of procalcitonin was considered present when levels exceeded 0.20 ng/mL. In-hospital and post-discharge outcomes were compared between groups of patients with and without elevated procalcitonin levels. Results: Procalcitonin >= 0.20 ng/mL was seen in 6.0% of patients (N = 104). This group of patients had lower serum albumin, lower hemoglobin, higher leukocyte count, higher C-reactive protein, higher blood urea nitrogen, higher heart rate and more pulmonary rales. Interestingly, no significant differences were observed between the two groups in terms of severity of heart failure evidenced by left ventricular ejection fraction (LVEF) or B-type natriuretic peptide (BNP) levels. Patients with significantly elevated procalcitonin levels were more often classified as treatment failure or unchanged status, and had an increased risk of 30-day all-cause mortality even after adjustment for established prognosticators; HR = 2.3 (95% CI, 1.3-4.2), (P = 0.005). Conclusion: Patients with acute heart failure and significantly elevated procalcitonin levels, indicating probable undiagnosed/untreated bacterial infection, had poorer in-hospital and post-discharge outcomes, despite similar severity of heart failure. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Demissei, Biniyam G.; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Demissei, Biniyam G.; Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, London, England. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Davison, Beth; Cotter, Gad] Momentum Res, Durham, NC USA. [Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Brigham & Womens Hosp, Boston, MA USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard] Univ Iowa, Carver Coll Med, Abboud Cardiovasc Res Ctr, Iowa City, IA 52242 USA. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Cleland, John/0000-0002-1471-7016 FU NovaCardia FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Alere and Singulex kindly provided assays and performed biomarker measurements. NR 32 TC 3 Z9 3 U1 0 U2 12 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD FEB 1 PY 2016 VL 204 BP 164 EP 171 DI 10.1016/j.ijcard.2015.11.141 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CZ3MM UT WOS:000367008200048 PM 26666342 ER PT J AU Bergman, AA Jaynes, HA Gonzalvo, JD Hudmon, KS Frankel, RM Kobylinski, AL Zillich, AJ AF Bergman, Alicia A. Jaynes, Heather A. Gonzalvo, Jasmine D. Hudmon, Karen Suchanek Frankel, Richard M. Kobylinski, Amanda L. Zillich, Alan J. TI Pharmaceutical Role Expansion and Developments in Pharmacist-Physician Communication SO HEALTH COMMUNICATION LA English DT Article ID MEDICAL HOME; PRIMARY-CARE; ORDER ENTRY; COLLABORATION; MANAGEMENT; COMPETENCES; AVIATION; TEAMS; FACE AB Expanded clinical pharmacist professional roles in the team-based patient-centered medical home (PCMH) primary care environment require cooperative and collaborative relationships among pharmacists and primary care physicians (PCPs), but many PCPs have not previously worked in such a direct fashion with pharmacists. Additional roles, including formulary control, add further elements of complexity to the clinical pharmacist-PCP relationship that are not well described. Our objective was to characterize the nature of clinical pharmacist-PCP interprofessional collaboration across seven federally funded hospitals and associated primary care clinics, following pharmacist placement in primary care clinics and incorporation of expanded pharmacist roles. In-depth and semistructured interviews were conducted with 25 practicing clinical pharmacists and 17 PCPs. Qualitative thematic analysis revealed three major themes: (1) the complexities of electronic communication (particularly electronic nonformulary requests) as contributing to interprofessional tensions or misunderstandings for both groups, (2) the navigation of new roles and traditional hierarchy, with pharmacists using indirect communication to prevent PCP defensiveness to recommendations, and (3) a preference for onsite colocation for enhanced communication and professional relationships. Clinical pharmacists' indirect communication practices may hold important implications for patient safety in the context of medication use, and it is important to foster effective communication skills and an environment where all team members across hierarchies can feel comfortable speaking up to reduce error when problems are suspected. Also, the lack of institutional communication about managing drug formulary issues and related electronic nonformulary request processes was apparent in this study and merits further attention for both researchers and practitioners. C1 [Bergman, Alicia A.; Frankel, Richard M.; Kobylinski, Amanda L.; Zillich, Alan J.] Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. [Jaynes, Heather A.; Gonzalvo, Jasmine D.; Hudmon, Karen Suchanek] Purdue Univ, Coll Pharm, W Lafayette, IN 47907 USA. RP Bergman, AA (reprint author), VA Greater Los Angeles Healthcare Syst, Ctr Study Healthcare Innovat Implementat & Policy, 16111 Plummer St,Bldg 25, North Hills, CA 91343 USA. EM Alicia.Bergman@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development [PI: Zillich-CDA RCD06304-1]; Department of Veterans Affairs, Veterans Health Administration Health Services Research and Development (HSR&D) Associated Health Fellowship Program (Bergman); Purdue/Lilly Foundation grant FX The project reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (PI: Zillich-CDA RCD06304-1), the Department of Veterans Affairs, Veterans Health Administration Health Services Research and Development (HSR&D) Associated Health Fellowship Program (Bergman), and partially supported by a Purdue/Lilly Foundation grant. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. NR 45 TC 0 Z9 0 U1 6 U2 35 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1041-0236 EI 1532-7027 J9 HEALTH COMMUN JI Health Commun. PD FEB 1 PY 2016 VL 31 IS 2 BP 161 EP 170 DI 10.1080/10410236.2014.940672 PG 10 WC Communication; Health Policy & Services SC Communication; Health Care Sciences & Services GA CU7WD UT WOS:000363751600003 PM 26266465 ER PT J AU Latif, R Lau, Z Cheung, P Felsenfeld, DP Davies, TF AF Latif, Rauf Lau, Zerlina Cheung, Pamela Felsenfeld, Dan P. Davies, Terry F. TI The "TSH Receptor Glo Assay" - A High-Throughput Detection System for Thyroid Stimulation SO FRONTIERS IN ENDOCRINOLOGY LA English DT Article DE TSH receptor; small molecule; screening; high-throughput; thyroid-stimulating hormone ID SMALL-MOLECULE AGONISTS; THYROTROPIN RECEPTOR; GRAVES-DISEASE; HORMONE; AUTOANTIBODIES; EXPRESSION; CLEAVAGE; ANTIBODY; BINDING AB Background: To identify novel small molecules against the TSH receptor, we developed a sensitive transcription-based luciferase high-throughput screening (HIS) system named the TSHR-Glo Assay (TSHR-Glo). Methods: This assay uses double-transfected Chinese hamster ovary cells stably expressing the human TSHR and a cAMP-response element (CRE) construct fused to an improved luciferase reporter gene. Results: The assay was highly responsive toward TSH in a dose-dependent manner with a TSH sensitivity of 10(-10)M (10 +/- 1.12 mu U/ml) and thyroid-stimulating antibodies, a hallmark of Graves' disease, could also be detected. The assay was validated against the standard indicator of HTS performance - the Z-factor (Z') - producing a score of 0.895. Using the TSHR-Glo assay, we screened 48,224 compounds from a diverse chemical library in duplicate plates at a fixed dose of 17 mu M. Twenty molecules with the greatest activity out of 62 molecules that were identified by this technique were subsequently screened against the parent luciferase stable cell line in order to eliminate false positive stimulators. Conclusion: Using this approach, we were able to identify specific agonists against the TSH receptor leading to the characterization of several TSH agonist molecules. Hence, the TSHR-Glo assay was a one-step cell-based HTS assay, which was successful in the discovery of novel small molecular agonists and for the detection of stimulating antibodies to the TSH receptor. C1 [Latif, Rauf; Davies, Terry F.] Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, New York, NY 10029 USA. [Latif, Rauf; Davies, Terry F.] James J Peters VA Med Ctr, New York, NY USA. [Lau, Zerlina; Cheung, Pamela; Felsenfeld, Dan P.] Icahn Sch Med Mt Sinai, Integrated Screening Core, Expt Therapeut Inst, New York, NY 10029 USA. RP Latif, R (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, New York, NY 10029 USA.; Latif, R (reprint author), James J Peters VA Med Ctr, New York, NY USA. EM rauf.latif@mssm.edu FU NIH [DK069713, DK052464]; David Owen Segal Fund; VA Merit Award program FX This work was supported in part by NIH grants DK069713 and DK052464, the David Owen Segal Fund, and the VA Merit Award program (to TD). NR 30 TC 1 Z9 1 U1 5 U2 8 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PD JAN 28 PY 2016 VL 7 AR 3 DI 10.3389/fendo.2016.00003 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DP4XY UT WOS:000378501800001 PM 26858688 ER PT J AU Lehavot, K Williams, EC Millard, SP Bradley, KA Simpson, TL AF Lehavot, Keren Williams, Emily C. Millard, Steven P. Bradley, Katharine A. Simpson, Tracy L. TI Association of Alcohol Misuse With Sexual Identity and Sexual Behavior in Women Veterans SO SUBSTANCE USE & MISUSE LA English DT Article DE sexual orientation; AUDIT-C; lesbian and bisexual women; Women veterans; alcohol disparities ID SERVICES-TASK-FORCE; SUBSTANCE USE; MENTAL-HEALTH; ORIENTATION DISPARITIES; DRINKING CONTEXTS; MINORITY VETERANS; BISEXUAL WOMEN; UNITED-STATES; ADULT HEALTH; YOUNG-ADULTS AB Background: Sexual minority women report greater alcohol misuse than heterosexual women in the general population, with more pronounced differences found among younger age groups. It is unknown whether these differences exist among women veterans. Objective: We evaluated differences in alcohol misuse across two dimensions of sexual orientation (identity and behavior) among women veterans, and examined whether these differences were modified by age. Methods: Women veterans were recruited via the internet to participate in an online survey. Participants provided information on their self-reported sexual identity and behavior and responded to the validated 3-item Alcohol Use Disorders Identification Test-Consumption questionnaire (AUDIT-C). Regression models were used to compare the prevalence of alcohol misuse (AUDIT-C >= 3) and severity (AUDIT-C scores) across sexual identity and behavior and to test effect modification by age. Results: Among the 702 participants (36% lesbian/bisexual), prevalence and severity of alcohol misuse varied by both sexual identity and behavior, but there were significant interactions with age. Prevalence and severity of alcohol misuse were higher among relatively younger self-identified lesbians compared to heterosexual women. Similarly, both prevalence and severity of alcohol misuse were generally higher among younger women who had any sex with women compared to those who had sex only with men. Conclusions/Importance: In this online study of women veterans, younger sexual minority women were more likely to screen positive for alcohol misuse, and they had more severe alcohol misuse, than their heterosexual counterparts. Prevention and treatment efforts focused specifically on sexual minority women veterans may be needed. C1 [Lehavot, Keren; Williams, Emily C.; Bradley, Katharine A.] VA Puget Sound, VA Hlth Serv Res & Dev, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Seattle, WA USA. [Lehavot, Keren; Millard, Steven P.; Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr MIRECC, Seattle, WA 98108 USA. [Lehavot, Keren; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lehavot, Keren; Williams, Emily C.; Bradley, Katharine A.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. [Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. RP Lehavot, K (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way,116-POC, Seattle, WA 98108 USA. EM klehavot@uw.edu FU VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC); VA Career Development Award from CSRD [CX000867]; VA Career Development Award from HSRD [CDA 12-276] FX This research was supported by a research grant to K. Lehavot and T. Simpson from the VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC). Drs. Lehavot and Williams are supported by VA Career Development Awards from CSR&D (CX000867) and HSR&D (CDA 12-276), respectively. NR 45 TC 0 Z9 0 U1 3 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1082-6084 EI 1532-2491 J9 SUBST USE MISUSE JI Subst. Use Misuse PD JAN 28 PY 2016 VL 51 IS 2 BP 216 EP 229 DI 10.3109/10826084.2015.1092988 PG 14 WC Substance Abuse; Psychiatry; Psychology SC Substance Abuse; Psychiatry; Psychology GA DE3YX UT WOS:000370567500008 PM 26800263 ER PT J AU Depp, TB McGinnis, KA Kraemer, K Akgun, KM Edelman, EJ Fiellin, DA Butt, AA Crystal, S Gordon, AJ Freiberg, M Gibert, CL Rimland, D Bryant, KJ Crothers, K AF Depp, Timothy B. McGinnis, Kathleen A. Kraemer, Kevin Akguen, Kathleen M. Edelman, E. Jennifer Fiellin, David A. Butt, Adeel A. Crystal, Stephen Gordon, Adam J. Freiberg, Matthew Gibert, Cynthia L. Rimland, David Bryant, Kendall J. Crothers, Kristina TI Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients SO AIDS LA English DT Article DE acute exacerbation; AECOPD; AIDS/HIV; chronic obstructive pulmonary disease; cigarette smoking; COPD; tobacco use; unhealthy alcohol use ID ANTIRETROVIRAL THERAPY ERA; COPD EXACERBATIONS; UNITED-STATES; LUNG-DISEASE; ALCOHOL-USE; CARE; HEALTH; VETERANS; EPIDEMIOLOGY; MORTALITY AB Objective:To determine the association between HIV infection and other risk factors for acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Design:Longitudinal, national Veterans Aging Cohort Study including 43 618 HIV-infected and 86 492 uninfected veterans.Methods:AECOPD was defined as an inpatient or outpatient COPD ICD-9 diagnosis accompanied by steroid and/or antibiotic prescription within 5 days. We calculated incidence rate ratios (IRR) and 95% confidence intervals (CI) for first AECOPD over 2 years and used Poisson regression models to adjust for risk factors.Results:Over 234099 person-years of follow-up, 1428 HIV-infected and 2104 uninfected patients had at least one AECOPD. HIV-infected patients had an increased rate of AECOPD compared with uninfected (18.8 vs. 13.3 per 1000 person-years, P<0.001). In adjusted models, AECOPD risk was greater in HIV-infected individuals overall (IRR 1.54; 95% CI 1.44-1.65), particularly in those with more severe immune suppression when stratified by CD4(+) cell count (cells/l) compared with uninfected (HIV-infected CD4(+)<200: IRR 2.30, 95% CI 2.10-2.53, HIV-infected CD4(+) 200-349: IRR 1.32, 95% CI 1.15-1.51, HIV-infected CD4(+)350: IRR 0.99, 95% CI 0.88-1.10). HIV infection also modified the association between current smoking and alcohol-related diagnoses with risk for AECOPD such that interaction terms for HIV and current smoking or HIV and alcohol-related diagnoses were each significantly associated with AECOPD.Conclusion:HIV infection, especially with lower CD4(+) cell count, is an independent risk factor for AECOPD. Enhanced susceptibility to harm from current smoking or unhealthy alcohol use in HIV-infected patients may also contribute to the greater rate of AECOPD. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved. C1 [Depp, Timothy B.] Univ S Carolina, Columbia, SC 29208 USA. [Depp, Timothy B.; McGinnis, Kathleen A.; Kraemer, Kevin; Butt, Adeel A.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kraemer, Kevin; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Akguen, Kathleen M.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Akguen, Kathleen M.; Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Sch Med, New Haven, CT USA. [Butt, Adeel A.] Hamad Healthcare Qual Inst, Doha, Qatar. [Butt, Adeel A.] Hamad Med Corp, Doha, Qatar. [Crystal, Stephen] Rutgers State Univ, New Brunswick, NJ 08903 USA. [Freiberg, Matthew] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Gibert, Cynthia L.] Washington DC VA Med Ctr, Washington, DC USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Bryant, Kendall J.] NIAAA, NIH, Bethesda, MD USA. [Crothers, Kristina] Univ Washington, Seattle, WA 98195 USA. RP Crothers, K (reprint author), Univ Washington, Harborview Med Ctr, 325 9th Ave,POB 359762, Seattle, WA 98104 USA. EM crothk@uw.edu OI Edelman, E. Jennifer/0000-0002-9375-0489; Fiellin, David/0000-0002-4006-010X; Crothers, Kristina/0000-0001-9702-0371 FU NIH/NHLBI [R01 HL090342]; NIAAA [U24-AA020794]; AHRQ [U19HS021, R18HS023258, U10 AA013566] FX NIH/NHLBI R01 HL090342, NIAAA U24-AA020794, AHRQ U19HS021, R18HS023258 and U10 AA013566. NR 69 TC 5 Z9 5 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JAN 28 PY 2016 VL 30 IS 3 BP 455 EP 463 DI 10.1097/QAD.0000000000000940 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA DC6CB UT WOS:000369306300003 PM 26765938 ER PT J AU Rouch, JD Scott, A Lei, NY Solorzano-Vargas, RS Wang, JF Hanson, EM Kobayashi, M Lewis, M Stelzner, MG Dunn, JCY Eckmann, L Martin, MG AF Rouch, Joshua D. Scott, Andrew Lei, Nan Ye Solorzano-Vargas, R. Sergio Wang, Jiafang Hanson, Elaine M. Kobayashi, Masae Lewis, Michael Stelzner, Matthias G. Dunn, James C. Y. Eckmann, Lars Martin, Martin G. TI Development of Functional Microfold (M) Cells from Intestinal Stem Cells in Primary Human Enteroids SO PLOS ONE LA English DT Article ID EPITHELIAL M-CELLS; PATCH M-CELLS; NF-KAPPA-B; MESENCHYMAL TRANSITION; TRANSEPITHELIAL TRANSPORT; MOUSE INTESTINE; PEYERS-PATCHES; IN-VITRO; DIFFERENTIATION; EXPRESSION AB Background & Aims Intestinal microfold (M) cells are specialized epithelial cells that act as gatekeepers of luminal antigens in the intestinal tract. They play a critical role in the intestinal mucosal immune response through transport of viruses, bacteria and other particles and antigens across the epithelium to immune cells within Peyer's patch regions and other mucosal sites. Recent studies in mice have demonstrated that M cells are generated from Lgr5+ intestinal stem cells (ISCs), and that infection with Salmonella enterica serovar Typhimurium increases M cell formation. However, it is not known whether and how these findings apply to primary human small intestinal epithelium propagated in an in vitro setting. Methods Human intestinal crypts were grown as monolayers with growth factors and treated with recombinant RANKL, and assessed for mRNA transcripts, immunofluorescence and uptake of microparticles and S. Typhimurium. Results Functional M cells were generated by short-term culture of freshly isolated human intestinal crypts in a dose-and time-dependent fashion. RANKL stimulation of the monolayer cultures caused dramatic induction of the M cell-specific markers, SPIB, and Glycoprotein-2 (GP2) in a process primed by canonical WNT signaling. Confocal microscopy demonstrated a pseudopod phenotype of GP2-positive M cells that preferentially take up microparticles. Furthermore, infection of the M cell-enriched cultures with the M cell-tropic enteric pathogen, S. Typhimurium, led to preferential association of the bacteria with M cells, particularly at lower inoculum sizes. Larger inocula caused rapid induction of M cells. Conclusions Human intestinal crypts containing ISCs can be cultured and differentiate into an epithelial layer with functional M cells with characteristic morphological and functional properties. This study is the first to demonstrate that M cells can be induced to form from primary human intestinal epithelium, and that S. Typhimurium preferentially infect these cells in an in vitro setting. We anticipate that this model can be used to generate large numbers of M cells for further functional studies of these key cells of intestinal immune induction and their impact on controlling enteric pathogens and the intestinal microbiome. C1 [Rouch, Joshua D.; Scott, Andrew; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Surg, Div Pediat Surg, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Lei, Nan Ye; Kobayashi, Masae; Dunn, James C. Y.] Univ Calif Los Angeles, Dept Bioengn, Henry Samueli Sch Engn, Los Angeles, CA USA. [Solorzano-Vargas, R. Sergio; Wang, Jiafang; Martin, Martin G.] Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Mattel Childrens Hosp, Los Angeles, CA 90024 USA. [Solorzano-Vargas, R. Sergio; Wang, Jiafang; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Hanson, Elaine M.; Eckmann, Lars] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Stelzner, Matthias G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Martin, Martin G.] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA. RP Martin, MG (reprint author), Univ Calif Los Angeles, Dept Pediat, Div Gastroenterol & Nutr, Mattel Childrens Hosp, Los Angeles, CA 90024 USA.; Martin, MG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Martin, MG (reprint author), Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA USA. EM mmartin@mednet.ucla.edu RI Solorano, Sergio/D-4869-2016 FU Intestinal Stem Cell Consortium - National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases [DK085535]; NIDDK [DK083762, DK083319]; California Institute for Regenerative Medicine [RT2-01985] FX This work was supported by the Intestinal Stem Cell Consortium (https://iscc.coh.org), a collaborative research project funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases (DK085535); and other grants from NIDDK (DK083762, and DK083319), and the California Institute for Regenerative Medicine (RT2-01985). NR 37 TC 3 Z9 3 U1 6 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 28 PY 2016 VL 11 IS 1 AR e0148216 DI 10.1371/journal.pone.0148216 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DC9GF UT WOS:000369528400076 PM 26820624 ER PT J AU Yu, L Morishima, C Ioannou, GN AF Yu, Lei Morishima, Chihiro Ioannou, George N. TI Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Diets; Cholesterol; Cirrhosis; Sex differences; Hepatitis C virus ID LONG-TERM TREATMENT; TOTAL-ENERGY INTAKE; DISEASE PROGRESSION; FIBROSIS PROGRESSION; CIRRHOSIS TRIAL; UNITED-STATES; GENOTYPE 1; THERAPY; INTERFERON; MODEL AB Dietary cholesterol induces hepatic inflammation and fibrosis in animals. We aimed to determine whether dietary cholesterol affects liver-related mortality in hepatitis C virus (HCV)-infected patients. We performed a retrospective cohort study using extended follow-up data from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. The study included HCV patients with advanced fibrosis and compensated cirrhosis. The analysis included 657 patients who completed two FFQ. We assessed whether cholesterol intake, measured in mg/4184 kJ (mg/1000 kcal) of energy intake, was associated with liver-related death or transplantation. In 4.7 (SD 1.6) years, the incidence of liver-related death (n 46) or transplantation (n 52) was 31.8/1000 person-years. The relationship between cholesterol intake and liver-related death or transplantation was significantly different between men and women (test for interaction, P value = 0.01). Each higher quartile of cholesterol intake was associated with an increased risk for liver-related death or transplantation in women (adjusted hazard ratio (AHR) 1.83; 95 % CI 1.12, 2.99; P-trend= 0.02), but not in men (AHR 0.96; 95 % CI 0.76, 1.22; P-trend = 0.73). Compared with women whose cholesterol intake was within the recommended guidelines (300 mg/d with a 8368 kJ (2000 kcal) diet), women who consumed more cholesterol had significantly increased risk for liver-related death or transplantation (AHR 4.04; 95 % CI 1.42, 11.5). High dietary cholesterol was associated with an increased risk for liver-related death and transplantation in HCV-infected women with advanced fibrosis or compensated cirrhosis. Future studies should assess whether reducing cholesterol intake, among women who consume an excessive amount, can decrease HCV-related mortality. C1 [Yu, Lei; Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Morishima, Chihiro] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Yu, L (reprint author), Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. EM leiy@medicine.washington.edu FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Research Enhancement Award Program, Office of Research and Development, Veterans Affairs United States FX The Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial was conducted by the HALT-C investigators and supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The data from the HALT-C Trial reported here was supplied by the NIDDK Central Repository. This manuscript does not necessarily reflect the opinions or views of the HALT-C study, the NIDDK Central Repository or the NIDDK. G. N. I. is supported by Research Enhancement Award Program, Office of Research and Development, Veterans Affairs United States. NR 38 TC 0 Z9 1 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 EI 1475-2662 J9 BRIT J NUTR JI Br. J. Nutr. PD JAN 28 PY 2016 VL 115 IS 2 BP 193 EP 201 DI 10.1017/S0007114515004158 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CZ6UJ UT WOS:000367236200001 PM 26541123 ER PT J AU Gong, B Radulovic, M Figueiredo-Pereira, ME Cardozo, C AF Gong, Bing Radulovic, Miroslav Figueiredo-Pereira, Maria E. Cardozo, Christopher TI The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury SO FRONTIERS IN MOLECULAR NEUROSCIENCE LA English DT Review DE ubiquitin-proteasome system; Alzheimer's disease; spinal cord injuries; beta-amyloid clearance; neuroregeneration ID AMYLOID PRECURSOR PROTEIN; TERMINAL HYDROLASE L1; AMYOTROPHIC-LATERAL-SCLEROSIS; PERIPHERAL NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; BETA-SECRETASE BACE1; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASE; MITOCHONDRIAL DYSFUNCTION; TRANSIENT ISCHEMIA AB The ubiquitin-proteasome system (UPS) is a crucial protein degradation system in eukaryotes. Herein, we will review advances in the understanding of the role of several proteins of the UPS in Alzheimer's disease (AD) and functional recovery after spinal cord injury (SCI). The UPS consists of many factors that include E3 ubiquitin ligases, ubiquitin hydrolases, ubiquitin and ubiquitin-like molecules, and the proteasome itself. An extensive body of work links UPS dysfunction with AD pathogenesis and progression. More recently, the UPS has been shown to have vital roles in recovery of function after SCI. The ubiquitin hydrolase (Uch-L1) has been proposed to increase cellular levels of mono-ubiquitin and hence to increase rates of protein turnover by the UPS. A low Uch-L1 level has been linked with A beta accumulation in AD and reduced neuroregeneration after SCI. One likely mechanism for these beneficial effects of Uch-L1 is reduced turnover of the PKA regulatory subunit and consequently, reduced signaling via CREB. The neuron-specific F-box protein Fbx2 ubiquitinates beta-secretase thus targeting it for proteasomal degradation and reducing generation of A beta. Both Uch-L1 and Fbx2 improve synaptic plasticity and cognitive function in mouse AD models. The role of Fbx2 after SCI has not been examined, but abolishing B-secretase reduces neuronal recovery after SCI, associated with reduced myelination. UBB(+)1, which arises through a frame-shift mutation in the ubiquitin gene that adds 19 amino acids to the C-terminus of ubiquitin, inhibits proteasomal function and is associated with increased neurofibrillary tangles in patients with AD, Pick's disease and Down's syndrome. These advances in understanding of the roles of the UPS in AD and SCI raise new questions but, also, identify attractive and exciting targets for potential, future therapeutic interventions. C1 [Gong, Bing; Radulovic, Miroslav; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Gong, Bing; Radulovic, Miroslav; Cardozo, Christopher] James J Peters Vet Affairs Med Ctr, Med, Bronx, NY USA. [Radulovic, Miroslav; Cardozo, Christopher] Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. [Figueiredo-Pereira, Maria E.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA. [Figueiredo-Pereira, Maria E.] CUNY Grad Sch & Univ Ctr, New York, NY 10036 USA. RP Cardozo, C (reprint author), Mt Sinai Sch Med, Dept Med, New York, NY USA.; Cardozo, C (reprint author), James J Peters Vet Affairs Med Ctr, Med, Bronx, NY USA.; Cardozo, C (reprint author), Natl Ctr Excellence Med Consequences Spinal Cord, Bronx, NY USA. EM christopher.cardozo@va.gov FU Alzheimer's Association [IIRG-12-242345]; Rehabilitation Research and Development Service Center for the Medical Consequences of Spinal Cord Injury [B9212C] FX The studies described here were supported in part by grant from Alzheimer's Association (IIRG-12-242345) to BC and by the Rehabilitation Research and Development Service Center for the Medical Consequences of Spinal Cord Injury (B9212C). We thank Dr. Anand and Mr. Jin for critical reading of the manuscript and preparation of the figures. NR 172 TC 7 Z9 7 U1 5 U2 16 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5099 J9 FRONT MOL NEUROSCI JI Front. Molec. Neurosci. PD JAN 26 PY 2016 VL 9 AR 4 DI 10.3389/fnmol.2015.00004 PG 16 WC Neurosciences SC Neurosciences & Neurology GA DE3UD UT WOS:000370554900002 PM 26858599 ER PT J AU Barnhart, C McClymont, K Smith, AK Au-Yeung, A Lee, SJ AF Barnhart, Caroline McClymont, Keelan Smith, Alex K. Au-Yeung, Alvin Lee, Sei J. TI "Everyone else gets ice cream here more often than I do-It burns me up" - Perspectives on Diabetes Care from Nursing Home Residents and their Doctors SO BMC GERIATRICS LA English DT Article DE Diabetes mellitus; Quality of Life; Geriatrics; Fingerstick ID OLDER PATIENTS; MELLITUS; PREVALENCE; MANAGEMENT; PEOPLE; ADULTS; GOALS AB Background: To explore the perspectives of nursing home (NH) residents with diabetes and their doctors regarding the burdens of living with diabetes and diabetes treatments. Methods: Qualitative study of nursing home residents aged 65 and older with diabetes (n = 14) and nursing home physicians (n = 9) at a Department of Veterans Affairs nursing home (known as the Community Living Center). A semi-structured interview was used to elicit nursing home residents' and physicians' perspectives on the burden of diabetes and diabetes treatments. Transcripts were analyzed using constant comparative methods. Results: The mean age of the nursing home residents was 74; Most (93 %) were male and 50 % self-identified themselves as white. The mean age of nursing home physicians was 39 and 55 % were geriatricians. Dietary restrictions, loss of independence and fingersticks/insulin were noted to be the most burdensome aspects of diabetes. Nursing home residents with a more positive outlook were generally more engaged in their care, while nursing home residents with a more pessimistic outlook were less engaged, allowing their physicians to assume complete control of their care. While physicians noted the potential negative impact of dietary restrictions, nursing home residents' comments suggest that physicians underestimate the burden of dietary restrictions. Conclusions: Veterans Affairs nursing home residents were substantially burdened by their diabetes treatments, especially dietary restrictions and fingerstick monitoring. Since there is little evidence that dietary restrictions improve outcomes, fewer dietary restrictions may be appropriate and lead to lower treatment burdens for nursing home residents with diabetes. C1 [Barnhart, Caroline; McClymont, Keelan; Smith, Alex K.; Au-Yeung, Alvin; Lee, Sei J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Barnhart, Caroline; McClymont, Keelan; Smith, Alex K.; Au-Yeung, Alvin; Lee, Sei J.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Room 220 F, San Francisco, CA 94121 USA. RP Lee, SJ (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA.; Lee, SJ (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Bldg 1,Room 220 F, San Francisco, CA 94121 USA. EM sei.lee@ucsf.edu FU National Institute on Aging at the National Institutes of Health; American Federation for Aging Research [K23AG040779]; UCSF Claude D. Pepper Older Americans Independence Center [P30AG044281] FX This work was supported by the National Institute on Aging at the National Institutes of Health and the American Federation for Aging Research through the Beeson Career Development [K23AG040779]. This work was also supported by the UCSF Claude D. Pepper Older Americans Independence Center [P30AG044281]. NR 24 TC 0 Z9 0 U1 3 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PD JAN 26 PY 2016 VL 16 AR 28 DI 10.1186/s12877-016-0199-0 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA DB5SG UT WOS:000368573300001 PM 26813788 ER PT J AU Siu, AL Bibbins-Domingo, K Grossman, DC Baumann, LC Davidson, KW Ebell, M Garcia, FAR Gillman, M Herzstein, J Kemper, AR Krist, AH Kurth, AE Owens, DK Phillips, WR Phipps, MG Pignone, MP AF Siu, Albert L. Bibbins-Domingo, Kirsten Grossman, David C. Baumann, Linda Ciofu Davidson, Karina W. Ebell, Mark Garcia, Francisco A. R. Gillman, Matthew Herzstein, Jessica Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Owens, Douglas K. Phillips, William R. Phipps, Maureen G. Pignone, Michael P. CA USPSTF TI Screening for Depression in Adults US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; PRIMARY-CARE; POSTPARTUM DEPRESSION; PERINATAL DEPRESSION; POSTNATAL DEPRESSION; QUALITY IMPROVEMENT; WOMEN; PHARMACOTHERAPY; SYMPTOMATOLOGY AB DESCRIPTION Update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for depression in adults. METHODS The USPSTF reviewed the evidence on the benefits and harms of screening for depression in adult populations, including older adults and pregnant and postpartum women; the accuracy of depression screening instruments; and the benefits and harms of depression treatment in these populations. POPULATION This recommendation applies to adults 18 years and older. RECOMMENDATION The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation) C1 [Siu, Albert L.] Mt Sinai Sch Med, New York, NY USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Baumann, Linda Ciofu] Univ Wisconsin, Madison, WI 53706 USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Ebell, Mark] Univ Georgia, Athens, GA 30602 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Gillman, Matthew] Harvard Univ, Sch Med, Boston, MA USA. [Gillman, Matthew] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] NYU, New York, NY USA. [Owens, Douglas K.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Owens, Douglas K.] Stanford Univ, Stanford, CA 94305 USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Pignone, Michael P.] Univ N Carolina, Chapel Hill, NC USA. RP Siu, AL (reprint author), Mt Sinai Sch Med, New York, NY USA.; Siu, AL (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY USA. EM albert.siu@mssm.edu OI Phillips, William/0000-0003-2802-4349 FU USPSTF FX The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF. NR 34 TC 83 Z9 84 U1 6 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 26 PY 2016 VL 315 IS 4 BP 380 EP 387 DI 10.1001/jama.2015.18392 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DB5YI UT WOS:000368589500016 PM 26813211 ER PT J AU Cadoni, S Liggi, M Falt, P Sanna, S Argiolas, M Fanari, V Gallittu, P Mura, D Porcedda, ML Smajstrla, V Erriu, M Leung, FW AF Cadoni, Sergio Liggi, Mauro Falt, Premysl Sanna, Stefano Argiolas, Mariangela Fanari, Viviana Gallittu, Paolo Mura, Donatella Porcedda, Maria L. Smajstrla, Vit Erriu, Matteo Leung, Felix W. TI Evidence to suggest adoption of water exchange deserves broader consideration: Its pain alleviating impact occurs in 90% of investigators SO WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY LA English DT Article DE Colonoscopy; Painless colonoscopy; Water immersion; Water exchange; Colonoscopy pain ID IRRITABLE-BOWEL-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; UNSEDATED COLONOSCOPY; AIDED COLONOSCOPY; AIR INSUFFLATION; PERCEPTION; DIFFICULTY; IMMERSION; ENDOSCOPY; SEDATION AB AIM: To determine variations in colonoscopy real-time insertion pain among investigators using three different insertion techniques. METHODS: From March 2013 through June 2014, 18-85-year-old diagnostic and 50-70-year-old screening patients were enrolled at each center to on-demand sedation colonoscopy with water exchange (WE), water immersion (WI) and insufflation with air or CO2 for insertion and withdrawal [air or carbon dioxide (AICD)]. Data were aggregated for analysis. Primary outcome: Variations in real-time maximum insertion pain (0 = none, 1-2 = discomfort, 10 = worst). RESULTS: One thousand and ninety-one cases analyzed: WE (n = 371); WI (n = 338); AICD (n = 382). Demographics and indications were comparable. The WE group had the lowest real-time maximum insertion pain score, mean (95% CI): WE 2.8 (2.6-3.0), WI 3.8 (3.5-4.1) and AICD 4.4 (4.1-4.7), P < 0.0005. Ninety percent of the colonoscopists were able to use water exchange to significantly decrease maximum insertion pain scores. One investigator had high insertion pain in all groups, nonetheless WE achieved the lowest real-time maximum insertion pain score. WE had the highest proportions of patients with painless unsedated colonoscopy (vs WI, P = 0.013; vs AICD, P < 0.0005); unsedated colonoscopy with only minor discomfort (vs AICD, P < 0.0005), and completion without sedation (vs AICD, P < 0.0005). CONCLUSION: Aggregate data confirm superiority of WE in lowering colonoscopy real-time maximum insertion pain and need for sedation. Ninety percent of investigators were able to use water exchange to significantly decrease maximum insertion pain scores. Our results suggest that the technique deserves consideration in a broader scale. C1 [Cadoni, Sergio; Liggi, Mauro; Gallittu, Paolo; Mura, Donatella] St Barbara Hosp, Digest Endoscopy Unit, Via San Leonardo 1, I-09016 Iglesias, Italy. [Falt, Premysl; Smajstrla, Vit] Vitkovice Hosp, Ctr Digest Dis, Ostrava 70384, Czech Republic. [Sanna, Stefano; Argiolas, Mariangela; Fanari, Viviana; Porcedda, Maria L.] NS di Bonaria Hosp, Digest Endoscopy Unit, I-09037 San Gavino Monreale, Italy. [Erriu, Matteo] Univ Cagliari, Dept Surg Sci, I-09121 Cagliari, Italy. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA 91343 USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. RP Cadoni, S (reprint author), St Barbara Hosp, Digest Endoscopy Unit, Via San Leonardo 1, I-09016 Iglesias, Italy. EM cadonisergio@gmail.com NR 40 TC 0 Z9 0 U1 0 U2 2 PU BAISHIDENG PUBLISHING GROUP INC PI PLEASANTON PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA SN 1948-5190 J9 WORLD J GASTROINTEST JI World J. Gastrointest. Endosc. PD JAN 25 PY 2016 VL 8 IS 2 BP 113 EP 121 DI 10.4253/wjge.v8.i2.113 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DD1UM UT WOS:000369707500008 PM 26839651 ER PT J AU Penney, LS Ritenbaugh, C Elder, C Schneider, J Deyo, RA DeBar, LL AF Penney, Lauren S. Ritenbaugh, Cheryl Elder, Charles Schneider, Jennifer Deyo, Richard A. DeBar, Lynn L. TI Primary care physicians, acupuncture and chiropractic clinicians, and chronic pain patients: a qualitative analysis of communication and care coordination patterns SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Article DE Chronic musculoskeletal pain; Complementary and alternative medicine; Managed care system; Interprofessional communication; Chronic care; Acupuncture; Chiropractic ID LOW-BACK-PAIN; ALTERNATIVE MEDICINE; HEALTH-CARE; COMPLEMENTARY PRACTITIONERS; RANDOMIZED-TRIAL; OLDER PATIENTS; INTEGRATION; MANIPULATION; PREVALENCE; CHALLENGE AB Background: A variety of people, with multiple perspectives, make up the system comprising chronic musculoskeletal pain (CMP) treatment. While there are frequently problems in communication and coordination of care within conventional health systems, more opportunities for communicative disruptions seem possible when providers use different explanatory models and are not within the same health management system. We sought to describe the communication system surrounding the management of chronic pain from the perspectives of allopathic providers, acupuncture and chiropractor (A/C) providers, and CMP patients. Methods: We collected qualitative data from CMP patients (n = 90) and primary care physicians (PCPs) (n = 25) in a managed care system, and community acupuncture and chiropractic care providers (n = 14) who received high levels of referrals from the system, in the context of a longitudinal study of CMP patients' experience. Results: Multiple points of divergence and communicative barriers were identified among the main stakeholders in the system. Those that were most frequently mentioned included issues surrounding the referral process (requesting, approving) and lack of consistent information flow back to providers that impairs overall management of patient care. We found that because of these problems, CMP patients were frequently tasked and sometimes overwhelmed with integrating and coordinating their own care, with little help from the system. Conclusions: Patients, PCPs, and A/C providers desire more communication; thus systems need to be created to facilitate more open communication which could positively benefit patient outcomes. C1 [Penney, Lauren S.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Ritenbaugh, Cheryl] Univ Arizona, Dept Family & Community Med, 1450 N Cherry Ave, Tucson, AZ 85719 USA. [Elder, Charles; Schneider, Jennifer; DeBar, Lynn L.] Kaiser Permanente Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. [Deyo, Richard A.] Oregon Hlth & Sci Univ, Dept Family Med, Mail Code FM,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. RP DeBar, LL (reprint author), Kaiser Permanente Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM lynn.debar@kpchr.org FU National Institutes of Health, National Center for Complementary and Alternative Medicine Grant [R01 AT005896] FX The authors gratefully acknowledge that our study received funding support from the National Institutes of Health, National Center for Complementary and Alternative Medicine Grant (R01 AT005896). NR 44 TC 0 Z9 0 U1 2 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6882 J9 BMC COMPLEM ALTERN M JI BMC Complement. Altern. Med. PD JAN 25 PY 2016 VL 16 AR 30 DI 10.1186/s12906-016-1005-4 PG 11 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DB9ZO UT WOS:000368876600002 PM 26810302 ER PT J AU Chen, HI Jgamadze, D Serruya, MD Cullen, DK Wolf, JA Smith, DH AF Chen, H. Isaac Jgamadze, Dennis Serruya, Mijail D. Cullen, D. Kacy Wolf, John A. Smith, Douglas H. TI Neural Substrate Expansion for the Restoration of Brain Function SO FRONTIERS IN SYSTEMS NEUROSCIENCE LA English DT Review DE axons; brain repair; neural interfaces; neuronal networks; stem cells; tissue engineering ID PLURIPOTENT STEM-CELLS; LONG-TERM SURVIVAL; CORTICAL-NEURONS; MOTOR CORTEX; IN-VIVO; SUBVENTRICULAR ZONE; AXON REGENERATION; CEREBRAL-CORTEX; ADULT BRAIN; 3D CULTURE AB Restoring neurological and cognitive function in individuals who have suffered brain damage is one of the principal objectives of modern translational neuroscience. Electrical stimulation approaches, such as deep-brain stimulation, have achieved the most clinical success, but they ultimately may be limited by the computational capacity of the residual cerebral circuitry. An alternative strategy is brain substrate expansion, in which the computational capacity of the brain is augmented through the addition of new processing units and the reconstitution of network connectivity. This latter approach has been explored to some degree using both biological and electronic means but thus far has not demonstrated the ability to reestablish the function of large-scale neuronal networks. In this review, we contend that fulfilling the potential of brain substrate expansion will require a significant shift from current methods that emphasize direct manipulations of the brain (e.g., injections of cellular suspensions and the implantation of multi-electrode arrays) to the generation of more sophisticated neural tissues and neural-electric hybrids in vitro that are subsequently transplanted into the brain. Drawing from neural tissue engineering, stem cell biology, and neural interface technologies, this strategy makes greater use of the manifold techniques available in the laboratory to create biocompatible constructs that recapitulate brain architecture and thus are more easily recognized and utilized by brain networks. C1 [Chen, H. Isaac; Jgamadze, Dennis; Cullen, D. Kacy; Wolf, John A.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA. [Chen, H. Isaac; Cullen, D. Kacy; Wolf, John A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Serruya, Mijail D.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA. RP Chen, HI (reprint author), Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA.; Chen, HI (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM isaac.chen@uphs.upenn.edu FU RRD VA [IK2 RX001479] NR 107 TC 0 Z9 0 U1 8 U2 21 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1662-5137 J9 FRONT SYST NEUROSCI JI Front. Syst. Neurosci. PD JAN 25 PY 2016 VL 10 AR 1 DI 10.3389/fnsys.2016.00001 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DB6HG UT WOS:000368614700001 PM 26834579 ER PT J AU Graf, SA Gopal, AK AF Graf, Solomon A. Gopal, Ajay K. TI Idelalisib for the treatment of non-Hodgkin lymphoma SO EXPERT OPINION ON PHARMACOTHERAPY LA English DT Review DE Idelalisib; B-cell; lymphoma; indolent ID CHRONIC LYMPHOCYTIC-LEUKEMIA; MANTLE-CELL LYMPHOMA; FOLLICULAR LYMPHOMA; INDOLENT LYMPHOMA; PHASE-II; PHOSPHATIDYLINOSITOL 3-KINASE-DELTA; PHOSPHOINOSITIDE 3-KINASE; PROTEASOME INHIBITOR; COMBINATION THERAPY; UNTREATED PATIENTS AB IntroductionB-cell Non-Hodgkin lymphomas (B-NHLs) include a number of disease subtypes, each defined by the tempo of disease progression and the identity of the cancerous cell. Idelalisib is a potent, selective inhibitor of the delta isoform of phosphatidylinositol-3-kinase (PI3K), a lipid kinase whose over-activity in B-NHL drives disease progression. Idelalisib has demonstrated activity in indolent B-NHL (iB-NHL) and is approved for use as monotherapy in patients with follicular lymphoma and small lymphocytic lymphoma and in combination with rituximab in patients with chronic lymphocytic leukemia.Areas CoveredHerein we review the development and pharmacology of idelalisib, its safety and efficacy in clinical studies of iB-NHL, and its potential for inclusion in future applications in iB-NHL and in combination with other therapies.Expert OpinionIdelalisib adds to the growing arsenal of iB-NHL pharmacotherapeutics and to the progression of the field toward precision agents with good efficacy and reduced toxicities. Nevertheless, idelalisib carries important risks that require careful patient counseling and monitoring. The appropriate sequencing of idelalisib with other proven treatment options in addition to its potential for combination with established or novel drugs will be borne out in ongoing and planned investigations. C1 [Graf, Solomon A.; Gopal, Ajay K.] Univ Washington, Dept Med, Seattle, WA USA. [Graf, Solomon A.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Graf, Solomon A.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Gopal, AK (reprint author), Univ Washington, Med, 825 Eastlake Ave E, Seattle, WA USA. EM agopal@u.washington.edu FU NCI [P01CA44991, K24CA184039]; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center [P30 CA015704]; NIH [5T32HL007093]; Seattle Genetics Inc; Gilead Sciences; Janssen Pharmaceuticals; Spectrum Pharmaceuticals FX This work was supported by research funding from NCI P01CA44991, K24CA184039, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant P30 CA015704, and gifts from Frank and Betty Vandermeer, Don and Debbie Hunkins, and the Mary Aileen Wright Memorial Fund. S.A.G. received support from NIH 5T32HL007093. A Gopal has received consulting fees from Seattle Genetics Inc, Gilead Sciences, Janssen Pharmaceuticals and Spectrum Pharmaceuticals within the last 12 months. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed NR 69 TC 5 Z9 5 U1 1 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1465-6566 EI 1744-7666 J9 EXPERT OPIN PHARMACO JI Expert Opin. Pharmacother. PD JAN 22 PY 2016 VL 17 IS 2 BP 265 EP 274 DI 10.1517/14656566.2016.1135130 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DD8HT UT WOS:000370167700001 PM 26818003 ER PT J AU Novgorodov, SA Riley, CL Keffler, JA Yu, J Kindy, MS Macklin, WB Lombard, DB Gudz, TI AF Novgorodov, Sergei A. Riley, Christopher L. Keffler, Jarryd A. Yu, Jin Kindy, Mark S. Macklin, Wendy B. Lombard, David B. Gudz, Tatyana I. TI SIRT3 Deacetylates Ceramide Synthases IMPLICATIONS FOR MITOCHONDRIAL DYSFUNCTION AND BRAIN INJURY SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FOCAL CEREBRAL-ISCHEMIA; MANGANESE SUPEROXIDE-DISMUTASE; PERMEABILITY TRANSITION PORE; RADIATION-INDUCED APOPTOSIS; OXYGEN SPECIES GENERATION; REACTIVE OXYGEN; CYCLOPHILIN-D; CELL-DEATH; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID BIOSYNTHESIS AB Experimental evidence supports the role of mitochondrial ceramide accumulation as a cause of mitochondrial dysfunction and brain injury after stroke. Herein, we report that SIRT3 regulates mitochondrial ceramide biosynthesis via deacetylation of ceramide synthase (CerS) 1, 2, and 6. Reciprocal immunoprecipitation experiments revealed that CerS1, CerS2, and CerS6, but not CerS4, are associated with SIRT3 in cerebral mitochondria. Furthermore, CerS1, -2, and -6 are hyperacetylated in the mitochondria of SIRT3-null mice, and SIRT3 directly deacetylates the ceramide synthases in aNAD(+)-dependent manner that increases enzyme activity. Investigation of the SIRT3 role in mitochondrial response to brain ischemia/reperfusion (IR) showed that SIRT3-mediated deacetylation of ceramide synthases increased enzyme activity and ceramide accumulation after IR. Functional studies demonstrated that absence of SIRT3 rescued the IR-induced blockade of the electron transport chain at the level of complex III, attenuated mitochondrial outer membrane permeabilization, and decreased reactive oxygen species generation and protein carbonyls in mitochondria. Importantly, Sirt3 gene ablation reduced the brain injury after IR. These data support the hypothesis that IR triggers SIRT3-dependent deacetylation of ceramide synthases and the elevation of ceramide, which could inhibit complex III, leading to increased reactive oxygen species generation and brain injury. The results of these studies highlight a novel mechanism of SIRT3 involvement in modulating mitochondrial ceramide biosynthesis and suggest an important role of SIRT3 in mitochondrial dysfunction and brain injury after experimental stroke. C1 [Riley, Christopher L.; Kindy, Mark S.; Gudz, Tatyana I.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Novgorodov, Sergei A.; Keffler, Jarryd A.; Yu, Jin; Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci Med, Charleston, SC 29425 USA. [Macklin, Wendy B.] Univ Colorado, Dept Cell & Dev Biol, Aurora, CO 80045 USA. [Lombard, David B.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA. [Lombard, David B.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA. RP Gudz, TI (reprint author), 114 Doughty St, Charleston, SC 29425 USA. EM gudz@musc.edu FU National Institutes of Health [R01NS083544, R01GM101171, P30 GM103339]; Veterans Affairs Merit Award [I01BX001104] FX This work was supported in part by National Institutes of Health Grants R01NS083544 (to T. I. G.), R01GM101171 (to D. B. L.), and P30 GM103339 (to Lipidomics Core Facility. Medical University of South Carolina) and Veterans Affairs Merit Award I01BX001104 (to T. I. G.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 81 TC 5 Z9 5 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 22 PY 2016 VL 291 IS 4 BP 1957 EP 1973 DI 10.1074/jbc.M115.668228 PG 17 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DB6JI UT WOS:000368620700033 PM 26620563 ER PT J AU Toro, ML Eke, C Pearlman, J AF Toro, Maria L. Eke, Chika Pearlman, Jonathan TI The impact of the World Health Organization 8-steps in wheelchair service provision in wheelchair users in a less resourced setting: a cohort study in Indonesia SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Wheelchairs; Wheelchair service provision; Quality of life; Participation; Wheelchair skills; Less resourced settings ID SPINAL-CORD-INJURY; ASSISTIVE TECHNOLOGY USE; LOW-COST WHEELCHAIR; QUALITY-OF-LIFE; DEVELOPING-COUNTRIES; ADVERSE CONSEQUENCES; SKILLS; REHABILITATION; DISABILITIES; CONVENTION AB Background: For people who have a mobility impairment, access to an appropriate wheelchair is an important step towards social inclusion and participation. The World Health Organization Guidelines for the Provision of Manual Wheelchairs in Less Resourced Settings emphasize the eight critical steps for appropriate wheelchair services, which include: referral, assessment, prescription, funding and ordering, product preparation, fitting and adjusting, user training, and follow-up and maintenance/repairs. The purpose of this study was to investigate how the provision of wheelchairs according to the World Health Organization's service provision process by United Cerebral Palsy Wheels for Humanity in Indonesia affects wheelchair recipients compared to wait-listed controls. Methods: This study used a convenience sample (N = 344) of Children, Children with proxies, Adults, and Adults with proxies who were on a waiting list to receive a wheelchair as well as those who received one. Interviews were conducted at baseline and a 6 month follow-up to collect the following data: Demographics and wheelchair use questions, the World Health Organization Quality of Life-BREF, Functional Mobility Assessment, Craig Handicap Assessment Recording Technique Short Form. The Wheelchair Assessment Checklist and Wheelchair Skills Test Questionnaire were administered at follow up only. Results: 167 participants were on the waiting list and 142 received a wheelchair. Physical health domain in the World Health Organization Quality of Life-BREF improved significantly for women who received a wheelchair (p = 0.044) and environmental health improved significantly for women and men who received a wheelchair as compared to those on the waiting list (p < 0.017). Satisfaction with the mobility device improved significantly for Adults with proxies and Children with proxies as compared to the waiting list (p < 0.022). Only 11 % of Adults who received a wheelchair reported being able to perform a "wheelie". The condition of Roughrider wheelchairs was significantly better than the condition of kids wheelchairs for Children with proxies as measured by the Wheelchair Assessment Checklist (p = 0.019). Conclusions: Wheelchair provision according to World Health Organization's 8-Steps in a less-resourced setting has a range of positive outcomes including increased satisfaction with the mobility device and better quality of life. Wheelchair provision service could be improved by providing more hours of wheelchair skills training. There is a need for outcome measures that are validated across cultures and languages. C1 [Toro, Maria L.; Pearlman, Jonathan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Toro, Maria L.; Pearlman, Jonathan] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Toro, Maria L.] Escuela Ingn Antioquia, Programa Ingn Biomed, Envigado, Antioquia, Colombia. [Toro, Maria L.] Univ CES, Envigado, Antioquia, Colombia. [Eke, Chika] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. RP Pearlman, J (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA.; Pearlman, J (reprint author), Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. EM Jlp46@pitt.edu FU United States Agency for International Development grant [GPO-A-00-04-00021-00 SPANS 001]; National Science Foundation; ASPIRE Grant [1262670]; VA Center Grant [B6789C] FX Funding provided by United States Agency for International Development grant to World Learning GPO-A-00-04-00021-00 SPANS 001, the National Science Foundation, ASPIRE Grant #1262670 and VA Center Grant #B6789C. The contents of this paper do not represent the views of the Department of Veterans Affairs or the United States Government. The authors would like to thank the personnel of UCP Wheels for Humanity and UCP Roda Untuk Kemanusiaan specially Heny Prabaningrum. The authors will like to thank Dr. Andi Saptono for his contribution during the on-site training week in Indonesia. NR 72 TC 1 Z9 1 U1 3 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD JAN 22 PY 2016 VL 16 AR 26 DI 10.1186/s12913-016-1268-y PG 12 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DB5SL UT WOS:000368573800001 PM 26801984 ER PT J AU Moe, EL Borsch, C Garg, B Dobek, JC Doggett, R Graff, JN Beer, TM Winters-Stone, KM AF Moe, Esther L. Borsch, Carolyn Garg, Bharti Dobek, Jessica C. Doggett, Rumen Graff, Julie Nicole Beer, Tomasz M. Winters-Stone, Kerri M. TI Falls and frailty in prostate cancer survivors on androgen deprivation therapy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Cancer Survivorship Symposium on Advancing Care and Research CY JAN 15-16, 2016 CL San Francisco, CA C1 Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Oregon State Univ, Corvallis, OR 97331 USA. OHSU Knight Canc Inst, Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 20 PY 2016 VL 34 IS 3 SU S MA 134 PG 1 WC Oncology SC Oncology GA DO9MA UT WOS:000378109500128 ER PT J AU Sudore, R Le, GM McMahan, R Feuz, M Katen, M Barnes, DE AF Sudore, Rebecca Le, Gem M. McMahan, Ryan Feuz, Mariko Katen, Mary Barnes, Deborah E. TI The advance care planning PREPARE study among older Veterans with serious and chronic illness: study protocol for a randomized controlled trial (vol 16, 570, 2015) SO TRIALS LA English DT Correction C1 [Sudore, Rebecca; Le, Gem M.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca; McMahan, Ryan; Feuz, Mariko; Katen, Mary] San Francisco Vet Adm Med Ctr, San Francisco, CA 94121 USA. [Le, Gem M.] Univ Calif San Francisco, San Francisco Gen Hosp, Ctr Vulnerable Populat, Div Gen Internal Med, San Francisco, CA 94110 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Sudore, R (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, 3333 Calif St Suite 380, San Francisco, CA 94143 USA. EM rebecca.sudore@ucsf.edu NR 1 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1745-6215 J9 TRIALS JI Trials PD JAN 20 PY 2016 VL 17 AR 42 DI 10.1186/s13063-016-1182-y PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DB3HA UT WOS:000368399700006 PM 26791078 ER PT J AU Singh, JA Schleck, C Harmsen, WS Lewallen, DG AF Singh, Jasvinder A. Schleck, Cathy Harmsen, W. Scott Lewallen, David G. TI Validation of the Mayo Hip Score: construct validity, reliability and responsiveness to change SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE Validation; Mayo hip score; Mayo hip questionnaire; Total hip arthroplasty; Total hip replacement; Validity; Responsiveness; Minimal clinically meaningful difference; MCID; Revision risk; Reliability ID REPLACEMENT CLINICAL-TRIALS; KNEE ARTHROPLASTY; OUTCOME MEASURES; HARRIS HIP; PREDICTORS; COMORBIDITY AB Background: Previous studies have provided the initial evidence for construct validity and test-retest reliability of the Mayo Hip Score. Instruments used for Total Hip Arthroplasty (THA) outcomes assessment should be valid, reliable and responsive to change. Our main objective was to examine the responsiveness to change, association with subsequent revision and the construct validity of the Mayo hip score. Methods: Discriminant ability was assessed by calculating effect size (ES), standardized response mean (SRM) and Guyatt's responsiveness index (GRI). Minimal clinically important difference (MCII) and moderate improvement thresholds were calculated. We assessed construct validity by examining association of scores with preoperative patient characteristics and correlation with Harris hip score, and assessed association of scores with the risk of subsequent revision. Results: Five thousand three hundred seven provided baseline data; of those with baseline data, 2,278 and 2,089 (39 %) provided 2- and 5-year data, respectively. Large ES, SRM and GRI ranging 2.66-2.78, 2.42-2.61 and 1.67-1.88 were noted for Mayo hip scores with THA, respectively. The MCII and moderate improvement thresholds were 22.4-22.7 and 39.4-40.5 respectively. Hazard ratios of revision surgery were higher with lower final score or less improvement in Mayo hip score at 2-years and borderline significant/non-significant at 5-years, respectively: (1) score <= 55 with hazard ratios of 2.24 (95 % CI, 1.45, 3.46; p = 0.0003) and 1.70 (95 % CI, 1.00, 2.92; p = 0.05) of implant revision subsequently, compared to 72-80 points; (2) no improvement or worsening score with hazard ratios 3.94 (95 % CI, 1.50, 10.30; p = 0.005) and 2.72 (95 % CI, 0.85,8.70; p = 0.09), compared to improvement >50-points. Mayo hip score had significant positive correlation with younger age, male gender, lower BMI, lower ASA class and lower Deyo-Charlson index (p <= 0.003 for each) and with Harris hip scores (p < 0.001). Conclusions: Mayo Hip Score is valid, sensitive to change and associated with future risk of revision surgery in patients with primary THA. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Dept Orthoped Surg, Sch Med, Rochester, MN USA. [Schleck, Cathy; Harmsen, W. Scott] Mayo Clin, Sch Med, Dept Biostat, Rochester, MN USA. [Singh, Jasvinder A.; Lewallen, David G.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Mayo Clin, Dept Orthoped Surg, Sch Med, Rochester, MN USA.; Singh, JA (reprint author), Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Department of Orthopedic Surgery, Mayo Clinic School of Medicine, Rochester, MN, USA FX We thank Youlonda Lochler for her assistance in data abstraction from the Mayo Clinic Total Joint Registry for this project. This material is the result of work supported by the Department of Orthopedic Surgery, Mayo Clinic School of Medicine, Rochester, MN, USA. JAS is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. NR 26 TC 0 Z9 0 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD JAN 19 PY 2016 VL 17 AR 39 DI 10.1186/s12891-016-0868-3 PG 7 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA DB4IC UT WOS:000368475700001 PM 26785640 ER PT J AU Emanuel, EJ Ubel, PA Kessler, JB Meyer, G Muller, RW Navathe, AS Patel, P Pearl, R Rosenthal, MB Sacks, L Sen, AP Sherman, P Volpp, KG AF Emanuel, Ezekiel J. Ubel, Peter A. Kessler, Judd B. Meyer, Gregg Muller, Ralph W. Navathe, Amol S. Patel, Pankaj Pearl, Robert Rosenthal, Meredith B. Sacks, Lee Sen, Aditi P. Sherman, Paul Volpp, Kevin G. TI Using Behavioral Economics to Design Physician Incentives That Deliver High-Value Care SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PAY-FOR-PERFORMANCE; METAANALYSIS; DEFAULTS; QUALITY AB Behavioral economics provides insights about the development of effective incentives for physicians to deliver high-value care. It suggests that the structure and delivery of incentives can shape behavior, as can thoughtful design of the decision-making environment. This article discusses several principles of behavioral economics, including inertia, loss aversion, choice overload, and relative social ranking. Whereas these principles have been applied to motivate personal health decisions, retirement planning, and savings behavior, they have been largely ignored in the design of physician incentive programs. Applying these principles to physician incentives can improve their effectiveness through better alignment with performance goals. Anecdotal examples of successful incentive programs that apply behavioral economics principles are provided, even as the authors recognize that its application to the design of physician incentives is largely untested, and many outstanding questions exist. Application and rigorous evaluation of infrastructure changes and incentives are needed to design payment systems that incentivize high-quality, cost-conscious care. C1 [Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Leonard Davis Inst, CHIBE,Univ Penn Hlth Syst, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA. [Ubel, Peter A.] Duke Univ, Sanford Sch Publ Policy, Durham, NC 27708 USA. [Meyer, Gregg] Partners Healthcare Syst, Boston, MA 02199 USA. Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Sacks, Lee] Advocate Phys Partners, Chicago, IL USA. [Pearl, Robert] Permanente Med Grp Inc, Oakland, CA 94612 USA. Grp Hlth, Seattle, WA USA. RP Emanuel, EJ (reprint author), Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 122 Coll Hall, Philadelphia, PA 19104 USA. EM vp-global@upenn.edu FU Commonwealth Fund FX In part by The Commonwealth Fund. The funding source reviewed the manuscript but did not make any fundamental alterations. NR 38 TC 18 Z9 18 U1 3 U2 14 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 19 PY 2016 VL 164 IS 2 BP 114 EP + DI 10.7326/M15-1330 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DB0CI UT WOS:000368175800015 PM 26595370 ER PT J AU Shekelle, P AF Shekelle, Paul TI In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Shekelle, Paul] Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA. RP Shekelle, P (reprint author), Greater Los Angeles VA Hlth Care Syst, Los Angeles, CA 90095 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 19 PY 2016 VL 164 IS 2 BP JC2 EP JC2 DI 10.7326/ACPJC-2015-163-12-002 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DB0CI UT WOS:000368175800001 PM 26784492 ER PT J AU Watson, CT Roussos, P Garg, P Ho, DJ Azam, N Katsel, PL Haroutunian, V Sharp, AJ AF Watson, Corey T. Roussos, Panos Garg, Paras Ho, Daniel J. Azam, Nidha Katsel, Pavel L. Haroutunian, Vahram Sharp, Andrew J. TI Genome-wide12 DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer's disease SO GENOME MEDICINE LA English DT Article ID GENOME-WIDE ASSOCIATION; HUMAN PREFRONTAL CORTEX; GENE-EXPRESSION; HUMAN BRAIN; NEUROFIBRILLARY TANGLES; STEM-CELLS; RISK; LOCI; AGE; VARIANTS AB Background: Alzheimer's disease affects similar to 13 % of people in the United States 65 years and older, making it the most common neurodegenerative disorder. Recent work has identified roles for environmental, genetic, and epigenetic factors in Alzheimer's disease risk. Methods: We performed a genome-wide screen of DNA methylation using the Illumina Infinium HumanMethylation450 platform on bulk tissue samples from the superior temporal gyrus of patients with Alzheimer's disease and non-demented controls. We paired a sliding window approach with multivariate linear regression to characterize Alzheimer's disease-associated differentially methylated regions (DMRs). Results: We identified 479 DMRs exhibiting a strong bias for hypermethylated changes, a subset of which were independently associated with aging. DMR intervals overlapped 475 RefSeq genes enriched for gene ontology categories with relevant roles in neuron function and development, as well as cellular metabolism, and included genes reported in Alzheimer's disease genome-wide and epigenome-wide association studies. DMRs were enriched for brain-specific histone signatures and for binding motifs of transcription factors with roles in the brain and Alzheimer's disease pathology. Notably, hypermethylated DMRs preferentially overlapped poised promoter regions, marked by H3K27me3 and H3K4me3, previously shown to co-localize with aging-ssociated hypermethylation. Finally, the integration of DMR-associated single nucleotide polymorphisms with Alzheimer's disease genome-wide association study risk loci and brain expression quantitative trait loci highlights multiple potential DMRs of interest for further functional analysis. Conclusion: We have characterized changes in DNA methylation in the superior temporal gyrus of patients with Alzheimer's disease, highlighting novel loci that facilitate better characterization of pathways and mechanisms underlying Alzheimer's disease pathogenesis, and improve our understanding of epigenetic signatures that may contribute to the development of disease. C1 [Watson, Corey T.; Roussos, Panos; Garg, Paras; Ho, Daniel J.; Azam, Nidha; Sharp, Andrew J.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Roussos, Panos; Katsel, Pavel L.; Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos; Haroutunian, Vahram] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. [Katsel, Pavel L.; Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. RP Sharp, AJ (reprint author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. EM andrew.sharp@mssm.edu RI Roussos, Panos/J-7090-2013 OI Roussos, Panos/0000-0002-4640-6239 FU Alzheimer's Association [2012ALZNIRG69983, NIRG-340998]; NIH [DA033660, HG006696, HD073731, MH097018, R01AG050986, AG05138, HHSN271291300031]; March of Dimes [6-FY13-92]; Brain Behavior Research Foundation [20540]; Veterans Affairs Merit grant [BX002395] FX This work was supported by a New Investigator Research Grant from the Alzheimer's Association (2012ALZNIRG69983) to AJS; NIH grants DA033660, HG006696, HD073731, and MH097018 to AJS; research grant 6-FY13-92 from the March of Dimes to AJS; NIH grant R01AG050986 to PR; a Brain Behavior Research Foundation grant 20540 to PR; an Alzheimer's Association grant NIRG-340998 to PR; a Veterans Affairs Merit grant BX002395 to PR; and NIH grants AG05138 and HHSN271291300031 to VH. The authors thank Dr. Zachary Kaminsky for useful discussion regarding the estimation of neuronal/glial cell proportions from bulk tissue methylation profiles. NR 105 TC 5 Z9 5 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PD JAN 19 PY 2016 VL 8 AR 5 DI 10.1186/s13073-015-0258-8 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA DB0YP UT WOS:000368234900001 PM 26787419 ER PT J AU Dehmer, GJ Jennings, J Madden, RA Malenka, DJ Masoudi, FA McKay, CR Ness, DL Rao, SV Resnic, FS Ring, ME Rumsfeld, JS Shelton, ME Simanowith, MC Slattery, LE Weintraub, WS Lovett, A Normand, SL AF Dehmer, Gregory J. Jennings, Jonathan Madden, Ruth A. Malenka, David J. Masoudi, Frederick A. McKay, Charles R. Ness, Debra L. Rao, Sunil V. Resnic, Frederic S. Ring, Michael E. Rumsfeld, John S. Shelton, Marc E. Simanowith, Michael C. Slattery, Lara E. Weintraub, William S. Lovett, Ann Normand, Sharon-Lise TI The National Cardiovascular Data Registry Voluntary Public Reporting Program An Interim Report From the NCDR Public Reporting Advisory Group SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE health care reform; outcomes; quality ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; MORTALITY RISK PREDICTION; QUALITY MEASURES INFORM; SURGERY REPORT CARDS; HOSPITAL PERFORMANCE; ADMINISTRATIVE DATA; CLINICAL-OUTCOMES; IMPACT; CONSEQUENCES AB Public reporting of health care data continues to proliferate as consumers and other stakeholders seek information on the quality and outcomes of care. Medicare's Hospital Compare website, the U.S. News & World Report hospital rankings, and several state-level programs are well known. Many rely heavily on administrative data as a surrogate to reflect clinical reality. Clinical data are traditionally more difficult and costly to collect, but more accurately reflect patients' clinical status, thus enhancing the validity of quality metrics. We describe the public reporting effort being launched by the American College of Cardiology and partnering professional organizations using clinical data from the National Cardiovascular Data Registry (NCDR) programs. This hospital-level voluntary effort will initially report process of care measures from the percutaneous coronary intervention (CathPCI) and implantable cardioverter-defibrillator (ICD) registries of the NCDR. Over time, additional process, outcomes, and composite performance metrics will be reported. (C) 2016 by the American College of Cardiology Foundation. C1 [Dehmer, Gregory J.] Texas A&M Hlth Sci Ctr, Baylor Scott & White Hlth, Div Cardiol, Temple, TX USA. [Jennings, Jonathan] Hosp Corp Amer, Nashville, TN USA. [Madden, Ruth A.] Cleveland Clin, Dept Cardiovasc Med, Cardiac Electrophysiol & Pacing Sect, Cleveland, OH 44106 USA. [Malenka, David J.] Dartmouth Hitchcock Med Ctr, Div Cardiol, Lebanon, NH 03766 USA. [Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Denver, CO 80202 USA. [McKay, Charles R.] Harbor UCLA Med Ctr, Dept Med Cardiol, Torrance, CA 90509 USA. [Ness, Debra L.] Natl Partnership Women & Families, Washington, DC USA. [Rao, Sunil V.] Duke Clin Res Inst, Durham, NC USA. [Resnic, Frederic S.] Tufts Univ, Sch Med, Lahey Hosp, Cardiol Div, Burlington, MA USA. [Resnic, Frederic S.] Tufts Univ, Sch Med, Med Ctr, Burlington, MA USA. [Ring, Michael E.] Providence Sacred Heart Med Ctr, Spokane, WA USA. [Rumsfeld, John S.] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA. [Shelton, Marc E.] Prairie Cardiovasc, Springfield, IL USA. [Simanowith, Michael C.; Slattery, Lara E.] Amer Coll Cardiol, Washington, DC USA. [Weintraub, William S.] Ctr Heart & Vasc Hlth, Christiana Care Hlth Serv, Newark, DE USA. [Lovett, Ann; Normand, Sharon-Lise] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA. [Lovett, Ann; Normand, Sharon-Lise] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Dehmer, GJ (reprint author), Baylor Scott & White Hlth, Div Cardiol, MS 33-ST156,2401 South 31st St, Temple, TX 76508 USA. EM gdehmer@sw.org FU NIGMS NIH HHS [U54 GM104941] NR 52 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 19 PY 2016 VL 67 IS 2 BP 205 EP 215 DI 10.1016/j.jacc.2015.11.001 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DA9FO UT WOS:000368114400013 PM 26603176 ER PT J AU Ledreux, A Boger, HA Hinson, VK Cantwell, K Granholm, AC AF Ledreux, Aurelie Boger, Heather A. Hinson, Vanessa K. Cantwell, Kelsey Granholm, Ann-Charlotte TI BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson's disease SO BRAIN RESEARCH LA English DT Article DE Parkinson's disease; Dopamine; Norepinephrine; Monoamine oxidase inhibitors; Cognition; Neuroprotection ID DOPA-INDUCED DYSKINESIA; NEUROTROPHIC FACTOR; MONOAMINE-OXIDASE; LOCUS-CERULEUS; NEURODEGENERATIVE DISORDERS; SIGNALING PATHWAY; SUBSTANTIA-NIGRA; SH-SY5Y CELLS; MOTOR; SELEGILINE AB The anti-Parkinsonian drug rasagiline is a selective, irreversible inhibitor of monoamine oxidase and is used in the treatment of Parkinson's disease (PD). Its postulated neuroprotective effects may be attributed to MAO inhibition, or to its propargylamine moiety. The major metabolite of rasagiline, aminoindan, has shown promising neuroprotective properties in vitro but there is a paucity of studies investigating in vivo effects of this compound. Therefore, we examined neuroprotective effects of rasagiline and its metabolite aminoindan in a double lesion model of PD. Male Fisher 344 rats received i.p. injections of the noradrenergic neurotoxin DSP-4 and intra-striatal stereotaxic microinjections of the dopamine neurotoxin 6-OHDA. Saline, rasagiline or aminoindan (3 mg/kg/day s.c.) were delivered via Alzet minipumps for 4 weeks. Rats were then tested for spontaneous locomotion and a novel object recognition task. Following behavioral testing, brain tissue was processed for ELISA measurements of growth factors and immunohistochemistry. Double-lesioned rats treated with rasagiline or aminoindan had reduced behavioral deficits, both in motor and cognitive tasks compared to saline-treated double-lesioned rats. BDNF levels were significantly increased in the hippocampus and striatum of the rasagiline- and aminoindan-lesioned groups compared to the saline-treated lesioned group. Double-lesioned rats treated with rasagiline or aminoindan exhibited a sparing in the mitochondrial marker Hsp60, suggesting mitochondrial involvement in neuroprotection. Tyrosine hydroxylase (TH) immunohistochemistry revealed a sparing of TH-immunoreactive terminals in double-lesioned rats treated with rasagiline or aminoindan in the striatum, hippocampus, and substantia nigra. These data provide evidence of neuroprotection by aminoindan and rasagiline via their ability to enhance BDNF levels. Published by Elsevier B.V. C1 [Ledreux, Aurelie; Boger, Heather A.; Granholm, Ann-Charlotte] Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave, Charleston, SC 29425 USA. [Ledreux, Aurelie; Boger, Heather A.; Granholm, Ann-Charlotte] Med Univ S Carolina, Ctr Aging, Charleston, SC 29425 USA. [Hinson, Vanessa K.] Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. [Hinson, Vanessa K.] Ralph H Johnson VA Med Ctr, Neurol Serv, Charleston, SC USA. [Cantwell, Kelsey] Coll Charleston, Psychol, Charleston, SC 29401 USA. [Cantwell, Kelsey] Coll Charleston, Program Neurosci, Charleston, SC 29401 USA. RP Granholm, AC (reprint author), Med Univ S Carolina, Dept Neurosci, 173 Ashley Ave, Charleston, SC 29425 USA. EM granholm@musc.edu FU TEVA Pharmaceuticals FX This work was made possible by a Grant from TEVA Pharmaceuticals, and a Medical Accuracy Review was conducted by Teva. The authors would like to thank Mr. Alfred Moore, Ms. Claudia Umphlet, and Ms. Laura Columbo for expert technical support for this project. NR 56 TC 0 Z9 1 U1 2 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD JAN 15 PY 2016 VL 1631 BP 34 EP 45 DI 10.1016/j.brainres.2015.11.028 PG 12 WC Neurosciences SC Neurosciences & Neurology GA DD7IK UT WOS:000370096700004 PM 26607251 ER PT J AU Swenson, ER AF Swenson, Erik R. TI Pharmacology of acute mountain sickness: old drugs and newer thinking SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Review DE hypoxia; acid-base; acute mountain sickness; carbonic anhydrase; acetazolamide; aquaporin; radical oxygen species; corticosteroid; dexamethasone; hypoxia inducible factor; sympathetic nervous system; cytokine ID BLOOD-BRAIN-BARRIER; ALTITUDE PULMONARY-EDEMA; SOLUBLE ADENYLYL-CYCLASE; CARBONIC-ANHYDRASE INHIBITION; GLUCOCORTICOID-RECEPTOR; CEREBRAL EDEMA; IN-VITRO; INTRACEREBRAL HEMORRHAGE; AQUAPORIN-4 EXPRESSION; NEUROEPITHELIAL BODIES AB Pharmacotherapy in acute mountain sickness (AMS) for the past half century has largely rested on the use of carbonic anhydrase (CA) inhibitors, such as acetazolamide, and corticosteroids, such as dexamethasone. The benefits of CA inhibitors are thought to arise from their known ventilatory stimulation and resultant greater arterial oxygenation from inhibition of renal CA and generation of a mild metabolic acidosis. The benefits of corticosteroids include their broad-based anti-inflammatory and anti-edemagenic effects. What has emerged from more recent work is the strong likelihood that drugs in both classes act on other pathways and signaling beyond their classical actions to prevent and treat AMS. For the CA inhibitors, these include reduction in aquaporinmediated transmembrane water transport, anti-oxidant actions, vasodilation, and anti-inflammatory effects. In the case of corticosteroids, these include protection against increases in vascular endothelial and blood-brain barrier permeability, suppression of inflammatory cytokines and reactive oxygen species production, and sympatholysis. The loci of action of both classes of drug include the brain, but may also involve the lung as revealed by benefits that arise with selective administration to the lungs by inhalation. Greater understanding of their pluripotent actions and sites of action in AMS may help guide development of better drugs with more selective action and fewer side effects. C1 [Swenson, Erik R.] Univ Washington, Div Pulm & Crit Care Med, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Swenson, ER (reprint author), Univ Washington, Div Pulm & Crit Care Med, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. EM eswenson@u.washington.edu NR 159 TC 8 Z9 8 U1 2 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN 15 PY 2016 VL 120 IS 2 BP 204 EP 215 DI 10.1152/japplphysiol.00443.2015 PG 12 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA DC2ML UT WOS:000369050700013 PM 26294748 ER PT J AU Korthuis, PT McGinnis, KA Kraemer, KL Gordon, AJ Skanderson, M Justice, AC Crystal, S Goetz, MB Gibert, CL Rimland, D Fiellin, LE Gaither, JR Wang, K Asch, SM McInnes, DK Ohl, ME Bryant, K Tate, JP Duggal, M Fiellin, DA AF Korthuis, Philip Todd McGinnis, Kathleen A. Kraemer, Kevin L. Gordon, Adam J. Skanderson, Melissa Justice, Amy C. Crystal, Stephen Goetz, Matthew Bidwell Gibert, Cynthia L. Rimland, David Fiellin, Lynn E. Gaither, Julie R. Wang, Karen Asch, Steven M. McInnes, Donald Keith Ohl, Michael E. Bryant, Kendall Tate, Janet P. Duggal, Mona Fiellin, David A. CA Veterans Aging Cohort Study TI Quality of HIV Care and Mortality Rates in HIV-Infected Patients SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE alcohol; quality of health care; HIV; health care; opioid-related disorders ID HUMAN-IMMUNODEFICIENCY-VIRUS; VETERANS AGING COHORT; OF-CARE; PERFORMANCE-MEASURES; ANTIRETROVIRAL THERAPY; ALCOHOL-CONSUMPTION; UNHEALTHY ALCOHOL; UNITED-STATES; SYSTEM; TRANSFORMATION AB Background. The Patient Protection and Affordable Care Act encourages healthcare systems to track quality-of-care measures; little is known about their impact on mortality rates. The objective of this study was to assess associations between HIV quality of care and mortality rates. Methods. A longitudinal survival analysis of the Veterans Aging Cohort Study included 3038 human immunodeficiency virus (HIV)-infected patients enrolled between June 2002 and July 2008. The independent variable was receipt of >= 80% of 9 HIV quality indicators (QIs) abstracted from medical records in the 12 months after enrollment. Overall mortality rates through 2014 were assessed from the Veterans Health Administration, Medicare, and Social Security National Death Index records. We assessed associations between receiving >= 80% of HIV QIs and mortality rates using Kaplan-Meier survival analysis and adjusted Cox proportional hazards models. Results were stratified by unhealthy alcohol and illicit drug use. Results. The majority of participants were male (97.5%) and black (66.8%), with a mean (standard deviation) age of 49.0 (8.8) years. Overall, 25.9% reported past-year unhealthy alcohol use and 28.4% reported past-year illicit drug use. During 24 805 person-years of follow-up (mean [standard deviation], 8.2 [3.3] years), those who received >= 80% of QIs experienced lower age-adjusted mortality rates (adjusted hazard ratio, 0.75; 95% confidence interval,.65-.86). Adjustment for disease severity attenuated the association. Conclusions. Receipt of >= 80% of select HIV QIs is associated with improved survival in a sample of predominantly male, black, HIV-infected patients but was insufficient to overcome adjustment for disease severity. Interventions to ensure high-quality care and address underlying chronic illness may improve survival in HIV-infected patients. C1 [Korthuis, Philip Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15260 USA. [McGinnis, Kathleen A.; Kraemer, Kevin L.; Skanderson, Melissa] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Gordon, Adam J.] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Div Gen Internal Med, 930 Scaife Hall, Pittsburgh, PA 15260 USA. [Justice, Amy C.; Fiellin, Lynn E.; Wang, Karen; Tate, Janet P.; Fiellin, David A.] Yale Univ, Sch Med, Ctr Interdisciplinary Res AIDS, Div Gen Internal Med, New Haven, CT USA. [Gaither, Julie R.] Yale Univ, Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA. [Justice, Amy C.; Tate, Janet P.] Vet Aging Cohort Study Coordinating Ctr, West Haven, CT USA. [Duggal, Mona] VA Connecticut Care Syst, West Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08903 USA. [Goetz, Matthew Bidwell] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst & David Geffen, Los Angeles, CA 90024 USA. [Asch, Steven M.] VA Greater Palo Alto Healthcare Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Stanford, CA 94305 USA. [Gibert, Cynthia L.] VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ, Med Ctr, Washington, DC 20037 USA. [Rimland, David] VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA 30322 USA. [McInnes, Donald Keith] Boston Univ, Boston, MA 02215 USA. [Ohl, Michael E.] Univ Iowa, Carver Coll Med, Iowa City, IA USA. [Bryant, Kendall] NIAAA, HIV AIDS Res, Rockville, MD 20852 USA. [Duggal, Mona] Postgrad Inst Med Educ & Res, Chandigarh, India. RP Korthuis, PT (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code L-475, Portland, OR 97239 USA. EM korthuis@ohsu.edu OI Fiellin, David/0000-0002-4006-010X; Justice, Amy/0000-0003-0139-5502 FU National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA) [U24-AA020794, NIAAA U01-AA020790, NIAAA R01-AA022886]; NIH, National Institute on Drug Abuse [K23 DA019809] FX This work was supported by the National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA; grants U24-AA020794, NIAAA U01-AA020790, and NIAAA R01-AA022886) and the NIH, National Institute on Drug Abuse (grant K23 DA019809). NR 38 TC 5 Z9 5 U1 3 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2016 VL 62 IS 2 BP 233 EP 239 DI 10.1093/cid/civ762 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DB6JW UT WOS:000368622300022 PM 26338783 ER PT J AU Mandal, CC Das, F Ganapathy, S Harris, SE Choudhury, GG Ghosh-Choudhury, N AF Mandal, Chandi C. Das, Falguni Ganapathy, Suthakar Harris, Stephen E. Choudhury, Goutam Ghosh Ghosh-Choudhury, Nandini TI Bone Morphogenetic Protein-2 ( BMP-2) Activates NFATc1 Transcription Factor via an Autoregulatory Loop Involving Smad/Akt/Ca2+ Signaling SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID KAPPA-B LIGAND; GLYCOGEN-SYNTHASE KINASE-3; EFFECTOR T-CELLS; OSTEOBLAST DIFFERENTIATION; OSTEOCLAST DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR ACTIVATOR; NF-ATC; GENE-TRANSCRIPTION; EXPRESSION AB Background: Mutations in NFATc1 and BMP-2 genes result in bone abnormalities in mice. Results: BMP-2 activates intracellular Ca2+ release, thus activating calcineurin phosphatase to induce NFATc1 expression involving canonical Smad and noncanonical PI 3-kinase in osteoblasts. Conclusion: BMP-2-stimulated Ca-2 -calcineurin-NFATc1 axis potentiates osteoblast differentiation. Significance: NFATc1 autoregulates its expression in response to BMP-2 in osteoblasts. C1 [Choudhury, Goutam Ghosh; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Vet Affairs Res, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Mandal, Chandi C.; Ganapathy, Suthakar; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Das, Falguni; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Harris, Stephen E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Periodont, San Antonio, TX 78229 USA. RP Ghosh-Choudhury, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. EM choudhury@uthscsa.edu FU Veterans Affairs Merit Review grants; National Institutes of Health [RO1 AR52425, RO1 DK50190]; Cancer Prevention Research Institute of Texas fellowship; Veterans Affairs Senior Research Career Scientist Award FX This work was supported in part by Veterans Affairs Merit Review grants and National Institutes of Health Grant RO1 AR52425 (to N.G.-C.)and National Institutes of Health Grant RO1 DK50190 and Veterans Affairs Merit Review grants (to G.G.C.). The authors do not have any conflict of interests. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Recipient of a Cancer Prevention Research Institute of Texas fellowship. Present address: Dept. of Biochemistry, School of Life Sciences, Central University of Rajasthan, Ajmer 305801, India.; Recipient of a Veterans Affairs Senior Research Career Scientist Award. NR 49 TC 2 Z9 2 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 15 PY 2016 VL 291 IS 3 BP 1148 EP 1161 DI 10.1074/jbc.M115.668939 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DA8PR UT WOS:000368068300011 PM 26472929 ER PT J AU Watts, LT Long, JA Boggs, RC Manga, H Huang, SL Shen, Q Duong, TQ AF Watts, Lora Talley Long, Justin Alexander Boggs, Robert Cole Manga, Hemanth Huang, Shiliang Shen, Qiang Duong, Timothy Q. TI Delayed Methylene Blue Improves Lesion Volume, Multi-Parametric Quantitative Magnetic Resonance Imaging Measurements, and Behavioral Outcome after Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE behavioral outcomes; CCI; methylene blue; mitochondria; MRI; TBI ID DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURIES; WHITE-MATTER INJURY; CYCLOSPORINE-A; OXIDATIVE STRESS; IN-VIVO; DAMAGE; NEUROPROTECTION; RAT; ISCHEMIA AB Traumatic brain injury (TBI) remains a primary cause of death and disability in both civilian and military populations worldwide. There is a critical need for the development of neuroprotective agents that can circumvent damage and provide functional recovery. We previously showed that methylene blue (MB), a U.S. Food and Drug Administration-grandfathered drug with energy-enhancing and antioxidant properties, given 1 and 3h post-TBI, had neuroprotective effects in rats. This study aimed to further investigate the neuroprotection of delayed MB treatment (24h postinjury) post-TBI as measured by lesion volume and functional outcomes. Comparisons were made with vehicle and acute MB treatment. Multi-modal magnetic resonance imaging and behavioral studies were performed at 1 and 3h and 2, 7, and 14 days after an impact to the primary forelimb somatosensory cortex. We found that delaying MB treatment 24h postinjury still minimized lesion volume and functional deficits, compared to vehicle-treated animals. The data further support the potential for MB as a neuroprotective treatment, especially when medical teatment is not readily available. MB has an excellent safety profile and is clinically approved for other indications. MB clinical trials on TBI can thus be readily explored. C1 [Watts, Lora Talley; Long, Justin Alexander; Boggs, Robert Cole; Manga, Hemanth; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Div Res, San Antonio, TX USA. RP Watts, LT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wattsl@uthscsa.edu FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01 NS45879]; Clinical Translational Science Awards (CTSA) [TL1, KL2, 8UL1TR000149, TL1TR001119, TR001118]; Mike Hogg Fund FX This work was supported, in part, by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01 NS45879; to T.Q.D.), a TL1 grant (to J.A.L.) and KL2 (to L.T.W.) through the Clinical Translational Science Awards (CTSA; parent grant 8UL1TR000149, TL1TR001119, and TR001118), and the Mike Hogg Fund (to L.T.W.). NR 56 TC 3 Z9 3 U1 0 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD JAN 15 PY 2016 VL 33 IS 2 BP 194 EP 202 DI 10.1089/neu.2015.3904 PG 9 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA DA7PH UT WOS:000367995800005 ER PT J AU Black, AC Cooney, NL Justice, AC Fiellin, LE Pietrzak, RH Lazar, CM Rosen, MI AF Black, Anne C. Cooney, Ned L. Justice, Amy C. Fiellin, Lynn E. Pietrzak, Robert H. Lazar, Christina M. Rosen, Marc I. TI Momentary assessment of PTSD symptoms and sexual risk behavior in male OEF/OIF/OND Veterans SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE PTSD; Veterans; Sexual risk; HIV; Substance use; EMA ID POSTTRAUMATIC-STRESS-DISORDER; RESIDENTIAL-TREATMENT; HIV-INFECTION; PREVALENCE; ALCOHOL; COMBAT AB Background: Post-traumatic stress disorder (PTSD) in Veterans is associated with increased sexual risk behaviors, but the nature of this association is not well understood. Typical PTSD measurement deriving a summary estimate of symptom severity over a period of time precludes inferences about symptom variability, and whether momentary changes in symptom severity predict risk behavior. Methods: We assessed the feasibility of measuring daily PTSD symptoms, substance use, and high-risk sexual behavior in Veterans using ecological momentary assessment (EMA). Feasibility indicators were survey completion, PTSD symptom variability, and variability in rates of substance use and sexual risk behavior. Nine male Veterans completed web-based questionnaires by cell phone three times per day for 28 days. Results: Median within-day survey completion rates maintained near 90%, and PTSD symptoms showed high within-person variability, ranging up to 59 points on the 80-point scale. Six Veterans reported alcohol or substance use, and substance users reported use of more than one drug. Eight Veterans reported 1 to 28 high-risk sexual events. Heightened PTSD-related negative affect and externalizing behaviors preceded high-risk sexual events. Greater PTSD symptom instability was associated with having multiple sexual partners in the 28-day period. Limitations: These results are preliminary, given this small sample size, and multiple comparisons, and should be verified with larger Veteran samples. Conclusions: Results support the feasibility and utility of using of EMA to better understand the relationship between PTSD symptoms and sexual risk behavior in Veterans. Specific antecedent-risk behavior patterns provide promise for focused clinical interventions. Published by Elsevier B.V. C1 [Black, Anne C.; Cooney, Ned L.; Justice, Amy C.; Fiellin, Lynn E.; Pietrzak, Robert H.; Lazar, Christina M.; Rosen, Marc I.] Yale Univ, Sch Med, New Haven, CT 06519 USA. [Justice, Amy C.] Yale Univ, Sch Publ Hlth, New Haven, CT 06519 USA. [Black, Anne C.; Cooney, Ned L.; Justice, Amy C.; Pietrzak, Robert H.; Lazar, Christina M.; Rosen, Marc I.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. [Pietrzak, Robert H.] US Dept Vet Affairs, Natl Ctr PTSD, White River Jct, VT USA. RP Black, AC (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave 116A-4, West Haven, CT 06516 USA. EM anne.black@yale.edu; ned.cooney@va.gov; amy.justice2@va.gov; lynn.fiellin@yale.edu; robert.pietrzak@yale.edu; christina.lazar@yale.edu; marc.rosen@yale.edu OI Justice, Amy/0000-0003-0139-5502 FU VA VISN-1 Pain Research, Informatics, Multi-morbidities, and Education (PRIME) Center; LIPS [96-008]; National Institute on Drug Abuse (NIDA); [R21 DA039038] FX This study was funded by the VA VISN-1 Pain Research, Informatics, Multi-morbidities, and Education (PRIME) Center; LIPS #96-008 and National Institute on Drug Abuse (NIDA); R21 DA039038 (ACB). NR 24 TC 0 Z9 0 U1 3 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD JAN 15 PY 2016 VL 190 BP 424 EP 428 DI 10.1016/j.jad.2015.10.039 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CY5QT UT WOS:000366463000062 PM 26551400 ER PT J AU Bruno, N ter Maaten, JM Ovchinnikova, ES Vegter, EL Valente, MAE van der Meer, P de Boer, RA van der Harst, P Schmitter, D Metra, M O'Connor, CM Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JG Givertz, MM Bloomfield, DM Dittrich, HC Pinto, YM van Veldhuisen, DJ Hillege, HL Berezikov, E Voors, AA AF Bruno, Noemi ter Maaten, Jozine M. Ovchinnikova, Ekaterina S. Vegter, Eline L. Valente, Mattia A. E. van der Meer, Peter de Boer, Rudolf A. van der Harst, Pim Schmitter, Daniela Metra, Marco O'Connor, Christopher M. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. Pinto, Yigal M. van Veldhuisen, Dirk J. Hillege, Hans L. Berezikov, Eugene Voors, Adriaan A. TI MicroRNAs relate to early worsening of renal function in patients with acute heart failure SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article DE Circulating microRNA; Acute heart failure; Worsening renal function ID ISCHEMIA-REPERFUSION INJURY; ACUTE KIDNEY INJURY; EXPRESSION; DISEASE; BIOMARKERS; METAANALYSIS; PLAYERS; HFREF; HFPEF AB Background: Deregulation of microRNAs (miRNAs) may be involved in the pathogenesis of heart failure (HF) and renal disease. Our aim is to describe miRNA levels related to early worsening renal function in acute HF patients. Method and results: We studied the association between 12 circulating miRNAs and Worsening Renal Function (WRF; defined as an increase in the serum creatinine level of 0.3 mg per deciliter or more from admission to day 3), absolute change in creatinine and Neutrophil Gelatinase Associated Lipocalin (NGAL) from admission to day 3 in 98 patients hospitalized for acute HF. At baseline, circulating levels of all miRNAs were lower in patients with WRF, with statistically significant decreased levels of miR-199a-3p, miR-423-3p, and miR-let-7i-5p (p-value < 0.05). The increase in creatinine during the first 3 days of hospitalization was significantly associated with lower levels of miR-199a-3p, miR-27a-3p, miR-652-3p, miR-423-5p, and miR-let-7i-5p, while the increase in NGAL was significantly associated with lower levels of miR-18a-5p, miR-106a-5p, miR-223-3p, miR-199a-3p and miR-423-3p. MiR-199a-3p was the strongest predictor of WRF, with an Odds Ratio of 1.48 (1.061-2.065; p-value = 0.021) and a C-index of 0.701. Conclusions: Our results show that the levels of circulating miRNAs at hospital admission for acute HF were consistently lower in patients who developed worsening of renal function. MiR-199a-3p was the best predictor of WRF in these patients. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Bruno, Noemi; ter Maaten, Jozine M.; Vegter, Eline L.; Valente, Mattia A. E.; van der Meer, Peter; de Boer, Rudolf A.; van der Harst, Pim; van Veldhuisen, Dirk J.; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Ovchinnikova, Ekaterina S.; Berezikov, Eugene] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands. [Schmitter, Daniela] Momentum Res Inc, Allschwil, Switzerland. [Metra, Marco] Univ Brescia, Dept Cardiol, Brescia, Italy. [O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Cleland, John G.] Univ London Imperial Coll Sci Technol & Med, Harefield Hosp, Natl Heart & Lung Inst, London, England. [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Pinto, Yigal M.] Univ Amsterdam, Amsterdam, Netherlands. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Berezikov, Eugene/0000-0002-1145-2884; Cleland, John/0000-0002-1471-7016 FU Dutch Heart Foundation: Approaching Heart Failure By Translational Research Of RNA Mechanisms (ARENA); NovaCardia FX This study was supported by a Grant from the Dutch Heart Foundation: Approaching Heart Failure By Translational Research Of RNA Mechanisms (ARENA). The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. NR 33 TC 4 Z9 5 U1 1 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD JAN 15 PY 2016 VL 203 BP 564 EP 569 DI 10.1016/j.ijcard.2015.10.217 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA CZ3MC UT WOS:000367007200145 PM 26569364 ER PT J AU Hazlett, EA AF Hazlett, Erin A. TI Neural Substrates of Emotion-Processing Abnormalities in Borderline Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; HIPPOCAMPAL VOLUME; METAANALYSIS; AMYGDALA C1 [Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Hazlett, Erin A.] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Vet Integrated Serv Network 3, Bronx, NY 10468 USA. RP Hazlett, EA (reprint author), James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr, 130 West Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM erin.hazlett@mssm.edu NR 10 TC 0 Z9 0 U1 3 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD JAN 15 PY 2016 VL 79 IS 2 BP 74 EP 75 DI 10.1016/j.biopsych.2015.10.008 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA CY7GF UT WOS:000366575900001 PM 26674587 ER PT J AU Edelman, EJ Hansen, NB Cutter, CJ Danton, C Fiellin, LE O'Connor, PG Williams, EC Maisto, SA Bryant, KJ Fiellin, DA AF Edelman, E. Jennifer Hansen, Nathan B. Cutter, Christopher J. Danton, Cheryl Fiellin, Lynn E. O'Connor, Patrick G. Williams, Emily C. Maisto, Stephen A. Bryant, Kendall J. Fiellin, David A. TI Implementation of integrated stepped care for unhealthy alcohol use in HIV clinics SO ADDICTION SCIENCE & CLINICAL PRACTICE LA English DT Article DE HIV; Alcohol-related disorders; Qualitative methods; Diffusion of innovation ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE-ABUSE TREATMENT; QUALITATIVE CONTENT-ANALYSIS; CENTERED MEDICAL HOME; BRIEF INTERVENTION; ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; USE DISORDERS; EMERGENCY-DEPARTMENT; HEPATITIS-C AB Background: Effective counseling and pharmacotherapy for unhealthy alcohol use are rarely provided in HIV treatment settings to patients. Our goal was to describe factors influencing implementation of a stepped care model to address unhealthy alcohol use in HIV clinics from the perspectives of social workers, psychologists and addiction psychiatrists. Methods: We conducted two focus groups with Social Workers (n = 4), Psychologists (n = 2), and Addiction Psychiatrists (n = 4) involved in an ongoing randomized controlled trial evaluating the effectiveness of integrated stepped care for unhealthy alcohol use in HIV-infected patients at five Veterans Health Administration (VA) HIV clinics. Data collection and analyses were guided by the Consolidated Framework for Implementation Research (CFIR) domains, with a focus on the three domains which we considered to be most relevant: intervention characteristics (i.e. motivational interviewing, pharmacotherapy), the inner setting (i.e. HIV clinics), and characteristics of individuals (i.e. the providers). A multidisciplinary team used directed content analysis to identify major themes. Results: From the providers' perspective, the major implementation themes that emerged by CFIR domain included: (1) Intervention characteristics: providers valued tools and processes for facilitating patient motivation for treatment of unhealthy alcohol use given their perceived lack of motivation, but expressed a desire for greater flexibility; (2) Inner setting: treating unhealthy alcohol use in HIV clinics was perceived by providers to be consistent with VA priorities; and (3) Characteristics of individuals: there was high self-efficacy to conduct the intervention, an expressed need for more consistent utilization to maintain skills, and consideration of alternative models for delivering the components of the intervention. Conclusions: Use of the CFIR framework reveals that implementation of integrated stepped care for unhealthy alcohol use in HIV clinics is facilitated by tools to help providers enhance patient motivation or address unhealthy alcohol use among patients perceived to be unmotivated. Implementation may be facilitated by its consistency with organizational values and existing models of care and attention to optimizing provider self-efficacy and roles (i.e. approaches to treatment integration). C1 [Edelman, E. Jennifer; Cutter, Christopher J.; Danton, Cheryl; Fiellin, Lynn E.; O'Connor, Patrick G.; Fiellin, David A.] Yale Univ, Sch Med, ESH A, 367 Cedar St, New Haven, CT 06510 USA. [Edelman, E. Jennifer; Hansen, Nathan B.; Fiellin, Lynn E.; Fiellin, David A.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, 135 Coll St, New Haven, CT 06510 USA. [Hansen, Nathan B.] Univ Georgia, Coll Publ Hlth, 131 Wright Hall,Hlth Sci Campus, Athens, GA 30602 USA. [Williams, Emily C.] VA Puget Sound Hlth Care Syst, Ctr Innovat Veteran Ctr & Value Driven Care, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. [Williams, Emily C.] Univ Washington, Dept Hlth Serv, Magnuson Hlth Sci Ctr, 1959 NE Pacific St,Room H-664, Seattle, WA 98195 USA. [Maisto, Stephen A.] Syracuse Univ, 430 Huntington Hall, Syracuse, NY 13244 USA. [Bryant, Kendall J.] NIAAA, HIV AIDS Program, 5635 Fishers Lane, Bethesda, MD 20892 USA. RP Edelman, EJ (reprint author), Yale Univ, Sch Med, ESH A, 367 Cedar St, New Haven, CT 06510 USA. EM ejennifer.edelman@yale.edu RI Hansen, Nathan/F-2074-2016 FU NIAAA NIH HHS [K05 AA016928, 1U01AA020795, 2K05 AA16928, U01 AA020795]; NIDA NIH HHS [K12 DA033312, K12DA033312-02]; NIMH NIH HHS [R25 MH080916, R25 MH080916-01A2] NR 78 TC 3 Z9 3 U1 6 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1940-0640 J9 ADDICT SCI CLIN PRAC JI Addict. Sci. Clin. Pract. PD JAN 13 PY 2016 VL 11 AR 1 DI 10.1186/s13722-015-0048-z PG 14 WC Substance Abuse SC Substance Abuse GA DP0AC UT WOS:000378148900001 PM 26763048 ER PT J AU Meabon, JS Huber, BR Cross, DJ Richards, TL Minoshima, S Pagulayan, KF Li, G Meeker, KD Kraemer, BC Petrie, EC Raskind, MA Peskind, ER Cook, DG AF Meabon, James S. Huber, Bertrand R. Cross, Donna J. Richards, Todd L. Minoshima, Satoshi Pagulayan, Kathleen F. Li, Ge Meeker, Kole D. Kraemer, Brian C. Petrie, Eric C. Raskind, Murray A. Peskind, Elaine R. Cook, David G. TI Repetitive blast exposure in mice and combat veterans causes persistent cerebellar dysfunction SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID TRAUMATIC BRAIN-INJURY; AFGHANISTAN WAR VETERANS; CENTRAL-NERVOUS-SYSTEM; VS. BLUNT FORCES; HEAD-INJURY; CEREBROSPINAL-FLUID; INDUCED NEUROTRAUMA; MILITARY PERSONNEL; ALZHEIMERS-DISEASE; GLUCOSE-METABOLISM AB m Blast exposure can cause mild traumatic brain injury (TBI) in mice and other mammals. However, there are important gaps in our understanding of the neuropathology underlying repetitive blast exposure in animal models compared to the neuroimaging abnormalities observed in blast-exposed veterans. Moreover, how an increase in the number of blast exposures affects neuroimaging endpoints in blast-exposed humans is not well understood. We asked whether there is a dose-response relationship between the number of blast-related mild TBIs and uptake of F-18-fluorodeoxyglucose (FDG), a commonly used indicator of neuronal activity, in the brains of blast-exposed veterans with mild TBI. We found that the number of blast exposures correlated with FDG uptake in the cerebellum of veterans. In mice, blast exposure produced microlesions in the blood-brain barrier (BBB) predominantly in the ventral cerebellum. Purkinje cells associated with these BBB microlesions displayed plasma membrane disruptions and aberrant expression of phosphorylated tau protein. Purkinje cell loss was most pronounced in the ventral cerebellar lobules, suggesting that early-stage breakdown of BBB integrity may be an important factor driving long-term brain changes. Blast exposure caused reactive gliosis in mouse cerebellum, particularly in the deep cerebellar nuclei. Diffusion tensor imaging tractography of the cerebellum of blast-exposed veterans revealed that mean diffusivity correlated negatively with the number of blast-related mild TBIs. Together, these results argue that the cerebellum is vulnerable to repetitive mild TBI in both mice and humans. C1 [Meabon, James S.; Pagulayan, Kathleen F.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] VA Puget Sound Hlth Care Syst VA Puget Sound, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Meabon, James S.; Pagulayan, Kathleen F.; Li, Ge; Petrie, Eric C.; Raskind, Murray A.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Huber, Bertrand R.] Boston Univ, Sch Med, VA Jama Plain, Dept Neurol, Jamaica Plain, MA 02130 USA. [Cross, Donna J.; Richards, Todd L.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Minoshima, Satoshi] Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA. [Li, Ge; Meeker, Kole D.; Kraemer, Brian C.; Cook, David G.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Kraemer, Brian C.; Cook, David G.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Cook, David G.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Cook, DG (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA.; Cook, DG (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA.; Cook, DG (reprint author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. EM dgcook@u.washington.edu FU Department of Veterans Affairs Office of Research and Development Medical Research Service; VA Rehabilitation Research & Development Service; University of Washington Friends of Alzheimer's Research; University of Washington Royalty Research Fund; Northwest Network Mental Illness Research, Education and Clinical Center; Office of Academic Affiliations Advanced Fellowship Program Mental Illness Research and Treatment, Department of Veterans Affairs; VA Clinical Science R&D Career Development Award Program [CX00516] FX This work was supported by the Department of Veterans Affairs Office of Research and Development Medical Research Service (D.G.C. and B.C.K.); VA Rehabilitation Research & Development Service (E.R.P.); University of Washington Friends of Alzheimer's Research (D.G.C. and E.R.P.); University of Washington Royalty Research Fund (D.G.C.); Northwest Network Mental Illness Research, Education and Clinical Center (J.S.M., B.R.H., K.F.P., E.C.P., M.A.R., and E.R.P.); Office of Academic Affiliations Advanced Fellowship Program Mental Illness Research and Treatment, Department of Veterans Affairs (B.R.H.); NIH T32 AG000258 (J.S.M.); and VA Clinical Science R&D Career Development Award Program # CX00516 (K.F.P.). Author contributions: J.S.M. and B.R.H. conducted blast procedures, biochemistry experiments, and microscopy. K.D.M. conducted biochemistry experiments. J.S.M., B.R.H., D.J.C., T.L.R., S.M., G.L., E.C.P., M.A.R., E.R.P., and D.G.C. contributed to study design. J.S.M., D.J.C., E.R.P., G.L., E.R.P., M.A.R., and D.G.C. performed data analysis and data interpretation. J.S.M., D.J.C., T.L.R., K.F.P., G.L., B.C.K., E.C.P., M.A.R., E.R.P., and D.G.C. drafted the manuscript and/or edited it critically for important intellectual content. NR 100 TC 3 Z9 3 U1 5 U2 12 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD JAN 13 PY 2016 VL 8 IS 321 DI 10.1126/scitranslmed.aaa9585 PG 15 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA DB4VD UT WOS:000368510800004 ER PT J AU Dawes, AJ Maggard-Gibbons, M Maher, AR Booth, MJ Miake-Lye, I Beroes, JM Shekelle, PG AF Dawes, Aaron J. Maggard-Gibbons, Melinda Maher, Alicia R. Booth, Marika J. Miake-Lye, Isomi Beroes, Jessica M. Shekelle, Paul G. TI Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery A Meta-analysis SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID COMORBIDITY SURVEY REPLICATION; GASTRIC BYPASS-SURGERY; BINGE-EATING DISORDER; WEIGHT-LOSS; DEPRESSIVE SYMPTOMS; SYSTEMATIC REVIEWS; CONTROLLED-TRIAL; PREVALENCE; ASSOCIATION; CANDIDATES AB IMPORTANCE Bariatric surgery is associated with sustained weight loss and improved physical health status for severely obese individuals. Mental health conditions may be common among patients seeking bariatric surgery; however, the prevalence of these conditions and whether they are associated with postoperative outcomes remains unknown. OBJECTIVE To determine the prevalence of mental health conditions among bariatric surgery candidates and recipients, to evaluate the association between preoperative mental health conditions and health outcomes following bariatric surgery, and to evaluate the association between surgery and the clinical course of mental health conditions. DATA SOURCES We searched PubMed. MEDLINE on OVID, and PsycINFO for studies published between January 1988 and November 2015. Study quality was assessed using an adapted tool for risk of bias; quality of evidence was rated based on GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria. FINDINGS We identified 68 publications meeting inclusion criteria: 59 reporting the prevalence of preoperative mental health conditions (65 363 patients) and 27 reporting associations between preoperative mental health conditions and postoperative outcomes (50182 patients). Among patients seeking and undergoing bariatric surgery, the most common mental health conditions, based on random-effects estimates of prevalence, were depression (19% [95% CI, 14%-25%]) and binge eating disorder (17% [95% CI, 13%-21%]). There was conflicting evidence regarding the association between preoperative mental health conditions and postoperative weight loss. Neither depression nor binge eating disorder was consistently associated with differences in weight outcomes. Bariatric surgery was, however, consistently associated with postoperative decreases in the prevalence of depression (7 studies; 8%-74% decrease) and the severity of depressive symptoms (6 studies; 40%-70% decrease). CONCLUSIONS AND RELEVANCE Mental health conditions are common among bariatric surgery patients in particular, depression and binge eating disorder. There is inconsistent evidence regarding the association between preoperative mental health conditions and postoperative weight loss. Moderate-quality evidence supports an association between bariatric surgery and lower rates of depression postoperatively. C1 [Dawes, Aaron J.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Dawes, Aaron J.; Maggard-Gibbons, Melinda; Miake-Lye, Isomi; Beroes, Jessica M.; Shekelle, Paul G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dawes, Aaron J.] Univ Calif Los Angeles, Vet Affairs RobertWood Johnson Clin Scholars Prog, Los Angeles, CA 90095 USA. [Dawes, Aaron J.; Miake-Lye, Isomi] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA. [Maggard-Gibbons, Melinda; Maher, Alicia R.; Booth, Marika J.; Shekelle, Paul G.] RAND Corp, Southern Calif Evidence Based Practice Ctr, Santa Monica, CA USA. [Maher, Alicia R.] Akasha Ctr Integrat Med, Santa Monica, CA USA. RP Dawes, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Ronald Reagan UCLA Med Ctr, 757Westwood Plaza,B711, Los Angeles, CA 90095 USA. EM adawes@mednet.ucla.edu OI Dawes, Aaron/0000-0003-4574-6765 FU Department of Veterans Affairs; VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program FX The publication is based on a systematic review conducted by the Evidence-based Synthesis program funded by the Department of Veterans Affairs. Dr Dawes was supported by the VA Office of Academic Affiliations through the VA/Robert Wood Johnson Clinical Scholars Program. NR 67 TC 17 Z9 18 U1 3 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 12 PY 2016 VL 315 IS 2 BP 150 EP 163 DI 10.1001/jama.2015.18118 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA DA6XO UT WOS:000367949200017 PM 26757464 ER PT J AU Soragni, A Janzen, DM Johnson, LM Lindgren, AG Nguyen, ATQ Tiourin, E Soriaga, AB Lu, J Jiang, L Faull, KF Pellegrini, M Memarzadeh, S Eisenberg, DS AF Soragni, Alice Janzen, Deanna M. Johnson, Lisa M. Lindgren, Anne G. Anh Thai-Quynh Nguyen Tiourin, Ekaterina Soriaga, Angela B. Lu, Jing Jiang, Lin Faull, Kym F. Pellegrini, Matteo Memarzadeh, Sanaz Eisenberg, David S. TI A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas SO CANCER CELL LA English DT Article ID MUTANT P53; CANCER-CELLS; IN-VIVO; SV40-TRANSFORMED CELLS; MEVALONATE PATHWAY; AMYLOID FORMATION; GENE-EXPRESSION; REACTIVATION; APOPTOSIS; PROTEINS AB Half of all human cancers lose p53 function by missense mutations, with an unknown fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a cell-penetrating peptide, ReACp53, designed to inhibit p53 amyloid formation, rescues p53 function in cancer cell lines and in organoids derived from high-grade serous ovarian carcinomas (HGSOC), an aggressive cancer characterized by ubiquitous p53 mutations. Rescued p53 behaves similarly to its wild-type counterpart in regulating target genes, reducing cell proliferation and increasing cell death. Intraperitoneal administration decreases tumor proliferation and shrinks xenografts in vivo. Our data show the effectiveness of targeting a specific aggregation defect of p53 and its potential applicability to HGSOCs. C1 [Soragni, Alice; Johnson, Lisa M.; Anh Thai-Quynh Nguyen; Soriaga, Angela B.; Jiang, Lin; Eisenberg, David S.] Univ Calif Los Angeles, DOE Inst, HHMI, Dept Biol Chem, Los Angeles, CA 90095 USA. [Soragni, Alice; Johnson, Lisa M.; Anh Thai-Quynh Nguyen; Soriaga, Angela B.; Jiang, Lin; Eisenberg, David S.] Univ Calif Los Angeles, DOE Inst, HHMI, Dept Chem & Biochem, Los Angeles, CA 90095 USA. [Janzen, Deanna M.; Lindgren, Anne G.; Tiourin, Ekaterina; Memarzadeh, Sanaz] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Lu, Jing; Pellegrini, Matteo] Univ Calif Los Angeles, Mol Cell & Dev Biol, Los Angeles, CA 90095 USA. [Faull, Kym F.] Semel Inst, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Eisenberg, DS (reprint author), Univ Calif Los Angeles, DOE Inst, HHMI, Dept Biol Chem, 611 South Charles E Young Dr, Los Angeles, CA 90095 USA. EM smemarzadeh@mednet.ucla.edu; david@mbi.ucla.edu OI Soragni, Alice/0000-0002-6634-2885 FU NIH [1S10RR023718-01A2, AG-029430, R01CA183877]; Pardee Foundation; NIH/National Center for Advancing Translational Science UCLA CTSI Grant [UL1TR000124]; American Cancer Society [RSG-14-217-01-TBG]; National Science Foundation [MCB 0958111]; Jonsson Cancer Center Foundation/UCLA; Lynne Cohen Foundation; Phase One Foundation; Ovarian Cancer Circle; Leath L. and Marcia L. Millen Family Fund; G.O. Discovery Lab Foundation; HHMI; VA CDA-2 award [1 K12 BX 001305-01] FX We thank Dr. Gregory Lawson for assisting with histological examination of tissues and Dr. Jiaoti Huang for sharing the lentiviral GFP/R175H p53 construct; Dr. Stuart Sievers and Jung-Reem Woo for support with the initial p53 structural characterization; Marco Morselli, Arturo Rinaldi and Dr. Ludmilla Rubbi for help with preparation of the libraries; Dr. Hans-Uwe Simon for helpful discussions. We acknowledge the support of Austin Quach and Farbod Fazlollahi with the MRM assay; the Pasarow Mass Spectrometry Laboratory is supported by NIH grant 1S10RR023718-01A2. This work was supported by grants from the Pardee Foundation (to A.S.), the NIH (AG-029430 to D.S.E; R01CA183877 to S.M.), the NIH/National Center for Advancing Translational Science UCLA CTSI Grant UL1TR000124 (to A.S. and D.S.E.), the American Cancer Society (RSG-14-217-01-TBG to S.M.), the National Science Foundation (MCB 0958111, to D.S.E.), the Jonsson Cancer Center Foundation/UCLA (to S.M. and D.S.E.); the Lynne Cohen Foundation, the Phase One Foundation, the Ovarian Cancer Circle Inspired by Robin Babbini, the Leath L. and Marcia L. Millen Family Fund and the G.O. Discovery Lab Foundation (to S.M.), the HHMI (to D.S.E.) and in part by a VA CDA-2 award (1 K12 BX 001305-01 to S.M.). A.S., L.J. and D.S.E. are inventors on a patent application based on ReACp53 (WO2014182961 A1). A.S. is a consultant for ADRx, Inc.; D.S.E. is a founder, head of the scientific advisory board and equity holder of ADRx, Inc. NR 56 TC 32 Z9 32 U1 9 U2 34 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1535-6108 EI 1878-3686 J9 CANCER CELL JI Cancer Cell PD JAN 11 PY 2016 VL 29 IS 1 BP 90 EP 103 DI 10.1016/j.ccell.2015.12.002 PG 14 WC Oncology; Cell Biology SC Oncology; Cell Biology GA DA9HB UT WOS:000368118500009 PM 26748848 ER PT J AU Parikh, RV Ma, YF Scherzer, R Heringer, AS Macgregor, JS Martin, JN Deeks, SG Ganz, P Hsue, PY AF Parikh, Rushi V. Ma, Yifei Scherzer, Rebecca Heringer, Amanda S. Macgregor, John S. Martin, Jeffrey N. Deeks, Steven G. Ganz, Peter Hsue, Priscilla Y. TI Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection SO PLOS ONE LA English DT Article ID ASYMMETRIC DIMETHYLARGININE; DOPPLER-ECHOCARDIOGRAPHY; AMBRISENTAN THERAPY; PROGNOSTIC-FACTORS; PLASMA-LEVELS; BOSENTAN; DISEASE; ERA; PATHOGENESIS; INDIVIDUALS AB Background HIV infection is an independent risk factor for PAH, but the underlying pathogenesis remains unclear. ET-1 is a robust vasoconstrictor and key mediator of pulmonary vascular homeostasis. Higher levels of ET-1 predict disease severity and mortality in other forms of PAH, and endothelin receptor antagonists are central to treatment, including in HIV-associated PAH. The direct relationship between ET-1 and PAH in HIV-infected individuals is not well described. Methods We measured ET-1 and estimated pulmonary artery systolic pressure (PASP) with transthoracic echocardiography (TTE) in 106 HIV-infected individuals. Participants with a PASP >= 30 mmHg (n = 65) underwent right heart catheterization (RHC) to definitively diagnose PAH. We conducted multivariable analysis to identify factors associated with PAH. Results Among 106 HIV-infected participants, 80% were male, the median age was 52 years and 77% were on antiretroviral therapy. ET-1 was significantly associated with higher values of PASP [14% per 0.1 pg/mL increase in ET-1, p = 0.05] and PASP >= 30 mmHg [PR (prevalence ratio) = 1.24, p = 0.012] on TTE after multivariable adjustment for PAH risk factors. Similarly, among the 65 individuals who underwent RHC, ET-1 was significantly associated with higher values of mean pulmonary artery pressure and PAH (34%, p = 0.003 and PR = 2.43, p = 0.032, respectively) in the multivariable analyses. Conclusions Higher levels of ET-1 are independently associated with HIV-associated PAH as hemodynamically assessed by RHC. Our findings suggest that excessive ET-1 production in the setting of HIV infection impairs pulmonary endothelial function and contributes to the development of PAH. C1 [Parikh, Rushi V.] Stanford Univ, Dept Cardiovasc Med, Stanford, CA 94305 USA. [Ma, Yifei] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. [Scherzer, Rebecca] San Francisco VA Med Ctr, Div Endocrinol & Metab, San Francisco, CA USA. [Heringer, Amanda S.; Macgregor, John S.; Ganz, Peter; Hsue, Priscilla Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94117 USA. [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA USA. RP Hsue, PY (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Div Cardiol, San Francisco, CA 94117 USA. EM priscilla.hsue@ucsf.edu FU National Institutes of Health [R01HL095130, R01HL095126, K24AI112393] FX The study received National Institutes of Health grant support from R01HL095130 (PYH), R01HL095126 (PYH), K24AI112393 (PYH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 11 PY 2016 VL 11 IS 1 AR e0146355 DI 10.1371/journal.pone.0146355 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA DA6CA UT WOS:000367888100069 PM 26752193 ER PT J AU Anscher, MS Chang, MG Moghanaki, D Rosu, M Mikkelsen, R Holdford, D Skinner, V Grob, BM Sanyal, AJ Mukhopadhyay, N AF Anscher, Mitchell Steven Chang, Michael G. Moghanaki, Drew Rosu, Mihaela Mikkelsen, Ross Holdford, Diane Skinner, Vicki Grob, B. Mayer Sanyal, Arun J. Mukhopadhyay, Nitai TI Phase II study of lovastatin to prevent rectal injury from radiation therapy for prostate cancer. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Genitourinary Cancers Symposium CY JAN 07-09, 2016 CL San Francisco, CA C1 Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA. US Dept Vet Affairs, Richmond, VA USA. McGuire Vet Affairs Med Ctr, Richmond, VA USA. Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 10 PY 2016 VL 34 IS 2 SU S MA 120 PG 1 WC Oncology SC Oncology GA DO9LW UT WOS:000378109100120 ER PT J AU Filson, CP Shelton, JB Tan, HJ Kwan, L Skolarus, TA Saigal, C Litwin, MS AF Filson, Christopher Paul Shelton, Jeremy B. Tan, Hung-Jui Kwan, Lorna Skolarus, Ted A. Saigal, Christopher Litwin, Mark S. TI Expectant management of veterans with early-stage prostate cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Genitourinary Cancers Symposium CY JAN 07-09, 2016 CL San Francisco, CA C1 Emory Univ, Sch Med, Dept Urol, Atlanta VA Med Ctr, Atlanta, GA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. VA Greater Los Angeles Med Ctr, Los Angeles, CA USA. Ann Arbor VA Med Ctr, VA Ctr Clin Management Res, Ann Arbor, MI USA. Univ Michigan, Dept Urol, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 10 PY 2016 VL 34 IS 2 SU S MA 13 PG 1 WC Oncology SC Oncology GA DO9LW UT WOS:000378109100013 ER PT J AU Serrano, NA Moghanaki, D Asher, D Karlin, J Schutzer, M Chang, MG Hagan, MP AF Serrano, Nicholas A. Moghanaki, Drew Asher, David Karlin, Jeremy Schutzer, Matthew Chang, Michael G. Hagan, Michael Philip TI Comparative study of late rectal toxicity in veterans undergoing low-dose rate prostate brachytherapy treated with or without supplemental external beam radiotherapy. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Genitourinary Cancers Symposium CY JAN 07-09, 2016 CL San Francisco, CA C1 Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA USA. US Dept Vet Affairs, Richmond, VA USA. Univ Miami, Miami, FL USA. Virginia Commonwealth Univ, Richmond, VA USA. Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA. Virginia Commonwealth Univ, Mineral, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD JAN 10 PY 2016 VL 34 IS 2 SU S MA 112 PG 1 WC Oncology SC Oncology GA DO9LW UT WOS:000378109100112 ER PT J AU Streit, BR Kant, R Tokmina-Lukaszewska, M Celis, AI Machovina, MM Skaar, EP Bothner, B DuBois, JL AF Streit, Bennett R. Kant, Ravi Tokmina-Lukaszewska, Monika Celis, Arianna I. Machovina, Melodie M. Skaar, Eric P. Bothner, Brian DuBois, Jennifer L. TI Time-resolved Studies of IsdG Protein Identify Molecular Signposts along the Non-canonical Heme Oxygenase Pathway SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID STAPHYLOCOCCUS-AUREUS ISDG; PSEUDOMONAS-AERUGINOSA HEME; MYCOBACTERIUM-TUBERCULOSIS; DEGRADING ENZYMES; CRYSTAL-STRUCTURE; DEGRADATION; HYDROXYLATION; MACROCYCLE; MONOXIDE; COMPLEX AB IsdGs are heme monooxygenases that break open the tetrapyrrole, releasing the iron, and thereby allowing bacteria expressing this protein to use heme as a nutritional iron source. Little is currently known about the mechanism by which IsdGs degrade heme, although the products differ from those generated by canonical heme oxygenases. A synthesis of time-resolved techniques, including in proteo mass spectrometry and conventional and stopped-flow UV/visible spectroscopy, was used in conjunction with analytical methods to define the reaction steps mediated by IsdG from Staphylococcus aureus and their time scales. An apparent meso-hydroxyheme (forming with k = 0.6 min(-1), pH7.4, 10 mM ascorbate, 10 mu M IsdG-heme, 22 degrees C) was identified as a likely common intermediate with the canonical heme oxygenases. Unlike heme oxygenases, this intermediate does not form with added H2O2 nor does it convert to verdoheme and CO. Rather, the next observable intermediates (k = 0.16 min(-1)) were a set of formyloxobilin isomers, similar to the mycobilin products of the IsdG homolog from Mycobacterium tuberculosis (MhuD). These converted in separate fast and slow phases to beta-/delta-staphylobilin isomers and formaldehyde (CH2O). Controlled release of this unusual C1 product may support IsdG's dual role as both an oxygenase and a sensor of heme availability in S. aureus. C1 [Streit, Bennett R.; Kant, Ravi; Tokmina-Lukaszewska, Monika; Celis, Arianna I.; Machovina, Melodie M.; Bothner, Brian; DuBois, Jennifer L.] Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59715 USA. [Skaar, Eric P.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA. RP DuBois, JL (reprint author), Montana State Univ, Dept Chem & Biochem, 221 Chem & Biochem Bldg, Bozeman, MT 59715 USA. EM jdubois@chemistry.montana.edu FU Murdock Charitable Trust; National Institutes of Health of the CoBRE program [5P20RR02437] FX We acknowledge Dr. Jonathan Hilmer for sharing technical expertise in mass spectrometry. We thank Garrett Moraski for helpful discussions. Dr. Sunil Ojha is thanked for contributing to the initiation of this project. The mass spectrometry facility at Montana State University receives funding from the Murdock Charitable Trust and National Institutes of Health Grant 5P20RR02437 of the CoBRE program. NR 31 TC 6 Z9 6 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD JAN 8 PY 2016 VL 291 IS 2 BP 862 EP 871 DI 10.1074/jbc.M115.666560 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DA5GF UT WOS:000367830500032 PM 26534961 ER PT J AU Walwyn, WM Chen, WL Kim, H Minasyan, A Ennes, HS McRoberts, JA Marvizon, JCG AF Walwyn, Wendy M. Chen, Wenling Kim, Hyeyoung Minasyan, Ani Ennes, Helena S. McRoberts, James A. Marvizon, Juan Carlos G. TI Sustained Suppression of Hyperalgesia during Latent Sensitization by mu-, delta-, and kappa-opioid receptors and alpha(2A) Adrenergic Receptors: Role of Constitutive Activity SO JOURNAL OF NEUROSCIENCE LA English DT Article DE adrenergic receptor; constitutive activity; hyperalgesia; kappa-opioid receptor; latent sensitization; mu-opioid receptor ID RAT SPINAL-CORD; TERNARY COMPLEX MODEL; DORSAL-HORN NEURONS; PROTEIN-KINASE-C; NEUROPATHIC PAIN; MICE LACKING; MORPHINE-WITHDRAWAL; INFLAMMATORY PAIN; PRIMARY AFFERENTS; INDUCED ANALGESIA AB Many chronic pain disorders alternate between bouts of pain and periods of remission. The latent sensitization model reproduces this in rodents by showing that the apparent recovery ("remission") from inflammatory or neuropathic pain can be reversed by opioid antagonists. Therefore, this remission represents an opioid receptor-mediated suppression of a sustained hyperalgesic state. To identify the receptors involved, we induced latent sensitization in mice and rats by injecting complete Freund's adjuvant (CFA) in the hindpaw. In WT mice, responses to mechanical stimulation returned to baseline 3 weeks after CFA. In mu-opioid receptor (MOR) knock-out (KO) mice, responses did not return to baseline but partially recovered from peak hyperalgesia. Antagonists of alpha(2A)-adrenergic and delta-opioid receptors reinstated hyperalgesia in WT mice and abolished the partial recovery from hyperalgesia in MOR KO mice. In rats, antagonists of alpha(2A) adrenergic and mu-, delta-, and kappa-opioid receptors reinstated hyperalgesia during remission from CFA-induced hyperalgesia. Therefore, these four receptors suppress hyperalgesia in latent sensitization. We further demonstrated that suppression of hyperalgesia by MORs was due to their constitutive activity because of the following: (1) CFA-induced hyperalgesia was reinstated by the MOR inverse agonist naltrexone (NTX), but not by its neutral antagonist 6 beta-naltrexol; (2) pro-enkephalin, pro-opiomelanocortin, and pro-dynorphin KO mice showed recovery from hyperalgesia and reinstatement by NTX; (3) there was no MOR internalization during remission; (4) MORs immunoprecipitated from the spinal cord during remission had increased Ser(375) phosphorylation; and (5) electrophysiology recordings from dorsal root ganglion neurons collected during remission showed constitutive MOR inhibition of calcium channels. C1 [Walwyn, Wendy M.; Minasyan, Ani] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Chen, Wenling; Kim, Hyeyoung; Ennes, Helena S.; McRoberts, James A.; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Marvizon, Juan Carlos G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Marvizon, JCG (reprint author), VA Greater Los Angeles Healthcare syst, 11301 Wilshire Blvd,Bldg 115, Los Angeles, CA 90073 USA. EM marvizon@g.ucla.edu FU Rehabilitation Research and Development Service, Department of Veterans Affairs [1I01RX000378]; National Institutes of Health-National Institute of Drug Abuse [R01-DA033059, DA005010]; Shirley and Stefas Hatos Center for the Study of Opioid Receptors FX This work was supported by the Rehabilitation Research and Development Service, Department of Veterans Affairs (Grant 1I01RX000378 to J.C.G.M.), the National Institutes of Health-National Institute of Drug Abuse (Grant R01-DA033059 to J.C.G.M. and J.A.M. and Grant DA005010 to W.M.W and A.M.), and by the Shirley and Stefas Hatos Center for the Study of Opioid Receptors. This study was under the venue of the following UCLA institutes: the Brain Research Institute, the Center for the Study of Opioid Receptors and Drugs of Abuse, the CURE: Digestive Diseases Research Center, and the Oppenheimer Family Center for Neurobiology of Stress. We thank Bradley K. Taylor for critical discussion. NR 77 TC 3 Z9 3 U1 1 U2 4 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD JAN 6 PY 2016 VL 36 IS 1 BP 204 EP 221 DI 10.1523/JNEUROSCI.1751-15.2016 PG 18 WC Neurosciences SC Neurosciences & Neurology GA DB2OE UT WOS:000368348100022 PM 26740662 ER PT J AU Singh, JA Yu, SH AF Singh, Jasvinder A. Yu, Shaohua TI Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the US National Emergency Department Sample (NEDS) SO RESPIRATORY RESEARCH LA English DT Article ID QUALITY-OF-LIFE; ACUTE EXACERBATION; UNITED-STATES; RISK-FACTORS; HOSPITAL ADMISSION; INPATIENT SAMPLE; ECONOMIC BURDEN; LUNG-FUNCTION; COPD PATIENTS; BODE INDEX AB Background: Previous studies of healthcare utilization for chronic obstructive pulmonary disease (COPD) have focused on time-trends in COPD visits or COPD treatments, or the effect of hospital volume on mortality. Few data are available regarding outcomes after an ED visit (and subsequent hospitalization) for COPD, which are both very common in patients with COPD. Our objective was to assess time-trends and predictors of emergency department and subsequent inpatient health care utilization and charges associated with COPD in the U.S. Method: We used the 2009-12 U.S. Nationwide Emergency Department Sample (NEDS) to study the incidence of ED visits and subsequent hospitalizations with COPD as the primary diagnosis. We used the 2012 NEDS data to study key patient/hospital factors associated with outcomes, including charges, hospitalization and dischage from hospital to home. Results: ED visits for COPD as the primary diagnosis increased from 1.02 million in 2009 to 1.04 in 2010 to 1.10 million in 2012 (0.79-0.82 % of all ED visits); respective charges were $2.13, $2.32, and $3.09 billion. In 2012, mean ED charges/visit were $2,812, hospitalization charges/visit were $29,043 and the length of hospital stay was 4.3 days. 49 % were hospitalized after an ED visit. Older age, higher median income, metropolitan residence and comorbidities (diabetes, hypertension, HF, hyperlipidemia, CHD, renal failure and osteoarthritis) were associated with higher risk whereas male sex, Medicaid or self pay insurance status, hospital location in Midwest, South or West U.S. were associated with lower risk of hospitalization. 65.4 % of all patients hospitalized for COPD from ED were discharged home. Older age, comorbidities (diabetes, HF, CHD, renal failure, osteoarthritis) and metropolitan residence were associated with lower odds of discharge to home, whereas male sex, payer other than Medicare, Midwest, South or West U.S. hospital location were associated with higher odds. Conclusion: Health care utilization and costs in patients with COPD are significant and increasing. COPD constitutes a major public health burden in the U.S. We identified risk factors for hospitalization, costs, and home discharge in patients with COPD that will allow future studies to investigate interventions to potentially reduce COPD-associated utilization. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Yu, Shaohua] UAB, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. EM Jasvinder.md@gmail.com FU National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) [P50 AR060772]; UAB Division of Rheumatology FX This material is the result of work supported by research funds from UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. JAS is also supported by grant from the National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) P50 AR060772. NR 48 TC 2 Z9 2 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD JAN 6 PY 2016 VL 17 AR 1 DI 10.1186/s12931-015-0319-y PG 12 WC Respiratory System SC Respiratory System GA DA1TN UT WOS:000367578500001 PM 26739476 ER PT J AU Kindy, MS Yu, J Zhu, H Smith, MT Gattoni-Celli, S AF Kindy, Mark S. Yu, Jin Zhu, Hong Smith, Michael T. Gattoni-Celli, Sebastiano TI A therapeutic cancer vaccine against GL261 murine glioma SO JOURNAL OF TRANSLATIONAL MEDICINE LA English DT Article DE Glioblastoma; Immunotherapy; Semi-allogeneic; Cancer; Vaccine ID BRAIN-TUMORS; CELL HYBRIDS; GLIOBLASTOMA; MICROGLIA; MODEL AB Background: Glioblastoma (GBM) is the deadliest of brain tumors. Standard treatment for GBM is surgery, followed by combined radiation therapy and chemotherapy. Current therapy prolongs survival but does not offer a cure. We report on a novel immunotherapy against GBM, tested in an animal model of C57BL/6 mice injected intra-cranially with a lethal dose of murine GL261 glioma cells. Methods: Ten week-old C57BL/6 mice were anesthetized before injection of 2 x 10(4) GL261 cells in the right cerebral hemisphere and after 3 days half of the mice were administered a single subcutaneous (s.c.) injection of irradiated semi-allogeneic vaccine, while mock-vaccinated mice received a s.c. injection of phosphate-buffered saline (PBS). Tumor engraftment was monitored through bioluminescence imaging (BLI). Length of animal survival was measured by Kaplan-Meier graphs and statistics. At time of sacrifice brain tissue was processed for estimation of tumor size and immunohistochemical studies. Results: Overall survival of vaccinated mice was significantly longer compared to mock-vaccinated mice. Five to ten percent of vaccinated mice survived more than 90 days following the engraftment of GL261 cells in the brain and appeared to be free of disease by BLI. Tumor volume in the brain of vaccinated mice was on average five to ten-fold smaller compared to mock-vaccinated mice. In vaccinated mice, conspicuous microglia infiltrates were observed in tumor tissue sections and activated microglia appeared to form a fence along the perimeter of the tumor cells. The results of these animal studies persuaded the Office of Orphan Products Development of the Food and Drug Administration (FDA) to grant Orphan Drug Designation for treatment of GBM with irradiated, semi-allogeneic vaccines. Conclusions: Our preclinical observations suggest that semi-allogeneic vaccines could be tested clinically on subjects with GBM, as an adjuvant to standard treatment. C1 [Kindy, Mark S.; Yu, Jin; Zhu, Hong] Univ S Florida, Dept Pharmaceut Sci, Tampa, FL 33612 USA. [Smith, Michael T.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano] Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Gattoni-Celli, S (reprint author), Med Univ S Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. EM gattonis@musc.edu FU Veterans Administration (VA) CSRD Merit Awards [CX000753, RRD RX001450]; National Institutes of Health [NIH R01 ES016774-01, R21AG043718, 1P20GM109091, 2P20GM103444, 5P30GM103342]; National Science Foundation [IIP-0903795] FX We thank Dr. Mark P. Rubinstein (Department of Surgery, MUSC) for helping with the FACS experiments. This research was funded by Veterans Administration (VA) CSR&D Merit Awards CX000753 to SG-C, RR&D RX001450, National Institutes of Health (NIH R01 ES016774-01, R21AG043718, 1P20GM109091, 2P20GM103444, and 5P30GM103342, and a grant from the National Science Foundation (IIP-0903795) to MSK. Mark S. Kindy is a Senior Research Career Scientist in the VA. NR 14 TC 1 Z9 1 U1 3 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1479-5876 J9 J TRANSL MED JI J. Transl. Med. PD JAN 5 PY 2016 VL 14 DI 10.1186/s12967-015-0757-9 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DA8LT UT WOS:000368057000001 ER PT J AU Sgro, G Gladwin, MT Teng, A Moghe, A Zimmer, SM AF Sgro, Gaetan Gladwin, Mark T. Teng, Alexander Moghe, Akshata Zimmer, Shanta M. TI Shining a Light on the Dark Side SO ANNALS OF INTERNAL MEDICINE LA English DT Letter C1 [Sgro, Gaetan] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. [Gladwin, Mark T.; Zimmer, Shanta M.] Univ Pittsburgh, Pittsburgh, PA USA. [Teng, Alexander; Moghe, Akshata] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. RP Sgro, G (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 5 PY 2016 VL 164 IS 1 BP 69 EP 69 DI 10.7326/L16-0013 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA DA4WC UT WOS:000367801700018 PM 26747309 ER PT J AU Stroud, CB Hershenberg, R Cardenas, S Greiter, E Richmond, M AF Stroud, Catherine B. Hershenberg, Rachel Cardenas, Stephanie Greiter, Elizabeth Richmond, Margaret TI U.S. College Students' Sexual Activity: The Unique and Interactive Effects of Emotion Regulation Difficulties and Attachment Style SO INTERNATIONAL JOURNAL OF SEXUAL HEALTH LA English DT Article DE gender differences; Emotion regulation difficulties; sexual activity; attachment anxiety; attachment avoidance ID ADULT ATTACHMENT; INDIVIDUAL-DIFFERENCES; ROMANTIC RELATIONSHIPS; EXPERIENCES; BEHAVIOR; DYSREGULATION; CONSEQUENCES; MOTIVATIONS; HOOKING; MODEL AB ABSTACT Objectives: This study explored the association between emotion regulation difficulties and sexual activity, and whether emotion regulation difficulties moderated the link between attachment and sexual activity. Methods: U.S. college students (N = 373) from two institutions completed self-report measures of sexual activity, emotion regulation difficulties and attachment. Results: Findings indicated that greater emotion regulation difficulties were associated with less frequent exclusive sexual activity. Moreover, emotion regulation difficulties moderated links between attachment avoidance and sexual activity, and associations varied according to relational context and gender. Conclusions: Implications for promoting sexual health and relationship intimacy are discussed. C1 [Stroud, Catherine B.; Cardenas, Stephanie; Greiter, Elizabeth; Richmond, Margaret] Williams Coll, Dept Psychol, Williamstown, MA 01267 USA. [Hershenberg, Rachel] Univ Penn, Educ & Clin Ctr, VISN Mental Illness Res 4, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Hershenberg, Rachel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Stroud, CB (reprint author), Williams Coll, Dept Psychol, Bronfman Sci Ctr, 18 Hoxsey St, Williamstown, MA 01267 USA. EM Catherine.B.Stroud@williams.edu FU Williams College; the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA FX This research was supported by institutional funds from Williams College. Catherine B. Stroud was supported by institutional funds from Williams College. This article was prepared with the support of the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA. NR 56 TC 0 Z9 0 U1 2 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1931-7611 EI 1931-762X J9 INT J SEX HEALTH JI Int. J. Sex. Health PD JAN 2 PY 2016 VL 28 IS 1 BP 37 EP 49 DI 10.1080/19317611.2015.1073824 PG 13 WC Psychology, Clinical; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Psychology; Public, Environmental & Occupational Health; Social Sciences - Other Topics GA DJ0SC UT WOS:000373913700005 ER PT J AU Binswanger, IA Gordon, AJ AF Binswanger, Ingrid A. Gordon, Adam J. TI From risk reduction to implementation: Addressing the opioid epidemic and continued challenges to our field SO SUBSTANCE ABUSE LA English DT Editorial Material C1 [Binswanger, Ingrid A.] Kaiser Permanente Colorado, Inst Hlth Res, POB 378066, Denver, CO USA. [Binswanger, Ingrid A.] Univ Colorado, Sch Med, Aurora, CO USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Binswanger, IA (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, POB 378066, Denver, CO USA. EM Ingrid.A.Binswanger@kp.org FU Substance Abuse Mental Health Services Administration (SAMHSA) [5H79TI025595] FX Funding for this initiative was made possible (in part) by Providers' Clinical Support System for Opioid Therapies (grant no. 5H79TI025595) from the Substance Abuse Mental Health Services Administration (SAMHSA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the US government. NR 17 TC 3 Z9 3 U1 1 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JAN 2 PY 2016 VL 37 IS 1 BP 1 EP 3 DI 10.1080/08897077.2015.1134152 PG 3 WC Substance Abuse SC Substance Abuse GA DH4GQ UT WOS:000372743900001 PM 26820257 ER PT J AU Burns, RM Pacula, RL Bauhoff, S Gordon, AJ Hendrikson, H Leslie, DL Stein, BD AF Burns, Rachel M. Pacula, Rosalie L. Bauhoff, Sebastian Gordon, Adam J. Hendrikson, Hollie Leslie, Douglas L. Stein, Bradley D. TI Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013 SO SUBSTANCE ABUSE LA English DT Article DE policy; Buprenorphine; opioid use disorder ID SUBSTANCE-ABUSE TREATMENT; METHADONE-MAINTENANCE TREATMENT; OFFICE-BASED TREATMENT; COST-EFFECTIVENESS; UNITED-STATES; MEDICAID POPULATION; ADDICTION TREATMENT; PRIOR AUTHORIZATION; OPIATE ADDICTION; HEROIN-ADDICTION AB Background: State Medicaid policies play an important role in Medicaid enrollees' access to and use of opioid agonists, such as methadone and buprenorphine, in the treatment of opioid use disorders. Little information is available, however, regarding the evolution of state policies facilitating or hindering access to opioid agonists among Medicaid enrollees. Methods: During 2013-2014, we surveyed state Medicaid officials and other designated state substance abuse treatment specialists about their state's recent history of Medicaid coverage and policies pertaining to methadone and buprenorphine. We describe the evolution of such coverage and policies and present an overview of the Medicaid policy environment with respect to opioid agonist therapy from 2004 to 2013. Results: Among our sample of 45 states with information on buprenorphine and methadone coverage, we found a gradual trend toward adoption of coverage for opioid agonist therapies in state Medicaid agencies. In 2013, only 11% of states in our sample (n = 5) had Medicaid policies that excluded coverage for methadone and buprenorphine, whereas 71% (n = 32) had adopted or maintained policies to cover both buprenorphine and methadone among Medicaid enrollees. We also noted an increase in policies over the time period that may have hindered access to buprenorphine and/or methadone. Conclusions: There appears to be a trend for states to enact policies increasing Medicaid coverage of opioid agonist therapies, while in recent years also enacting policies, such as prior authorization requirements, that potentially serve as barriers to opioid agonist therapy utilization. Greater empirical information about the potential benefits and potential unintended consequences of such policies can provide policymakers and others with a more informed understanding of their policy decisions. C1 [Burns, Rachel M.; Pacula, Rosalie L.; Bauhoff, Sebastian; Stein, Bradley D.] RAND Corp, 4570 Fifth Ave, Pittsburgh, PA USA. [Gordon, Adam J.; Stein, Bradley D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Hendrikson, Hollie] Natl Conf State Legislatures, Denver, CO USA. [Leslie, Douglas L.] Penn State Coll Med, Hershey, PA USA. RP Burns, RM (reprint author), RAND Corp, 4570 Fifth Ave, Pittsburgh, PA USA. EM rachel@rand.org FU National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) [1R01DA032881-01A1] FX The National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) provided support (award 1R01DA032881-01A1) for this study. The study's results and interpretation are those of the authors and do not represent those of NIDA or the NIH. The authors declare that they have no conflicts of interest. NR 61 TC 4 Z9 4 U1 4 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JAN 2 PY 2016 VL 37 IS 1 BP 63 EP 69 DI 10.1080/08897077.2015.1080208 PG 7 WC Substance Abuse SC Substance Abuse GA DH4GQ UT WOS:000372743900013 PM 26566761 ER PT J AU Mitchell, MA Poyrazli, S Broyles, LM AF Mitchell, Michael A. Poyrazli, Senel Broyles, Lauren Matukaitis TI Hazardous alcohol use and cultural adjustment among U.S. college students abroad in Italy: Findings and recommendations for study abroad staff and researchers SO SUBSTANCE ABUSE LA English DT Article DE alcohol drinking; students; binge drinking; Italy; young adults; Acculturation ID DISORDERS IDENTIFICATION TEST; BINGE DRINKING; UNIVERSITY-STUDENTS AB Background: Italy is a top destination for U.S. college students studying abroad. Both international and local Italian media outlets, such as city newspapers, have cited the discordance between Italian cultural norms and U.S. college students' drinking behaviors. Hazardous alcohol consumption abroad, such as binge drinking, can result in individual- (e.g., physical injury) and social- (e.g., promotion of negative stereotypes) level adverse consequences. Methods: We assessed the prevalence of hazardous alcohol use and recent binge drinking in a sample of U.S. college students studying abroad in Italy (n = 111). We evaluated associations among drinking and cultural adjustment and determined which sociocultural factors predicted binge drinking for students abroad. Results: Forty-six percent of students were classified as hazardous drinkers and 63% reported recent binge drinking. Socializing with American peers was a significant predictor for binge drinking abroad. Conclusions: Binge drinking was quite prevalent in our sample of students studying abroad in Italy. Study abroad advisors, instructors, and staff should consider diverse strategies to screen, educate, prevent, and/or intervene on alcohol misuse with their students. These strategies should be personalized to both the student as well as the host culture's norms. C1 [Mitchell, Michael A.] VA Pittsburgh Healthcare Syst, VA Pittsburgh Healthcare Syst Interdisciplinary A, Univ Dr C,151C, Pittsburgh, PA 15240 USA. [Poyrazli, Senel] Penn State Univ Harrisburg, Behav Sci & Educ, Middletown, PA USA. [Broyles, Lauren Matukaitis] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Broyles, Lauren Matukaitis] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA 15240 USA. [Broyles, Lauren Matukaitis] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. RP Mitchell, MA (reprint author), VA Pittsburgh Healthcare Syst, VA Pittsburgh Healthcare Syst Interdisciplinary A, Univ Dr C,151C, Pittsburgh, PA 15240 USA. EM Mitchellm59@gmail.com FU Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Addiction Treatment; Career Development Award from the Health Services Research & Development service (CDA) [10-014] FX This work was partially supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Addiction Treatment (M. Mitchell), a Career Development Award from the Health Services Research & Development service (CDA 10-014, Principal Investigator [PI]: L. Broyles), and with resources and facilities at the VA Pittsburgh Healthcare System, Pittsburgh, PA. The views expressed in this article are those of the authors and do not necessarily reflect the position of the Department of Veterans Affairs or the United States government. NR 39 TC 1 Z9 1 U1 1 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PD JAN 2 PY 2016 VL 37 IS 1 BP 215 EP 221 DI 10.1080/08897077.2015.1019663 PG 7 WC Substance Abuse SC Substance Abuse GA DH4GQ UT WOS:000372743900036 PM 26848514 ER PT J AU Casaletto, KB Moore, DJ Woods, SP Umlauf, A Scott, JC Heaton, RK AF Casaletto, Kaitlin B. Moore, David J. Woods, Steven Paul Umlauf, Anya Scott, J. C. Heaton, Robert K. TI Abbreviated Goal Management Training Shows Preliminary Evidence as a Neurorehabilitation Tool for HIV-associated Neurocognitive Disorders among Substance Users SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Activities of daily living; Executive functions; Compensatory strategies.; Awareness ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE DAMAGE; METHAMPHETAMINE DEPENDENCE; NEUROPSYCHOLOGICAL IMPAIRMENT; ANTIRETROVIRAL THERAPY; SELF-AWARENESS; MEDICATION ADHERENCE; EXECUTIVE FUNCTIONS; METAMEMORY DEFICIT AB Objective: Substance use disorders are highly comorbid with and contribute to the increased prevalence of neurocognitive dysfunction observed in HIV infection. Despite their adverse impact on everyday functioning, there are currently no compensatory-based neurorehabilitation interventions validated for use among HIV+ substance users (HIV/SUD). This study examined the effectiveness of goal management training (GMT) alone or GMT as part of a metacognitive training among HIV/SUD individuals with executive dysfunction. Methods: Ninety HIV/SUD individuals were randomized to a single 15-min session: (1) GMT (n=30); (2) GMT plus metacognitive training (neurocognitive awareness; GMT+Meta; n=30); or (3) active control (n=30). Following a brief neurocognitive battery and study condition, participants performed a complex laboratory-based function task, Everyday Multitasking Test (Everyday MT), during which metacognition (awareness) was evaluated. Results: There was an increasing, but non-significant tendency for better Everyday MT performances across study conditions (Control <= GMT <= GMT+Meta; ps<.08). Post hoc analyses showed that GMT and GMT+Meta groups demonstrated small benefits (d=.20-.27) compared to the control arm but did not differ from one another (ds<.10). When GMT groups were combined, there were significant medium effect size benefits in Everyday MT performance and metacognitive task appraisals as compared to the control condition. Among participants who underwent GMT, benefits were most prominent in persons with poorer pre-training dual-tasking ability, depression, and methamphetamine use disorders (ds=.35-1.04). Conclusions: A brief compensatory strategy has benefits for everyday multitasking and metacognition among HIV+ substance users with executive dysfunction. Future work exploring more intensive trainings, potentially complimentary to other restorative approaches and/or pharmacological treatments, is warranted. C1 [Casaletto, Kaitlin B.] SDSU UCSD Joint Doctoral Program Clin Psychol, San Diego, CA USA. [Moore, David J.; Umlauf, Anya; Heaton, Robert K.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Woods, Steven Paul] Univ Houston, Dept Psychol, Houston, TX USA. [Scott, J. C.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Scott, J. C.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA USA. RP Casaletto, KB (reprint author), Univ Calif San Diego, Dept Psychiat, HIV Neurobehav Res Program, 220 Dickinson St,Suite B, San Diego, CA 92103 USA. EM kablackstone@ucsd.edu FU CSRD VA [IK2 CX000772]; NIDA NIH HHS [F31 DA035708, F31-DA035708, P50 DA026306]; NIMH NIH HHS [P30 MH062512] NR 66 TC 0 Z9 0 U1 0 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PD JAN 2 PY 2016 VL 30 IS 1 BP 107 EP 130 DI 10.1080/13854046.2015.1129437 PG 24 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA DH4CM UT WOS:000372733100008 PM 26753986 ER PT J AU Henley, SS Kashner, TM Golden, RM Westover, AN AF Henley, Steven S. Kashner, T. Michael Golden, Richard M. Westover, Arthur N. TI Response to letter regarding "A systematic approach to subgroup analyses in a smoking cessation trial" SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Letter C1 [Henley, Steven S.] Martingale Res Corp, Plano, TX USA. [Henley, Steven S.; Kashner, T. Michael] Loma Linda Univ, Sch Med, Dept Med, Loma Linda, CA 92354 USA. [Golden, Richard M.] Univ Texas Dallas, Sch Behav & Brain Sci, Richardson, TX 75083 USA. [Westover, Arthur N.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Westover, Arthur N.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. [Kashner, T. Michael] US Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA. RP Westover, AN (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Westover, AN (reprint author), Univ Texas SW Med Ctr Dallas, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM arthur.westover@utsouthwestern.edu FU NCI NIH HHS [R44 CA139607]; NIAAA NIH HHS [R44 AA013351, R43 AA013351, R43 AA014302, R43 AA013670, R44 AA011607]; NIGMS NIH HHS [R43 GM106465] NR 14 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD JAN 2 PY 2016 VL 42 IS 1 BP 112 EP 113 DI 10.3109/00952990.2015.1117482 PG 2 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DG1CP UT WOS:000371803200014 PM 26717302 ER PT J AU Kalapatapu, RK Delucchi, KL Wang, S Harbison, JD Nelson, EE Kramer, JH AF Kalapatapu, Raj K. Delucchi, Kevin L. Wang, Sophia Harbison, John D. Nelson, Emily E. Kramer, Joel H. TI Substance use history in behavioral-variant frontotemporal dementia versus primary progressive aphasia SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE Frontotemporal; dementia; cigarette smoking; alcohol; substance use; drug ID UNIFORM DATA SET; ALCOHOL-USE DISORDERS; OLDER-ADULTS; DISEASE CENTERS; ABUSE; ADDICTIONS; REWARD; METHAMPHETAMINE; EPIDEMIOLOGY; POPULATION AB As older adults are prone to cognitive disorders, the interaction of the fields of substance use and misuse and cognitive neuroscience is an emerging area of research. Substance use has been reported in some subtypes of frontotemporal dementia, such as behavioral variant frontotemporal dementia. However, characterization of substance use in other subtypes of frontotemporal dementia, such as primary progressive aphasia, is unknown. The objective of this baseline analysis was to explore whether any measures of substance use history differed significantly among behavioral variant frontotemporal dementia (n = 842) and primary progressive aphasia (n = 526) in a large national dataset. The National Alzheimer's Coordinating Center's Uniform Data Set study is a national dataset that collects data on patients with various cognitive disorders and includes some questions on substance use. Each substance use variable was used as the outcome and the frontotemporal dementia subtype as the predictor. Total years smoked cigarettes, age when last smoked cigarettes, average number of packs/day smoked when participants smoked, and any recent, remote, or combined recent/remote history of alcohol abuse or drug abuse did not significantly differ between the behavioral variant frontotemporal dementia and primary progressive aphasia subtypes (all p-values > .001). A significantly greater percentage of participants smoked in the last 30 days in the behavioral variant frontotemporal dementia subtype (10.4%, n = 834) compared to the primary progressive aphasia subtype (3.3%, n = 517; p < .001). Clinical providers in both the dementia and substance use fields are encouraged to screen for and monitor substance use in all frontotemporal dementia subtypes. C1 [Kalapatapu, Raj K.; Delucchi, Kevin L.; Harbison, John D.; Nelson, Emily E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kalapatapu, Raj K.; Nelson, Emily E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Kalapatapu, Raj K.; Harbison, John D.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Wang, Sophia] Indiana Univ, Ctr Hlth Innovat & Implementat Sci, Dept Psychiat, Indianapolis, IN 46204 USA. [Kramer, Joel H.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA. RP Kalapatapu, RK (reprint author), San Francisco VA Med Ctr, Opioid Treatment Program, Bldg 1,Ground Floor,Room 24,Mailstop 116F,4150 Cl, San Francisco, CA 94121 USA. EM kalapatapu.raj.k@gmail.com FU National Institute on Aging [UO1 AG016976]; [K23DA034883]; [P50DA009253]; [P50AG023501]; [R01AG022983]; [R01AG032289] FX The NACC is funded by the National Institute on Aging (UO1 AG016976) and located in the Department of Epidemiology at the University of Washington School of Public Health. Dr. Kalapatapu is currently funded by K23DA034883. Dr. Delucchi is currently funded by P50DA009253. Dr. Kramer is currently funded by P50AG023501, R01AG022983, and R01AG032289. NR 49 TC 1 Z9 1 U1 3 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1055-0887 EI 1545-0848 J9 J ADDICT DIS JI J. Addict. Dis. PD JAN 2 PY 2016 VL 35 IS 1 BP 36 EP 41 DI 10.1080/10550887.2015.1102026 PG 6 WC Substance Abuse SC Substance Abuse GA DB7TW UT WOS:000368720200006 PM 26485480 ER PT J AU Cornford, EM Hyman, S Cornford, ME Chytrova, G Rhee, J Suzuki, T Yamagata, T Yamakawa, K Penichet, ML Pardridge, WM AF Cornford, Eain M. Hyman, Shigeyo Cornford, Marcia E. Chytrova, Gabriela Rhee, Jennifer Suzuki, Toshimitsu Yamagata, Tetsushi Yamakawa, Kazuhiro Penichet, Manuel L. Pardridge, William M. TI Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes SO JOURNAL OF DRUG TARGETING LA English DT Article DE Adult and fetal blood-brain barrier; EPM2a null mutant mice; Lafora's disease; non-invasive gene delivery; PEGylated immunoliposome; transferrin receptor-mediated endocytosis; transplacental gene transfer ID RECEPTOR EXPRESSION; EXOGENOUS GENE; EPM2A GENE; IN-VIVO; DELIVERY; BARRIER; MOUSE; TRIAL; MICE; IRON AB Research was undertaken to establish transplacental delivery of active genes to fetal brain by a non-viral vector, antibody-specific targeted therapeutic procedure. PEGylated immunoliposomes (PILs) containing firefly luciferase DNA under the influence of the SV40 promoter injected intravenously into near-term pregnant mice produced luminometric evidence of CNS tissue luciferase activity at 48-h post-injection in all newborn pups. In utero delivery of this pGL3 DNA was shown after a single i.v. injection in maternal and neonatal brains, spleen and lesser amounts in lungs, with only negligible background levels in negative controls exposed to unencapsulated pDNA. In addition to studies of normal wild-type mice, we similarly injected pregnant Lafora Knockout (EPM2a null-mutant) and demonstrated luciferase activity days later in the maternal and newborn pup brains of both types. Delivery of PILs containing a second reporter gene (the pSV40 beta-galactosidase transgene) transplacentally by the same procedure was also successful. Histochemical and biochemical demonstration of beta-galactosidase was documented for all mutant and non-mutant neonates. Brain areas of highest Lafora body development (such as the hippocampus and pontine nuclei) showed intraneuronal beta-glucosidase activity. We conclude that receptor-mediated transport of PIL-borne gene therapeutics across both the placental barrier as well as the fetal BBB in utero is feasible. C1 [Cornford, Eain M.; Hyman, Shigeyo; Chytrova, Gabriela; Rhee, Jennifer] West Los Angeles Med Ctr, VA Greater Los Angeles Healthcare Syst, Neurol & Res Serv, Los Angeles, CA 90073 USA. [Cornford, Eain M.; Hyman, Shigeyo; Chytrova, Gabriela] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Cornford, Marcia E.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA. [Cornford, Marcia E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Suzuki, Toshimitsu; Yamagata, Tetsushi; Yamakawa, Kazuhiro] RIKEN, Brain Sci Inst, Saitama, Japan. [Penichet, Manuel L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Surg Oncol, Los Angeles, CA 90095 USA. [Penichet, Manuel L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Penichet, Manuel L.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Penichet, Manuel L.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. [Pardridge, William M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Cornford, EM (reprint author), West Los Angeles Med Ctr, VA Greater Los Angeles Healthcare Syst, Neurol & Res Serv, Bldg 114 Room 217B, Los Angeles, CA 90073 USA. EM cornford@ucla.edu FU National Institutes of Health [1RO1 NS 052456]; France Lafora; Lysosomal Storage Diseases Research Consortium FX Supported by grants from the National Institutes of Health [1RO1 NS 052456], France Lafora, and the Lysosomal Storage Diseases Research Consortium. The authors report no declarations of interest. NR 33 TC 0 Z9 0 U1 1 U2 8 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1061-186X EI 1029-2330 J9 J DRUG TARGET JI J. Drug Target. PD JAN 2 PY 2016 VL 24 IS 1 BP 58 EP 67 DI 10.3109/1061186X.2015.1055569 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DB3ZZ UT WOS:000368453800006 PM 26133964 ER PT J AU Kondo, KK Rossi, JS Schwartz, SJ Zamboanga, BL Scalf, CD AF Kondo, Karli K. Rossi, Joseph S. Schwartz, Seth J. Zamboanga, Byron L. Scalf, Carissa D. TI Acculturation and cigarette smoking in Hispanic women: A meta-analysis SO JOURNAL OF ETHNICITY IN SUBSTANCE ABUSE LA English DT Article DE Acculturation; Hispanic; meta-analysis; smoking ID HEALTH-RISK BEHAVIORS; SUBSTANCE USE; ALCOHOL-CONSUMPTION; MEXICAN-AMERICANS; UNITED-STATES; ADOLESCENTS; EDUCATION; LANGUAGE; GENDER; MODEL AB The present study was a random-effects model meta-analysis of 26 studies published between 1990 and 2010 (k=32; n=39,777) that (a) examined the association between acculturation and cigarette smoking in Hispanic women and (b) evaluated age, national origin, and measure and dimensionality (unidimensional vs. bidimensional) of acculturation as moderating variables. Results indicate a strong positive relationship and suggest larger effects of acculturation on cigarette smoking in women of Mexican descent as compared with women originating from other Latin American countries for current and lifetime smoking, as well as smoking overall. The effect of acculturation on cigarette smoking was larger in adults as compared with adolescents for current smoking and smoking overall. Few differences in effect size by measure or dimensionality of acculturation emerged. Results are discussed with regard to implications for future research and the measurement of acculturation. C1 [Kondo, Karli K.] Portland VA Med Ctr, Portland, OR 97239 USA. [Kondo, Karli K.; Scalf, Carissa D.] Univ Pacific, Hillsboro, OR USA. [Rossi, Joseph S.] Univ Rhode Isl, Kingston, RI 02881 USA. [Schwartz, Seth J.] Univ Miami, Miami, FL USA. [Zamboanga, Byron L.] Smith Coll, Northampton, MA 01063 USA. RP Kondo, KK (reprint author), Portland VA Med Ctr, Mailcode RD71,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM karli.kondo@va.gov FU National Center for Research Resources of the National Institutes of Health [G20RR030883] FX This research was supported in part by the National Center for Research Resources of the National Institutes of Health under Award Number G20RR030883. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 68 TC 2 Z9 2 U1 5 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1533-2640 EI 1533-2659 J9 J ETHN SUBST ABUSE JI J. Ethn. Subst. Abuse PD JAN 2 PY 2016 VL 15 IS 1 BP 46 EP 72 DI 10.1080/15332640.2014.1002878 PG 27 WC Substance Abuse SC Substance Abuse GA DB4YF UT WOS:000368518800004 PM 26114872 ER PT J AU Liu, LCY Dorhout, B van der Meer, P Teerlink, JR Voors, AA AF Liu, Licette C. Y. Dorhout, Bernard van der Meer, Peter Teerlink, John R. Voors, Adriaan A. TI Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure SO EXPERT OPINION ON INVESTIGATIONAL DRUGS LA English DT Article DE cardiac myosin activator; CK-1827452; heart failure with reduced ejection fraction; omecamtiv mecarbil ID DOUBLE-BLIND; DOBUTAMINE; TRIAL; CARDIOMYOPATHY; MILRINONE; 1ST; LEVOSIMENDAN; MYOFILAMENTS; ASSOCIATION; SAFETY AB Introduction: Current available inotropic agents increase cardiac contractility, but are associated with myocardial ischemia, arrhythmias, and mortality. A novel selective cardiac myosin activator, omecamtiv mecarbil (CK-1827452/ AMG-423) is a small molecule that activates the sarcomere proteins directly, resulting in prolonged systolic ejection time and increased cardiac contractility. Areas covered: This paper discusses the chemistry, pharmacokinetics, clinical efficacy and safety of omecamtiv mecarbil. Omecamtiv mecarbil represents a novel therapeutic approach to directly improve cardiac function and is therefore proposed as a potential new treatment of patients with systolic heart failure. The authors review results of previous studies investigating the effect of omecamtiv mecarbil in heart failure animal models, healthy volunteers, and patients with acute and chronic systolic heart failure. Expert opinion: Results of phase I and phase II studies demonstrate that omecamtiv mecarbil is safe and well tolerated both as an intravenous and oral formulation. In healthy volunteers and chronic systolic heart failure patients, administration of omecamtiv mecarbil resulted in a concentration-dependent increase of left ventricular ejection time, ejection fraction, fractional shortening, and stroke volume. The first results of a double-blind, randomized, placebo-controlled phase IIb dose-finding study with the oral formulation of omecamtiv mecarbil demonstrated beneficial effects on cardiac function and N-terminal pro-brain natriuretic peptide levels. This study will provide essential dosing information for the requisite phase III trials which will investigate whether the beneficial effects of omecamtiv mecarbil translate into improved clinical outcomes. C1 [Liu, Licette C. Y.; Dorhout, Bernard; van der Meer, Peter; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Sect Cardiol, San Francisco, CA 94143 USA. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl FU Amgen Inc; Bayer Healthcare; Novartis; Servier; Stealth Peptides; Trevena Inc; Vifor Pharma; ZS Pharma; Cytokinetics; Theravance FX AA Voors has received consultancy fees and or research grants from Amgen Inc, Bayer Healthcare, Novartis, Servier, Stealth Peptides, Trevena Inc, Vifor Pharma and ZS Pharma. JR Teerlink has received consultancy fees and/or research grants from Amgen Inc, Bayer Healthcare, Cytokinetics, Novartis, Servier, Stealth Peptides, Theravance, Trevena Inc and ZS Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 31 TC 2 Z9 2 U1 2 U2 9 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1354-3784 EI 1744-7658 J9 EXPERT OPIN INV DRUG JI Expert Opin. Investig. Drugs PD JAN 2 PY 2016 VL 25 IS 1 BP 117 EP 127 DI 10.1517/13543784.2016.1123248 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DA7ZI UT WOS:000368023700001 PM 26587768 ER PT J AU Byrne, T Treglia, D Culhane, DP Kuhn, J Kane, V AF Byrne, Thomas Treglia, Dan Culhane, Dennis P. Kuhn, John Kane, Vincent TI Predictors of Homelessness Among Families and Single Adults After Exit From Homelessness Prevention and Rapid Re-Housing Programs: Evidence From the Department of Veterans Affairs Supportive Services for Veteran Families Program SO HOUSING POLICY DEBATE LA English DT Article DE homelessness; veterans; rapid re-housing; homelessness prevention; housing assistance programs ID NEW-YORK-CITY; SHELTER; RISK AB This article assesses the extent and predictors of homelessness among veterans (both veterans in families with children and single adults veterans) exiting the Supportive Services for Veteran Families (SSVF) program, which is a nationwide homelessness prevention and rapid re-housing program geared primarily toward those experiencing crisis homelessness. Among rapid re-housing participants, 16% and 26% of single adult veterans experienced an episode of homelessness at 1 and 2 years post-SSVF exit; the comparable figures at those follow-up times for veterans in families were 9.4% and 15.5%, respectively. Relatively fewer single adult veterans and veterans in families receiving homelessness prevention services experienced an episode of homelessness at 1 and 2 years post-SSVF exit. veteran-level characteristics, including age, gender, prior history of homelessness, and recent engagement with U.S. Department of Veterans Affairs (VA) health care, were generally more salient predictors of homelessness following SSVF exit than variables measuring SSVF program factors or community-level housing market conditions. C1 [Byrne, Thomas; Treglia, Dan; Culhane, Dennis P.; Kuhn, John; Kane, Vincent] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19144 USA. [Byrne, Thomas] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Treglia, Dan; Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Byrne, T (reprint author), US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19144 USA. EM tbyrne@bu.edu FU U.S. Department of Veterans Affairs (VA), National Center on Homelessness Among Veterans FX This study was funded by the U.S. Department of Veterans Affairs (VA), National Center on Homelessness Among Veterans. The contents of this article do not necessarily represent the views of the VA or the United States Government. NR 52 TC 0 Z9 0 U1 4 U2 17 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1051-1482 EI 2152-050X J9 HOUS POLICY DEBATE JI Hous. Policy Debate PD JAN 2 PY 2016 VL 26 IS 1 BP 252 EP 275 DI 10.1080/10511482.2015.1060249 PG 24 WC Planning & Development; Urban Studies SC Public Administration; Urban Studies GA CY7UK UT WOS:000366614600001 ER PT J AU Fossett, TRD McNeil, MR Pratt, SR Tompkins, CA Shuster, LI AF Fossett, Tepanta R. D. McNeil, Malcolm R. Pratt, Sheila R. Tompkins, Connie A. Shuster, Linda I. TI The effect of speaking rate on serial-order sound-level errors in normal healthy controls and persons with aphasia SO APHASIOLOGY LA English DT Article DE phonologic encoding; speech production; aphasia; serial-order errors; speech rate ID SPEECH PRODUCTION; LANGUAGE PRODUCTION; REACTION-TIME; NORMAL SPEAKERS; MOTOR ERRORS; APRAXIA; TONGUE; MODEL; RETRIEVAL; PATTERNS AB Background: Although many speech errors can be generated at either a linguistic or motoric level of production, phonetically well-formed sound-level serial-order errors are generally assumed to result from disruption of phonologic encoding (PE) processes. An influential model of PE predicts that speaking rate should affect the relative proportion of these serial-order sound errors (anticipations, perseverations, exchanges). These predictions have been extended to, and have special relevance for persons with aphasia (PWA) because of the increased frequency with which speech errors occur and because their localisation within the functional linguistic architecture may help in diagnosis and treatment. Supporting evidence regarding the effect of speaking rate on phonological encoding has been provided by studies using young normal language (NL) speakers and computer simulations. Limited data exist for older NL users and no group data exist for PWA.Aims: This study tested the phonologic encoding properties of Dell's model of speech production, which predicts that increasing speaking rate affects the relative proportion of serial-order sound errors (i.e., anticipations, perseverations and exchanges).Methods & Procedures: The effects of speech rate on the error ratios of anticipation/exchange (AE), anticipation/perseveration (AP) and vocal reaction time (VRT) were examined in 16 normal healthy controls (NHC) and 16 PWA without concomitant motor speech disorders. The participants were recorded performing a phonologically challenging (tongue twister) speech production task at their typical and two faster speaking rates.Outcomes & Results: A significant effect of increased rate was obtained for the AP but not the AE ratio. Significant effects of group and rate were obtained for VRT.Conclusion: Although the significant effect of rate for the AP ratio provided evidence that changes in speaking rate did affect PE, the results failed to support the model-derived predictions regarding the direction of change for error-type proportions. The current findings argued for an alternative concept of the role of activation and decay in influencing types of serial-order sound errors. Rather than a slow activation decay rate, the results of the current study were more compatible with an alternative explanation of rapid activation decay or slow build-up of residual activation. C1 [Fossett, Tepanta R. D.; McNeil, Malcolm R.; Pratt, Sheila R.; Tompkins, Connie A.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [McNeil, Malcolm R.; Pratt, Sheila R.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Tompkins, Connie A.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA. [Tompkins, Connie A.] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Shuster, Linda I.] W Virginia Univ, Dept Speech Pathol & Audiol, Morgantown, WV 26506 USA. RP Fossett, TRD (reprint author), Loyola Univ Maryland, Dept Speech & Language Pathol, Baltimore, MD 21210 USA. EM trfossett@loyola.edu FU National Institutes of Health (NIH) F31 Pre-doctoral Fellowship [1 F31 DC005940-01]; Provost's Development and Faculty of Arts and Sciences (FAS) African American Summer Graduate Research Awards from the University of Pittsburgh FX This research was supported by a National Institutes of Health (NIH) F31 Pre-doctoral Fellowship award [grant number 1 F31 DC005940-01] and by the Provost's Development and Faculty of Arts and Sciences (FAS) African American Summer Graduate Research Awards from the University of Pittsburgh. NR 67 TC 0 Z9 0 U1 3 U2 23 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0268-7038 EI 1464-5041 J9 APHASIOLOGY JI Aphasiology PD JAN 2 PY 2016 VL 30 IS 1 BP 74 EP 95 DI 10.1080/02687038.2015.1063581 PG 22 WC Clinical Neurology SC Neurosciences & Neurology GA CU1TI UT WOS:000363303800004 PM 26973373 ER PT S AU Bowers, ME Yehuda, R AF Bowers, Mallory E. Yehuda, Rachel BE Spengler, D Binder, E TI Intergenerational Effects of PTSD on Offspring Glucocorticoid Receptor Methylation SO EPIGENETICS AND NEUROENDOCRINOLOGY: CLINICAL FOCUS ON PSYCHIATRY, VOL 2 SE Epigenetics and Human Health LA English DT Article; Book Chapter DE PTSD; CpG island; Glucocorticoid receptor; Stress; Offspring; Methylation ID POSTTRAUMATIC-STRESS-DISORDER; DNA METHYLATION; HOLOCAUST SURVIVORS; CORTISOL RESPONSE; GENE NR3C1; TRAUMA EXPOSURE; HPA-AXIS; 2ND-GENERATION; INHERITANCE; DEPRESSION AB Posttraumatic stress disorder is precipitated by the experience of extreme stress in a subset of vulnerable individuals. Data now suggest that PTSD in parents confers vulnerability to PTSD in offspring. This is underlined by the observation that offspring born to individuals with PTSD exhibit low baseline cortisol levels, a neuroendocrine risk factor for PTSD. Several mechanisms have been proposed to mediate intergenerational inheritance of PTSD, including genetics and social learning. However, there is also the possibility that biological changes associated with PTSD in parents directly impact offspring, potentially via changes to gametes, fetuses in utero, or via changes in early postnatal care. The exact mechanism of this form of "intergenerational transmission" is unknown; however changes in epigenetic signatures, including DNA methylation, provide an appealing candidate. Animal studies have prompted investigation into methylation of the NR3C1 promoter, which regulates transcription of the glucocorticoid receptor gene. Here, we review evidence of NR3C1 methylation alterations in offspring of parents exposed to extreme stress and offspring of parents who developed PTSD in response to extreme stress. We propose several hypotheses based on the current evidence and suggest future directions related to these interpretations. C1 [Bowers, Mallory E.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Neurosci, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.; Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosci, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov NR 56 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 2191-2262 BN 978-3-319-29901-3; 978-3-319-29900-6 J9 EPIGENETICS HUM HLTH PY 2016 BP 141 EP 155 DI 10.1007/978-3-319-29901-3_6 D2 10.1007/978-3-319-29901-3 PG 15 WC Genetics & Heredity; Neurosciences SC Genetics & Heredity; Neurosciences & Neurology GA BH1HI UT WOS:000398034400007 ER PT S AU Matkovic, E Schwalbe, M Matkowskyj, KA AF Matkovic, Eduard Schwalbe, Michael Matkowskyj, Kristina A. BE Bentrem, D Benson, A TI Pathologic Features of Esophageal and Gastric Malignancies SO GASTROINTESTINAL MALIGNANCIES SE Cancer Treatment and Research LA English DT Article; Book Chapter DE Esophageal squamous cell carcinoma; Esophageal adenocarcinoma; Adenosquamous carcinoma; Adenoid cystic carcinoma; Gastric adenocarcinoma; Helicobacter pylori ID SQUAMOUS-CELL-CARCINOMA; BARRETTS-ESOPHAGUS; ESOPHAGOGASTRIC JUNCTION; RISK-FACTORS; PREOPERATIVE CHEMORADIATION; PROGNOSTIC-SIGNIFICANCE; CANCER RISK; CYCLIN D1; ADENOCARCINOMA; EXPRESSION AB Esophageal and gastric carcinomas affect millions of individuals worldwide, placing a considerable burden on society. Unfortunately, preventative medicine falls short as screening methods for the upper gastrointestinal tract lack the ability to detect early onset disease. The overwhelming majority of cases present after symptoms appear when individuals have advanced disease with a poor prognosis. Further complicating matters, the anatomic location of these neoplasms engenders rapid tumor progression, which repeatedly thwarts successful surgical treatment. This chapter will focus on the pathological features of malignant neoplasms of the esophagus and stomach. C1 [Matkovic, Eduard; Schwalbe, Michael; Matkowskyj, Kristina A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Matkovic, Eduard; Schwalbe, Michael; Matkowskyj, Kristina A.] UW Carbone Canc Ctr, Madison, WI 53706 USA. [Matkovic, Eduard; Schwalbe, Michael; Matkowskyj, Kristina A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Matkowskyj, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA.; Matkowskyj, KA (reprint author), UW Carbone Canc Ctr, Madison, WI 53706 USA. EM matkowskyj@wisc.edu NR 67 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0927-3042 BN 978-3-319-34244-3; 978-3-319-34242-9 J9 CANCER TREAT RES JI Canc. Treat. Res. PY 2016 VL 168 BP 17 EP 43 DI 10.1007/978-3-319-34244-3_2 D2 10.1007/978-3-319-34244-3 PG 27 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BH1KN UT WOS:000398098200002 ER PT S AU Matkovic, E Schwalbe, M Matkowskyj, KA AF Matkovic, Eduard Schwalbe, Michael Matkowskyj, Kristina A. BE Bentrem, D Benson, A TI Pathologic Features of Miscellaneous Foregut Malignancies SO GASTROINTESTINAL MALIGNANCIES SE Cancer Treatment and Research LA English DT Article; Book Chapter DE Neuroendocrine tumor; Mixed adenoneuroendocrine carcinoma; Gastrointestinal stromal tumor; Synovial sarcoma; Leiomyosarcoma; Rhabdomyosarcoma; Melanoma; Lymphoma ID GASTROINTESTINAL STROMAL TUMORS; ENDOCRINE NEOPLASIA TYPE-1; SYNOVIAL SARCOMA; ESOPHAGUS; PROGNOSIS; RHABDOMYOSARCOMA; CARCINOMA; LYMPHOMA; STOMACH AB In addition to tumors arising from the primary mucosal epithelium, the foregut is host to a variety of non-epithelial precursor cells which may give rise to neoplasms of neuroendocrine, mesenchymal, and hematolymphoid lineages. Many of these lesions also occur outside of the gastrointestinal tract, such as the extranodal lymphomas and many of the sarcomas, and in many cases share the features of their non-alimentary counterparts. This heterogeneous collection of malignancies features a wide spectrum of clinical presentations, morphologic and histopathologic features, genetic underpinnings, and treatment considerations. Although encountered less frequently than primary carcinomas, it is important to correctly recognize and classify these lesions to effectively manage and prognosticate the patients in which they occur. In this chapter, we focus on the clinical, morphologic, and genetic features of the primary esophageal and gastric neoplasms of neuroendocrine, mesenchymal, and lymphoid origin. C1 [Matkovic, Eduard; Schwalbe, Michael; Matkowskyj, Kristina A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Matkovic, Eduard; Schwalbe, Michael; Matkowskyj, Kristina A.] UW Carbone Canc Ctr, Madison, WI 53706 USA. [Matkovic, Eduard; Schwalbe, Michael; Matkowskyj, Kristina A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Matkovic, E (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA.; Matkovic, E (reprint author), UW Carbone Canc Ctr, Madison, WI 53706 USA.; Schwalbe, M (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM matkowskyj@wisc.edu NR 38 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0927-3042 BN 978-3-319-34244-3; 978-3-319-34242-9 J9 CANCER TREAT RES JI Canc. Treat. Res. PY 2016 VL 168 BP 45 EP 58 DI 10.1007/978-3-319-34244-3_3 D2 10.1007/978-3-319-34244-3 PG 14 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BH1KN UT WOS:000398098200003 ER PT S AU Cunningham, AM Rush, PS Matkowskyj, KA AF Cunningham, Ashley M. Rush, Patrick S. Matkowskyj, Kristina A. BE Bentrem, D Benson, A TI Pathologic Features of Primary Pancreatic Malignancies SO GASTROINTESTINAL MALIGNANCIES SE Cancer Treatment and Research LA English DT Article; Book Chapter DE Solid pseudopapillary neoplasm; Mucinous cystic neoplasm; Pancreatic intraepithelial neoplasia; Intraductal papillary mucinous neoplasm; Pancreatic ductal adenocarcinoma; Pancreatic neuroendocrine tumor; Acinar cell carcinoma; Pancreatoblastoma ID NEUROENDOCRINE TUMORS; ADENOCARCINOMAS; MANAGEMENT; CARCINOMA; DIAGNOSIS; CANCER AB This chapter explores the pathologic features of benign and malignant lesions of the pancreas. As pathologic classifications evolve, particularly for cystic lesions and neuroendocrine tumors, it is important for physicians who treat patients with pancreatic neoplasms to fully evaluate these pathologic classifications. C1 [Cunningham, Ashley M.; Rush, Patrick S.; Matkowskyj, Kristina A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI USA. UW Carbone Canc Ctr, Madison, WI USA. [Cunningham, Ashley M.; Rush, Patrick S.; Matkowskyj, Kristina A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Cunningham, AM; Rush, PS (reprint author), William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. EM matkowskyj@wisc.edu NR 34 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0927-3042 BN 978-3-319-34244-3; 978-3-319-34242-9 J9 CANCER TREAT RES JI Canc. Treat. Res. PY 2016 VL 168 BP 77 EP 100 DI 10.1007/978-3-319-34244-3_5 D2 10.1007/978-3-319-34244-3 PG 24 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BH1KN UT WOS:000398098200005 ER PT S AU Matkowskyj, KA Rao, MS Yang, GY AF Matkowskyj, Kristina A. Rao, M. Sambasiva Yang, Guang-Yu BE Bentrem, D Benson, A TI Pathologic Features of Primary and Metastatic Hepatic Malignancies SO GASTROINTESTINAL MALIGNANCIES SE Cancer Treatment and Research LA English DT Article; Book Chapter DE Hepatocellular carcinoma; Cholangiocarcinoma; Hepatoblastoma; Undifferentiated (embryonal) sarcoma; Epithelioid hemangioendothelioma; Metastatic tumors ID CELL HEPATOCELLULAR-CARCINOMA; UNDIFFERENTIATED EMBRYONAL SARCOMA; INTRADUCTAL PAPILLARY NEOPLASM; PRIMARY EXTRAMEDULLARY PLASMACYTOMA; GASTROINTESTINAL STROMAL TUMORS; FAMILIAL ADENOMATOUS POLYPOSIS; BILIARY-TRACT CANCERS; INTRAHEPATIC CHOLANGIOCARCINOMA; BREAST-CANCER; COLORECTAL-CARCINOMA AB In the mammalian liver, 60% of the cellular components are hepatocytes while the remainder (35 %) includes biliary epithelium, Kupffer cells, endothelial cells, fat storing cells and connective tissue cells. Although neoplasms of hepatocytes are the most common, a significant number of both benign and malignant primary liver neoplasms arising from other cell types can develop, such as tumors of bile duct epithelium (Table 1). In addition, the liver is one of the most susceptible sites for metastatic tumors arising from other organs of the body. Not too long ago, liver tumors were left untreated because the liver was considered a complex and mysterious organ inaccessible to surgery. Advances in imaging procedures and surgical techniques over the past 40 years have revolutionized the approaches to the treatment of benign and malignant liver tumors. Subsegmentectomy, segmentectomy, lobectomy, and transplantation are routinely performed for the treatment of primary and metastatic liver tumors with minimal morbidity and mortality. Since accurate diagnosis remains the key to clinical and surgical management, the emphasis of this chapter is on classification, morphological features and differential diagnosis of malignant neoplasms of the liver. C1 [Matkowskyj, Kristina A.] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Matkowskyj, Kristina A.] UW Carbone Canc Ctr, Madison, WI 53706 USA. [Rao, M. Sambasiva; Yang, Guang-Yu] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA. [Matkowskyj, Kristina A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Matkowskyj, KA (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53706 USA.; Matkowskyj, KA (reprint author), UW Carbone Canc Ctr, Madison, WI 53706 USA. EM matkowskyj@wisc.edu NR 160 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0927-3042 BN 978-3-319-34244-3; 978-3-319-34242-9 J9 CANCER TREAT RES JI Canc. Treat. Res. PY 2016 VL 168 BP 257 EP 293 DI 10.1007/978-3-319-34244-3_13 D2 10.1007/978-3-319-34244-3 PG 37 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BH1KN UT WOS:000398098200013 ER PT S AU Sundling, KE Zhang, RR Matkowskyj, KA AF Sundling, Kaitlin E. Zhang, Ranran Matkowskyj, Kristina A. BE Bentrem, D Benson, A TI Pathologic Features of Primary Colon, Rectal, and Anal Malignancies SO GASTROINTESTINAL MALIGNANCIES SE Cancer Treatment and Research LA English DT Article; Book Chapter DE Tubular adenoma; Sessile serrated adenoma; Traditional serrated adenoma; Conventional colorectal adenocarcinoma; Medullary carcinoma; Hereditary colon cancer syndromes; Neuroendocrine tumors; Lymphomas; Gastrointestinal stromal tumors; Appendiceal neoplasms; Anal carcinoma ID MANTLE CELL LYMPHOMA; GASTROINTESTINAL STROMAL TUMORS; POPULATION-BASED ANALYSIS; NEUROENDOCRINE TUMORS; MICROSATELLITE-INSTABILITY; MEDULLARY CARCINOMA; COLORECTAL-CARCINOMA; SERRATED PATHWAY; CANCER; EXPRESSION AB In the United States, colorectal cancer is the third most commonly diagnosed cancer in both men and women, as well as the third leading cause of cancer deaths (Colorectal cancer facts & figures 2014-2016, 2014 [2]). Worldwide, colorectal cancer is the fourth leading cause of death and causes almost 700,000 deaths each year (Cancer: fact sheet No. 297, 2015 [55]). This chapter discusses the clinical and pathologic features of the spectrum of epithelial, hematolymphoid, and mesenchymal malignant tumors of the colon, rectum, appendix, and anus. C1 [Sundling, Kaitlin E.; Zhang, Ranran; Matkowskyj, Kristina A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Sundling, Kaitlin E.; Zhang, Ranran; Matkowskyj, Kristina A.] UW Carbone Canc Ctr, Madison, WI 53706 USA. [Sundling, Kaitlin E.; Zhang, Ranran; Matkowskyj, Kristina A.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Matkowskyj, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53706 USA.; Matkowskyj, KA (reprint author), UW Carbone Canc Ctr, Madison, WI 53706 USA. EM matkowskyj@wisc.edu OI Sundling, Kaitlin/0000-0001-5531-0573 NR 57 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0927-3042 BN 978-3-319-34244-3; 978-3-319-34242-9 J9 CANCER TREAT RES JI Canc. Treat. Res. PY 2016 VL 168 BP 309 EP 330 DI 10.1007/978-3-319-34244-3_15 D2 10.1007/978-3-319-34244-3 PG 22 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA BH1KN UT WOS:000398098200015 ER PT J AU Winsett, RE Day, HM Anstead, GM AF Winsett, Robert E. Day, Holly M. Anstead, Gregory M. TI No light at the end of the tunnel ... an unfortunate case of varicella-associated progressive outer retinal necrosis in a patient with neglected HIV infection SO IDCASES LA English DT Article ID VIRUS; CYTOMEGALOVIRUS; THERAPY C1 [Winsett, Robert E.; Day, Holly M.; Anstead, Gregory M.] South Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. [Winsett, Robert E.; Day, Holly M.; Anstead, Gregory M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. RP Winsett, RE (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM winsett@uthscsa.edu NR 11 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2214-2509 J9 IDCases JI IDCases PY 2016 VL 6 BP 97 EP 99 DI 10.1016/j.idcr.2016.09.010 PG 3 WC Infectious Diseases SC Infectious Diseases GA ER9MV UT WOS:000399151400031 PM 27882300 ER PT S AU Kobeissy, F Dixon, CE Hayes, RL Mondello, S AF Kobeissy, Firas Dixon, C. Edward Hayes, Ronald L. Mondello, Stefania BE Kobeissy, F Dixon, CE Hayes, RL Mondello, S TI Injury Models of the Central Nervous System Methods and Protocols Preface SO INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Editorial Material; Book Chapter C1 [Kobeissy, Firas; Hayes, Ronald L.; Mondello, Stefania] Banyan Biomarkers Inc, Alachua, FL 32615 USA. [Kobeissy, Firas] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon. [Kobeissy, Firas] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA. [Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA. [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy. RP Kobeissy, F (reprint author), Banyan Biomarkers Inc, Alachua, FL 32615 USA.; Kobeissy, F (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon.; Kobeissy, F (reprint author), Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3816-2; 978-1-4939-3814-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1462 BP IX EP X D2 10.1007/978-1-4939-3816-2 PG 2 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BH1UG UT WOS:000398551500002 ER PT S AU Osier, N Dixon, CE AF Osier, Nicole Dixon, C. Edward BE Kobeissy, F Dixon, CE Hayes, RL Mondello, S TI The Controlled Cortical Impact Model of Experimental Brain Trauma: Overview, Research Applications, and Protocol SO INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Traumatic brain injury (TBI); Experimental brain injury; Preclinical; Animal model; Controlled cortical impact (CCI); Common data elements (CDE) ID LATERAL FLUID PERCUSSION; ENVIRONMENTAL ENRICHMENT; COGNITIVE DEFICITS; CEREBRAL CONCUSSION; DEPENDENT RESPONSE; HEMORRHAGIC-SHOCK; AXONAL INJURY; MOUSE MODEL; HEAD-INJURY; RAT MODEL AB Controlled cortical impact (CCI) is a commonly used and highly regarded model of brain trauma that uses a pneumatically or electromagnetically controlled piston to induce reproducible and well-controlled injury. The CCI model was originally used in ferrets and it has since been scaled for use in many other species. This chapter will describe the historical development of the CCI model, compare and contrast the pneumatic and electromagnetic models, and summarize key short-and long-term consequences of TBI that have been gleaned using this model. In accordance with the recent efforts to promote high-quality evidence through the reporting of common data elements (CDEs), relevant study details-that should be reported in CCI studies-will be noted. C1 [Osier, Nicole; Dixon, C. Edward] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA. [Osier, Nicole] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. [Dixon, C. Edward] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Osier, N (reprint author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Osier, N (reprint author), Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA. FU NINDS NIH HHS [R01 NS079061, R01 NS084967, R01 NS091062]; NINR NIH HHS [F31 NR014957, T32 NR009759]; RRD VA [I01 RX001127] NR 69 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3816-2; 978-1-4939-3814-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1462 BP 177 EP 192 DI 10.1007/978-1-4939-3816-2_11 D2 10.1007/978-1-4939-3816-2 PG 16 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BH1UG UT WOS:000398551500013 PM 27604719 ER PT S AU Cullen, DK Harris, JP Browne, KD Wolf, JA Duda, JE Meaney, DF Margulies, SS Smith, DH AF Cullen, D. Kacy Harris, James P. Browne, Kevin D. Wolf, John A. Duda, John E. Meaney, David F. Margulies, Susan S. Smith, Douglas H. BE Kobeissy, F Dixon, CE Hayes, RL Mondello, S TI A Porcine Model of Traumatic Brain Injury via Head Rotational Acceleration SO INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Traumatic brain injury (TBI); Biomechanics; Neuropathology; Diffuse brain injury (DBI); Axonal injury; Modeling; Degeneration; Concussion ID DIFFUSE AXONAL INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; SWINE MODEL; CEREBRAL CONCUSSION; ANIMAL-MODELS; AMYLOID-BETA; INTRACRANIAL HEMORRHAGE; WHITE-MATTER; NEONATAL PIG; CORTICAL-NEURONS AB Unique from other brain disorders, traumatic brain injury (TBI) generally results from a discrete biomechanical event that induces rapid head movement. The large size and high organization of the human brain makes it particularly vulnerable to traumatic injury from rotational accelerations that can cause dynamic deformation of the brain tissue. Therefore, replicating the injury biomechanics of human TBI in animal models presents a substantial challenge, particularly with regard to addressing brain size and injury parameters. Here we present the historical development and use of a porcine model of head rotational acceleration. By scaling up the rotational forces to account for difference in brain mass between swine and humans, this model has been shown to produce the same tissue deformations and identical neuropathologies found in human TBI. The parameters of scaled rapid angular accelerations applied for the model reproduce inertial forces generated when the human head suddenly accelerates or decelerates in falls, collisions, or blunt impacts. The model uses custom-built linkage assemblies and a powerful linear actuator designed to produce purely impulsive nonimpact head rotation in different angular planes at controlled rotational acceleration levels. Through a range of head rotational kinematics, this model can produce functional and neuropathological changes across the spectrum from concussion to severe TBI. Notably, however, the model is very difficult to employ, requiring a highly skilled team for medical management, biomechanics, neurological recovery, and specialized outcome measures including neuromonitoring, neurophysiology, neuroimaging, and neuropathology. Nonetheless, while challenging, this clinically relevant model has proven valuable for identifying mechanisms of acute and progressive neuropathologies as well as for the evaluation of noninvasive diagnostic techniques and potential neuroprotective treatments following TBI. C1 [Cullen, D. Kacy; Harris, James P.; Browne, Kevin D.; Wolf, John A.; Meaney, David F.; Margulies, Susan S.; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA. [Harris, James P.; Browne, Kevin D.; Wolf, John A.; Duda, John E.] Philadelphia Vet Affairs Med Ctr, Perelman Sch Med, Dept Neurol, Philadelphia, PA USA. [Margulies, Susan S.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA. RP Cullen, DK (reprint author), Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, Dept Neurosurg, Philadelphia, PA 19104 USA. FU RRD VA [I01 RX001097] NR 157 TC 1 Z9 1 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3816-2; 978-1-4939-3814-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1462 BP 289 EP 324 DI 10.1007/978-1-4939-3816-2_17 D2 10.1007/978-1-4939-3816-2 PG 36 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BH1UG UT WOS:000398551500019 PM 27604725 ER PT S AU Alawieh, A Wang, WX Narang, A Tomlinson, S AF Alawieh, Ali Wang, Wenxue Narang, Aarti Tomlinson, Stephen BE Kobeissy, F Dixon, CE Hayes, RL Mondello, S TI Thromboembolic Model of Cerebral Ischemia and Reperfusion in Mice SO INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Cerebral ischemia reperfusion; Stroke; Thromboembolic stroke; Microemboli; Thrombolytic therapy; Tissue-plasminogen activator ID MAGNETIC-RESONANCE; EMBOLIC STROKE; ARTERY OCCLUSION; MOUSE MODEL; RT-PA; RAT; BRAIN; THROMBOLYSIS; ENDOTHELIN-1; INFARCTION AB Ischemic stroke is the fourth leading cause of death in the USA and a prominent cause of death globally. Besides thrombolytic therapy used in a small subset of patients, no alternative therapeutic strategy has been shown to improve the outcome of stroke patients. Preclinical models of ischemic stroke are an essential tool for investigating pathogenic processes that happen after the ischemic insult, as well as to screen for candidate therapeutic interventions. There are several models of rodent ischemic stroke including mechanical occlusion, thromboembolic stroke, and photothrombotic stroke. However, models that permit studying stroke in the context of thrombolytic therapy, such as thromboembolic models, are becoming of increasing interest to the research community. In this chapter, we describe a thromboembolic model of ischemic stroke with and without tissue-plasminogen activator-induced reperfusion. We describe protocols for microemboli preparation, surgical procedure, and post-stroke assessment of animals. C1 [Alawieh, Ali; Wang, Wenxue; Narang, Aarti; Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Alawieh, Ali; Wang, Wenxue; Narang, Aarti; Tomlinson, Stephen] Med Univ South Carolina, Neurosci Inst, Charleston, SC 29425 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Alawieh, A (reprint author), Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.; Alawieh, A (reprint author), Med Univ South Carolina, Neurosci Inst, Charleston, SC 29425 USA. NR 30 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3816-2; 978-1-4939-3814-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1462 BP 357 EP 372 DI 10.1007/978-1-4939-3816-2_20 D2 10.1007/978-1-4939-3816-2 PG 16 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BH1UG UT WOS:000398551500022 PM 27604728 ER PT S AU Shen, Q Watts, LT Li, W Duong, TQ AF Shen, Qiang Watts, Lora Tally Li, Wei Duong, Timothy Q. BE Kobeissy, F Dixon, CE Hayes, RL Mondello, S TI Magnetic Resonance Imaging in Experimental Traumatic Brain Injury SO INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE MRI; Traumatic brain injury; ADC; CBF; DWI; PWI; BBB; Experimental TBI model; Rodents; fMRI ID CEREBRAL-BLOOD-FLOW; DIFFUSE AXONAL INJURY; HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES; METHYLENE-BLUE; RATS; MRI; EDEMA; PERFUSION; BARRIER AB Traumatic brain injury (TBI) is a leading cause of death and disability in the USA. Common causes of TBI include falls, violence, injuries from wars, and vehicular and sporting accidents. The initial direct mechanical damage in TBI is followed by progressive secondary injuries such as brain swelling, perturbed cerebral blood flow (CBF), abnormal cerebrovascular reactivity (CR), metabolic dysfunction, blood-brain-barrier disruption, inflammation, oxidative stress, and excitotoxicity, among others. Magnetic resonance imaging (MRI) offers the means to noninvasively probe many of these secondary injuries. MRI has been used to image anatomical, physiological, and functional changes associated with TBI in a longitudinal manner. This chapter describes controlled cortical impact (CCI) TBI surgical procedures, a few common MRI protocols used in TBI imaging, and, finally, image analysis pertaining to experimental TBI imaging in rats. C1 [Shen, Qiang; Watts, Lora Tally; Li, Wei; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Shen, Qiang; Li, Wei; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Watts, Lora Tally] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Shen, Q (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.; Shen, Q (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.; Shen, Q (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. NR 50 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3816-2; 978-1-4939-3814-8 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1462 BP 645 EP 658 DI 10.1007/978-1-4939-3816-2_35 D2 10.1007/978-1-4939-3816-2 PG 14 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA BH1UG UT WOS:000398551500037 PM 27604743 ER PT J AU Asselah, T Shafran, S Bourgeois, S Lai, CL Cramp, M Mathurin, P Willems, B Nguyen, MH Davis, MN Huang, KC Svarovskaia, E Osinusi, A Mcnally, J Brainard, D McHutchison, J Shaikh, OS Tran, TT AF Asselah, T. Shafran, S. Bourgeois, S. Lai, C. -L. Cramp, M. Mathurin, P. Willems, B. Nguyen, M. H. Davis, M. N. Huang, K. C. Svarovskaia, E. Osinusi, A. Mcnally, J. Brainard, D. McHutchison, J. Shaikh, O. S. Tran, T. T. TI SOFOSBUVIR/VELPATASVIR FIXED DOSE COMBINATION FOR 12 WEEKS IN HCV INFECTED PATIENTS PREVIOUSLY TREATED WITH PLACEBO: RESULTS OF THE DEFERRED TREATMENT STUDY (GS-US-342-1446 STUDY) SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [Asselah, T.] Univ Paris Diderot, INSERM, U773, Paris, France. [Shafran, S.] Univ Alberta, Edmonton, AB, Canada. [Bourgeois, S.] STER, ZNA, Dept Internal Med, Campus Stuivenberg, Antwerp, Belgium. [Lai, C. -L.] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Cramp, M.] South West Liver Unit, Plymouth, Devon, England. [Cramp, M.] Peninsula Sch Med, Plymouth, Devon, England. [Cramp, M.] Peninsula Sch Dent, Plymouth, Devon, England. [Mathurin, P.] Hop Claude Huriez, Serv Malad Appareil Digestif, Lille, France. [Willems, B.] Univ Montreal, Montreal, PQ, Canada. [Nguyen, M. H.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. [Davis, M. N.] South Florida Ctr Gastroenterol, Wellington, FL USA. [Huang, K. C.; Svarovskaia, E.; Osinusi, A.; Mcnally, J.; Brainard, D.; McHutchison, J.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Shaikh, O. S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Tran, T. T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. EM anu.osinusi@gilead.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA SAT-279 BP S827 EP S828 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER9GH UT WOS:000399133800204 ER PT J AU Basu, PP Shah, NJ Aloysius, MM Kavali, L Shehi, E Brown, RS AF Basu, P. P. Shah, N. J. Aloysius, M. M. Kavali, L. Shehi, E. Brown, R. S., Jr. TI SOFOSBUVIR AND LEDIPASVIR VERSUS SOFOSBUVIR AND SIMEPREVIR COMBINATION THERAPY IN THE MANAGEMENT OF ACUTE HEPATITIS C: A RANDOMIZED OPEN LABEL PROSPECTIVE CLINICAL PILOT STUDY. SLAM C STUDY SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [Basu, P. P.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Shah, N. J.] Univ N Carolina, Sch Med, Carolinas Med Ctr, Liver Transplant Ctr, Charlotte, NC USA. [Aloysius, M. M.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Kavali, L.; Shehi, E.] Kings Cty Hosp Med Ctr, New York, NY USA. [Brown, R. S., Jr.] Weill Cornell Med Coll, New York, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA SAT-234 BP S806 EP S806 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER9GH UT WOS:000399133800159 ER PT J AU Basu, PP Shah, NJ Aloysius, M Kavali, L Shehi, E AF Basu, P. P. Shah, N. J. Aloysius, M. Kavali, L. Shehi, E. TI OMBITASVIR (ABT 267), RITANAVIR BOOST WITH DASTASBUVIR (ABT 333) AND PRATASPRAVIR (ABT 450) WITH OR WITHOUT RIBAVIRIN (RBV) IN G1 SPECIAL POPULATION IN HEMODIALYSIS (HD) IN CHRONIC HEPATITIS C (HCV) PATIENTS DROP C TRIAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [Basu, P. P.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Shah, N. J.] Univ N Carolina, Liver Transplant Ctr, Sch Med, Carolinas Med Ctr, Charlotte, NC USA. [Aloysius, M.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Kavali, L.; Shehi, E.] Kings Cty Hosp Med Ctr, New York, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA SAT-237 BP S807 EP S808 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER9GH UT WOS:000399133800162 ER PT J AU Basu, PP Shah, NJ Aloysius, MM Kavali, L Shehi, E Brown, RS AF Basu, P. P. Shah, N. J. Aloysius, M. M. Kavali, L. Shehi, E. Brown, R. S., Jr. TI SOFOSBUVIR AND LEDIPASVIR IN ATTAINMENT OF SVR12 IN SICKLE CELL DISEASE (SCD) SUB-POPULATION WITH CHRONIC HEPATITIS C (CHC) A SINGLE CENTER PROSPECTIVE OPEN LABEL CLINICAL PILOT STUDY - SLASH C TRIAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [Basu, P. P.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Shah, N. J.] Univ N Carolina, Liver Transplant Ctr, Sch Med, Carolinas Med Ctr, Charlotte, NC USA. [Aloysius, M. M.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Kavali, L.; Shehi, E.] Kings Cty Hosp Med Ctr, New York, NY USA. [Brown, R. S., Jr.] Weill Cornell Med Coll, New York, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA SAT-235 BP S806 EP S807 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER9GH UT WOS:000399133800160 ER PT J AU Basu, PP Shah, NJ Aloysius, MM Kavali, L Shehi, E Brown, RS AF Basu, P. P. Shah, N. J. Aloysius, M. M. Kavali, L. Shehi, E. Brown, R. S., Jr. TI SOFOSBUVIR, LEDIPASVIR IN IBD TREATED PATIENTS WITH ADVANCED BIOLOGICS INCLUDING RIBAVIRIN ERADICATING CHRONIC HEPATITIS C: SOLATAIRE C TRIAL. A MULTI-CENTER CLINICAL PROSPECTIVE PILOT STUDY SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [Basu, P. P.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Shah, N. J.] Univ N Carolina, Liver Transplant Ctr, Sch Med, Carolinas Med Ctr, Charlotte, NC USA. [Aloysius, M. M.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Kavali, L.; Shehi, E.] Kings Cty Hosp Med Ctr, New York, NY USA. [Brown, R. S., Jr.] Weill Cornell Med Coll, New York, NY USA. EM basu.patrick@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA SAT-236 BP S807 EP S807 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER9GH UT WOS:000399133800161 ER PT J AU Jacobson, I Brau, N Bourgeois, S Mathurin, P Thuluvath, P Fessel, WJ Ryder, S Gerken, G Liu, L Ding, X McNally, J Osinusi, A Brainard, D Subramanian, M Foster, G AF Jacobson, I. Brau, N. Bourgeois, S. Mathurin, P. Thuluvath, P. Fessel, W. J. Ryder, S. Gerken, G. Liu, L. Ding, X. McNally, J. Osinusi, A. Brainard, D. Subramanian, M. Foster, G. TI THE TOLERABILITY OF SOF/VEL FOR 12 WEEKS IN > 1,000 PATIENTS TREATED IN THE ASTRAL-1, ASTRAL-2, AND ASTRAL-3 STUDIES: AN INTEGRATED SAFETY ANALYSIS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [Jacobson, I.] Mt Sinai Beth Israel Med Ctr, New York, NY USA. [Brau, N.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Bourgeois, S.] Campus Stuivenberg, Antwerp, Belgium. [Mathurin, P.] CHU Lille, Lille, France. [Mathurin, P.] Univ Nord de France, Lille, France. [Thuluvath, P.] Inst Digest Hlth & Liver Dis, Baltimore, MD USA. [Fessel, W. J.] Kaiser Permanente, San Francisco, CA USA. [Ryder, S.] Queens Med Ctr Campus, Nottingham, England. [Gerken, G.] Klin Gastroenterol & Hepatol, Med Zentrum, Essen, Germany. [Liu, L.; Ding, X.; McNally, J.; Osinusi, A.; Brainard, D.; Subramanian, M.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Foster, G.] Queen Mary Univ London, London, England. EM john.mcnally@gilead.com NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA SAT-168 BP S773 EP S774 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER9GH UT WOS:000399133800093 ER PT J AU McCombs, J McGinnis, J Fox, S Tonnu-Mihara, I AF McCombs, J. McGinnis, J. Fox, S. Tonnu-Mihara, I. TI ANALYSIS OF THE REAL-WORLD EFFECTIVENESS OF DIRECT ACTING ANTIVIRAL TREATMENTS FOR HEPATITIS C IN A LARGE POPULATION SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [McCombs, J.; McGinnis, J.; Fox, S.] Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA. [McGinnis, J.; Tonnu-Mihara, I.] US Dept Vet Affairs, Vet Hlth Adm, Long Beach, CA USA. [Fox, S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. EM justin.mcginnis@usc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA LBP510 BP S217 EP S217 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER3QE UT WOS:000398711700182 ER PT J AU McGinnis, J McCombs, J Mehta, D Fox, S Tonnu-Mihara, I AF McGinnis, J. McCombs, J. Mehta, D. Fox, S. Tonnu-Mihara, I. TI ANALYSIS OF THE IMPACT OF HIV CO-INFECTION ON HEPATITIS C TREATMENT EFFECTIVENESS FOR PATIENTS USING NEW DIRECT-ACTING ANTIVIRALS SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT EASL International Liver Congress CY APR 13-17, 2016 CL Barcelona, SPAIN SP EASL C1 [McGinnis, J.; McCombs, J.; Mehta, D.; Fox, S.] Univ Southern Calif, Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA. [McGinnis, J.; Tonnu-Mihara, I.] US Dept Vet Affairs, Vet Hlth Adm, Long Beach, CA USA. [Fox, S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. EM justin.mcginnis@usc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PY 2016 VL 64 SU 2 MA LBP514 BP S219 EP S220 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER3QE UT WOS:000398711700186 ER PT S AU Swenson, ER AF Swenson, Erik R. BE Roach, RC Wagner, PD Hackett, PH TI Hypoxia and Its Acid-Base Consequences: From Mountains to Malignancy SO HYPOXIA: TRANSLATION IN PROGRESS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Hypoxia; HIF; pH regulation; Alkalosis; Acidosis; Exercise; Cancer; Shock; Ischemia; Altitude; Lactate; Carbonic anhydrase ID CARBONIC-ANHYDRASE-IX; ALTITUDE PULMONARY-EDEMA; HUMAN-TUMOR XENOGRAFTS; HUMAN SKELETAL-MUSCLE; ACUTE LUNG INJURY; INTRACELLULAR PH; EXTRACELLULAR PH; LACTIC-ACIDOSIS; HYPERCAPNIC ACIDOSIS; METABOLIC-ACIDOSIS AB Hypoxia, depending upon its magnitude and circumstances, evokes a spectrum of mild to severe acid-base changes ranging from alkalosis to acidosis, which can alter many responses to hypoxia at both non-genomic and genomic levels, in part via altered hypoxiainducible factor (HIF) metabolism. Healthy people at high altitude and persons hyperventilating to non-hypoxic stimuli can become alkalotic and alkalemic with arterial pH acutely rising as high as 7.7. Hypoxia-mediated respiratory alkalosis reduces sympathetic tone, blunts hypoxic pulmonary vasoconstriction and hypoxic cerebral vasodilation, and increases hemoglobin oxygen affinity. These effects and others can be salutary or counterproductive to tissue oxygen delivery and utilization, based upon magnitude of each effect and summation. With severe hypoxia either in the setting of profound arterial hemoglobin desaturation and reduced O-2 content or poor perfusion (ischemia) at the global or local level, metabolic and hypercapnic acidosis develop along with considerable lactate formation and pH falling to below 6.8. Although conventionally considered to be injurious and deleterious to cell function and survival, both acidoses may be cytoprotective by various anti-inflammatory, antioxidant, and anti-apoptotic mechanisms which limit total hypoxic or ischemic-reperfusion injury. Attempts to correct acidosis by giving bicarbonate or other alkaline agents under these circumstances ahead of or concurrent with reoxygenation efforts may be ill advised. Better understanding of this so-called "pH paradox" or permissive acidosis may offer therapeutic possibilities. Rapidly growing cancers often outstrip their vascular supply compromising both oxygen and nutrient delivery and metabolic waste disposal, thus limiting their growth and metastatic potential. However, their excessive glycolysis and lactate formation may not necessarily represent oxygen insufficiency, but rather the Warburg effect-an attempt to provide a large amount of small carbon intermediates to supply the many synthetic pathways of proliferative cell growth. In either case, there is expression and upregulation of many genes involved in acid-base homeostasis, in part by HIF-1 signaling. These include a unique isoform of carbonic anhydrase (CA-IX) and numerous membrane acid-base transporters engaged to maintain an optimal intracellular and extracellular pH for maximal growth. Inhibition of these proteins or gene suppression may have important therapeutic application in cancer chemotherapy. C1 [Swenson, Erik R.] Univ Washington, Dept Med, Pulm & Crit Care Med, Seattle, WA 98195 USA. [Swenson, Erik R.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA. [Swenson, Erik R.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Swenson, ER (reprint author), Univ Washington, Dept Med, Pulm & Crit Care Med, Seattle, WA 98195 USA.; Swenson, ER (reprint author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.; Swenson, ER (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM eswenson@u.washington.edu NR 171 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0065-2598 BN 978-1-4899-7678-9; 978-1-4899-7676-5 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 903 BP 301 EP 323 DI 10.1007/978-1-4899-7678-9_21 D2 10.1007/978-1-4899-7678-9 PG 23 WC Medicine, Research & Experimental; Physiology; Respiratory System SC Research & Experimental Medicine; Physiology; Respiratory System GA BH0SN UT WOS:000396397300021 PM 27343105 ER PT J AU Kuffer, AL Thoma, MV Maercker, A AF Kuffer, Andreas L. Thoma, Myriam V. Maercker, Andreas TI Transgenerational aspects of former Swiss child laborers: do second generations suffer from their parents' adverse early-life experiences? SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE Childhood maltreatment; transgenerational effect; psychopathology; parental rearing behavior; sense of coherence; pessimism/optimism ID QUESTIONNAIRE-SHORT-FORM; KHMER-ROUGE REGIME; TRAUMA QUESTIONNAIRE; REARING BEHAVIOR; HOLOCAUST SURVIVORS; MENTAL-HEALTH; T TESTS; ADULTHOOD; ANXIETY; SAMPLE AB Background: Recent research suggests that childhood adversity exerts a lasting impact not only on the affected individuals but also on their offspring. Little is known about the role of parental rearing behavior in the transgenerational conveyance of parental childhood adversity and filial psychological health. Objective: Hence, it was the aim of the current study to investigate the relationship between parental rearing behavior of former Swiss indentured child laborers ("Verdingkinder'') and psychological health of their adult offspring. Methods: We applied a two-generation control-group design with two parental samples (n = 16, former "Verdingkinder,'' M-age = 76.13, SD = 6.81 and n = 19, parental controls, M-age = 72.63, SD = 5.96) and their offspring (n = 21, former "Verdingkinder'' offspring, M-age = 52.91, SD = 5.90, and n = 29 offspring controls, M-age = 44.55, SD = 7.71). Parental rearing behavior, childhood trauma, and psychological health were assessed with questionnaires. Data were analyzed using Bayesian analyses, where Bayes factors (BF) of 3 or higher were considered as substantial evidence for the tested hypotheses. Results: We found that "Verdingkinder'' offspring reported more physical abuse (BF10 = 5.197) and higher total childhood trauma exposure (BF10 = 2.476). They described both their fathers (BF10 = 14.246) and mothers (BF10 = 24.153) as less emotional and their mothers as more punitive (BF10 = 18.725). An increased sense of reflection, for instance, one's ability to take different perspectives, was found in the offspring controls (BF10 = 5.245). Furthermore, exploratory analyses revealed that lower perceived familial emotionality was associated with higher psychopathology (all BF10 = 10.471) and higher pessimism (all BF10 = 5.396). Discussion: Our data provide cross-sectional evidence of a meaningful transgenerational relationship between parental childhood adversity, dysfunctional rearing behavior, and psychological health of offspring. Prospective studies are needed to investigate these findings in a longitudinal setting. C1 [Kuffer, Andreas L.; Thoma, Myriam V.; Maercker, Andreas] Univ Zurich, Div Psychopathol & Clin Intervent, Dept Psychol, Zurich, Switzerland. [Kuffer, Andreas L.; Thoma, Myriam V.; Maercker, Andreas] Univ Zurich, Univ Res Prior Program Dynam Hlth Aging, Zurich, Switzerland. [Kuffer, Andreas L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Kuffer, Andreas L.] San Francisco VA Med Ctr, 4150 Clement St P 116, San Francisco, CA 94121 USA. RP Kuffer, AL (reprint author), San Francisco VA Med Ctr, 4150 Clement St P 116, San Francisco, CA 94121 USA. EM Andreas.kueffer@ucsf.edu FU University Research Priority Program "Dynamics of Healthy Aging'' at the University of Zurich FX This study was supported by the University Research Priority Program "Dynamics of Healthy Aging'' at the University of Zurich. NR 46 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2016 VL 7 AR 30804 DI 10.3402/ejpt.v7.30804 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EN7GJ UT WOS:000396169800001 PM 27784510 ER PT J AU Yehuda, R Spiegel, D Southwick, S Davis, LL Neylan, TC Krystal, JH AF Yehuda, Rachel Spiegel, David Southwick, Steven Davis, Lori L. Neylan, Thomas C. Krystal, John H. TI What I have changed my mind about and why SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE PTSD; resilience; evidenced based treatments; fear extinction; alternative treatments; neurobiology; pharmacotherapy; novel approaches; mindfulness; randomized clinical trials ID POSTTRAUMATIC-STRESS-DISORDER; VETERANS; TRIAL AB This paper is based upon a panel discussion "What I Have Changed My Mind About and Why'' held on 5 November in New Orleans, Louisiana (USA), as part of the ISTSS 2015 annual meeting "Back to Basics: Integrating Clinical and Scientific Knowledge to Advance the Field of Trauma.'' The panel was chaired by Professor Dr. Rachel Yehuda of the Icahn School of Medicine at Mount Sinai and the James J. Peters Veterans Affairs, and included five clinician-scholars who exchanged thoughts about what they have changed their minds about over the years: Dr. David Spiegel, Dr. Steven Southwick, Dr. Lori Davis, Dr. Thomas Neylan, and Dr. John Krystal. This paper provides a summary of the salient points made by each expert and the questions and discussion that ensured. Major issues raised included the increasingly clear limitations to the fear-based model that has advanced the field. While treatments for PTSD have improved, there are some aspects of trauma exposure that cannot be entirely repaired. Research providing an evidence base to treatment has led to overly specific treatment guidelines that may obscure more general principles of effective treatment. Treatment might be viewed as a way to increase the plasticity of the brain in the context of processing social cues. A variety of novel and integrative therapies include comprehensive holistic care, exercise, returning to competitive work, logotherapy, mindfulness, enhancing wellbeing and resilience, and medications with novel mechanisms, such as ketamine. C1 [Yehuda, Rachel] James J Peters Vet Affairs, New York, NY USA. [Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Spiegel, David] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA USA. [Southwick, Steven; Krystal, John H.] Yale Univ, Sch Med, New Haven, CT USA. [Southwick, Steven; Krystal, John H.] Vet Adm, Natl Ctr PTSD, Clin Neurosci Div, West Haven, CT USA. [Davis, Lori L.] Univ Alabama Hlth Syst, Dept Psychiat & Behav Neurobiol, Birmingham, AL USA. [Neylan, Thomas C.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Neylan, Thomas C.] San Francisco VA, San Francisco, CA USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.yehuda@va.gov NR 24 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2016 VL 7 AR 33768 DI 10.3402/ejpt.v7.33768 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EN7GL UT WOS:000396170000001 PM 27837585 ER PT J AU Sharma, A Hoover, DR Shi, QH Holman, S Plankey, MW Wheeler, AL Weber, K Floris-Moore, M Bolivar, HH Vance, DE Mack, WJ Golub, ET Holstad, MM Yin, MT AF Sharma, Anjali Hoover, Donald R. Shi, Qiuhu Holman, Susan Plankey, Michael W. Wheeler, Amber L. Weber, Kathleen Floris-Moore, Michelle Bolivar, Hector H. Vance, David E. Mack, Wendy J. Golub, Elizabeth T. Holstad, Marcia McDonnell Yin, Michael T. TI Falls among middle-aged women in the Women's Interagency HIV Study SO ANTIVIRAL THERAPY LA English DT Article ID RISK-FACTORS; ANTIRETROVIRAL THERAPY; INFECTED PERSONS; ELDERLY PERSONS; OLDER-ADULTS; GERIATRIC SYNDROMES; GENERAL-POPULATION; FRACTURES; COHORT; POLYPHARMACY AB Background: To determine the frequency and risk factors for falls among middle-aged HIV+ and HIV-women in the Women's Interagency HIV Study (WIHS). Methods: We quantified self-report of any and multiple (>= 2) falls in the prior 6 months among 1,412 HIV+ and 650 HIV-women with mean age 48 years. Logistic regression was used to evaluate associations of demographics, behavioural factors, comorbid conditions and medications with odds of any fall (versus none) and multiple falls (versus <= 1 fall). Results: At least one fall was reported in 263 HIV+ (19%) versus 119 HIV-(18%) women, and >= 2 falls reported in 133 HIV+ (9%) versus 65 HIV-(10%) women. HIV infection was not associated with falls in multivariate analyses. Factors independently associated with any fall included age (adjusted odds ratio [aOR] 1.71, 95% CI 1.17, 2.49 age 50-59 versus < 39 years; aOR 2.26, 95% CI 1.38, 3.71 age >= 60 versus < 39), current marijuana use (aOR 2.19, 95% CI 1.53, 3.13) depressive symptoms (aOR 1.57, 95% CI 1.21, 2.05 for Center for Epidemiology Studies Depression score >= 16), subjective cognitive complaints (aOR 2.19, 95% CI 1.56, 3.08), neuropathy (aOR 1.59, 95% CI 1.19, 2.13), obesity (aOR 1.39, 95% CI 1.08, 1.80), number of central nervous system active agents (aOR 2.98, 95% CI 1.90, 4.68 for >= 3 agents versus 0) and WIHS site. Factors associated with >= 2 falls included age, marijuana use, number of central nervous system active agents, subjective cognitive complaints, depressive symptoms, neuropathy and study site. Conclusions: Falls were associated with factors affecting cognition, but not HIV status in this large cohort of women. Longitudinal studies are needed to determine the incidence and consequences of falls by HIV status as women age. C1 [Sharma, Anjali] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Shi, Qiuhu] New York Med Coll, Dept Epidemiol & Community Hlth, Valhalla, NY 10595 USA. [Holman, Susan] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Plankey, Michael W.] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Wheeler, Amber L.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Weber, Kathleen] John H Stroger Jr Hosp Cook Cty, Dept Med, Chicago, IL USA. [Floris-Moore, Michelle] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC USA. [Bolivar, Hector H.] Univ Miami Hlth Syst, Dept Med, Miami, FL USA. [Vance, David E.] Univ Alabama Birmingham, Sch Nursing, Birmingham, AL USA. [Mack, Wendy J.] Univ Southern Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Golub, Elizabeth T.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Holstad, Marcia McDonnell] Emory Sch Nursing, Off Acad Adv, Atlanta, GA USA. [Yin, Michael T.] Columbia Univ, Dept Med, Med Ctr, New York, NY USA. RP Sharma, A (reprint author), Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. EM anjali.sharma@einstein.yu.edu FU National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Cancer Institute (NCI); National Institute on Drug Abuse (NIDA); National Institute on Mental Health (NIMH); National Institute of Dental and Craniofacial Research (NIDCR); National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute on Deafness and other Communication Disorders (NIDCD); NIH Office of Research on Women's Health; National Institutes of Health [K23AR06199301] FX Data in this manuscript were collected by the WIHS. The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH). The WIHS is funded primarily by the National Institute of Allergy and Infectious Diseases (NIAID), with additional co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Cancer Institute (NCI), the National Institute on Drug Abuse (NIDA) and the National Institute on Mental Health (NIMH). Targeted supplemental funding for specific projects is also provided by the National Institute of Dental and Craniofacial Research (NIDCR), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Deafness and other Communication Disorders (NIDCD) and the NIH Office of Research on Women's Health. WIHS data collection is also supported by UL1-TR000004 (UCSF CTSA) and UL1-TR000454 (Atlanta CTSA). This research was also supported by National Institutes of Health K23AR06199301 (AS). NR 49 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2016 VL 21 IS 8 BP 697 EP 706 DI 10.3851/IMP3070 PG 10 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA EN6BP UT WOS:000396089800007 PM 27427794 ER PT S AU Niquet, J Baldwin, R Suchomelova, L Lumley, L Naylor, D Eavey, R Wasterlain, CG AF Niquet, Jerome Baldwin, Roger Suchomelova, Lucie Lumley, Lucille Naylor, David Eavey, Roland Wasterlain, Claude G. BE Laskin, JD Braaten, D TI Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment SO COUNTERMEASURES AGAINST CHEMICAL THREATS II SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE refractory status epilepticus; cholinergic seizures; pharmacoresistance; polytherapy; nerve agent ID SUSTAINING STATUS EPILEPTICUS; LIMBIC STATUS EPILEPTICUS; CONVULSIVE STATUS EPILEPTICUS; RECEPTOR ANTAGONISTS; GABA(A) RECEPTORS; PERFORANT-PATH; RECTAL GEL; STIMULATION; SEIZURES; RATS AB Cholinergic status epilepticus (CSE) quickly becomes self-sustaining, independent of its initial trigger, and resistant to benzodiazepines and other antiepileptic drugs. We review a few of the many physiological changes associated with CSE, with an emphasis on receptor trafficking. Time-dependent internalization of synaptic gamma-aminobutyric acid (GABA)(A) receptors explains, in part, the loss of inhibition and the loss of response to benzodiazepines in the early stages of CSE. The increase in N-methyl-D-aspartate receptors may contribute to the runaway excitation and excitotoxicity of CSE. These changes have therapeutic implications. The time-dependent increase in maladaptive changes points to the importance of early treatment. The involvement of both inhibitory and excitatory systems challenges current therapeutic guidelines, which recommend treating only one system, and questions the rationale for monotherapy. It suggests that polytherapy may be needed, especially when treatment is delayed, so that drugs can only reach amuch reduced number of GABA(A) receptors. Finally, it raises the possibility that the current practice of waiting for one treatment to fail before starting the next drug may need to be reevaluated. C1 [Niquet, Jerome; Naylor, David; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Niquet, Jerome; Baldwin, Roger; Suchomelova, Lucie; Eavey, Roland; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, 11301 Wilshire Blvd,Bldg 114,Room 139, West Los Angeles, CA 90073 USA. [Lumley, Lucille] USAMRICD, Aberdeen, MD USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, 11301 Wilshire Blvd,Bldg 114,Room 139, West Los Angeles, CA 90073 USA. EM jniquet@ucla.edu FU BLRD VA [I01 BX000273]; NINDS NIH HHS [U01 NS074926] NR 37 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1378 BP 166 EP 173 DI 10.1111/nyas.13147 PG 8 WC Chemistry, Applied; Public, Environmental & Occupational Health; Toxicology SC Chemistry; Public, Environmental & Occupational Health; Toxicology GA BG9XR UT WOS:000394087800018 PM 27392038 ER PT S AU Hodes, RJ Sierra, F Austad, SN Epel, E Neigh, GN Erlandson, KM Schafer, MJ LeBrasseur, NK Wiley, C Campisi, J Sehl, ME Scalia, R Eguchi, S Kasinath, BS Halter, JB Cohen, HJ Demark-Wahnefried, W Ahles, TA Barzilai, N Hurria, A Hunt, PW AF Hodes, Richard J. Sierra, Felipe Austad, Steven N. Epel, Elissa Neigh, Gretchen N. Erlandson, Kristine M. Schafer, Marissa J. LeBrasseur, Nathan K. Wiley, Christopher Campisi, Judith Sehl, Mary E. Scalia, Rosario Eguchi, Satoru Kasinath, Balakuntalam S. Halter, Jeffrey B. Cohen, Harvey Jay Demark-Wahnefried, Wendy Ahles, Tim A. Barzilai, Nir Hurria, Arti Hunt, Peter W. GP NY Acad Sci BE Braaten, D TI Disease drivers of aging SO ANNALS REPORTS, VOL 1386 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE disease; aging; pathology; chronic; prevention; age-related; HIV; diabetes; cancer ID QUALITY-OF-LIFE; BETA-CELL PROLIFERATION; TERM CANCER SURVIVORS; CHRONIC HIV-INFECTION; INSULIN-RESISTANCE; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; ISCHEMIA-REPERFUSION; HYDROGEN-SULFIDE; OXIDATIVE-STRESS AB It has long been known that aging, at both the cellular and organismal levels, contributes to the development and progression of the pathology of many chronic diseases. However, much less research has examined the inverse relationship-the contribution of chronic diseases and their treatments to the progression of aging-related phenotypes. Here, we discuss the impact of three chronic diseases (cancer, HIV/AIDS, and diabetes) and their treatments on aging, putative mechanisms by which these effects are mediated, and the open questions and future research directions required to understand the relationships between these diseases and aging. C1 [Hodes, Richard J.; Sierra, Felipe] NIA, Bethesda, MD 20892 USA. [Austad, Steven N.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA. [Epel, Elissa] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Neigh, Gretchen N.] Virginia Commonwealth Univ, Richmond, VA USA. [Erlandson, Kristine M.] Univ Colorado, Anschutz Med Ctr, Aurora, CO USA. [Schafer, Marissa J.; LeBrasseur, Nathan K.] Mayo Clin, Coll Med, Robert & Arlene Kogod Ctr Aging, Rochester, MN USA. [Schafer, Marissa J.; LeBrasseur, Nathan K.] Mayo Clin, Coll Med, Dept Phys Med & Rehabil, Rochester, MN USA. [Wiley, Christopher; Campisi, Judith] Buck Inst Res Aging, Novato, CA USA. [Sehl, Mary E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Scalia, Rosario; Eguchi, Satoru] Temple Univ, Lewis Katz Sch Med, Dept Physiol, Philadelphia, PA 19122 USA. [Scalia, Rosario; Eguchi, Satoru] Temple Univ, Lewis Katz Sch Med, Cardiovasc Res Ctr, Philadelphia, PA 19122 USA. [Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Halter, Jeffrey B.] Univ Michigan, Div Geriatr & Palliat Med, Ann Arbor, MI 48109 USA. [Cohen, Harvey Jay] Duke Univ, Sch Med, Durham, NC USA. [Demark-Wahnefried, Wendy] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Ahles, Tim A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Barzilai, Nir] Albert Einstein Coll Med, Inst Aging Res, New York, NY USA. [Hurria, Arti] City Hope Natl Med Ctr, Natl Med Ctr, Duarte, CA USA. [Hunt, Peter W.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. RP Hodes, RJ (reprint author), NIA, Bethesda, MD 20892 USA. EM annals@nyas.org OI Scalia, Rosario/0000-0002-1829-943X FU NIA NIH HHS [P30 AG038072, K23 AG050260, P30 AG050886]; NIDDK NIH HHS [P30 DK079626] NR 160 TC 1 Z9 1 U1 2 U2 2 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1386 BP 45 EP 68 DI 10.1111/nyas.13299 PG 24 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BG9XT UT WOS:000394090800004 PM 27943360 ER PT J AU Moin, T Damschroder, LJ Youles, B Makki, F Billington, C Yancy, W Maciejewski, ML Kinsinger, LS Weinreb, JE Steinle, N Richardson, CR AF Moin, Tannaz Damschroder, Laura J. Youles, Bradley Makki, Fatima Billington, Charles Yancy, William Maciejewski, Matthew L. Kinsinger, Linda S. Weinreb, Jane E. Steinle, Nanette Richardson, Caroline R. TI Implementation of a prediabetes identification algorithm for overweight and obese Veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE diabetes; diabetes prevention; guidelines; health services research; implementation research; obesity; prediabetes; screening; Veterans; weight management ID FINNISH DIABETES PREVENTION; WEIGHT-MANAGEMENT PROGRAM; LIFE-STYLE INTERVENTIONS; FOLLOW-UP; TYPE-2; REDUCTION; ADULTS; RISK; HEMOGLOBIN; CRITERIA AB Type 2 diabetes prevention is an important national goal for the Veterans Health Administration (VHA): one in four Veterans has diabetes. We implemented a prediabetes identification algorithm to estimate prediabetes prevalence among overweight and obese Veterans at Department of Veterans Affairs (VA) medical centers (VAMCs) in preparation for the launch of a pragmatic study of Diabetes Prevention Program (DPP) delivery to Veterans with prediabetes. This project was embedded within the VA DPP Clinical Demonstration Project conducted from 2012 to 2015. Veterans who attended orientation sessions for an established VHA weight-loss program (MOVE!) were recruited from VAMCs with geographically and racially diverse populations using existing referral processes. Each site implemented and adapted the prediabetes identification algorithm to best fit its local clinical context. Sites relied on an existing referral process in which a prediabetes identification algorithm was implemented in parallel with existing clinical flow; this approach limited the number of overweight and obese Veterans who were assessed and screened. We evaluated 1,830 patients through chart reviews, interviews, and/or laboratory tests. In this cohort, our estimated prevalence rates for normal glycemic status, prediabetes, and diabetes were 29% (n = 530), 28% (n = 504), and 43% (n = 796), respectively. Implementation of targeted prediabetes identification programs requires careful consideration of how prediabetes assessment and screening will occur. C1 [Moin, Tannaz; Weinreb, Jane E.] Dept Vet Affairs VA Greater Los Angeles Healthcar, Los Angeles, CA USA. [Moin, Tannaz; Weinreb, Jane E.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Moin, Tannaz] VA Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev, Ctr Study Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Damschroder, Laura J.; Youles, Bradley; Makki, Fatima; Richardson, Caroline R.] VA Ctr Clin Management Res, Ann Arbor, MI USA. [Billington, Charles] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Billington, Charles] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Yancy, William; Maciejewski, Matthew L.] Durham VA Med Ctr VAMC, Durham, NC USA. [Yancy, William; Maciejewski, Matthew L.] Duke Univ, Sch Med, Durham, NC USA. [Kinsinger, Linda S.] Vet Hlth Adm, Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA. [Steinle, Nanette] Baltimore VAMC, Baltimore, MD USA. [Steinle, Nanette] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Richardson, Caroline R.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Richardson, Caroline R.] VA Diabet Qual Enhancement Res Initiat, Ann Arbor, MI USA. RP Moin, T (reprint author), VA Greater Los Angeles Healthcare Syst, Mail Code 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Tannaz.moin@va.gov FU VA [XVA 41-048, RRP 12-440, SDP 12-549]; VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program, VA Greater Los Angeles [TPM65-010] FX This material was based on work supported by the VA (awards XVA 41-048, RRP 12-440, and SDP 12-549). Dr. Moin received support from the VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program (award TPM65-010), VA Greater Los Angeles, from 2011 to 2014. NR 31 TC 0 Z9 0 U1 1 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2016 VL 53 IS 6 BP 853 EP 862 DI 10.1682/JRRD.2015.06.0104 PG 10 WC Rehabilitation SC Rehabilitation GA EK5SC UT WOS:000393985100017 PM 28273326 ER PT J AU Weinstein, SR Meehan, KB Cain, NM Ripoll, LH Boussi, AR Papouchis, N Siever, LJ New, AS AF Weinstein, Shauna R. Meehan, Kevin B. Cain, Nicole M. Ripoll, Luis H. Boussi, Ayelet R. Papouchis, Nicholas Siever, Larry J. New, Antonia S. TI Mental State Identification, Borderline Pathology, and the Neglected Role of Childhood Trauma SO PERSONALITY DISORDERS-THEORY RESEARCH AND TREATMENT LA English DT Article DE borderline personality disorder; childhood trauma; mental state identification; mentalization; RMET ID POSTTRAUMATIC-STRESS-DISORDER; PERSONALITY-DISORDER; ASPERGER-SYNDROME; NORMAL ADULTS; EYES TEST; EMOTION; MIND; RECOGNITION; AUTISM; WOMEN AB Research evaluating mental state identification in individuals with borderline pathology has yielded inconsistent results; contradictory findings were hypothesized to be driven by moderating effects of childhood trauma. Participants were 105 ethnically diverse men and women who exhibited a range of borderline pathology measured by Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for borderline personality disorder. Mental state identification accuracy was measured using the Reading the Mind in the Eyes Test (RMET). Greater childhood abuse, but not childhood neglect, was associated with enhanced mental state identification accuracy on negative stimuli, when controlling for dissociation (ps < .05); these findings could not be explained by reaction time (RT) or response bias. Childhood abuse and childhood neglect were not related to mental state identification accuracy on neutral or positive stimuli, and they did not moderate the relationship between borderline pathology and mental state identification accuracy on negative, neutral, or positive stimuli. Borderline pathology was not independently related to mental state identification accuracy on negative, neutral, or positive stimuli. Greater childhood neglect, but not childhood abuse, was related to slower RTs on negative, neutral, and positive stimuli (ps < .05). Results underline the importance of separately assessing childhood abuse and childhood neglect and of controlling for dissociation, and they suggest borderline pathology may not universally hinder complex mental state identification. C1 [Weinstein, Shauna R.; Meehan, Kevin B.; Cain, Nicole M.; Boussi, Ayelet R.; Papouchis, Nicholas] Long Isl Univ, Dept Psychol, Brooklyn Campus, Brookville, NY USA. [Ripoll, Luis H.; Siever, Larry J.; New, Antonia S.] James J Peters VA Med Ctr, MIRECC, Bronx, NY USA. [Ripoll, Luis H.; Boussi, Ayelet R.; Siever, Larry J.; New, Antonia S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Weinstein, Shauna R.] Elmhurst Hosp Ctr, Queens, NY USA. [Ripoll, Luis H.] New York Psychoanalyt Inst, New York, NY USA. RP Weinstein, SR (reprint author), Long Isl Univ, Dept Psychol, 1 Univ Plaza, Brooklyn, NY 11201 USA. EM shaunaweinstein3@gmail.com NR 34 TC 0 Z9 0 U1 1 U2 2 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1949-2715 EI 1949-2723 J9 PERSONAL DISORD JI Personal. Disord. PD JAN PY 2016 VL 7 IS 1 BP 61 EP 71 DI 10.1037/per0000139 PG 11 WC Psychology, Clinical SC Psychology GA EL3GH UT WOS:000394507100008 PM 26461046 ER PT J AU Allahabadi, S Haroun, KB Musher, DM Lipsky, BA Barshes, NR AF Allahabadi, Sachin Haroun, Kareem B. Musher, Daniel M. Lipsky, Benjamin A. Barshes, Neal R. TI Consensus on surgical aspects of managing osteomyelitis in the diabetic foot SO DIABETIC FOOT & ANKLE LA English DT Article DE osteomyelitis; foot infection; foot ulcer; forefoot; diabetic foot; diabetes; consensus; Delphi methodology; consensus ID RANDOMIZED CONTROLLED-TRIAL; CONSERVATIVE SURGERY; CLINICAL-TRIAL; AMPUTATION; THERAPY; ULCERS; TRANSMETATARSAL; ANTIBIOTICS; MULTICENTER; MANAGEMENT AB Background: The aim of this study was to develop consensus statements that may help share or even establish 'best practices' in the surgical aspects of managing diabetic foot osteomyelitis (DFO) that can be applied in appropriate clinical situations pending the publication of more high-quality data. Methods: We asked 14 panelists with expertise in DFO management to participate. Delphi methodology was used to develop consensus statements. First, a questionnaire elicited practices and beliefs concerning various aspects of the surgical management of DFO. Thereafter, we constructed 63 statements for analysis and, using a nine-point Likert scale, asked the panelists to indicate the extent to which they agreed or disagreed with the statements. We defined consensus as a mean score of greater than 7.0. Results: The panelists reached consensus on 38 items after three rounds. Among these, seven provide guidance on initial diagnosis of DFO and selection of patients for surgical management. Another 15 statements provide guidance on specific aspects of operative management, including the timing of operations and the type of specimens to be obtained. Ten statements provide guidance on postoperative management, including wound closure and offloading, and six statements summarize the panelists' agreement on general principles for surgical management of DFO. Conclusions: Consensus statement on the perioperative management of DFO were formed with an expert panel comprised of a variety of surgical specialties. We believe these statements may serve as 'best practice' guidelines until properly performed studies provide more robust evidence to support or refute specific surgical management steps in DFO. C1 [Allahabadi, Sachin; Haroun, Kareem B.] Baylor Coll Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Div Infect Dis, Houston, TX 77030 USA. [Lipsky, Benjamin A.] Univ Washington, Dept Med, Seattle, WA USA. [Lipsky, Benjamin A.] Univ Geneva, Dept Med Infect Dis, Geneva, Switzerland. [Lipsky, Benjamin A.] Univ Oxford, Dept Med, Green Templeton Coll, Oxford, England. [Barshes, Neal R.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 28 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 2000-625X J9 DIABET FOOT ANKLE JI Diabet. Foot Ankle PY 2016 VL 7 AR 30079 DI 10.3402/dfa.v7.30079 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EJ3QB UT WOS:000393125600003 PM 27414481 ER PT J AU Brown, GK Karlin, BE Trockel, M Gordienko, M Yesavage, J Taylor, CB AF Brown, Gregory K. Karlin, Bradley E. Trockel, Mickey Gordienko, Maria Yesavage, Jerry Taylor, C. Barr TI Effectiveness of Cognitive Behavioral Therapy for Veterans with Depression and Suicidal Ideation SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE cognitive behavioral therapy; depression; suicide; suicidal ideation; veterans ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE-SYSTEM; NATIONAL-DISSEMINATION AB The current study examined suicidal ideation (SI) and depression outcomes among Veterans receiving Cognitive Behavioral Therapy for depression (CBT-D) throughout the Department of Veterans Affairs health care system. Patient outcomes included Beck Depression Inventory-II total score and SI item. Of 902 patients, 427 (47%) had no SI, 405 (45%) had SI but no suicidal intent, 26 (3%) indicated suicidal desire, 8 (1%) indicated suicide intent if they had the chance, and 36 (4%) did not answer this question at session one. The odds of SI decreased by 64% from 1.03 at session one to 0.37 at final assessment (OR = 0.36; 95% CI: 0.31, 0.43). Findings reveal that CBT-D was associated with significant decreases in SI and depression among Veterans. C1 [Brown, Gregory K.] US Dept Vet Affairs, VISN Mental Illness Res Educ & Clin Ctr 4, Philadelphia, PA USA. [Brown, Gregory K.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Karlin, Bradley E.] US Dept Vet Affairs, Mental Hlth Serv, Cent Off, Washington, DC USA. [Karlin, Bradley E.] Educ Dev Ctr Inc, Waltham, MA USA. [Karlin, Bradley E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Trockel, Mickey; Gordienko, Maria; Yesavage, Jerry; Taylor, C. Barr] Stanford Univ, Med Ctr, Dept Psychiat, Palo Alto, CA 94304 USA. [Trockel, Mickey; Gordienko, Maria; Yesavage, Jerry; Taylor, C. Barr] US Dept Vet Affairs, VISN Mental Illness Res Educ & Clin Ctr 21, Palo Alto, CA USA. [Karlin, Bradley E.] Johns Hopkins Univ, Educ Dev Ctr, Baltimore, MD 21218 USA. [Karlin, Bradley E.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. RP Karlin, BE (reprint author), Educ Dev Ctr Inc, 96 Morton St,7th Floor, New York, NY 10014 USA. EM bkarlin@edc.org FU Mental Health Services, U. S. Department of Veterans Affairs Central Office FX This project was supported by Mental Health Services, U. S. Department of Veterans Affairs Central Office. NR 16 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1381-1118 EI 1543-6136 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2016 VL 20 IS 4 BP 677 EP 682 DI 10.1080/13811118.2016.1162238 PG 6 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA EJ1PH UT WOS:000392982200014 PM 26983897 ER PT J AU Solinsky, R Svircev, JN James, JJ Burns, SP Bunnell, AE AF Solinsky, Ryan Svircev, Jelena N. James, Jennifer J. Burns, Stephen P. Bunnell, Aaron E. TI A retrospective review of safety using a nursing driven protocol for autonomic dysreflexia in patients with spinal cord injuries SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Review DE Autonomic dysreflexia; Spinal cord injuries; Hydralazine; Nitroglycerin ID AMBULATORY BLOOD-PRESSURE; MANAGEMENT; COMPLICATIONS; HYPERTENSION; BLADDER; BLOCKER; AGE AB Objective/Background: Autonomic dysreflexia is a potentially life-threatening condition which afflicts a significant proportion of individuals with spinal cord injuries (SCI). To date, the safety and efficacy of several commonly used interventions for this condition have not been studied. Design: A retrospective chart review of the safety of a previously implemented nursing driven inpatient autonomic dysreflexia protocol. Methods: Seventy-eight male patients with SCI who experienced autonomic dysreflexia while inpatient at our Veterans Affairs SCI unit over a 3-1/2-year period were included. The safety of a nursing driven protocol utilizing conservative measures, nitroglycerin paste, and oral hydralazine was evaluated. Outcome Measures: Occurrence of adverse events and relative hypotensive events during all episodes treated with the protocol, and efficacy of attaining target blood pressure for all episodes with protocol adherence and for initial episode experienced by each patient. Results: Four hundred forty-five episodes of autonomic dysreflexia were recorded in the study period, with 92% adherence to the protocol. When the protocol was followed, target blood pressure was achieved for 97.6% of all episodes. Twenty-three total adverse events occurred (5.2% of all episodes). All adverse events were due to hypotension and only 0.9% required interventions beyond clinical monitoring. Of each patient's initial autonomic dysreflexia episode, 97.3% resolved using the protocol without need for further escalation of care. Conclusion: This inpatient nursing driven-protocol for treating autonomic dysreflexia utilizing conservative measures, nitroglycerin paste and oral hydralazine achieved target blood pressure with a high success rate and a low incidence of adverse events. C1 [Solinsky, Ryan; Svircev, Jelena N.; Burns, Stephen P.; Bunnell, Aaron E.] Univ Washington, Dept Rehabil Med, 1959 NE Pacific St, Seattle, WA 98195 USA. [Svircev, Jelena N.; Burns, Stephen P.] Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. [James, Jennifer J.] Northwest Phys Med, Seattle, WA USA. [Bunnell, Aaron E.] Harborview Med Ctr, Seattle, WA USA. RP Solinsky, R (reprint author), Univ Washington, Dept Rehabil Med, 1959 NE Pacific St, Seattle, WA 98195 USA. NR 21 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2016 VL 39 IS 6 BP 713 EP 719 DI 10.1080/10790268.2015.1118186 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EJ0RI UT WOS:000392917600014 PM 26838482 ER PT J AU Melton, BL Zillich, AJ Saleem, JJ Russ, AL Tisdale, JE Overholser, BR AF Melton, Brittany L. Zillich, Alan J. Saleem, Jason J. Russ, Alissa L. Tisdale, James E. Overholser, Brian R. TI Iterative Development and Evaluation of a Pharmacogenomic-Guided Clinical Decision Support System for Warfarin Dosing SO APPLIED CLINICAL INFORMATICS LA English DT Article DE Clinical decision support systems; pharmacogenetics; CPOE; computer-assisted drug therapy; warfarin ID PERSONALIZED MEDICINE; RANDOMIZED-TRIAL; IMPLEMENTATION; PROGRAM; ANTICOAGULATION; INFORMATICS; UNIVERSITY; PROJECT; SERVICE; DESIGN AB Objective: Pharmacogenomic-guided dosing has the potential to improve patient outcomes but its implementation has been met with clinical challenges. Our objective was to develop and evaluate a clinical decision support system (CDSS) for pharmacogenomic-guided warfarin dosing designed for physicians and pharmacists. Methods: Twelve physicians and pharmacists completed 6 prescribing tasks using simulated patient scenarios in two iterations (development and validation phases) of a newly developed pharmacogenomic-driven CDSS prototype. For each scenario, usability was measured via efficiency, recorded as time to task completion, and participants' perceived satisfaction which were compared using Kruskal-Wallis and Mann Whitney U tests, respectively. Debrief interviews were conducted and qualitatively analyzed. Usability findings from the first (i.e. development) iteration were incorporated into the CDSS design for the second (i.e. validation) iteration. Results: During the CDSS validation iteration, participants took more time to complete tasks with a median (IQR) of 183 (124-247) seconds versus 101 (73.5-197) seconds in the development iteration (p=0.01). This increase in time on task was due to the increase in time spent in the CDSS corresponding to several design changes. Efficiency differences that were observed between pharmacists and physicians in the development iteration were eliminated in the validation iteration. The increased use of the CDSS corresponded to a greater acceptance of CDSS recommended doses in the validation iteration (4% in the first iteration vs. 37.5% in the second iteration, p<0.001). Overall satisfaction did not change statistically between the iterations but the qualitative analysis revealed greater trust in the second prototype. Conclusions: A pharmacogenomic-guided CDSS has been developed using warfarin as the test drug. The final CDSS prototype was trusted by prescribers and significantly increased the time using the tool and acceptance of the recommended doses. This study is an important step toward incorporating pharmacogenomics into CDSS design for clinical testing. C1 [Melton, Brittany L.] Univ Kansas, Sch Pharm, Lawrence, KS 66045 USA. [Zillich, Alan J.; Russ, Alissa L.; Tisdale, James E.; Overholser, Brian R.] Purdue Univ, Coll Pharm, Res Inst 2,Room 402,950 W Walnut St, Indianapolis, IN 46202 USA. [Zillich, Alan J.; Russ, Alissa L.] US Dept Vet Affairs, Ctr Hlth Informat & Commun, Vet Hlth Adm, Hlth Serv Res & Dev, Washington, DC USA. [Zillich, Alan J.; Russ, Alissa L.] Regenstrief Inst Inc, Indianapolis, IN USA. [Zillich, Alan J.; Russ, Alissa L.] Indiana Univ, Ctr Hlth Serv & Outcomes Res, Bloomington, IN 47405 USA. [Saleem, Jason J.] Univ Louisville, Dept Ind Engn, Louisville, KY 40292 USA. [Tisdale, James E.; Overholser, Brian R.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Overholser, BR (reprint author), Purdue Univ, Coll Pharm, Res Inst 2,Room 402,950 W Walnut St, Indianapolis, IN 46202 USA. EM boverhol@purdue.edu FU Lilly seed grant; VA HSR&D Research Career Development Award [CDA 11-214]; National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD) [K08HL095655] FX This work was supported by a Lilly seed grant to the Purdue University College of Pharmacy. Drs. Russ was supported in part by a VA HSR&D Research Career Development Award (CDA 11-214) and Dr. Overholser was supported in part by K08HL095655 (BRO) from the National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD). Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the U.S. government. NR 45 TC 0 Z9 0 U1 0 U2 0 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 1869-0327 J9 APPL CLIN INFORM JI Appl. Clin. Inform. PY 2016 VL 7 IS 4 BP 1088 EP 1106 DI 10.4338/ACI-2016-05-RA-0081 PG 19 WC Medical Informatics SC Medical Informatics GA EH7MZ UT WOS:000391958400012 PM 27878205 ER PT J AU Morillon, MB Stamp, L Taylor, W Fransen, J Dalbeth, N Singh, JA Christensen, R Lassere, M AF Morillon, Melanie B. Stamp, Lisa Taylor, William Fransen, Jaap Dalbeth, Nicola Singh, Jasvinder A. Christensen, Robin Lassere, Marissa TI Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis SO BMJ OPEN LA English DT Review ID THRESHOLD EFFECT STE; HIERARCHICAL LEVELS; EVALUATION SCHEMA; MANAGEMENT; SURVIVAL; TRIALS; METAANALYSIS; CRITERIA; CANCER; HYPERURICEMIA AB Introduction: Gout is the most common inflammatory arthritis in men over 40 years of age. Long-term urate-lowering therapy is considered a key strategy for effective gout management. The primary outcome measure for efficacy in clinical trials of urate-lowering therapy is serum urate levels, effectively acting as a surrogate for patient-centred outcomes such as frequency of gout attacks or pain. Yet it is not clearly demonstrated that the strength of the relationship between serum urate and clinically relevant outcomes is sufficiently strong for serum urate to be considered an adequate surrogate. Our objective is to investigate the strength of the relationship between changes in serum urate in randomised controlled trials and changes in clinically relevant outcomes according to the 'Biomarker-Surrogacy Evaluation Schema version 3' (BSES3), documenting the validity of selected instruments by applying the 'OMERACT Filter 2.0'. Methods and analysis: A systematic review described in terms of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines will identify all relevant studies. Standardised data elements will be extracted from each study by 2 independent reviewers and disagreements are resolved by discussion. The data will be analysed by meta-regression of the between-arm differences in the change in serum urate level (independent variable) from baseline to 3 months (or 6 and 12 months if 3-month values are not available) against flare rate, tophus size and number and pain at the final study visit (dependent variables). Ethics and dissemination: This study will not require specific ethics approval since it is based on analysis of published (aggregated) data. The intended audience will include healthcare researchers, policymakers and clinicians. Results of the study will be disseminated by peer-reviewed publications. C1 [Morillon, Melanie B.; Christensen, Robin] Copenhagen Univ Hosp, Parker Inst, Dept Rheumatol, Musculoskeletal Stat Unit, Frederiksberg, Denmark. [Morillon, Melanie B.] Odense Univ Hosp, Dept Rheumatol, Svendborg, Denmark. [Stamp, Lisa] Univ Otago, Dept Med, Christchurch, New Zealand. [Taylor, William] Univ Otago, Dept Med, Wellington, New Zealand. [Fransen, Jaap] Radboud Univ Nijmegen, Med Ctr, JF Dept Rheumatol, Nijmegen, Netherlands. [Dalbeth, Nicola] Univ Auckland, Dept Med, Auckland, New Zealand. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Lassere, Marissa] Univ NSW, St George Hosp, Dept Rheumatol, Sydney, NSW, Australia. RP Morillon, MB (reprint author), Copenhagen Univ Hosp, Parker Inst, Dept Rheumatol, Musculoskeletal Stat Unit, Frederiksberg, Denmark.; Morillon, MB (reprint author), Odense Univ Hosp, Dept Rheumatol, Svendborg, Denmark. EM melanie.birger.morillon@rsyd.dk OI Christensen, Robin/0000-0002-6600-0631 FU Oak Foundation FX Musculoskeletal Statistics Unit at the Parker Institute is supported by grants from the Oak Foundation. NR 26 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 9 AR e012026 DI 10.1136/bmjopen-2016-012026 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EG8JL UT WOS:000391302900134 ER PT J AU Akgun, KM Gruenewald, D Wertheimer, D Gabriel, M Rizzo, D Zuccaro, M Luhrs, C AF Akgun, K. M. Gruenewald, D. Wertheimer, D. Gabriel, M. Rizzo, D. Zuccaro, M. Luhrs, C. TI A National Va Palliative Care Quality Improvement Project For Improving Intensive Care Unit Family Meetings (icu-Fms) SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Akgun, K. M.] VA Connecticut, West Haven, CT USA. [Akgun, K. M.] Yale Univ, Sch Med, West Haven, CT 06516 USA. [Gruenewald, D.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Wertheimer, D.] VA Maryland Hlth Care Syst, Baltimore, MD USA. [Gabriel, M.; Zuccaro, M.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Rizzo, D.] Salem Vet Affairs Med Ctr, Salem, VA USA. [Luhrs, C.] Vet Affairs New York Harbor Healthcare Syst, Brooklyn, NY USA. EM kathleen.akgun@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A7925 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749608014 ER PT J AU Becerra, MB Becerra, BJ Teodorescu, M AF Becerra, M. B. Becerra, B. J. Teodorescu, M. TI Health Resource Utilization Of Asthma Hospitalizations With Comorbid Sleep Apnea And Obesity: Results From The Nationwide Inpatient Sample SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Becerra, M. B.] Calif State Univ San Bernardino, San Bernardino, CA 92407 USA. [Becerra, B. J.] Loma Linda Univ, Loma Linda, CA 92350 USA. [Teodorescu, M.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. EM mbecerra@csusb.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A3111 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749602359 ER PT J AU Chan, ED Bai, A Bai, X AF Chan, E. D. Bai, A. Bai, X. TI Aat Reduces Burden Of Mycobacterium Intracellulare In Human Macrophages By Inducing Phagosome-Lysosome Fusion SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Chan, E. D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Bai, A.; Bai, X.] Natl Jewish Hlth, Denver, CO USA. EM chane@njhealth.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A3747 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749603131 ER PT J AU Chan, ED Stitzel, J Bai, A Phillips, M Bai, X AF Chan, E. D. Stitzel, J. Bai, A. Phillips, M. Bai, X. TI Nicotine Impairs Macrophage Control Of Mycobacterium Tuberculosis By Binding To Nicotinic Acetylcholine Receptor, Activating Nfkappab And Inhibiting Autophagy SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Chan, E. D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Stitzel, J.] Univ Colorado, Boulder, CO 80309 USA. [Bai, A.; Phillips, M.; Bai, X.] Natl Jewish Hlth, Denver, CO USA. EM ChanE@njhealth.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A2892 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749602140 ER PT J AU Crothers, KA Kross, EK Shahrir, SF Reisch, LM Slatore, CG Zeliadt, SB Triplette, M Meza, R Elmore, JG AF Crothers, K. A. Kross, E. K. Shahrir, S. F. Reisch, L. M. Slatore, C. G. Zeliadt, S. B. Triplette, M. Meza, R. Elmore, J. G. TI Attitudes Regarding Lung Cancer Screening And Decision Aids: A Survey And Focus Group Study SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Crothers, K. A.; Kross, E. K.; Shahrir, S. F.; Reisch, L. M.; Triplette, M.; Elmore, J. G.] Univ Washington, Seattle, WA 98195 USA. [Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. [Zeliadt, S. B.] Seattle VA, Seattle, WA USA. [Zeliadt, S. B.] Univ Washington, Seattle, WA 98195 USA. [Meza, R.] Univ Michigan, Ann Arbor, MI 48109 USA. EM KCrothers@medicine.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1274 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600274 ER PT J AU Dada, LA Tokhtaeva, E Soni, PN Ridge, KM Sachs, G Sznajder, JI Vagin, O AF Dada, L. A. Tokhtaeva, E. Soni, P. N. Ridge, K. M. Sachs, G. Sznajder, J. I. Vagin, O. TI The O-Glycosylated Ectodomain Of Fxyd5 Impairs Alveolar Epithelial Integrity By Inhibiting The Intercellular Trans-Dimerization Of The Na,k-Atpase SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Dada, L. A.; Soni, P. N.; Ridge, K. M.; Sznajder, J. I.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Tokhtaeva, E.; Sachs, G.; Vagin, O.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Tokhtaeva, E.; Sachs, G.; Vagin, O.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM lauradada@northwestern.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A5763 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749605425 ER PT J AU Dahl, R Anzueto, A Metzdorf, N Mueller, A Calverley, PM AF Dahl, R. Anzueto, A. Metzdorf, N. Mueller, A. Calverley, P. M. TI Using Different Sets Of Patient-Relevant Outcomes In Chronic Obstructive Pulmonary Disease To Evaluate Efficacy Of Tiotropium Respimat (R) - A Post-Hoc Analysis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Dahl, R.] Odense Univ Hosp, Odense C, Denmark. [Anzueto, A.] Univ Texas San Antonio, San Antonio, TX USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Metzdorf, N.] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. [Mueller, A.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. [Calverley, P. M.] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool, Merseyside, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A6803 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749606574 ER PT J AU Deshane, JS Trevor, J Wang, Y Zhi, D Curtiss, M Wang, F Eipers, PG William, V Morrow, C Dransfield, MT AF Deshane, J. S. Trevor, J. Wang, Y. Zhi, D. Curtiss, M. Wang, F. Eipers, P. G. William, V. Morrow, C. Dransfield, M. T. TI Longitudinal Changes In Airway Microbiome Signatures And Immunoregulatory Cell Dynamics Following Bronchial Thermoplasty SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Deshane, J. S.; Trevor, J.; Wang, Y.; Zhi, D.; Curtiss, M.; Wang, F.; Eipers, P. G.; William, V.; Morrow, C.; Dransfield, M. T.] Univ Alabama Birmingham, Birmingham, AL USA. [Trevor, J.; Wang, Y.; Dransfield, M. T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. EM treena@uab.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1057 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600057 ER PT J AU Dudley, K Lobato, R Wong, J Maxwell, B Rhoads, K Zamanian, RT AF Dudley, K. Lobato, R. Wong, J. Maxwell, B. Rhoads, K. Zamanian, R. T. TI Perioperative Morbidity And Mortality In Patients With Pulmonary Hypertension Undergoing Non-Cardiac Surgery: An Analysis Of Admission Records From The Nationwide Inpatient Sample From 2005-2009 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Dudley, K.; Wong, J.; Rhoads, K.; Zamanian, R. T.] Stanford Univ, Stanford, CA 94305 USA. [Lobato, R.] VA Greater Los Angeles, Los Angeles, CA USA. [Maxwell, B.] Legacy Emanuel Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A6310 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749606082 ER PT J AU Emery, MJ Anderson, J Swenson, ER AF Emery, M. J. Anderson, J. Swenson, E. R. TI Ventilation Heterogeneity Is Substantially Decreased When Breathing 5% Carbon Dioxide SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Emery, M. J.; Anderson, J.; Swenson, E. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Swenson, E. R.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A5960 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749605620 ER PT J AU Guo, L Freeman, CM Budoff, MJ Dransfield, MT Han, MK Hokanson, JE Kinney, GL Regan, EA Wells, JM Curtis, JL Martinez, CH AF Guo, L. Freeman, C. M. Budoff, M. J. Dransfield, M. T. Han, M. K. Hokanson, J. E. Kinney, G. L. Regan, E. A. Wells, J. M. Curtis, J. L. Martinez, C. H. CA COPDGene Investigators TI Greater Walking Distance Is Associated With Lower Levels Of Growth Differentiation Factor-15 in COPD: An Analysis Of The COPDgene Cohort SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Guo, L.] Univ Hosp Elect Sci & Technol China, Sichuan Provincal Peoples Hosp, Sichuan Acad Med Sci, Chengdu, Peoples R China. [Freeman, C. M.; Curtis, J. L.] Univ Michigan, Ann Arbor, MI 48109 USA. [Freeman, C. M.; Curtis, J. L.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. [Budoff, M. J.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Dransfield, M. T.; Wells, J. M.] Univ Alabama Birmingham, Birmingham, AL USA. [Dransfield, M. T.; Wells, J. M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Martinez, C. H.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Kinney, G. L.] Univ Colorado, Aurora, CO USA. [Regan, E. A.] Natl Jewish Hlth & Res Ctr, Denver, CO USA. [Regan, E. A.] Univ Colorado, Denver, CO 80202 USA. EM 18981838226@163.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A3483 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749602730 ER PT J AU Honda, JR Hasan, NA Zhou, Y Chan, ED AF Honda, J. R. Hasan, N. A. Zhou, Y. Chan, E. D. TI Clinical And Environmental Nontuberculous Mycobacteria From Hawai'i Demonstrate Varying Degrees Of Virulence SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Honda, J. R.] Univ Colorado, Anschutz Med Campus, Aurora, CO USA. [Hasan, N. A.; Zhou, Y.] Natl Jewish Hlth, Denver, CO USA. [Chan, E. D.] Denver Vet Affairs Med Ctr, Denver, CO USA. EM Jennifer.Honda@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A7501 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749607436 ER PT J AU Iaccarino, J Simmons, J Slatore, CG Gould, MK Wiener, RS AF Iaccarino, J. Simmons, J. Slatore, C. G. Gould, M. K. Wiener, R. S. TI Availability Of Resources And Processes Of Care For Pulmonary Nodule Evaluation: A National Survey Of American Thoracic Society Clinicians SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Iaccarino, J.; Simmons, J.] Boston Univ, Med Ctr, Boston, MA USA. [Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. [Gould, M. K.] Kaiser Permanente Southern Calif, Pasadena, CA USA. [Wiener, R. S.] Boston Univ, Sch Med, Boston, MA 02118 USA. EM jmi@bu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1294 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600294 ER PT J AU Jones, BE Brown, KA Jones, MM Huttner, B Greene, T Sauer, B Madaras-Kelly, K Rubin, M Goetz, MB Samore, M AF Jones, B. E. Brown, K. A. Jones, M. M. Huttner, B. Greene, T. Sauer, B. Madaras-Kelly, K. Rubin, M. Goetz, M. B. Samore, M. TI Variation In Detection And Coverage Of Resistant Pathogens In Hospitalized Veterans With Pneumonia At 128 Medical Centers SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Jones, B. E.; Brown, K. A.; Huttner, B.; Greene, T.; Sauer, B.] Univ Utah, Salt Lake City, UT USA. [Jones, M. M.; Rubin, M.; Samore, M.] Div Epidemiol, Salt Lake City, UT USA. [Madaras-Kelly, K.] Coll Pharm, Boise, ID USA. [Goetz, M. B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. EM barbara.jones@hsc.utah.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A2104 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749601244 ER PT J AU Lindenauer, PK Stefan, MS Feemster, LC Shieh, MS Carson, SS Au, DH Krishnan, JA AF Lindenauer, P. K. Stefan, M. S. Feemster, L. C. Shieh, M. -S. Carson, S. S. Au, D. H. Krishnan, J. A. TI Overuse Of Antibiotics Among Patients Hospitalized For Exacerbations Of Asthma SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Lindenauer, P. K.; Shieh, M. -S.] Univ Massachusetts, Med Sch Baystate, Springfield, MA USA. [Stefan, M. S.] Baystate Med Ctr, Springfield, MA USA. [Feemster, L. C.] Puget Sound VA, Seattle, WA USA. [Feemster, L. C.] Univ Washington, Seattle, WA 98195 USA. [Carson, S. S.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA. [Au, D. H.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Krishnan, J. A.] Univ Illinois, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A7878 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749607811 ER PT J AU Lynch, Y Clark, B Taylor, H Treviso, L Macht, M White, SD Wimbish, T Moss, M AF Lynch, Y. Clark, B. Taylor, H. Treviso, L. Macht, M. White, S. D. Wimbish, T. Moss, M. TI Accuracy Of The Bedside Swallowing Evaluation And 3-Ounce Water Swallow Test For Diagnosing Aspiration In Survivors Of Acute Respiratory Failure SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Lynch, Y.] Denver VA Med Ctr, Denver, CO USA. [Clark, B.; Moss, M.] Univ Colorado, Sch Med, Aurora, CO USA. [Taylor, H.; Treviso, L.; White, S. D.; Wimbish, T.] Univ Colorado Hosp, Aurora, CO USA. [Macht, M.] Crit Care Pulm & Sleep Associates Prof LLP, Lakewood, CO USA. EM ylinne.lynch@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1157 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600157 ER PT J AU Melzer, AC Feemster, LC Crothers, KA Gillespie, SE Henderson, AG Krishnan, JA Lindenauer, PK McBurnie, M Mularski, RA Naureckas, ET Pickard, S Au, DH AF Melzer, A. C. Feemster, L. C. Crothers, K. A. Gillespie, S. E. Henderson, A. G. Krishnan, J. A. Lindenauer, P. K. McBurnie, M. Mularski, R. A. Naureckas, E. T. Pickard, S. Au, D. H. CA CONCERT TI Respiratory Symptoms Predict Motivation To Quit Smoking Among Smokers With And Without COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Melzer, A. C.; Au, D. H.] VA Puget Sound, Seattle, WA USA. [Feemster, L. C.; Crothers, K. A.] Univ Washington, Seattle, WA 98195 USA. [Gillespie, S. E.; McBurnie, M.; Mularski, R. A.] Kaiser Permanente Northwest, Portland, OR USA. [Henderson, A. G.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA. [Krishnan, J. A.; Naureckas, E. T.] Univ Illinois, Chicago, IL USA. [Lindenauer, P. K.] Bay State Med Ctr, Springfield, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A6515 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749606286 ER PT J AU Mortensen, EM Metersky, ML Frei, CR Attridge, RT Anzueto, A AF Mortensen, E. M. Metersky, M. L. Frei, C. R. Attridge, R. T. Anzueto, A. TI Azithromycin Is Associated With Improved Survival In Patients With Healthcare-Associated Pneumonia SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Mortensen, E. M.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Metersky, M. L.] Univ Connecticut, Sch Med, Farmington, CT USA. [Frei, C. R.] UTHSCSA, San Antonio, TX USA. [Attridge, R. T.] Univ Incarnate Word, San Antonio, TX USA. [Anzueto, A.] Univ Texas San Antonio, San Antonio, TX USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A2139 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749601279 ER PT J AU Patino, CM Au, DH Lane, CJ Buist, AS Vollmer, WM AF Patino, C. M. Au, D. H. Lane, C. J. Buist, A. S. Vollmer, W. M. TI Building Research Capacity In Middle And Low-Income Countries Through Research Methodology And Career Development Education SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Patino, C. M.; Lane, C. J.] Univ Southern Calif, Los Angeles, CA 90032 USA. [Au, D. H.] VA Puget Sound, Seattle, WA USA. [Buist, A. S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Vollmer, W. M.] Kaiser Permanente, Portland, OR USA. EM patinosu@usc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A7567 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749607502 ER PT J AU Pickerodt, PA Kronfeldt, S Russ, M Vorbrodt, K Lother, P Busch, T Boemke, W Swenson, ER Francis, RCE AF Pickerodt, P. A. Kronfeldt, S. Russ, M. Vorbrodt, K. Lother, P. Busch, T. Boemke, W. Swenson, E. R. Francis, R. C. E. TI Carbonic Anhydrase Is Not A Relevant Nitrite Reductase In The Lung SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Pickerodt, P. A.; Kronfeldt, S.; Russ, M.; Vorbrodt, K.; Lother, P.; Boemke, W.; Francis, R. C. E.] Charite Univ Med Berlin, Berlin, Germany. [Busch, T.] Univ Leipzig, Leipzig, Germany. [Swenson, E. R.] Univ Washington, Seattle, WA 98195 USA. [Swenson, E. R.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. EM philipp.pickerodt@charite.de NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A3891 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749603275 ER PT J AU Putcha, N Dusser, D Anzueto, A Metzdorf, N Mueller, A Wise, RA AF Putcha, N. Dusser, D. Anzueto, A. Metzdorf, N. Mueller, A. Wise, R. A. TI Mortality And Exacerbation Risk By Body Mass Index In The (tiospir (R)) Trial SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Putcha, N.; Wise, R. A.] Johns Hopkins Univ, Baltimore, MD USA. [Dusser, D.] Hop Cochin, Serv Pneumol, Paris, France. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Metzdorf, N.] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. [Mueller, A.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A3530 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749602777 ER PT J AU Reynolds, IR Chan, ED AF Reynolds, I. R. Chan, E. D. TI An Update On The Trends And Treatment In Multidrug-Resistant Tuberculosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Reynolds, I. R.] Univ Colorado, Denver, CO USA. [Chan, E. D.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A5533 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749605196 ER PT J AU Rinne, S Bastian, LA Lindenauer, PK Kaboli, P Cook, MA Wong, ES Liu, CF AF Rinne, S. Bastian, L. A. Lindenauer, P. K. Kaboli, P. Cook, M. A. Wong, E. S. Liu, C. -F. TI Organizational Factors Associated With Length Of Stay For Veterans With Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Rinne, S.] Yale Univ, New Haven, CT USA. [Bastian, L. A.] VA Connecticut Healthcare Syst, Newington, CT USA. [Lindenauer, P. K.] Baystate Med Ctr, Springfield, MA USA. [Kaboli, P.] Iowa City Va Hlth Care Syst, Iowa City, IA USA. [Cook, M. A.; Wong, E. S.; Liu, C. -F.] VA Puget Sound Healthcare Syst, Seattle, WA USA. EM seppo.rinne@yale.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A6154 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749605814 ER PT J AU Rinne, S Gerity, AH Thayer, LM Liu, CF Cook, MA Bastian, LA AF Rinne, S. Gerity, A. H. Thayer, L. M. Liu, C. -F. Cook, M. A. Bastian, L. A. TI Gender Differences In Appropriate Treatment For Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Rinne, S.] Yale Univ, New Haven, CT USA. [Gerity, A. H.; Thayer, L. M.; Bastian, L. A.] VA Connecticut Healthcare Syst, Newington, CT USA. [Liu, C. -F.; Cook, M. A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. EM seppo.rinne@yale.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A4560 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749604076 ER PT J AU Russell, DW Payne, GA Xing, D Wu, Y Viera, L Szul, T Gautney, J McNicholas-Bevensee, CM Gaggar, A Yang, Q Xu, X Jackson, PL Dransfield, MT Blalock, JE Wells, JM AF Russell, D. W. Payne, G. A. Xing, D. Wu, Y. Viera, L. Szul, T. Gautney, J. McNicholas-Bevensee, C. M. Gaggar, A. Yang, Q. Xu, X. Jackson, P. L. Dransfield, M. T. Blalock, J. E. Wells, J. M. TI The Extracellular Matrix Collagen Fragment Acpgp Facilitates Pulmonary Vascular Remodeling Through Rho Kinase Signaling SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Payne, G. A.; Xing, D.; Wu, Y.; Viera, L.; McNicholas-Bevensee, C. M.; Yang, Q.; Blalock, J. E.] Univ Alabama Birmingham, Birmingham, AL USA. [Dransfield, M. T.; Wells, J. M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A2798 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749602047 ER PT J AU Sullivan, DR Golden, SE Ganzini, L Wiener, RS Slatore, CG AF Sullivan, D. R. Golden, S. E. Ganzini, L. Wiener, R. S. Slatore, C. G. TI Association Of Actual And Preferred Decision-Making Roles With Patient-Reported Satisfaction And Quality Of Medical Care Among Patients With Pulmonary Nodules SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Sullivan, D. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Golden, S. E.; Ganzini, L.; Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. [Wiener, R. S.] Boston Univ, Sch Med, Boston, MA 02118 USA. EM sullivad@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A2684 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749601824 ER PT J AU Teshome, M Denman, T Teodorescu, M AF Teshome, M. Denman, T. Teodorescu, M. TI Obstructive Sleep Apnea Features, Lower Airway Obstruction And Inflammation In Patients With Asthma SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Teshome, M.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Denman, T.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Teodorescu, M.] Univ Wisconsin, Sch Med, Madison, WI USA. EM mteshome@uwhealth.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A6639 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749606410 ER PT J AU Tham, A AF Tham, A. TI Modeling Vascular Inflammation And Atherogenicity After Inhalation Of Ambient Levels Of Ozone: Exploratory Lessons From Transcriptomics SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Tham, A.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1183 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600183 ER PT J AU Trevor, J Zhi, D Wang, F Dransfield, MT Curtiss, M Deshane, J AF Trevor, J. Zhi, D. Wang, F. Dransfield, M. T. Curtiss, M. Deshane, J. TI Longitudinal Changes In Proportions Of Regulatory T Cell And Myeloid Cell Populations Following Bronchial Thermoplasty SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Trevor, J.; Zhi, D.; Wang, F.; Dransfield, M. T.; Curtiss, M.] Univ Alabama Birmingham, Birmingham, AL USA. [Trevor, J.; Dransfield, M. T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Deshane, J.] UAB, Birmingham, AL USA. EM jtrevor@uab.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1335 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600335 ER PT J AU Tukey, MH Clark, J Bolton, R Slatore, CG Au, DH Wiener, RS AF Tukey, M. H. Clark, J. Bolton, R. Slatore, C. G. Au, D. H. Wiener, R. S. TI Readiness For Implementation Of CT Lung Cancer Screening Within A National Healthcare System SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society (ATS) CY MAY 13-18, 2016 CL San Francisco, CA SP Amer Thorac Soc C1 [Tukey, M. H.] Rhode Isl Hosp, Providence, RI USA. [Clark, J.; Bolton, R.] ENRM VA Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. [Au, D. H.] VA Puget Sound, Seattle, WA USA. [Wiener, R. S.] Boston Univ, Sch Med, Boston, MA 02118 USA. EM mtukey@lifespan.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2016 VL 193 MA A1280 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EG0VE UT WOS:000390749600280 ER PT J AU Giladi, N Nicholas, AP Asgharnejad, M Dohin, E Woltering, F Bauer, L Poewe, W AF Giladi, Nir Nicholas, Anthony P. Asgharnejad, Mahnaz Dohin, Elisabeth Woltering, Franz Bauer, Lars Poewe, Werner TI Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage SO JOURNAL OF PARKINSONS DISEASE LA English DT Article DE Dopamine receptor agonist; Parkinson's disease; disease progression; treatment efficacy; clinical trial ID TRANSDERMAL ROTIGOTINE; DOUBLE-BLIND; INITIATION; PROGRESSION; RECOMMENDATIONS; IMPAIRMENTS; PLACEBO; PROFILE; SCALE; GAIT AB Background: The efficacy of rotigotine has been demonstrated in studies of patients with early (i.e. not receiving levodopa) and advanced (i.e. not adequately controlled on levodopa; average 2.5 h/day in 'off' state) Parkinson's disease (PD). Objective: To further investigate the efficacy of rotigotine transdermal patch across different stages of PD symptom severity and functional disability, according to baseline Hoehn and Yahr (HY) staging. Methods: Post hoc analysis of six placebo-controlled studies of rotigotine in patients with early PD (SP506, SP512, SP513; rotigotine <= 8 mg/24 h) or advanced-PD (CLEOPATRA-PD, PREFER, SP921; rotigotine <= 16 mg/24 h). Data were pooled and analyzed according to baseline HY stage (1, 2, 3 or 4) for change from baseline to end of maintenance in Unified Parkinson's Disease Rating Scale (UPDRS) II (activities of daily living), UPDRS III (motor) and UPDRS II+III; statistical tests are exploratory. Results: Data were available for 2057 patients (HY 1 : 262; HY 2 : 1230; HY 3 : 524; HY 4 : 41). Patients at higher HY stages were older, had a longer time since PD diagnosis and higher baseline UPDRS II+III scores vs patients at lower HY stages. Rotigotine improved UPDRS II+III versus placebo for each individual HY stage (p < 0.05 for each HY stage), with treatment differences increasing with increasing HY stages. Similar results were observed for UPDRS II and UPDRS III. Conclusions: This post hoc analysis suggests that rotigotine may be efficacious across a broad range of progressive stages of PD symptom severity and functional disability (HY stages 1-4). C1 [Giladi, Nir] Tel Aviv Univ, Tel Aviv Med Ctr, Neurol Inst, Tel Aviv, Israel. [Giladi, Nir] Tel Aviv Univ, Dept Neurol & Neurosurg, Sackler Sch Med, Sagol Sch Neurosci, Tel Aviv, Israel. [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA. [Nicholas, Anthony P.] Birmingham VA Med Ctr, Birmingham, AL USA. [Asgharnejad, Mahnaz] UCB Pharma, Raleigh, NC USA. [Dohin, Elisabeth] UCB Pharma, Brussels, Belgium. [Woltering, Franz; Bauer, Lars] UCB Pharma, Monheim, Germany. [Poewe, Werner] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria. RP Giladi, N (reprint author), Tel Aviv Med Ctr & Sch Med, Neurol Inst, 6 Weizmann St, IL-64239 Tel Aviv, Israel. EM nirg@tlvmc.gov.il FU UCB Pharma; UCB Pharma, Brussels, Belgium FX This post hoc analysis was supported by UCB Pharma, Monheim am Rhein, Germany. The analysis and manuscript development was a full partnership between the sponsor (UCB Pharma) and academic experts in the field of PD, who were investigators/principal investigators for the original double-blind studies included. The final data reported in this manuscript are the outcome of scientific discussions between all authors. Specifically, the original analysis was initially designed by the study sponsor, and subsequently modified upon review by the academic authors. All authors contributed significantly to the design/specifics of the analyses included in the manuscript, reviewed the data, were involved in the interpretation of the results, and reviewed and critiqued the manuscript. The sponsor statistician author was involved in running the data analysis. The authors thank the patients and their caregivers in addition to the investigators and their teams who contributed to the studies included in these analyses. The authors also acknowledge Karolina Rzeniewicz, PhD (Evidence Scientific Solutions, London, UK) for writing assistance, which was funded by UCB Pharma, Brussels, Belgium, and Cedric Laloyaux (Strategic Publication Lead Neurology, UCB Pharma, Brussels, Belgium) for publication coordination. The authors also acknowledge Marc Derycke, MSc (UCB Pharma, Monheim am Rhein, Germany) for his contributions to the specifications and programming of the post hoc analyses. NR 30 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1877-7171 EI 1877-718X J9 J PARKINSON DIS JI J. Parkinsons Dis. PY 2016 VL 6 IS 4 BP 741 EP 749 DI 10.3233/JPD-160847 PG 9 WC Neurosciences SC Neurosciences & Neurology GA EH0CO UT WOS:000391430300010 PM 27567886 ER PT J AU Wei, W Ramos, PS Hunt, KJ Wolf, BJ Hardiman, G Chung, DJ AF Wei, Wei Ramos, Paula S. Hunt, Kelly J. Wolf, Bethany J. Hardiman, Gary Chung, Dongjun TI GPA-MDS: A Visualization Approach to Investigate Genetic Architecture among Phenotypes Using GWAS Results SO INTERNATIONAL JOURNAL OF GENOMICS LA English DT Article ID DISEASE AB Genome-wide association studies (GWAS) have identified tens of thousands of genetic variants associated with hundreds of phenotypes and diseases, which have provided clinical and medical benefits to patients with novel biomarkers and therapeutic targets. Recently, there has been accumulating evidence suggesting that different complex traits share a common risk basis, namely, pleiotropy. Previously, a statistical method, namely, GPA (Genetic analysis incorporating Pleiotropy and Annotation), was developed to improve identification of risk variants and to investigate pleiotropic structure through a joint analysis of multiple GWAS datasets. While GPA provides a statistically rigorous framework to evaluate pleiotropy between phenotypes, it is still not trivial to investigate genetic relationships among a large number of phenotypes using the GPA framework. In order to address this challenge, in this paper, we propose a novel approach, GPA-MDS, to visualize genetic relationships among phenotypes using the GPA algorithm and multidimensional scaling (MDS). This tool will help researchers to investigate common etiology among diseases, which can potentially lead to development of common treatments across diseases. We evaluate the proposed GPA-MDS framework using a simulation study and apply it to jointly analyze GWAS datasets examining 18 unique phenotypes, which helps reveal the shared genetic architecture of these phenotypes. C1 [Wei, Wei; Ramos, Paula S.; Hunt, Kelly J.; Wolf, Bethany J.; Hardiman, Gary; Chung, Dongjun] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Ramos, Paula S.; Hardiman, Gary] Med Univ South Carolina, Dept Med, Charleston, SC USA. [Hunt, Kelly J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Hardiman, Gary] Med Univ South Carolina, Ctr Genom Med, Charleston, SC USA. RP Chung, DJ (reprint author), Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. EM chungd@musc.edu OI Ramos, Paula/0000-0002-9433-6634; Chung, Dongjun/0000-0002-8072-5671 FU US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [K01 AR067280, P60 AR062755]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01 DK088778]; National Institute of General Medical Sciences (NIGMS) [R01 GM122078]; National Cancer Institute (NCI) from the National Institutes of Health (NIH) [R21 CA209848] FX This work was supported by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grants K01 AR067280 (Paula S. Ramos) and P60 AR062755 (Paula S. Ramos and Bethany J. Wolf), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R01 DK088778 (Kelly J. Hunt), National Institute of General Medical Sciences (NIGMS) grant R01 GM122078, and National Cancer Institute (NCI) grant R21 CA209848 (Dongjun Chung and Gary Hardiman) from the National Institutes of Health (NIH). NR 14 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-436X EI 2314-4378 J9 INT J GENOMICS JI Int. J. Genomics PY 2016 AR 6589843 DI 10.1155/2016/6589843 PG 6 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA EF8JA UT WOS:000390573900001 ER PT J AU Harrison, KL Taylor, HA AF Harrison, Krista Lyn Taylor, Holly A. TI Healthcare resource allocation decisions affecting uninsured services SO JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT LA English DT Article DE Organizational culture; Decision making; Values; Policy; Healthcare; Uninsured ID POPULATION HEALTH AB Purpose - Using the example of community access programs (CAPs), the purpose of this paper is to describe resource allocation and policy decisions related to providing health services for the uninsured in the USA and the organizational values affecting these decisions. Design/methodology/approach - The study used comparative case study methodology at two geographically diverse sites. Researchers collected data from program documents, meeting observations, and interviews with program stakeholders. Findings - Five resource allocation or policy decisions relevant to providing healthcare services were described at each site across three categories: designing the health plan, reacting to funding changes, and revising policies. Organizational values of access to care and stewardship most frequently affected resource allocation and policy decisions, while economic and political pressures affect the relative prioritization of values. Research limitations/implications - Small sample size, the potential for social desirability or recall bias, and the exclusion of provider, member or community perspectives beyond those represented among participating board members. Practical implications - Program directors or researchers can use this study to assess the extent to which resource allocation and policy decisions align with organizational values and mission statements. Social implications - The description of how healthcare decisions are actually made can be matched with literature that describes how healthcare resource decisions ought to be made, in order to provide a normative grounding for future decisions. Originality/value - This study addresses a gap in literature regarding how CAPs actually make resource allocation decisions that affect access to healthcare services. C1 [Harrison, Krista Lyn] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Harrison, Krista Lyn] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Taylor, Holly A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA. [Taylor, Holly A.] Johns Hopkins Univ, Berman Inst Bioeth, Baltimore, MD USA. RP Harrison, KL (reprint author), Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.; Harrison, KL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. FU AHRQ NRSA Health Services Research and Policy Traineeship [T32-HS00029]; Victor P. Raymond Memorial Fund Health Policy and Management Endowment Award; National Institute of Aging [T32-AG000212] FX The authors would like to thank the study participants and the hard work of people who run Community Access Programs and other safety net programs to provide people with access to healthcare. The authors would also like to thank Drs Anne Riley, Shannon Frattaroli, Maria Merritt, Ruth Faden, David Holtgrave, Bradley Herring, Carlton Haywood Jr, and Jessica Holzer for their feedback on earlier versions of this work. Dr Harrison was supported by the AHRQ NRSA Health Services Research and Policy Traineeship (No. T32-HS00029) and the Victor P. Raymond Memorial Fund Health Policy and Management Endowment Award when conducting this work, and is currently supported by the National Institute of Aging (No. T32-AG000212). NR 44 TC 0 Z9 0 U1 1 U2 1 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1477-7266 EI 1758-7247 J9 J HEALTH ORGAN MANAG JI J. Health Organ. Manag. PY 2016 VL 30 IS 8 BP 1162 EP 1182 DI 10.1108/JHOM-01-2016-0003 PG 21 WC Health Policy & Services SC Health Care Sciences & Services GA EG0JG UT WOS:000390717700001 PM 27934550 ER PT J AU Pope, C Davis, BH North-Lee, B Egede, L AF Pope, Charlene Davis, Boyd H. North-Lee, Bertha Egede, Leonard TI Searching for Empathy in the Talk of Veterans With Diabetes and Their Primary Care Providers: A Mixed-Methods Study SO INTERNATIONAL JOURNAL OF QUALITATIVE METHODS LA English DT Meeting Abstract C1 [Pope, Charlene] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC USA. [Davis, Boyd H.] Univ N Carolina, Charlotte, NC USA. [North-Lee, Bertha; Egede, Leonard] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1609-4069 J9 INT J QUAL METH JI Int. J. Qual. Meth. PD JAN-DEC PY 2016 VL 15 IS 1 PG 1 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA EE9BW UT WOS:000389921700386 ER PT J AU Arentsen, TJ Panos, S Thames, AD Arbid, JN Castellon, SA Hinkin, CH AF Arentsen, Timothy J. Panos, Stella Thames, April D. Arbid, J. Natalie Castellon, Steven A. Hinkin, Charles H. TI Psychosocial correlates of medication adherence among HIV-positive, cognitively impaired individuals SO JOURNAL OF HIV-AIDS & SOCIAL SERVICES LA English DT Article DE cognitively impaired; HIV; medication adherence; stimulant use; stress ID ACTIVE ANTIRETROVIRAL THERAPY; SELF-REPORTED ADHERENCE; DRUG-USE; NEUROPSYCHOLOGICAL IMPAIRMENT; NEUROCOGNITIVE IMPAIRMENT; PROSPECTIVE MEMORY; IMPROVE ADHERENCE; INFECTED ADULTS; VIRAL LOAD; NONADHERENCE AB Although cognitive impairment has been shown to adversely affect antiviral medication adherence, a subset of cognitively impaired adults nonetheless are able to adequately adhere to their medication regimen. However, little is known about factors that serve as buffers against suboptimal adherence among the cognitively impaired. This study consisted of 160 HIV-positive, cognitively impaired adults (Global Deficit Score >= 0.50) whose medication adherence was monitored over 6 months using an electronic monitoring device (MEMS caps). Logistic regressions were run to determine psychosocial variables associated with medication adherence. Higher self-efficacy, greater perception of treatment-related support, a stable medication regimen, stable stress levels, and absence of current stimulant use were predictive of optimal adherence. A distinct array of psychosocial factors was found that buffer against the adverse effects of cognitive impairment on medication adherence. Assessment and interventions targeting these factors may improve adherence rates among cognitively impaired adults. C1 [Arentsen, Timothy J.] Memphis Vet Affairs Med Ctr, 1030 Jefferson Ave, Memphis, TN 38104 USA. [Panos, Stella; Castellon, Steven A.; Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Panos, Stella; Thames, April D.; Castellon, Steven A.; Hinkin, Charles H.] Univ Calif Los Angeles, Psychiat & Biobehav Sci, Los Angeles, CA USA. [Arbid, J. Natalie] Univ Massachusetts, Boston, MA 02125 USA. RP Arentsen, TJ (reprint author), Memphis Vet Affairs Med Ctr, 1030 Jefferson Ave, Memphis, TN 38104 USA. EM Timothy.Arentsen2@va.gov NR 47 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1538-1501 EI 1538-151X J9 J HIV-AIDS SOC SERV JI J. HIV-AIDS Soc. Serv. PY 2016 VL 15 IS 4 BP 404 EP 416 DI 10.1080/15381501.2016.1228309 PG 13 WC Social Work SC Social Work GA EF2RT UT WOS:000390172700005 ER PT S AU Palmer, LD Skaar, EP AF Palmer, Lauren D. Skaar, Eric P. BE Bonini, NM TI Transition Metals and Virulence in Bacteria SO ANNUAL REVIEW OF GENETICS, VOL 50 SE Annual Review of Genetics LA English DT Review; Book Chapter DE host-pathogen interface; metal acquisition; metal homeostasis; nutritional immunity; transition metal ID STAPHYLOCOCCUS-AUREUS INFECTION; LACTOFERRIN-BINDING PROTEIN; INNATE IMMUNE-RESPONSE; HELICOBACTER-PYLORI; PSEUDOMONAS-AERUGINOSA; MYCOBACTERIUM-TUBERCULOSIS; STREPTOCOCCUS-PNEUMONIAE; NUTRITIONAL IMMUNITY; PATHOGENIC BACTERIA; ESCHERICHIA-COLI AB Transition metals are required trace elements for all forms of life. Due to their unique inorganic and redox properties, transition metals serve as cofactors for enzymes and other proteins. In bacterial pathogenesis, the vertebrate host represents a rich source of nutrient metals, and bacteria have evolved diverse metal acquisition strategies. Host metal homeostasis changes dramatically in response to bacterial infections, including production of metal sequestering proteins and the bombardment of bacteria with toxic levels of metals. In response, bacteria have evolved systems to subvert metal sequestration and toxicity. The coevolution of hosts and their bacterial pathogens in the battle for metals has uncovered emerging paradigms in social microbiology, rapid evolution, host specificity, and metal homeostasis across domains. This review focuses on recent advances and open questions in our understanding of the complex role of transition metals at the host-pathogen interface. C1 [Palmer, Lauren D.; Skaar, Eric P.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Skaar, Eric P.] Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA.; Skaar, EP (reprint author), Tennessee Valley Healthcare Syst, US Dept Vet Affairs, Nashville, TN 37212 USA. EM eric.skaar@vanderbilt.edu FU BLRD VA [I01 BX002482]; NIAID NIH HHS [F32 AI122516, R01 AI069233, R01 AI101171, R21 AI107233] NR 152 TC 1 Z9 1 U1 9 U2 9 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4197 BN 978-0-8243-1250-3 J9 ANNU REV GENET JI Annu. Rev. Genet. PY 2016 VL 50 BP 67 EP 91 DI 10.1146/annurev-genet-120215-035146 PG 25 WC Genetics & Heredity SC Genetics & Heredity GA BG5NP UT WOS:000389584800004 PM 27617971 ER PT J AU Sharma, A Ma, Y Tien, PC Scherzer, R Anastos, K Cohen, M Hans, D Yin, MT AF Sharma, A. Ma, Y. Tien, P. C. Scherzer, R. Anastos, K. Cohen, M. Hans, D. Yin, M. T. TI Measurement of bone microarchitecture among HIV-infected and uninfected women using trabecular bone score SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT 18th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV CY SEP 12-13, 2016 CL New York, NY C1 [Sharma, A.; Anastos, K.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ma, Y.; Tien, P. C.; Scherzer, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tien, P. C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, M.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. [Hans, D.] Univ Lausanne Hosp, Ctr Bone Dis, Lausanne, Switzerland. [Yin, M. T.] Columbia Univ, Coll Phys & Surg, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2016 VL 21 SU 1 MA O04 BP A6 EP A6 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA EE6UF UT WOS:000389747500005 ER PT J AU Gonzalez, C Droguett, K Rios, M Cohen, NA Villalon, M AF Gonzalez, Claudia Droguett, Karla Rios, Mariana Cohen, Noam A. Villalon, Manuel TI TNF alpha Affects Ciliary Beat Response to Increased Viscosity in Human Pediatric Airway Epithelium SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID TUMOR-NECROSIS-FACTOR; CELLS IN-VITRO; SMOOTH-MUSCLE; EXPRESSION; RECEPTORS; CYTOKINES; MUCUS; CA2+; FREQUENCY; IL-1-BETA AB In airway epithelium, mucociliary clearance (MCC) velocity depends on the ciliary beat frequency (CBF), and it is affected by mucus viscoelastic properties. Local inflammation induces secretion of cytokines (TNF alpha) that can alter mucus viscosity; however airway ciliated cells have an autoregulatory mechanism to prevent the collapse of CBF in response to increase in mucus viscosity, mechanism that is associated with an increment in intracellular Ca+2 level ([Ca (2+)] i). We studied the effect of TNF alpha on the autoregulatory mechanism that regulates CBF in response to increased viscosity using dextran solutions, in ciliated cells cultured from human pediatric epithelial adenoid tissue. Cultures were treated with TNF alpha, before and after the viscous load was changed. TNF alpha treatment produced a significantly larger decrease in CBF in cultures exposed to dextran. Furthermore, an increment in [Ca2+] i was observed, which was significantly larger after TNF alpha treatment. In conclusion, although TNF alpha has deleterious effects on ciliated cells in response to maintaining CBF after increasing viscous loading, it has a positive effect, since increasing [Ca2+] i may prevent the MCC collapse. These findings suggest that augmented levels of TNF alpha associated with an inflammatory response of the nasopharyngeal epitheliummay have dual effects that contribute to maintaining the effectiveness of MCC in the upper airways. C1 [Gonzalez, Claudia] Pontificia Univ Catolica Chile, Fac Med, Dept Otorhinolaryngol, Santiago, Chile. [Droguett, Karla; Rios, Mariana; Villalon, Manuel] Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile. [Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Villalon, M (reprint author), Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile. EM mvilla@uc.cl FU Puente [21/2014]; Flight Attendants Medical Research Institute [082478]; Fondecyt [3150652] FX This work was supported by Puente [21/2014]; the Flight Attendants Medical Research Institute [082478], and Fondecyt [3150652 (Karla Droguett)]. NR 43 TC 0 Z9 0 U1 3 U2 3 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 3628501 DI 10.1155/2016/3628501 PG 9 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA EE9II UT WOS:000389939200001 ER PT J AU Singh, JA Hossain, A Ghogomu, ET Mudano, AS Tugwella, P Wellsb, GA AF Singh, Jasvinder A. Hossain, Alomgir Ghogomu, Elizabeth Tanjong Mudano, Amy S. Tugwella, Peter Wellsb, George A. TI Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA) SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; ANTITUMOR NECROSIS FACTOR; RANDOMIZED-CONTROLLED-TRIAL; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ADALIMUMAB PLUS METHOTREXATE; ALPHA MONOCLONAL-ANTIBODY; QUALITY-OF-LIFE; RECEIVING CONCOMITANT METHOTREXATE; PATIENT-REPORTED OUTCOMES; TREAT-TO-TARGET AB Background We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). Objectives To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced. Methods We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2015, Issue 6, June), MEDLINE (viaOVID 1946 to June 2015), and Embase (via OVID1947 to June 2015). Article selection, data extraction and risk of bias and GRADE assessments were done in duplicate. We calculated direct estimates with 95% confidence intervals (CI) using standard meta-analysis. We used a Bayesian mixed treatment comparisons (MTC) approach for NMA estimates with 95% credible intervals (CrI). We converted odds ratios (OR) to risk ratios (RR) for ease of understanding. We calculated absolute measures as risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB). Main results This update includes 40 new RCTs for a total of 46 RCTs, of which 41 studies with 14,049 participants provided data. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients). Monotherapy versus placebo Based on moderate-quality direct evidence, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in American College of Rheumatology score (ACR50) and physical function, as measured by the Health Assessment Questionnaire (HAQ) versus placebo. RR was 4.68 for ACR50 (95% CI, 2.93 to 7.48); absolute benefit RD 23% (95% CI, 18% to 29%); and NNTB = 5 (95% CI, 3 to 8). The mean difference (MD) was -0.32 for HAQ (95% CI, -0.42 to -0.23; a negative sign represents greater HAQ improvement); absolute benefit of -10.7% (95% CI, -14% to 7.7%); and NNTB = 4 (95% CI, 3 to 5). Direct and NMA estimates for TNF biologic, non-TNF biologic or tofacitinib monotherapy showed similar results for ACR50, downgraded to moderate-quality evidence. Direct and NMA estimates for TNF biologic, anakinra or tofacitinib monotherapy showed a similar results for HAQ versus placebo with mostly moderate quality evidence. Based onmoderate-quality direct evidence, biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of disease remission versus placebo with RR 1.12 (95% CI 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%; NNTB = 10 (95% CI, 8 to 21)). Based on low-quality direct evidence, results for biologic monotherapy for withdrawals due to adverse events and serious adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase. The direct estimate for TNF monotherapy for withdrawals due to adverse events showed a clinically meaningful and statistically significant result with RR 2.02 (95% CI, 1.08 to 3.78), absolute benefit RD 3% (95% CI, 1% to 4%), based on moderate-quality evidence. The NMA estimates for TNF biologic, non-TNF biologic, anakinra, or tofacitinib monotherapy for withdrawals due to adverse events and for serious adverse events were all inconclusive and downgraded to low-quality evidence. Monotherapy versus active comparator (MTX/other DMARDs) Based on direct evidence of moderate quality, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in ACR50 and HAQ scores versus MTX/other DMARDs with a RR of 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26) and a mean difference in HAQ of -0.27 (95% CI, -0.40 to -0.14); absolute benefit of -9% (95% CI, -13.3% to -4.7%), NNTB = 2 (95% CI, 2 to 4). Direct and NMA estimates for TNF monotherapy and NMA estimate for non-TNF biologic monotherapy for ACR50 showed similar results, based on moderate-quality evidence. Direct and NMA estimates for non-TNF biologic monotherapy, but not TNF monotherapy, showed similar HAQ improvements, based on mostly moderate-quality evidence. There were no statistically significant or clinically meaningful differences for direct estimates of biologic monotherapy versus active comparator for RA disease remission. NMA estimates showed a statistically significant and clinically meaningful difference versus active comparator for TNF monotherapy (absolute improvement 7% (95% CI, 2% to 14%)) and non-TNF monotherapy (absolute improvement 19% (95% CrI, 7% to 36%)), both downgraded to moderate quality. Based on moderate-quality direct evidence from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD-4.34 (95% CI, -7.56 to -1.12), though the absolute reduction was small, -0.97% (95% CI, -1.69% to -0.25%). We are not sure of the clinical relevance of this reduction. Direct and NMA evidence (downgraded to low quality), showed inconclusive results for withdrawals due to adverse events, serious adverse events and cancer, with wide confidence intervals encompassing the null effect and evidence of an important increase. Authors' conclusions Based mostly on RCTs of six to 12-month duration in people with RA who had previously experienced and failed treatment with MTX/other DMARDs, biologic monotherapy improved ACR50, function and RA remission rates compared to placebo or MTX/other DMARDs. Radiographic progression was reduced versus active comparator, although the clinical significance was unclear. Results were inconclusive for whether biologic monotherapy was associated with an increased risk of withdrawals due to adverse events, serious adverse events or cancer, versus placebo (no data on cancer) or MTX/other DMARDs. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. [Hossain, Alomgir] Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada. [Ghogomu, Elizabeth Tanjong] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada. [Mudano, Amy S.] Univ Alabama Birmingham, Dept Med Rheumatol, Birmingham, AL USA. [Tugwella, Peter] Univ Ottawa, Fac Med, Dept Med, Ottawa, ON, Canada. [Wellsb, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI Tugwell, Peter/0000-0001-5062-0556 NR 283 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 11 AR CD012437 DI 10.1002/14651858.CD012437 PG 124 WC Medicine, General & Internal SC General & Internal Medicine GA EE4UH UT WOS:000389600300041 ER PT J AU Jindal, RD AF Jindal, Ripu D. TI Sleep and Weight among Our Veterans SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; CLINICAL-TRIAL; DISORDERS; METABOLISM; MANAGEMENT; INSOMNIA; IMPACT; PAIN; NEED C1 [Jindal, Ripu D.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Jindal, Ripu D.] Univ Alabama Birmingham, Birmingham, AL USA. RP Jindal, RD (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA.; Jindal, RD (reprint author), Univ Alabama Birmingham, Psychiat & Neurol, Birmingham, AL 35294 USA. EM ripu.jindal@va.gov NR 29 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 7 BP 943 EP 945 DI 10.5664/jcsm.5918 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EF0AQ UT WOS:000389988200002 PM 27306395 ER PT J AU Dietch, JR Taylor, DJ Sethi, K Kelly, K Bramoweth, AD Roane, BM AF Dietch, Jessica R. Taylor, Daniel J. Sethi, Kevin Kelly, Kimberly Bramoweth, Adam D. Roane, Brandy M. TI Psychometric Evaluation of the PSQI in US College Students SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE PSQI; sleep quality; students; college; psychometrics; validation; undergraduate; insomnia ID SLEEP QUALITY INDEX; TEST-RETEST RELIABILITY; CANCER-PATIENTS; MENTAL-HEALTH; INSOMNIA; VALIDITY; VALIDATION; EPIDEMIOLOGY; DEPRESSION; INVENTORY AB Study Objectives: Examine the psychometric properties of the PSQI in two U.S. college samples. Methods: Study I assessed convergent and divergent validity in 866 undergraduates who completed a sleep diary, PSQI, and other sleep and psychosocial measures. Study II assessed PSQI insomnia diagnostic accuracy in a separate sample of 147 healthy undergraduates with and without insomnia. Results: The PSQI global score had only moderate convergent validity with sleep diary sleep efficiency (prospective global measure of sleep continuity; r = 0.53), the Insomnia Severity Index (r = 0.63), and fatigue (r = 0.44). The PSQI global score demonstrated good divergent validity with measures of excessive daytime sleepiness (r = 0.18), circadian preference (r = -0.08), alcohol (r = 0.08) and marijuana (r = 0.05) abuse scales, and poor divergent validity with depression (r = 0.48), anxiety (r = 0.40), and perceived stress (r = 0.33). Examination of other analogous PSQI and sleep diary components showed low to moderate convergent validity: sleep latency (r = 0.70), wake after sleep onset (r = 0.37), sleep duration (r = 0.51), and sleep efficiency (r = -0.32). Diagnostic accuracy of the PSQI to detect insomnia was very high (area under the curve = 0.999). Sensitivity and specificity were maximized at a cutoff of 6. Conclusions: The PSQI demonstrated moderate convergent validity compared to measures of insomnia and fatigue and good divergent validity with measures of daytime sleepiness, circadian phase preference, and alcohol and marijuana use. The PSQI demonstrated considerable overlap with depression, anxiety, and perceived stress. Therefore, caution should be used with interpretation. C1 [Dietch, Jessica R.; Taylor, Daniel J.; Sethi, Kevin; Kelly, Kimberly] Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Roane, Brandy M.] Univ North Texas Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX USA. RP Taylor, DJ (reprint author), Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. EM Daniel.Taylor@unt.edu FU University of North Texas [G69250]; National Institute of Allergy and Infectious Diseases [1R15AI085558-01A2] FX This was not an industry supported study. This study was supported by a grant from the University of North Texas (G69250) and from the National Institute of Allergy and Infectious Diseases (1R15AI085558-01A2). Dr. Roane has consulted for Johnson & Johnson. The other authors have indicated no financial conflicts of interest. The study was performed at the University of North Texas, Denton, TX. NR 49 TC 0 Z9 0 U1 4 U2 4 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 8 BP 1121 EP 1129 DI 10.5664/jcsm.6050 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA EF0BE UT WOS:000389989600009 PM 27166299 ER PT J AU Aurora, RN Bista, SR Casey, KR Chowdhuri, S Kristo, DA Mallea, JM Ramar, K Rowley, JA Zak, RS Heald, JL AF Aurora, R. Nisha Bista, Sabin R. Casey, Kenneth R. Chowdhuri, Susmita Kristo, David A. Mallea, Jorge M. Ramar, Kannan Rowley, James A. Zak, Rochelle S. Heald, Jonathan L. TI Keep Calm and Debate On SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Letter ID ADAPTIVE SERVO-VENTILATION; CENTRAL SLEEP-APNEA; HEART-FAILURE PATIENTS; PROGNOSIS C1 [Aurora, R. Nisha] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Bista, Sabin R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Casey, Kenneth R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Chowdhuri, Susmita] John D Dingell VA Med Ctr, Detroit, MI USA. [Chowdhuri, Susmita] Wayne State Univ, Detroit, MI USA. [Kristo, David A.] Univ Pittsburgh, Pittsburgh, PA USA. [Mallea, Jorge M.] Mayo Clin Florida, Transplant Ctr, Jacksonville, FL USA. [Ramar, Kannan] Mayo Clin, Rochester, MN USA. [Rowley, James A.] Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA. [Zak, Rochelle S.] Univ Calif San Francisco, Sleep Disorders Ctr, San Francisco, CA 94143 USA. [Heald, Jonathan L.] Amer Acad Sleep Med, Darien, IL USA. RP Aurora, RN (reprint author), Johns Hopkins Sleep Disorders Ctr, Johns Hopkins Sch Med, Baltimore, MD 21224 USA. EM research@aasmnet.org NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 9 BP 1315 EP 1316 DI 10.5664/jcsm.6148 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EF0CF UT WOS:000389992400020 PM 27568903 ER PT J AU Palen, BN Donovan, LM Parsons, EC AF Palen, Brian N. Donovan, Lucas M. Parsons, Elizabeth C. TI An Unexpected Polysomnogram Finding SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; REM-SLEEP; BUPROPION C1 [Palen, Brian N.; Parsons, Elizabeth C.] VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA USA. [Palen, Brian N.; Donovan, Lucas M.; Parsons, Elizabeth C.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Parsons, EC (reprint author), 1660 S Columbian Way,S-111 Pulm, Seattle, WA 98118 USA. EM elizabeth.parsons@va.gov FU NHLBI NIH HHS [T32 HL007287] NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 11 BP 1567 EP 1569 DI 10.5664/jcsm.6294 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EF0DU UT WOS:000389996700019 PM 27707444 ER PT J AU Haverhals, LM Manheim, CE Gilman, CV Jones, J Levy, C AF Haverhals, Leah M. Manheim, Chelsea E. Gilman, Carrie V. Jones, Jacqueline Levy, Cari TI Caregivers Create a Veteran-Centric Community in VHA Medical Foster Homes SO JOURNAL OF GERONTOLOGICAL SOCIAL WORK LA English DT Article DE caregiving/informal care; community-based service providers/systems; Veterans ID LONG-TERM-CARE; NURSING-HOME; FAMILY; VIEWS; INTERVIEW; BURDEN; LABOR; WANT; RACE AB The Veteran's Health Administration's Medical Foster Home program offers a unique long-term care option for veterans who require nursing-home-or assisted-living-level care. Veterans in a medical foster home reside with community-based caregivers who provide 24-hr-a-day care and monitoring. The veterans often remain in the medical foster home until end of life. Support and oversight is provided to the caregiver from the Veteran's Health Administration's community-based medical team. This qualitative descriptive study is based on secondary analysis of interviews with 20 medical foster home caregivers from 7 programs across the United States. The study's research aims are to describe and explain (a) the type of care backgrounds and skills these caregivers possess, (b) caregivers' primary motivations to open their homes to veterans who often have complex medical and social needs, and (c) how caregivers function in their role as primary caregiver for veterans. Findings indicated that caregivers interviewed had worked in long-term care settings and/or cared for family members. A strong desire to serve veterans was a primary motivation for caregivers, rather than financial gain. The caregivers' long-term care skills aided them in building and sustaining the unique medical foster home family-like community. C1 [Haverhals, Leah M.; Manheim, Chelsea E.; Gilman, Carrie V.; Jones, Jacqueline; Levy, Cari] Denver Vet Affairs Med Ctr, Denver Seattle Ctr Innovat, 1055 Clermont St Res A151, Denver, CO 80220 USA. [Jones, Jacqueline] Univ Colorado, Sch Nursing, Anschutz Med Campus, Aurora, CO USA. [Levy, Cari] Univ Colorado, Sch Med, Dept Med, Div Hlth Care Policy & Res, Anschutz Med Campus, Aurora, CO USA. RP Manheim, CE (reprint author), Denver Vet Affairs Med Ctr, Denver Seattle Ctr Innovat, 1055 Clermont St Res A151, Denver, CO 80220 USA. EM chelsea.manheim@va.gov NR 35 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1540-4048 EI 0163-4372 J9 J GERONTOL SOC WORK JI J. Gerontol. Soc. Work PY 2016 VL 59 IS 6 BP 441 EP 457 DI 10.1080/01634372.2016.1231730 PG 17 WC Geriatrics & Gerontology; Social Work SC Geriatrics & Gerontology; Social Work GA EE7JL UT WOS:000389791800002 PM 27598768 ER PT J AU Ford, JM Roach, BJ Palzes, VA Mathalon, DH AF Ford, Judith M. Roach, Brian J. Palzes, Vanessa A. Mathalon, Daniel H. TI Using concurrent EEG and fMRI to probe the state of the brain in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE Concurrent EEG plus fMRI; Perception; N100; P200; Schizophrenia; Avolition/apathy ID EVENT-RELATED POTENTIALS; HUMAN AUDITORY-CORTEX; SELECTIVE-ATTENTION; DEFAULT MODE; NEUROMAGNETIC RESPONSES; FUNCTIONAL MRI; RESTING-STATE; COMPONENT; HALLUCINATIONS; PERCEPTION AB Perceptional abnormalities in schizophrenia are associated with hallucinations and delusions, but alsowith negative symptoms and poor functional outcome. Perception can be studied using EEG-derived event related potentials (ERPs). Because of their excellent temporal resolution, ERPs have been used to ask when perception is affected by schizophrenia. Because of its excellent spatial resolution, functional magnetic resonance imaging (fMRI) has been used to ask where in the brain these effects are seen. We acquired EEG and fMRI data simultaneously to explore when and where auditory perception is affected by schizophrenia. Thirty schizophrenia (SZ) patients and 23 healthy comparison subjects (HC) listened to 1000 Hz tones occurring about every second. We used joint independent components analysis (jICA) to combine EEG-based event-related potential (ERP) and fMRI responses to tones. Five ERP-fMRI joint independent components (JIC) were extracted. The "N100" JIC had temporal weights during N100 (peaking at 100 ms post-tone onset) and fMRI spatial weights in superior and middle temporal gyri (STG/MTG); however, it did not differ between groups. The "P200" JIC had temporal weights during P200 and positive fMRI spatial weights in STG/MTG and frontal areas, and negative spatial weights in the nodes of the default mode network (DMN) and visual cortex. Groups differed on the "P200" JIC: SZ had smaller "P200" JIC, especially those with more severe avolition/apathy. This is consistent with negative symptoms being related to perceptual deficits, and suggests patients with avolition/apathy may allocate too few resources to processing external auditory events and too many to processing internal events. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Ford, Judith M.; Roach, Brian J.; Palzes, Vanessa A.; Mathalon, Daniel H.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM Judith.Ford@ucsf.edu; Brian.Roach@ncire.org; Vanessa.Palzes@ncire.org; Daniel.Mathalon@ucsf.edu FU National Institute of Mental Health [MH58262]; VA [I01 CX000497] FX This work was supported by grants from National Institute of Mental Health (MH58262 to JMF) and the VA (I01 CX000497 to JMF). DHM consults for Boehringer Ingelheim. The authors have declared that there are no conflicts of interest in relation to the subject of this study. NR 71 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 429 EP 441 DI 10.1016/j.nicl.2016.08.009 PG 13 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400050 PM 27622140 ER PT J AU Yu, J Zhu, H Gattoni-Celli, S Taheri, S Kindy, MS AF Yu, Jin Zhu, Hong Gattoni-Celli, Sebastiano Taheri, Saeid Kindy, Mark Stephen TI Dietary supplementation of GrandFusion (R) mitigates cerebral ischemia-induced neuronal damage and attenuates inflammation SO NUTRITIONAL NEUROSCIENCE LA English DT Article DE Cerebral ischemia; Inflammation; Oxidative stress; Diet; Neuroprotection ID BRAIN-INJURY; REPERFUSION INJURY; OXIDATIVE STRESS; VEGETABLE CONSUMPTION; BEHAVIORAL DEFICITS; ANTIOXIDANT ENZYMES; EXPERIMENTAL STROKE; TRANSIENT ISCHEMIA; GLOBAL BURDEN; CATHEPSIN-B AB Objectives: Dietary supplementation of fruits and vegetables has been the main stay for nutritional benefit and overall well-being. GrandFusion (R) is a nutritional supplement that contains the natural nutrients from whole fruits and vegetables that include complex nutrients and phytonutrients that contain anti-oxidant, anti-inflammatory, and neuroprotective properties. Methods: In this study, C57BL/6 mice were fed a diet supplemented with GrandFusion (R) for 2 months prior to 1 hour of ischemia induced by occlusion of the middle cerebral artery (MCAo) followed by various times of reperfusion. Mice were subjected to MCAo for 1 hour and then at various times following reperfusion, animals were assessed for behavioral outcomes (open field testing, rotarod, and adhesive test removal), and infarct volumes (cresyl violet and triphenyltetrazolium chloride). In addition, to determine the potential mechanisms associated with treatment, the brain tissue was examined for changes in oxidative stress and inflammatory markers. Results: The GrandFusion (R) diet was able to show a significant protection from infarct damage in the brain and an improvement in neurological outcomes. The diet did not alter heart rate, blood pressure, pO(2), pCO(2), or pH. In addition, the diet mitigated inflammation by reducing microglial and astrocytic activation following ischemia and reperfusion and limiting oxidative stress. Discussion: The study demonstrates the neuroprotective effect of a diet rich in fruits and vegetables that contain anti-oxidant and anti-inflammatory against the impact of cerebral ischemia and reperfusion injury. C1 [Yu, Jin; Zhu, Hong; Taheri, Saeid; Kindy, Mark Stephen] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano] Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano; Kindy, Mark Stephen] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kindy, Mark Stephen] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA. [Kindy, Mark Stephen] James A Haley VA Med Ctr, Tampa, FL 33612 USA. RP Kindy, MS (reprint author), MUSC, Charleston, SC 29403 USA. EM kindym@health.usf.edu NR 68 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1028-415X EI 1476-8305 J9 NUTR NEUROSCI JI Nutr. Neurosci. PY 2016 VL 19 IS 7 BP 290 EP 300 DI 10.1179/1476830515Y.0000000021 PG 11 WC Neurosciences; Nutrition & Dietetics SC Neurosciences & Neurology; Nutrition & Dietetics GA DW5SP UT WOS:000383707500003 PM 25879584 ER PT J AU Narayanan, AK Harding, JD Saba, SK Conley, J Gordon, AJ AF Narayanan, Arthi K. Harding, John D. Saba, Shaddy K. Conley, James Gordon, Adam J. TI Left, right, and meeting in the middle: Addressing addiction is something we can agree about SO Substance Abuse LA English DT Editorial Material DE Addiction crisis; addiction policy; Democratic; policy review; Republican; United States Election 2016 ID PRESCRIPTION-OPIOID USE; PARTY PLATFORMS AB The United States faces an addiction health crisis. Presidential election cycles in the United States are cause for creation of political party platforms. These platforms provide general stances and specific policies on a variety of issues. We undertook a review of the addiction policies of the 2016 Republican and Democratic platforms. Despite differences in focus, we found more similarities than differences between the two. We call upon those in political power to use every evidence-based policy at their disposal to promote addiction treatment and prevention. C1 [Narayanan, Arthi K.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Harding, John D.; Conley, James; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot CHERP, Pittsburgh, PA USA. [Harding, John D.; Conley, James; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Saba, Shaddy K.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, VA Pittsburgh Healthcare Syst Interdisciplinary A, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Univ Dr C,Mailcode 151-C, Pittsburgh, PA 15240 USA.; Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,Mailcode 151-C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 495 EP 497 DI 10.1080/08897077.2016.1238655 PG 3 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600001 PM 27648701 ER PT J AU Stringfellow, EJ Kim, TW Gordon, AJ Pollio, DE Grucza, RA Austin, EL Johnson, NK Kertesz, SG AF Stringfellow, Erin J. Kim, Theresa W. Gordon, Adam J. Pollio, David E. Grucza, Richard A. Austin, Erika L. Johnson, N. Kay Kertesz, Stefan G. TI Substance use among persons with homeless experience in primary care SO SUBSTANCE ABUSE LA English DT Article DE Homeless; primary care; substance use ID NATIONAL EPIDEMIOLOGIC SURVEY; EXTENDED-RELEASE NALTREXONE; RANDOMIZED CLINICAL-TRIAL; DRUG-USE; BRIEF INTERVENTION; UNITED-STATES; HEALTH-CARE; PSYCHIATRIC-DISORDERS; RELAPSE PREVENTION; MEDICAID EXPANSION AB Background: Community survey data suggest high prevalence of substance use disorders among currently homeless individuals. There are less data regarding illicit drug and alcohol use problems of homeless-experienced persons engaged in primary care. They may have less severe use and require different care responses from primary care teams. Methods: The authors surveyed currently and formerly homeless, i.e., homeless-experienced, persons engaged in primary care at five federally funded programs in the United States, administering the World Health Organization (WHO) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The ASSIST definitions of lower, moderate, and high risk were used to assess a spectrum of lifetime and recent substance use, from any use to likely dependence, and to identify sociodemographic and health status characteristics associated with severity of use. Results: Almost one half of the sample (N = 601) had recently (within the past three months) used alcohol, and one third had recently used an illicit drug. The most commonly used illicit drugs in the past three months were cannabis (19%), cocaine (16%), and opioids (7.5%). Over one half (59%) of respondents had ASSIST-defined moderate- or high-risk substance use. A significant proportion (31%) of those identified as at moderate risk had no recent substance use, but did report past problematic use. Ten percent of the lower-risk group had past problematic use of alcohol. Severity of use was associated with worse health status, but not with housing status or type of homelessness experienced. Conclusions: Less severe (moderate-risk) use and past problematic use, potentially indicative of remitted substance use disorders, were more common than high-risk use in this primary care, homeless-experienced sample. These findings highlight the urgency of identifying effective ways to reduce risky substance use and prevent relapse in homeless-experienced persons. C1 [Stringfellow, Erin J.] Washington Univ, George Warren Brown Sch Social Work, One Brookings Dr,Campus Box 1196, St Louis, MO 63130 USA. [Kim, Theresa W.] Boston Med Ctr, Gen Internal Med Sect, Dept Med, Clin Addict Res & Educ CARE Unit, Boston, MA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Pollio, David E.] Univ Alabama Birmingham, Dept Social Work, Birmingham, AL USA. [Grucza, Richard A.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Austin, Erika L.; Johnson, N. Kay; Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Austin, Erika L.] Univ Alabama Birmingham, Dept Biostat, Birmingham Sch Publ Hlth, Birmingham, AL 35294 USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. RP Stringfellow, EJ (reprint author), Washington Univ, George Warren Brown Sch Social Work, One Brookings Dr,Campus Box 1196, St Louis, MO 63130 USA. EM estringfellow@wustl.edu OI Kertesz, Stefan/0000-0001-6101-8421 FU Department of Veterans Affairs Health Services Research & Development Branch [IAA-07-069-2]; Social Work Training in Addictions Research Institutional Predoctoral Fellowship through the National Institute on Drug Abuse (NIDA) [T32 DA015035] FX The Department of Veterans Affairs Health Services Research & Development Branch (grant IAA-07-069-2) provided funding for the data collection on which this analysis is based. The Social Work Training in Addictions Research Institutional Predoctoral Fellowship (T32 DA015035) through the National Institute on Drug Abuse (NIDA) provided funding for the writing of the manuscript. NR 69 TC 1 Z9 1 U1 8 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 534 EP 541 DI 10.1080/08897077.2016.1145616 PG 8 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600009 PM 26914448 ER PT J AU Haibach, JP Homish, GG Collins, RL Ambrosone, CB Giovino, GA AF Haibach, Jeffrey P. Homish, Gregory G. Collins, R. Lorraine Ambrosone, Christine B. Giovino, Gary A. TI Fruit and vegetable intake as a moderator of the association between depressive symptoms and cigarette smoking SO SUBSTANCE ABUSE LA English DT Article DE Cigarette smoking; depression; depressive symptoms; fruit; moderation; vegetable; young adult ID NICOTINE DEPENDENCE; MONOAMINE-OXIDASE; MAJOR DEPRESSION; NUTRIENT INTAKE; SERUM COTININE; UNITED-STATES; DIETARY PATTERN; MENTAL-HEALTH; EX-SMOKERS; CESSATION AB Background: Studies have consistently reported associations among depression, cigarette smoking, and fruit and vegetable intake (FVI). This study evaluated FVI as a moderator of the association between depressive symptoms and smoking. Methods: The authors analyzed data from the National Longitudinal Survey of Youth 1979: Child and Young Adult. The study sample was adults aged 19-33years at baseline in the year 2004 from the Young Adult Survey portion. Moderation analyses were performed using the Johnson-Neyman technique to assess whether baseline FVI moderated the association between depressive symptoms and smoking status cross-sectionally and as a predictor of smoking cessation longitudinally at 4-year follow-up. Results: Cross-sectionally, at lower levels of FVI (<4.9 times/day), there was a significant association between smoking and depressive symptoms (P < .05), but not at higher levels of FVI (4.9 times/day; P > .05). Longitudinally, there was an inverse association between depressive symptoms and quitting smoking at FVI <1.2 times/day (P < .05), but there was not a significant association at FVI 1.2 times/day (P .05). Conclusions: FVI moderated the association between depressive symptoms and cigarette smoking cross-sectionally and longitudinally. The cross-sectional findings might be partially explained by the longitudinal findings paired with prior research; there might be fewer smokers with high FVI because depressive symptoms are removed as an impediment to cessation. Further experimental research is warranted to test the efficacy of increased FVI as an adjunct to smoking cessation, with a possible mechanism of action being reduced depressive symptoms during quit attempts. C1 [Haibach, Jeffrey P.; Homish, Gregory G.; Collins, R. Lorraine; Giovino, Gary A.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Community Hlth & Hlth Behav, Buffalo, NY USA. [Haibach, Jeffrey P.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DE USA. [Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA. RP Haibach, JP (reprint author), US Dept Vet Affairs, 810 Vermont Ave NW,10P9H, Washington, DC 20420 USA. EM Jeffrey.Haibach@va.gov NR 73 TC 1 Z9 1 U1 10 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 571 EP 578 DI 10.1080/08897077.2016.1179703 PG 8 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600014 PM 27093192 ER PT J AU Mufson, EJ Perez, SE Nadeem, M Mahady, L Kanaan, NM Abrahamson, EE Ikonomovic, MD Crawford, F Alvarez, V Stein, T McKee, AC AF Mufson, Elliott J. Perez, Sylvia E. Nadeem, Muhammad Mahady, Laura Kanaan, Nicholas M. Abrahamson, Eric E. Ikonomovic, Milos D. Crawford, Fiona Alvarez, Victor Stein, Thor McKee, Ann C. TI Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study SO BRAIN INJURY LA English DT Article DE Cognition; head injury; memory; mild brain injury; traumatic brain injury ID MILD COGNITIVE IMPAIRMENT; NERVE GROWTH-FACTOR; BETA-AMYLOID DEPOSITION; ALZHEIMERS-DISEASE; BRAIN-INJURY; HEAD-INJURY; ACETYLTRANSFERASE ACTIVITY; FOREBRAIN NEURONS; CASPASE CLEAVAGE; UP-REGULATION AB Objective: To test the hypothesis that the nucleus basalis of Meynert (nbM), a cholinergic basal forebrain (CBF) cortical projection system, develops neurofibrillary tangles (NFTs) during the progressive pathological stages of chronic traumatic encephalopathy (CTE) in the brain of athletes.Method: To characterize NFT pathology, tau-antibodies marking early, intermediate and late stages of NFT development in CBF tissue obtained at autopsy from eighteen former athletes and veterans with a history of repetitive mild traumatic brain injury (TBI) were used.Results: Analysis revealed that cholinergic nbM neurons develop intracellular tau-immunoreactive changes progressively across the pathological stages of CTE. In particular, there was an increase in pre-tangle (phosphorylated pS422) and oligomeric (TOC1 and TNT1) forms of tau in stage IV compared to stage II CTE cases. The nbM neurons also displayed pathologic TDP-43 inclusions and diffuse extracellular and vascular amyloid- (A) deposits in CTE. A higher percentage of pS422/p75(NTR), pS422 and TNT1 labelled neurons were significantly correlated with age at symptom onset, interval between symptom onset and death and age at death.Conclusion: The development of NFTs within the cholinergic nbM neurons could contribute to an axonal disconnection in CTE. Further studies are needed to determine the mechanism driving NFT formation in the nbM neurons and its relation to chronic cognitive dysfunction in CTE. C1 [Mufson, Elliott J.; Perez, Sylvia E.; Nadeem, Muhammad; Mahady, Laura] Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA. [Kanaan, Nicholas M.] Michigan State Univ, Dept Translat Sci & Mol Med, Coll Human Med, Grand Rapids, MI USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol & Psychiat, Pittsburgh, PA USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Hlthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Crawford, Fiona] Roskamp Inst, Sarasota, FL USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, VA Boston HlthCare Syst, Alzheimer Dis Ctr, Boston, MA USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, CTE Program, Boston, MA USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA USA. RP Mufson, EJ (reprint author), Barrow Neurol Inst, Alzheimers Dis Res Lab, 350 W Thomas St, Phoenix, AZ 85013 USA. EM elliott.mufson@dignityhealth.org FU US Army Medical Research and Material Command; US Department of Veterans Affairs [W81XWH-13-2-0095]; Department of Veterans Affairs [I01 RX001774]; National Institute of Neurological Disorders and Stroke; National Institute of Biomedical Imaging and Bioengineering [U01NS086659-01]; National Institute of Aging, Boston University AD Center [P30AG13846, 0572063345-5]; Veterans Affairs Biorepository [CSP 501]; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment; National Football League FX The authors report no conflicts of interest. This material is based upon work supported by the US Army Medical Research and Material Command and from the US Department of Veterans Affairs [2] under Award No. W81XWH-13-2-0095. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the US Government, or the US Department of Veterans Affairs, and no official endorsement should be inferred. This work was also supported by an award from the Department of Veterans Affairs No. I01 RX001774, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (U01NS086659-01) and National Institute of Aging, Boston University AD Center (P30AG13846; supplement 0572063345-5), the Veterans Affairs Biorepository (CSP 501), the National Operating Committee on Standards for Athletic Equipment, the Concussion Legacy Foundation, the Andlinger Foundation and the World Wrestling Entertainment and the National Football League. NR 83 TC 0 Z9 0 U1 4 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 12 BP 1399 EP 1413 DI 10.1080/02699052.2016.1219058 PG 15 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA ED1IO UT WOS:000388599100002 PM 27834536 ER PT J AU Pugh, MJ Finley, EP Wang, CP Copeland, LA Jaramillo, CA Swan, AA Elnitsky, CA Leykum, LK Mortensen, EM Eapen, BA Noel, PH Pugh, JA AF Pugh, Mary Jo Finley, Erin P. Wang, Chen-Pin Copeland, Laurel A. Jaramillo, Carlos A. Swan, Alicia A. Elnitsky, Christine A. Leykum, Luci K. Mortensen, Eric M. Eapen, Blessen A. Noel, Polly H. Pugh, Jacqueline A. CA TRACC Res Team TI A retrospective cohort study of comorbidity trajectories associated with traumatic brain injury in veterans of the Iraq and Afghanistan wars SO BRAIN INJURY LA English DT Article DE Comorbidity; Trajectories; Iraq and Afghanistan wars; veteran; healthcare; brain injury ID POLYTRAUMA-CLINICAL-TRIAD; SUBSTANCE USE DISORDERS; COMBAT DEPLOYMENT; OEF/OIF VETERANS; MENTAL-HEALTH; GENDER-DIFFERENCES; MILITARY PERSONNEL; ALCOHOL-USE; CARE; PREVALENCE AB Objectives: To identify and validate trajectories of comorbidity associated with traumatic brain injury in male and female Iraq and Afghanistan war Veterans (IAV).Methods: Derivation and validation cohorts were compiled of IAV who entered the Department of Veterans Affairs (VA) care and received 3 years of VA care between 2002-2011. Chronic disease and comorbidities associated with deployment including TBI were identified using diagnosis codes. A latent class analysis (LCA) of longitudinal comorbidity data was used to identify trajectories of comorbidity.Results: LCA revealed five trajectories that were similar for women and men: (1) Healthy, (2) Chronic Disease, (3) Mental Health, (4) Pain and (5) Polytrauma Clinical Triad (PCT: pain, mental health and TBI). Two additional classes found in men were 6) Minor Chronic and 7) PCT with chronic disease. Among these gender-stratified trajectories, it was found that women were more likely to experience headache (Pain trajectory) and depression (Mental Health trajectory), while men were more likely to experience lower back pain (Pain trajectory) and substance use disorder (Mental Health trajectory). The probability of TBI was highest in the PCT-related trajectories, with significantly lower probabilities in other trajectories.Conclusions: It was found that TBI was most common in PCT-related trajectories, indicating that TBI is commonly comorbid with pain and mental health conditions for both men and women. The relatively young age of this cohort raises important questions regarding how disease burden, including the possibility of neurodegenerative sequelae, will accrue alongside normal age-related decline in individuals with TBI. Additional big data' methods and a longer observation period may allow the development of predictive models to identify individuals with TBI that are at-risk for adverse outcomes. C1 [Pugh, Mary Jo; Finley, Erin P.; Jaramillo, Carlos A.; Swan, Alicia A.; Leykum, Luci K.; Eapen, Blessen A.; Noel, Polly H.; Pugh, Jacqueline A.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Pugh, Mary Jo; Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Finley, Erin P.; Swan, Alicia A.; Leykum, Luci K.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Cent Texas Vet Hlth Baylor Scott & White, Ctr Appl Hlth Res, Temple, TX USA. [Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Dept Med, Bryan, TX USA. [Elnitsky, Christine A.; TRACC Res Team] Univ N Carolina, Sch Nursing, Coll Hlth & Human Serv, Charlotte, NC USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA. [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr Dallas, Div Gen Internal Med, Dallas, TX USA. [Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209; Mortensen, Eric/0000-0002-3880-5563; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Healthcare System/Audie L. Murphy Division; Edith Nourse Rogers VA Memorial Hospital; VA Research and Development FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). The funding agency had no role in data collection, analysis or manuscript development. The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the Edith Nourse Rogers VA Memorial Hospital. We also acknowledge assistance with manuscript preparation by Natalie Rohde, Margaret Wells, Barbara Elizondo and Kathleen Franklin. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Drs. Pugh, Finley, Copeland, Jaramillo, Leykum, Mortensen, Eapen and Pugh are VA employees; this study was funded by VA Research and Development. NR 53 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 12 BP 1481 EP 1490 DI 10.1080/02699052.2016.1219055 PG 10 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA ED1IO UT WOS:000388599100010 PM 27834535 ER PT J AU Bu, YQ Zhou, XH AF Bu, Yunqi Zhou, Xiao-Hua TI Statistical evaluation of drug efficacy for bridging study in companion diagnostic test trials SO JOURNAL OF BIOPHARMACEUTICAL STATISTICS LA English DT Article DE Bridging study; causal inference; clinical trial assay; companion diagnostic assay; covariate imbalance; device-drug pivotal clinical trial; doubly robust estimator; drug efficacy; optimal matching; personalized medicine AB Personalized medicine is an area of growing attention in medical research and practice. A market-ready companion diagnostic test (CDx) is used in personalized medicine for identifying the best treatment for an individual patient. Unfortunately, development of CDx may lag behind the development of the drug, and consequently we use a clinical trial assay (CTA) to enroll patients into the drug pivotal clinical trial instead. Thus, when CDx becomes available, a bridging study will be required to assess the drug efficacy in the CDx intended use (CDx IU) population. Due to missingness of the CDx results that could be associated with randomization, one challenge we face in a bridging study is covariate imbalance between treatment arms for the subpopulation with both positive CDx and CTA. In this paper, we evaluate the performance of two methods in bridging studies under a causal inference framework. Particularly, we aim to use the propensity score method with doubly robust estimation and optimal matching to address the challenge. We extend under a current framework on drug efficacy estimation in the CDx IU population, using data from both the bridging study and the CTA drug pivotal clinical trial. Both approaches are discussed in the context of a randomized bridging study, and a targeted design clinical trial with simulations, followed by analyzing simulated data that mimic a real ongoing clinic trial. C1 [Bu, Yunqi; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, Seattle Denver HSR&D Ctr Innovat, Biostat Unit, Seattle, WA 98108 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA.; Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, Seattle Denver HSR&D Ctr Innovat, Biostat Unit, Seattle, WA 98108 USA.; Zhou, XH (reprint author), Univ Washington, HSB, Met Pk West 1400,Puget Care Syst Care & H 655E, Seattle, WA USA. EM azhou@uw.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1054-3406 EI 1520-5711 J9 J BIOPHARM STAT JI J. Biopharm. Stat. PY 2016 VL 26 IS 6 SI SI BP 1118 EP 1124 DI 10.1080/10543406.2016.1226328 PG 7 WC Pharmacology & Pharmacy; Statistics & Probability SC Pharmacology & Pharmacy; Mathematics GA ED1HS UT WOS:000388596600011 PM 27649095 ER PT J AU DiPiro, ND Embry, AE Fritz, SL Middleton, A Krause, JS Gregory, CM AF DiPiro, N. D. Embry, A. E. Fritz, S. L. Middleton, A. Krause, J. S. Gregory, C. M. TI Effects of aerobic exercise training on fitness and walking-related outcomes in ambulatory individuals with chronic incomplete spinal cord injury SO SPINAL CORD LA English DT Article ID MULTIPLE-SCLEROSIS; OXYGEN-CONSUMPTION; PHYSICAL CAPACITY; CHRONIC STROKE; ADULTS; GAIT; RELIABILITY; PERFORMANCE; VALIDITY; DETERMINANTS AB Study design: Single group, pretest-post-test study. Objectives: To determine the effects of a non-task-specific, voluntary, progressive aerobic exercise training (AET) intervention on fitness and walking-related outcomes in ambulatory adults with chronic motor-incomplete SCI. Setting: Rehabilitation research center. Methods: Ten ambulatory individuals (50% female; 57.94 +/- 9.33 years old; 11.11 +/- 9.66 years postinjury) completed voluntary, progressive moderate-to-vigorous intensity AET on a recumbent stepper 3 days per week for 6 weeks. The primary outcome measures were aerobic capacity (VO2peak (volume of oxygen that the body can use during physical exertion)) and self-selected overground walking speed (OGWS). Secondary outcome measures included walking economy, 6-minute walk test (6MWT), daily step counts, Walking Index for Spinal Cord Injury (WISCI-II), Dynamic Gait Index (DGI) and Berg Balance Scale (BBS). Results: Nine participants completed all testing and training. Significant improvements in aerobic capacity (P= 0.011), OGWS (P= 0.023), the percentage of VO2peak used while walking at self-selected speed (P= 0.03) and daily step counts (P= 0.025) resulted following training. Conclusions: The results indicate that total-body, voluntary, progressive AET is safe, feasible, and effective for improving aerobic capacity, walking speed, and select walking- related outcomes in an exclusively ambulatory SCI sample. This study suggests the potential for non-task-specific aerobic exercise to improve walking following incomplete SCI and builds a foundation for further investigation aimed at the development of exercise based rehabilitation strategies to target functionally limiting impairments in ambulatory individuals with chronic SCI. C1 [DiPiro, N. D.; Embry, A. E.; Krause, J. S.; Gregory, C. M.] Med Univ South Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. [Embry, A. E.; Gregory, C. M.] Med Univ South Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Embry, A. E.; Gregory, C. M.] Ralph H Johnson VAMC, Charleston, SC USA. [Fritz, S. L.; Middleton, A.] Univ South Carolina, Dept Exercise Sci, Phys Therapy Program, Columbia, SC USA. RP DiPiro, ND (reprint author), Med Univ South Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM nicole.dipiro@gmail.com FU South Carolina Clinical and Translational Research (SCTR) Institute; NIH [UL1 TR000062, TL1 TR000061]; South Carolina Spinal Cord Injury Research Fund [13-003]; South Carolina Spinal Cord Injury Association FX This work was supported by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Number UL1 TR000062 and TL1 TR000061. Additional support was provided by the South Carolina Spinal Cord Injury Research Fund (Grant No. 13-003) and the South Carolina Spinal Cord Injury Association. We thank the staff Physical Therapist, Dr Lindsay Perry, and the project coordinators, Patrick Morgan and Katy Holthaus, for their assistance with study management and data collection. NR 55 TC 0 Z9 0 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PY 2016 VL 54 IS 9 BP 675 EP 681 DI 10.1038/sc.2015.212 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DW3ZK UT WOS:000383581400008 PM 26666508 ER PT J AU Gerding, DN File, TM McDonald, LC AF Gerding, Dale N. File, Thomas M., Jr. McDonald, L. Clifford TI Diagnosis and Treatment of Clostridium difficile Infection SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Article DE Clostridium difficile; CDI; diagnostic test; treatment AB Early and accurate diagnosis is essential for optimal treatment of individuals with Clostridium difficile infection (CDI) and for implementation of effective infection control procedures. The decision about which diagnostic test to use is an important one that should be based on test sensitivity, specificity, and predictive value. The challenges of CDI go beyond rapid identification and management of symptomatic patients. Asymptomatic carriage has long been suspected in C. difficile transmission, but it may play a larger role than previously thought. Emerging information also shows that patients treated for CDI remain colonized for many weeks after symptom resolution. In fact, stool culture positivity increases during the first weeks after treatment completion. Treatments that reduce the duration and degree of asymptomatic shedding could have added benefit for reduced transmission. C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ, Chicago Stritch Sch Med, Chicago, IL 60611 USA. [File, Thomas M., Jr.] Summa Hlth Syst, Div Infect Dis, Akron, OH 44304 USA. [File, Thomas M., Jr.] Northeast Ohio Med Univ, Infect Dis Sect, Rootstown, OH USA. [McDonald, L. Clifford] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP File, TM (reprint author), Summa Hlth Syst, Div Infect Dis, 75Arch St,Suite 506, Akron, OH 44304 USA. EM FileT@summahealth.org NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1056-9103 EI 1536-9943 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD JAN PY 2016 VL 24 IS 1 BP 3 EP 10 DI 10.1097/IPC.0000000000000350 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DA5CU UT WOS:000367820600002 ER PT J AU Habib, SL Yadav, A Kidane, D Weiss, RH Liang, ST AF Habib, Samy L. Yadav, Anamika Kidane, Dawit Weiss, Robert H. Liang, Sitai TI Novel protective mechanism of reducing renal cell damage in diabetes: Activation AMPK by AICAR increased NRF2/OGG1 proteins and reduced oxidative DNA damage SO CELL CYCLE LA English DT Article DE AMPK; AICAR; diabetes; mTOR; Nrf2; OGG1 ID ENDOPLASMIC-RETICULUM STRESS; REPAIR ENZYME OGG1; DB/DB MICE; GLUCOSE; EXPRESSION; COMPLICATIONS; INJURY; OXYGEN; NRF2; NEPHROPATHY AB Exposure of renal cells to high glucose (HG) during diabetes has been recently proposed to be involved in renal injury. In the present study, we investigated a potential mechanism by which AICAR treatment regulates the DNA repair enzyme, 8-oxoG-DNA glycosylase (OGG1) in renal proximal tubular mouse cells exposed to HG and in kidney of db/db mice. Cells treated with HG for 2 days show inhibition in OGG1 promoter activity as well as OGG1 and Nrf2 protein expression. In addition, activation of AMPK by AICAR resulted in an increase raptor phosphorylation at Ser792 and leads to increase the promoter activity of OGG1 through upregulation of Nrf2. Downregulation of AMPK by DN-AMPK and raptor and Nrf2 by siRNA resulted in significant decease in promoter activity and protein expression of OGG1. On the other hand, downregulation of Akt by DN-Akt and rictor by siRNA resulted in significant increase in promoter activity and protein expression of Nrf2 and OGG1. Moreover, gel shift analysis shows reduction of Nrf2 binding to OGG1 promoter in cells treated with HG while cells treated with AICAR reversed the effect of HG. Furthermore, db/db mice treated with AICAR show significant increased in AMPK and raptor phosphroylation as well as OGG1 and Nrf2 protein expression that associated with significant decrease in oxidative DNA damage (8-oxodG) compared to non-treated mice. In summary, our data provide a novel protective mechanism by which AICAR prevents renal cell damage in diabetes and the consequence complications of hyperglycemia with a specific focus on nephropathy. C1 [Habib, Samy L.; Yadav, Anamika; Liang, Sitai] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Habib, Samy L.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA. [Kidane, Dawit] Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Dell Pediat Res Inst, Austin, TX 78712 USA. [Weiss, Robert H.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Weiss, Robert H.] Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM habib@uthscsa.edu FU American Heart Association; South Texas Veterans Healthcare System FX This work was supported in part by grants from the American Heart Association and Merit Review Award from South Texas Veterans Healthcare System (to S.L.H.). NR 35 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 22 BP 3048 EP 3059 DI 10.1080/15384101.2016.1231259 PG 12 WC Cell Biology SC Cell Biology GA EC8EX UT WOS:000388374500020 PM 27611085 ER PT J AU Helke, KL McCrackin, MA Galloway, AM Poole, AZ Salgado, CD Marriott, BP AF Helke, Kristi L. McCrackin, M. A. Galloway, Ashley M. Poole, Ann Z. Salgado, Cassandra D. Marriott, Bernadette P. TI Effects of antimicrobial use in agricultural animals on drug-resistant foodborne salmonellosis in humans: A systematic literature review SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION LA English DT Review DE Food safety; tetracycline; streptomycin; farm-to-fork; meat ID ENTERICA SEROVAR ENTERITIDIS; UNITED-STATES; ESCHERICHIA-COLI; DAIRY-CATTLE; RETAIL MEATS; NONTYPHOIDAL SALMONELLA; MOLECULAR CHARACTERIZATION; GENETIC-CHARACTERIZATION; MULTIDRUG-RESISTANCE; SEROTYPE TYPHIMURIUM AB Controversy continues concerning antimicrobial use in food animals and its relationship to drug-resistant infections in humans. We systematically reviewed published literature for evidence of a relationship between antimicrobial use in agricultural animals and drug-resistant meat or dairy-borne non-typhoidal salmonellosis in humans. Based on publications from the United States (U.S.), Canada, and Denmark from January 2010 to July 2014, 858 articles received title and abstract review, 104 met study criteria for full article review with 68 retained for which data are presented. Antibiotic exposure in both cattle and humans found an increased likelihood of Salmonella colonization, whereas in chickens, animals not exposed to antibiotics (organic) were more likely to be Salmonella positive and those that had antibiotic exposure were more likely to harbor antimicrobial resistant Salmonella organisms. In swine literature, only tylosin exposure was examined and no correlation was found among exposure, Salmonella colonization, or antimicrobial resistance. No studies that identified farm antimicrobial use also traced antimicrobial-resistant Salmonella from farm to fork. C1 [Helke, Kristi L.; McCrackin, M. A.] Med Univ South Carolina, Dept Comparat Med, Charleston, SC USA. [Helke, Kristi L.] Ralph H Johnson VA Med Ctr, Dept Res Serv, Charleston, SC USA. [McCrackin, M. A.; Galloway, Ashley M.; Marriott, Bernadette P.] Med Univ South Carolina, Div Gastroenterol, Nutr Sect, Dept Med, Charleston, SC USA. [Salgado, Cassandra D.] Med Univ South Carolina, Div Infect Dis, Dept Med, Charleston, SC USA. [Marriott, Bernadette P.] Med Univ South Carolina, Div Gastroenterol, Nutr Sect, Dept Psychiat, Charleston, SC USA. RP Marriott, BP (reprint author), Dept Med, Nutr Sect, Div Gastroenterol & Hepatol, 114 Doughty St STB 630D,MSC 770, Charleston, SC 29425 USA.; Marriott, BP (reprint author), Dept Psychiat & Behav Sci, Mil Div, 114 Doughty St STB 630D,MSC 770, Charleston, SC 29425 USA. EM marriobp@musc.edu OI Helke, Kris/0000-0001-9746-0764 FU Animal Health Institute FX Funding for this project was received from the Animal Health Institute. The funders had no role in study design, data collection and analysis, decision to publish or preparation of manuscript. NR 101 TC 0 Z9 0 U1 18 U2 18 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1040-8398 EI 1549-7852 J9 CRIT REV FOOD SCI JI Crit. Rev. Food Sci. Nutr. PY 2016 VL 57 IS 3 BP 472 EP 488 DI 10.1080/10408398.2016.1230088 PG 17 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA EC0BY UT WOS:000387763800002 PM 27602884 ER PT S AU Iafe, NA Phasukkijwatana, N Sarraf, D AF Iafe, Nicholas A. Phasukkijwatana, Nopasak Sarraf, David BE Bandello, F Souied, EH Querques, G TI Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration SO OCT ANGIOGRAPHY IN RETINAL AND MACULAR DISEASES SE Developments in Ophthalmology LA English DT Article; Book Chapter ID CHOROIDAL NEOVASCULARIZATION; THERAPY; ANGIOGENESIS; EYES; CLASSIFICATION; FIBROSIS AB Age-related macular degeneration continues to be the leading cause of severe central vision loss in older adults of European descent. Optical coherence tomography angiography (OCT-A) enables more accurate identification of type 1 neovascularization in age-related macular degeneration than traditional fluorescein and indocyanine green angiographies. In addition, OCT-A facilitates the morphological classification of type 1 lesions, including features characteristic of early, mature, and fibrotic lesions. Vessel complex analysis, including lesion area and capillary density quantification, can also be readily measured and monitored over time. Performing this analysis following anti-vascular endothelial growth factor therapy may lead to a better understanding of the efficacies and responses to such treatments. Although some limitations currently exist, OCT-A is a promising imaging modality that could prove to have profound implications if incorporated into regular clinical practice. (C) 2016 S. Karger AG, Basel C1 [Iafe, Nicholas A.; Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM Niafe@mednet.ucla.edu; nopasak.sioph@gmail.com; dsarraf@ucla.edu NR 20 TC 3 Z9 3 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0250-3751 BN 978-3-318-05830-7; 978-3-318-05829-1 J9 DEV OPHTHALMOL JI Dev. Ophthalmol. PY 2016 VL 56 BP 45 EP 51 DI 10.1159/000442776 D2 10.1159/isbn.978-3-318-05830-7 PG 7 WC Ophthalmology SC Ophthalmology GA BG2CY UT WOS:000387260100008 PM 27023719 ER PT S AU Nemiroff, J Phasukkijwatana, N Sarraf, D AF Nemiroff, Julia Phasukkijwatana, Nopasak Sarraf, David BE Bandello, F Souied, EH Querques, G TI Optical Coherence Tomography Angiography of Deep Capillary Ischemia SO OCT ANGIOGRAPHY IN RETINAL AND MACULAR DISEASES SE Developments in Ophthalmology LA English DT Article; Book Chapter ID ACUTE MIDDLE MACULOPATHY; ACUTE MACULAR NEURORETINOPATHY; NITRIC-OXIDE SYNTHASE; RETINAL ISCHEMIA; REPERFUSION INJURY; OCCLUSION; SPECTRUM AB Paracentral acute middle maculopathy (PAMM) is defined by the spectral-domain optical coherence tomography (OCT) finding of paracentral hyper-reflective band-like lesions of the inner nuclear layer (INL) of the macula that progress to corresponding areas of severe INL thinning. En face analysis has enabled more detailed analyses and quantifications of these lesions and has provided insights into the pathogenesis of this abnormality. While there is a wealth of demographic and anatomical data indicating that these PAMM lesions are the result of an INL infarct, OCT angiography is the first modality to provide direct evidence. Several studies have recently shown that old PAMM lesions are indeed associated with ischemia of the deep capillary retinal plexus, while acute lesions may or may not show initial perfusion of the deep capillary retinal plexus. (C) 2016 S. Karger AG, Basel C1 [Nemiroff, Julia; Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM jnemiroff@gmail.com; nopasak.sioph@gmail.com; dsarraf@ucla.edu NR 18 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0250-3751 BN 978-3-318-05830-7; 978-3-318-05829-1 J9 DEV OPHTHALMOL JI Dev. Ophthalmol. PY 2016 VL 56 BP 139 EP 145 DI 10.1159/000442806 D2 10.1159/isbn.978-3-318-05830-7 PG 7 WC Ophthalmology SC Ophthalmology GA BG2CY UT WOS:000387260100021 PM 27022753 ER PT J AU Sher, L AF Sher, Leo TI NARCISSISTIC PERSONALITY DISORDER AND SUICIDE SO PSYCHIATRIA DANUBINA LA English DT Letter ID BORDERLINE C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 7 TC 0 Z9 0 U1 1 U2 1 PU MEDICINSKA NAKLADA PI ZAGREB PA VLASKA 69, HR-10000 ZAGREB, CROATIA SN 0353-5053 J9 PSYCHIAT DANUB JI Psychiatr. Danub. PY 2016 VL 28 IS 3 BP 307 EP 307 PG 1 WC Psychiatry SC Psychiatry GA EC8OI UT WOS:000388400900015 ER PT J AU Allan, NP Gros, DF Hom, MA Joiner, TE Stecker, T AF Allan, Nicholas P. Gros, Daniel F. Hom, Melanie A. Joiner, Thomas E. Stecker, Tracy TI Suicidal Ideation and Interpersonal Needs: Factor Structure of a Short Version of the Interpersonal Needs Questionnaire in an At-Risk Military Sample SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID PERCEIVED BURDENSOMENESS; THWARTED BELONGINGNESS; PSYCHOLOGICAL THEORY; MODEL; PERSONNEL; VETERANS; VALIDITY; ARMY; FIT; RELIABILITY AB Objective: The interpersonal-psychological theory of suicide posits that perceived burdensomeness (PB; i.e., the belief that others would be better off if one were dead) and thwarted belongingness (TB; i.e., the belief that one lacks meaningful social connections) are both necessary risk factors for the development of suicidal ideation. To test these relations, measures are needed that are well validated, especially in samples of at-risk adults. Method: The current study was designed to examine the factor structure of an eight-item version of the Interpersonal Needs Questionnaire (INQ) in a sample of 405 U.S. past and current military personnel (M-age = 31.57 years, SD = 7.28; 90.4% male) who endorsed either current suicidal ideation and/or a past suicide attempt. Analyses were conducted using confirmatory factor analysis (CFA). Results: A bifactor model comprising a general factor, labeled interpersonal needs, and two specific factors, labeled PB and TB, fit the data best. The general factor captured a high proportion of overall variance (81.9%). In contrast, the TB factor captured only a modest amount of variance in items meant to capture this factor (59.1%) and the PB factor captured very little variance in items meant to capture this factor (13.5%). Further, only the interpersonal needs factor was associated with lifetime and past-week suicidal ideation as well as suicidal ideation frequency and duration. Conclusions: The current findings indicate that, for the INQ-8 in high-risk military personnel, a general interpersonal needs factor accounted for the relations PB and TB share with suicidal ideation. C1 [Allan, Nicholas P.; Gros, Daniel F.; Stecker, Tracy] Med Univ South Carolina, Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Allan, Nicholas P.; Gros, Daniel F.; Stecker, Tracy] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Hom, Melanie A.; Joiner, Thomas E.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Department of Defense Grant [W81XWH-13-2-0032]; Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award [CX000845] FX This study is supported by a Department of Defense Grant (W81XWH-13-2-0032; PI: Stecker) and a Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award (CX000845; PI:Gros). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. There are no conflicts of interest. NR 40 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0033-2747 EI 1943-281X J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PY 2016 VL 79 IS 3 BP 249 EP 261 DI 10.1080/00332747.2016.1185893 PG 13 WC Psychiatry SC Psychiatry GA EC8FC UT WOS:000388375200009 PM 27880629 ER PT J AU Romanoff, A Freed, J Heimann, T AF Romanoff, Anya Freed, Jeffrey Heimann, Tomas TI A case report of necrotizing fasciitis of the abdominal wall: A rare, life-threatening complication of a common disease process SO INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS LA English DT Article DE Necrotizing fasciitis; Perforated appendicitis; Case report AB INTRODUCTION: Acute appendicitis is one of the most common surgical diseases, but perforated appendicitis resulting in necrotizing fasciitis of the abdominal wall is exceedingly rare. PRESENTATION OF CASE: A 71-year-old male presented to the emergency department with one week of severe right-sided abdominal pain. He was hypothermic, hypotensive, and tachycardic. His abdomen was distended, with a large, tender, erythematous region over the right abdominal wall. Laboratory evaluation revealed leukocytosis, acute kidney injury, and lactic acidosis. CT scan revealed large collections of fluid and gas in the right abdominal wall as well as inflammation surrounding the right colon. The patient was resuscitated with intra-venous fluid, started on broad-spectrum antibiotics, and emergently brought to the operating room. The patient underwent an exploratory laparotomy, and was found to have appendicitis, which perforated into his abdominal wall resulting in a necrotizing soft tissue infection. DISCUSSION: The diagnosis of perforated appendicitis resulting in necrotizing fasciitis is often delayed due to the unusual presentation of this common disease. Necrotizing fasciitis is associated with significant mortality and requires immediate intervention. CONCLUSION: It is imperative to maintain a high index of suspicion for intra-abdominal pathology in patients who present with necrotizing infections of the abdominal wall, flank, back, or groin. The importance of recognizing this complication early and proceeding immediately to the operating room cannot be overstated. (C) 2016 The Authors. Published by Elsevier Ltd C1 [Romanoff, Anya] Icahn Sch Med Mt Sinai, Dept Gen Surg, New York, NY 10029 USA. [Romanoff, Anya; Freed, Jeffrey; Heimann, Tomas] James J Peters VA Med Ctr, Dept Gen Surg, Bronx, NY USA. RP Romanoff, A (reprint author), Mt Sinai Med Ctr, Dept Gen Surg, Floor 15,5 East 98th St, New York, NY 10029 USA. EM anya.romanoff@mountsinai.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2210-2612 J9 INT J SURG CASE REP JI Int. J. Surg. Case Rep. PY 2016 VL 28 BP 355 EP 356 DI 10.1016/j.ijscr.2016.09.005 PG 2 WC Surgery SC Surgery GA EC0MY UT WOS:000387796500090 PM 27794239 ER PT J AU Mehta, RL Andringa, KK Sanders, PW Agarwal, A AF Mehta, Ravindra L. Andringa, Kelly K. Sanders, Paul W. Agarwal, Anupam TI Changing Paradigms in Acute Kidney Injury: From Mechanisms to Management SO NEPHRON LA English DT Editorial Material C1 [Mehta, Ravindra L.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. [Andringa, Kelly K.; Sanders, Paul W.; Agarwal, Anupam] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. [Sanders, Paul W.; Agarwal, Anupam] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Agarwal, A (reprint author), Univ Alabama Birmingham, Div Nephrol, THT 647, 1900 Univ Blvd, Birmingham, AL 35294 USA. EM agarwal@uab.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-8151 EI 2235-3186 J9 NEPHRON JI Nephron PY 2016 VL 134 IS 3 BP 131 EP 132 DI 10.1159/000447676 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA EC2SM UT WOS:000387974200001 PM 27597998 ER PT S AU Ngo, GH Eickhoff, SB Fox, PT Yeo, BTT AF Ngo, Gia H. Eickhoff, Simon B. Fox, Peter T. Yeo, B. T. Thomas GP IEEE TI Collapsed Variational Bayesian Inference of the Author-Topic Model: Application to Large-Scale Coordinate-Based Meta-Analysis SO 2016 6TH INTERNATIONAL WORKSHOP ON PATTERN RECOGNITION IN NEUROIMAGING (PRNI) SE International Workshop on Pattern Recognition in Neuroimaging LA English DT Proceedings Paper CT 6th International Workshop on Pattern Recognition in Neuroimaging (PRNI) CY JUN 22-24, 2016 CL Trento, ITALY SP Fondazione Bruno Kessler, Ctr Mind Brain Sci, Univ Degli Studi Trento, Max Planck Gesellschaft, Informat Math ID FUNCTIONAL ARCHITECTURE; CONNECTIVITY NETWORKS; HUMAN BRAIN; CORTEX AB The author-topic (AT) model has been recently used to discover the relationships between brain regions, cognitive components and behavioral tasks in the human brain. In this work, we propose a novel Collapsed Variational Bayesian (CVB) inference algorithm for the AT model. The proposed algorithm is compared with the Expectation-Maximization (EM) algorithm on the large-scale BrainMap database of brain activation coordinates and behavioral tasks. Experiments suggest that the proposed CVB algorithm produces parameter estimates with better generalization power than the EM algorithm. C1 [Ngo, Gia H.; Yeo, B. T. Thomas] Natl Univ Singapore, Singapore Inst Neurotechnol, Clin Imaging Res Ctr, Dept Elect & Comp Engn, Singapore, Singapore. [Ngo, Gia H.; Yeo, B. T. Thomas] Natl Univ Singapore, Memory Networks Programme, Singapore, Singapore. [Eickhoff, Simon B.] Heinrich Heine Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Simon B.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ngo, GH (reprint author), Natl Univ Singapore, Singapore Inst Neurotechnol, Clin Imaging Res Ctr, Dept Elect & Comp Engn, Singapore, Singapore.; Ngo, GH (reprint author), Natl Univ Singapore, Memory Networks Programme, Singapore, Singapore. EM ngohgia@u.nus.edu; thomas.yeo@nus.edu.sg NR 20 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 2330-9989 BN 978-1-4673-6530-7 J9 INT WORKSHOP PATTERN PY 2016 BP 25 EP 28 PG 4 WC Computer Science, Interdisciplinary Applications; Neuroimaging SC Computer Science; Neurosciences & Neurology GA BG1SQ UT WOS:000387080100007 ER PT J AU Huang, IC Cheing, G Rumrill, P Bengtson, K Chan, F Telzlaff, J Snitker, M AF Huang, I-Chun Cheing, Gladys Rumrill, Philip Bengtson, Kevin Chan, Fong Telzlaff, Jana Snitker, Mikael TI Characteristics of people with disabilities receiving assistive technology services in vocational rehabilitation: A logistic regression analysis SO JOURNAL OF VOCATIONAL REHABILITATION LA English DT Article DE Assistive technology; people with disabilities; vocational rehabilitation AB BACKGROUND: The provision of assistive technology (AT) services could help people with disabilities overcome social and environmental barriers in the workplace to facilitate employment outcomes. However, little is known about the types of consumers who receive assistive technology services and who can most benefit from the services in vocational rehabilitation (VR). OBJECTIVE: This study investigated the characteristics of consumers receiving AT services in state VR agencies and identified complementary VR services associated with the provision of AT services. METHODS: A 10% random sample of VR consumers (N=32,088) whose cases were closed in fiscal year 2009 (FY 2009) were extracted from the Rehabilitation Services Administration (RSA) database for a secondary data analysis multivariate logistic regression. RESULTS: Only 10.4% of VR consumers closed in FY 2009 received AT services. The majority of AT recipients reported sensory impairments (60.4%) and physical impairments (27.6%). Consumers older than 65 years of age (odds ratio [OR]=1.43; 95% confidence intervals [CI]: 1.18-1.74), with associate's degrees (OR=1.27; 95% CI: 1.15-1.41) and bachelor's degrees or higher (OR=1.77; 95% CI: 1.55-2.01), reporting sensory impairments (OR=3.78; 95% CI: 3.39-4.21), receiving cash benefits (OR=1.44; 95% CI: 1.29-1.60) and being employed at the time of application (OR=1.79; 95% CI: 1.62-1.98) were more likely to receive AT services. Compared to European Americans, African American (OR=0.77; 95% CI: 0.69-0.87) and Hispanic Americans (OR=0.84; 95% CI: 0.73-0.98) were less likely to receive AT services. Moreover, AT recipients were more likely to also obtain comprehensive assessment (OR=1.49; 95% CI: 1.38 to 1.66), college or university training (OR=1.56; 95% CI: 1.38 to 1.76), occupational or vocational training (OR=1.20; 95% CI: 1.05 to 1.37), augmentative skills training (OR=2.48; 95% CI: 2.09 to 2.94), and miscellaneous training (OR=1.47; 95% CI: 1.30 to 1.66); but less likely to obtain job readiness training (OR=0.75; 95% CI: 0.64 to 0.87) and job search assistance (OR=0.87; 95% CI: 0.76 to 0.99). CONCLUSION: The results provide insights into AT recipients in the state VR system. VR professionals and practitioners need to be aware of AT devices and job accommodation services as resources for people with disabilities to increase employability. Further consideration should be given to developing a systematic understanding of the provision of AT services in the VR system and evaluating its effectiveness. C1 [Huang, I-Chun] Natl Changhua Univ Educ, Changhua, Taiwan. [Cheing, Gladys] Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China. [Rumrill, Philip] Kent State Univ, Kent, OH 44242 USA. [Bengtson, Kevin; Chan, Fong; Telzlaff, Jana] Univ Wisconsin, Madison, WI USA. [Snitker, Mikael] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Huang, IC (reprint author), Natl Changhua Univ Educ, Grad Inst Rehabil Counseling, 1 Jin De Rd, Changhua 500, Taiwan. EM ichunhuang@cc.ncue.edu.tw NR 16 TC 1 Z9 1 U1 2 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1052-2263 EI 1878-6316 J9 J VOCAT REHABIL JI J. Vocat. Rehabil. PY 2016 VL 45 IS 1 BP 63 EP 72 DI 10.3233/JVR-160811 PG 10 WC Rehabilitation SC Rehabilitation GA EB7NJ UT WOS:000387574300007 ER PT J AU Hong, EK Dicianno, BE Pearlman, J Cooper, R Cooper, RA AF Hong, Eun-Kyoung Dicianno, Brad E. Pearlman, Jon Cooper, Rosemarie Cooper, Rory A. TI Comfort and stability of wheelchair backrests according to the TAWC (tool for assessing wheelchair discomfort) SO DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY LA English DT Article DE Assessment; backrest; comfort; discomfort; wheelchair ID SPINAL-CORD-INJURY; TECHNOLOGY AB Purpose: The goal of this study was thus to determine if people with different types of wheelchair backrests on their personal wheelchairs reported different levels of comfort as measured by the Tool for Assessing Wheelchair disComfort (TAWC). Methods: Participants were between 18 and 80 years of age and were manual wheelchair users. The TAWC was used to assess the participants' wheelchair seating discomfort levels with the wheelchair and seating systems. Results: We surveyed 131 wheelchair users to assess the comfort of their backrests on their personal wheelchairs and found a trend suggesting that rigid backrests are were less comfortable as compared with sling backrests. This finding was statistically significant in a subgroup of participants with tetraplegia. Conclusions: Although many clinicians expect rigid backrests to be more comfortable because they may provide more support, the higher discomfort ratings among rigid backrest users with tetraplegia may be due to sub-optimal shape, fit, adjustment or user preferences. C1 [Hong, Eun-Kyoung; Dicianno, Brad E.; Pearlman, Jon; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Hong, Eun-Kyoung; Dicianno, Brad E.; Pearlman, Jon; Cooper, Rosemarie; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 NR 17 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1748-3107 EI 1748-3115 J9 DISABIL REHABIL-ASSI JI Disabil. Rehabil.-Assist. Technol. PY 2016 VL 11 IS 3 BP 223 EP 227 DI 10.3109/17483107.2014.938365 PG 5 WC Rehabilitation SC Rehabilitation GA EA2WC UT WOS:000386455500006 PM 25036985 ER PT J AU Darrah, SD Dicianno, BE Berthold, J McCoy, A Haas, M Cooper, RA AF Darrah, Shaun D. Dicianno, Brad E. Berthold, Justin McCoy, Andrew Haas, Matthew Cooper, Rory A. TI Measuring static seated pressure distributions and risk for skin pressure ulceration in ice sledge hockey players SO DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY LA English DT Article DE Adaptive sports; cerebral palsy; hockey; spina bifida; spinal cord injury ID DEFORMITY; SPINE AB Purpose: To determine whether sledge hockey players with physical disability have higher average seated pressures compared to non-disabled controls. Method: Fifteen age-matched controls without physical disability and 15 experimental participants with physical disability were studied using a pressure mapping device to determine risk for skin pressure ulceration and the impact of cushioning and knee angle positioning on seated pressure distributions. Results: Regardless of participant group, cushioning, or knee angle, average seated pressures exceeded clinically acceptable seated pressures. Controls had significantly higher average seated pressures than the disability group when knees were flexed, both with the cushion (p = 0.013) and without (p = 0.015). Knee extension showed significantly lower average pressures in controls, both with the cushion (p<0.001) and without (p<0.001). Placement of the cushion resulted in significantly lower average pressure in controls when knees were extended (p = 0.024) but not when flexed (p = 0.248). Placement of the cushion resulted in no difference in pressure (p = 0.443) in the disability group. Conclusions: Pressures recorded indicate high risk for skin ulceration. Cushioning was effective only in the control group with knees extended. That knee extension significantly lowered average seated pressures is important, as many sledge hockey players utilize positioning with larger knee flexion angles. C1 [Darrah, Shaun D.; Dicianno, Brad E.; Berthold, Justin; McCoy, Andrew; Haas, Matthew; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA USA. [Darrah, Shaun D.; Dicianno, Brad E.; Berthold, Justin; McCoy, Andrew; Haas, Matthew; Cooper, Rory A.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [McCoy, Andrew] Univ Pittsburgh, Drexel Univ, Coll Med, Pittsburgh, PA USA. [Haas, Matthew] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. EM dicibe@upmc.edu NR 9 TC 0 Z9 0 U1 2 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1748-3107 EI 1748-3115 J9 DISABIL REHABIL-ASSI JI Disabil. Rehabil.-Assist. Technol. PY 2016 VL 11 IS 3 BP 241 EP 246 DI 10.3109/17483107.2014.921939 PG 6 WC Rehabilitation SC Rehabilitation GA EA2WC UT WOS:000386455500009 PM 24875641 ER PT J AU Hong, EK Cooper, RA Pearlman, JL Hargroder, T AF Hong, Eun-Kyoung Cooper, Rory A. Pearlman, Jonathan L. Hargroder, Todd TI Design, testing and evaluation of angle-adjustable backrest hardware SO DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY LA English DT Article DE Adjustment; backrest; design; focus group; ISO testing; wheelchair ID SPINAL-CORD-INJURY; WHEELCHAIR PROPULSION; CONFIGURATION AB Purpose: The purpose of this study was to design and evaluate a final design prototype of angle-adjustable backrest hardware. Methods: A traditional iterative design development protocol was undertaken and completed. Before evaluation by a focus group, testing of the prototype was performed in strict accordance with ISO standards. Focus group participants were between 18 and 80 years of age, used a manual wheelchair as their primary means of mobility, and transferred independently. Individuals with pressure sores or who required of the use of specialized or custom seating for trunk support were excluded from the study. A questionnaire was administered to elicit participants' opinions on the adjustability, function and appearance of the angle-adjustable backrest device. Results: The prototype successfully met the ISO testing standards. Wheelchair users (n = 8) who evaluated the device in a focus group had an overall positive response. Things they most liked about the prototype were comfort, support (function/activities) and adjustability, while things they most disliked about the prototype were problems with string and reaching back position to adjust. Conclusions: The prototype had a positive impression from participants, however, improvements on the operation method and usability were suggested. C1 [Hong, Eun-Kyoung; Cooper, Rory A.; Pearlman, Jonathan L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. [Hong, Eun-Kyoung; Cooper, Rory A.; Pearlman, Jonathan L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Hargroder, Todd] Accessible Designs Inc, San Antonio, TX USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu FU NICHD NIH HHS [2R44HD056705-02A1] NR 12 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1748-3107 EI 1748-3115 J9 DISABIL REHABIL-ASSI JI Disabil. Rehabil.-Assist. Technol. PY 2016 VL 11 IS 4 BP 325 EP 332 DI 10.3109/17483107.2014.938364 PG 8 WC Rehabilitation SC Rehabilitation GA EA2WP UT WOS:000386457100008 PM 24999560 ER PT J AU Harel, NY Carmel, JB AF Harel, Noam Y. Carmel, Jason B. TI Paired Stimulation to Promote Lasting Augmentation of Corticospinal Circuits SO NEURAL PLASTICITY LA English DT Review ID SPINAL-CORD-INJURY; HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; TIMING-DEPENDENT PLASTICITY; THETA-BURST STIMULATION; ELECTRICAL-STIMULATION; HETEROSYNAPTIC FACILITATION; ASSOCIATIVE STIMULATION; SYNAPTIC PLASTICITY; STROKE PATIENTS AB After injury, electrical stimulation of the nervous system can augment plasticity of spared or latent circuits through focal modulation. Pairing stimulation of two parts of a spared circuit can target modulation more specifically to the intended circuit. We discuss 3 kinds of paired stimulation in the context of the corticospinal system, because of its importance in clinical neurorehabilitation. The first uses principles of Hebbian plasticity: by altering the stimulation timing of presynaptic neurons and their postsynaptic targets, synapse function can be modulated up or down. The second form uses synchronized presynaptic inputs onto a common synaptic target. We dub this a "convergent" mechanism, because stimuli have to converge on a common target with coordinated timing. The third form induces focal modulation by tonic excitation of one region (e.g., the spinal cord) during phasic stimulation of another (e.g., motor cortex). Additionally, endogenous neural activity may be paired with exogenous electrical stimulation. This review addresses what is known about paired stimulation of the corticospinal system of both humans and animal models, emphasizes how it qualitatively differs from single-site stimulation, and discusses the gaps in knowledge that must be addressed to maximize its use and efficacy in neurorehabilitation. C1 [Harel, Noam Y.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Harel, Noam Y.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Carmel, Jason B.] Burke Med Res Inst, White Plains, NY 10605 USA. [Carmel, Jason B.] Weill Cornell Med Coll, New York, NY 10065 USA. RP Harel, NY (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.; Harel, NY (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.; Carmel, JB (reprint author), Burke Med Res Inst, White Plains, NY 10605 USA.; Carmel, JB (reprint author), Weill Cornell Med Coll, New York, NY 10065 USA. EM noam.harel@mssm.edu; jason.carmel@med.cornell.edu FU VA RRD Grants [B-0881W, B-4162C]; NY State Spinal Cord Injury Board Grants [C030090, C030171, C30599GG]; Travis Roy Foundation; NIH [1R01NS092875, 1R21EB020318, K08NS073796] FX The authors thank Asht Mishra, Ph.D., for helping in preparing Figure 1. Noam Y. Harel is supported by VA RR&D Grants B-0881W and B-4162C and NY State Spinal Cord Injury Board Grants C030090, C030171, and C30599GG. Jason B. Carmel is supported by the Travis Roy Foundation and NIH Grants 1R01NS092875, 1R21EB020318, and K08NS073796. NR 106 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-5904 EI 1687-5443 J9 NEURAL PLAST JI Neural. Plast. PY 2016 AR 7043767 DI 10.1155/2016/7043767 PG 11 WC Neurosciences SC Neurosciences & Neurology GA EA5CE UT WOS:000386633600001 ER PT J AU Williams, CS Spitz, MC Foley, JF Weaver, LK Lindblad, AS Wierzbicki, MR AF Williams, Christopher S. Spitz, Mark C. Foley, John F. Weaver, Lindell K. Lindblad, Anne S. Wierzbicki, Michael R. TI Baseline EEG abnormalities in mild traumatic brain injury from the BIMA study SO UNDERSEA AND HYPERBARIC MEDICINE LA English DT Article DE mild traumatic brain injury; EEG; slowing ID HEAD-INJURY; CONCUSSION; CARE AB The Brain Injury and Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms after Mild Traumatic Brain Injury (BIMA), sponsored by the Department of Defense, is a randomized, double-blind, sham controlled trial of hyperbaric oxygen (HBO2) in service members with persistent post-concussive symptoms following mild TBI, undergoing comprehensive assessments. The clinical EEG was assessed by neurologists for slow wave activity, ictal/interictal epileptiform abnormalities, and background periodic discharges. There is scant literature about EEG findings in this population, so we report baseline clinical EEG results and explore associations with other evaluations, including demographics, medication, neurological assessments, and clinical MRI outcomes. Seventy-one participants were enrolled: median age 32 years, 99% male, 49% comorbid PTSD, 28% with mTBI in the previous year, 32% blast injuries only, and 73% multiple injuries. All participants reported medication use (mean medications = 8, SD = 5). Slowing was present in 39%: generalized 37%, localized 8%, both 6%. No other abnormalities were identified. Slowing was not significantly associated with demographics, medication or neurological evaluation. Participants without EEG abnormalities paradoxically had significantly higher number of white matter hyperintensities as identified on MRI (p = 0.003). EEG slowing is present in more than one-third of participants in this study without evidence of associations with demographics, medications or neurological findings. C1 [Williams, Christopher S.; Spitz, Mark C.; Foley, John F.] Lovelace Biomed Res, Albuquerque, NM USA. [Williams, Christopher S.] Univ Colorado, CHMG Neurosci, Colorado Springs, CO 80907 USA. [Spitz, Mark C.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. [Spitz, Mark C.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Foley, John F.] Intermt LDS Hosp, Rocky Mt Neurol Associates, Salt Lake City, UT USA. [Weaver, Lindell K.] Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA. [Weaver, Lindell K.] Intermt LDS Hosp, Salt Lake City, UT 84143 USA. [Weaver, Lindell K.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA. [Lindblad, Anne S.; Wierzbicki, Michael R.] Emmes Corp, Rockville, MD USA. RP Weaver, LK (reprint author), Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA.; Weaver, LK (reprint author), Intermt LDS Hosp, Salt Lake City, UT 84143 USA.; Weaver, LK (reprint author), Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA. EM lindell.weaver@imail.org FU U.S. Army Medical Materiel Development Activity FX This work was supported by the U.S. Army Medical Materiel Development Activity. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the U.S. Army or its subordinate activities. Because the BIMA study is still ongoing, clinical trial data summarized in this publication has not yet been locked and is therefore subject to change. NR 25 TC 1 Z9 1 U1 0 U2 0 PU UNDERSEA & HYPERBARIC MEDICAL SOC INC PI DURHAM PA 21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA SN 1066-2936 J9 UNDERSEA HYPERBAR M JI Undersea Hyperb. Med. PY 2016 VL 43 IS 5 SI SI BP 521 EP 530 PG 10 WC Marine & Freshwater Biology; Medicine, Research & Experimental SC Marine & Freshwater Biology; Research & Experimental Medicine GA EA8EE UT WOS:000386867300004 ER PT J AU Canbay, A Sowa, JP Syn, WK Treckmann, J AF Canbay, Ali Sowa, Jan-Peter Syn, Wing-Kin Treckmann, Juergen TI NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed? SO VISCERAL MEDICINE LA English DT Review DE Non-alcoholic fatty liver disease, NAFLD; Non-alcoholic steatohepatitis, NASH; Alcoholic steatohepatitis, ASH; Transplantation ID FREE FATTY-ACIDS; NONALCOHOLIC STEATOHEPATITIS; HEPATOCELLULAR-CARCINOMA; BARIATRIC SURGERY; DISEASE; KIDNEY; RECIPIENTS; STEATOSIS; MORTALITY; OUTCOMES AB Background: Non-alcoholic fatty liver disease (NAFLD) is a continuously increasing cause of chronic liver disease and a health burden in all populations affected by the obesity and metabolic syndrome pandemic. Cirrhotic alterations or hepatocellular carcinoma developing from NAFLD may require liver transplantation (LTx). Methods: Current literature was screened for data on LTx in the setting of NAFLD. Results: NAFLD-associated LTx is expected to increase in number and relevance during the next decade. NAFLD is part of the metabolic syndrome and thus connected to various metabolic alterations and comorbidities such as diabetes or hyperlipidemia. Moreover, NAFLD comprises an independent risk factor for cardiovascular and chronic kidney disease, which again are important risk factors for outcome of surgical interventions. Postoperative immunosuppression, possible steatosis of the liver graft, and a continued presence of metabolic alterations may lead to early recurrence of steatosis or even non-alcoholic steatohepatitis. Currently, no data are available on combined approaches of weight loss and LTx for NAFLD. Conclusion: Specific guidelines on how to manage NAFLD-associated LTx are lacking. This particular situation requires close monitoring of metabolic syndrome-associated comorbidities. NAFLD represents a novel challenge to established LTx procedures. (C) 2016 S. Karger GmbH, Freiburg C1 [Canbay, Ali; Sowa, Jan-Peter] Univ Duisburg, Univ Hosp, Dept Gastroenterol & Hepatol, Essen, Germany. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA. [Syn, Wing-Kin] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. [Treckmann, Juergen] Univ Duisburg, Univ Hosp, Dept Gen Visceral & Transplantat Surg, Essen, Germany. RP Canbay, A (reprint author), Univ Klin Essen, Klin Gastroenterol & Hepatol, Hufelandstr 55, D-45122 Essen, Germany. EM ali.canbay@uni-due.de NR 37 TC 3 Z9 3 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 2297-4725 EI 2297-475X J9 VISC MED JI Visc. Med. PY 2016 VL 32 IS 4 BP 234 EP 238 DI 10.1159/000446379 PG 5 WC Surgery SC Surgery GA EB0SG UT WOS:000387055100002 PM 27722159 ER PT J AU Akay, M Dragomir, A Akay, YM Chen, FH Post, A Jneid, H Paniagua, D Denktas, A Bozkurt, B AF Akay, Metin Dragomir, Andrei Akay, Yasemin M. Chen, Feihua Post, Allison Jneid, Hani Paniagua, David Denktas, AlI Bozkurt, Biykem TI The Assessment of Stent Effectiveness Using a Wearable Beamforming MEMS Microphone Array System SO IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE-JTEHM LA English DT Article DE Coronary artery disease; nonlinear dynamics analysis; MEMs microphone array; approximate entropy ID CORONARY-ARTERY STENOSIS; SIROLIMUS-ELUTING STENT; DIASTOLIC MURMUR; NONINVASIVE DETECTION; APPROXIMATE ENTROPY; COMPLEXITY-MEASURES; SOURCE LOCALIZATION; STANDARD STENT; DISEASE; PHONOANGIOGRAPHY AB Studies involving turbulent flow have been carried out in many parts of the cardiovascular system, and it has been widely reported that turbulence related to stenosis (narrowing) of arteries creates audible sounds, which may be analyzed to yield information about the nature and severity of the blockage. Results so far indicate that the high frequency content of the sounds generally increases with the degree of stenosis. In this paper, we designed and built an MEMs microphone array and a signal acquisition board to improve the detection of coronary occlusions using an approach based on the recording and analysis of isolated diastolic heart sounds associated with turbulent blood flow in occluded coronary arteries. The nonlinear dynamic analysis method based on approximate entropy has been proposed for the analysis of diastolic heart sounds from patients with single coronary occlusions, before and after stent placement procedures. The nonlinear dynamic analysis (approximate entropy) measures of the diastolic heart sounds recorded from eight patients with single coronary occlusions and two normal subjects were estimated. In addition, a spectral analysis based on the fast Fourier transform was used to estimate the energy content of the recorded signals. Results suggest the presence of high nonlinear (approximate entropy) values of diastolic heart sounds associated with coronary artery disease (p < 0.01) as well as significant differences in the energy content of the heart sound signals above and below 150 Hz (p < 0.05). C1 [Akay, Metin; Dragomir, Andrei; Akay, Yasemin M.; Chen, Feihua; Post, Allison] Univ Houston, Dept Biomed Engn, Houston, TX 77204 USA. [Jneid, Hani; Paniagua, David; Denktas, AlI; Bozkurt, Biykem] DeBakey VA Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. [Jneid, Hani; Paniagua, David; Denktas, AlI; Bozkurt, Biykem] Baylor Coll Med, Cardiovasc Res Inst, Houston, TX 77030 USA. RP Akay, M (reprint author), Univ Houston, Dept Biomed Engn, Houston, TX 77204 USA. EM makay58@gmail.com OI Akay, Metin/0000-0002-2988-4669 NR 56 TC 0 Z9 0 U1 1 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2372 J9 IEEE J TRANSL ENG HE JI IEEE J. Transl. Eng. Health Med.-JTEHM PY 2016 VL 4 AR 1900310 DI 10.1109/JTEHM.2016.2609901 PG 10 WC Engineering, Biomedical SC Engineering GA EA0CE UT WOS:000386251500001 ER PT J AU Adams, ZW McCauley, JL Back, SE Flanagan, JC Hanson, RF Killeen, TK Danielson, CK AF Adams, Zachary W. McCauley, Jenna L. Back, Sudie E. Flanagan, Julianne C. Hanson, Rochelle F. Killeen, Therese K. Danielson, Carla Kmett TI Clinician Perspectives on Treating Adolescents with Co-occurring Post-Traumatic Stress Disorder, Substance Use, and Other Problems SO JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE LA English DT Article DE adolescents; comorbidity; PTSD; substance use; treating adolescents ID RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH; NATIONAL-SURVEY; ABUSE; PTSD; TRAUMA; COMORBIDITY; RISK; CHALLENGES; DEPRESSION AB Clinicians (N = 138) who treat adolescents with co-occurring Post-Traumatic Stress Disorder (PTSD) and substance use disorder (SUD), (PTSD+SUD) were surveyed about their attitudes and practice behaviors. Most providers were trained in PTSD treatment; fewer were trained in SUD or PTSD+SUD treatments. PTSD+SUD treatment was rated more difficult than treatment of other diagnoses. Providers typically addressed symptoms of PTSD and SUD separately and sequentially, rather than with integrated approaches. There was no consensus about which clinical strategies to use with adolescent PTSD+SUD. Continued treatment development, training, and dissemination efforts are needed to equip providers with resources to deliver effective treatments to adolescents with PTSD+SUD. C1 [Adams, Zachary W.; McCauley, Jenna L.; Back, Sudie E.; Flanagan, Julianne C.; Hanson, Rochelle F.; Killeen, Therese K.; Danielson, Carla Kmett] Med Univ South Carolina, Charleston, SC USA. [Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Adams, ZW (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. EM adamsz@musc.edu FU NIDA [K12 DA031794, K23 DA036566, K23 DA038257, K02 DA039229, K24 DA039783, R01DA031285, DA030143]; NIAAA [P50 AA010761]; NICHD [K12 HD 055885]; SAMHSA [1 U79SM061269]; NIH/NCATS [UL1TR000062]; NIH/NCRR [UL1 RR029882] FX The preparation of this manuscript was supported by NIDA grants K12 DA031794 (sponsoring ZWA; PIs: Kathleen Brady and Robert Malcolm), K23 DA036566 (PI: McCauley), K23 DA038257 (PI: Adams), K02 DA039229 (PI: Back), K24 DA039783 (PI: Danielson), and R01DA031285 (PI: Danielson), NIAAA grant P50 AA010761 (PI of Center: Howard Becker; PI of Clinical Component 5: Danielson), NICHD grant K12 HD 055885 (PI: Brady) and SAMHSA grant 1 U79SM061269 (PI: Rochelle Hanson). The study was also facilitated by NIH/NCATS grant UL1TR000062 (PI: Kathleen Brady) and NIH/NCRR grant UL1 RR029882 (PI: Kathleen Brady), which supports the South Carolina Clinical and Translational Research Institute (SCTR), as well as NIDA grant DA030143 (PI: Back). The funding sources did not have any involvement in the study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the article for publication. NR 38 TC 0 Z9 0 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1067-828X EI 1547-0652 J9 J CHILD ADOLES SUBST JI J. Child Adolesc. Subst. Abus. PY 2016 VL 25 IS 6 BP 575 EP 583 DI 10.1080/1067828X.2016.1153555 PG 9 WC Substance Abuse SC Substance Abuse GA EA3GF UT WOS:000386489100009 PM 27840568 ER PT J AU Nickel, E Hansen, A Pearlman, J Goldish, G AF Nickel, Eric Hansen, Andrew Pearlman, Jonathan Goldish, Gary TI A drive system to add standing mobility to a manual standing wheelchair SO ASSISTIVE TECHNOLOGY LA English DT Article DE accessibility; chain drive; manual; mid-wheel drive; mobile; spinal cord injury; stability; standing; wheelchair ID SPINAL-CORD-INJURY; PRESSURE; POSITION; PEOPLE AB Current manual standing wheelchairs are not mobile in the standing position. The addition of standing mobility may lead to improved health and function for the user and may increase utilization of standing wheelchairs. In this project, a chain drive system was fitted to a manual standing wheelchair, adding mobility in the standing position. The hand rims are accessible from both seated and standing positions. The prototype uses 16-inch drive wheels in front with casters in the rear. Additional anterior casters are elevated when seated for navigating obstacles and then descend when standing to create a six-wheeled base with extended anterior support. Stability testing shows the center of pressure remains within the base of support when leaning to the sides or front in both seated and standing positions. Four veterans with spinal cord injury provided feedback on the design and reported that mobility during standing was very important or extremely important to them. The veterans liked the perceived stability and mobility of the prototype and provided feedback for future refinements. For example, reducing the overall width (width from hand rim to hand rim) and weight could make this system more functional for users. C1 [Nickel, Eric; Hansen, Andrew] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Hansen, Andrew] Univ Minnesota, Program Rehabil Sci, Minneapolis, MN USA. [Pearlman, Jonathan] Univ Pittsburgh, Dept Rehab Sci & Technol, Pittsburgh, PA USA. [Pearlman, Jonathan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Goldish, Gary] Minneapolis VA Hlth Care Syst, Extended Care & Rehabil, Minneapolis, MN USA. [Goldish, Gary] Univ Minnesota, Phys Med & Rehabil, Minneapolis, MN USA. RP Goldish, G (reprint author), Minneapolis VA Med Ctr 11M, Extended Care & Rehabil, One Vet Dr, Minneapolis, MN 55417 USA. EM Gary.Goldish@va.gov FU Paralyzed Veterans of America [2012PVA000RES0000075260]; Department of Veterans Affairs, Rehabilitation Research and Development Service FX The research reported here was supported by the Paralyzed Veterans of America grant no. 2012PVA000RES0000075260 and the Department of Veterans Affairs, Rehabilitation Research and Development Service. NR 12 TC 0 Z9 0 U1 1 U2 1 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 EI 1949-3614 J9 ASSIST TECHNOL JI Assist. Technol. PY 2016 VL 28 IS 4 BP 218 EP 224 DI 10.1080/10400435.2016.1165757 PG 7 WC Rehabilitation SC Rehabilitation GA DY8KS UT WOS:000385379500004 ER PT J AU Cusack, M Montgomery, AE Blonigen, D Gabrielian, S Marsh, L AF Cusack, Meagan Montgomery, Ann Elizabeth Blonigen, Daniel Gabrielian, Sonya Marsh, Laura TI Veteran Returns to Homelessness Following Exits From Permanent Supportive Housing: Health and Supportive Services Use Proximal to Exit SO FAMILIES IN SOCIETY-THE JOURNAL OF CONTEMPORARY SOCIAL SERVICES LA English DT Article ID CRITICAL TIME INTERVENTION; PUBLIC SHELTER UTILIZATION; NEW-YORK-CITY; MENTAL-ILLNESS; INDIVIDUALS; TRANSITIONS; STABILITY; DISCHARGE; PATTERNS AB Permanent supportive housing (PSH) programs have been shown to increase housing retention for "hard to house" individuals and been used to address veteran homelessness. Departures from PSH (referred to as "exits") can represent a positive outcome for some veterans, while others may return to homelessness. This study analyzed administrative and primary data to identify individual- and institutional-level factors associated with veterans' returns to homelessness following exits from a PSH program. Findings suggest that a number of factors increase the risk of a return to homelessness, including admissions to inpatient substance abuse and behavioral health treatment programs and emergency department visits both pre- and post-exit. Targeted interventions may reduce the likelihood of subsequent homelessness. C1 [Cusack, Meagan] VA Ctr Hlth Equ Res & Promot, 4100 Chester Ave,Suite 202, Philadelphia, PA 19104 USA. [Montgomery, Ann Elizabeth] VA Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Blonigen, Daniel] VA Palo Hlth Care Syst, Livermore, CA USA. [Gabrielian, Sonya] VA Greater Los Angeles, Los Angeles, CA USA. [Marsh, Laura] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Cusack, M (reprint author), VA Ctr Hlth Equ Res & Promot, 4100 Chester Ave,Suite 202, Philadelphia, PA 19104 USA. EM meagan.cusack@va.gov NR 28 TC 0 Z9 0 U1 1 U2 1 PU ALLIANCE CHILDREN & FAMILIES PI MILWAUKEE PA 11700 WEST LAKE PARK DRIVE, MILWAUKEE, WI 53224 USA SN 1044-3894 EI 1945-1350 J9 FAM SOC JI Fam. Soc. PY 2016 VL 97 IS 3 BP 221 EP 229 DI 10.1606/1044-3894.2016.97.23 PG 9 WC Family Studies; Social Work SC Family Studies; Social Work GA DX9YX UT WOS:000384754400009 ER PT J AU Biglan, KM Shoulson, I Kieburtz, K Oakes, D Kayson, E Shinaman, MA Zhao, HW Romer, M Young, A Hersch, S Penney, J Marder, K Paulsen, J Quaid, K Siemers, E Tanner, C Mallonee, W Suter, G Dubinsky, R Gray, C Nance, M Bundlie, S Radtke, D Kostyk, S Baic, C Caress, J Walker, F Hunt, V O'Neill, C Chouinard, S Factor, S Greenamyre, T Wood-Siverio, C Corey-Bloom, J Song, D Peavy, G Moskowitz, C Wesson, M Samii, A Bird, T Lipe, H Blindauer, K Marshall, F Zimmerman, C Goldstein, J Rosas, D Novak, P Caviness, J Adler, C Duffy, A Wheelock, V Tempkin, T Richman, D Seeberger, L Albin, R Chou, KL Racette, B Perlmutter, JS Perlman, S Bordelon, Y Martin, W Wieler, M Leavitt, B Raymond, L Decolongon, J Clarke, L Jankovic, J Hunter, C Hauser, RA Sanchez-Ramos, J Furtado, S Suchowersky, O Klimek, ML Guttman, M Sethna, R Feigin, A Cox, M Shannon, B Percy, A Dure, L Harrison, M Johnson, W Higgins, D Molho, E Nickerson, C Evans, S Hobson, D Singer, C Galvez-Jimenez, N Shannon, K Comella, C Ross, C Saint-Hilaire, MH Testa, C Rosenblatt, A Hogarth, P Weiner, W Como, P Kumar, R Cotto, C Stout, J Brocht, A Watts, A Eberly, S Weaver, C Foroud, T Gusella, J MacDonald, M Myers, R Fahn, S Shults, C AF Biglan, Kevin Michael Shoulson, Ira Kieburtz, Karl Oakes, David Kayson, Elise Shinaman, M. Aileen Zhao, Hongwei Romer, Megan Young, Anne Hersch, Steven Penney, Jack Marder, Karen Paulsen, Jane Quaid, Kimberly Siemers, Eric Tanner, Caroline Mallonee, William Suter, Greg Dubinsky, Richard Gray, Carolyn Nance, Martha Bundlie, Scott Radtke, Dawn Kostyk, Sandra Baic, Corrine Caress, James Walker, Francis Hunt, Victoria O'Neill, Christine Chouinard, Sylvain Factor, Stewart Greenamyre, Timothy Wood-Siverio, Cathy Corey-Bloom, Jody Song, David Peavy, Guerry Moskowitz, Carol Wesson, Melissa Samii, Ali Bird, Thomas Lipe, Hillary Blindauer, Karen Marshall, Frederick Zimmerman, Carol Goldstein, Jody Rosas, Diana Novak, Peter Caviness, John Adler, Charles Duffy, Amy Wheelock, Vicki Tempkin, Teresa Richman, David Seeberger, Lauren Albin, Roger Chou, Kelvin L. Racette, Brad Perlmutter, Joel S. Perlman, Susan Bordelon, Yvette Martin, Wayne Wieler, Marguerite Leavitt, Blair Raymond, Lynn Decolongon, Joji Clarke, Lorne Jankovic, Joseph Hunter, Christine Hauser, Robert A. Sanchez-Ramos, Juan Furtado, Sarah Suchowersky, Oksana Klimek, Mary Lou Guttman, Mark Sethna, Rustom Feigin, Andrew Cox, Marie Shannon, Barbara Percy, Alan Dure, Leon Harrison, Madaline Johnson, William Higgins, Donald Molho, Eric Nickerson, Constance Evans, Sharon Hobson, Douglas Singer, Carlos Galvez-Jimenez, Nestor Shannon, Kathleen Comella, Cynthia Ross, Christopher Saint-Hilaire, Marie H. Testa, Claudia Rosenblatt, Adam Hogarth, Penelope Weiner, William Como, Peter Kumar, Rajeev Cotto, Candace Stout, Julie Brocht, Alicia Watts, Arthur Eberly, Shirley Weaver, Christine Foroud, Tatiana Gusella, James MacDonald, Marcy Myers, Richard Fahn, Stanley Shults, Clifford CA Huntington Study Grp PHAROS Invest TI Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS) Implications for Clinical Trials SO JAMA NEUROLOGY LA English DT Article ID CAG REPEAT LENGTH; PREDICT-HD; COGNITIVE DECLINE; FLUENCY DEFICITS; TRACK-HD; DISEASE; PREMANIFEST; PROGRESSION; DIAGNOSIS; CARRIERS AB IMPORTANCE Identifying measures that are associated with the cytosine-adenine-guanine (CAG) expansion in individuals before diagnosis of Huntington disease (HD) has implications for designing clinical trials. OBJECTIVE To identify the earliest features associated with the motor diagnosis of HD in the Prospective Huntington at Risk Observational Study (PHAROS). DESIGN, SETTING, AND PARTICIPANTS A prospective, multicenter, longitudinal cohort study was conducted at 43 US and Canadian Huntington Study Group research sites from July 9, 1999, through December 17, 2009. Participants included 983 unaffected adults at risk for HD who had chosen to remain unaware of their mutation status. Baseline comparability between CAG expansion (>= 37 repeats) and nonexpansion (<37 repeats) groups was assessed. All participants and investigators were blinded to individual CAG analysis. A repeated-measures analysis adjusting for age and sex was used to assess the divergence of the linear trend between the expanded and nonexpanded groups. Data were analyzed from April 27, 2010, to September 3, 2013. EXPOSURE Huntington disease mutation status in individuals with CAG expansion vs without CAG expansion. MAIN OUTCOMES AND MEASURES Unified Huntington's Disease Rating Scale motor (score range, 0-124; higher scores indicate greater impairment), cognitive (symbol digits modality is the total number of correct responses in 90 seconds; lower scores indicate greater impairment), behavioral (score range, 0-176; higher scores indicate greater behavioral symptoms), and functional (Total Functional Capacity score range, 0-13; lower scores indicate reduced functional ability) domains were assessed at baseline and every 9 months up to a maximum of 10 years. RESULTS Among the 983 research participants at risk for HD in the longitudinal cohort, 345 (35.1%) carried the CAG expansion and 638 (64.9%) did not. The mean (SD) duration of follow-up was 5.8 (3.0) years. At baseline, participants with expansions had more impaired motor (3.0 [4.2] vs 1.9 [2.8]; P < .001), cognitive (P < .05 for all measures except Verbal Fluency, P = .52), and behavioral domain scores (9.4 [11.4] vs 6.5 [8.5]; P < .001) but not significantly different measures of functional capacity (12.9 [0.3] vs 13.0 [0.2]; P = .23). With findings reported as mean slope (95% CI), in the longitudinal analyses, participants with CAG expansions showed significant worsening in motor (0.84 [0.73 to 0.95] vs 0.03 [-0.05 to 0.11]), cognitive (-0.54 [-0.67 to -0.40] vs 0.22 [0.12 to 0.32]), and functional (-0.08 [-0.09 to -0.06] vs -0.01 [-0.02 to 0]) measures compared with those without expansion (P < .001 for all); behavioral domain scores did not diverge significantly between groups. CONCLUSIONS AND RELEVANCE Using these prospectively accrued clinical data, relatively large treatment effects would be required to mount a randomized, placebo-controlled clinical trial involving premanifest HD individuals who carry the CAG expansion. C1 [Biglan, Kevin Michael; Kieburtz, Karl; Kayson, Elise; Shinaman, M. Aileen; Marshall, Frederick; Zimmerman, Carol; Goldstein, Jody; Brocht, Alicia; Watts, Arthur; Weaver, Christine] Univ Rochester, Dept Neurol, Rochester, NY 14642 USA. [Shoulson, Ira] Georgetown Univ, Dept Neurol, Washington, DC USA. [Oakes, David; Eberly, Shirley] Univ Rochester, Dept Biostat, Rochester, NY USA. [Zhao, Hongwei] Texas A&M, Dept Epidemiol & Biostat, College Stn, TX USA. [Romer, Megan] Penn State Univ, Dept Stat, University Pk, PA 16802 USA. [Young, Anne; Hersch, Steven; Penney, Jack; Rosas, Diana; Novak, Peter; Gusella, James; MacDonald, Marcy] Massachusetts Gen Hosp, Charleston, SC USA. [Marder, Karen; Fahn, Stanley] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA. [Paulsen, Jane] Univ Iowa, Dept Psychiat & Neurol, Iowa City, IA USA. [Quaid, Kimberly; Wesson, Melissa; Foroud, Tatiana] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. [Siemers, Eric] Lilly Corp Ctr, Indianapolis, IN USA. [Tanner, Caroline] Parkinsons Inst, Sunnyvale, CA USA. [Mallonee, William] Hereditary Neurol Dis Ctr, Wichita, KS USA. [Suter, Greg; Dubinsky, Richard; Gray, Carolyn] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA. [Nance, Martha; Bundlie, Scott; Radtke, Dawn] Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA. [Kostyk, Sandra; Baic, Corrine] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA. [Caress, James; Walker, Francis; Hunt, Victoria; O'Neill, Christine] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Chouinard, Sylvain] Hotel Dieu Hosp CHUM, Montreal, PQ, Canada. [Factor, Stewart; Greenamyre, Timothy; Wood-Siverio, Cathy] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Corey-Bloom, Jody; Song, David; Peavy, Guerry; Shults, Clifford] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Samii, Ali; Bird, Thomas; Lipe, Hillary] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Samii, Ali; Bird, Thomas; Lipe, Hillary] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Blindauer, Karen] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA. [Caviness, John; Adler, Charles; Duffy, Amy] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA. [Wheelock, Vicki; Tempkin, Teresa; Richman, David] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. [Seeberger, Lauren] Idaho Elks Rehabil Hosp, Boise, ID USA. [Albin, Roger; Chou, Kelvin L.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Racette, Brad; Perlmutter, Joel S.] Washington Univ, Dept Neurol, St Louis, MO USA. [Perlman, Susan; Bordelon, Yvette] Univ Calif Los Angeles, Med Ctr, Dept Neurol, Los Angeles, CA 90024 USA. [Martin, Wayne; Wieler, Marguerite] Univ Alberta, Dept Neurol, Edmonton, AB, Canada. [Leavitt, Blair; Raymond, Lynn; Decolongon, Joji; Clarke, Lorne] Univ British Columbia, Dept Neurol, Vancouver, BC, Canada. [Jankovic, Joseph; Hunter, Christine; Klimek, Mary Lou] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Hauser, Robert A.; Sanchez-Ramos, Juan] Univ S Florida, Dept Neurol, Tampa, FL USA. [Furtado, Sarah; Suchowersky, Oksana] Univ Calgary, Dept Neurol, Calgary, AB, Canada. [Guttman, Mark; Sethna, Rustom] Ctr Addict & Mental Hlth, Markham, ON, Canada. [Feigin, Andrew; Cox, Marie; Shannon, Barbara] North Shore LIJ Univ Hosp, Dept Neurol, Manhasset, NY USA. [Percy, Alan; Dure, Leon] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA. [Harrison, Madaline] Univ Virginia, Dept Neurol, Charlottesville, VA USA. [Johnson, William] Univ Med & Dent New Jersey, Dept Neurol, Robert Wood Johnson Med Ctr, Stratford, NJ USA. [Higgins, Donald; Molho, Eric; Nickerson, Constance; Evans, Sharon] Albany Med Coll, Dept Neurol, Albany, NY 12208 USA. [Hobson, Douglas] Winnipeg Clin, Winnipeg, MB, Canada. [Singer, Carlos; Galvez-Jimenez, Nestor] Univ Miami, Dept Neurol, Miami, FL USA. [Shannon, Kathleen; Comella, Cynthia] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA. [Ross, Christopher] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Saint-Hilaire, Marie H.; Myers, Richard] Boston Univ, Dept Neurol, Boston, MA USA. [Testa, Claudia; Rosenblatt, Adam] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23284 USA. [Hogarth, Penelope] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Weiner, William] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Como, Peter] US FDA, Rockville, MD 20857 USA. [Kumar, Rajeev] Rocky Mt Movement Disorders Ctr, Dept Neurol, Denver, CO USA. [Cotto, Candace] Inst Neurodegenerat Disorders, Dept Neurol, New Haven, CT USA. [Stout, Julie] Monash Univ, Clin & Cognit Neurosci Lab, Melbourne, Vic, Australia. RP Biglan, KM (reprint author), Univ Rochester, Dept Neurol, Rochester, NY 14642 USA. OI Raymond, Lynn/0000-0002-8610-1042 FU National Human Genome Research Institute; National Institutes of Health NINDS [5RO1-HG-02449]; High Q Foundation/CHDI Foundation, Inc; Huntington's Disease Society of America; Hereditary Disease Foundation; Huntington Society of Canada; Fox Family Foundation FX This research was supported by grants and awards from the National Human Genome Research Institute and grant 5RO1-HG-02449 from the National Institutes of Health NINDS (Dr Shoulson), the High Q Foundation/CHDI Foundation, Inc, the Huntington's Disease Society of America, the Hereditary Disease Foundation, the Huntington Society of Canada, and the Fox Family Foundation. NR 35 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2016 VL 73 IS 1 BP 102 EP 110 DI 10.1001/jamaneurol.2015.2736 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DZ4RZ UT WOS:000385848500015 ER PT J AU Vasuthasawat, A Yoo, EM Trinh, KR Lichtenstein, A Timmerman, JM Morrison, SL AF Vasuthasawat, Alex Yoo, Esther M. Trinh, Kham R. Lichtenstein, Alan Timmerman, John M. Morrison, Sherie L. TI Targeted immunotherapy using anti-CD138-interferon fusion proteins and bortezomib results in synergistic protection against multiple myeloma SO MABS LA English DT Article DE Antibody engineering; antibody immunotherapy; bortezomib; interferon; multiple myeloma ID INDEPENDENT CELL-DEATH; OXYGEN SPECIES GENERATION; ALPHA-INDUCED APOPTOSIS; IFN-ALPHA; INTERFERON-ALPHA; I INTERFERON; CANCER-CELLS; PROTEASOME INHIBITOR; ANTITUMOR ACTIVITIES; LYMPHOMA AB Although recent advances have substantially improved the management of multiple myeloma, it remains an incurable malignancy. We now demonstrate that anti-CD138 molecules genetically fused to type I interferons (IFN) synergize with the approved therapeutic bortezomib in arresting the proliferation of human multiple myeloma cell lines both in vitro and in vivo. The anti-CD138-IFN14 fusion protein was active in inducing increased expression of signal transducer and activator of transcription 1 (STAT1) and its phosphorylation while the cell death pathway induced by bortezomib included generation of reactive oxygen species. Interferon regulatory factor 4 (IRF4), an important survival factor for myeloma cells, was down regulated following combination treatment. Induction of cell death appeared to be caspase-independent because treatment with inhibitors of caspase activation did not decrease the level of cell death. The observed caspase-independent synergistic cell death involved mitochondrial membrane depolarization, and poly(ADP-ribose) polymerase-1 (PARP-1) cleavage, and resulted in enhanced induction of apoptosis. Importantly, using 2 different in vivo xenograft models, we found that combination therapy of anti-CD138-IFN14 and bortezomib was able to cure animals with established tumors (7 of 8 using OCI-My5 or 8 of 8 using NCI-H929). Thus, the combination of anti-CD138-IFN with bortezomib shows great promise as a novel therapeutic approach for the treatment of multiple myeloma, a malignancy for which there are currently no cures. C1 [Vasuthasawat, Alex; Yoo, Esther M.; Trinh, Kham R.; Morrison, Sherie L.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Vasuthasawat, Alex; Yoo, Esther M.; Trinh, Kham R.; Morrison, Sherie L.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA. [Lichtenstein, Alan] Greater Los Angeles Vet Adm Healthcare Ctr, Los Angeles, CA USA. [Lichtenstein, Alan; Timmerman, John M.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Lichtenstein, Alan; Timmerman, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Dept Med, Los Angeles, CA 90095 USA. RP Yoo, EM (reprint author), Univ Calif Los Angeles, Microbiol Immunol & Mol Genet, 247 BSRB,615 Charles E Young Dr East, Los Angeles, CA 90095 USA. EM eyoo@ucla.edu FU Multiple Myeloma Research Foundation; National Institutes of Health [CA162964] FX This work was supported by a Senior Research Award and the Dean Assink MMRF Senior Research Award from the Multiple Myeloma Research Foundation, and by the National Institutes of Health grant CA162964. NR 43 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1942-0862 EI 1942-0870 J9 MABS-AUSTIN JI mAbs PY 2016 VL 8 IS 7 BP 1386 EP 1397 DI 10.1080/19420862.2016.1207030 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DZ0ZY UT WOS:000385569400017 PM 27362935 ER PT J AU Liu, XH Ning, AY Chang, NC Kim, H Nissenson, R Wang, LP Feeley, BT AF Liu, Xuhui Ning, Anne Y. Chang, Nai Chen Kim, Hubert Nissenson, Robert Wang, Liping Feeley, Brian T. TI Investigating the cellular origin of rotator cuff muscle fatty infiltration and fibrosis after injury SO MLTJ-MUSCLES LIGAMENTS AND TENDONS JOURNAL LA English DT Article DE rotator cuff tear; fatty infiltration; fibrosis; fibro-adipogenic progenitors; Tie2; muscle ID SKELETAL-MUSCLE; FIBRO/ADIPOGENIC PROGENITORS; HETEROTOPIC OSSIFICATION; MESENCHYMAL PROGENITORS; SUPRASCAPULAR NERVE; RAT MODEL; TEAR; REPAIR; IDENTIFICATION; DEGENERATION AB Background: rotator cuff muscle atrophy, fibrosis and fatty infiltration are common complications after large and massive rotator cuff tears. Currently, there are no effective treatments for these muscle pathologies after injury. Furthermore, the cellular source for fibrotic and adipose tissues in rotator cuff muscle after injury remains unknown. In this study, we proposed that two groups of muscle resident progenitors, Tie2+ muscle mesenchymal progenitors and PDGFR alpha(+) fibro/adipogenic progenitor cells (FAPs), contribute significantly to rotator cuff muscle fibrosis and fatty infiltration. Methods: we tested our hypothesis using reporter mice. Rotator cuff muscles from Tie2-GFP and PDGFR alpha-GFP reporter mice were harvested at 2 and 6 weeks after unilateral massive rotator cuff tear surgeries. Immunofluorescent staining for fibroblast and adipocyte markers was conducted. Results: our results showed significant co-localization of Tie2+ cells with fibrotic markers vimentin and aSMA. In the PDGFR alpha-GFP reporter mice, GFP signal was seen in only a small fraction of cells staining positive for vimentin and aSMA. However, PDGFR alpha showed significant co-localization with adipocyte markers, including PPAR-gamma, adiponectin, and perilipin A. Oil red O staining confirmed that the mature adipocytes appearing in rotator cuff muscles after injury are also PDGFR alpha(+). Conclusion: these data demonstrated that the Tie2(+) muscle mesenchymal progenitors are the major source of fibroblasts while PDGFR alpha(+) FAPs are the major source of adipocytes in rotator cuff muscle fatty infiltration. Basic Science Study. C1 [Liu, Xuhui; Ning, Anne Y.; Kim, Hubert; Nissenson, Robert; Wang, Liping; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, 1700 Owens St Rm 361, San Francisco, CA 94158 USA. [Chang, Nai Chen] San Francisco VA Med Ctr, San Francisco, CA USA. RP Ning, AY (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 1700 Owens St Rm 361, San Francisco, CA 94158 USA. EM anneyning@gmail.com FU BLRD VA [I01 BX002680] NR 29 TC 1 Z9 1 U1 0 U2 0 PU CIC EDIZIONI INT PI ROME PA CORSO TRIESTE 42, ROME, 00198, ITALY SN 2240-4554 J9 MLTJ-MUSCLE LIGAMENT JI MLTJ-Muscles Ligaments Tendons J. PD JAN-MAR PY 2016 VL 6 IS 1 BP 6 EP 15 DI 10.11138/mltj/2016.6.1.006 PG 10 WC Orthopedics SC Orthopedics GA DZ2UB UT WOS:000385696000003 PM 27331027 ER PT J AU Reddy, AT Lakshmi, SP Reddy, RC AF Reddy, Aravind T. Lakshmi, Sowmya P. Reddy, Raju C. TI PPAR gamma in Bacterial Infections: A Friend or Foe? SO PPAR RESEARCH LA English DT Review ID ACTIVATED-RECEPTOR-GAMMA; CHRONIC GRANULOMATOUS-DISEASE; ACUTE LUNG INJURY; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SYSTEMIC INFLAMMATION; ALVEOLAR MACROPHAGES; POLYMICROBIAL SEPSIS; INDUCE APOPTOSIS; EXPRESSION; CELLS AB Peroxisome proliferator-activated receptor gamma (PPAR gamma) is now recognized as an important modulator of leukocyte inflammatory responses and function. Its immunoregulatory function has been studied in a variety of contexts, including bacterial infections of the lungs and central nervous system, sepsis, and conditions such as chronic granulomatous disease. Although it is generally believed that PPAR gamma activation is beneficial for the host during bacterial infections via its anti-inflammatory and antibacterial properties, PPAR gamma agonists have also been shown to dampen the host immune response and in some cases exacerbate infection by promoting leukocyte apoptosis and interfering with leukocyte migration and infiltration. In this review we discuss the role of PPAR gamma and its activation during bacterial infections, with focus on the potential of PPAR gamma agonists and perhaps antagonists as novel therapeutic modalities. We conclude that adjustment in the dosage and timing of PPAR gamma agonist administration, based on the competence of host antimicrobial defenses and the extent of inflammatory response and tissue injury, is critical for achieving the essential balance between pro- and anti-inflammatory effects on the immune system. C1 [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU Merit Review award from the US Department of Veterans Affairs; National Institutes of Health Grants [HL093196, AI125338] FX This work was supported by a Merit Review award from the US Department of Veterans Affairs and National Institutes of Health Grants HL093196 and AI125338 (to Raju C. Reddy). NR 56 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-4757 EI 1687-4765 J9 PPAR RES JI PPAR Res. PY 2016 AR 7963540 DI 10.1155/2016/7963540 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DY5EN UT WOS:000385121900001 ER PT J AU Yalcha, MM Black, JA Martin, LF Levendosky, AA AF Yalcha, Matthew M. Black, J. Audie Martin, Lia Field Levendosky, Alytia A. TI Effects of Prenatal and Postbirth Intimate Partner Violence on Preschool-Age Children's Dissociative Symptoms SO JOURNAL OF AGGRESSION MALTREATMENT & TRAUMA LA English DT Article DE Bayesian; children; dissociation; domestic violence; intimate partner violence ID INFANT-MOTHER ATTACHMENT; DOMESTIC VIOLENCE; TRAUMA SYMPTOMS; CHILDHOOD AB Studies on the effects of intimate partner violence (IPV) on children have typically focused on IPV to which children were exposed after their birth. However, research has also demonstrated the effect of prenatal IPV on children's psychological functioning, although this has not yet been studied with respect to dissociation. In this study, we examined the association between prenatal and postbirth IPV and dissociative symptoms among preschool-age children using a Bayesian approach to multiple regression. Results indicated that prenatal IPV predicts child dissociative symptoms over and above postbirth IPV and other negative life events that the child has experienced. These results provide further evidence for the role prenatal IPV plays in the development of child psychopathology and suggest directions for future research and intervention. C1 [Yalcha, Matthew M.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Black, J. Audie] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Martin, Lia Field] Justice Resource Inst, Ctr Trauma, Brookline, MA USA. [Levendosky, Alytia A.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. RP Yalcha, MM (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM yalchster@gmail.com NR 41 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1092-6771 EI 1545-083X J9 J AGGRESS MALTREAT T JI J. Aggress. Maltreatment Trauma PY 2016 VL 25 IS 7 BP 741 EP 752 DI 10.1080/10926771.2016.1194937 PG 12 WC Psychology, Clinical; Criminology & Penology; Family Studies; Psychiatry SC Psychology; Criminology & Penology; Family Studies; Psychiatry GA DY3HS UT WOS:000384982200005 ER PT J AU Aggarwal, V Waldo, SW Armstrong, EJ AF Aggarwal, Vikas Waldo, Stephen W. Armstrong, Ehrin J. TI Endovascular revascularization for aortoiliac atherosclerotic disease SO VASCULAR HEALTH AND RISK MANAGEMENT LA English DT Review DE peripheral artery disease; iliac artery; balloon expandable stent; self expanding stent; covered stent; claudication; endovascular ID ILIAC ARTERY OCCLUSIONS; EXPANDABLE STENTS; VASCULAR STENT; KISSING STENTS; OUTCOMES; ANGIOPLASTY; RECONSTRUCTION; BIFURCATION; RESTENOSIS; TRIAL AB Atherosclerotic iliac artery disease is increasingly being treated with endovascular techniques. A number of new stent technologies can be utilized with high long-term patency, including self-expanding stents, balloon-expandable stents, and covered stents, but comparative data on these stent types and in more complex lesions are lacking. This article provides a review of currently available iliac stent technologies, as well as complex procedural aspects of iliac artery interventions, including approaches to the treatment of iliac bifurcation disease, long segment occlusions, choice of stent type, and treatment of iliac artery in-stent restenosis. C1 [Aggarwal, Vikas] St Johns Hosp, Prairie Heart Inst, Springfield, IL USA. [Waldo, Stephen W.; Armstrong, Ehrin J.] Denver Vet Affairs Med Ctr, Sect Cardiol, 1055 Clermont St, Denver, CO 80220 USA. [Waldo, Stephen W.; Armstrong, Ehrin J.] Univ Colorado, Sect Cardiol, Aurora, CO USA. RP Armstrong, EJ (reprint author), Denver Vet Affairs Med Ctr, Sect Cardiol, 1055 Clermont St, Denver, CO 80220 USA. EM ehrin.armstrong@gmail.com NR 42 TC 1 Z9 1 U1 3 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-6344 EI 1178-2048 J9 VASC HEALTH RISK MAN JI Vasc. Health Risk Manag. PY 2016 VL 12 BP 117 EP 127 DI 10.2147/VHRM.S98721 PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DW5PT UT WOS:000383699300002 PM 27099509 ER PT J AU Turner, TH Renfroe, JB Elm, J Duppstadt-Delambo, A Hinson, VK AF Turner, T. H. Renfroe, J. B. Elm, J. Duppstadt-Delambo, A. Hinson, V. K. TI Robustness of reliable change indices to variability in Parkinson's disease with mild cognitive impairment SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE Problem solving; test construction; tests; treatment ID FLUCTUATIONS; ATTENTION; DEMENTIA; DISORDER; CRITERIA AB Ability to identify change is crucial for measuring response to interventions and tracking disease progression. Beyond psychometrics, investigations of Parkinson's disease with mild cognitive impairment (PD-MCI) must consider fluctuating medication, motor, and mental status. One solution is to employ 90% reliable change indices (RCIs) from test manuals to account for account measurement error and practice effects. The current study examined robustness of 90% RCIs for 19 commonly used executive function tests in 14 PD-MCI subjects assigned to the placebo arm of a 10-week randomized controlled trial of atomoxetine in PD-MCI. Using 90% RCIs, the typical participant showed spurious improvement on one measure, and spurious decline on another. Reliability estimates from healthy adults standardization samples and PD-MCI were similar. In contrast to healthy adult samples, practice effects were minimal in this PD-MCI group. Separate 90% RCIs based on the PD-MCI sample did not further reduce error rate. In the present study, application of 90% RCIs based on healthy adults in standardization samples effectively reduced misidentification of change in a sample of PD-MCI. Our findings support continued application of 90% RCIs when using executive function tests to assess change in neurological populations with fluctuating status. C1 [Turner, T. H.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Turner, T. H.] Med Univ South Carolina, Dept Psychiat Behav Sci, Charleston, SC USA. [Renfroe, J. B.; Duppstadt-Delambo, A.; Hinson, V. K.] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. [Elm, J.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Hinson, V. K.] Ralph H Johnson Vet Affairs Med Ctr, Neurol Serv, Charleston, SC USA. RP Turner, TH (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM turnertr@musc.edu FU Michael J. Fox Foundation for Parkinson's Research FX Funding was provided by the Michael J. Fox Foundation for Parkinson's Research; NCT01738191. NR 16 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PY 2016 VL 23 IS 6 BP 399 EP 402 DI 10.1080/23279095.2016.1160907 PG 4 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA DX6XV UT WOS:000384530300002 PM 27144494 ER PT J AU Sudore, RL Barnes, DE Le, GM Ramos, R Osua, SJ Richardson, SA Boscardin, J Schillinger, D AF Sudore, Rebecca L. Barnes, Deborah E. Le, Gem M. Ramos, Roberto Osua, Stacy J. Richardson, Sarah A. Boscardin, John Schillinger, Dean TI Improving advance care planning for English-speaking and Spanish-speaking older adults: study protocol for the PREPARE randomised controlled trial SO BMJ OPEN LA English DT Article ID OF-LIFE CARE; MENTAL STATUS QUESTIONNAIRE; DECISIONAL CONFLICT SCALE; LIMITED HEALTH LITERACY; ADMINISTRATIVE DATA; ADVANCED CANCER; CONTROL PREFERENCES; COMORBIDITY INDEX; SOCIAL SUPPORT; MINI-COG AB Introduction: Advance care planning (ACP) is a process that allows patients to identify their goals for medical care. Traditionally, ACP has focused on completing advance directives; however, we have expanded the ACP paradigm to also prepare patients to communicate their wishes and make informed decisions. To this end, we created an ACP website called PREPARE (http://www.prepareforyourcare.org) to prepare diverse English-speaking and Spanish-speaking older adults for medical decision-making. Here, we describe the study protocol for a randomised controlled efficacy trial of PREPARE in a safety-net setting. The goal is to determine the efficacy of PREPARE to engage diverse English-speaking and Spanish-speaking older adults in a full spectrum of ACP behaviours. Methods and analysis: We include English-speaking and Spanish-speaking adults from an urban public hospital who are >= 55 years old, have >= 2 chronic medical conditions and have seen a primary care physician >= 2 times in the last year. Participants are randomised to the PREPARE intervention (review PREPARE and an easy-to-read advance directive) or the control arm (only the easy-to-read advance directive). The primary outcome is documentation of an advance directive and/or ACP discussion. Secondary outcomes include ACP behaviour change processes measured with validated surveys (eg, self-efficacy, readiness) and a broad range of ACP actions (eg, choosing a surrogate, identifying goals for care, discussing ACP with clinicians and/or surrogates). Using blinded outcome ascertainment, outcomes will be measured at 1 week and at 3, 6 and 12 months, and compared between study arms using mixed-effects logistic regression and mixed-effects linear, Poisson or negative binomial regression. Ethics and dissemination: This study has been approved by the appropriate Institutional Review Boards and is guided by input from patient and clinical advisory boards and a data safety monitoring board. The results of this study will be disseminated to academic and community stakeholders. C1 [Sudore, Rebecca L.; Le, Gem M.; Ramos, Roberto; Osua, Stacy J.; Richardson, Sarah A.; Boscardin, John] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca L.; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sudore, Rebecca L.; Le, Gem M.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, Zuckerberg San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Barnes, Deborah E.; Boscardin, John] Univ Calif San Francisco, Dept Med, Dept Epidemiol, San Francisco, CA USA. [Barnes, Deborah E.; Boscardin, John] Univ Calif San Francisco, Dept Med, Dept Biostat, San Francisco, CA USA. [Le, Gem M.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Ramos, Roberto; Osua, Stacy J.; Richardson, Sarah A.] Northern Calif Inst Res & Educ, San Francisco, CA USA. RP Sudore, RL (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.; Sudore, RL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Sudore, RL (reprint author), Univ Calif San Francisco, Dept Med, Zuckerberg San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. EM Rebecca.Sudore@ucsf.edu FU National Institute on Aging [R01 AG045043]; Patient-Centered Outcomes Research Institute [CDR-1306-01500] FX This work is supported by the National Institute on Aging (R01 AG045043) and the Patient-Centered Outcomes Research Institute (CDR-1306-01500). NR 81 TC 0 Z9 0 U1 4 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 7 AR e011705 DI 10.1136/bmjopen-2016-011705 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA DU5LB UT WOS:000382252100120 PM 27401363 ER PT J AU Roos, LE Afifi, TO Martin, CG Pietrzak, RH Tsai, J Sareen, J AF Roos, Leslie E. Afifi, Tracie O. Martin, Christina Gamache Pietrzak, Robert H. Tsai, Jack Sareen, Jitender TI Linking Typologies of Childhood Adversity to Adult Incarceration: Findings From a Nationally Representative Sample SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE child maltreatment; adverse childhood experiences; latent class analysis; incarceration ID HOUSEHOLD DYSFUNCTION; FEMALE PRISONERS; SEXUAL-ABUSE; ALCOHOL-USE; DRUG-USE; EXPERIENCES; MALTREATMENT; WOMEN; DISORDERS; OUTCOMES AB Ecologically valid typologies of adverse child experiences (ACEs) were identified to investigate the link between ACEs and adult incarceration. In a nationally representative sample (N = 34,653, age 20+), latent class analysis (LCA) was conducted with childhood maltreatment (physical, sexual, and emotional abuse, interpersonal violence [IPV] exposure, physical neglect) and caregiver maladjustment (substance use, incarceration, mental illness, and suicidal behavior) indicators. LCA identified a 5-typology model (1. Low Adversity Risk; 2. Caregiver Substance Use, and Maltreatment Acts of Omission; 3. Physical and Emotional Maltreatment; 4. Severe Cross-Subtype Maltreatment and Caregiver Substance Use; and 5. Caregiver Maladjustment). Controlling for sociodemographics and substance use problems, logistic regression analyses determined that, compared with the Low Adversity Risk typology, all typologies (except Caregiver Maladjustment) had elevated incarceration risk (adjusted odds ratios: 1.76-4.18). Maltreatment experiences were more predictive of incarceration for women versus men. Childhood maltreatment confers risk for incarceration beyond established risk factors, but caregiver maladjustment, alone, does not. Preventative efforts should focus on understanding and targeting pathways to delinquency for individuals with childhood maltreatment. C1 [Roos, Leslie E.; Martin, Christina Gamache] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. [Roos, Leslie E.] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada. [Afifi, Tracie O.; Sareen, Jitender] Univ Manitoba, Dept Psychiat, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada. [Afifi, Tracie O.] Univ Manitoba, Dept Family Social Serv, Winnipeg, MB R3T 2N2, Canada. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzak, Robert H.; Tsai, Jack] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Tsai, Jack] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA. [Sareen, Jitender] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. RP Roos, LE (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. EM leslie.roos@gmail.com OI Roos, Leslie/0000-0001-7083-4017 FU Manitoba Health Research Council (MHRC); Canadian Institutes of Health Research (CIHR); Preventing Violence Across the Lifespan (PreVAiL) Network FX Preparation of this article was supported by a Manitoba Health Research Council (MHRC) establishment award (TOA), and a Canadian Institutes of Health Research (CIHR) New Investigator award (TOA). Funding was also provided by the Preventing Violence Across the Lifespan (PreVAiL) Network (LER, TOA, and JS). NR 51 TC 0 Z9 0 U1 7 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PY 2016 VL 86 IS 5 BP 584 EP 593 DI 10.1037/ort0000144 PG 10 WC Psychiatry; Social Work SC Psychiatry; Social Work GA DX2VI UT WOS:000384229900011 PM 27078049 ER PT J AU Varghese, M Santa-Maria, I Ho, L Ward, L Yemul, S Dubner, L Ksiezak-Reding, H Pasinetti, GM AF Varghese, Merina Santa-Maria, Ismael Ho, Lap Ward, Libby Yemul, Shrishailam Dubner, Lauren Ksiezak-Reding, Hanna Pasinetti, Giulio Maria TI Extracellular Tau Paired Helical Filaments Differentially Affect Tau Pathogenic Mechanisms in Mitotic and Post-Mitotic Cells: Implications for Mechanisms of Tau Propagation in the Brain SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; neuropathology; proteasome; tau ID PROGRESSIVE SUPRANUCLEAR PALSY; INCLUSION-BODY FORMATION; ALZHEIMERS-DISEASE; PROTEIN-TAU; AGGRESOME FORMATION; PRIMARY NEURONS; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; AUTOPHAGOSOME DYNAMICS; MICROTUBULE NUCLEATION AB The release of paired helical (PHFs) from neurons into the extracellular space may contribute to the propagation of tau pathology across brain regions in Alzheimer's disease (AD) and other tauopathies. The majority of available mechanistic studies exploring the pathologic role of extracellular PHFs are conducted in proliferating cell lines. Here, we compare how extracellular PHFs induce tauopathy in mitotic cells and in post-mitotic brain neurons. In a mitotic cell line (HEK 293T), extracellular exposure to AD PHFs leads to an intracellular "aggresomal" type deposition of tau, coincidental with redistribution of dynein, a retrograde motor protein. We also observed that PHFs impaired proteasome degradation, but not autophagy. Exposure of cells to proteasome inhibitors was sufficient to induce intracellular tau aggregate formation as well as reorganization of dynein and the intermediate filament protein, vimentin. Thus, in mitotic cells, extracellular PHFs promote cellular tau aggregation, in part, by interfering with cellular proteasome degradation processes. In contrast with our observations with proliferating cells, exposure of post-mitotic primary neuronal cultures to AD PHFs did not promote "aggresomal" tau deposition, but instead resulted in a widespread accumulation of phosphorylated tau-immunoreactive swellings in neuritic processes, characterized by disturbed cytoskeletal organization of dynein and vimentin. Collectively, our observations suggest that extracellular PHFs may contribute to the propagation of tau pathology by independent mechanisms in post-mitotic and mitotic brain cells. These outcomes indicate that in addition to post-mitotic brain neurons, mitotic brain cells should also be considered as targets for therapeutic interventions to attenuate propagation of tauopathy. C1 [Varghese, Merina; Ho, Lap; Ward, Libby; Yemul, Shrishailam; Dubner, Lauren; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Varghese, Merina] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Varghese, Merina; Yemul, Shrishailam; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Santa-Maria, Ismael] Columbia Univ, Dept Pathol & Cell Biol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. RP Pasinetti, GM (reprint author), One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 FU CurePSP - Foundation for PSP \ CBD and Related Brain Diseases, NIH [PO1 AT004511]; MERIT Review grant from Veterans Administration; NIH-NCI [5R24 CA095823-04]; NSF Major Research Instrumentation grant [DBI-9724504]; NIH shared instrumentation grant [1 S10 RR0 9145-01] FX We would like to thank Miguel Gama-Sosa for his expertise in confocal microscopy and Shimul Begum for her effort in western blotting studies. The authors gratefully acknowledge financial as well as inspirational support from CurePSP - Foundation for PSP vertical bar CBD and Related Brain Diseases, NIH PO1 AT004511, and in part from MERIT Review grant from Veterans Administration to Dr. Pasinetti. Confocal laser scanning microscopy was performed at the James J. Peters Veterans Affairs Medical Center and conventional fluorescent microscopy at the Icahn School of Medicine at Mount Sinai-Microscopy Shared Resource Facility, supported with funding from NIH-NCI shared resources grant (5R24 CA095823-04), NSF Major Research Instrumentation grant (DBI-9724504) and NIH shared instrumentation grant (1 S10 RR0 9145-01). This material is the result of work supported in part with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, NY. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We also acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 113 TC 0 Z9 0 U1 3 U2 4 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 2 BP 477 EP 496 DI 10.3233/JAD-160166 PG 20 WC Neurosciences SC Neurosciences & Neurology GA DX0WO UT WOS:000384087200006 PM 27567821 ER PT J AU Renfroe, JB Turner, TH Hinson, VK AF Renfroe, Jenna B. Turner, Travis H. Hinson, Vanessa K. TI Prevalence, impact, and management of depression and anxiety in patients with Parkinson's disease SO JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME LA English DT Review DE Parkinson's disease; depression; anxiety; prevalence; treatment ID TRANSCRANIAL MAGNETIC STIMULATION; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; PLACEBO-CONTROLLED TRIAL; NONMOTOR SYMPTOMS; NEUROPSYCHIATRIC SYMPTOMS; DOUBLE-BLIND; MOTOR SUBTYPES; RISK-FACTORS; DISORDERS AB Individuals with Parkinson's disease (PD) exhibit higher rates of depression and anxiety than the general and other medically disabled populations. Evidence suggests that mood and anxiety symptoms are related to disease pathology. Rates of depression and anxiety in PD vary depending on how these symptoms are measured, but they are estimated to occur in up to 40% of patients. These conditions have adverse effects on patient and caregivers' quality of life, level of disability, and mortality, with several studies suggesting greater contribution than motor symptom severity. Pharmacological and psychotherapeutic interventions, particularly in combination, have demonstrated efficacy in treating depression and anxiety in PD. However, additional randomized controlled trials are needed to better delineate when and how to best treat these disabling symptoms. C1 [Renfroe, Jenna B.; Hinson, Vanessa K.] Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. [Turner, Travis H.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Turner, Travis H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Hinson, Vanessa K.] Ralph H Johnson VA Med Ctr, Neurol Serv, Charleston, SC USA. RP Renfroe, JB (reprint author), Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. EM renfroe@musc.edu NR 104 TC 0 Z9 0 U1 4 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1927-7733 J9 J PARKINSONISM RESTL JI J. PARKINSONISM RESTLESS LEGS SYNDR. PY 2016 VL 6 BP 15 EP 22 DI 10.2147/JPRLS.S83165 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DX2TS UT WOS:000384224500001 ER PT J AU Williams, JS Walker, RJ Egede, LE AF Williams, Joni Strom Walker, Rebekah J. Egede, Leonard E. TI Achieving Equity in an Evolving Healthcare System: Opportunities and Challenges SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Health disparities; Health equity ID UNITED-STATES; DISPARITIES RESEARCH; ETHNIC DISPARITIES; KIDNEY-DISEASE; ACCESS; POLICY; ISSUES; RACE; INSURANCE; COVERAGE AB For decades, disparities in health have been well documented in the United States and regrettably, remain prevalent despite evidence and appeals for their elimination. Compared with the majority, racial and ethnic minorities continue to have poorer health status and health outcomes for most chronic conditions, including diabetes mellitus, cardiovascular disease, cancer and end-stage renal disease. Many factors, such as affordability, access and diversity in the healthcare system, influence care and outcomes, creating challenges that make the task of eliminating health disparities and achieving health equity daunting and elusive. Novel strategies are needed to bring about much needed change in the complex and evolving United States healthcare system. Although not exhaustive, opportunities such as(1) developing standardized race measurements across health systems,(2) implementing effective interventions, (3) improving workforce diversity,(4) using technological advances and(5) adopting practices such as personalized medicine may serve as appropriate starting points for moving toward health equity. Over the past several decades, diversity in the U.S. population has increased significantly and is expected to increase exponentially in the near future. As the population becomes more diverse, it is important to recognize the possibilities of new and emerging disparities. It is imperative that steps are taken to eliminate the current gap in care and prevent new disparities from developing. Therefore, we present challenges and offer recommendations for facilitating the process of eliminating health disparities and achieving health equity across diverse populations. C1 [Williams, Joni Strom; Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. [Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Dept Med, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu FU HSRD VA [I50 HX001229]; NIDDK NIH HHS [K24 DK093699] NR 56 TC 0 Z9 0 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2016 VL 351 IS 1 BP 33 EP 43 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DV1EN UT WOS:000382663000007 PM 26802756 ER PT J AU Rivin, BE Diekema, DS Mastroianni, AC Krieger, JN Klausner, JD Morris, BJ AF Rivin, Beth E. Diekema, Douglas S. Mastroianni, Anna C. Krieger, John N. Klausner, Jeffrey D. Morris, Brian J. TI Critical Evaluation of Adler's Challenge to the CDC's Male Circumcision Recommendations SO INTERNATIONAL JOURNAL OF CHILDRENS RIGHTS LA English DT Article DE male circumcision; children's rights; critical perspective; Centers for Disease Control and Prevention; policy ID URINARY-TRACT-INFECTIONS; MALE INFANT CIRCUMCISION; NEONATAL MALE CIRCUMCISION; LIDOCAINE-PRILOCAINE CREAM; SUB-SAHARAN AFRICA; SEXUAL SATISFACTION; UNITED-STATES; POLICY STATEMENT; RANDOMIZED-TRIAL; HIV PREVENTION AB We evaluate Peter Adler's challenge to the Centers for Disease Control and Prevention (CDC) draft recommendations on male circumcision (this issue, see pp. 237-262). The CDC advocates elective male circumcision (MC) to improve public health in the USA based on strong scientific evidence. In marked contrast to the CDC, Adler's criticisms depend on-speculative claims and obfuscation of the scientific data. Adler's central argument that circumcision in infancy should be delayed to allow a boy to make up his own mind as an adult fails to appreciate that circumcision later in life is a more complex operation, entails higher risk, is more likely to involve general anaesthesia and presents financial, psychological and organisational barriers. These limitations are avoided by circumcision early in infancy, when it is convenient, safe, quick, low risk, usually involves local anaesthesia and provides benefits immediately. Benefits of male circumcision include: protection against: urinary tract infections that are ten times higher in uncircumcised infants; inflammatory skin conditions; other foreskin problems; sexually transmitted infections and genital cancers in the male and his female sexual partners. Circumcision during infancy is also associated with faster healing and improved cosmetic outcomes. Circumcision does not impair sexual function or pleasure. Some authorities regard the failure to offer circumcision as unethical, just as it would be unethical to fail to encourage paediatric vaccination. Since the benefits vastly outweigh the risks, each intervention is in the best interests of the child. In conclusion, Adler's criticisms of the CDC's evidence-based male circumcision policy are flawed scientifically, ethically and legally, and should be dismissed as endangering public health and individual well-being. C1 [Rivin, Beth E.] Univ Washington, Sch Law, Seattle, WA 98195 USA. [Diekema, Douglas S.] Seattle Childrens Hosp, Treuman Katz Ctr Pediat Bioeth, Seattle, WA USA. [Mastroianni, Anna C.] Univ Washington, Urol Sect, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Mastroianni, Anna C.] Univ Washington, Sch Med, Seattle, WA USA. [Krieger, John N.; Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Dept Med, Los Angeles, CA 90024 USA. [Morris, Brian J.] Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. EM brivin@uw.edu; diek@uw.edu; amastroi@uw.edu; jkrieger@uw.edu; jdklausner@mednet.ucla.edu; brian.morris@sydney.edu.au NR 156 TC 2 Z9 2 U1 3 U2 3 PU BRILL ACADEMIC PUBLISHERS PI LEIDEN PA PLANTIJNSTRAAT 2, P O BOX 9000, 2300 PA LEIDEN, NETHERLANDS SN 0927-5568 EI 1571-8182 J9 INT J CHILD RIGHTS JI Int. J. Child. Rights PY 2016 VL 24 IS 2 BP 265 EP 303 DI 10.1163/15718182-02402004 PG 39 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA DW8EM UT WOS:000383886900003 ER PT J AU Durazzo, TC Korecka, M Trojanowski, JQ Weiner, MW Hara, RO Ashford, JW Shaw, LM AF Durazzo, Timothy C. Korecka, Magdalena Trojanowski, John Q. Weiner, Michael W. Hara, Ruth O' Ashford, John W. Shaw, Leslie M. CA Alzheimer's Dis Neuroimaging Initi TI Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; cigarette smoking; F-2-isoprostanes; hippocampus; mild cognitive impairment ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; TOBACCO-SMOKE; LIPID-PEROXIDATION; IN-VIVO; BRAIN; ISOPROSTANES; DAMAGE; F-2-ISOPROSTANES; QUANTITATION AB Neurodegenerative diseases and chronic cigarette smoking are associated with increased cerebral oxidative stress (OxS). Elevated F-2-isoprostane levels in biological fluid is a recognized marker of OxS. This study assessed the association of active cigarette smoking with F-2-isoprostane in concentrations in cognitively-normal elders (CN), and those with mild cognitive impairment (MCI) and probable Alzheimer's disease (AD). Smoking and non-smoking CN (n = 83), MCI (n = 164), and probable AD (n = 101) were compared on cerebrospinal fluid (CSF) iPF(2 alpha)-III and 8,12, iso-iPF(2 alpha)-VI F-2-isoprostane concentrations. Associations between F-2-isoprostane levels and hippocampal volumes were also evaluated. In CN and AD, smokers had higher iPF(2 alpha)-III concentration; overall, smoking AD showed the highest iPF(2 alpha)-III concentration across groups. Smoking and non-smoking MCI did not differ on iPF(2 alpha)-III concentration. No group differences were apparent on 8,12, iso-iPF(2 alpha)-VI concentration, but across AD, higher 8,12, iso-iPF(2 alpha)-VI level was related to smaller left and total hippocampal volumes. Results indicate that active cigarette smoking in CN and probable AD is associated with increased central nervous system OxS. Further investigation of factors mediating/moderating the absence of smoking effects on CSF F-2-isoprostane levels in MCI is warranted. In AD, increasing magnitude of OxS appeared to be related to smaller hippocampal volume. This study contributes additional novel information to the mounting body of evidence that cigarette smoking is associated with adverse effects on the human central nervous system across the lifespan. C1 [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] VA Palo Alto Hlth Care Syst, Mental Illness Res Ctr, Palo Alto, CA USA. [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] VA Palo Alto Hlth Care Syst, Educ Clin Ctr, Palo Alto, CA USA. [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] VA Palo Alto Hlth Care Syst, Sierra Pacific War Related Illness & Injury Study, Palo Alto, CA USA. [Korecka, Magdalena; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Korecka, Magdalena; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychol, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Shaw, Leslie M.] San Francisco VA Med Ctr, CIND, San Francisco, CA USA. RP Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, War Related Illness Ctr, Mental Illness Res Ctr, 3801 Miranda Ave, Palo Alto, CA 94304 USA.; Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, Injury Study Ctr, Mental Illness Res Ctr, 3801 Miranda Ave, Palo Alto, CA 94304 USA.; Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, Educ Clin Ctr 151Y, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM tdurazzo@stanford.edu FU National Institutes of Health [NIH DA24136]; ADNI; National Institute on Aging [U01 AG024904]; National Institute of Biomedical Imaging and Bioengineering; Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan Corporation; Genentech; GE Healthcare; GlaxoSmithKline; Fujirebio Europe; Johnson and Johnson; Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; Wyeth; NIH [P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435]; Dana Foundation; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; U.S. FDA FX This work was supported by the National Institutes of Health (NIH DA24136 to TCD) and by the use of resources and facilities at the VA San Francisco and Palo Alto. All data collection and sharing for this project was supported by ADNI. ADNI1 was funded by the National Institute on Aging (U01 AG024904), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Fujirebio Europe, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., and Wyeth, and non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. FDA. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at the University Southern California. This research was also supported by NIH grants P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435, and The Dana Foundation. The funding agencies had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript. Original data used in preparation of this article were obtained from the ADNI database (http://www.loni.usc.edu/ADNI). As such, the investigators, other than those listed, contributed to the design and implementation of ADNI and/or provided data, but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledg ement_List.pdf. NR 51 TC 2 Z9 2 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 1 BP 99 EP 107 DI 10.3233/JAD-160413 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DW7NS UT WOS:000383838400009 PM 27472882 ER PT J AU Rosenberg, PB Lanctot, KL Herrmann, N Mintzer, JE Porsteinsson, AP Sun, XY Raman, R AF Rosenberg, Paul B. Lanctot, Krista L. Herrmann, Nathan Mintzer, Jacobo E. Porsteinsson, Anton P. Sun, Xiaoying Raman, Rema TI Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; clinical trial; depression; neuropsychiatry ID QUALITY-OF-LIFE; LONG-TERM-CARE; CLINICAL-TRIALS; CACHE COUNTY; SYMPTOMS; DEMENTIA; DEPRESSION; CITALOPRAM; INHIBITORS; AGITATION AB Background: In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD). Objective: We sought to examine the effect of semagacestat treatment on neuropsychiatric symptoms (NPS). Methods: 1,537 participants with mild to moderate AD were randomized to 76 weeks' treatment with placebo versus two doses of semagacestat. NPS were assessed with the Neuropsychiatric Inventory (NPI-Total and subdomains). Cognition was assessed with the Alzheimer's Disease Assessment Scale-Cognitive (first 11 items, ADAS11). Mixed-Model Repeated Measures was used to compare the effects of treatment assignment on change in NPI-total and subdomains over time. Survival analysis was used to assess the treatment effect on time to first worsening of NPS (NPI-Total >= 10 or NPI subdomain >= 4) for subjects with no or minor NPS at baseline. Results: Participants on high dose semagecestat (140 mg) had greater increase in NPI-Total and greater risk of incident first worsening in NPI-Total and in subdomains of aberrant motor behavior, appetite, depression/dysphoria, and sleep. ADAS11 increased more in participants whose NPI-Total increased. Conclusion: In participants with mild to moderate AD, high dose semagacestat treatment was associated with greater severity and faster worsening of NPS in a pattern resembling an agitated depression. Increased NPS was associated with cognitive decline regardless of treatment assignment. These findings suggest that greater NPS may be the result of gamma-secretase treatment and emphasize the importance of monitoring NPS as potential adverse events in trials of novel treatments for AD. C1 [Rosenberg, Paul B.] Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Lanctot, Krista L.] Sunnybrook Res Inst, Hurvitz Brain Sci Program, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Pharmacol Toxicol, Toronto, ON, Canada. [Herrmann, Nathan] Sunnybrook Hlth Sci Ctr, Div Geriatr Psychiat, Toronto, ON, Canada. [Herrmann, Nathan] Univ Toronto, Div Geriatr Psychiat, Dept Psychiat, Toronto, ON, Canada. [Mintzer, Jacobo E.] Roper St Francis Clin Biotechnol Res Inst, Charleston, SC USA. [Mintzer, Jacobo E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Mintzer, Jacobo E.] Med Univ South Carolina, Charleston, SC 29425 USA. [Mintzer, Jacobo E.] Univ South Carolina, Sch Internal Med, Columbia, SC 29208 USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Sun, Xiaoying] Univ Calif San Diego, Biostat Res Ctr, La Jolla, CA 92093 USA. [Raman, Rema] Univ Southern Calif, Keck Sch Med, ATRI, Los Angeles, CA 90033 USA. RP Rosenberg, PB (reprint author), Johns Hopkins Univ, Johns Hopkins Bayview Med Ctr, Sch Med, 5300 Alpha Commons Dr,4th Floor, Baltimore, MD 21224 USA. EM prosenb9@jhmi.edu FU Eli Lilly; University of California at San Diego FX Supported by Eli Lilly and the University of California at San Diego (the latter as a fiduciary for the Alzheimer's Disease Cooperative Study), a clinical trials consortium established by the National Institute on Aging. NR 29 TC 0 Z9 0 U1 1 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 1 BP 373 EP 381 DI 10.3233/JAD-151113 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DW7NS UT WOS:000383838400034 PM 27567808 ER PT J AU Ong, MK Romano, PS Edgington, S Auerbach, AD Black, JT Escarce, JJ Ganiats, TG Greenfield, S Kimchi, A Fonarow, GC AF Ong, M. K. Romano, P. S. Edgington, S. Auerbach, A. D. Black, J. T. Escarce, J. J. Ganiats, T. G. Greenfield, S. Kimchi, A. Fonarow, G. C. TI EFFECTIVENESS OF REMOTE PATIENT MONITORING AFTER DISCHARGE OF HOSPITALIZED PATIENTS WITH HEART FAILURE: THE BETTER EFFECTIVENESS AFTER TRANSITION-HEART FAILURE (BEAT-HF) RANDOMIZED CLINICAL TRIAL SO CARDIOLOGY LA English DT Meeting Abstract C1 [Ong, M. K.; Edgington, S.; Escarce, J. J.; Fonarow, G. C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Romano, P. S.] Univ Calif Davis, Davis, CA 95616 USA. [Greenfield, S.] Univ Calif Irvine, Irvine, CA USA. [Ganiats, T. G.] Univ Calif San Diego, San Diego, CA 92103 USA. [Auerbach, A. D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Black, J. T.; Kimchi, A.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Escarce, J. J.] Univ Miami, RAND Corp, Coral Gables, FL 33124 USA. [Ganiats, T. G.] Univ Miami, Coral Gables, FL 33124 USA. [Ong, M. K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 008 BP 21 EP 21 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200009 ER PT J AU Sun, HB Greenland, JR Kopchaliiska, D Gae, DD Singer, JP Golden, JA Hays, SR Calabrese, D Kukreja, J Rajalingam, R AF Sun, Haibo Greenland, John R. Kopchaliiska, Dessislava Gae, David D. Singer, Jonathan P. Golden, Jeffrey A. Hays, Steven R. Calabrese, Daniel Kukreja, Jasleen Rajalingam, Raja TI RECIPIENT FCGR3A-158V HOMOZYGOUS GENOTYPE IS ASSOCIATED WITH AN INCREASED RISK OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY SEP 26-30, 2016 CL St Louis, MO SP Amer Soc Histocompatibil & Immunogenet C1 [Sun, Haibo; Kopchaliiska, Dessislava; Gae, David D.; Rajalingam, Raja] Univ Calif San Francisco, Dept Surg, Immunogenet & Transplantat Lab, San Francisco, CA USA. [Greenland, John R.; Singer, Jonathan P.; Golden, Jeffrey A.; Hays, Steven R.; Calabrese, Daniel] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Greenland, John R.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Kukreja, Jasleen] Univ Calif San Francisco, Dept Surg, Div Cardiothorac Surg, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 EI 1879-1166 J9 HUM IMMUNOL JI Hum. Immunol. PY 2016 VL 77 SU 1 MA OR24 BP 19 EP 20 PG 2 WC Immunology SC Immunology GA DW0EK UT WOS:000383313500025 ER PT J AU Brown, K Poppe, A Kaminetzky, CP Wipf, JA Woods, NF AF Brown, Kameka Poppe, Anne Kaminetzky, Catherine P. Wipf, Joyce A. Woods, Nancy Fugate TI Reflections of the Veterans Administration Puget Sound Health Care System Regional Nurse Practitioner Residency Forum SO NURSING FORUM LA English DT Article DE Education; interprofessional education; professional issue; workforce ID EDUCATION AB PROBLEM. There is a proliferation of advanced practice residency programs. However, there is no uniform model of developing and evaluating program success. METHODS. An information forum was convened by Veterans Health Administration Puget Sound Health Care System's Center for Primary Care Education on September 17, 2013, in Seattle, Washington, to explore critical aspects of residency models. The three objectives of this forum were to develop a shared understanding of key elements needed to support nurse practitioner residencies; define the unique needs of nurse practitioner trainees who are interested in applying for a residency; and examine the viability of designing a replicable nurse practitioner residency model benchmarking stakeholder best practices. FINDINGS. This article describes the organization of the forum and summarizes the presentations during the program. The companion article explores key recommendations from the forum related to future development of residency "toolkits" to aid in future evaluation and accreditation. CONCLUSION. As nurse practitioner residencies continue to develop and evolve, more is needed in the area of structure and alignment. C1 [Brown, Kameka] VA Northern Calif Hlth Care Syst, Primary Care Serv, Seattle, WA USA. [Brown, Kameka; Woods, Nancy Fugate] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Poppe, Anne; Wipf, Joyce A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Primary Care Educ, 1660 S Columbian Way S-123-COE, Seattle, WA 98108 USA. [Kaminetzky, Catherine P.] VA Puget Sound Hlth Care Syst, Educ, Seattle, WA USA. [Kaminetzky, Catherine P.; Wipf, Joyce A.] Univ Washington, Sch Med, Seattle, WA USA. RP Brown, K (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Primary Care Educ, 1660 S Columbian Way S-123-COE, Seattle, WA 98108 USA. EM kameka.brown@va.gov NR 14 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0029-6473 EI 1744-6198 J9 NURS FORUM JI Nurs. Forum PD JAN-MAR PY 2016 VL 51 IS 1 BP 70 EP 76 DI 10.1111/nuf.12127 PG 7 WC Nursing SC Nursing GA DU4GX UT WOS:000382172000009 PM 25737307 ER PT J AU Reddy, AT Lakshmi, SP Reddy, RC AF Reddy, Aravind T. Lakshmi, Sowmya P. Reddy, Raju C. TI PPAR gamma as a Novel Therapeutic Target in Lung Cancer SO PPAR RESEARCH LA English DT Review ID ACTIVATED-RECEPTOR-GAMMA; EPITHELIAL-MESENCHYMAL TRANSITION; NITRATED FATTY-ACIDS; CELL-GROWTH; TUMOR PROGRESSION; CARCINOMA-CELLS; PULMONARY-FIBROSIS; GENE-EXPRESSION; COLON-CANCER; LIGANDS AB Lung cancer is the leading cause of cancer-related death, with more than half the patients having advanced-stage disease at the time of initial diagnosis and thus facing a poor prognosis. This dire situation poses a need for new approaches in prevention and treatment. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. Its involvement in adipocyte differentiation and glucose and lipid homeostasis is well-recognized, but accumulating evidence now suggests that PPAR gamma may also function as a tumor suppressor, inhibiting development of primary tumors and metastases in lung cancer and other malignancies. Besides having prodifferentiation, antiproliferative, and proapoptotic effects, PPAR gamma agonists have been shown to prevent cancer cells from acquiring the migratory and invasive capabilities essential for successful metastasis. Angiogenesis and secretion of certain matrix metalloproteinases and extracellular matrix proteins within the tumor microenvironment are also regulated by PPAR gamma. This review of the current literature highlights the potential of PPAR gamma agonists as novel therapeutic modalities in lung cancer, either as monotherapy or in combination with standard cytotoxic chemotherapy. C1 [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU U.S. Department of Veterans Affairs; National Institutes of Health [HL093196, AI125338] FX This work was supported by a Merit Review award from the U.S. Department of Veterans Affairs and National Institutes of Health grants HL093196 and AI125338 (to Raju C. Reddy). NR 63 TC 0 Z9 0 U1 2 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-4757 EI 1687-4765 J9 PPAR RES JI PPAR Res. PY 2016 AR 8972570 DI 10.1155/2016/8972570 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DW2MV UT WOS:000383477400001 ER PT J AU Katz, LS Park, SE Cojucar, G Huffman, C Douglas, S AF Katz, Lori S. Park, Sam E. Cojucar, Geta Huffman, Cristi Douglas, Sarah TI Improved Attachment Style for Female Veterans Who Graduated Warrior Renew Sexual Trauma Treatment SO VIOLENCE AND VICTIMS LA English DT Article DE sexual trauma; women veterans; military sexual trauma; holographic reprocessing ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; WOMEN VETERANS; MENTAL-HEALTH; PSYCHOTHERAPY/; ADULTS; ABUSE; PTSD AB The Warrior Renew sexual trauma treatment program proposes to target perceived attachment style and the internal working models of interpersonal relationships. This study examined scores on the Relationships Scales Questionnaire and Brief Symptom Inventory pre- and post-treatment in a sample of 62 female veterans who graduated the program. Findings revealed that graduates of Warrior Renew reported significant decreases in fearful and dismissive insecure attachment and significant increases in secure attachment. Scores were significantly correlated with symptoms. Findings lend support to an upward spiral hypothesis associated with long-term positive outcomes found in previous research on Warrior Renew. C1 [Katz, Lori S.] Univ Southern Calif, VA Puget Sound Hlth Care Syst, Los Angeles, CA USA. [Park, Sam E.; Cojucar, Geta; Huffman, Cristi; Douglas, Sarah] VA Long Beach Healthcare Syst, Long Beach, CA USA. RP Katz, LS (reprint author), VA Puget Sound Hlth Care Syst, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM Lorikmail@yahoo.com NR 41 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA SN 0886-6708 EI 1945-7073 J9 VIOLENCE VICTIMS JI Violence Vict. PY 2016 VL 31 IS 4 BP 680 EP 691 DI 10.1891/0886-6708.VV-D-14-00182 PG 12 WC Criminology & Penology SC Criminology & Penology GA DV7PJ UT WOS:000383128300006 PM 27302913 ER PT J AU Lynn, DD Umari, T Dunnick, CA Dellavalle, RP AF Lynn, Darren D. Umari, Tamara Dunnick, Cory A. Dellavalle, Robert P. TI The epidemiology of acne vulgaris in late adolescence SO ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS LA English DT Review DE review; epidemiology; GBD; hormones; diet ID GLYCEMIC-LOAD DIET; GROWTH-FACTOR-I; ORAL-CONTRACEPTIVES; AFRICAN-AMERICAN; RETINOID THERAPY; IMPROVE OUTCOMES; CONTROLLED-TRIAL; GLOBAL ALLIANCE; FEMALE-PATIENTS; HIGH-SCHOOL AB Importance: Acne vulgaris is the most common skin condition affecting late adolescents across the globe. Although prior studies have evaluated epidemiologic patterns of acne vulgaris in various ethnicities and regions, adequate understanding of the worldwide burden of the disease associated with patients in their late adolescence (15-19-year olds) remains lacking. Objective: To assess the global burden of the disease associated with acne vulgaris for late adolescents (15-19-year olds) and provide an overview of the epidemiology, pathophysiology, and treatment options for acne in this population. Design: Database summary study. Setting: Global Burden of Disease Study 2010 database. Participants: Global Burden of Disease regions comprised countries with prevalence of acne vulgaris between the ages of 15 and 19 years. Main outcomes and measures: Geographic region-level disability-adjusted life year rates (per 100,000 persons) associated with acne vulgaris in years 1990 through 2010. Median percentage change in disability-adjusted life year rates was estimated for each region across the specified study period. Conclusion and relevance: Acne vulgaris-associated disease burden exhibits global distribution and has continued to grow in prevalence over time within this population. This continued growth suggests an unmet dermatologic need worldwide for this disorder and potential opportunities for improved access and delivery of dermatologic care. Our analysis of the literature reveals numerous opportunities for enhanced patient care. To that end, we highlight some of the effective and promising treatments currently available and address important factors, such as sex, nationality, genetics, pathophysiology, and diet, as they relate to acne vulgaris in late adolescence. C1 [Lynn, Darren D.; Umari, Tamara] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Dunnick, Cory A.; Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dunnick, Cory A.; Dellavalle, Robert P.] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Dermatol Serv, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA. RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu NR 97 TC 5 Z9 5 U1 3 U2 5 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-318X J9 ADOLESC HEALTH MED T JI ADOLESC. HEALTH MED. THER. PY 2016 VL 7 BP 13 EP 25 DI 10.2147/AHMT.S55832 PG 13 WC Pediatrics SC Pediatrics GA DU4UD UT WOS:000382207200001 PM 26955297 ER PT J AU Baig, KRKK Wilcox, CM AF Baig, Kondal Rao Kyanam Kabir Wilcox, Charles Melbern TI Translational and clinical perspectives on sphincter of Oddi dysfunction SO CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY LA English DT Review DE SOD; abdominal pain; pancreatitis; sphincter dysfunction; abnormal liver tests; biliary dilation ID ENDOSCOPIC SPHINCTEROTOMY; BOTULINUM TOXIN; SUSPECTED SPHINCTER; BILIARY PAIN; CHOLECYSTECTOMY; TRIAL; MANOMETRY; CHOLECYSTOKININ; MICROLITHIASIS; GALLBLADDER AB Sphincter of Oddi dysfunction is a complex pathophysiologic entity that is associated with significant morbidity causing abdominal pain, nausea, and vomiting. The purpose of this review is to describe the anatomy and physiology of the sphincter of Oddi, to understand the pathologic mechanisms thought to be responsible for symptomatology, review recent major studies, explore endoscopic and pharmacologic therapies and their efficacy, and to explore future research avenues. C1 [Wilcox, Charles Melbern] Univ Alabama Birmingham, Div Gastroenterol & Hepatol, 1720 Second Ave South,BDB 380, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Wilcox, CM (reprint author), Univ Alabama Birmingham, Div Gastroenterol & Hepatol, 1720 Second Ave South,BDB 380, Birmingham, AL 35294 USA. EM melw@uab.edu NR 36 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-7023 J9 CLIN EXP GASTROENTER JI Clin. Exp. Gastroenterol. PY 2016 VL 9 BP 191 EP 195 DI 10.2147/CEG.S84018 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU6KP UT WOS:000382323800001 ER PT J AU Kullgren, JT Williams, GC Resnicow, K An, LC Rothberg, A Volpp, KG Heisler, M AF Kullgren, Jeffrey T. Williams, Geoffrey C. Resnicow, Kenneth An, Lawrence C. Rothberg, Amy Volpp, Kevin G. Heisler, Michele TI The promise of tailoring incentives for healthy behaviors SO INTERNATIONAL JOURNAL OF WORKPLACE HEALTH MANAGEMENT LA English DT Article DE Self-determination theory; Behaviour change; Behavioural economics; Financial incentives; Employee behaviour; Workplace wellness; Motivation psychology; Behaviour modification; Health promotion; Wellness interventions ID SELF-DETERMINATION THEORY; RANDOMIZED CONTROLLED-TRIAL; FINANCIAL INCENTIVES; WEIGHT-LOSS; INTRINSIC MOTIVATION; PHYSICAL-ACTIVITY; SMOKING-CESSATION; VEGETABLE INTERVENTION; AUTONOMY SUPPORT; EXERCISE AB Purpose - The purpose of this paper is to describe how tailoring financial incentives for healthy behaviors to employees' goals, values, and aspirations might improve the efficacy of incentives. Design/methodology/approach - The authors integrate insights from self-determination theory (SDT) with principles from behavioral economics in the design of financial incentives by linking how incentives could help meet an employee's life goals, values, or aspirations. Findings - Tailored financial incentives could be more effective than standard incentives in promoting autonomous motivation necessary to initiate healthy behaviors and sustain them after incentives are removed. Research limitations/implications - Previous efforts to improve the design of financial incentives have tested different incentive designs that vary the size, schedule, timing, and target of incentives. The strategy for tailoring incentives builds on strong evidence that difficult behavior changes are more successful when integrated with important life goals and values. The authors outline necessary research to examine the effectiveness of this approach among at-risk employees. Practical implications - Instead of offering simple financial rewards for engaging in healthy behaviors, existing programs could leverage incentives to promote employees' autonomous motivation for sustained health improvements. Social implications - Effective application of these concepts could lead to programs more effective at improving health, potentially at lower cost. Originality/value - The approach for the first time integrates key insights from SDT, behavioral economics, and tailoring to turn an extrinsic reward for behavior change into an internalized, self-sustaining motivator for long-term engagement in risk-reducing behaviors. C1 [Kullgren, Jeffrey T.; Heisler, Michele] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Kullgren, Jeffrey T.; An, Lawrence C.; Rothberg, Amy; Heisler, Michele] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Williams, Geoffrey C.] Univ Rochester, Dept Med, Rochester, NY USA. [Williams, Geoffrey C.] Univ Rochester, Dept Clin Social Sci Psychol, Rochester, NY USA. [Resnicow, Kenneth] Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA. [Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Kullgren, JT (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA.; Kullgren, JT (reprint author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. EM jkullgre@med.umich.edu NR 59 TC 0 Z9 0 U1 13 U2 14 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1753-8351 EI 1753-836X J9 INT J WORKPLACE HEAL JI Int. J. Workplace Health Manag. PY 2016 VL 9 IS 1 BP 2 EP 16 DI 10.1108/IJWHM-12-2014-0060 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DU9QR UT WOS:000382553100001 ER PT J AU Pi-Sunyer, X Shanahan, W Fain, R Ma, T Garvey, WT AF Pi-Sunyer, Xavier Shanahan, William Fain, Randi Ma, Tony Garvey, W. Timothy TI Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders SO POSTGRADUATE MEDICINE LA English DT Article DE Obesity; overweight; diabetes mellitus; weight loss; lorcaserin ID NEURONS REGULATE ENERGY; SEROTONIN 2C RECEPTORS; WEIGHT-LOSS; CLINICAL ENDOCRINOLOGISTS; AMERICAN ASSOCIATION; GLUCOSE-HOMEOSTASIS; UNITED-STATES; MANAGEMENT; MELLITUS; TRIAL AB Objectives: Treatment guidelines for type 2 diabetes mellitus (T2DM) suggest weight loss as a means to maintain glycemic control. Lorcaserin has been approved for chronic weight management in the United States as an adjunct to a reduced-calorie diet and exercise, and the previous phase 3 Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study has shown that, in addition to weight loss, lorcaserin is associated with improvements in glycemic parameters. In this post hoc analysis of the BLOOM-DM trial, the relationship between responder status (patients achieving 5% weight loss at Week 52) and glycemic and cardiometabolic parameters is evaluated.Methods: Data are presented for patients receiving lorcaserin 10mg twice daily or placebo for 52 weeks.Results: More than twice as many patients receiving lorcaserin plus diet and exercise counseling were classified as Week 52 responders compared to those receiving diet and exercise counseling alone (37.5% vs. 16.1%, respectively; p<0.001), and lorcaserin Week 52 responders had greater improvements vs. placebo Week 52 responders in FPG (-38.1mg/dL vs. -26.0mg/dL) and HbA1c (-1.3% vs. -1.0%). Furthermore, more lorcaserin-treated Week 52 responders decreased the number of concomitant oral antidiabetic medications (OADs) used, and fewer increased the number of OADs used, compared to placebo. Unexpectedly, lorcaserin Week 52 nonresponders also had substantial reductions in glycemic levels, despite very modest weight loss.Conclusions: These data support lorcaserin use in overweight and obese patients with T2DM to promote weight loss and facilitate glycemic control.Clinical trial registration: www.clinicaltrials.gov identifier is NCT00603291 C1 [Pi-Sunyer, Xavier] Columbia Univ, Med Ctr, Div Endocrinol, New York, NY USA. [Shanahan, William] Arena Pharmaceut Inc, Div Preclin & Clin Drug Dev, San Diego, CA USA. [Fain, Randi; Ma, Tony] Eisai Inc, Global Neurosci Business Unit, Woodcliff Lake, NJ USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Pi-Sunyer, X (reprint author), Columbia Univ, Med Ctr, New York Obes Nutr Res Ctr, Russ Berrie Pavil,1150 St Nicholas Ave, New York, NY 10032 USA. EM fxp1@columbia.edu FU Arena Pharmaceuticals, Inc.; Eisai Inc. FX The BLOOM-DM study was funded by Arena Pharmaceuticals, Inc., and this post hoc analysis was funded by Eisai Inc. Editorial support was provided by Medicus International New York and Imprint Publication Science, New York, NY, USA, with funding from Eisai Inc. X Pi-Sunyer is on Scientific Advisory Committees for Lilly, Novo Nordisk, Vivus, Eisai, and Zafgen. WT Garvey has served on advisory boards for Eisai Inc., Novo Nordisk, Daiichi-Sankyo, Liposcience, Vivus, Takeda, Janssen, Boehringer Ingelheim, and AstraZeneca; and has conducted research for Eisai Inc., Merck, Sanofi, AstraZeneca, Weight Watchers, Pfizer, Lexicon, Elcelyx Therapeutics, and Novo Nordisk. T Ma and R Fain are former employees of Eisai Inc. W Shanahan is a former employee of Arena Pharmaceuticals, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 34 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PY 2016 VL 128 IS 6 BP 591 EP 597 DI 10.1080/00325481.2016.1208618 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DU7GO UT WOS:000382382000009 PM 27389084 ER PT J AU Gordon, AJ Saba, SK AF Gordon, Adam J. Saba, Shaddy K. TI Confronting the opioid epidemic through publication, promotion, and dissemination of evidence-based addiction scholarship SO SUBSTANCE ABUSE LA English DT Editorial Material ID CHRONIC PAIN; PRESCRIBING OPIOIDS; CDC GUIDELINE; UNITED-STATES; STIGMA C1 [Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Gordon, Adam J.; Saba, Shaddy K.] VA Pittsburgh Healthcare Syst, VA Off Acad Affiliat, Interdisciplinary Addict Program Educ & Res VIPER, Pittsburgh, PA 15240 USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Univ Dr C Mailcode 151-C, Pittsburgh, PA 15240 USA.; Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C Mailcode 151-C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 3 BP 379 EP 380 DI 10.1080/08897077.2016.1208988 PG 2 WC Substance Abuse SC Substance Abuse GA DV2RW UT WOS:000382769800001 PM 27712565 ER PT J AU Clark, BJ Rubinsky, AD Ho, PM Au, DH Chavez, LJ Moss, M Bradley, KA AF Clark, Brendan J. Rubinsky, Anna D. Ho, P. Michael Au, David H. Chavez, Laura J. Moss, Marc Bradley, Katharine A. TI Alcohol screening scores and the risk of intensive care unit admission and hospital readmission SO SUBSTANCE ABUSE LA English DT Article DE Alcohol abuse; alcohol consumption; alcohol-related disorders; intensive care units; patient readmission; health care utilization ID RESPIRATORY-DISTRESS-SYNDROME; MULTIPLE ORGAN DYSFUNCTION; SERVICES TASK-FORCE; USE DISORDERS; BRIEF INTERVENTION; MECHANICAL VENTILATION; CONSUMPTION QUESTIONS; CONTROLLED-TRIAL; SEPTIC SHOCK; AUDIT-C AB Background: The association between alcohol misuse and the need for intensive care unit admission as well as hospital readmission among those discharged from the hospital following a critical illness is unclear. This study sought to determine whether alcohol misuse was associated with (1) admission to an intensive care unit (ICU) among a cohort of patients receiving outpatient care and (2) hospital readmission among those discharged from the hospital following critical illness. Methods: This was a retrospective cohort study conducted with data from 24 Veterans Affairs (VA) health care facilities between 2004 and 2007. Scores on the Alcohol Use Disorders Identification TestConsumption (AUDIT-C) questionnaire were used to identify patients with past-year abstinence, lower-risk alcohol use, moderate alcohol misuse, or severe alcohol misuse. The primary outcome was admission to a VA intensive care unit within the year following administration of the AUDIT-C. In an analysis focused on patients discharged from the ICU, the 2 main outcomes were hospital readmission within 1year and within 30days. Results: Among 486,115 veterans receiving outpatient care, the adjusted probability of ICU admission within 1year was 2.0% (95% confidence interval [CI]: 1.7%-2.3%) for abstinent patients, 1.6% (95% CI: 1.3%-1.8%) for patients with lower-risk alcohol use, 1.8% (1.4%-2.3%) for patients with moderate alcohol misuse, and 2.5% (2.0%-2.9%) for patients with severe alcohol misuse. Among the 9,030 patients discharged from an ICU, the adjusted probability of hospital readmission within 1year was 48% (46%-49%) in abstinent patients, 44% (42%-45%) in patients with lower-risk alcohol use, 42% (39%-45%) in patients with moderate alcohol misuse, and 55% (49%-60%) in patients with severe alcohol misuse. Conclusions: Alcohol misuse may represent a modifiable risk factor for a cycle of ICU admission and subsequent hospital readmission. C1 [Clark, Brendan J.; Moss, Marc] Univ Colorado, Div Pulm Sci & Crit Care Med, RC2,Box C272,9th Floor,12700 East 19th Ave, Aurora, CO 80045 USA. [Rubinsky, Anna D.; Bradley, Katharine A.] Dept Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Rubinsky, Anna D.; Au, David H.; Chavez, Laura J.; Bradley, Katharine A.] Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Ho, P. Michael] Denver VA Med Ctr, Div Cardiol, Dept Med, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Div Cardiol, Dept Med, Aurora, CO 80045 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Clark, BJ (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, RC2,Box C272,9th Floor,12700 East 19th Ave, Aurora, CO 80045 USA. EM Brendan.clark@ucdenver.edu FU Merit Review Award [. IIR 08-314]; United States Department of Veterans Affairs Health Services Research and Development Program; Center of Excellence for Substance Abuse Treatment and Education; NIH/NCATS Colorado CTSI [UL1 TR001082]; National Institute on Alcohol Abuse and Alcoholism [K23 AA 021814]; National Heart Lung and Blood Institute [K24 HL 089223]; Agency for Healthcare Research and Quality [R36 HS 022800]; VA Information Resource Center [SDR 02-237, SDR 98-004] FX This work was supported by Merit Review Award no. IIR 08-314 from the United States Department of Veterans Affairs Health Services Research and Development Program, the Center of Excellence for Substance Abuse Treatment and Education, NIH/NCATS Colorado CTSI Grant Number UL1 TR001082, the National Institute on Alcohol Abuse and Alcoholism (K23 AA 021814), the National Heart Lung and Blood Institute (K24 HL 089223), and the Agency for Healthcare Research and Quality (R36 HS 022800). Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (project numbers SDR 02-237 and 98-004). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the United States Government, or any of the authors' institutions. The funding agencies were not involved in the design of this study, analysis of data, or preparation of the manuscript. The authors declare that they have no conflicts of interest. NR 62 TC 1 Z9 1 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 3 BP 466 EP 473 DI 10.1080/08897077.2015.1137259 PG 8 WC Substance Abuse SC Substance Abuse GA DV2RW UT WOS:000382769800015 PM 26730984 ER PT J AU Canterberry, M Peltier, MR Brady, KT Hanlon, CA AF Canterberry, Melanie Peltier, MacKenzie R. Brady, Kathleen T. Hanlon, Colleen A. TI Attenuated neural response to emotional cues in cocaine-dependence: a preliminary analysis of gender differences SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Cocaine; emotion; fMRI; addiction; gender ID SUBSTANCE USE DISORDERS; FUNCTIONAL NEUROANATOMY; PREFRONTAL CORTEX; CHOICE PROCEDURE; NEGATIVE AFFECT; SEX-DIFFERENCES; DRUG-ADDICTION; ACTIVATION; FMRI; METAANALYSIS AB Background: Cocaine users often report a loss of arousal for nondrug-related stimuli, which may contribute to their response to drug-related rewards. However, little is known about users' neural reactivity to emotional nondrug-related stimuli and the potential influence of gender. Objectives: Test the hypotheses that cocaine-dependent individuals have an attenuated neural response to arousing stimuli relative to controls and that this difference is amplified in women. Methods: The brain response to typically arousing positive and negative images as well as neutral images from the International Affective Picture System was measured in 40 individuals (20 non-treatment seeking cocaine-dependent and 20 age- and gender-matched control participants; 50% of whom were women). Images were displayed for 4 s each in blocks of five across two 270-second runs. General linear models assessed within and between group activation differences for the emotional images. Results: Cocaine-dependent individuals had a significantly lower response to typically arousing positive and negative images than controls, with attenuated neural activity present in the medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC). Analyses by gender revealed less mPFC/ACC activation among female users, but not males, for both positive and negative images. Conclusion: The dampened neural response to typically arousing stimuli among cocaine-dependent polydrug users suggests decreased salience processing for nondrug stimuli, particularly among female users. This decreased responding is consistent with data from other substance using populations and suggests that this may be a general feature of addiction. Amplifying the neural response to naturally arousing nondrug-related reinforcers may present an opportunity for unique behavioral and brain stimulation therapies. C1 [Canterberry, Melanie; Peltier, MacKenzie R.; Brady, Kathleen T.; Hanlon, Colleen A.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Peltier, MacKenzie R.] Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA. [Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ South Carolina, Dept Psychiat, 67 President St,Room 502 North, Charleston, SC 29425 USA. EM hanlon@musc.edu FU National Institutes of Health [F32DA036329, K01DA0267756] FX The effort for this research was supported by the National Institutes of Health (F32DA036329 to MC and K01DA0267756 to CAH). NR 53 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PY 2016 VL 42 IS 5 BP 577 EP 586 DI 10.1080/00952990.2016.1192183 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DU7XX UT WOS:000382429000013 PM 27441590 ER PT J AU Howard, M Bonham, AJ Heyland, DK Sudore, R Fassbender, K Robinson, CA McKenzie, M Elston, D You, JJ AF Howard, Michelle Bonham, Aaron J. Heyland, Daren K. Sudore, Rebecca Fassbender, Konrad Robinson, Carole A. McKenzie, Michael Elston, Dawn You, John J. TI Measuring engagement in advance care planning: a cross-sectional multicentre feasibility study SO BMJ OPEN LA English DT Article DE advance care planning; communication; survey; measurement ID OF-LIFE CARE; DECISION-MAKING; FAMILY SATISFACTION; ELDERLY-PATIENTS; MEASURE PATIENT; END; QUESTIONNAIRE; VALIDATION AB Objectives To assess the feasibility, acceptability and clinical sensibility of a novel survey, the advance care planning (ACP) Engagement Survey, in various healthcare settings. Setting A target sample of 50 patients from each of primary care, hospital, cancer care and dialysis care settings. Participants A convenience sample of patients without cognitive impairment who could speak and read English was recruited. Patients 50 and older were eligible in primary care; patients 80 and older or 55 and older with clinical markers of advanced chronic disease were recruited in hospital; patients aged 19 and older were recruited in cancer and renal dialysis centres. Outcomes We assessed feasibility, acceptability and clinical sensibility of the ACP Engagement Survey using a 6-point scale. The ACP Engagement Survey measures ACP processes (knowledge, contemplation, self-efficacy and readiness) on 5-point Likert scales and actions (yes/no). Results 196 patients (38-96years old, 50.5% women) participated. Mean (SD) time to administer was 48.8 +/- 19.6min. Mean acceptability scores ranged from 3.2 +/- 1.3 in hospital to 4.7 +/- 0.9 in primary care, and mean relevance ranged from 3.5 +/- 1.0 in hospital to 4.9 +/- 0.9 in dialysis centres (p<0.001 for both). The mean process score was 3.1 +/- 0.6 and the mean action score was 11.2 +/- 5.6 (of a possible 25). Conclusions The ACP Engagement Survey demonstrated feasibility and acceptability in outpatient settings but was less feasible and acceptable among hospitalised patients due to length. A shorter version may improve feasibility. Engagement in ACP was low to moderate. C1 [Howard, Michelle; Elston, Dawn] McMaster Univ, Dept Family Med, Hamilton, ON, Canada. [Bonham, Aaron J.; You, John J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Heyland, Daren K.] Kingston Gen Hosp, Clin Evaluat Res Unit, Kingston, ON, Canada. [Heyland, Daren K.] Queens Univ, Dept Publ Hlth, Kingston, ON, Canada. [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Fassbender, Konrad] Covenant Hlth Palliat Inst, Edmonton, AB, Canada. [Robinson, Carole A.] Univ British Columbia, Sch Nursing, Kelowna, BC, Canada. [McKenzie, Michael] British Columbia Canc Agcy, Vancouver Canc Ctr, Radiat Therapy Program, Vancouver, BC, Canada. [You, John J.] McMaster Univ, Med, Hamilton, ON, Canada. RP Howard, M (reprint author), McMaster Univ, Dept Family Med, Hamilton, ON, Canada. EM mhoward@mcmaster.ca NR 17 TC 0 Z9 0 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 6 AR e010375 DI 10.1136/bmjopen-2015-010375 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DR9ST UT WOS:000380237100031 PM 27338877 ER PT J AU Liman, AD Liman, AK Shields, J Englert, B Shah, R AF Liman, Andrew D. Liman, Agnes K. Shields, Jenna Englert, Becky Shah, Rashmikant TI A Case of Metastatic Adamantinoma That Responded Well to Sunitinib SO CASE REPORTS IN ONCOLOGICAL MEDICINE LA English DT Article ID LONG BONES; HISTOGENESIS AB Adamantinoma is a rare low-grade malignant bone tumor of epithelial origin. Metastatic adamantinoma has been reported to be resistant to chemotherapy. We report a case of metastatic adamantinoma to the lung, 10 years after the initial diagnosis of tibial mass. The patient received radiation therapy to the lung with partial response. A surveillance PET scan revealed progression of the lung mass and biopsy confirmed to be progressive residual metastatic adamantinoma. He received carboplatin and etoposide for 7 months and achieved a partial response. Four months later, PET scan showed disease progression. We started him on sunitinib, a multikinase inhibitor. He achieved a good partial response for 3 years. He died due to pneumonia at the age of 72. C1 [Liman, Andrew D.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Hematol & Oncol, Sch Med, Pittsburgh, PA 15240 USA. [Liman, Agnes K.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pathol, Sch Med, Pittsburgh, PA 15240 USA. [Shields, Jenna] VA Pittsburgh Healthcare Syst, Pharm, Pittsburgh, PA 15240 USA. [Englert, Becky] VA Pittsburgh Healthcare Syst, Hematol & Oncol, Pittsburgh, PA 15240 USA. [Shah, Rashmikant] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Radiol, Sch Med, Pittsburgh, PA 15240 USA. RP Liman, AD (reprint author), Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Hematol & Oncol, Sch Med, Pittsburgh, PA 15240 USA. EM andrew.liman@va.gov NR 16 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA EI 2090-6714 J9 CASE REP ONCOL MED JI Case Rep. Oncol. Med. PY 2016 AR 5982313 DI 10.1155/2016/5982313 PG 5 WC Oncology SC Oncology GA DU2YF UT WOS:000382076700001 ER PT J AU Kantarci, K Lowe, VJ Lesnick, TG Tosakulwong, N Bailey, KR Fields, JA Shuster, LT Zuk, SM Senjem, ML Mielke, MM Gleason, C Jack, CR Rocca, WA Miller, VM AF Kantarci, Kejal Lowe, Val J. Lesnick, Timothy G. Tosakulwong, Nirubol Bailey, Kent R. Fields, Julie A. Shuster, Lynne T. Zuk, Samantha M. Senjem, Matthew L. Mielke, Michelle M. Gleason, Carey Jack, Clifford R., Jr. Rocca, Walter A. Miller, Virginia M. TI Early Postmenopausal Transdermal 17 beta-Estradiol Therapy and Amyloid-beta Deposition SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; cognitive function; estrogen; hormone therapy; menopause; PET; prevention ID CONJUGATED EQUINE ESTROGENS; HORMONE REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; CACHE COUNTY; WOMEN; RISK; DEMENTIA; APOE AB Background: It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer's disease (AD). Objective: To investigate the effects of hormone therapy on amyloid-beta deposition in recently postmenopausal women. Methods: Participants within 5-36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-controlled clinical trial, were randomized to: 1) 0.45 mg/day oral conjugated equine estrogens (CEE); 2) 50 mu g/day transdermal 17 beta-estradiol; or 3) placebo pills and patch for four years. Oral progesterone (200 mg/day) was given to active treatment groups for 12 days each month. C-11 Pittsburgh compound B (PiB) PET imaging was performed in 68 of the 118 participants at Mayo Clinic approximately seven years post randomization and three years after stopping randomized treatment. PiB Standard unit value ratio (SUVR) was calculated. Results: Women (age = 52-65) randomized to transdermal 17 beta-estradiol (n = 21) had lower PiB SUVR compared to placebo (n = 30) after adjusting for age [odds ratio (95% CI) = 0.31(0.11-0.83)]. In the APOE epsilon 4 carriers, transdermal 17 beta-estradiol treated women (n = 10) had lower PiB SUVR compared to either placebo (n = 5) [odds ratio (95% CI) = 0.04(0.004-0.44)], or the oral CEE treated group (n = 3) [odds ratio (95% CI) = 0.01(0.0006-0.23)] after adjusting for age. Hormone therapy was not associated with PiB SUVR in the APOE epsilon 4 non-carriers. Conclusion: In this pilot study, transdermal 17 beta-estradiol therapy in recently postmenopausal women was associated with a reduced amyloid-beta deposition, particularly in APOE epsilon 4 carriers. This finding may have important implications for the prevention of AD in postmenopausal women, and needs to be confirmed in a larger sample. C1 [Kantarci, Kejal; Lowe, Val J.; Zuk, Samantha M.; Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA. [Lesnick, Timothy G.; Tosakulwong, Nirubol; Bailey, Kent R.; Mielke, Michelle M.; Rocca, Walter A.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Fields, Julie A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Shuster, Lynne T.] Mayo Clin, Dept Internal Med, Rochester, MN USA. [Senjem, Matthew L.] Mayo Clin, Dept Informat Technol, Rochester, MN USA. [Mielke, Michelle M.; Rocca, Walter A.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Gleason, Carey] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gleason, Carey] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Miller, Virginia M.] Mayo Clin, Dept Surg, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Physiol, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Biomed Engn, Rochester, MN USA. RP Kantarci, K (reprint author), Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA. EM kantarci.kejal@mayo.edu FU Aurora Foundation; NIH [NS66147, AG029624, AG44170] FX This study is funded by the Aurora Foundation to the Kronos Longevity Research Institute, NIH (NS66147, AG029624 and AG44170). The authors thank Ms. Kim Jensen for consenting and scheduling of the participants. The authors do not have any conflicts of interest related to the submitted work. The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. NR 44 TC 4 Z9 4 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 2 BP 547 EP 556 DI 10.3233/JAD-160258 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DT0XY UT WOS:000381207500015 PM 27163830 ER PT S AU Munos, B Baker, PC Bot, BM Crouthamel, M de Vries, G Ferguson, I Hixson, JD Malek, LA Mastrototaro, JJ Misra, V Ozcan, A Sacks, L Wang, P AF Munos, Bernard Baker, Pamela C. Bot, Brian M. Crouthamel, Michelle de Vries, Glen Ferguson, Ian Hixson, John D. Malek, Linda A. Mastrototaro, John J. Misra, Veena Ozcan, Aydogan Sacks, Leonard Wang, Pei GP Annals New York Acad Sci TI Mobile health: the power of wearables, sensors, and apps to transform clinical trials SO SPECIAL ISSUE: ANNALS REPORTS, VOL 1375 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE biosensors; mobile technology; wireless; medical device; health care; data; clinical study ID ON-CHIP MICROSCOPY AB Mobile technology has become a ubiquitous part of everyday life, and the practical utility of mobile devices for improving human health is only now being realized. Wireless medical sensors, or mobile biosensors, are one such technology that is allowing the accumulation of real-time biometric data that may hold valuable clues for treating even some of the most devastating human diseases. From wearable gadgets to sophisticated implantable medical devices, the information retrieved from mobile technology has the potential to revolutionize how clinical research is conducted and how disease therapies are delivered in the coming years. Encompassing the fields of science and engineering, analytics, health care, business, and government, this report explores the promise that wearable biosensors, along with integrated mobile apps, hold for improving the quality of patient care and clinical outcomes. The discussion focuses on groundbreaking device innovation, data optimization and validation, commercial platform integration, clinical implementation and regulation, and the broad societal implications of using mobile health technologies. C1 [Munos, Bernard] Milken Inst, FasterCures, Washington, DC 20005 USA. [Baker, Pamela C.] Questex Media Grp LLC, FierceBigData, Newton, MA USA. [Bot, Brian M.] Sage Bionetworks, Seattle, WA USA. [Crouthamel, Michelle] GlaxoSmithKline, Collegeville, PA USA. [de Vries, Glen] Medidata Solut, New York, NY USA. [Ferguson, Ian] ARM, San Francisco, CA USA. [Hixson, John D.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Hixson, John D.] San Francisco VA Med Ctr, San Francisco, CA USA. [Malek, Linda A.] Moses & Singer LLP, Healthcare & Privacy & Cybersecur Practices, New York, NY USA. [Mastrototaro, John J.] Medtronic PLC, Los Angeles, CA USA. [Misra, Veena] North Carolina State Univ, NSF Nanosyst Engn Res Ctr NERC Adv Self Powered S, Raleigh, NC USA. [Ozcan, Aydogan] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA. [Ozcan, Aydogan] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Ozcan, Aydogan] Univ Calif Los Angeles, Dept Elect Engn, Los Angeles, CA 90024 USA. [Sacks, Leonard] US FDA, Silver Spring, MD USA. [Wang, Pei] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Munos, B (reprint author), Milken Inst, FasterCures, Washington, DC 20005 USA. EM annals@nyas.org RI Emchi, Karma/Q-1952-2016 NR 40 TC 1 Z9 1 U1 10 U2 15 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1375 BP 3 EP 18 DI 10.1111/nyas.13117 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BF5HR UT WOS:000382005200001 PM 27384501 ER PT J AU Zorick, T Smith, J AF Zorick, Todd Smith, Jason TI Generalized Information Equilibrium Approaches to EEG Sleep Stage Discrimination SO Computational and Mathematical Methods in Medicine LA English DT Article ID FUNCTIONAL-STATE; BRAIN AB Recent advances in neuroscience have raised the hypothesis that the underlying pattern of neuronal activation which results in electroencephalography (EEG) signals is via power-law distributed neuronal avalanches, while EEG signals are nonstationary. Therefore, spectral analysis of EEG may miss many properties inherent in such signals. A complete understanding of such dynamical systems requires knowledge of the underlying nonequilibrium thermodynamics. In recent work by Fielitz and Borchardt (2011, 2014), the concept of information equilibrium (IE) in information transfer processes has successfully characterized many different systems far from thermodynamic equilibrium. We utilized a publicly available database of polysomnogram EEG data from fourteen subjects with eight different one-minute tracings of sleep stage 2 and waking and an overlapping set of eleven subjects with eight different one-minute tracings of sleep stage 3. We applied principles of IE to model EEG as a system that transfers (equilibrates) information from the time domain to scalp-recorded voltages. We find that waking consciousness is readily distinguished from sleep stages 2 and 3 by several differences in mean information transfer constants. Principles of IE applied to EEG may therefore prove to be useful in the study of changes in brain function more generally. C1 [Zorick, Todd] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. [Zorick, Todd] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Smith, Jason] Boeing Co, Seattle, WA 98124 USA. RP Zorick, T (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.; Zorick, T (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM tzorick@mednet.ucla.edu FU United States Veterans Administration Career Development Award [I01 BX007080] FX Todd Zorick is supported by a United States Veterans Administration Career Development Award no. I01 BX007080. The authors thank Drs. P. Fielitz and G. Borchardt for helpful discussions and comments on the paper. NR 31 TC 0 Z9 0 U1 2 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1748-670X EI 1748-6718 J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2016 AR 6450126 DI 10.1155/2016/6450126 PG 8 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA DS3PI UT WOS:000380694700001 ER PT J AU Hunnicutt, JL Aaron, SE Embry, AE Cence, B Morgan, P Bowden, MG Gregory, CM AF Hunnicutt, Jennifer L. Aaron, Stacey E. Embry, Aaron E. Cence, Brian Morgan, Patrick Bowden, Mark G. Gregory, Chris M. TI The Effects of POWER Training in Young and Older Adults after Stroke SO Stroke Research and Treatment LA English DT Article ID GAIT SPEED; PHYSICAL PERFORMANCE; LEG POWER; REHABILITATION; RELIABILITY; POSTSTROKE; MOBILITY; TORQUE AB Background. Approximately 35,000 strokes occur annually in adults below the age of 40, and there is disappointingly little data describing their responses to rehabilitation. The purpose of this analysis was to determine the effects of Poststroke Optimization of Walking using Explosive Resistance (POWER) training in young (<40 years) and older (>60 years) adults and to describe relationships between training-induced improvements in muscular and locomotor function. Methods. Data was analyzed from 16 individuals with chronic stroke who participated in 24 sessions of POWER training. Outcomes included muscle power generation, self-selected walking speed (SSWS), 6-minute walk test, Fugl-Meyer motor assessment, Berg Balance Scale, and Dynamic Gait Index. Results. There were no significant differences between groups at baseline. Within-group comparisons revealed significant improvements in paretic and nonparetic knee extensor muscle power generation in both groups. Additionally, young participants significantly improved SSWS. Improvements in SSWS were more strongly associated with improvements in power generation on both sides in young versus older participants. Conclusions. Younger adults after stroke seem to preferentially benefit from POWER training, particularly when increasing gait speed is a rehabilitation goal. Future research should aim to further understand age-related differences in response to training to provide optimal treatments for all individuals following stroke. C1 [Hunnicutt, Jennifer L.; Aaron, Stacey E.; Embry, Aaron E.; Cence, Brian; Morgan, Patrick; Bowden, Mark G.; Gregory, Chris M.] Med Univ South Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. [Embry, Aaron E.; Bowden, Mark G.; Gregory, Chris M.] Med Univ South Carolina, Coll Hlth Profess, Div Phys Therapy, 151-B Rutledge Ave,MSC 962, Charleston, SC 29425 USA. [Embry, Aaron E.; Cence, Brian; Bowden, Mark G.; Gregory, Chris M.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. RP Hunnicutt, JL (reprint author), Med Univ South Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM hunnicuj@musc.edu NR 19 TC 0 Z9 0 U1 3 U2 3 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-8105 EI 2042-0056 J9 STROKE RES TREAT JI Stroke Res. Treat. PY 2016 AR 7316250 DI 10.1155/2016/7316250 PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DT0EV UT WOS:000381156800001 ER PT J AU Britton, PC Kopacz, MS Stephens, B Bossarte, RM AF Britton, Peter C. Kopacz, Marek S. Stephens, Brady Bossarte, Robert M. TI Veterans Crisis Line Callers With and Without Prior VHA Service Use SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE suicide; telephone counseling; veterans ID SUICIDE-PREVENTION; HEALTH; RISK AB This study examines differences between Veterans with and without prior Veterans Health Administration service use who received a clinical referral from the Veterans' Crisis Line. Differences between groups were identified using data taken from 13,444 calls and medical records. Approximately 91% of Veterans had a history of service use and 9% did not. Callers with prior service use were older, had more mental health disorders, made in-person contact more quickly, and used more outpatient mental healthcare. Those without prior service use were younger, had more mental health problems, and presented for care later. Callers with suicide-related diagnoses had high rates of service contact. These groups represent different subpopulations with unique healthcare needs and practices. C1 [Britton, Peter C.; Kopacz, Marek S.; Stephens, Brady] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Britton, Peter C.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY USA. [Bossarte, Robert M.] US Dept Vet Affairs, Postdeployment Hlth Serv, Washington, DC USA. RP Britton, PC (reprint author), Canandaigua VA Med Ctr, Ctr Excellence Suicide Prevent, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM peter.britton@va.gov FU Department of Veterans Affairs Office of Research Development, Clinical Science Research and Development (CSRD) [IK2CX000641] FX This paper was funded in part by a Career Development Award (IK2CX000641) from the Department of Veterans Affairs Office of Research Development, Clinical Science Research and Development (CSR&D). NR 17 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1381-1118 EI 1543-6136 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2016 VL 20 IS 3 BP 314 EP 322 DI 10.1080/13811118.2015.1017681 PG 9 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DR2KY UT WOS:000379734600002 PM 26649615 ER PT J AU El Gaamouch, F Jing, P Xia, JH Cai, DM AF El Gaamouch, Farida Jing, Ping Xia, Jiahong Cai, Dongming TI Alzheimer's Disease Risk Genes and Lipid Regulators SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; apolipoproteins; lipids; amyloid; cholesterol; phospholipids ID AMYLOID-BETA-PEPTIDE; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; CELLULAR CHOLESTEROL EFFLUX; MILD COGNITIVE IMPAIRMENT; ISOFORM-SPECIFIC BINDING; CENTRAL-NERVOUS-SYSTEM; PEROXIDATION IN-VIVO; BLOOD-BRAIN-BARRIER; A-BETA AB Brain lipid homeostasis plays an important role in Alzheimer's disease (AD) and other neurodegenerative disorders. Aggregation of amyloid-beta peptide is one of the major events in AD. The complex interplay between lipids and amyloid-beta accumulation has been intensively investigated. The proportions of lipid components including phospholipids, sphingolipids, and cholesterol are roughly similar across different brain regions under physiological conditions. However, disruption of brain lipid homeostasis has been described in AD and implicated in disease pathogenesis. Moreover, studies suggest that analysis of lipid composition in plasma and cerebrospinal fluid could improve our understanding of the disease development and progression, which could potentially serve as disease biomarkers and prognostic indicators for AD therapies. Here, we summarize the functional roles of AD risk genes and lipid regulators that modulate brain lipid homeostasis including different lipid species, lipid complexes, and lipid transporters, particularly their effects on amyloid processing, clearance, and aggregation, as well as neuro-toxicities that contribute to AD pathogenesis. C1 [El Gaamouch, Farida; Cai, Dongming] James J Peters VA Med Ctr, Res & Dev, Bronx, NY USA. [El Gaamouch, Farida; Cai, Dongming] Icahn Sch Med Mt Sinai, Dept Neurol, Alzheimer Dis Res Ctr, New York, NY 10029 USA. [Jing, Ping; Xia, Jiahong; Cai, Dongming] Cent Hosp Wuhan, Wuhan, Peoples R China. RP Cai, DM (reprint author), 130W Kings Bridge Rd, Bronx, NY 10468 USA. EM dongming.cai@mssm.edu OI Cai, Dongming/0000-0002-0601-6826 FU Alzheimer's Association [NIRP14-304720]; Department of Veteran Affairs RRDSPiRE [1I21RX001558-01A1]; NIH R01 [1R01AG048923-01] FX We thank Dr. Minghao Zhong, Gregory Elder, and Christopher Cardozo for critical reading of the manuscript. This work was supported in whole or in part, by funding from the Alzheimer's Association (NIRP14-304720), Department of Veteran Affairs RR&DSPiRE (1I21RX001558-01A1), and NIH R01 (1R01AG048923-01) for DC. NR 195 TC 1 Z9 1 U1 5 U2 9 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 1 BP 15 EP 29 DI 10.3233/JAD-160169 PG 15 WC Neurosciences SC Neurosciences & Neurology GA DR2NW UT WOS:000379742200002 PM 27128373 ER PT J AU Neugroschl, J Sewell, M De La Fuente, A Umpierre, M Luo, XD Sano, M AF Neugroschl, Judith Sewell, Margaret De La Fuente, Angelica Umpierre, Mari Luo, Xiaodong Sano, Mary TI Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Attitude; dementia; elderly; memory; minority; research ID ALZHEIMER-DISEASE; RESEARCH PARTICIPATION; BIOMEDICAL-RESEARCH; AFRICAN-AMERICANS; WILLINGNESS; LATINOS; PEOPLE; RISK AB In dementia trials, minority participation is low. We assessed attitudes toward research in a community based urban poor minority sample of elderly adults attending senior center talks using the 7-item Research Attitudes Questionnaire (RAQ). Presentations on cognitive aging were given at senior centers, and 123 attendees completed the RAQ-7. On trust and safety questions, a significant minority (42-48%) responded neutrally or negatively. Encouragingly, on questions concerning the importance of research, 72-81% answered positively. More work can be done to capitalize on these findings to engage and foster trust, and this can be a focus of outreach. C1 [Neugroschl, Judith; Sewell, Margaret; De La Fuente, Angelica; Umpierre, Mari; Luo, Xiaodong; Sano, Mary] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA. [De La Fuente, Angelica] Yeshiva Univ, Ferkauf Grad Sch, Bronx, NY USA. RP Neugroschl, J (reprint author), Mt Sinai Dept Psychiat, 1 Gustave Levy Pl Box 1230, New York, NY 10029 USA. EM Judith.neugroschl@mssm.edu FU Ichan School of Medicine, The Alzheimer's Disease Research Center (ADRC) [U01 P50 AG005138]; New York State Alzheimer's Disease Assistance Center at Mount Sinai (ADAC) [C020360] FX This work was supported by the Ichan School of Medicine, The Alzheimer's Disease Research Center (ADRC: U01 P50 AG005138) and the New York State Alzheimer's Disease Assistance Center at Mount Sinai (ADAC: C020360). NR 14 TC 0 Z9 0 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 1 BP 69 EP 72 DI 10.3233/JAD-151072 PG 4 WC Neurosciences SC Neurosciences & Neurology GA DR2NW UT WOS:000379742200005 PM 27128368 ER PT J AU Paholpak, P Li-Jung, L Carr, DR Jimenez, E Barrows, RJ Sabodash, V Mendez, MF AF Paholpak, Pongsatorn Li-Jung, Liang Carr, Drew R. Jimenez, Elvira Barrows, Robin J. Sabodash, Valeiry Mendez, Mario F. TI Prolonged Visual Facial Grasp in Frontotemporal Dementia SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; eye movements; frontotemporal dementia; social behavior ID LOBAR DEGENERATION; ALZHEIMERS-DISEASE; BEHAVIORAL-VARIANT; SEMANTIC DEMENTIA; GAZE; RECOGNITION; DYSFUNCTION; CRITERIA; EMOTION; ATROPHY AB Background: Gaze and eye contact is a critical aspect of social interaction. Patients with behavioral variant frontotemporal dementia (bvFTD) may exhibit abnormally prolonged stare toward human faces. Objective: To study characteristics of social gaze in patients with bvFTD compared to age and education matched-patients with early-onset Alzheimer's disease (eAD) and healthy controls (HC). Method: Fifty picture stimuli were presented to each participant (bvFTD = 12, eAD = 18, HC=13). Each stimuli contained two properties: face (facial versus non-facial) and valence (positive, negative, and neutral). The "facial" stimuli contained human faces. The participants Visual Fixation Time (VFT) was measured for each picture stimuli of interest (per facial expressions on the Facial Action Coding System). A linear mixed-effects regression model with participant-level of random effects was used to compare VFTs between groups. Results: The patients with bvFTD showed significantly prolonged VFTs to faces than the patients with eAD and the HC, regardless of valence (all p < 0.01). There were no differences in VFTs for non-facial stimuli between patients with bvFTD and eAD. However, patients with bvFTD and eAD had significantly prolonged VFTs to negative non-facial stimuli than the HC (p = 0.006 and 0.019, respectively). Conclusion: Patients with bvFTD exhibited a prolonged stare toward human faces. This prolonged visual facial grasp may contribute to the disturbed social interactions of patients with bvFTD and can help distinguish them from those with Alzheimer's disease and other conditions. Additionally, both dementia groups tended to stare at negative stimuli whether faces or non-faces. C1 [Paholpak, Pongsatorn; Carr, Drew R.; Jimenez, Elvira; Barrows, Robin J.; Sabodash, Valeiry; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Li-Jung, Liang; Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Barrows, Robin J.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Dept Psychiat, Khon Kaen, Thailand. RP Paholpak, P (reprint author), West Angeles Los VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ppaholpak@yahoo.com FU National Institute on Aging (NIA) [5R01AG034499-05]; VA GRECC Advanced Fellowship in Geriatrics FX This work was performed at the Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 and at Greater Los Angeles VA Healthcare System, West Los Angeles, CA 90073. It was supported by grant 5R01AG034499-05 from the National Institute on Aging (NIA). A.R. Carr is funded by the VA GRECC Advanced Fellowship in Geriatrics. NR 29 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 1 BP 327 EP 335 DI 10.3233/JAD-150864 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DR2NW UT WOS:000379742200028 PM 27163801 ER PT J AU Singh, T Prasad, R Katiyar, SK AF Singh, Tripti Prasad, Ram Katiyar, Santosh K. TI Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression SO AMERICAN JOURNAL OF CANCER RESEARCH LA English DT Article DE Silymarin; non-small cell lung cancer cells; cancer cell migration; HDACs; miR-203; E-cadherin; ZEB1 transcription factor ID HISTONE DEACETYLASE INHIBITORS; DOWN-REGULATION; CYCLE ARREST; IN-VIVO; MICRORNAS; ANGIOGENESIS; PROMOTES; INVASION; STEMNESS; PROGRESS AB Lung cancer and its metastasis is the leading cause of cancer-related mortality world-wide. Non-small cell lung cancer (NSCLC) accounts for about 90% of total lung cancer cases. Despite advancements in therapeutic approaches, only limited improvement has been achieved. Therefore, alternative strategies are required for the management of lung cancer. Here we report the chemotherapeutic effect of silymarin, a phytochemical from milk thistle plant (Silybum marianum L. Gaertn.), on NSCLC cell migration using metastatic human NSCLC cell lines (A549, H1299 and H460) together with the molecular targets underlying these effects. Using an in vitro cell migration assay, we found that treatment of human NSCLC cells (A549, H1299 and H460) with silymarin (0, 5, 10 and 20 mu g/mL) for 24 h resulted in concentration-dependent inhibition of cell migration, which was associated with the inhibition of histone deacetylase (HDAC) activity and reduced levels of class 1 HDAC proteins (HDAC1, HDAC2, HDAC3 and HDAC8) and concomitant increases in the levels of histone acetyltransferase activity (HAT). Known HDAC inhibitors (sodium butyrate and trichostatin A) exhibited similar patterns of therapeutic effects on the lung cancer cells. Treatment of A549 and H460 cells with silymarin reduced the expression of the transcription factor ZEB1 and restored expression of E-cadherin. The siRNA knockdown of ZEB1 also reduced the expression of HDAC proteins and enhanced re-expression of the levels of E-cadherin in NSCLC cells. MicroRNA-203 (miR-203) acts as a tumor suppressor, regulates tumor cell invasion and is repressed by ZEB1 in cancer cells. Silymarin treatment restored the levels of miR-203 in NSCLC cells. These findings indicate that silymarin can effectively inhibit lung cancer cell migration and provide a coherent model of its mechanism of action suggesting that silymarin may be an important therapeutic option for the prevention or treatment of lung cancer metastasis when administered either alone or with standard cancer therapeutic drugs. C1 [Singh, Tripti; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award [1IO1 BX001410] FX This work was financially supported by the Veterans Administration Merit Review Award (1IO1 BX001410) to S.K.K. The funding agency had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 0 Z9 0 U1 0 U2 0 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2156-6976 J9 AM J CANCER RES JI Am. J. Cancer Res. PY 2016 VL 6 IS 6 BP 1287 EP 1301 PG 15 WC Oncology SC Oncology GA DQ8GX UT WOS:000379448200007 PM 27429844 ER PT J AU Goldstein, G He, JB Ruthven, L Walker, J AF Goldstein, Gerald He, Jibo Ruthven, Leslie Walker, Jon TI An introduction to the Ruthven Impairment Assessment (RIA): A stability study SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE Assessment; computerized testing; test reliability ID HIGH-ALTITUDE; DYSFUNCTION; BATTERY AB The Ruthven Impairment Assessment (RIA) is introduced as a new neurocognitive test for the evaluation of complex attentional, reasoning, and working-memory abilities. It contains 5 subtests and is administered by computer within 15min. The subtests include measures of simple and complex attention, working memory, sequential reasoning, and problem-solving abilities. A clock is presented on the computer screen and the participant is instructed to use the space bar or a mouse to respond to the test items. Scores include reaction time and accuracy measures. The present study evaluates the stability of the RIA in healthy, normal individuals by repeating the procedure 3 times and comparing performance with analyses of variance (ANOVAs). The ANOVA results with 1 exception were nonsignificant, indicating that the RIA scores are stable in normal individuals and do not fluctuate significantly across testing. C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Univ Dr, Pittsburgh, PA 15240 USA. [He, Jibo] Wichita State Univ, Dept Psychol, Wichita, KS 67208 USA. [Ruthven, Leslie] Preferred Mental Management Inc, Wichita, KS USA. [Walker, Jon] VA Pittsburgh Healthcare Syst, Res Serv, Pittsburgh, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Univ Dr, Pittsburgh, PA 15240 USA. EM ggold@nb.net OI He, Jibo/0000-0002-5110-581X FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; VISN 4 Mental Illness Research, Education, and Clinical Center, VA Pittsburgh Healthcare System FX This article is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The project was funded by infrastructure support funding from the VISN 4 Mental Illness Research, Education, and Clinical Center (Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. NR 16 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PY 2016 VL 23 IS 4 BP 302 EP 308 DI 10.1080/23279095.2015.1079715 PG 7 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA DQ7XA UT WOS:000379420300007 PM 26943004 ER PT J AU Xin, SJ Ye, L Man, G Lv, CZ Elias, PM Man, MQ AF Xin, Shujun Ye, Li Man, George Lv, Chengzhi Elias, Peter M. Man, Mao-Qiang TI Heavy Cigarette Smokers in a Chinese Population Display a Compromised Permeability Barrier SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; PROINFLAMMATORY CYTOKINE RELEASE; STRATUM-CORNEUM HYDRATION; ALVEOLAR EPITHELIAL-CELLS; ATOPIC-DERMATITIS; SKIN BARRIER; HUMAN KERATINOCYTES; HIP FRACTURE; ALLERGIC SENSITIZATION; EPIDERMAL BARRIER AB Cigarette smoking is associated with various cutaneous disorders with defective permeability. Yet, whether cigarette smoking influences epidermal permeability barrier function is largely unknown. Here, we measured skin biophysical properties, including permeability barrier homeostasis, stratum corneum (SC) integrity, SC hydration, skin surface pH, and skin melanin/erythema index, in cigarette smokers. A total of 99 male volunteers were enrolled in this study. Smokers were categorized as light-to-moderate (<20 cigarettes/day) or heavy smokers (>= 20 cigarettes/day). An MPA5 was used to measure SC hydration and skin melanin/erythema index on the dorsal hand, forehead, and cheek. Basal transepidermal water loss (TEWL) and barrier recovery rates were assessed on the forearm. A Skin-pH-Meter pH900 was used to measure skin surface pH. Our results showed that heavy cigarette smokers exhibited delayed barrier recovery after acute abrogation (1.02% +/- 13.06 versus 16.48% +/- 6.07), and barrier recovery rates correlated negatively with the number of daily cigarettes consumption (p = 0.0087). Changes in biophysical parameters in cigarette smokers varied with body sites. In conclusion, heavy cigarette smokers display compromised permeability barrier homeostasis, which could contribute, in part, to the increased prevalence of certain cutaneous disorders characterized by defective permeability. Thus, improving epidermal permeability barrier should be considered for heavy cigarette smokers. C1 [Xin, Shujun; Ye, Li; Lv, Chengzhi] Dalian Skin Dis Hosp, Dalian 116021, Liaoning, Peoples R China. [Man, George; Elias, Peter M.; Man, Mao-Qiang] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA. [Man, George; Elias, Peter M.; Man, Mao-Qiang] Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Lv, CZ (reprint author), Dalian Skin Dis Hosp, Dalian 116021, Liaoning, Peoples R China.; Man, MQ (reprint author), San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA.; Man, MQ (reprint author), Univ Calif San Francisco, San Francisco, CA 94121 USA. EM dlpfb@126.com; mqman@hotmail.com NR 74 TC 1 Z9 1 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 9704598 DI 10.1155/2016/9704598 PG 7 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA DR2VO UT WOS:000379762200001 ER PT J AU Wu, XH Burivong, W Ma, DQ Edelman, JD Richardson, ML Chen, H Stern, EJ AF Wu, Xiaohua Burivong, Wanaporn Ma, Daqing Edelman, Jeffrey D. Richardson, Michael L. Chen, Hui Stern, Eric J. TI CT findings of native lung after single lung transplantation in patients with idiopathic pulmonary fibrosis: long-term outcomes SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE LA English DT Article DE Lung transplant; idiopathic interstitial pneumonia; usual interstitial pneumonia; computed tomography; progression ID USUAL INTERSTITIAL PNEUMONIA; RESOLUTION COMPUTED-TOMOGRAPHY; THIN-SECTION CT; SERIAL EVALUATION; PROGRESSION; DIAGNOSIS; PROGNOSIS AB To evaluate the progression of native lung fibrosis on thin-section computed tomography (CT) scans from patients with IPF after SLT, we retrospectively studied thin-section CT findings of the patients who survived more than 3 years. Three radiologists independently reviewed serial CT images from 12 patients who underwent SLT for IPF. Initial CT scans were performed up to 7 months before SLT or <= 12 months after SLT, and follow-up CT scan were performed >36 months after SLT. CT measurements of the total lung volume were performed on native lungs. CT scores were evaluated for native lung findings for each thin-section CT, including the fibrosis score (FS), ground-glass opacity score (GGS), and traction bronchiectasis score (TBS). Twelve patients survived 43-110 months after SLT. In the native lung, the FS and TBS values were positively correlated with time. Rates of increase in the FS and TBS values were 0.300/year and 0.147/year, respectively. The GGS showed a slight negative correlation with the lung volume from the CT reconstruction. Rates of decrease of the GGS and lung volume measurements were 0.307/year and 5.47%/year, respectively. The results show that despite more powerful immunosuppression, fibrosis of native lung continues to progress in patients who receive SLT for IPF. C1 [Wu, Xiaohua; Ma, Daqing] Capital Med Univ, Beijing Friendship Hosp, Dept Radiol, Beijing 100050, Peoples R China. [Wu, Xiaohua; Burivong, Wanaporn; Stern, Eric J.] Univ Washington, Dept Radiol, Seattle, WA 98105 USA. [Burivong, Wanaporn] Srinakharinwirot Univ, Dept Radiol, HRH Princess Maha Chakri Sirindhorn Med Ctr, Fac Med, Nakorn Nayok 26120, Thailand. [Edelman, Jeffrey D.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Richardson, Michael L.] Univ Washington, Dept Radiol, UW Roosevelt Radiol, Seattle, WA 98105 USA. [Chen, Hui] Capital Med Univ, Sch Biomed Engn, Beijing 100060, Peoples R China. RP Ma, DQ (reprint author), Capital Med Univ, Beijing Friendship Hosp, Dept Radiol, Beijing 100050, Peoples R China.; Stern, EJ (reprint author), Univ Washington, Dept Radiol, Seattle, WA 98105 USA. EM madaqing@vip.163.com; estern@uw.edu NR 21 TC 0 Z9 0 U1 1 U2 1 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1940-5901 J9 INT J CLIN EXP MED JI Int. J. Clin. Exp. Med. PY 2016 VL 9 IS 6 BP 9087 EP 9093 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DQ4EF UT WOS:000379156000023 ER PT J AU Abroms, M Sher, L AF Abroms, Mark Sher, Leo TI Dual Disorders and Suicide SO JOURNAL OF DUAL DIAGNOSIS LA English DT Letter ID DEPENDENCE C1 [Abroms, Mark] Mt Sinai St Lukes Roosevelt Hosp Ctr, 1090 Amsterdam Ave, New York, NY 10027 USA. [Abroms, Mark; Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. RP Abroms, M (reprint author), Mt Sinai St Lukes Roosevelt Hosp Ctr, 1090 Amsterdam Ave, New York, NY 10027 USA. EM maabroms@chpnet.org NR 10 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1550-4263 EI 1550-4271 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2016 VL 12 IS 2 BP 148 EP 149 DI 10.1080/15504263.2016.1172898 PG 2 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA DR0QW UT WOS:000379613000006 PM 27064735 ER PT J AU McCaskill, GM Bolland, KA Burgio, KL Leeper, J AF McCaskill, Gina M. Bolland, Kathleen A. Burgio, Kathryn L. Leeper, James TI Development and validation of a diabetes self-management instrument for older African-Americans SO SOCIAL WORK IN HEALTH CARE LA English DT Article DE Diabetes self-management; instrument validation; older African-Americans ID QUALITY-OF-LIFE; HEALTH LITERACY; CARE PROFILE; ADULTS; SCALE; ASSOCIATION; DISPARITIES; WOMEN; DISTRESS; EFFICACY AB The objective of this study was to develop and validate a new diabetes self-management instrument for older African-Americans 65 years of age and older. The Self-Care Utility Geriatric African-American Rating (SUGAAR) was developed using the American Diabetes Association's standards for the management of type 2 diabetes in older adults and cognitive interviews with older African-Americans. The instrument underwent extensive review by a panel of experts, two rounds of cognitive interviews, and a pilot test before it was administered in an interview format to 125 community-dwelling older African-Americans. The instrument demonstrated content validity and significant, but modest, convergent validity with items from an established diabetes self-management instrument. Social workers and health care professionals can use the SUGARR to assess diabetes self-management and to identify areas for education and support for older African-Americans with type 2 diabetes. C1 [McCaskill, Gina M.; Burgio, Kathryn L.] US Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Birmingham, AL USA. [McCaskill, Gina M.; Burgio, Kathryn L.] Univ Alabama Birmingham, Sch Med, Comprehens Ctr Hlth Aging, Birmingham, AL USA. [Bolland, Kathleen A.] Univ Alabama, Sch Social Work, Tuscaloosa, AL USA. [Leeper, James] Univ Alabama, Dept Community & Rural Med, Tuscaloosa, AL USA. RP McCaskill, GM (reprint author), Birmingham VAMC, 700 S 19th St, Birmingham, AL 35233 USA. EM gina.mccaskill@va.gov FU John A. Hartford Foundation Geriatric Social Work Initiative; Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Department of Veterans Affairs, Birmingham VA Medical Center, Birmingham, Alabama FX This work was supported by a dissertation award from the John A. Hartford Foundation Geriatric Social Work Initiative and the Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Department of Veterans Affairs, Birmingham VA Medical Center, Birmingham, Alabama. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Veterans Affairs. NR 48 TC 0 Z9 0 U1 5 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0098-1389 EI 1541-034X J9 SOC WORK HEALTH CARE JI Soc. Work Health Care PY 2016 VL 55 IS 5 BP 381 EP 394 DI 10.1080/00981389.2015.1129012 PG 14 WC Social Work SC Social Work GA DR1VW UT WOS:000379694000003 PM 27045578 ER PT J AU Gordon, AJ AF Gordon, Adam J. TI Integrating policy and research into addiction practice, AMERSA abstracts, and an appreciation to our reviewers SO SUBSTANCE ABUSE LA English DT Editorial Material ID ADOLESCENT SUBSTANCE USE C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Treatment Res & Educ Addict Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151-C Univ Dr C, Pittsburgh, PA 15215 USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151-C Univ Dr C, Pittsburgh, PA 15215 USA. EM gordona@medschool.pitt.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 2 BP 271 EP 275 DI 10.1080/08897077.2016.1170091 PG 5 WC Substance Abuse SC Substance Abuse GA DR1WH UT WOS:000379695100001 PM 27168047 ER PT J AU Kaminer, Y Gordon, AJ AF Kaminer, Yifrah Gordon, Adam J. TI The blind side of addiction: A call for increased awareness of developmentally informed youth addiction scholarship SO SUBSTANCE ABUSE LA English DT Editorial Material ID SUBSTANCE USE DISORDERS; CANNABIS USE; BRIEF INTERVENTION; NATIONAL-SURVEY; CURRICULUM; RESIDENTS; EDUCATION C1 [Kaminer, Yifrah] Univ Connecticut, Ctr Hlth, Dept Psychiat, Alcohol Res Ctr, Farmington, CT 06032 USA. [Kaminer, Yifrah] Univ Connecticut, Ctr Hlth, Dept Pediat, Alcohol Res Ctr, Farmington, CT USA. [Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. RP Kaminer, Y (reprint author), Univ Connecticut, Sch Med, Farmington, CT 06030 USA. EM kaminer@uchc.edu NR 16 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 2 BP 276 EP 277 DI 10.1080/08897077.2016.1167808 PG 2 WC Substance Abuse SC Substance Abuse GA DR1WH UT WOS:000379695100002 PM 27168048 ER PT J AU Margolis, ML AF Margolis, Mitchell L. TI Lung Cancer Screening Kit with LUNG-RADS, Version 3.0 SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Editorial Material C1 [Margolis, Mitchell L.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Pulm Sect, Philadelphia, PA 19104 USA. RP Margolis, ML (reprint author), Philadelphia Vet Affairs Med Ctr, Pulm Sect, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM mitchell.margolis@va.gov NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD JAN PY 2016 VL 13 IS 1 BP 145 EP 145 DI 10.1513/AnnalsATS.201510-720OT PG 1 WC Respiratory System SC Respiratory System GA DQ4DM UT WOS:000379154100029 PM 26730876 ER PT J AU Dimitrov, DH Lee, S Yantis, J Honaker, C Braida, N Walss-Bass, C AF Dimitrov, Dimitre H. Lee, Shuko Yantis, Jesse Honaker, Craig Braida, Nicole Walss-Bass, Consuelo TI ElevatSerumed Levels of High-Sensitivity C-Reactive Proteins Are Associated With Severe Delusional Symptoms in a Subgroup of Patients With Schizophrenia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter ID PSYCHOPATHOLOGY C1 [Dimitrov, Dimitre H.; Lee, Shuko; Yantis, Jesse; Honaker, Craig; Braida, Nicole] South Texas Vet Hlth Care Syst, San Antonio, TX 78228 USA. [Dimitrov, Dimitre H.; Braida, Nicole; Walss-Bass, Consuelo] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Walss-Bass, Consuelo] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Dimitrov, DH (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78228 USA.; Dimitrov, DH (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. EM dimitre.dimitrov@va.gov NR 7 TC 3 Z9 3 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2016 VL 77 IS 1 BP 131 EP U175 DI 10.4088/JCP.15109833 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MU UT WOS:000379250300023 PM 26845270 ER PT J AU Brewer-Smyth, K Pohlig, RT Bucurescu, G AF Brewer-Smyth, Kathleen Pohlig, Ryan T. Bucurescu, Gabriel TI Female children with incarcerated adult family members at risk for lifelong neurological decline SO HEALTH CARE FOR WOMEN INTERNATIONAL LA English DT Article ID TRAUMATIC BRAIN-INJURY; PARENTAL INCARCERATION; CHILDHOOD ABUSE; MENTAL-ILLNESS; SEXUAL-ABUSE; YOUNG-ADULTS; HEALTH; CONSEQUENCES; IMPRISONMENT; EXPERIENCES AB A secondary analysis of data from adult female prison inmates in the mid-Atlantic United States defined relationships between having incarcerated adult family members during childhood and neurological outcomes. Of 135 inmates, 99 (60%) had one or more incarcerated adult family members during childhood. Regression analyses revealed that having incarcerated adult family members was related to greater frequency and severity of childhood abuse and higher incidence of neurological deficits in adulthood, especially related to traumatic brain injuries, compared to those without incarcerated adult family members. Along with being role models, adult family members impact the neurological health of children throughout their life-span. C1 [Brewer-Smyth, Kathleen] Univ Delaware, Sch Nursing, Coll Hlth Sci, McDowell Hall, Newark, DE 19716 USA. [Pohlig, Ryan T.] Univ Delaware, Coll Hlth Sci, Newark, DE 19716 USA. [Bucurescu, Gabriel] US Dept Vet Affairs, Philadelphia, PA USA. RP Brewer-Smyth, K (reprint author), Univ Delaware, Sch Nursing, Coll Hlth Sci, McDowell Hall, Newark, DE 19716 USA. EM kbsmyth@udel.edu FU National Institutes of Health [20RR016472-04, T32NR07036]; Sigma Theta Tau International Honor Society; Rehabilitation Nursing Foundation; Baxter Foundation; University of Delaware General University Research Fund; University of Delaware Research Foundation FX Data collection for this study was funded in part by the National Institutes of Health 20RR016472-04, T32NR07036, Sigma Theta Tau International Honor Society, Rehabilitation Nursing Foundation, The Baxter Foundation, University of Delaware General University Research Fund, and University of Delaware Research Foundation. NR 29 TC 0 Z9 0 U1 3 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0739-9332 EI 1096-4665 J9 HEALTH CARE WOMEN IN JI Health Care Women Int. PY 2016 VL 37 IS 7 BP 802 EP 813 DI 10.1080/07399332.2016.1140768 PG 12 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DP7WO UT WOS:000378710100009 PM 26788781 ER PT J AU Hoscheidt, SM Starks, EJ Oh, JM Zetterberg, H Blennow, K Krause, RA Gleason, CE Puglielli, L Atwood, CS Carlsson, CM Asthana, S Johnson, SC Bendlin, BB AF Hoscheidt, Siobhan M. Starks, Erika J. Oh, Jennifer M. Zetterberg, Henrik Blennow, Kaj Krause, Rachel A. Gleason, Carey E. Puglielli, Luigi Atwood, Craig S. Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Bendlin, Barbara B. TI Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE APOE epsilon 4; CSF AD biomarkers; insulin resistance; memory function ID AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; CENTRAL-NERVOUS-SYSTEM; LATE-ONSET ALZHEIMERS; GRAY-MATTER VOLUME; SYNAPTIC PLASTICITY; FAMILY-HISTORY; DIABETES-MELLITUS; DEGRADING ENZYME AB Background: Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. Objective: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOE epsilon 4 carriage would be associated with greater CSF AD pathology and poor memory performance. Methods: Cognitively asymptomatic middle-aged adults (N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-beta protein precursor beta (sA beta PP beta), amyloid-beta 42 (A beta(42)), and phosphorylated tau (P-tau(181)) were examined with respect to HOMA-IR and APOE epsilon 4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOE epsilon 4 status. Results: Higher HOMA-IR was associated with higher sA beta PP beta and A beta(42). APOE epsilon 4 carriers had significantly higher levels of sA beta PP beta, sA beta PP beta, and P-tau(181)/A beta(42) compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. Conclusion: Overall, the findings suggest that IR and APOE epsilon 4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD. C1 [Hoscheidt, Siobhan M.; Starks, Erika J.; Oh, Jennifer M.; Krause, Rachel A.; Gleason, Carey E.; Puglielli, Luigi; Atwood, Craig S.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Gothenburg, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England. [Gleason, Carey E.; Puglielli, Luigi; Atwood, Craig S.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Ctr Clin Sci, J5-1M,600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu FU NIH [P50 AG033514]; University of Wisconsin Institute for Clinical and Translational Research through National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award [1UL1RR025011]; National Center for Research Resources; United States National Institutes of Health; Swedish Research Council; Swedish Brain Foundation; Torsten Soderberg's Foundation FX This research was supported by NIH grant P50 AG033514, University of Wisconsin Institute for Clinical and Translational Research, funded through a National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award, 1UL1RR025011, a program of the National Center for Research Resources, United States National Institutes of Health, the Swedish Research Council, the Swedish Brain Foundation, and Torsten Soderberg's Foundation to the University of Gothenburg. We want to thank the MRI staff at the Wisconsin Institute for Medical Research, Chuck Illingworth, the staff at the Wisconsin ADRC, and, above all, our dedicated participants. NR 79 TC 1 Z9 1 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 52 IS 4 BP 1373 EP 1383 DI 10.3233/JAD-160110 PG 11 WC Neurosciences SC Neurosciences & Neurology GA DP9BQ UT WOS:000378792100019 PM 27079723 ER PT J AU Li, XY Xu, Z Bai, JP Yang, SY Zhao, SL Zhang, YJ Chen, XD Wang, YM AF Li, Xiuying Xu, Zhuo Bai, Jinping Yang, Shuyuan Zhao, Shuli Zhang, Yingjie Chen, Xiaodong Wang, Yimin TI Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Induce T Lymphocyte Apoptosis and Cell Cycle Arrest by Expression of Indoleamine 2, 3-Dioxygenase SO STEM CELLS INTERNATIONAL LA English DT Article ID BONE-MARROW; IMMUNOSUPPRESSIVE PROPERTIES; DEPENDENT KINASES; STROMAL CELLS; IFN-GAMMA; DIFFERENTIATION; PROLIFERATION; INHIBITION; MOLECULES; PLACENTA AB It has been reported that human mesenchymal stem cells are able to inhibit T lymphocyte activation; however, the discrepancy among different sources of MSCs is not well documented. In this study, we have compared the MSCs from bone marrow (BM), adipose tissue (AT), placenta (PL), and umbilical cord (UC) to determine which one displayed the most efficient immunosuppressive effects on phytohemagglutinin-induced T cell proliferation. Among them we found that hUC-MSC has the strongest effects on inhibiting T cell proliferation and is chosen to do the further study. We observed that T lymphocyte spontaneously released abundant IFN-gamma And IFN-gamma secreted by T lymphocyte could induce the expression of indoleamine 2, 3-dioxygenase (IDO) in hUC-MSCs. IDO was previously reported to induce T lymphocyte apoptosis and cell cycle arrest in S phase. When cocultured with hUC-MSCs, T lymphocyte expression of caspase 3 was significantly increased, while Bcl2 and CDK4mRNA expression decreased dramatically. Addition of 1-methyl tryptophan (1-MT), an IDO inhibitor, restored T lymphocyte proliferation, reduced apoptosis, and induced resumption of the cell cycle. In addition, the changes in caspase 3, CDK4, and Bcl2 expression were reversed by 1-MT. These findings demonstrate that hUC-MSCs induce T lymphocyte apoptosis and cell cycle arrest by expressing abundant IDO and provide an explanation for some of the immunomodulatory effects of MSCs. C1 [Li, Xiuying; Bai, Jinping; Wang, Yimin] Jilin Univ, China Japan Union Hosp, Ctr Sci Res, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China. [Xu, Zhuo] Jilin Univ, China Japan Union Hosp, Rehabil Dept, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China. [Yang, Shuyuan; Zhao, Shuli] Shulanshi Peoples Hosp, Shulan 132600, Jilin, Peoples R China. [Zhang, Yingjie] Eugenom Inc, 11107 Roselle St, San Diego, CA 92121 USA. [Chen, Xiaodong] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Res Serv, San Antonio, TX 78229 USA. [Chen, Xiaodong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Wang, YM (reprint author), Jilin Univ, China Japan Union Hosp, Ctr Sci Res, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China. EM yiminwang@hotmail.com NR 38 TC 2 Z9 2 U1 3 U2 6 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-966X EI 1687-9678 J9 STEM CELLS INT JI Stem Cells Int. PY 2016 AR 7495135 DI 10.1155/2016/7495135 PG 11 WC Cell & Tissue Engineering SC Cell Biology GA DQ2XC UT WOS:000379065900001 ER PT J AU Hanson, AJ Banks, WA Saucedo, HH Craft, S AF Hanson, Angela J. Banks, William A. Saucedo, Hector Hernandez Craft, Suzanne TI Apolipoprotein E Genotype and Sex Influence Glucose Tolerance in Older Adults: A Cross-Sectional Study SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA LA English DT Article DE Apolipoprotein epsilon 4 allele; Glucose intolerance; Alzheimer's disease; Oral glucose tolerance test ID MODERATE ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; E POLYMORPHISM; APOE GENOTYPE; INTRANASAL INSULIN; RISK; METABOLISM; POPULATION; BRAIN; ASSOCIATION AB Background: Glucose intolerance and apolipoprotein epsilon 4 allele (epsilon 4+) are risk factors for Alzheimer's disease (AD). Insulin sensitizers show promise for treating AD, but are less effective in E4+ individuals. Little is known about how the APOE genotype influences glucose metabolism. Methods: Cross-sectional analysis of 319 older adults who underwent oral glucose tolerance tests; a subset had insulin, amyloid beta (A beta(42)), and Mini Mental Status Examination. Glucose and insulin patterns with respect to cognitive diagnosis, E4 status, and sex were examined with analysis of covariance and Pearson correlation. Results: People with cognitive impairment had higher fasting insulin levels. E4 status did not affect fasting glucose values, whereas men had higher fasting glucose levels than women. E4+ men had the lowest and E4+ women had the highest glucose levels, compared to E4-groups; insulin did not differ by sex or E4 group. E4 status and sex moderated correlations between metabolic measures and AD risk factors including age and A beta. Conclusions: Insulin resistance was associated with cognitive impairment, and sex, E4 status, and glucose values are interrelated in older adults at risk of AD. Understanding glucose metabolism for different APOE and sex groups may help elucidate differences in therapeutic responses. (C) 2016 The Author(s) Published by S. Karger AG, Basel C1 [Hanson, Angela J.; Banks, William A.] Univ Washington, Sch Med, Dept Med, 325 9th Ave,POB 359755, Seattle, WA 98104 USA. [Hanson, Angela J.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Saucedo, Hector Hernandez; Craft, Suzanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Winston Salem, NC 27103 USA. RP Hanson, AJ (reprint author), Univ Washington, Med Ctr, Dept Med, 325 9th Ave,POB 359755, Seattle, WA 98104 USA. EM hansonaj@uw.edu FU NIA NIH HHS [T32 AG000258, R01 AG046619] NR 38 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1664-5464 J9 DEMENT GER COGN D EX JI Dement. Geriatr. Cogn. Disord. Extra PY 2016 VL 6 IS 1 BP 78 EP 89 DI 10.1159/000444079 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA DP3VC UT WOS:000378422800008 PM 27065114 ER PT J AU Fogelberg, DJ Hughes, AJ Vitiello, MV Hoffman, JM Amtmann, D AF Fogelberg, Donald J. Hughes, Abbey J. Vitiello, Michael V. Hoffman, Jeanne M. Amtmann, Dagmar TI Comparison of Sleep Problems in Individuals with Spinal Cord Injury and Multiple Sclerosis SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE multiple sclerosis; self-reported health outcomes; sleep; spinal cord injury ID RESTLESS LEGS SYNDROME; DISABILITY STATUS SCALE; QUALITY-OF-LIFE; FATIGUE; PREVALENCE; INSOMNIA; DISTURBANCES; DYSFUNCTION; POPULATION; SYMPTOMS AB Study Objectives: Sleep problems are common in spinal cord injury (SCI) and multiple sclerosis (MS). However, the degree to which sleep problems differ between these distinct clinical populations has not been evaluated. In this study, we examined self-reported sleep problems in individuals with SCI and those with MS, and compared these clinical groups on the Medical Outcomes Study Sleep Scale (MOS-SS). Methods: Participants were 1,677 individuals (SCI = 581; MS = 1,096) enrolled in longitudinal study of self-reported health outcomes in SCI and MS. Univariate and multivariate analysis of covariance examined group differences on global sleep problems and domain-specific subscales of the MOS-SS. Results: Individuals with SCI reported an average of 30 fewer min of sleep per night (Sleep Quantity subscale) and significantly greater difficulty initiating and maintaining sleep (Sleep Disturbance subscale) compared to individuals with MS. However, groups did not differ on global sleep problems (Sleep Problems Index 9). Conclusions: Although global sleep problems are more common in SCI and MS than in the general population, these groups exhibit differing sleep problem profiles, and thus may require unique treatment approaches to address the specific domains of sleep affected. For individuals with SCI, an additional focus on increasing sleep quantity and reducing sleep disruptions may be warranted. C1 [Fogelberg, Donald J.; Hughes, Abbey J.; Hoffman, Jeanne M.; Amtmann, Dagmar] Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA. [Hughes, Abbey J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Vitiello, Michael V.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Fogelberg, DJ (reprint author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA. EM fogelberg@uw.edu FU Department of Education [NIDRR H133B031129, H133B080025]; National Institutes of Health [NIAMS 5U01AR052171, NICHD K01HD076183]; National Multiple Sclerosis Society [MB 0026] FX This was not an industry supported study. The contents of this article were developed under grants from the Department of Education (NIDRR H133B031129 & H133B080025) and the National Institutes of Health (NIAMS 5U01AR052171 and NICHD K01HD076183). The contents of this paper do not represent the view of the National Institutes of Health or the Department of Education. In addition, the work reported in this manuscript was supported by a mentor-based fellowship grant from the National Multiple Sclerosis Society (MB 0026). The authors have indicated no financial conflicts of interest. The research reported in this manuscript was completed at the University of Washington. NR 43 TC 0 Z9 0 U1 2 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 5 BP 695 EP 701 DI 10.5664/jcsm.5798 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DP2QD UT WOS:000378333300012 PM 26857058 ER PT J AU Aurora, RN Bista, SR Casey, KR Chowdhuri, S Kristo, DA Mallea, JM Ramar, K Rowley, JA Zak, RS Heald, JL AF Aurora, R. Nisha Bista, Sabin R. Casey, Kenneth R. Chowdhuri, Susmita Kristo, David A. Mallea, Jorge M. Ramar, Kannan Rowley, James A. Zak, Rochelle S. Heald, Jonathan L. TI Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses" SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE central sleep apnea; adaptive servo-ventilation; clinical practice guideline ID CHRONIC HEART-FAILURE; CHEYNE-STOKES RESPIRATION; POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; SYMPATHETIC-NERVE ACTIVITY; IMPROVES CARDIAC-FUNCTION; AUTO-SERVOVENTILATION; PROGNOSIS; THERAPY AB An update of the 2012 systematic review and meta-analyses were performed and a modified-GRADE approach was used to update the recommendation for the use of adaptive servo-ventilation (ASV) for the treatment of central sleep apnea syndrome (CSAS) related to congestive heart failure (CHF). Meta-analyses demonstrated an improvement in LVEF and a normalization of AHI in all patients. Analyses also demonstrated an increased risk of cardiac mortality in patients with an LVEF of <= 45% and moderate or severe CSA predominant sleep-disordered breathing. These data support a Standard level recommendation against the use of ASV to treat CHF-associated CSAS in patients with an LVEF of <= 45% and moderate or severe CSAS, and an Option level recommendation for the use of ASV in the treatment CHF-associated CSAS in patients with an LVEF > 45% or mild CHF-related CSAS. The application of these recommendations is limited to the target patient populations; the ultimate judgment regarding propriety of any specific care must be made by the clinician. C1 [Aurora, R. Nisha] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Bista, Sabin R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Casey, Kenneth R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Chowdhuri, Susmita] John D Dingell VA Med Ctr, Detroit, MI USA. [Chowdhuri, Susmita] Wayne State Univ, Detroit, MI USA. [Kristo, David A.] Univ Pittsburgh, Pittsburgh, PA USA. [Mallea, Jorge M.] Mayo Clin Florida, Transplant Ctr, Jacksonville, FL USA. [Ramar, Kannan] Mayo Clin, Rochester, MN USA. [Rowley, James A.] Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA. [Zak, Rochelle S.] Univ Calif San Francisco, Sleep Disorders Ctr, San Francisco, CA 94143 USA. [Heald, Jonathan L.] Amer Acad Sleep Med, Darien, IL USA. RP Aurora, RN (reprint author), Johns Hopkins Sleep Disorders Ctr, Johns Hopkins Sch Med, Baltimore, MD USA. EM research@aasmnet.org NR 33 TC 6 Z9 6 U1 3 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 5 BP 757 EP 761 DI 10.5664/jcsm.5812 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA DP2QD UT WOS:000378333300019 PM 27092695 ER PT J AU Singh, JA Hossain, A Ghogomu, ET Kotb, A Christensen, R Mudano, AS Maxwell, LJ Shah, NP Tugwell, P Wells, GA AF Singh, Jasvinder A. Hossain, Alomgir Ghogomu, Elizabeth Tanjong Kotb, Ahmed Christensen, Robin Mudano, Amy S. Maxwell, Lara J. Shah, Nipam P. Tugwell, Peter Wells, George A. TI Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; ANTITUMOR NECROSIS FACTOR; RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ALPHA MONOCLONAL-ANTIBODY; RECEIVING CONCOMITANT METHOTREXATE; CONVENTIONAL COMBINATION TREATMENT; COSTIMULATION MODULATOR ABATACEPT; ADALIMUMAB PLUS METHOTREXATE AB Background This is an update of the 2009 Cochrane overview and network meta-analysis (NMA) of biologics for rheumatoid arthritis (RA). Objectives To assess the benefits and harms of nine biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib, versus comparator(MTX, DMARD, placebo (PL), or a combination) in adults with rheumatoid arthritis who have failed to respond tomethotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs), i.e., MTX/DMARD incomplete responders (MTX/DMARD-IR). Methods We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (via The Cochrane Library Issue 6, June 2015), MEDLINE (via OVID 1946 to June 2015), and EMBASE (via OVID 1947 to June 2015). Data extraction, risk of bias and GRADE assessments were done in duplicate. We calculated both direct estimates using standard meta-analysis and used Bayesian mixed treatment comparisons approach for NMA estimates to calculate odds ratios (OR) and 95% credible intervals (CrI). We converted OR to risk ratios (RR) which are reported in the abstract for the ease of interpretation. Main results This update included 73 new RCTs for a total of 90 RCTs; 79 RCTs with 32,874 participants provided usable data. Few trials were at high risk of bias for blinding of assessors/participants (13% to 21%), selective reporting (4%) or major baseline imbalance (8%); a large number had unclear risk of bias for random sequence generation (68%) or allocation concealment (74%). Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with a statistically significant and clinically meaningful improvement in ACR50 versus comparator (RR 2.71 (95% confidence interval (CI) 2.36 to 3.10); absolute benefit 24% more patients (95% CI 19% to 29%), number needed to treat for an additional beneficial outcome (NNTB) = 5 (4 to 6). NMA estimates for ACR50 in tumor necrosis factor (TNF) biologic+MTX/DMARD (RR 3.23 (95% credible interval (Crl) 2.75 to 3.79), non-TNF biologic+MTX/DMARD (RR 2.99; 95% Crl 2.36 to 3.74), and anakinra + MTX/DMARD (RR 2.37 (95% Crl 1.00 to 4.70) were similar to the direct estimates. Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with a clinically and statistically important improvement in function measured by the Health Assessment Questionnaire (0 to 3 scale, higher = worse function) with a mean difference (MD) based on direct evidence of -0.25 (95% CI -0.28 to -0.22); absolute benefit of -8.3% (95% CI -9.3% to -7.3%), NNTB = 3 (95% CI 2 to 4). NMA estimates for TNF biologic+MTX/DMARD (absolute benefit, -10.3% (95% Crl -14% to -6.7%) and non-TNF biologic+MTX/DMARD (absolute benefit, -7.3% (95% Crl -13.6% to -0.67%) were similar to respective direct estimates. Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with clinically and statistically significantly greater proportion of participants achieving remission in RA (defined by disease activity score DAS < 1.6 or DAS28 < 2.6) versus comparator (RR 2.81 (95% CI, 2.23 to 3.53); absolute benefit 18% more patients (95% CI 12% to 25%), NNTB = 6 (4 to 9)). NMA estimates for TNF biologic+MTX/DMARD (absolute improvement 17% (95% Crl 11% to 23%)) and non-TNF biologic+MTX/DMARD (absolute improvement 19% (95% Crl 12% to 28%) were similar to respective direct estimates. Based on direct evidence of moderate quality (downgraded for inconsistency), radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologics+MTX/DMARDs versus comparator, MD -2.61 (95% CI -4.08 to -1.14). The absolute reduction was small, -0.58% (95% CI -0.91% to -0.25%) and we are unsure of the clinical relevance of this reduction. NMA estimates of TNF biologic+MTX/DMARD (absolute reduction -0.67% (95% Crl -1.4% to -0.12%) and non-TNF biologic+MTX/DMARD (absolute reduction, -0.68% (95% Crl -2.36% to 0.92%)) were similar to respective direct estimates. Based on direct evidence of moderate quality (downgraded for imprecision), results for withdrawals due to adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase in withdrawals, RR 1.11 (95% CI 0.96 to 1.30). The NMA estimates of TNF biologic+MTX/DMARD (RR 1.24 (95% Crl 0.99 to 1.57)) and non-TNF biologic+MTX/DMARD (RR 1.20 (95% Crl 0.87 to 1.67)) were similarly inconclusive and downgraded to low for both imprecision and indirectness. Based on direct evidence of high quality, biologic+MTX/DMARD was associated with clinically significantly increased risk (statistically borderline significant) of serious adverse events on biologic+MTX/DMARD (Peto OR [can be interpreted as RR due to low event rate] 1.12 (95% CI 0.99 to 1.27); absolute risk 1% (0% to 2%), As well, the NMA estimate for TNF biologic+MTX/DMARD (Peto OR 1.20 (95% Crl 1.01 to 1.43)) showed moderate quality evidence of an increase in the risk of serious adverse events. The other two NMA estimates were downgraded to low quality due to imprecision and indirectness and had wide confidence intervals resulting in uncertainty around the estimates: non-TNF biologics+MTX/DMARD: 1.07 (95% Crl 0.89 to 1.29) and anakinra: RR 1.06 (95% Crl 0.65 to 1.75). Based on direct evidence of low quality (downgraded for serious imprecision), results were inconclusive for cancer (Peto OR 1.07 (95% CI 0.68 to 1.68) for all biologic+MTX/DMARD combinations. The NMA estimates of TNF biologic+MTX/DMARD (Peto OR 1.21 (95% Crl 0.63 to 2.38) and non-TNF biologic+MTX/DMARD (Peto OR 0.99 (95% Crl 0.58 to 1.78)) were similarly inconclusive and downgraded to low quality for both imprecision and indirectness. Main results text shows the results for tofacitinib and differences between medications. Authors' conclusions Based primarily on RCTs of 6 months' to 12 months' duration, there is moderate quality evidence that the use of biologic+MTX/DMARD in people with rheumatoid arthritis who have failed to respond to MTX or other DMARDs results in clinically important improvement in function and higher ACR50 and remission rates, and increased risk of serious adverse events than the comparator (MTX/DMARD/PL; high quality evidence). Radiographic progression is slowed but its clinical relevance is uncertain. Results were inconclusive for whether biologics + MTX/DMARDs are associated with an increased risk of cancer or withdrawals due to adverse events. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. [Hossain, Alomgir; Kotb, Ahmed] Univ Ottawa Heart Inst, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada. [Ghogomu, Elizabeth Tanjong] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada. [Christensen, Robin] Copenhagen Univ Hosp, Parker Inst, Musculoskeletal Stat Unit, Copenhagen, Denmark. [Mudano, Amy S.] Univ Alabama Birmingham, Dept Med Rheumatol, Birmingham, AL USA. [Maxwell, Lara J.] Ottawa Hosp, OHRI, CPCR, Gen Campus, Ottawa, ON, Canada. [Shah, Nipam P.] Univ Alabama Birmingham, Dept Clin Immunol & Rheumatol, Birmingham, AL USA. [Tugwell, Peter] Univ Ottawa, Dept Med, Fac Med, Ottawa, ON, Canada. [Wells, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI Tugwell, Peter/0000-0001-5062-0556 NR 257 TC 5 Z9 5 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 5 AR CD012183 DI 10.1002/14651858.CD012183 PG 75 WC Medicine, General & Internal SC General & Internal Medicine GA DO7KQ UT WOS:000377961800124 PM 27175934 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Inverse Association Between Helicobacter pylori Gastritis and Microscopic Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE demographic characteristics; environmental epidemiology; socioeconomic risk factors; ZIP codes ID INFLAMMATORY-BOWEL-DISEASE; ESOPHAGEAL EOSINOPHILIA; PATHOLOGY DATABASE; NEGATIVE GASTRITIS; INFECTION; RISK; PREVALENCE; POLYPS; COLON AB Background: Inflammatory bowel disease is known to be inversely associated with Helicobacter pylori infection of the upper gastrointestinal tract. We hypothesized that a similar inverse association also applied to microscopic colitis. Methods: The associations between microscopic colitis and presence of H. pylori-positive chronic active gastritis (CAG), H. pylori-negative CAG, intestinal metaplasia, or gastric atrophy were expressed as odds ratios with their 95% confidence intervals. Multivariate logistic regression analyses were used to adjust these associations for sex, age, percentage residents per ZIP code with white, black, Hispanic, or Asian ethnicity, percentage with college education, average housing values, annual income, and population size of individual ZIP codes. Results: H. pylori-positive CAG was less common among patients with than without microscopic colitis (odds ratio = 0.61; 95% confidence interval, 0.52-0.70). Intestinal metaplasia also occurred less frequently among patients with than without microscopic colitis (0.75, 0.65-0.86). These inverse associations remained unaffected by adjustments for parameters of ethnicity and socioeconomic status. In contradistinction with H. pylori-positive CAG, H. pylori-negative CAG was more common in patients with than without microscopic colitis (1.54, 1.17-1.97). Conclusions: H. pylori infection and microscopic colitis are inversely associated. This observation is consistent with similar inverse associations found between H. pylori and inflammatory bowel disease. These relationships may provide clues about the yet unknown etiology of microscopic colitis. C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 22 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2016 VL 22 IS 1 BP 182 EP 186 DI 10.1097/MIB.0000000000000595 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO3ZR UT WOS:000377721800025 PM 26383914 ER PT J AU Luckianow, GM Smith, D Bullen, D Kaplan, LJ AF Luckianow, Gina M. Smith, David Bullen, David Kaplan, Lewis J. TI Understanding percutaneous and subcutaneous central venous access devices SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Review DE central venous access devices; catheters; percutaneous; thrombosis; peripherally inserted central catheters; hemodialysis ID CATHETER-RELATED INFECTIONS; PREVENTION; GUIDELINES; ADULTS AB Central venous access devices (CVADs) are commonly used in the inpatient and outpatient settings. Physician assistants must understand CVADs' indications, intended uses, functional lifespans, complications, and indications for removal. This article describes common CVADs used for administering medications, nutrition, and chemotherapy, and for hemodialysis and venous access for laboratory sampling. C1 [Luckianow, Gina M.] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA. [Smith, David; Bullen, David] Philadelphia VA Med Ctr, Surg ICU, Philadelphia, PA USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Surg, Philadelphia, PA USA. [Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Surg, Philadelphia, PA 19104 USA. RP Luckianow, GM (reprint author), Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD JAN PY 2016 VL 29 IS 1 BP 33 EP 36 DI 10.1097/01.JAA.0000472630.68218.42 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DO3PC UT WOS:000377692500011 PM 26704651 ER PT J AU Beshai, J Smedley, K Beshai, T AF Beshai, James Smedley, Kerrie Beshai, Teresa TI The relationship between NEO personality factors and Hoge's Intrinsic Religious Motivation SO JOURNAL OF BELIEFS & VALUES-STUDIES IN RELIGION & EDUCATION LA English DT Article DE Psychology of religion; religious orientation; personality ID OPENNESS AB Personality traits have shown variable relationships to measures of religious motivation. For example, Costa and McCrae (1985) and McCrae and Costa (1999) suggested that individuals who are high in agreeableness and conscientious gravitate toward religion once they 'meet' with religion as a cultural identity Openness to experience involves varied expressions including sensitivity to aesthetics, and egalitarian values (e.g. McCrae and Costa, 1996). As such, it has been shown to be negatively correlated with measures of religious fundamentalism, and positively correlated with intrinsic religious motivation. However, other reviews have found only small correlations between personality and religious motivation. Our study was designed to test the relationships among the Big 5 personality factors with Hoge's Intrinsic Religious Motivation in an undergraduate sample. Results showed that only openness to experience and intrinsic religious motivation were significantly correlated, providing further support for the idea that religious motivation and personality factors may require further research elaboration. C1 [Beshai, James] US Dept Vet Affairs, Lebanon, PA USA. [Smedley, Kerrie] Lebanon Valley Coll, Dept Psychol, Annville, PA USA. RP Beshai, J (reprint author), US Dept Vet Affairs, Lebanon, PA USA. EM Jimmy.Beshai@gmail.com NR 9 TC 0 Z9 0 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1361-7672 EI 1469-9362 J9 J BELIEFS VALUES JI J. Beliefs Values-Stud. Relig. Educ. PY 2016 VL 37 IS 1 BP 114 EP 117 DI 10.1080/13617672.2016.1142124 PG 4 WC Education & Educational Research; Religion SC Education & Educational Research; Religion GA DO7TE UT WOS:000377985100010 ER PT J AU Soble, JR Marceaux, JC Galindo, J Sordahl, JA Highsmith, JM O'Rourke, JJF Gonzalez, DA Critchfield, EA Mccoy, KJM AF Soble, Jason R. Marceaux, Janice C. Galindo, Juliette Sordahl, Jeffrey A. Highsmith, Jonathan M. O'Rourke, Justin J. F. Gonzalez, David Andres Critchfield, Edan A. McCoy, Karin J. M. TI The effect of perceptual reasoning abilities on confrontation naming performance: An examination of three naming tests SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Boston Naming Test; Visual Naming Test; Neuropsychological Assessment Battery; language; perceptual reasoning abilities; mediation ID MEMORY-MALINGERING TOMM; ALZHEIMERS-DISEASE; ASSOCIATION; FAMILIARITY; ACCURACY; TRIAL-1; MODELS; NORMS AB Introduction: Confrontation naming tests are a common neuropsychological method of assessing language and a critical diagnostic tool in identifying certain neurodegenerative diseases; however, there is limited literature examining the visual-perceptual demands of these tasks. This study investigated the effect of perceptual reasoning abilities on three confrontation naming tests, the Boston Naming Test (BNT), Neuropsychological Assessment Battery (NAB) Naming Test, and Visual Naming Test (VNT) to elucidate the diverse cognitive functions underlying these tasks to assist with test selection procedures and increase diagnostic accuracy. Method: A mixed clinical sample of 121 veterans were administered the BNT, NAB, VNT, and Wechsler Adult Intelligence Scale-4th Edition (WAIS-IV) Verbal Comprehension Index (VCI) and Perceptual Reasoning Index (PRI) as part of a comprehensive neuropsychological evaluation. Results: Multiple regression indicated that PRI accounted for 23%, 13%, and 15% of the variance in BNT, VNT, and NAB scores, respectively, but dropped out as a significant predictor once VCI was added. Follow-up bootstrap mediation analyses revealed that PRI had a significant indirect effect on naming performance after controlling education, primary language, and severity of cognitive impairment, as well as the mediating effect of general verbal abilities for the BNT (B = 0.13; 95% confidence interval, CI [.07,.20]), VNT (B = 0.01; 95% CI [.002,.03]), and NAB (B = 0.03; 95% CI [.01,.06]). Conclusions: Findings revealed a complex relationship between perceptual reasoning abilities and confrontation naming that is mediated by general verbal abilities. However, when verbal abilities were statistically controlled, perceptual reasoning abilities were found to have a significant indirect effect on performance across all three confrontation naming measures with the largest effect noted with the BNT relative to the VNT and NAB Naming Test. C1 [Soble, Jason R.; Marceaux, Janice C.; Galindo, Juliette; Sordahl, Jeffrey A.; Highsmith, Jonathan M.; O'Rourke, Justin J. F.; Gonzalez, David Andres; Critchfield, Edan A.; McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Galindo, Juliette] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [Sordahl, Jeffrey A.] Boise VA Med Ctr, Neuropsychol Serv, Boise, ID USA. [Galindo, Juliette] Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA. RP Soble, JR (reprint author), South Texas Vet Healthcare Syst Psychol Serv 116B, 7400 Merton Minter, San Antonio, TX 78229 USA. EM Jason.Soble@va.gov NR 34 TC 1 Z9 1 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1380-3395 EI 1744-411X J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2016 VL 38 IS 3 BP 284 EP 292 DI 10.1080/13803395.2015.1107030 PG 9 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA DO7TQ UT WOS:000377986300003 PM 26644041 ER PT J AU Waldron, PR Belitskaya-Levy, I Chary, A Won, J Winters, M Monto, A Ryan, J Lazzeroni, LC Holodniy, M AF Waldron, Paul Ravi Belitskaya-Levy, Ilana Chary, Aarthi Won, Johann Winters, Mark Monto, Alexander Ryan, James Lazzeroni, Laura C. Holodniy, Mark TI Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection SO JOURNAL OF IMMUNOLOGY RESEARCH LA English DT Article ID WHOLE-GENOME ASSOCIATION; COINFECTED PATIENTS; INTERLEUKIN-6; INTERFERON; IL28B; POLYMORPHISMS; PREDICTORS; CYTOKINES; RIBAVIRIN; THERAPY AB Background. Millions of people are infected with hepatitis C virus (HCV) worldwide and 30% spontaneously clear the infection. Reasons for HCV clearance without antiviral treatment are not well understood. Methods. Blood was collected for DNA analysis from patients with chronic HCV infection or evidence of spontaneous clearance. To overcome anticipated limitations of small sample size, primary analyses consisted of a candidate gene analysis of 12 preselected genes based on known association with host immunologic response to HCV infection. To further reduce the impact of multiple testing on power, a single likelihood ratio test was conducted for each gene using all associated SNPs assayed on the Illumina Quad 610/660W chip. Step-down permutation methods were used to adjust for multiple testing in all analyses. Results. Ninety-five and 62 patients with HCV chronic infection or spontaneous clearance, respectively, were included for analysis. HLA-DQB1 (p = 1.76 * 10(-5)) and IL-6 (p = 0.0007) genes were significantly associated with spontaneous HCV clearance. IL-28B was not significantly associated with spontaneous clearance (p = 0.17). Conclusion. Our whole-gene analytic strategy identified a previously unreported association of IL-6 with spontaneous clearance of HCV infection. We also confirmed the finding that HLA-DQB1 is associated with spontaneous resolution of HCV infection. C1 [Waldron, Paul Ravi; Chary, Aarthi; Winters, Mark; Holodniy, Mark] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Waldron, Paul Ravi; Chary, Aarthi; Winters, Mark; Holodniy, Mark] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. [Belitskaya-Levy, Ilana; Won, Johann; Lazzeroni, Laura C.] VA Palo Alto Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, Palo Alto, CA 94304 USA. [Monto, Alexander; Ryan, James] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Monto, Alexander; Ryan, James] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. RP Waldron, PR (reprint author), VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.; Waldron, PR (reprint author), Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. EM pwaldron@stanford.edu FU Clinical Science Research & Development Service of the Department of Veterans Affairs (A Cooperative Studies Program-Wide DNA Bank, CSP) [478]; NIH [T32 AI007502] FX This work was supported by research funding to Mark Holodniy and the Cooperative Studies Program Coordinating Center, Palo Alto, from the Clinical Science Research & Development Service of the Department of Veterans Affairs (A Cooperative Studies Program-Wide DNA Bank, CSP #478). Additional support was provided by NIH Training Grant T32 AI007502 (Upinder Singh PI). NR 37 TC 0 Z9 0 U1 1 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-8861 EI 2314-7156 J9 J IMMUNOL RES JI J Immunol. Res. PY 2016 AR 6530436 DI 10.1155/2016/6530436 PG 9 WC Immunology SC Immunology GA DO6DV UT WOS:000377874400001 ER EF